symptoms,diseases,diagnosis
"['Intellectual disability', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Intellectual disability**: A hallmark of TBCK syndrome, linked to biallelic loss-of-function mutations in the *TBCK* gene, which disrupt neuronal development and synaptic function.  
2. **Hypotonia**: Consistently observed in TBCK patients due to combined central (brain-related) and peripheral (motor neuron/neuropathy) mechanisms.  
3. **Global developmental delay**: Matches the syndrome’s profile of impaired motor, speech, and cognitive milestones, often with regression or plateauing.  
4. **Reduced tendon reflexes**: Reflects peripheral nervous system involvement, such as axonal neuropathy or lower motor neuron dysfunction, reported in TBCK cases.  
5. **Absence of progressive neurodegeneration**: Distinguishes it from disorders like SMA or lysosomal storage diseases, aligning with TBCK’s stable/non-degenerative course.  
6. **Genetic confirmation**: Definitive diagnosis requires identifying pathogenic *TBCK* variants, but clinical features strongly prioritize this evaluation."
"['Death in infancy', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient's symptoms of **elevated urinary carboxylic acids** and **abnormal circulating glycine** align with a defect in leucine catabolism. 3-Methylcrotonyl-CoA carboxylase (MCC) deficiency disrupts the breakdown of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, causing accumulation of 3-methylcrotonylglycine and 3-hydroxyisovaleric acid in urine. These metabolites explain the **elevated urinary carboxylic acids**. Conjugation of glycine with toxic intermediates (e.g., 3-methylcrotonylglycine) depletes glycine, leading to **abnormal glycine levels**. **Aminoaciduria** arises due to renal tubular dysfunction from metabolite overload. Severe metabolic decompensation in infancy (hypoglycemia, acidosis) can result in **death** if untreated.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This is the same disorder as above, with naming variation. MCC deficiency (OMIM 210200) is an autosomal recessive disorder caused by mutations in *MCCC1* or *MCCC2*, encoding MCC subunits. The biochemical hallmarks—**elevated urinary 3-hydroxyisovaleric acid** and **3-methylcrotonylglycine**—correlate with the listed symptoms. **Aminoaciduria** is secondary to proximal tubule damage from acidic metabolites. Glycine abnormalities stem from its utilization in detoxification pathways. Early-onset severe metabolic crises (e.g., hypoglycemia, hyperammonemia) in infancy are life-threatening without dietary leucine restriction and carnitine supplementation."
"['Weight loss', 'Arthralgia', 'Elevated circulating creatinine concentration', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Fatigue', 'Restless legs', 'Abnormality of nail color']","['Scleroderma, familial progressive', 'Systemic sclerosi; SSc/Systemic sclerosis', 'Diffuse cutaneous systemic sclerosis', 'Limited cutaneous systemic sclerosis', 'CREST syndrome']","Systemic sclerosis/Systemic scleroderma; SSc/Systemic sclerosis: The patient exhibits hallmark features of systemic sclerosis (SSc), including antinuclear antibody positivity (present in >95% of cases), arthralgia, and elevated creatinine (suggesting possible renal involvement). Weight loss and fatigue may reflect gastrointestinal or multisystem disease. Abnormal nail color could indicate nailfold capillary changes, a key microvascular feature of SSc.  

Diffuse cutaneous systemic sclerosis: Elevated creatinine raises concern for scleroderma renal crisis (SRC), a life-threatening complication strongly associated with diffuse cutaneous SSc. Rapid progression of skin thickening (not explicitly listed but inferred from systemic symptoms) and early internal organ involvement (renal, musculoskeletal) align with this subtype.  

Limited cutaneous systemic sclerosis: Arthralgia, fatigue, and ANA positivity are consistent, but the absence of explicit CREST features (e.g., calcinosis, telangiectasia) or isolated distal skin thickening makes this less definitive. However, subtle nailfold abnormalities and restless legs (linked to vascular dysfunction) may suggest early limited disease.  

CREST syndrome: Requires at least two of Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, or Telangiectasia. While restless legs and nail changes might hint at vascular dysfunction (Raynaud’s-like), insufficient specific CREST features are documented to prioritize this diagnosis.  

Scleroderma, familial progressive: This rare inherited form presents similarly to SSc but typically manifests in childhood with progressive skin hardening. The absence of family history or pediatric-onset clues makes this less likely compared to acquired systemic sclerosis.  

**Final Emphasis:** The combination of renal involvement (elevated creatinine), autoimmune markers (ANA+), and systemic symptoms strongly favors **diffuse cutaneous systemic sclerosis** with incipient scleroderma renal crisis. Urgent evaluation for hypertension, proteinuria, and renal imaging is critical."
"['Seizure', 'Spastic diplegia', 'Encephalopathy', 'Death in infancy', 'Fever', 'Spastic tetraplegia', 'Tachypnea', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of elevated glutaric acid in urine, a hallmark of GA-I due to GCDH enzyme deficiency.  
2. **Encephalopathy & Seizures**: Metabolic crises in GA-I cause neurotoxicity (glutaric acid accumulation), damaging the basal ganglia and leading to acute encephalopathy and seizures.  
3. **Spastic diplegia/tetraplegia**: Striatal injury during metabolic decompensation results in irreversible dystonia and spasticity, progressing to tetraplegia in severe cases.  
4. **Death in infancy**: Untreated GA-I often leads to early mortality from metabolic crises or secondary complications (e.g., rhabdomyolysis, cerebral edema).  
5. **Fever & Tachypnea**: Common triggers (infections, catabolic stress) precipitate metabolic decompensation, manifesting as fever and respiratory distress.  
6. **Exclusion of mimics**: Symptoms align with GA-I rather than other organic acidemias (e.g., no maple syrup odor for MSUD) or mitochondrial disorders (no lactic acidosis typically).  
**Diagnosis confirmed via**: Urinary organic acid analysis (glutaric/3-hydroxyglutaric acid elevation), GCDH enzyme assay, or genetic testing."
"['Wide mouth', 'Epicanthus', 'Carious teeth', 'Hyperinsulinemia', 'Sparse hair', 'Seizure', 'Death in infancy', 'Hypoglycemia', 'Neonatal death', 'Death in childhood', 'Abnormal hemoglobin', 'Feeding difficulties']","['Hyperinsulinemic hypoglycemia, familial, 2', 'Congenital hyperinsulinemic hypoglycemia; CHI']","Disease: Hyperinsulinemic hypoglycemia, familial, 2  
Reasoning: The patient exhibits **hyperinsulinemia** and **hypoglycemia**, core features of this condition. Persistent hypoglycemia explains **seizures** and **feeding difficulties**, while severe, unmanaged cases can lead to **neonatal death**, **death in infancy**, or **death in childhood**. Familial type 2 is linked to *ABCC8* mutations, which disrupt insulin regulation. Although dysmorphic features (e.g., **wide mouth**, **epicanthus**) are atypical for isolated hyperinsulinemia, they may arise from syndromic forms or secondary effects of chronic metabolic stress. **Abnormal hemoglobin** could indicate compensatory erythropoiesis due to hypoxia from hypoglycemic episodes.  

Disease: Congenital hyperinsulinemic hypoglycemia (CHI)  
Reasoning: CHI encompasses genetic causes of hyperinsulinemic hypoglycemia, including *ABCC8/KCNJ11* mutations. Symptoms align with severe neonatal-onset hypoglycemia (**hypoglycemia**, **hyperinsulinemia**), leading to **seizures** and high mortality (**neonatal/childhood death**). **Sparse hair** and **carious teeth** may reflect chronic malnutrition or metabolic derangements. While **epicanthus** and **wide mouth** are not classic CHI features, they could suggest an overlapping genetic syndrome or phenocopy. **Abnormal hemoglobin** might be incidental or related to oxidative stress from recurrent hypoglycemia. CHI is the broader diagnostic category, with familial type 2 representing a specific genetic subtype."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD can cause intrauterine stress due to impaired fatty acid oxidation, leading to developmental abnormalities.  
2. **Death in infancy/Neonatal death/Death in childhood**: Untreated MCADD predisposes to life-threatening hypoglycemia and metabolic crises during fasting, common in infancy/childhood.  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs as carnitine binds to accumulating toxic acyl-CoA intermediates, reducing free carnitine levels.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misreporting or indirect effect; MCADD directly involves medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, disrupting β-oxidation. Accumulated metabolites may suppress downstream enzymes like 3-hydroxyacyl-CoA dehydrogenase.  

The clinical and biochemical profile aligns with MCADD, a fatty acid oxidation disorder requiring prompt management to prevent fatal outcomes."
"['Diabetes mellitus', 'Abnormal nervous system physiology', 'Impaired glucose tolerance', 'Death in early adulthood']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: MODY (Maturity-onset diabetes of the young)  
Reasoning: The patient presents with early-onset diabetes mellitus and impaired glucose tolerance, hallmark features of MODY—a monogenic form of diabetes. MODY typically manifests in adolescence or early adulthood (aligning with the patient’s age-related context) and is autosomal dominant. While MODY subtypes vary, the absence of severe obesity or autoimmune markers supports this diagnosis over type 1 or type 2 diabetes.  

Disease: Maturity-onset diabetes of the young, type 1 (MODY1, HNF4A-related)  
Reasoning: MODY1 is caused by mutations in the *HNF4A* gene, disrupting pancreatic beta-cell function and insulin secretion. The patient’s early adulthood mortality could stem from acute metabolic complications (e.g., diabetic ketoacidosis) due to delayed diagnosis or poor glycemic control. While ""abnormal nervous system physiology"" is atypical for MODY1, it may reflect secondary neurological damage from severe hypoglycemia/hyperglycemia or an unrelated comorbidity. This subtype is sulfonylurea-responsive, but untreated cases may progress rapidly, contributing to premature death."
"['Myopia', 'Nyctalopia', 'Hyperammonemia', 'Death in childhood', 'Death in adolescence', 'Hyperornithinemia']",['Gyrate atrophy of choroid and retina/Gyrate atrophy of choroid and retina with or without ornithinemia'],"Disease: Gyrate atrophy of choroid and retina with ornithinemia  
Reasoning:  
1. **Myopia and Nyctalopia**: These ocular symptoms align with progressive retinal degeneration, a hallmark of gyrate atrophy. The disease causes atrophy of the choroid and retina, leading to severe nearsightedness and impaired night vision.  
2. **Hyperornithinemia**: Elevated ornithine levels are pathognomonic for gyrate atrophy, caused by deficient ornithine aminotransferase (OAT) activity. This enzyme deficiency disrupts the urea cycle and ornithine metabolism.  
3. **Hyperammonemia**: Secondary urea cycle dysfunction due to ornithine accumulation can lead to episodic hyperammonemia, though this is less common and typically milder than in primary urea cycle disorders.  
4. **Early Mortality**: Untreated cases often result in death in childhood/adolescence due to metabolic decompensation or complications from advanced retinal degeneration (e.g., blindness-related accidents).  
5. **Exclusion of Alternatives**: The combination of retinal pathology with hyperornithinemia distinguishes this from other urea cycle disorders (e.g., OTC deficiency) or isolated retinal dystrophies."
"['Microcephaly', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Premature birth', 'Anemia', 'Abnormal facial shape', 'Opisthotonus', 'Abnormal calvaria morphology', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** are pathognomonic for galactosemia, directly indicating impaired galactose processing.  
2. **Failure to thrive**, **motor delay**, and **generalized hypotonia** align with metabolic dysfunction and energy depletion from toxic galactitol accumulation.  
3. **Seizures** and **intellectual disability** result from neurotoxic effects of galactose metabolites, causing cerebral edema and neuronal damage.  
4. **Anemia** and **abnormal circulating porphyrin concentration** suggest hepatic involvement, a hallmark of untreated galactosemia.  
5. **Neonatal death**/**death in infancy** correlates with acute complications (e.g., sepsis, liver failure) in undiagnosed cases, exacerbated by lactose exposure post-birth.  
6. **Premature birth** may reflect maternal galactose metabolism stress during gestation.  
7. Atypical features (syndactyly, abnormal calvaria) are likely unrelated or secondary to severe metabolic disruption affecting development.  

Disease: Galactosemia/GAL  
Reasoning:  
1. Overlaps with classic galactosemia but may encompass milder variants. Core symptoms (hypergalactosemia, metabolic abnormalities, neurological deficits) remain consistent.  
2. **Delayed speech/language development** and **abnormal facial shape** are secondary to global neurodevelopmental impairment from chronic galactose toxicity.  
3. **Opisthotonus** reflects severe neurological involvement from galactitol-induced osmotic damage in the CNS.  
4. **Death in childhood** underscores disease severity without early dietary intervention (lactose/galactose restriction).  

*Note: Syndactyly and calvaria abnormalities are not typical of galactosemia and may suggest a concurrent condition or misreported findings.*"
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to secondary carnitine depletion. Excess unmetabolized acyl-CoA intermediates conjugate with carnitine, forming acylcarnitines excreted in urine, reducing free carnitine levels.  
2. **Neonatal death/Death in infancy**: MCADD typically manifests during metabolic stress (e.g., fasting, infection). Infants cannot generate ketones for energy, causing hypoketotic hypoglycemia, encephalopathy, and sudden death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD does not directly cause structural birth defects, metabolic instability in utero (e.g., placental insufficiency from maternal metabolic stress) may contribute to prenatal complications.  
4. **Exclusion of alternatives**: Symptoms align with MCADD rather than other fatty acid oxidation disorders (e.g., VLCADD, LCHADD), which often involve cardiomyopathy or dysmorphic features absent here. Neonatal hypoglycemia and carnitine abnormalities are hallmark features of MCADD."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Abnormal circulating cysteine concentration', 'Sepsis', 'Metabolic alkalosis']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated Branched-Chain Amino Acids (BCAAs):** Hypervalinemia (elevated valine) and hyperleucinemia (elevated leucine) are hallmark biochemical features of MSUD, caused by a defect in the branched-chain α-ketoacid dehydrogenase complex.  
2. **Neurological Symptoms:** Lethargy, generalized hypotonia, drowsiness, and sleep disturbance result from neurotoxic accumulation of BCAAs and their ketoacids, leading to cerebral edema and impaired neurotransmitter function.  
3. **Metabolic Dysregulation:** Hyperammonemia and metabolic alkalosis may occur secondary to catabolic stress or intercurrent illness (e.g., sepsis), exacerbating metabolic decompensation.  
4. **Life-Threatening Course:** Neonatal death or death in infancy is typical in untreated classic MSUD due to rapid metabolic deterioration, often triggered by infections (e.g., sepsis) or metabolic crises.  
5. **Abnormal Cysteine Levels:** Secondary disruption of sulfur-containing amino acid metabolism may explain abnormal circulating cysteine concentrations in severe metabolic instability.  

The combination of BCAA elevation, acute neurological decline, and metabolic disturbances strongly supports MSUD, despite overlapping features with other inborn errors of metabolism (e.g., urea cycle disorders). Confirmatory testing (plasma amino acid analysis, genetic testing) is critical."
"['Eczematoid dermatitis', 'Skin rash', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Hypoglycemia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral edema', 'Athetosis', 'Hyperglutaminemia', 'Oroticaciduria', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Myocarditis', 'Abnormal circulating creatine kinase concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder where impaired OTC enzyme activity prevents ammonia detoxification.  
2. **Oroticaciduria/Uraciluria**: Excess carbamoyl phosphate (from blocked urea cycle) enters pyrimidine synthesis, producing orotic acid and uracil.  
3. **Elevated plasma citrulline**: Unusual in classic OTCD (typically low citrulline), but may reflect partial enzyme activity or atypical presentation.  
4. **Neurological symptoms (coma, cerebral edema, athetosis)**: Result from ammonia toxicity and cerebral osmotic shifts.  
5. **Hypoglycemia/Generalized hypotonia**: Metabolic stress from hyperammonemia disrupts energy metabolism and neuromuscular function.  
6. **Gastrointestinal inflammation/vomiting**: Common in urea cycle disorders due to ammonia-induced mucosal irritation.  
7. **Early mortality (infancy/childhood)**: Severe OTCD often leads to fatal hyperammonemic crises without prompt treatment.  
8. **Abnormal arginine/proline**: Secondary metabolic disruptions in urea cycle intermediates and related pathways.  
9. **Recurrent infections/myelitis**: Immune dysfunction from metabolic imbalance or hyperammonemia-induced immunosuppression.  

Key diagnostic anchors: **Hyperammonemia + oroticaciduria**, despite atypical citrulline elevation, strongly suggest OTCD over other urea cycle defects (e.g., citrullinemia type 1 shows markedly elevated citrulline without oroticaciduria)."
"['High palate', 'Epicanthus', 'Wide nasal bridge', 'Deeply set eye', 'Autism', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Broad finger', 'Broad toe', 'Developmental regression', 'Scoliosis', 'Bipolar affective disorder', 'Mild global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Features**: The patient exhibits characteristic craniofacial anomalies (high palate, epicanthus, wide nasal bridge, deeply set eyes), which are hallmark signs of TBCK syndrome.  
2. **Neurodevelopmental Symptoms**: Intellectual disability, autism, delayed speech/language development, and mild global developmental delay align with the syndrome’s core phenotype of psychomotor retardation.  
3. **Neurological Involvement**: Hypotonia (a defining feature), seizures, and developmental regression are consistent with TBCK’s progressive neurological dysfunction.  
4. **Musculoskeletal Abnormalities**: Broad fingers/toes and scoliosis are recurrently reported in TBCK patients due to connective tissue and skeletal involvement.  
5. **Psychiatric Comorbidity**: While bipolar disorder is atypical, neuropsychiatric variability (e.g., autism) is recognized in TBCK cases.  
6. **Exclusion of Mimics**: The constellation of symptoms rules out similar disorders (e.g., Angelman, Rett, or chromosomal syndromes) lacking the TBCK-specific gene (TBC1-domain-containing kinase) mutation and phenotypic combination."
"['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Elevated hepatic transaminase', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Elevated hepatic transaminases and metabolic disturbances**: MCADD disrupts medium-chain fatty acid β-oxidation, leading to hepatic dysfunction and elevated transaminases during metabolic crises.  
2. **Abnormal amino acid/carnitine profiles**: Accumulation of toxic metabolites (e.g., medium-chain acylcarnitines) causes secondary carnitine deficiency and alters aspartate/alanine levels due to impaired energy metabolism and liver stress.  
3. **Neonatal/infant mortality**: Undiagnosed MCADD can trigger life-threatening hypoglycemia, metabolic acidosis, or liver failure during fasting, explaining neonatal death or death in infancy.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: Likely reflects secondary inhibition of mitochondrial β-oxidation enzymes due to metabolite overload (e.g., octanoyl-CoA), not a primary enzyme deficiency.  
5. **Skin manifestations**: Eczematoid dermatitis/rash may result from systemic inflammation or metabolic toxicity, though less specific to MCADD.  
6. **Prenatal abnormalities**: Not a core feature of MCADD but could reflect maternal metabolic stress or coincidental factors.  

Key diagnostic clues are the combination of fatty acid oxidation defects (carnitine/amino acid abnormalities), hepatic involvement, and critical metabolic decompensation in infancy. Confirmatory testing would include acylcarnitine profile (elevated C8-C10 species) and genetic analysis of *ACADM* gene variants."
"['Carious teeth', 'Intellectual disability', 'Tetany', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Hepatomegaly', 'Bone pain', 'Hypokalemia', 'Hypercholesterolemia', 'High serum calcitriol', 'Elevated circulating alkaline phosphatase concentration', 'Severe short stature', 'Death in childhood', 'Decreased plasma free carnitine', 'Death in adolescence']",['Fanconi-Bickel syndrome/Fanconi-Bickel syndrome'],"Disease: Fanconi-Bickel syndrome  
Reasoning:  
1. **Hepatomegaly**: Caused by glycogen accumulation in the liver due to GLUT2 transporter dysfunction.  
2. **Failure to thrive/Severe short stature**: Results from metabolic disturbances (impaired glucose/galactose utilization) and malabsorption.  
3. **Renal Fanconi syndrome features**:  
   - **Hypokalemia/Tetany**: Renal tubular wasting of potassium and electrolytes.  
   - **Bone pain/High serum calcitriol/Elevated alkaline phosphatase**: Hypophosphatemia from renal phosphate loss leads to rickets, compensatory calcitriol elevation, and bone turnover.  
4. **Hypercholesterolemia**: Hepatic dysfunction and altered lipid metabolism.  
5. **Decreased plasma free carnitine**: Secondary to renal losses or impaired synthesis.  
6. **Carious teeth**: Linked to chronic glycosuria promoting dental decay.  
7. **Generalized hypotonia**: Muscle weakness from electrolyte imbalances or carnitine deficiency.  
8. **Early mortality (infancy/childhood/adolescence)**: Reflects severe metabolic derangements and complications (e.g., liver failure, infections).  
9. **Intellectual disability**: Rare but possible due to chronic metabolic instability or hypoglycemic episodes affecting brain development.  
10. **Genetic basis**: Autosomal recessive SLC2A2 mutations confirm the diagnosis.  

The constellation of hepatic, renal, and metabolic abnormalities aligns pathognomonically with Fanconi-Bickel syndrome."
"['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Acute kidney injury', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Hyperuricemia', 'Hyperglycinemia', 'Tachypnea', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Neonatal death', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Elevated urinary carboxylic acid']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with methylmalonic acidemia and methylmalonic aciduria, which are direct indicators of MMA. Additional metabolic disturbances such as hyperammonemia, metabolic acidosis, hyperglycinemia, and hyperuricemia align with MMA's pathophysiology, where impaired methylmalonyl-CoA mutase activity leads to toxic metabolite accumulation. Elevated blood urea nitrogen, creatinine, and kidney injury/chronic disease reflect renal damage caused by chronic acidemia and tubular toxicity. Neonatal death and hypotonia are consistent with severe, early-onset forms of MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The B12-unresponsive subtype is confirmed by the absence of improvement with B12 supplementation (implied by ""B12-unresponsive""). Mutase deficiency directly disrupts methylmalonyl-CoA conversion to succinyl-CoA, exacerbating methylmalonic acid accumulation. Symptoms like tachypnea, fever, and acute kidney injury correlate with metabolic decompensation episodes. Chronic kidney disease and abnormal carnitine/porphyrin levels further support a severe, intractable enzyme deficiency. Death in infancy/adolescence underscores the disease's lethality in this subtype due to treatment resistance."
"['Lethargy', 'Spasticity', 'Generalized hypotonia', 'Hyperreflexia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency  
Reasoning:  
1. **Hyperammonemia** is a cardinal feature of urea cycle disorders, including CPS1 deficiency, due to impaired ammonia detoxification.  
2. **Lethargy, drowsiness, and feeding difficulties** align with acute hyperammonemic encephalopathy, common in neonates with urea cycle defects.  
3. **Spasticity and hyperreflexia** suggest neurological damage from ammonia toxicity.  
4. **Generalized hypotonia** reflects systemic metabolic decompensation.  
5. **Death in infancy/neonatal death** is typical in severe, untreated CPS1 deficiency due to rapid ammonia accumulation.  
6. **Sleep disturbance** may arise from encephalopathic fluctuations in ammonia levels.  
7. Exclusion of other urea cycle disorders (e.g., ornithine transcarbamylase deficiency) is supported by the absence of orotic aciduria, which is not seen in CPS1 deficiency."
"['Seizure', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Oroticaciduria', 'Neonatal death']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), where impaired ammonia detoxification occurs.  
2. **Oroticaciduria** specifically indicates a defect in the urea cycle enzyme ornithine transcarbamylase (OTC). OTC deficiency causes carbamoyl phosphate to accumulate, diverting into pyrimidine synthesis and producing excess orotic acid.  
3. **Cerebral edema** and **seizures** are secondary to acute hyperammonemia, as ammonia toxicity disrupts cerebral metabolism and osmotic balance.  
4. **Neonatal death**/**death in infancy** aligns with severe OTCD, an X-linked disorder that typically presents catastrophically in males shortly after birth due to metabolic collapse.  
5. The absence of other UCD-specific markers (e.g., citrullinemia, argininosuccinic aciduria) further narrows the diagnosis to OTCD."
"['Renal insufficiency', 'Nephrotic syndrome', 'Pericardial effusion', 'Pericarditis', 'Anemia', 'Elevated circulating creatinine concentration', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Complement deficiency', 'Fatigue', 'Moderate proteinuria', 'Heavy proteinuria']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus']","Disease: Systemic lupus erythematosus  
Reasoning: The patient presents with multi-system involvement, including renal insufficiency, nephrotic syndrome, pericarditis/pericardial effusion, and hematologic abnormalities (anemia). Antinuclear antibody (ANA) positivity and complement deficiency are hallmark immunologic features of SLE. Proteinuria (moderate to heavy) and elevated creatinine indicate lupus nephritis, a common complication. Fatigue and exercise intolerance align with systemic inflammation.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: Genetic susceptibility loci, such as those near *TNFSF4* or *STAT4*, may contribute to the patient’s presentation. While clinical symptoms define SLE, this subtype reflects a specific genetic predisposition linked to dysregulated immune pathways.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: If the patient is under 18, pediatric SLE is applicable. Children often present with severe renal involvement (nephrotic syndrome, heavy proteinuria) and constitutional symptoms like fatigue, consistent with this case.  

Disease: Systemic lupus erythematosus 16  
Reasoning: This subtype references a specific genetic association (e.g., *IRF5* or *HLA* polymorphisms). The clinical phenotype matches SLE criteria, and genetic markers may explain disease severity or organ tropism (e.g., renal/pericardial manifestations).  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: Less likely, as vitiligo or other autoimmune disorders (e.g., thyroid disease) are not reported. However, *NALP1* gene variants linked to this subtype could theoretically predispose to SLE-like autoimmunity, though primary evidence points to SLE itself."
"['Recurrent urinary tract infections', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
**Reasoning**:  
1. **Cystinuria** is characterized by impaired renal reabsorption of **cystine** and the dibasic amino acids **ornithine, arginine, and lysine** (COAL), leading to their excessive urinary excretion. The symptoms **cystinuria, argininuria, hyperlysinuria, and ornithinuria** directly align with this defect.  
2. **Recurrent urinary tract infections (UTIs)** are common in cystinuria due to cystine stone formation in the urinary tract, which predisposes to obstruction and infection.  
3. **Death in infancy** is atypical for classic cystinuria but may occur in severe cases with early-onset nephrolithiasis, obstructive uropathy, or sepsis secondary to recurrent UTIs, compounded by metabolic instability in infants.  
4. Other disorders (e.g., lysinuric protein intolerance) were excluded due to the absence of hallmark features (e.g., hyperammonemia, failure to thrive) and the presence of **cystinuria**, which is pathognomonic for this diagnosis.  
5. Genetic mutations in **SLC3A1** or **SLC7A9** disrupt the renal transporter responsible for COAL reabsorption, confirming cystinuria as the unifying diagnosis."
"['Delayed speech and language development', 'Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Delayed speech/language development**: Untreated PKU causes neurotoxic phenylalanine accumulation, impairing brain development.  
3. **Eczematoid dermatitis/Skin rash**: Elevated phenylalanine disrupts melanin and protein synthesis, leading to dermatologic manifestations.  
4. **Abnormality of prenatal development or birth**: Maternal PKU (untreated) exposes the fetus to high phenylalanine, causing congenital anomalies.  
5. **Death in infancy/childhood/Neonatal death**: Severe untreated PKU results in progressive neurodegeneration, seizures, and metabolic instability, which can be fatal.  
6. **Hypertyrosinemia**: Secondary tyrosine deficiency (from blocked phenylalanine metabolism) may paradoxically elevate tyrosine in some metabolic stress scenarios or assay cross-reactivity.  
7. **Recurrent viral infections/Fever**: Less specific but could reflect compromised health from chronic metabolic imbalance.  

*Note: Hypertyrosinemia and recurrent infections are atypical for classic PKU. These may suggest a concurrent condition (e.g., tyrosinemia type II) or diagnostic complexities (e.g., transient tyrosine fluctuations). However, hyperphenylalaninemia and neurodevelopmental features strongly anchor the diagnosis to PKU.*"
"['Hypertonia', 'Morphological central nervous system abnormality', 'Pneumothorax', 'Dilatation of the renal pelvis', 'Dyskinesia']",['Hereditary hyperekplexia/Hyperekplexia 1'],"Disease: Hereditary hyperekplexia/Hyperekplexia 1  
Reasoning:  
1. **Hypertonia**: A hallmark symptom of hereditary hyperekplexia, caused by mutations in the *GLRA1* gene, leading to glycine receptor dysfunction in the spinal cord and brainstem, resulting in sustained muscle stiffness.  
2. **Morphological central nervous system abnormality**: While hyperekplexia is primarily a functional disorder, rare cases may exhibit structural CNS anomalies (e.g., brainstem hypoplasia) due to disrupted glycine-mediated neurodevelopment.  
3. **Dyskinesia**: May arise from chronic hypertonia or compensatory mechanisms in motor pathways, though atypical for classic hyperekplexia. This could suggest a complex phenotype or overlapping movement disorder.  
4. **Pneumothorax and renal pelvis dilatation**: Not directly linked to hyperekplexia. These may represent unrelated comorbidities, secondary complications (e.g., trauma from severe spasms), or a syndromic form with multi-organ involvement (not well-documented in literature).  

Final diagnosis prioritizes the pathognomonic triad of hypertonia, exaggerated startle, and stiffness, while acknowledging atypical features that warrant further investigation for coexisting conditions."
"['Nocturia', 'Abnormality of the larynx', 'Weight loss', 'Thrombocytopenia', 'Anemia', 'Fever', 'Leukocytosis', 'Headache', 'Rheumatoid factor positive', 'Elevated circulating parathyroid hormone level', 'Smooth muscle antibody positivity', 'Myalgia', 'Abnormality of complement system', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Lower limb pain', 'Reduced left ventricular ejection fraction', 'Scrotal pain', 'Night sweats', 'Elevated gamma-glutamyltransferase level', 'Groin pain', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Myositis']",['Polymyositis'],"Polymyositis: The patient presents with myositis and myalgia, which are hallmark features of polymyositis. Elevated circulating IgG4 levels, leukocytosis, and elevated CRP indicate systemic inflammation, consistent with autoimmune-mediated muscle damage. Rheumatoid factor positivity and smooth muscle antibody positivity further support an autoimmune etiology. Systemic symptoms like fever, weight loss, and night sweats align with chronic inflammatory processes. While abnormalities in complement, sodium, and vitamin D suggest multi-organ involvement, these may arise secondary to chronic inflammation or autoimmunity. Muscle-specific manifestations (myositis, limb pain) remain the primary diagnostic anchors, distinguishing polymyositis from broader IgG4-related disease or overlap syndromes."
"['Spasticity', 'Death in infancy', 'Tachypnea', 'Decreased plasma free carnitine', 'Methylmalonic aciduria', 'Elevated urinary carboxylic acid', 'Elevated circulating acylcarnitine concentration']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits methylmalonic aciduria, elevated urinary carboxylic acid, and elevated circulating acylcarnitine, all hallmark biochemical features of MMA. Decreased plasma free carnitine occurs due to excessive conjugation with accumulating toxic metabolites. Spasticity and tachypnea reflect neurological and metabolic stress from acidemia, while death in infancy aligns with severe, early-onset forms of MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity for this subtype is supported by the lack of vitamin B12 responsiveness implied in the diagnosis. Methylmalonyl-CoA mutase (MUT) deficiency disrupts the conversion of methylmalonyl-CoA to succinyl-CoA, causing metabolite accumulation. Elevated acylcarnitine (e.g., propionylcarnitine) and urinary methylmalonate confirm this enzyme defect. Early lethality and severe metabolic decompensation further distinguish the B12-unresponsive MUT-deficient form from milder or B12-responsive variants."
"['Microcephaly', 'Single transverse palmar crease', 'Pallor', 'Abnormality of prenatal development or birth', 'Motor delay', 'Failure to thrive', 'Small for gestational age', 'Death in infancy', 'Anemia', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Pneumonia', 'Increased serum lactate', 'Increased CSF lactate', 'Hypocholesterolemia', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Core biochemical markers**: Methylmalonic aciduria, increased serum/CSF lactate, metabolic acidosis, hyperammonemia, and hypoglycemia are hallmarks of MMA due to disrupted propionate metabolism.  
2. **Enzyme deficiency**: Decreased methylmalonyl-CoA mutase activity directly confirms a defect in this enzyme, critical for converting methylmalonyl-CoA to succinyl-CoA.  
3. **Vitamin B12-unresponsiveness**: Absence of B12 deficiency signs (e.g., no megaloblastic anemia) and persistent symptoms suggest a primary mutase defect (mut⁰ or mut⁻ subtype).  
4. **Systemic manifestations**: Failure to thrive, feeding difficulties, vomiting, and neonatal death align with acute metabolic decompensation seen in MMA.  
5. **Metabolic sequelae**: Hypocholesterolemia and abnormal carnitine/porphyrin levels reflect secondary mitochondrial dysfunction and energy depletion.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Genetic confirmation**: The specificity of decreased methylmalonyl-CoA mutase activity excludes other MMA subtypes (e.g., cblA/cblB defects) and confirms mutase deficiency.  
2. **Early lethality**: Neonatal death and death in infancy are typical in severe mutase-deficient MMA due to intractable acidosis/hyperammonemia.  
3. **Prenatal involvement**: Small for gestational age and prenatal developmental abnormalities indicate in utero metabolic stress.  
4. **Lactic acidosis**: Increased lactate in serum/CSF reflects secondary mitochondrial impairment from toxic metabolite accumulation (methylmalonate, propionyl-CoA).  
5. **Absence of B12-responsive features**: Normal/high B12 levels and lack of hematologic improvement with B12 supplementation support mutase deficiency as the primary defect."
"['Abnormality of facial musculature', 'Bulbar palsy', 'Flexion contracture', 'Joint laxity', 'Loss of ambulation', 'Elevated circulating creatine kinase concentration', 'Scapular winging', 'Generalized muscle hypertrophy', 'Pelvic girdle muscle weakness', 'Progressive pulmonary function impairment', 'Proximal muscle weakness in lower limbs', 'Flaky paint dermatosis', 'Abnormal emotion/affect behavior']","['Muscular dystrophy, limb-girdle, type 2Z', 'POGLUT1-related limb-girdle muscular dystrophy R21']","Disease: Muscular dystrophy, limb-girdle, type 2Z (POGLUT1-related limb-girdle muscular dystrophy R21)  
Reasoning:  
1. **Pelvic girdle weakness** and **proximal lower limb weakness** align with the limb-girdle muscular dystrophy (LGMD) phenotype.  
2. **Elevated creatine kinase** indicates muscle breakdown, consistent with muscular dystrophy.  
3. **Scapular winging** and **loss of ambulation** reflect progressive shoulder and pelvic muscle degeneration.  
4. **Generalized muscle hypertrophy** (e.g., pseudoathletic appearance) is reported in POGLUT1-related LGMD due to fibrofatty muscle replacement.  
5. **Facial musculature abnormality** and **bulbar palsy** suggest cranial nerve involvement, a recognized feature of POGLUT1 mutations affecting Notch signaling.  
6. **Flaky paint dermatosis** (scaly/dry skin) may link to Notch pathway disruption, which impacts epidermal integrity.  
7. **Joint laxity** with **flexion contractures** mirrors the mixed connective tissue phenotype seen in collagen/Notch-related disorders.  
8. **Progressive pulmonary impairment** results from respiratory muscle weakness in advanced disease.  
9. **Abnormal emotion/affect behavior** could stem from chronic disability or rare CNS involvement via Notch signaling.  
10. Genetic confirmation of **POGLUT1 mutations** (causing LGMD2Z/R21) explains the multisystemic features, unifying muscular, dermatologic, and bulbar symptoms.  

*Note: Both listed diagnoses refer to the same condition (LGMD2Z is the historical name; R21 denotes the OMIM classification).*"
"['Hydronephrosis', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Fever', 'Opisthotonus', 'Athetosis', 'Kyphoscoliosis', 'Neonatal death', 'Death in childhood', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning: The patient exhibits elevated branched-chain amino acids (Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia) and elevated urinary carboxylic acids, indicative of a defect in branched-chain amino acid metabolism. Neurological symptoms (Opisthotonus, Athetosis, Intellectual disability, Motor delay) and feeding difficulties align with neurotoxicity caused by BCAA accumulation. Life-threatening metabolic crises explain early mortality (Neonatal death, Death in infancy/childhood/adolescence). Generalized hypotonia and developmental delays are secondary to metabolic dysfunction. While Hydronephrosis is atypical, it may reflect systemic metabolic stress or comorbid congenital factors. The biochemical and clinical profile is pathognomonic for MSUD."
"['Hypospadias', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Difficulty walking', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Difficulty running']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Generalized hypotonia** and **delayed speech/language development** align with BTDD’s neurological manifestations due to biotin-dependent metabolic dysfunction.  
2. **Difficulty walking, climbing stairs, and running** reflect progressive neuromuscular impairment, common in untreated BTDD.  
3. **Neonatal/childhood death** and **death in infancy** correlate with severe metabolic crises (e.g., lactic acidosis, hyperammonemia) in undiagnosed cases.  
4. **Abnormality of prenatal development or birth** may indicate intrauterine metabolic stress or growth issues secondary to enzyme deficiency.  
5. While **hypospadias** is atypical for BTDD, it could represent an incidental congenital anomaly or a rare association with metabolic disruption during organogenesis.  
6. Symptoms collectively match the late-onset multiple carboxylase deficiency phenotype, where biotinidase deficiency disrupts biotin recycling, impairing carboxylase enzymes critical for metabolism. Early diagnosis is life-saving with biotin supplementation."
"['Seizure', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits methylmalonic aciduria, a hallmark biochemical marker of MMA. Symptoms like seizures, lethargy, generalized hypotonia, feeding difficulties, and neonatal death align with this autosomal recessive disorder caused by impaired metabolism of methylmalonyl-CoA. MMA typically presents in infancy with acute metabolic decompensation triggered by catabolic stressors.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The severity of symptoms (neonatal death, death in infancy) and lack of response to B12 therapy (implied by persistent methylmalonic aciduria) suggest a mutase-deficient subtype. This variant results from mutations in the MUT gene, causing complete or near-complete loss of methylmalonyl-CoA mutase activity. The clinical course is more severe compared to B12-responsive forms, with rapid progression of metabolic crises and early mortality without aggressive intervention."
"['Smooth philtrum', 'Long philtrum', 'Micrognathia', 'Hearing impairment', 'Cataract', 'Long eyelashes', 'Carious teeth', 'Hypotonia', 'Motor delay', 'Bilateral ptosis', 'Frontal bossing', 'Recurrent respiratory infections', 'Feeding difficulties in infancy', 'Postnatal growth retardation', 'Retractile testis']",['Vici syndrome/Vici syndrome'],"Disease: Vici syndrome  
Reasoning: The patient presents with **cataracts**, a hallmark feature of Vici syndrome, alongside **recurrent respiratory infections** suggestive of immunodeficiency, another key component. **Hypotonia**, **motor delay**, and **postnatal growth retardation** align with neurodevelopmental and growth abnormalities seen in Vici syndrome. **Feeding difficulties in infancy** are consistent with multisystem involvement. Craniofacial features (**micrognathia**, **frontal bossing**, **bilateral ptosis**) and **long philtrum** may reflect dysmorphism associated with the disorder. While **hearing impairment** and **carious teeth** are less typical, they could occur due to syndromic variability. The absence of explicitly mentioned agenesis of the corpus callosum (a classic feature) is notable, but clinical heterogeneity may account for this. Overall, the constellation of immune deficiency, cataracts, neurodevelopmental delays, and craniofacial signs strongly supports Vici syndrome."
"['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with metabolic acidosis and decreased methylmalonyl-CoA mutase activity, hallmark features of methylmalonic acidemia (MMA). MMA is caused by impaired metabolism of methylmalonyl-CoA, leading to toxic accumulation of methylmalonic acid. The enzyme deficiency directly disrupts the propionate pathway, resulting in metabolic decompensation, which manifests as life-threatening acidosis. Early lethality (infancy/childhood) aligns with severe forms of MMA, where crises trigger multisystem failure.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specific mention of decreased methylmalonyl-CoA mutase activity confirms a defect in the MUT gene, encoding the mutase enzyme. This subtype is unresponsive to vitamin B12 therapy, as the mutation directly affects the enzyme’s structure/function rather than cofactor (adenosyl-B12) metabolism. Persistent enzyme dysfunction exacerbates metabolic instability, explaining the poor prognosis (death in infancy/childhood) despite standard interventions."
"['Seizure', 'Tongue fasciculations', 'Myoclonus', 'Bilateral tonic-clonic seizure', 'Resting tremor', 'Waddling gait', 'Gowers sign', 'Limb muscle weakness', 'Proximal muscle weakness', 'Atonic seizure', 'Tongue atrophy', 'Abnormal circulating creatine kinase concentration', 'Abnormal lactate dehydrogenase level']",['Spinal muscular atrophy-progressive myoclonic epilepsy syndrome/Spinal muscular atrophy with progressive myoclonic epilepsy'],"Disease: Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)  
Reasoning:  
1. **Proximal Muscle Weakness & Motor Neuron Signs**: Gowers sign, waddling gait, and proximal/limb muscle weakness indicate spinal muscular atrophy (SMA), reflecting lower motor neuron degeneration.  
2. **Seizures & Myoclonus**: Bilateral tonic-clonic, atonic seizures, and myoclonus align with progressive myoclonic epilepsy (PME), a hallmark of SMA-PME progression.  
3. **Neuromuscular Features**: Tongue fasciculations and atrophy suggest lower motor neuron involvement, consistent with SMA pathology.  
4. **Biomarkers**: Elevated creatine kinase (CK) and lactate dehydrogenase (LDH) indicate muscle damage, supporting SMA-related degeneration.  
5. **Exclusion of Mimics**: Symptoms lack features of mitochondrial disorders (e.g., multi-organ involvement) or Lafora disease (e.g., cognitive decline, Lafora bodies), narrowing the diagnosis to SMA-PME.  
6. **Genetic Correlation**: SMA-PME is linked to *ASAH1* mutations, which disrupt ceramide metabolism, explaining both neuromuscular and epileptic features."
"['Macrocephaly', 'Ataxia', 'Death in infancy', 'Dicarboxylic aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormality of movement']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated circulating glutaric acid concentration** and **dicarboxylic aciduria** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity.  
2. **Macrocephaly** is a common early sign due to abnormal brain development or subdural effusions.  
3. **Abnormality of movement** (e.g., dystonia, dyskinesia) and **ataxia** arise from striatal injury, particularly during metabolic crises triggered by catabolic stress.  
4. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from binding to accumulating glutaric acid.  
5. **Death in infancy/childhood** and **neonatal death** reflect severe metabolic decompensation if untreated, often precipitated by intercurrent illnesses.  
6. Symptom progression aligns with GA-I’s natural history: acute encephalopathic crises in early childhood, leading to irreversible neurological damage or fatality without dietary and metabolic management."
"['Coarse facial features', 'Epicanthus', 'Hypertelorism', 'Nystagmus', 'Intellectual disability', 'Seizure', 'Global developmental delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Secundum atrial septal defect', 'Inability to walk', 'Bronchomalacia', 'Recurrent lower respiratory tract infections', 'Aminoaciduria', 'Depressed nasal bridge', 'Mucopolysacchariduria', 'Oligosacchariduria', 'Abnormal nerve conduction velocity']","['Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome/Spinocerebellar ataxia, autosomal recessive 20']","Disease: Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome/Spinocerebellar ataxia, autosomal recessive 20 (SNX14-related disorder)  
Reasoning:  
1. **Core Features**:  
   - **Intellectual disability** and **global developmental delay** are hallmark features of SNX14-related disorders.  
   - **Coarse facial features** (epicanthus, hypertelorism, depressed nasal bridge) align with the syndrome’s characteristic facial dysmorphism.  
   - **Cerebellar atrophy** corresponds to ""cerebellar hypotrophy"" in the diagnosis, explaining **nystagmus**, **inability to walk** (ataxia), and **hypotonia**.  

2. **Neurological Manifestations**:  
   - **Seizures** and **abnormal nerve conduction velocity** are consistent with neuronal dysfunction caused by SNX14 mutations, which disrupt autophagy and lysosomal function.  

3. **Metabolic Abnormalities**:  
   - **Mucopolysacchariduria** and **oligosacchariduria** suggest lysosomal storage defects, likely secondary to SNX14’s role in lipid metabolism and lysosomal homeostasis.  
   - **Aminoaciduria** may reflect broader metabolic dysregulation.  

4. **Systemic Involvement**:  
   - **Secundum atrial septal defect** and **bronchomalacia** are atypical but reported in rare cases, possibly due to connective tissue or developmental impacts of SNX14 dysfunction.  
   - **Recurrent respiratory infections** are linked to hypotonia and bronchomalacia.  

5. **Exclusion of Alternatives**:  
   - While mucopolysacchariduria might suggest a lysosomal storage disease (e.g., Hurler syndrome), the combination of cerebellar atrophy, coarse facies, and autosomal recessive inheritance pattern matches SNX14-related disorder.  

**Conclusion**: The constellation of neurological, metabolic, and structural anomalies aligns with SNX14 mutations, confirming the diagnosis."
"['Delayed speech and language development', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Opisthotonus', 'Neonatal death', 'Death in childhood', 'D-2-hydroxyglutaric aciduria']",['D-2-Hydroxyglutaric aciduria 1'],"Disease: D-2-Hydroxyglutaric Aciduria 1  
Reasoning:  
1. **Biochemical Marker**: The presence of **D-2-hydroxyglutaric aciduria** is a hallmark of D-2-Hydroxyglutaric Aciduria (D-2-HGA), specifically linking to this metabolic disorder.  
2. **Neurological Symptoms**:  
   - **Seizures** and **opisthotonus** indicate severe neurological dysfunction, consistent with cerebral accumulation of toxic metabolites (D-2-hydroxyglutarate) disrupting energy metabolism.  
   - **Generalized hypotonia** aligns with diffuse neurometabolic impairment affecting muscle tone regulation.  
3. **Developmental Delays**: **Delayed speech and language development** reflects chronic neurodevelopmental deficits caused by progressive metabolic encephalopathy.  
4. **Early Mortality**: **Neonatal death**, **death in infancy**, or **death in childhood** are seen in severe D-2-HGA type 1 cases due to metabolic crises, intractable seizures, or neurodegenerative progression.  
5. **Genetic Confirmation**: D-2-HGA type 1 is caused by mutations in *D2HGDH*, leading to impaired enzyme activity and metabolite accumulation. While phenotypic severity varies, the combination of biochemical findings and clinical features confirms the diagnosis.  

This structured analysis integrates biochemical, clinical, and genetic evidence to pinpoint the diagnosis."
"['Nystagmus', 'Hyperactivity', 'Dysmetria', 'Joint stiffness', 'Thrombocytopenia', 'Neutropenia', 'Gait imbalance', 'Postural instability', 'Lower limb hyperreflexia', 'Immunodeficiency', 'Myelodysplasia', 'Attention deficit hyperactivity disorder', 'Bronchiolitis']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Neurological features**: Nystagmus, dysmetria, gait imbalance, and postural instability are hallmark signs of **cerebellar ataxia**, a core component of APS. Lower limb hyperreflexia suggests possible pyramidal tract involvement, which can occur in APS due to myelodysplasia-related spinal cord dysfunction.  
2. **Hematological abnormalities**: Thrombocytopenia, neutropenia, and myelodysplasia directly align with the ""pancytopenia"" aspect of APS. Myelodysplasia (ineffective blood cell production) is a defining feature.  
3. **Immunodeficiency**: Neutropenia and myelodysplasia impair immune function, explaining recurrent infections like bronchiolitis.  
4. **ADHD**: While not a primary feature of APS, neurodevelopmental/behavioral issues may arise from cerebellar dysfunction or chronic illness burden.  
5. **Exclusion of mimics**: The combination of ataxia with pancytopenia is highly specific for APS over isolated ataxias (e.g., Friedreich’s) or hematologic disorders (e.g., aplastic anemia). Genetic testing for SAMD9L mutations would confirm APS."
"['High palate', 'Microcephaly', 'Macrotia', 'Sensorineural hearing impairment', 'Convex nasal ridge', 'Deeply set eye', 'Microphthalmia', 'Large hands', 'Intellectual disability', 'Cerebellar hypoplasia', 'Scoliosis', 'Thickened calvaria', 'Kyphosis', 'Limb joint contracture', 'Short stature', 'Bilateral intracerebral calcifications', 'Postnatal growth retardation', 'Nasogastric tube feeding in infancy']","['Cockayne syndrome, type B']","Disease: Cockayne syndrome, type B  
Reasoning:  
1. **Neurological/Craniofacial Features**: Microcephaly, intellectual disability, cerebellar hypoplasia, and bilateral intracerebral calcifications are hallmark neurological signs of Cockayne syndrome (CS). Sensorineural hearing impairment and microphthalmia/deeply set eyes align with CS-related sensory deficits.  
2. **Growth Abnormalities**: Postnatal growth retardation, short stature, and nasogastric tube feeding in infancy reflect severe growth failure, characteristic of CS type B.  
3. **Skeletal Dysplasia**: Scoliosis, kyphosis, limb joint contractures, and thickened calvaria correlate with CS-associated skeletal dysplasia and premature aging.  
4. **Dysmorphic Features**: High palate, convex nasal ridge, and macrotia are consistent with CS type B’s craniofacial phenotype.  
5. **Exclusion of Mimics**: Differentiated from type A (more severe, earlier onset) and type C (atypical presentation) by partial postnatal development and later symptom progression. Intracerebral calcifications and cerebellar hypoplasia distinguish CS from other progeroid disorders (e.g., Hutchinson-Gilford progeria)."
"['Sloping forehead', 'Bulbous nose', 'Intellectual disability', 'Seizure', 'Global brain atrophy', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Dysmorphisms**: Sloping forehead, bulbous nose, and tented upper lip vermilion align with characteristic facies described in TBCK syndrome.  
2. **Neurological Features**: Severe global developmental delay, intellectual disability, and seizures correlate with TBCK-associated central nervous system involvement.  
3. **Hypotonia**: Severe muscular hypotonia is a hallmark of the disorder, reflecting neuromuscular dysfunction.  
4. **Neuroimaging Findings**: Global brain atrophy supports a progressive neurodegenerative process linked to TBCK mutations.  
5. **Genetic Consistency**: The constellation of symptoms matches the phenotype of TBCK-related syndromes, caused by biallelic loss-of-function variants in the *TBCK* gene, which disrupts mTOR signaling and lysosomal function.  
6. **Exclusion of Mimics**: Features distinguish it from other hypotonia-associated disorders (e.g., Prader-Willi, Rett syndrome) by the unique facial gestalt and absence of metabolic/storage disease markers."
"['Tall stature', 'Arachnodactyly', 'Kyphoscoliosis', 'Crumpled ear', 'Abnormal eye morphology', 'Camptodactyly']","['Congenital contractural arachnodactyly/Contractural arachnodactyly, congenital']","Disease: Congenital contractural arachnodactyly (Beals syndrome)  
Reasoning:  
1. **Arachnodactyly + Camptodactyly**: Key features of congenital contractural arachnodactyly (CCA), distinguishing it from Marfan syndrome (which lacks fixed finger contractures).  
2. **Kyphoscoliosis**: Common in CCA due to connective tissue abnormalities affecting spinal development.  
3. **Crumpled ear**: A pathognomonic sign of CCA caused by abnormal cartilage folding.  
4. **Tall stature**: Overlaps with Marfan syndrome but supports a connective tissue disorder diagnosis.  
5. **Abnormal eye morphology**: May include microcornea, iris coloboma, or myopia, consistent with FBN2 gene-related ocular manifestations in CCA.  
6. **Absence of cardiovascular anomalies**: Helps exclude Marfan syndrome (FBN1-related) and Loeys-Dietz syndrome.  
7. **Genetic basis**: Linked to FBN2 mutations, confirming the diagnosis if genetic testing is performed."
"['Inguinal hernia', 'Vesicoureteral reflux', 'Nasolacrimal duct obstruction', 'Carious teeth', 'Hypertension', 'Cutis laxa', 'Mitral regurgitation', 'Bronchiectasis', 'Aortic root aneurysm', 'Tricuspid regurgitation', 'Epiphora', 'Flat sella turcica']","['Cutis laxa, autosomal recessive, type IA']","Disease: Cutis laxa, autosomal recessive, type IA (ARCL1A)  
Reasoning:  
1. **Cutis laxa**: Primary symptom indicating a genetic disorder affecting elastic fibers.  
2. **Aortic root aneurysm** and **mitral/tricuspid regurgitation**: Reflect systemic connective tissue weakness, common in ARCL1A due to mutations in *FBLN5*, critical for elastin assembly.  
3. **Inguinal hernia** and **bronchiectasis**: Connective tissue fragility leads to hernias and airway damage from impaired elastic recoil.  
4. **Nasolacrimal duct obstruction** and **epiphora**: Elastic fiber defects disrupt tear drainage structures.  
5. **Vesicoureteral reflux**: Bladder-ureter junction laxity from deficient elastin.  
6. **Hypertension**: May arise from vascular stiffness or renal involvement secondary to reflux.  
7. **Flat sella turcica**: Associated with connective tissue defects altering skull base structure.  
8. **Carious teeth**: Potential enamel/dentin abnormalities linked to *FBLN5* mutations.  
9. Exclusion of other subtypes (e.g., ARCL2 with skeletal dysplasia, ARCL3 with neurodevelopmental issues) solidifies ARCL1A diagnosis."
"['Myopia', 'Diplopia', 'Dry skin', 'Abnormality of the hand', 'Hyporeflexia', 'Abnormal foot morphology', 'Neutropenia', 'Steatorrhea', 'Upper airway obstruction', 'Arthralgia', 'Hyperventilation', 'Elevated circulating creatine kinase concentration', 'Airway obstruction', 'Lower limb amyotrophy', 'Upper limb pain', 'Dysesthesia', 'Foot pain', 'Abnormal vitamin B12 level', 'Lymphocytosis', 'Dyspepsia']","['Primary erythromelalgia/Erythermalgia, primary']","Disease: Primary erythromelalgia/Erythermalgia, primary  
Reasoning:  
1. **Foot pain** and **upper limb pain** align with the hallmark of erythromelalgia: episodic burning pain in extremities.  
2. **Dysesthesia** (abnormal burning/pricking sensations) supports neuropathic pain, a key feature of the disease.  
3. **Abnormal foot morphology** may reflect chronic vascular or tissue changes from recurrent inflammation.  
4. **Elevated creatine kinase (CK)** could indicate secondary muscle stress due to prolonged pain episodes.  
5. **Hyporeflexia** and **lower limb amyotrophy** suggest peripheral neuropathy, which may coexist with erythromelalgia.  

**Exclusions/Considerations:**  
- Symptoms like **neutropenia**, **lymphocytosis**, **steatorrhea**, and **abnormal B12** suggest unrelated systemic or metabolic conditions (e.g., autoimmune disorders, malabsorption).  
- **Airway obstruction**, **arthralgia**, and **myopia/diplopia** lack direct mechanistic links to erythromelalgia and may indicate comorbidities.  
- The absence of explicit ""erythema"" or ""warmth"" in symptoms could reflect documentation gaps or atypical presentation, but pain and dysesthesia remain diagnostically critical.  

**Conclusion:** Core features (extremity pain, dysesthesia) dominate, supporting primary erythromelalgia, while additional symptoms warrant investigation for overlapping or secondary conditions."
"['Sinusitis', 'Abnormal nasal mucosa morphology', 'Hypertension', 'Goiter', 'Mitral regurgitation', 'Ankle swelling', 'Weight loss', 'Fever', 'Exertional dyspnea', 'Generalized muscle weakness', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Abnormality of the pulmonary vasculature', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Peripheral edema', 'Cough', 'Ground-glass opacification', 'Night sweats', 'Knee pain', 'Toe pain', 'Abnormal CD4:CD8 ratio', 'Lymphocytosis']",['Antisynthetase syndrome'],"Antisynthetase Syndrome:  
1. **Autoimmune Features**: Antinuclear antibody (ANA) positivity indicates an underlying autoimmune process, a hallmark of antisynthetase syndrome.  
2. **Myositis**: Generalized muscle weakness, exercise intolerance, and exertional dyspnea suggest inflammatory muscle involvement (myositis), a core feature of antisynthetase syndrome.  
3. **Interstitial Lung Disease (ILD)**: Cough, exertional dyspnea, and ground-glass opacification on imaging align with ILD, a critical diagnostic criterion for antisynthetase syndrome.  
4. **Systemic Inflammation**: Elevated C-reactive protein (CRP), fever, night sweats, and weight loss reflect systemic inflammation common in this syndrome.  
5. **Arthritis**: Knee and toe pain suggest inflammatory arthritis, frequently associated with antisynthetase syndrome.  
6. **Vascular/Edema Findings**: Peripheral/pedal edema and pulmonary vasculature abnormalities may stem from secondary pulmonary hypertension or cardiac involvement (e.g., mitral regurgitation) due to chronic inflammation.  
7. **Lymphocyte Dysregulation**: Lymphocytosis and abnormal CD4:CD8 ratio support immune dysregulation, consistent with autoimmune-driven pathology.  
8. **Exclusion of Overlaps**: Symptoms like sinusitis and nasal mucosal abnormalities could overlap with granulomatosis with polyangiitis, but the triad of myositis, ILD, and arthritis prioritizes antisynthetase syndrome."
"['Spasticity', 'Dysarthria', 'Cerebellar atrophy', 'Dysphagia', 'Gait ataxia']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spasticity and gait ataxia**: Core features of hereditary spastic paraplegias (HSPs), indicating upper motor neuron dysfunction.  
2. **Cerebellar atrophy**: Suggests a ""complicated"" HSP subtype; SPG76 is associated with cerebellar degeneration.  
3. **Dysarthria and dysphagia**: Reflects brainstem/cerebellar involvement, aligning with SPG76's extrapyramidal and bulbar symptoms.  
4. **Autosomal recessive inheritance**: Matches SPG76's genetic pattern (CAPN1 mutations), distinguishing it from dominant HSPs (e.g., SPG4/SPAST) or mitochondrial disorders.  
5. **Exclusion of mimics**: Differentiated from spinocerebellar ataxias (SCAs) by predominant spasticity over cerebellar signs and from SPG7 (also cerebellar atrophy) by genetic testing for CAPN1."
"['Failure to thrive', 'Death in infancy', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Failure to thrive** in infancy occurs due to metabolic disruption, neurotoxicity, and impaired protein synthesis from elevated phenylalanine levels.  
3. **Death in infancy** (if untreated) aligns with severe, classic PKU, where untreated hyperphenylalaninemia causes irreversible brain damage, seizures, and multiorgan failure.  
4. PKU is autosomal recessive; symptoms manifest shortly after birth when phenylalanine intake begins (e.g., via breast milk/formula). Early dietary management prevents complications, explaining why untreated cases match the described fatal trajectory.  
5. Rarer differentials (e.g., BH4 deficiency) were excluded due to the absence of neurological features (e.g., dystonia, hypotonia) and normal tyrosine levels (implied by isolated hyperphenylalaninemia)."
"['Coma', 'Death in infancy', 'Hyperkalemia', 'Hyponatremia', 'Neonatal death', 'Respiratory acidosis', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acids**: SSADHD causes accumulation of γ-hydroxybutyrate (GHB), a carboxylic acid derivative, due to defective succinic semialdehyde dehydrogenase. This aligns with elevated urinary GHB (detected as a carboxylic acid).  
2. **Neurological symptoms (Coma)**: GHB is neurotoxic and a CNS depressant, leading to coma in severe neonatal presentations.  
3. **Respiratory acidosis**: CNS depression from GHB toxicity impairs respiratory drive, causing hypoventilation and CO₂ retention.  
4. **Hyperkalemia/Hyponatremia**: Secondary to metabolic dysregulation or renal tubular dysfunction in critically ill infants, though not a primary feature of SSADHD.  
5. **Early lethality (Neonatal death/Death in infancy)**: Severe enzyme deficiency leads to rapid toxic metabolite accumulation, resulting in life-threatening neurological and respiratory compromise.  
6. **Exclusion of other organic acidurias**: Symptoms align with SSADHD-specific markers (GHB elevation) rather than classic organic acidemias (e.g., propionic/methylmalonic acidemia), which typically present with metabolic acidosis and hyperammonemia."
"['Abnormality of the kidney', 'Wide mouth', 'Hypertelorism', 'Choanal atresia', 'Anteverted nares', 'Synophrys', 'Atypical behavior', 'Compulsive behaviors', 'Autistic behavior', 'Abnormal repetitive mannerisms', 'Anxiety', 'Delayed speech and language development', 'Global developmental delay', 'Abnormal heart morphology', 'Sleep disturbance', 'Expressive language delay', 'Scoliosis', 'Poor gross motor coordination', 'Localized hirsutism', 'Abnormal eye morphology', 'Separation insecurity']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental Core Features**: The patient exhibits global developmental delay, expressive language delay, delayed speech, autistic behavior, compulsive behaviors, abnormal repetitive mannerisms, and anxiety—all hallmark neurodevelopmental symptoms of NEDBEH.  
2. **Structural Anomalies**:  
   - **Heart**: Abnormal heart morphology aligns with the ""cardiac anomalies"" spectrum of NEDBEH.  
   - **Eye**: Hypertelorism, abnormal eye morphology, and synophrys (unibrow) suggest ocular involvement.  
   - **Other Craniofacial Features**: Wide mouth, anteverted nares, and choanal atresia are consistent with dysmorphic traits seen in NEDBEH.  
3. **Systemic Abnormalities**: Abnormality of the kidney and scoliosis fit the variable systemic anomalies associated with this disorder.  
4. **Behavioral/Motor Symptoms**: Poor gross motor coordination, sleep disturbances, and separation insecurity further support a complex neurodevelopmental etiology.  
5. **Exclusion of Overlap Syndromes**: While choanal atresia and heart defects may suggest CHARGE syndrome, the absence of coloboma, ear anomalies, and the prominence of autistic/compulsive behaviors favor NEDBEH. Similarly, synophrys and hirsutism could evoke Cornelia de Lange syndrome, but the lack of limb anomalies or growth restriction makes NEDBEH more likely.  
6. **Genetic Basis**: NEDBEH is often linked to de novo variants in genes like *BRD4* or *HNRNPU*, which disrupt neurodevelopment and organogenesis—consistent with the multisystemic presentation here.  

This diagnosis integrates the patient’s neurodevelopmental, craniofacial, cardiac, and renal findings into a single genetic framework, typical of NEDBEH."
"['Ptosis', 'Blue sclerae', 'Dentinogenesis imperfecta', 'Platyspondyly', 'Osteopenia', 'Intellectual disability', 'Motor delay', 'Growth delay', 'Premature rupture of membranes', 'Recurrent fractures', 'Bowing of limbs due to multiple fractures']","['Osteogenesis imperfecta, type XV']","Disease: Osteogenesis imperfecta, type XV  
Reasoning:  
1. **Recurrent fractures & bowing of limbs**: Hallmarks of osteogenesis imperfecta (OI), indicating bone fragility.  
2. **Dentinogenesis imperfecta**: Associated with OI types affecting collagen (e.g., types III, IV), but also reported in type XV due to WNT1 mutations impacting dentin formation.  
3. **Blue sclerae**: Common in OI (collagen defects), though less typical in type XV; may reflect severe underlying connective tissue dysplasia.  
4. **Platyspondyly & osteopenia**: Suggest defective bone mineralization and vertebral flattening, consistent with severe OI phenotypes.  
5. **Intellectual disability & motor delay**: Linked to WNT1 mutations (type XV etiology), as WNT signaling is critical for neurodevelopment.  
6. **Growth delay**: Expected in severe OI due to skeletal deformities and systemic growth impairment.  
7. **Premature rupture of membranes (PROM)**: Rarely reported in OI type XV, possibly from abnormal fetal connective tissues.  
8. **Ptosis**: May arise from neuromuscular involvement secondary to WNT1 dysfunction.  
**Conclusion**: The constellation of skeletal, dental, neurological, and connective tissue abnormalities aligns with OI type XV (WNT1-related), distinguishing it from classical collagen-based OI types."
"['High palate', 'Thin upper lip vermilion', 'Small anterior fontanelle', 'Hypertelorism', 'Macrotia', 'Anteverted nares', 'Ptosis', 'Death in infancy', 'Frontal bossing', 'Depressed nasal bridge', 'Short hallux', '1-5 finger syndactyly', '1-5 toe syndactyly', 'Bicoronal synostosis', 'Metopic synostosis', 'Midface retrusion']",['Apert syndrome/Apert syndrome'],"Disease: Apert syndrome  
Reasoning:  
1. **Craniosynostosis**: Bicoronal and metopic synostosis are hallmarks of Apert syndrome, causing frontal bossing and midface retrusion.  
2. **Midface Hypoplasia**: Depressed nasal bridge, hypertelorism, and anteverted nares align with characteristic midface underdevelopment.  
3. **Syndactyly**: 1-5 finger/toe syndactyly (""mitten hands/socks"") is pathognomonic for Apert syndrome.  
4. **Craniofacial Features**: High palate, thin upper lip vermilion, and ptosis are consistent with FGFR2 mutation-related dysmorphology.  
5. **Severe Prognosis**: Death in infancy may occur due to airway complications or severe cranial constraints.  
6. **Exclusion of Alternatives**: Features like macrotia and short hallux further support Apert over similar syndromes (e.g., Crouzon/Pfeiffer)."
"['Delayed speech and language development', 'Hyperhidrosis', 'Abnormality of prenatal development or birth', 'Lethargy', 'Motor delay', 'Obesity', 'Death in infancy', 'Hypoglycemia', 'Respiratory alkalosis', 'Hyperammonemia', 'Hypothermia', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Oroticaciduria', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline', 'Pustule', 'Acute hepatitis', 'Chronic hepatitis']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia, Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Hyperammonemia & Elevated Plasma Citrulline**: Core features of citrullinemia type I due to argininosuccinate synthetase (ASS1) deficiency, disrupting the urea cycle and causing citrulline accumulation.  
2. **Oroticaciduria**: Secondary to carbamoyl phosphate shunting into pyrimidine synthesis, a hallmark of urea cycle disorders.  
3. **Neonatal/Infantile Crisis**: Symptoms like lethargy, drowsiness, hypothermia, tachypnea, and respiratory alkalosis reflect acute hyperammonemic encephalopathy. Death in infancy/childhood aligns with severe untreated cases.  
4. **Hepatic Dysfunction**: Acute/chronic hepatitis and hypoglycemia suggest metabolic liver stress, common in urea cycle defects.  
5. **Neurological & Developmental Delays**: Motor delay, speech delays, and sleep disturbances result from chronic ammonia toxicity affecting the CNS.  
6. **Prenatal/Perinatal Abnormalities**: Intrauterine growth restriction or birth complications may occur due to metabolic derangements.  
7. **Hyperhidrosis & Pustules**: Possible secondary effects of metabolic acidosis or autonomic dysregulation.  
8. **Obesity**: Uncommon but reported in late-onset cases due to dietary management or metabolic adaptations.  

This constellation of urea cycle dysfunction, citrulline elevation, and multisystemic involvement confirms **citrullinemia type I**."
"['Macrocephaly', 'Cystic hygroma', 'Death in infancy', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria and elevated glutaric acid**: These are hallmark biochemical findings of GA-I, caused by a deficiency in glutaryl-CoA dehydrogenase (GCDH), disrupting lysine and tryptophan metabolism.  
2. **Macrocephaly**: A common early feature of GA-I, often due to frontotemporal atrophy or enlarged subdural spaces, creating the appearance of an enlarged head.  
3. **Death in infancy**: Untreated GA-I leads to acute metabolic crises (triggered by infections or fasting), resulting in striatal necrosis, dystonia, and severe neurological deterioration, which can be fatal in early childhood.  
4. **Cystic hygroma**: While not a typical feature of GA-I, it may represent a coincidental finding or a prenatal manifestation of fluid accumulation due to altered metabolic stress.  
5. **Exclusion of alternatives**: Glutaric acidemia type II (GA-II) presents with different metabolic profiles (e.g., multiple acyl-CoA dehydrogenase deficiency), and other macrocephaly-associated disorders (e.g., Sotos syndrome) lack the biochemical markers seen here.  

The combination of macrocephaly, glutaric aciduria, and metabolic derangement strongly supports GA-I as the primary diagnosis."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Key Symptom - Body Odor**: The presence of a distinctive sweet, maple syrup-like odor (often noted in urine, sweat, or cerumen) is pathognomonic for MSUD, caused by accumulation of branched-chain keto acids.  
2. **Neonatal Onset & Severe Outcomes**: Symptoms like feeding difficulties, lethargy, and generalized hypotonia appearing in infancy, alongside neonatal death or death in infancy, align with the classic severe form of MSUD, which manifests within days of birth if untreated.  
3. **Neurological Involvement**: Drowsiness, sleep disturbances, and hypotonia result from neurotoxicity due to elevated branched-chain amino acids (leucine, isoleucine, valine) and their keto-acid derivatives, which disrupt cerebral function.  
4. **Hyperammonemia**: Though not a primary feature of MSUD, secondary hyperammonemia can occur during metabolic crises due to liver dysfunction or catabolic stress overwhelming urea cycle capacity.  
5. **Metabolic Crisis**: The combination of lethargy, feeding difficulties, and rapid deterioration reflects acute metabolic decompensation, a hallmark of untreated MSUD.  

This pattern of symptoms, especially the characteristic odor and neonatal presentation, strongly supports MSUD as the diagnosis."
"['Hyperreflexia', 'Babinski sign', 'Lower limb hypertonia', 'obsolete Toe walking']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Upper Motor Neuron Dysfunction**: Symptoms like hyperreflexia, Babinski sign, and lower limb hypertonia indicate upper motor neuron involvement, consistent with hereditary spastic paraplegias (HSPs).  
2. **Spastic Paraplegia Hallmarks**: Lower limb hypertonia and toe walking align with progressive spasticity and gait abnormalities characteristic of HSPs.  
3. **Genetic Inheritance**: Autosomal recessive SPG76 is linked to biallelic *CAPN1* mutations, which disrupt axonal integrity, explaining the pyramidal tract signs (e.g., Babinski reflex).  
4. **Exclusion of Mimics**: The absence of sensory deficits, cognitive decline, or cerebellar signs supports a ""pure"" HSP diagnosis, narrowing it to SPG76 over complex HSP subtypes or acquired causes (e.g., spinal cord injury).  
5. **Toe Walking Context**: Persistent toe walking in older children/adults, combined with spasticity, is a compensatory adaptation to calf muscle stiffness, reinforcing HSP as the etiology."
"['High palate', 'Periodontitis', 'Hyperextensible skin', 'Bruising susceptibility', 'Molluscoid pseudotumors', 'Soft, doughy skin', 'Fragile skin', 'Poor wound healing', 'Intellectual disability', 'Motor delay', 'Neonatal hypotonia', 'Umbilical hernia', 'Redundant skin', 'Pes planus', 'Varicose veins', 'Neonatal respiratory distress', 'Scoliosis', 'Low back pain', 'Intermittent claudication', 'Recurrent thrombophlebitis', 'Knee dislocation', 'Chronic fatigue', 'Widened atrophic scar']","['Classical-like Ehlers-Danlos syndrome type 2/Ehlers-Danlos syndrome, classic-like, 2']","Disease: Classical-like Ehlers-Danlos syndrome type 2  
Reasoning:  
1. **Connective Tissue Manifestations**: Symptoms like *hyperextensible skin*, *fragile skin*, *soft doughy skin*, and *widened atrophic scars* align with collagen defects typical of Ehlers-Danlos syndromes (EDS).  
2. **Classic EDS Overlap**: *Molluscoid pseudotumors* (pressure-point lesions) and *poor wound healing* are hallmarks of classical EDS, but their presence in classical-like EDS type 2 (clEDS-2) suggests a related but distinct subtype.  
3. **Oral/Craniofacial Features**: *High palate* and *periodontitis* correlate with TNXB-related clEDS-2, where connective tissue fragility affects oral structures.  
4. **Musculoskeletal Involvement**: *Neonatal hypotonia*, *motor delay*, *pes planus*, *scoliosis*, *knee dislocation*, and *umbilical hernia* reflect systemic joint hypermobility and connective tissue weakness.  
5. **Vascular/Soft Tissue Signs**: *Bruising susceptibility*, *varicose veins*, and *recurrent thrombophlebitis* indicate vascular fragility, while *redundant skin* and *chronic fatigue* further support connective tissue dysfunction.  
6. **Developmental Considerations**: *Intellectual disability* and *neonatal respiratory distress*, though atypical in most EDS subtypes, are reported in clEDS-2 due to TNXB mutations affecting tenascin-X, which influences neural and tissue development.  
7. **Exclusion of Other Subtypes**: Absence of severe arterial rupture (ruling out vascular EDS) and presence of atrophic scars (less severe than classical EDS scarring) refine the diagnosis to clEDS-2.  

This constellation of symptoms, particularly the overlap of classic EDS features with unique neuromuscular and developmental elements, strongly supports **Classical-like EDS type 2**. Genetic testing for TNXB mutations would confirm the diagnosis."
"['Microcephaly', 'Seizure', 'Spastic tetraparesis', 'Dystonia', 'Absent speech', 'Dysphagia', 'Ventriculomegaly', 'Cerebral cortical atrophy', 'Hyperglycinemia', 'Delayed gross motor development', 'Poor head control', 'Abnormal cerebral white matter morphology', 'Hyperalaninemia', 'Decreased body weight', 'Delayed myelination', 'Absent posterior alpha rhythm']","['Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities']","Disease: Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities  
Reasoning:  
1. **Hyperalaninemia & Metabolic Dysregulation**: Elevated alanine (hyperalaninemia) suggests pyruvate metabolism dysfunction, a hallmark of mitochondrial disorders. This aligns with lactic acidosis (implied in the diagnosis), as impaired oxidative phosphorylation forces pyruvate conversion to lactate.  
2. **CNS Structural Abnormalities**: Ventriculomegaly, cerebral cortical atrophy, delayed myelination, and abnormal white matter morphology indicate severe brain developmental defects, consistent with energy-deficient states in mitochondrial encephalopathies.  
3. **Neurological Symptoms**: Spastic tetraparesis, dystonia, seizures, and absent speech reflect widespread cortical and subcortical damage from metabolic stress. Microcephaly and delayed motor development further support impaired neurodevelopment.  
4. **Supportive Findings**: Dysphagia, poor head control, and decreased body weight correlate with global neurological dysfunction. Absent posterior alpha rhythm on EEG underscores abnormal cortical activity.  
5. **Hyperglycinemia**: Likely secondary to metabolic crisis disrupting amino acid homeostasis, rather than primary glycine encephalopathy (NKH), given the broader metabolic context (lactic acidosis/hyperalaninemia).  

This constellation of metabolic derangements, structural brain anomalies, and severe neurological deficits strongly aligns with a diagnosis of neonatal severe mitochondrial encephalopathy with lactic acidosis."
"['Sinusitis', 'Eosinophilia', 'Dyspnea', 'Pulmonary infiltrates', 'Colitis', 'Elevated hepatic transaminase', 'Increased circulating IgE level', 'Elevated circulating creatine kinase concentration', 'Chronic oral candidiasis', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Decreased glomerular filtration rate', 'Bronchitis', 'Decreased mean corpuscular volume', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Reduced FEV1/FVC ratio', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Nasal polyposis']",['Eosinophilic granulomatosis with polyangiitis'],"Disease: Eosinophilic granulomatosis with polyangiitis (EGPA)  
Reasoning:  
1. **Eosinophilia and Sinusitis/Nasal Polyposis**: EGPA is characterized by eosinophilic inflammation and upper respiratory involvement, explaining chronic sinusitis and nasal polyps.  
2. **Asthma Spectrum (Dyspnea, Bronchitis, Reduced FEV1/FVC)**: The reduced FEV1/FVC ratio and recurrent bronchitis align with the asthma-like airway obstruction typical in early EGPA.  
3. **Pulmonary Infiltrates and Nodular HRCT Pattern**: Pulmonary infiltrates and nodular lesions on imaging reflect eosinophilic lung involvement and vasculitic granulomas.  
4. **Multisystem Involvement**:  
   - **Colitis**: Gastrointestinal tract inflammation due to eosinophilic infiltration.  
   - **Elevated Hepatic Transaminases**: Liver involvement from vasculitis or eosinophilic tissue damage.  
   - **Decreased GFR**: Renal impairment secondary to glomerulonephritis or vasculitis.  
5. **Autoimmune Antibody Positivity**: ANCA (commonly MPO-ANCA) is positive in ~40% of EGPA cases, supporting vasculitic pathology.  
6. **Inflammatory Markers (Elevated CRP, Neutrophilia)**: Systemic inflammation correlates with active vasculitis.  
7. **Elevated IgE/IgG4**: IgE elevation reflects allergic predisposition, while IgG4 may indicate a Th2-driven immunologic overlap.  
8. **Elevated Creatine Kinase**: Suggests muscle inflammation (myositis), a rare but documented feature of EGPA.  
9. **Chronic Oral Candidiasis/Low Vitamin D**: Potential sequelae of prolonged corticosteroid use (implied but not explicitly stated in history).  
10. **Exclusion of Mimics**: Elevated IgG4 and nodular lung lesions could suggest IgG4-related disease, but eosinophilia, asthma, and ANCA positivity favor EGPA.  

EGPA integrates asthma, eosinophilia, and vasculitis across multiple organs, satisfying the 2022 ACR/EULAR diagnostic criteria."
"['Mental deterioration', 'Pes cavus', 'Lactic acidosis', 'Elevated circulating creatinine concentration', 'Myalgia', 'Thenar muscle atrophy', 'Muscle spasm', 'Exercise intolerance', 'Percussion-induced rapid rolling muscle contractions', 'Involuntary movements', 'Intrinsic hand muscle atrophy', 'Distal upper limb muscle weakness', 'Calf muscle hypertrophy', 'Hand muscle atrophy', 'Fatigue', 'Finger flexor weakness']","['Distal myopathy, Tateyama type/Myopathy, distal, Tateyama type']","Disease: Distal myopathy, Tateyama type  
Reasoning:  
1. **Distal muscle weakness and atrophy**: Symptoms like intrinsic hand muscle atrophy, thenar atrophy, hand muscle atrophy, and finger flexor weakness align with distal myopathies, which primarily affect distal muscles. Tateyama type specifically targets distal upper limbs.  
2. **Calf muscle hypertrophy**: A recognized feature in some distal myopathies, including Tateyama type, often compensating for proximal weakness or reflecting fibrofatty replacement.  
3. **Percussion-induced rapid rolling contractions**: Suggests hyperirritable muscle membranes, a rare but reported finding in hereditary myopathies, including certain distal subtypes.  
4. **Exercise intolerance and lactic acidosis**: Indicates impaired mitochondrial energy production or glycolytic pathway dysfunction, common in metabolic myopathies. Tateyama type may involve secondary metabolic disturbances.  
5. **Mental deterioration**: Uncommon in classic distal myopathies, but chronic metabolic stress (e.g., persistent lactic acidosis) or rare CNS involvement in genetic variants could explain this.  
6. **Pes cavus**: Likely secondary to long-standing muscle imbalance and atrophy in distal limbs.  
7. **Elevated creatinine**: Reflects muscle breakdown (myopathy-related rhabdomyolysis) rather than primary renal dysfunction.  
8. **Involuntary movements and myalgia**: May arise from neuromuscular irritability or compensatory mechanisms in degenerating muscles.  

The combination of distal-predominant weakness, metabolic derangements, and unique features (e.g., calf hypertrophy, percussion-induced contractions) strongly supports Tateyama type, a rare hereditary distal myopathy linked to specific genetic or metabolic dysfunction."
"['Sensorineural hearing impairment', 'Increased circulating renin level', 'Hypotonia', 'Polyhydramnios', 'Hyperuricemia', 'Hypercalciuria', 'Hyponatremia', 'Hypochloremia', 'Metabolic alkalosis']","['Bartter syndrome, type 4A, neonatal, with sensorineural deafness']","Disease: Bartter syndrome, type 4A, neonatal, with sensorineural deafness  
Reasoning:  
1. **Metabolic alkalosis, hypochloremia, and hyponatremia** indicate renal salt-wasting, a hallmark of Bartter syndrome.  
2. **Hypercalciuria** and **hyperuricemia** align with defective electrolyte reabsorption in the thick ascending limb of Henle (TAL), consistent with Bartter syndrome.  
3. **Increased circulating renin** reflects secondary hyperreninemia due to chronic volume depletion from renal salt loss.  
4. **Polyhydramnios** is a prenatal feature of neonatal Bartter syndromes, caused by fetal polyuria.  
5. **Sensorineural hearing impairment** specifically points to type 4A (BSND gene mutation), which disrupts chloride transport in both the kidney and inner ear.  
6. **Hypotonia** in neonates is linked to electrolyte imbalances (e.g., hypokalemia, though not explicitly listed) and chronic volume depletion.  
7. Type 4A is distinguished from other Bartter subtypes (types 1-3) by the presence of deafness and mutations affecting the barttin protein, critical for renal and cochlear function."
"['Hepatic steatosis', 'Paraparesis', 'Abnormality of the upper limb', 'Elevated hepatic transaminase', 'Abnormal EKG', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Myalgia', 'Antinuclear antibody positivity', 'Atrial fibrillation', 'Coronary artery stenosis', 'Necrotizing myopathy', 'Left bundle branch block', 'Decreased glomerular filtration rate', 'Moderate proteinuria', 'Heavy proteinuria', 'Antimitochondrial antibody positivity', 'Elevated gamma-glutamyltransferase level', 'Increased circulating NT-proBNP concentration', 'Arterial stenosis']","['Polymyositis', 'Primary sclerosing cholangitis']","Disease: Polymyositis  
Reasoning: The patient presents with myalgia, elevated creatine kinase, and necrotizing myopathy, all indicative of muscle inflammation and damage. Antinuclear antibody (ANA) positivity supports an autoimmune etiology. Paraparesis and upper limb abnormalities align with proximal muscle weakness typical of polymyositis. Elevated creatinine, decreased glomerular filtration rate (GFR), and proteinuria may result from myoglobinuria secondary to muscle breakdown, linking renal dysfunction to rhabdomyolysis.  

Disease: Primary sclerosing cholangitis  
Reasoning: Hepatic involvement (hepatic steatosis, elevated transaminases, and gamma-glutamyltransferase) suggests cholestatic liver disease. While antimitochondrial antibody (AMA) positivity is classically associated with primary biliary cholangitis (PBC), the diagnosis of primary sclerosing cholangitis (PSC) may rely on imaging evidence of bile duct strictures. Elevated gamma-glutamyltransferase (GGT) and cholestatic enzyme patterns further support PSC. The coexistence of ANA and AMA could indicate overlap syndromes or atypical serology, but clinical and imaging findings take precedence in diagnosing PSC."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Hepatomegaly', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating creatine kinase concentration', 'Preeclampsia']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by defective carnitine transport due to mutations in the *SLC22A5* gene.  
2. **Hyperammonemia** and **hepatomegaly** arise from impaired fatty acid oxidation, leading to toxic metabolite accumulation and hepatic dysfunction.  
3. **Increased total bilirubin** reflects secondary liver injury from metabolic stress.  
4. **Abnormal circulating aspartate/alanine concentrations** suggest disrupted amino acid metabolism due to energy crisis in hepatocytes.  
5. **Elevated creatine kinase** indicates muscle damage from insufficient energy production in skeletal/cardiac muscle.  
6. **Gastrointestinal inflammation** may result from mitochondrial dysfunction in enterocytes.  
7. **Premature birth** and **preeclampsia** are maternal-fetal complications linked to placental insufficiency in maternal PCD.  
8. **Infancy/childhood mortality** correlates with untreated metabolic crises (hypoketotic hypoglycemia, cardiomyopathy) characteristic of PCD.  
9. Neonatal presentations align with the classic severe phenotype of early-onset PCD.  

The constellation of metabolic derangements, organ dysfunction, and carnitine deficiency strongly supports this diagnosis over urea cycle disorders or mitochondrial fatty acid oxidation defects."
"['Optic neuropathy', 'Elevated hepatic transaminase', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Focal white matter lesions', 'Reduced visual acuity', 'CSF polymorphonuclear pleocytosis', 'Lupus anticoagulant', 'Neck pain', 'Elevated gamma-glutamyltransferase level', 'CSF lymphocytic pleiocytosis']","['Antiphospholipid syndrome, familial']","Disease: Antiphospholipid syndrome, familial  
Reasoning:  
1. **Lupus anticoagulant** is a key laboratory marker for antiphospholipid syndrome (APS), indicating the presence of antiphospholipid antibodies.  
2. **Optic neuropathy** and **reduced visual acuity** suggest thrombosis in the retinal or optic nerve vasculature, a common neurological manifestation of APS.  
3. **Focal white matter lesions** likely represent cerebral microthromboses or ischemic infarcts due to hypercoagulability.  
4. **Elevated hepatic transaminases** and **gamma-glutamyltransferase (GGT)** may indicate hepatic vein thrombosis (Budd-Chiari syndrome), a thrombotic complication of APS.  
5. **CSF pleocytosis** (both polymorphonuclear and lymphocytic) could reflect inflammatory responses secondary to ischemic brain injury or cerebral venous thrombosis.  
6. **Neck pain** may arise from cervical artery or venous thrombosis, a thrombotic event consistent with APS.  
7. **Hypercholesterolemia** and **elevated LDL** may exacerbate thrombotic risk, aligning with the familial presentation of APS where comorbid metabolic disorders could coexist.  
8. The **familial** designation implies a genetic predisposition, supported by recurrent thrombosis and laboratory criteria (persistent lupus anticoagulant) in family members.  

This constellation of multi-organ thrombotic events, serological evidence, and familial pattern confirms the diagnosis."
"['Talipes equinovarus', 'Short humerus', 'Multiple prenatal fractures', 'Short lower limbs', 'Bowing of the long bones']","['Osteogenesis imperfecta, type IX']","Disease: Osteogenesis imperfecta, type IX  
Reasoning:  
1. **Multiple prenatal fractures** are a hallmark of severe Osteogenesis Imperfecta (OI), particularly types with early-onset skeletal fragility.  
2. **Short humerus** and **short lower limbs** indicate impaired bone growth and remodeling, consistent with OI-related collagen defects.  
3. **Bowing of the long bones** suggests repeated fractures and abnormal bone formation during development, a feature seen in severe OI subtypes.  
4. **Talipes equinovarus** (clubfoot) is associated with connective tissue abnormalities and intrauterine limb positioning due to bone fragility.  
5. OI type IX is caused by biallelic *PPIB* mutations, leading to defective collagen post-translational modification. This subtype aligns with severe prenatal presentation, fractures, and disproportionate limb shortening.  
6. Exclusion of other OI types (e.g., type II is typically lethal neonatally; type III has progressive deforming features but distinct genetic causes)."
"['Urinary incontinence', 'Spastic paraplegia', 'Dysarthria', 'Brisk reflexes', 'Spastic gait', 'Difficulty walking', 'Babinski sign', 'Pes valgus']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core HSP Features**: Spastic paraplegia, spastic gait, difficulty walking, brisk reflexes, and Babinski sign are hallmark signs of hereditary spastic paraplegia (HSP), indicating upper motor neuron dysfunction.  
2. **Urinary Incontinence**: Common in HSP due to spinal cord involvement disrupting bladder control.  
3. **Dysarthria**: Suggests possible bulbar or cerebellar involvement, observed in some HSP subtypes, including SPG76.  
4. **Pes Valgus**: May arise from altered muscle tone or peripheral neuropathy, occasionally linked to HSP.  
5. **Autosomal Recessive Inheritance**: Matches SPG76’s genetic pattern (CAPN1 mutations), distinguishing it from dominant or X-linked HSP subtypes.  
6. **Exclusion of Mimics**: Symptoms align with SPG76’s progressive phenotype, ruling out acquired causes (e.g., spinal cord compression) and other HSP subtypes with overlapping features (e.g., SPG11/SPG15, which often include cognitive decline or thin corpus callosum)."
"['Progressive microcephaly', 'Pectus carinatum', 'Hypertrichosis', 'Seizure', 'Flexion contracture', 'Failure to thrive', 'Rocker bottom foot', 'Kyphosis', 'Babinski sign', 'Joint hyperflexibility', 'Abnormality of somatosensory evoked potentials', 'Palmoplantar hyperhidrosis', 'Increased muscle glycogen content', 'Abnormal activity of mitochondrial respiratory chain', 'Brain atrophy', 'Delayed myelination', 'Moderate hearing impairment']","['PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies']","Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Progressive microcephaly**: A hallmark of PLAA-associated disorder, aligning with the disease’s defining feature of progressive reduction in head circumference due to impaired brain growth.  
2. **Brain atrophy/Delayed myelination**: Consistent with brain anomalies described in the disorder, reflecting neurodegeneration and disrupted white matter development.  
3. **Seizures**: Commonly reported in PLAA-related neurodevelopmental dysfunction due to cortical hyperexcitability.  
4. **Babinski sign/Flexion contractures**: Indicate upper motor neuron involvement and spasticity, core features of the disorder.  
5. **Failure to thrive**: Linked to global developmental delay and metabolic dysregulation seen in PLAA mutations.  
6. **Rocker bottom foot/Kyphosis/Pectus carinatum**: Suggest skeletal involvement, which may arise from connective tissue or neuromuscular abnormalities secondary to PLAA dysfunction.  
7. **Abnormality of somatosensory evoked potentials**: Correlates with delayed myelination and disrupted sensory pathways.  
8. **Increased muscle glycogen content/Abnormal mitochondrial activity**: PLAA’s role in protein homeostasis may indirectly impair glycogen metabolism and mitochondrial function.  
9. **Hypertrichosis/Palmoplantar hyperhidrosis**: Rare but reported ectodermal features in neurogenetic disorders, possibly due to autonomic dysregulation.  
10. **Joint hyperflexibility**: Contrasts with spasticity but may reflect heterogeneous connective tissue effects.  
11. **Moderate hearing impairment**: Could stem from central auditory pathway deficits or neurodegeneration.  

The constellation of progressive microcephaly, spasticity, brain anomalies, and metabolic disturbances strongly supports PLAA-associated disorder, with other symptoms representing secondary multisystemic involvement."
"['Macroglossia', 'Wide nasal bridge', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Areflexia', 'Generalized hypotonia', 'Death in infancy', 'Abnormal foot morphology', 'Pneumonia', 'Difficulty walking', 'Kyphoscoliosis', 'Skeletal muscle atrophy', 'Abdominal distention', 'Difficulty climbing stairs', 'Death in childhood', 'Ichthyosis', 'Difficulty running', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Elevated circulating phytanic acid concentration', 'Death in adolescence', 'Severe hearing impairment']",['Refsum disease/Refsum disease'],"Disease: Refsum disease  
Reasoning:  
1. **Elevated circulating phytanic acid concentration**: Pathognomonic for Refsum disease due to impaired alpha-oxidation from PHYH/PEX7 mutations.  
2. **Ichthyosis**: A hallmark feature linked to lipid metabolism dysfunction.  
3. **Ataxia, Areflexia, Motor delay, Difficulty walking/climbing stairs**: Caused by peripheral neuropathy and cerebellar degeneration, common in Refsum disease.  
4. **Severe hearing impairment**: Sensorineural hearing loss is a frequent neurological manifestation.  
5. **Skeletal muscle atrophy, Generalized hypotonia**: Secondary to chronic neuropathy and metabolic myopathy.  
6. **Kyphoscoliosis, Abnormal foot morphology**: Result from progressive neuromuscular deficits.  
7. **Death in infancy/childhood/adolescence**: Severe or untreated cases can lead to early mortality due to respiratory complications (e.g., pneumonia) or cardiac arrhythmias.  
8. **Macroglossia, Wide nasal bridge**: Less typical but occasionally reported in atypical/peroxisomal spectrum presentations.  
9. **Abdominal distention**: May reflect autonomic neuropathy or hepatomegaly from lipid accumulation.  

Key exclusions: Symptoms like intellectual disability and neonatal death are more common in Zellweger spectrum disorders, but Refsum disease is prioritized here due to phytanic acid elevation and core neurological/cutaneous features."
"['Omphalocele', 'Intestinal obstruction', 'Intestinal atresia']",['Combined immunodeficiency-enteropathy spectrum/Gastrointestinal defects and immunodeficiency syndrome'],"Combined immunodeficiency-enteropathy spectrum/Gastrointestinal defects and immunodeficiency syndrome:  
- **Omphalocele** suggests a congenital midline abdominal wall defect, often linked to genetic syndromes affecting development.  
- **Intestinal atresia/obstruction** indicates structural gastrointestinal abnormalities, commonly seen in disorders like TTC7A-related syndromes, which disrupt intestinal and immune system development.  
- The co-occurrence of these defects with **immunodeficiency** points to a genetic etiology (e.g., TTC7A, FOXP3, or IL2RG mutations) causing both enteropathy and impaired immune cell function.  
- This triad aligns with syndromes in the combined immunodeficiency-enteropathy spectrum, where gastrointestinal malformations and immune dysfunction arise from shared molecular pathways."
"['Renal insufficiency', 'Trigonocephaly', 'Low-set ears', 'Microphthalmia', 'Hypotelorism', 'Ectropion', 'Natal tooth', 'Hepatosplenomegaly', 'Failure to thrive', 'Intrauterine growth retardation', 'Pes planus', 'Premature rupture of membranes', 'Thrombocytopenia', 'Neutropenia', 'Lymphopenia', 'Vomiting', 'Pyloric stenosis', 'Pneumonia', 'Hypophosphatemia', 'Hypocalcemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Congenital ichthyosiform erythroderma', 'Congenital nonbullous ichthyosiform erythroderma', 'Ichthyosis', 'Bilateral cryptorchidism', 'Eclabion']","['Trichothiodystrophy 3, photosensitive']","Disease: Trichothiodystrophy 3, photosensitive  
Reasoning:  
1. **Cutaneous Features**: The presence of congenital ichthyosiform erythroderma, ichthyosis, and eclabion aligns with the hallmark skin manifestations of trichothiodystrophy (TTD), a disorder characterized by sulfur-deficient brittle hair and photosensitivity. While hair abnormalities are not explicitly listed, the ichthyosiform erythroderma strongly suggests TTD.  
2. **Craniofacial Abnormalities**: Trigonocephaly, microphthalmia, hypotelorism, ectropion, and low-set ears reflect neuroectodermal dysplasia, consistent with TTD’s association with developmental defects. Natal teeth may indicate ectodermal involvement.  
3. **Growth and Metabolic Issues**: Intrauterine growth retardation, failure to thrive, hypoalbuminemia, and hypoproteinemia correlate with TTD’s systemic impact on nutrient absorption and metabolic dysfunction, often linked to DNA repair deficits.  
4. **Hematologic Dysfunction**: Neutropenia, lymphopenia, and thrombocytopenia suggest bone marrow involvement, plausible in TTD due to impaired DNA repair affecting rapidly dividing cells.  
5. **Hepatosplenomegaly and Renal Insufficiency**: May stem from metabolic derangements or progressive organ dysfunction in severe TTD phenotypes.  
6. **Photosensitivity**: Implicit in the diagnosis (subtype “photosensitive”), though not explicitly listed, is a key feature of TTD caused by mutations in DNA repair genes (e.g., ERCC2/XPD).  
7. **Miscellaneous Features**: Cryptorchidism and pyloric stenosis, while less typical, may occur in multisystem genetic syndromes. Pneumonia likely results from immunodeficiency secondary to neutropenia.  

The constellation of ectodermal, craniofacial, hematologic, and growth abnormalities, anchored by ichthyosiform erythroderma and implied photosensitivity, confirms the diagnosis of photosensitive TTD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine. Elevated phenylalanine levels are toxic to the brain.  
- **Abnormality of prenatal development or birth**: Maternal PKU (untreated during pregnancy) can cause congenital abnormalities (e.g., microcephaly, cardiac defects) in the fetus due to phenylalanine toxicity. If the patient is the affected infant, severe untreated PKU may manifest as developmental disruptions.  
- **Hypertyrosinemia**: While classic PKU typically results in *low* tyrosine (due to blocked PAH activity), transient hypertyrosinemia may occur in neonates with immature liver function or secondary to metabolic stress. Alternatively, this could indicate a coexisting or misclassified metabolic disorder (e.g., tyrosinemia type II), but PKU remains the primary diagnosis given hyperphenylalaninemia.  
- **Neonatal death/Death in infancy/childhood**: Untreated PKU leads to progressive neurological damage, seizures, and failure to thrive. Severe cases (e.g., malignant PKU or complete PAH deficiency) can result in early mortality without dietary intervention. Newborn screening and dietary management typically prevent this outcome, but historical or undiagnosed cases may present with fatal complications.  

**Note**: Hypertyrosinemia is atypical for PKU and warrants investigation for concurrent disorders (e.g., tyrosinemia, liver dysfunction) or assay errors. However, hyperphenylalaninemia and the clinical trajectory strongly prioritize PKU as the diagnosis."
"['Ptosis', 'Proptosis', 'Waddling gait', 'Bone pain', 'Arthralgia', 'Abnormal EKG', 'Elevated circulating alkaline phosphatase concentration', 'Skeletal muscle atrophy', 'Humeral cortical thickening', 'Prominent forehead', 'Abnormal circulating creatinine concentration', 'Cognitive impairment', 'Hyperostosis']",['Camurati-Engelmann disease/Camurati-Engelmann disease'],"Disease: Camurati-Engelmann disease  
Reasoning:  
1. **Hyperostosis**: A hallmark feature, evident in the humeral cortical thickening and skull involvement (proptosis, ptosis, prominent forehead).  
2. **Bone pain/Arthralgia**: Caused by progressive cortical bone thickening and medullary cavity narrowing.  
3. **Elevated alkaline phosphatase**: Reflects increased bone remodeling.  
4. **Waddling gait/Skeletal muscle atrophy**: Secondary to bone deformities and muscle weakness from nerve compression or reduced mobility.  
5. **Cranial manifestations**: Skull hyperostosis leads to proptosis (bulging eyes), ptosis (eyelid droop), and prominent forehead.  
6. **Abnormal EKG/Cognitive impairment**: Rare complications due to cranial hyperostosis compressing vasculature or neural structures.  
7. **Abnormal creatinine**: May arise from reduced muscle mass (atrophy) or secondary renal effects of chronic disease.  

The combination of skeletal hyperostosis, cranial abnormalities, and systemic markers aligns definitively with Camurati-Engelmann disease."
"['Intellectual disability', 'Ataxia', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Pancreatitis', 'Thrombocytopenia', 'Abnormal erythrocyte morphology', 'Leukopenia', 'Metabolic acidosis', 'Dehydration', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Kyphoscoliosis', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Methylmalonic aciduria', 'Severe hearing impairment', 'Sepsis']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: The patient exhibits *methylmalonic acidemia* and *methylmalonic aciduria*, hallmarks of methylmalonyl-CoA mutase deficiency. Elevated methylmalonic acid disrupts the propionate pathway, leading to metabolic crises.  
2. **Metabolic derangements**: Symptoms like *metabolic acidosis*, *hyperammonemia*, *increased serum lactate*, and *hyperglycinemia* align with impaired mitochondrial energy metabolism and toxic metabolite accumulation.  
3. **Organ system involvement**:  
   - **Neurological**: *Intellectual disability*, *ataxia*, *motor delay*, and *hypotonia* result from chronic neurotoxicity due to methylmalonic acid and ammonia.  
   - **Hematological**: *Thrombocytopenia*, *leukopenia*, and *abnormal erythrocyte morphology* stem from bone marrow suppression caused by metabolic stress.  
   - **Renal**: *Elevated creatinine*, *increased blood urea nitrogen*, and *hyperuricemia* indicate renal tubular dysfunction and acute kidney injury.  
4. **Systemic complications**: *Feeding difficulties*, *dehydration*, *gastrointestinal inflammation*, and *recurrent infections* (e.g., pneumonia, sepsis) reflect global metabolic instability and immune dysfunction.  
5. **Early mortality**: *Neonatal death*, *death in infancy/childhood/adolescence* are consistent with severe, B12-unresponsive MMA variants, where metabolic decompensation is irreversible without liver transplantation.  
6. **Carnitine/porphyrin abnormalities**: Secondary *abnormal carnitine* and *porphyrin levels* arise due to mitochondrial dysfunction and disrupted heme synthesis.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria (General Diagnosis)  
Reasoning:  
- **Clinical confirmation**: The presence of *methylmalonic acidemia* and *aciduria* in symptomology directly supports this overarching diagnosis.  
- **Phenotypic spectrum**: Symptoms like *obesity*, *kyphoscoliosis*, and *severe short stature* suggest chronic multisystemic disease progression, while *hyperalaninemia* and *hypoproteinemia* point to amino acid metabolism dysregulation.  
- **Diagnostic exclusion**: Lack of responsiveness to B12 supplementation (implied by the severity and early mortality) differentiates this from B12-responsive subtypes.  

The patient’s presentation is pathognomonic for **severe, mutase-deficient MMA**, characterized by enzymatic defects in methylmalonyl-CoA mutase, leading to catastrophic metabolic failure and early mortality."
"['Platyspondyly', 'Intellectual disability, mild', 'Hepatosplenomegaly', 'Abnormality of extrapyramidal motor function', 'Decreased beta-galactosidase activity', 'Cherry red spot of the macula']","['GM1-gangliosidosis, type III', 'GM1 gangliosidosis type 3']","Disease: GM1-gangliosidosis, type III / GM1 gangliosidosis type 3  
Reasoning:  
1. **Decreased beta-galactosidase activity** is a hallmark of GM1-gangliosidosis, directly linking to the enzymatic defect in this lysosomal storage disorder.  
2. **Cherry red spot of the macula** is a classic ocular finding in GM1-gangliosidosis due to ganglioside accumulation in retinal neurons.  
3. **Hepatosplenomegaly** reflects visceral involvement from substrate storage (glycoproteins/oligosaccharides) in lysosomes.  
4. **Platyspondyly** (flattened vertebrae) indicates skeletal dysplasia, a feature of chronic/subacute forms (type II/III) of GM1-gangliosidosis.  
5. **Mild intellectual disability** and **extrapyramidal motor dysfunction** correlate with progressive, later-onset neurodegeneration in type III, sparing severe cognitive decline seen in infantile (type I) cases.  
6. Type III aligns with partial enzyme activity, explaining slower progression and milder symptoms compared to earlier-onset subtypes."
"['Enlarged kidney', 'Ptosis', 'Photophobia', 'Lethargy', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Congestive heart failure', 'Exocrine pancreatic insufficiency', 'Thrombocytopenia', 'Neutropenia', 'Anemia', 'Acute kidney injury', 'Hypoglycemia', 'Renal Fanconi syndrome', 'Vomiting', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', '3-Methylglutaric aciduria', 'Increased serum pyruvate', 'Neonatal death', 'Death in childhood', 'Short stature', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Abnormal circulating monocarboxylic acid concentration', 'Localized skin lesion', 'Feeding difficulties', 'Chronic kidney disease', 'Elevated urinary 3-hydroxybutyric acid']",['Pearson syndrome/Pearson syndrome/Pearson marrow-pancreas syndrome'],"Disease: Pearson syndrome  
Reasoning:  
1. **Hematological Abnormalities**: Thrombocytopenia, neutropenia, and anemia align with Pearson syndrome’s hallmark sideroblastic bone marrow failure.  
2. **Exocrine Pancreatic Dysfunction**: Exocrine pancreatic insufficiency directly correlates with pancreatic involvement in Pearson syndrome.  
3. **Metabolic Derangements**: Elevated serum lactate, pyruvate, and urinary 3-hydroxybutyric acid indicate mitochondrial dysfunction, a core feature of Pearson syndrome. Hypoglycemia and 3-methylglutaric aciduria further support disrupted energy metabolism.  
4. **Renal Involvement**: Renal Fanconi syndrome, acute/chronic kidney injury, and enlarged kidney reflect mitochondrial nephropathy common in mitochondrial disorders.  
5. **Neurological Symptoms**: Ptosis, generalized hypotonia, lethargy, coma, and drowsiness suggest systemic mitochondrial failure affecting neuromuscular and CNS function.  
6. **Early Mortality**: Neonatal death, death in infancy/childhood, and short stature are consistent with the severe, multisystemic nature of Pearson syndrome.  
7. **Immune Vulnerability**: Recurrent viral infections arise from neutropenia due to bone marrow failure.  
8. **Cardiac and Nutritional Issues**: Congestive heart failure (mitochondrial cardiomyopathy) and feeding difficulties reflect multisystemic deterioration.  
9. **Biochemical Markers**: Decreased plasma free carnitine and abnormal monocarboxylic acids are typical of mitochondrial fatty acid oxidation defects.  

Pearson syndrome uniquely integrates bone marrow failure, pancreatic insufficiency, and renal/metabolic crises in infancy, distinguishing it from other mitochondrial disorders like Leigh syndrome or MELAS."
"['Renal insufficiency', 'Renal cyst', 'Microcephaly', 'Cyanosis', 'Partial agenesis of the corpus callosum', 'Death in infancy', 'Ventricular septal defect', 'Truncus arteriosus', 'Abnormal cardiac septum morphology', 'Overlapping toe', 'Pulmonary artery atresia', 'Persistent left superior vena cava', 'Generalized edema', 'Polydactyly', 'Partial anomalous pulmonary venous return', 'Interrupted aortic arch', 'Tricuspid atresia', 'Right aortic arch', 'Anasarca', 'Tetralogy of Fallot with pulmonary atresia', 'Heart murmur', 'Systolic heart murmur', 'Oliguria']",['Structural heart defects and renal anomalies syndrome'],"Structural heart defects and renal anomalies syndrome:  
1. **Cardiac anomalies**: The patient exhibits multiple severe congenital heart defects, including ventricular septal defect, truncus arteriosus, tetralogy of Fallot with pulmonary atresia, tricuspid atresia, interrupted aortic arch, and right aortic arch. These structural abnormalities align with the ""structural heart defects"" component of the syndrome.  
2. **Renal involvement**: Renal insufficiency, renal cysts, and oliguria indicate significant kidney dysfunction, fulfilling the ""renal anomalies"" criterion.  
3. **Supporting features**: Microcephaly, partial agenesis of the corpus callosum, and polydactyly suggest a syndromic genetic etiology. Overlapping toes, persistent left superior vena cava, and anomalous pulmonary venous return further support a multisystem developmental disorder.  
4. **Severity and prognosis**: Death in infancy, generalized edema (anasarca), and cyanosis reflect the life-threatening nature of the cardiac and renal defects, typical of this syndrome.  
This pattern matches a rare congenital disorder linking complex heart malformations with renal dysplasia, often caused by genetic or epigenetic disruptions in embryogenesis."
"['Micrognathia', 'Ptosis', 'Hypertension', 'Areflexia', 'Lumbar hyperlordosis', 'Elbow flexion contracture', 'Hyperlipidemia', 'Absence of subcutaneous fat', 'Prematurely aged appearance', 'Plantar flexion contracture', 'Proximal muscle weakness in lower limbs', 'Difficulty running']","['Emery-Dreifuss muscular dystrophy 3, autosomal recessive']","Disease: Emery-Dreifuss muscular dystrophy 3, autosomal recessive  
Reasoning:  
1. **Elbow/plantar flexion contractures**: Hallmark features of EDMD, caused by progressive fibrosis and tendon shortening.  
2. **Proximal muscle weakness in lower limbs/difficulty running**: Consistent with muscular dystrophy-related myopathy.  
3. **Lumbar hyperlordosis**: Compensatory posture due to pelvic muscle weakness and contractures.  
4. **Hypertension**: Suggests cardiac involvement (e.g., cardiomyopathy or arrhythmias), common in EDMD.  
5. **Prematurely aged appearance/absence of subcutaneous fat**: Linked to *LMNA* gene mutations causing laminopathies, which include lipodystrophy and progeroid features in recessive EDMD3.  
6. **Areflexia**: Secondary to muscle degeneration rather than neuropathy.  
7. **Micrognathia/ptosis**: Rarely reported in laminopathies but may occur due to craniofacial muscle involvement.  
8. **Hyperlipidemia**: Associated with lipodystrophy in *LMNA*-related disorders.  
The triad of **contractures, progressive muscle weakness, and cardiac complications** with autosomal recessive inheritance and progeroid/lipodystrophy signs confirms EDMD3."
"['Macrocephaly', 'Generalized hypotonia', 'Death in infancy', 'Abnormal cerebral morphology', 'Increased serum lactate', 'Hypercalcemia', 'Glutaric aciduria', 'Abnormal circulating lysine concentration', 'Abnormal circulating carnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** and **abnormal lysine/carnitine concentrations** directly indicate a defect in lysine, hydroxylysine, and tryptophan metabolism, consistent with glutaryl-CoA dehydrogenase deficiency.  
2. **Macrocephaly** and **abnormal cerebral morphology** (e.g., frontotemporal atrophy, subdural hemorrhages) are hallmark neurological features of GA-I.  
3. **Generalized hypotonia** aligns with metabolic encephalopathy and striatal injury caused by toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
4. **Increased serum lactate** suggests secondary mitochondrial dysfunction due to inhibition of the electron transport chain by organic acids.  
5. **Hypercalcemia** may result from renal tubular dysfunction secondary to chronic metabolic acidosis or vitamin D dysregulation in metabolic crises.  
6. **Death in infancy** reflects the high mortality risk during acute metabolic decompensation episodes if untreated.  
7. **Abnormal carnitine levels** occur due to secondary carnitine depletion from conjugation/excretion of glutaric acid.  

GA-I is confirmed by genetic testing for *GCDH* mutations or deficient glutaryl-CoA dehydrogenase enzyme activity. Early diagnosis and metabolic management (e.g., lysine-restricted diet, carnitine supplementation) are critical to prevent neurological damage."
"['Obesity', 'Death in infancy', 'Coarctation of aorta', 'Fever', 'Pneumonia', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants (e.g., BH4 deficiency) or secondary metabolic disruptions from untreated phenylalanine toxicity.  
3. **Early mortality** (infancy/childhood/adolescence) aligns with severe, untreated PKU, where neurotoxicity, seizures, and organ failure lead to premature death without dietary intervention.  
4. **Obesity** may reflect poor dietary management (high-carbohydrate/low-protein diets) or metabolic dysregulation.  
5. **Coarctation of the aorta** and **pneumonia/fever** are likely incidental or secondary complications (e.g., immune vulnerability due to chronic metabolic stress).  
6. **Neonatal death** suggests an acute presentation, though rare in isolated PKU, potentially indicating comorbid conditions or diagnostic delays.  

Key exclusion: Tyrosinemia type I (hypertyrosinemia + liver/kidney symptoms) and other metabolic disorders were considered but excluded due to the primary hyperphenylalaninemia and stated diagnosis."
"['Microcephaly', 'Cyanosis', 'Edema', 'Neonatal hypotonia', 'Death in infancy', 'Truncus arteriosus', 'Abnormal facial shape', 'Elevated circulating creatinine concentration', 'Pulmonary artery atresia', 'Persistent left superior vena cava', 'Generalized edema', 'Partial anomalous pulmonary venous return', 'Interrupted aortic arch', 'Tricuspid atresia', 'Right aortic arch', 'Tetralogy of Fallot with pulmonary atresia', 'Heart murmur', 'Systolic heart murmur', 'Aortopulmonary collateral arteries']",['Structural heart defects and renal anomalies syndrome'],"Disease: Structural heart defects and renal anomalies syndrome  
Reasoning:  
1. **Cardiac Anomalies**: Multiple severe congenital heart defects are present, including truncus arteriosus, tetralogy of Fallot with pulmonary atresia, interrupted aortic arch, tricuspid atresia, and aortopulmonary collaterals. These collectively explain symptoms like cyanosis, heart murmurs, and systolic murmurs due to impaired blood flow and mixing of oxygenated/deoxygenated blood.  
2. **Renal Involvement**: Elevated creatinine indicates renal dysfunction, a key feature of the syndrome. Edema (generalized and localized) may result from combined cardiac failure and renal fluid retention.  
3. **Dysmorphic Features**: Microcephaly and abnormal facial shape suggest a developmental/genetic etiology, aligning with syndromic diagnoses that involve multi-organ malformations.  
4. **Early Lethality**: Neonatal hypotonia, critical cardiac defects, and death in infancy reflect the syndrome’s severity, typical of disorders disrupting essential organogenesis.  
5. **Genetic Basis**: The constellation of cardiac, renal, and craniofacial anomalies points to a rare genetic syndrome affecting neural crest-derived structures (heart, great vessels) and renal development, though specific gene mutations (e.g., *NKX2-5*, *NOTCH1*, or chromatin regulators) may require further testing."
"['Strabismus', 'Irritability', 'Hyporeflexia', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Athetosis', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal circulating aspartate family amino acid concentration**: Canavan disease is caused by ASPA gene mutations, leading to aspartoacylase deficiency. This enzyme breaks down N-acetylaspartate (NAA), resulting in elevated NAA levels, a hallmark biochemical marker.  
2. **Neurological symptoms (Strabismus, Opisthotonus, Athetosis)**: Accumulated NAA causes spongy brain degeneration, damaging white matter and motor pathways. Strabismus arises from cranial nerve dysfunction, while opisthotonus (severe hypertonia) and athetosis (involuntary movements) reflect basal ganglia and motor pathway injury.  
3. **Hyporeflexia**: Progressive white matter destruction impairs neural signaling, reducing reflex responses.  
4. **Irritability**: Early neurological deterioration in infants manifests as irritability due to cerebral dysfunction.  
5. **Death in infancy**: Severe infantile-onset Canavan disease rapidly progresses, with life expectancy rarely beyond childhood.  
6. **Hyperammonemia**: Though atypical, disrupted aspartate metabolism (linked to urea cycle intermediates) may secondarily elevate ammonia. This aligns with the abnormal aspartate family amino acids noted, suggesting metabolic crossover effects.  

Conclusion: The constellation of neurological deficits, biochemical abnormalities (elevated NAA), and early lethality strongly support Canavan disease. Hyperammonemia, while uncommon, may arise indirectly from metabolic dysregulation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Neonatal death/death in infancy**: MCADD typically presents in infancy during metabolic stress (e.g., fasting), leading to life-threatening hypoglycemia and energy depletion.  
2. **Vomiting & gastrointestinal inflammation**: Episodic metabolic crises in MCADD cause nausea, vomiting, and gut dysfunction due to toxic metabolite accumulation (e.g., medium-chain acylcarnitines).  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs as excess unmetabolized fatty acids bind carnitine, forming acylcarnitines.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: While MCADD primarily involves medium-chain acyl-CoA dehydrogenase (MCAD), downstream β-oxidation enzymes like 3-hydroxyacyl-CoA dehydrogenase may show reduced activity due to substrate accumulation.  
5. **Prenatal abnormalities**: Though less common, severe MCADD variants may manifest prenatally as reduced fetal movement or growth restriction from impaired fatty acid metabolism.  

Key confirmation would require genetic testing for *ACADM* gene mutations and elevated C6-C10 acylcarnitines on tandem mass spectrometry."
"['Renal insufficiency', 'Renal hypoplasia', 'Focal segmental glomerulosclerosis', 'Hypothyroidism', 'Anemia', 'Diarrhea', 'Hyperkalemia', 'Hypoalbuminemia', 'Increased blood urea nitrogen', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatinine concentration', 'Decreased glomerular filtration rate', 'Mild proteinuria', 'Low levels of vitamin D', 'Papule']",['Fabry disease/Fabry disease/Fabry disease'],"Disease: Fabry disease  
Reasoning:  
1. **Renal Involvement**: Renal insufficiency, hypoplasia, focal segmental glomerulosclerosis (FSGS), elevated creatinine, and reduced GFR are hallmark renal manifestations of Fabry disease. FSGS and tubular dysfunction are common in advanced stages due to glycolipid accumulation.  
2. **Multisystem Symptoms**:  
   - **Hypothyroidism**: Fabry disease can cause endocrine dysfunction via cellular glycosphingolipid deposition.  
   - **Anemia/Hyperkalemia/Hypoalbuminemia**: Secondary to chronic kidney disease (CKD) from Fabry-related nephropathy.  
   - **Diarrhea**: Gastrointestinal involvement (e.g., autonomic neuropathy or vascular ischemia) is frequent.  
3. **Metabolic Abnormalities**: Elevated PTH and low vitamin D indicate CKD-mineral bone disorder, consistent with Fabry-induced renal failure.  
4. **Dermatologic Feature**: Papules (likely angiokeratomas), a pathognomonic sign of Fabry disease, caused by glycolipid deposits in skin vasculature.  
5. **Exclusion of Alternatives**: Combined renal, endocrine, and cutaneous symptoms rule out isolated CKD or thyroid disorders, aligning with Fabry’s lysosomal storage pathology (α-galactosidase A deficiency)."
"['Optic disc pallor', 'Nyctalopia', 'Reduced visual acuity', 'Bone spicule pigmentation of the retina', 'Attenuation of retinal blood vessels']",['Retinitis pigmentosa 11'],"Disease: Retinitis pigmentosa 11  
Reasoning:  
1. **Nyctalopia (night blindness)** is a hallmark early symptom of retinitis pigmentosa (RP), caused by rod photoreceptor dysfunction.  
2. **Bone spicule pigmentation of the retina** is a pathognomonic finding in RP, resulting from pigment migration into the retina due to photoreceptor degeneration.  
3. **Attenuation of retinal blood vessels** and **optic disc pallor** reflect progressive retinal atrophy and optic nerve degeneration, common in advanced RP.  
4. **Reduced visual acuity** correlates with cone photoreceptor involvement later in the disease.  
5. **RP11** is a specific autosomal dominant subtype linked to mutations in the *PRPF31* gene, which disrupts pre-mRNA splicing in photoreceptors. The clinical triad of nyctalopia, visual field loss, and retinal pigmentary changes aligns with this genetic diagnosis."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Fever', 'Diarrhea', 'Pneumonia', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning: Hyperphenylalaninemia is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity. Elevated urinary carboxylic acids may reflect phenylketone excretion (e.g., phenylpyruvate). Neonatal death or death in infancy/childhood can occur in severe untreated cases due to progressive neurological damage. Abnormality of prenatal development could stem from maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy. Obesity may arise later due to high-carbohydrate diets used to restrict phenylalanine. Recurrent infections (e.g., pneumonia) and chronic pulmonary issues may result from aspiration secondary to neurological dysfunction. Hypertyrosinemia is atypical for PKU and suggests a potential comorbid condition or diagnostic overlap, but the core diagnosis remains PKU based on hyperphenylalaninemia."
"['Renal cyst', 'Macrocephaly', 'Narrow chest', 'Specific learning disability', 'Ventriculomegaly', 'Hematochezia', 'Short distal phalanx of finger', 'Prominent forehead', 'Large intestinal polyposis']",['Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome/Smith-Kingsmore syndrome'],"Disease: Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome/Smith-Kingsmore syndrome  
Reasoning:  
1. **Macrocephaly**: A hallmark feature of Smith-Kingsmore syndrome, caused by MTOR gene mutations affecting cerebral growth.  
2. **Specific learning disability/neurodevelopmental disorder**: Aligns with intellectual disability and neurodevelopmental delays characteristic of the syndrome.  
3. **Narrow chest**: Matches the ""small thorax"" phenotype due to skeletal dysplasia.  
4. **Ventriculomegaly**: Reflects brain abnormalities linked to MTOR dysregulation, commonly seen in this disorder.  
5. **Prominent forehead**: Part of the distinct craniofacial features (macrocephaly with frontal bossing).  
6. **Short distal phalanx of finger**: Consistent with skeletal anomalies reported in MTOR-related syndromes.  
7. **Renal cyst**: Rarely reported but plausible, as MTOR pathway disruptions can affect renal development.  
8. **Large intestinal polyposis/Hematochezia**: Atypical but may represent gastrointestinal manifestations of MTOR hyperactivity, though further evaluation is needed to exclude concurrent conditions (e.g., PTEN-related syndromes).  

The diagnosis prioritizes core features (macrocephaly, neurodevelopmental deficits, small thorax, ventriculomegaly) while acknowledging atypical symptoms as potential phenotypic expansions or comorbidities. Genetic testing for MTOR variants is critical for confirmation."
"['Xerostomia', 'Visual impairment', 'Weight loss', 'Fever', 'Microscopic hematuria', 'Elevated hepatic transaminase', 'Back pain', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Enlargement of parotid gland', 'Anterior uveitis', 'Thin glomerular basement membrane', 'Mild proteinuria', 'Cervical lymphadenopathy', 'Night sweats', 'Ocular pain']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient presents with multisystem involvement characteristic of sarcoidosis. Anterior uveitis and visual impairment align with ocular sarcoidosis, while parotid gland enlargement and xerostomia suggest salivary gland infiltration. Systemic inflammation (fever, night sweats, elevated ESR/CRP) and lymphadenopathy reflect active granulomatous disease. Elevated hepatic transaminases indicate liver involvement, and renal findings (microscopic hematuria, mild proteinuria) may correlate with interstitial nephritis or hypercalcemia-induced nephropathy. Back pain could stem from musculoskeletal or granulomatous spinal lesions. Erythema may represent cutaneous sarcoidosis or erythema nodosum, a marker of acute disease. Exercise intolerance may arise from pulmonary or cardiac involvement (e.g., restrictive lung disease, arrhythmias). Genetic susceptibility (e.g., HLA-DRB1 variants in susceptibility type 1) could predispose to this dysregulated immune response.  

Sarcoidosis, susceptibility to, 2:  
The phenotypic overlap with susceptibility type 1 is significant, but susceptibility type 2 is linked to distinct genetic loci (e.g., ANXA11 mutations). The combination of anterior uveitis, parotid enlargement, and lymphadenopathy meets criteria for Heerfordt syndrome, a sarcoidosis subtype. Thin glomerular basement membrane and proteinuria may indicate concurrent IgA nephropathy or direct granulomatous renal injury, both reported in sarcoidosis. Persistent weight loss and poor appetite suggest chronic inflammatory burden. Ocular pain reinforces uveitis severity, while cervical lymphadenopathy and hepatic transaminase elevation underscore systemic granuloma formation. This presentation aligns with polygenic susceptibility (type 2), where environmental triggers exacerbate genetic risk."
"['Low-set ears', 'Anteverted nares', 'Ptosis', 'Delayed speech and language development', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'High, narrow palate', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Polydactyly', 'Elevated 7-dehydrocholesterol']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) paired with hypocholesterolemia are pathognomonic for SLOS, caused by DHCR7 mutations disrupting cholesterol synthesis.  
2. **Craniofacial features**: Low-set ears, anteverted nares, ptosis, and high/narrow palate align with SLOS-associated dysmorphisms.  
3. **Limb anomalies**: Syndactyly (often 2nd-3rd toes) and polydactyly are hallmark findings in SLOS.  
4. **Neurodevelopmental delays**: Intellectual disability, motor/speech delays, and hyperactivity reflect impaired cholesterol-dependent neurodevelopment.  
5. **Severe prognosis**: Neonatal death, infant/childhood mortality, and multisystem involvement indicate a severe SLOS phenotype (e.g., type II).  
6. **Exclusion of mimics**: No features suggesting other polydactyly-associated syndromes (e.g., Bardet-Biedl, Meckel-Gruber), and biochemical findings uniquely point to SLOS."
"['Skin rash', 'Death in infancy', 'Alopecia', 'Metabolic acidosis', 'Increased CSF lactate', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Core metabolic features**: Metabolic acidosis, elevated CSF lactate, and elevated urinary carboxylic acids indicate mitochondrial dysfunction in energy metabolism. These findings align with impaired activity of biotin-dependent carboxylases (propionyl-CoA, pyruvate, and 3-methylcrotonyl-CoA carboxylases), which require biotin as a cofactor.  
2. **Cutaneous manifestations**: Skin rash, erythematous plaques/macules/papules, and alopecia are classic signs of biotin deficiency, as biotin is critical for keratinocyte integrity and hair follicle health.  
3. **Neurological and systemic involvement**: Increased CSF lactate suggests central nervous system energy failure. Death in infancy reflects rapid metabolic decompensation if untreated.  
4. **Biochemical hallmarks**: Aminoaciduria and abnormal glycine levels arise from disrupted amino acid catabolism due to carboxylase deficiencies. Elevated urinary carboxylic acids (e.g., 3-hydroxyisovalerate, propionylglycine) directly reflect carboxylase dysfunction.  
5. **Diagnostic confirmation**: Biotinidase deficiency (BTDD) specifically disrupts biotin recycling, causing late-onset multiple carboxylase deficiency. Symptoms manifest after neonatal biotin stores are depleted, distinguishing it from holocarboxylase synthetase deficiency (early-onset). Rapid clinical improvement with biotin supplementation further supports BTDD."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Hypotonia', 'Mitral valve prolapse', 'Short foot', 'Unsteady gait', 'Delayed ability to walk']","['Mental retardation, autosomal recessive 38', 'Developmental delay with autism spectrum disorder and gait instability']","Disease: Mental retardation, autosomal recessive 38  
Reasoning: This autosomal recessive disorder is linked to intellectual disability and developmental delays, aligning with the patient’s intellectual disability, delayed speech, and hypotonia. Syndactyly and short foot may reflect skeletal anomalies occasionally associated with recessive intellectual disability syndromes. Hypotonia contributes to delayed walking, while mitral valve prolapse, though atypical, could occur as a variable feature or comorbid finding.  

Disease: Developmental delay with autism spectrum disorder and gait instability  
Reasoning: The patient’s abnormal repetitive mannerisms align with autism spectrum disorder. Developmental delays (speech, walking) and gait instability are core features of this diagnosis. Hypotonia exacerbates motor delays and unsteady gait. Mitral valve prolapse and syndactyly are less directly explained but may represent phenotypic variability or secondary manifestations of neuromuscular dysfunction."
"['Inguinal hernia', 'Jaundice', 'Global developmental delay', 'Hepatic steatosis', 'Growth abnormality', 'Hyperbilirubinemia', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Prolonged neonatal jaundice', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Copper accumulation in liver', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration', 'Hernia']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Abnormal protein N-linked glycosylation** is a hallmark of congenital disorders of glycosylation (CDG), specifically type II defects, which involve impaired processing of glycans.  
2. **Hepatic steatosis, elevated liver enzymes (AST/ALT), hyperbilirubinemia, and prolonged neonatal jaundice** indicate severe liver dysfunction. TMEM199-CDG is associated with chronic liver disease, including copper accumulation due to disrupted biliary excretion.  
3. **Decreased ceruloplasmin** aligns with defective glycosylation, as ceruloplasmin requires proper glycosylation for stability and secretion.  
4. **Hypercholesterolemia and elevated LDL** are common in TMEM199-CDG due to altered lipid metabolism linked to hepatic impairment.  
5. **Global developmental delay and growth abnormalities** reflect systemic consequences of glycosylation defects, impacting neurological and somatic development.  
6. **Hernias** (inguinal/other) may result from connective tissue weakness caused by improper glycosylation of structural proteins.  
7. **Elevated alkaline phosphatase and creatine kinase** suggest multi-organ involvement (liver, bone, muscle), consistent with TMEM199-CDG’s phenotype.  

*Note: ""Congenital disorder of glycosylation, type IIP"" and ""TMEM199-CDG"" refer to the same disease, with the latter specifying the genetic cause (TMEM199 mutation).*"
"['Spasticity', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Neonatal death', 'Abnormal circulating creatine kinase concentration', 'Increased urinary glycerol']",['Isolated glycerol kinase deficiency/Glycerol kinase deficiency'],"Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol**: A hallmark of glycerol kinase deficiency (GKD), caused by the enzyme's inability to metabolize glycerol, leading to its accumulation and urinary excretion.  
2. **Abnormal circulating creatine kinase (CK)**: Elevated CK suggests muscle damage, which can occur in metabolic disorders like GKD due to energy deficits in muscle cells.  
3. **Generalized hypotonia and hyporeflexia**: Result from impaired muscle metabolism and energy production secondary to glycerol accumulation and disrupted metabolic pathways.  
4. **Spasticity**: May arise later due to progressive neurological dysfunction or compensatory mechanisms in a metabolically stressed nervous system.  
5. **Neonatal death/Death in infancy**: Severe infantile GKD often leads to metabolic crises (e.g., hypoglycemia, hyperglycerolemia) and organ failure, explaining early mortality.  
6. **Exclusion of adrenal involvement**: The diagnosis specifies *isolated* GKD, distinguishing it from the adrenocortical insufficiency-associated form (e.g., Xp21 deletion syndrome)."
"['Mandibular prognathia', 'Conductive hearing impairment', 'Long eyelashes', 'Brachydactyly', 'Hypertonia', 'Areflexia', 'Joint stiffness', 'Abnormal heart morphology', 'Clumsiness', 'Highly arched eyebrow', 'Thickened calvaria', 'Lumbar hyperlordosis', 'Thoracic kyphosis', 'Enlarged vertebral pedicles', 'Bilateral conductive hearing impairment', 'Abnormal renal morphology', 'Abnormality of brain morphology', 'Keratosis pilaris']",['Myhre syndrome/Myhre syndrome'],"Disease: Myhre syndrome  
Reasoning:  
1. **Mandibular prognathia**: A hallmark of Myhre syndrome, characterized by a prominent, protruding jaw.  
2. **Conductive hearing impairment (bilateral)**: Common due to middle ear anomalies or ossicular chain abnormalities.  
3. **Long eyelashes/Highly arched eyebrows**: Part of the distinctive facial gestalt in Myhre syndrome.  
4. **Brachydactyly**: Shortened fingers/limbs are consistent with skeletal dysplasia seen in the syndrome.  
5. **Hypertonia/Joint stiffness/Clumsiness**: Linked to progressive musculoskeletal fibrosis and restricted joint mobility.  
6. **Thickened calvaria/Enlarged vertebral pedicles**: Reflects the characteristic progressive skeletal overgrowth and thickened bones.  
7. **Abnormal heart/renal/brain morphology**: Multisystem involvement, including cardiovascular, renal, and CNS structural anomalies, aligns with Myhre syndrome’s systemic impact.  
8. **Keratosis pilaris**: Reported in some cases as a cutaneous manifestation.  
9. **Thoracic kyphosis/Lumbar hyperlordosis**: Spinal deformities secondary to skeletal dysplasia and fibrosis.  
10. **Areflexia**: May relate to neurological involvement or muscle fibrosis.  

The constellation of craniofacial, skeletal, cardiovascular, and neurological abnormalities strongly supports a diagnosis of **Myhre syndrome**, a SMAD4-associated disorder."
"['Eczematoid dermatitis', 'Skin rash', 'Seizure', 'Death in infancy', 'Fever', 'Elevated circulating C-reactive protein concentration', 'L-2-hydroxyglutaric aciduria', 'Decreased serum iron']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Diagnostic Marker**: The patient has ""L-2-hydroxyglutaric aciduria"" listed as a symptom, which directly corresponds to elevated levels of L-2-hydroxyglutaric acid in urine—a hallmark diagnostic feature of this inborn error of metabolism.  
2. **Neurological Manifestations**: Seizures are a common symptom of L-2-HGA due to progressive leukoencephalopathy and neurotoxicity caused by metabolite accumulation.  
3. **Poor Prognosis**: ""Death in infancy"" aligns with severe forms of the disease, often resulting from metabolic decompensation, infections, or neurological deterioration.  
4. **Inflammatory/Secondary Features**: Elevated C-reactive protein and fever suggest systemic inflammation or infection, which may trigger metabolic crises in L-2-HGA. Eczematoid dermatitis and skin rash could reflect immune dysregulation or secondary infections.  
5. **Metabolic Disruption**: Decreased serum iron may indicate chronic disease anemia or mitochondrial dysfunction linked to impaired cellular metabolism in L-2-HGA.  

The diagnosis is confirmed by the presence of L-2-hydroxyglutaric aciduria, with other symptoms reflecting secondary complications or systemic effects of the underlying metabolic disorder."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
- **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine.  
- **Hypertyrosinemia**: While classic PKU typically results in **low or normal tyrosine levels** (due to blocked PAH activity), hypertyrosinemia here may indicate a secondary metabolic disruption, transient neonatal tyrosinemia, or overlap with another condition (e.g., maternal PKU syndrome or BH4 deficiency).  
- **Abnormality of prenatal development**: Maternal PKU during pregnancy can cause fetal developmental defects (e.g., microcephaly, congenital heart defects) due to phenylalanine toxicity, even if the infant itself has PKU.  
- **Neonatal death/Death in infancy**: Untreated severe PKU or BH4-deficient forms (malignant PKU) can lead to rapid neurological deterioration, seizures, and metabolic crises, resulting in early mortality.  
- **Conflict resolution**: The combination of hyperphenylalaninemia and hypertyrosinemia suggests possible comorbid tyrosinemia type II (genetically distinct) or transient tyrosinemia of the newborn. However, PKU remains the primary diagnosis due to the dominant hyperphenylalaninemia and clinical alignment with severe phenotypes. Early newborn screening and dietary management are critical to prevent fatal outcomes."
"['Intellectual disability', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Untreated PKU results in neurotoxic phenylalanine accumulation, damaging brain development and function.  
3. **Hypertyrosinemia**: Atypical in classic PKU but may arise secondary to dietary tyrosine supplementation, impaired tyrosine metabolism due to liver dysfunction, or overlap with a co-existing metabolic disorder (e.g., transient tyrosinemia).  
4. **Death in early adulthood**: Reflects severe untreated PKU complications, including neurodegeneration, seizures, and systemic organ damage, historically associated with poor prognosis before dietary management.  

While hypertyrosinemia is not a typical feature of isolated PKU, the core findings (hyperphenylalaninemia + intellectual disability) strongly support PKU as the primary diagnosis, with hypertyrosinemia warranting investigation for confounding factors or comorbidities."
"['Ataxia', 'Generalized hypotonia', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency (DPYD deficiency)  
Reasoning:  
1. **Uraciluria** and **abnormal circulating pyrimidine concentration** directly indicate a defect in pyrimidine catabolism, as dihydropyrimidine dehydrogenase (DPD) is responsible for degrading uracil and thymine. Deficiency leads to urinary excretion of unmetabolized uracil.  
2. **Ataxia** and **generalized hypotonia** are neurological manifestations linked to elevated pyrimidine metabolites (e.g., uracil), which may interfere with CNS function or neurotransmitter pathways.  
3. **Death in childhood** aligns with severe forms of DPYD deficiency, where toxic metabolite accumulation causes intractable seizures, developmental delay, and early mortality.  
4. The absence of other pyrimidine-related abnormalities (e.g., orotic aciduria) rules out disorders like urea cycle defects or orotic aciduria, narrowing the diagnosis to DPYD deficiency."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Neonatal death** or **death in infancy** in untreated cases may occur due to severe metabolic derangements, progressive neurological damage, or secondary complications (e.g., seizures, failure to thrive).  
3. Classic PKU is identified via newborn screening, but in unscreened populations or severe variants, rapid phenylalanine buildup can cause acute encephalopathy and early lethality.  
4. The triad of symptoms aligns with untreated PKU, where delayed diagnosis or lack of dietary intervention results in catastrophic outcomes."
"['Microcephaly', 'Strabismus', 'Alacrima', 'Oculomotor apraxia', 'Hypotonia', 'Global developmental delay', 'Hepatic fibrosis', 'Short foot', 'Constipation', 'Cerebral atrophy', 'Hypoplasia of the corpus callosum', 'Increased serum lactate', 'EEG abnormality', 'Small cerebral cortex', 'Elevated hepatic transaminase', 'Prolonged neonatal jaundice', 'Abnormal auditory evoked potentials', 'Chalazion', 'Hypoplastic anterior commissure', 'Abnormality of movement', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A hallmark feature of this syndrome, directly referenced in the disease name.  
2. **Hepatic fibrosis & elevated hepatic transaminases**: Matches the ""liver dysfunction"" component, common in deglycosylation disorders due to impaired protein quality control.  
3. **Hypoplasia of the corpus callosum, cerebral atrophy, small cerebral cortex**: Structural brain abnormalities linked to defective NGLY1, critical for neuronal development and glycosylation.  
4. **Global developmental delay, hypotonia, oculomotor apraxia, movement abnormalities**: Neurological manifestations from disrupted deglycosylation, affecting motor and cognitive pathways.  
5. **Increased serum lactate**: Suggests mitochondrial dysfunction, associated with NGLY1 deficiency.  
6. **Prolonged neonatal jaundice**: Consistent with early-onset liver involvement.  
7. **Chalazion, strabismus**: Ocular defects reported in NGLY1-related disorders.  
8. **Small hand/short foot, constipation**: Connective tissue or autonomic dysfunction due to glycosylation defects.  
9. **EEG/auditory evoked potential abnormalities**: Reflects widespread neuronal dysfunction.  
10. **Hypoplastic anterior commissure**: Rare finding specific to severe neurodevelopmental disorders like CDDG1.  

The triad of **alacrima, liver dysfunction, and movement disorders** (choreoathetosis) with multisystem involvement strongly supports this diagnosis. NGLY1 mutations disrupt endoplasmic reticulum-associated degradation (ERAD), causing systemic glycosylation defects."
"['Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Neonatal death', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Core features of HMG-CoA lyase deficiency due to impaired ketogenesis and leucine catabolism, leading to toxic metabolite accumulation.  
2. **Dicarboxylic aciduria and 3-Methylglutaric aciduria**: Pathognomonic urinary findings from disrupted HMG-CoA breakdown, causing elevated 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-methylglutaric acids.  
3. **Hepatomegaly**: Caused by hepatic accumulation of unmetabolized fatty acids and intermediates.  
4. **Tachypnea**: Compensatory response to metabolic acidosis.  
5. **Vomiting and fever**: Common triggers or consequences of metabolic decompensation during catabolic states (e.g., infections).  
6. **Neonatal death/infant mortality**: Reflects severe metabolic crises in untreated infants, exacerbated by fasting or illness.  
7. **Elevated urinary carboxylic acids**: Direct biochemical evidence of defective leucine metabolism and ketogenesis.  
The combination of these findings strongly aligns with HMG-CoA lyase deficiency, an autosomal recessive disorder affecting ketone body synthesis and leucine degradation."
"['Low-set ears', 'Wide nasal bridge', 'Anteverted nares', 'Ptosis', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Hypocholesterolemia, elevated 7-dehydrocholesterol (7-DHC), and elevated 8-dehydrocholesterol (8-DHC) are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in *DHCR7* leading to impaired cholesterol synthesis.  
2. **Dysmorphic features**: Low-set ears, wide nasal bridge, anteverted nares, ptosis, and syndactyly (especially 2-3 toe syndactyly) are classic craniofacial and limb anomalies in SLOS.  
3. **Neurodevelopmental issues**: Intellectual disability, motor delay, and generalized hypotonia align with SLOS-associated neurodevelopmental deficits due to disrupted cholesterol-dependent myelination and signaling.  
4. **Early lethality**: Neonatal death or death in infancy correlates with severe SLOS phenotypes, often linked to major organ malformations (e.g., cardiac, renal) or failure to thrive from feeding difficulties.  
5. **Feeding difficulties**: Result from hypotonia, poor suck/swallow coordination, and gastrointestinal abnormalities common in SLOS.  
The combination of cholesterol synthesis defects, characteristic dysmorphology, and systemic manifestations confirms SLOS."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Preeclampsia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: Unusual in classic PKU but may arise from secondary metabolic disruptions. High phenylalanine levels could inhibit tyrosine metabolism enzymes (e.g., tyrosine aminotransferase), leading to paradoxical tyrosine accumulation.  
3. **Preeclampsia**: Linked to maternal PKU syndrome. Uncontrolled phenylalanine levels during pregnancy damage fetal development and increase maternal vascular stress, predisposing to preeclampsia.  
4. **Death in early adulthood**: Untreated PKU causes severe neurological decline, seizures, and organ damage. Early mortality may result from complications like metabolic crises or secondary infections in neurologically compromised individuals.  

PKU unifies the symptoms, with hypertyrosinemia and preeclampsia reflecting downstream metabolic and obstetric complications. Early death underscores the critical need for lifelong dietary management to prevent irreversible outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline is a hallmark of citrullinemia, specifically type I (argininosuccinate synthetase deficiency). The symptoms of neonatal death, death in infancy/childhood, and prenatal developmental abnormalities align with severe urea cycle dysfunction. Type I typically presents with hyperammonemia-induced metabolic crises shortly after birth, leading to rapid neurological decline and early mortality if untreated. Prenatal abnormalities may reflect metabolic stress in utero or secondary complications.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Elevated citrulline is also seen in citrin deficiency (type II), though levels may fluctuate. Neonatal cholestasis (implied in the disease name) and liver dysfunction are key features, though not explicitly listed. Prenatal developmental abnormalities (e.g., intrauterine growth restriction) may arise from citrin’s role in mitochondrial energy metabolism. Early mortality could stem from liver failure or metabolic decompensation. The absence of explicit cholestasis in symptoms may reflect incomplete clinical documentation, but the diagnostic framework prioritizes citrulline elevation and neonatal-onset context."
"['Generalized hypotonia', 'Death in infancy', 'Hepatomegaly', 'Tachypnea', '3-Methylglutaconic aciduria', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency), hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia**: CPS1 deficiency disrupts the urea cycle, causing toxic ammonia accumulation. This aligns with neonatal lethality, feeding difficulties, and hypotonia due to neurotoxicity.  
2. **3-Methylglutaconic aciduria**: Though atypical for urea cycle disorders, it may arise secondary to mitochondrial dysfunction or metabolic stress from hyperammonemia.  
3. **Respiratory symptoms (tachypnea)**: Compensatory respiratory alkalosis from hyperammonemia-induced metabolic acidosis drives rapid breathing.  
4. **Hepatomegaly**: While uncommon in CPS1 deficiency, liver enlargement could reflect metabolic strain or secondary dysfunction from ammonia toxicity.  
5. **Neonatal/Infantile death**: Severe urea cycle defects like CPS1 deficiency often present acutely in infancy with fatal hyperammonemic crises if untreated.  
6. **Feeding difficulties and hypotonia**: Neurological impairment from ammonia toxicity leads to poor feeding and generalized muscle weakness.  

The constellation of symptoms, despite some atypical features (e.g., 3-methylglutaconic aciduria), strongly supports CPS1 deficiency as the primary diagnosis, with hyperammonemia as the central pathological mechanism."
"['Dysarthria', 'Cerebellar atrophy', 'Dysphagia', 'Gait ataxia', 'Paraparesis', 'Scoliosis', 'Ankle clonus']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Paraparesis** and **ankle clonus** are hallmark signs of upper motor neuron dysfunction, consistent with hereditary spastic paraplegia (HSP).  
2. **Cerebellar atrophy** and **gait ataxia** indicate cerebellar involvement, aligning with ""complicated"" HSP subtypes like SPG76, where CAPN1 mutations cause combined pyramidal and cerebellar pathology.  
3. **Dysarthria** and **dysphagia** suggest brainstem or cerebellar dysfunction, often seen in HSPs with extended neurological features.  
4. **Scoliosis** may arise secondary to chronic neuromuscular imbalance, a known skeletal complication in progressive HSPs.  
5. SPG76’s autosomal recessive inheritance and phenotypic overlap with spasticity-plus syndromes (e.g., cerebellar degeneration) distinguish it from pure motor HSPs (e.g., SPG4). The constellation of pyramidal, cerebellar, and bulbar symptoms strongly supports this diagnosis."
"['Nystagmus', 'Ataxia', 'Reduced tendon reflexes', 'Increased serum lactate', 'Increased CSF lactate', 'Glutaric aciduria', 'Increased serum pyruvate', 'Decreased plasma free carnitine', 'Abnormal immunoglobulin level', 'Hyperalbuminemia', 'Occipital neuralgia', 'Death in early adulthood']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Directly links to GA-I, caused by glutaryl-CoA dehydrogenase deficiency, leading to accumulation of glutaric acid.  
2. **Neurological symptoms (Nystagmus, Ataxia)**: GA-I damages the basal ganglia and white matter, causing dystonia, movement disorders, and cerebellar dysfunction.  
3. **Reduced tendon reflexes**: Suggests peripheral neuropathy, a known complication of metabolic toxicity in GA-I.  
4. **Elevated serum/CSF lactate & pyruvate**: Mitochondrial dysfunction from metabolic stress disrupts the tricarboxylic acid cycle, increasing anaerobic metabolism.  
5. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to toxic metabolites (e.g., glutaric acid) for excretion.  
6. **Death in early adulthood**: Untreated GA-I causes progressive neurodegeneration and metabolic crises, often leading to early mortality.  
7. **Hyperalbuminemia/Abnormal immunoglobulins**: Less specific but may reflect chronic metabolic stress or incidental findings; not core diagnostic criteria.  
8. **Occipital neuralgia**: Likely a secondary consequence of chronic neurological damage or unrelated comorbidity.  

Key exclusion: Other organic acidemias (e.g., MMA/PA) lack glutaric aciduria and typically present with severe ketoacidosis, which is less prominent in GA-I. The triad of glutaric aciduria, striatal injury, and characteristic biochemical profile confirms GA-I."
"['Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Abnormal vitamin B12 level', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU, caused by deficient phenylalanine hydroxylase (PAH), impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: A hallmark of untreated PKU due to neurotoxic phenylalanine accumulation.  
3. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate), excreted in urine as carboxylic acids.  
4. **Hypertyrosinemia discrepancy**: Unusual in classic PKU (tyrosine is typically low/normal). Potential explanations include dietary tyrosine intake, lab variability, or coexisting metabolic adjustments.  
5. **Abnormal vitamin B12 levels**: Likely linked to PKU dietary management (low-protein formulas may alter micronutrient balance).  
6. **Obesity**: Secondary to high-carbohydrate/low-protein PKU diets, promoting caloric excess.  

While hypertyrosinemia is atypical, core features (hyperphenylalaninemia, urinary metabolites, neurocognitive deficits) strongly align with PKU. Further testing (PAH activity, genetic analysis) would confirm the diagnosis."
"['Hypothyroidism', 'Intellectual disability', 'Seizure', 'Dysarthria', 'Confusion', 'Hyperammonemia', 'Myopathic facies', 'Gait ataxia', 'Clonus', 'Elevated circulating thyroid-stimulating hormone concentration', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Prolonged QTc interval', 'Hyperactive deep tendon reflexes', 'Lower limb muscle weakness', 'Distal lower limb muscle weakness']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Hyperammonemia, Confusion, Seizures**: Indicate recurrent metabolic encephalopathy, a hallmark of the syndrome, likely due to defects in energy metabolism or ammonia detoxification.  
2. **Rhabdomyolysis, Elevated CK**: Suggest recurrent muscle breakdown (rhabdomyolysis), consistent with metabolic crises triggered by stress, infection, or fasting.  
3. **Prolonged QTc Interval, Cardiac Arrhythmia Risk**: Aligns with cardiac involvement, a critical feature of the syndrome, potentially linked to electrolyte imbalances or mitochondrial dysfunction.  
4. **Intellectual Disability, Dysarthria, Gait Ataxia**: Reflect progressive neurodegeneration and CNS impairment, typical in chronic phases of the disorder.  
5. **Hypothyroidism with Elevated TSH**: May arise secondary to metabolic dysfunction or coexist as part of a multisystem mitochondrial disorder.  
6. **Myopathic Facies, Lower Limb Weakness, Hyperactive Reflexes**: Suggest mixed neuromuscular pathology, combining myopathy (weakness) and upper motor neuron involvement (hyperreflexia/clonus), atypical for isolated hypothyroidism.  
7. **Clonus and Ataxia**: Point to cerebellar/brainstem dysfunction, reinforcing the encephalomyopathic nature.  
The constellation of metabolic crises, rhabdomyolysis, cardiac arrhythmias, and neurodegeneration distinguishes this syndrome from isolated endocrine or neuromuscular disorders."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** may reflect untreated maternal PKU during pregnancy (maternal PKU syndrome), where high maternal phenylalanine levels disrupt fetal development (e.g., microcephaly, congenital heart defects). However, if the *infant* has PKU, prenatal abnormalities are unlikely unless compounded by maternal metabolic dysregulation.  
3. **Neonatal death/Death in infancy** aligns with severe, untreated PKU variants (e.g., classic PKU with near-complete PAH deficiency). Without early dietary intervention, hyperphenylalaninemia causes irreversible neurological damage, seizures, and failure to thrive, potentially leading to fatal complications (e.g., infections, metabolic crises) within infancy.  
4. PKU is identified via newborn screening; undiagnosed cases in unscreened populations may explain rapid progression to fatal outcomes.  

Conclusion: The combination of hyperphenylalaninemia with early mortality strongly supports PKU, emphasizing the critical need for prompt diagnosis and lifelong phenylalanine-restricted diets to prevent severe outcomes."
"['Thick lower lip vermilion', 'Thick upper lip vermilion', 'Microcephaly', 'Full cheeks', 'Abnormal midface morphology', 'Depressed nasal ridge', 'Short neck', 'Delayed speech and language development', 'Sacral dimple', 'Global developmental delay', 'Motor delay', 'Proportionate short stature', 'Hyperpigmented/hypopigmented macules', 'Congenital megaureter', 'Cone-shaped epiphyses of the phalanges of the hand', 'Feeding difficulties']",['Wiedemann-Steiner syndrome/Wiedemann-Steiner syndrome'],"Disease: Wiedemann-Steiner syndrome  
Reasoning:  
1. **Craniofacial features**: Thick upper/lower lip vermilion, full cheeks, depressed nasal ridge, and abnormal midface morphology align with characteristic facial dysmorphism in Wiedemann-Steiner syndrome (WSS).  
2. **Neurodevelopmental delays**: Global developmental delay, motor delay, and speech/language delays are hallmark features of WSS, often linked to *KMT2A* gene mutations.  
3. **Growth abnormalities**: Microcephaly and proportionate short stature correlate with growth deficiencies commonly seen in WSS.  
4. **Skeletal findings**: Cone-shaped epiphyses of the hand phalanges are a recognized skeletal anomaly in WSS.  
5. **Cutaneous features**: Hyper-/hypopigmented macules may reflect the hypertrichosis or pigmentary changes occasionally reported in WSS.  
6. **Supportive features**: Congenital megaureter and feeding difficulties are consistent with multi-system involvement seen in rare genetic syndromes like WSS. Sacral dimple, while nonspecific, adds to the phenotypic spectrum.  
7. **Exclusion**: The combination of facial dysmorphism, skeletal anomalies, and neurodevelopmental delays distinguishes WSS from mimics like Kabuki syndrome or Cornelia de Lange syndrome. Genetic testing for *KMT2A* variants would confirm the diagnosis."
"['Death in infancy', 'Fever', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently due to metabolic stress, secondary liver dysfunction, or overlapping tyrosinemia-like features in severe cases.  
3. **Severe short stature** aligns with untreated PKU, where chronic metabolic disruption impairs growth and development.  
4. **Neonatal death/Death in infancy/childhood** reflects untreated PKU complications (e.g., neurological collapse, seizures, or infections) in severe variants or delayed diagnosis.  
5. **Fever** may result from secondary infections exacerbated by metabolic instability or immunocompromise.  
6. While hypertyrosinemia suggests alternative diagnoses (e.g., tyrosinemia), PKU is prioritized here due to the explicit diagnostic label provided and the dominance of hyperphenylalaninemia.  

Note: Hypertyrosinemia warrants further investigation for coexisting conditions (e.g., tyrosinemia or BH4 deficiency), but PKU remains the primary diagnosis based on symptom prioritization."
"['Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Dyspnea', 'Apnea', 'Opisthotonus', 'Spastic tetraplegia', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated branched-chain amino acids (BCAAs):** Hypervalinemia, hyperleucinemia, and hyperisoleucinemia are pathognomonic for MSUD, as the disease disrupts the breakdown of BCAAs due to a deficiency in the branched-chain α-keto acid dehydrogenase complex.  
2. **Metabolic acidosis:** Accumulation of toxic keto acids (from BCAAs) overwhelms buffering systems, leading to acidosis.  
3. **Neurological symptoms:** Seizures, spastic diplegia/tetraplegia, motor delay, and opisthotonus result from neurotoxicity caused by elevated leucine and its metabolites.  
4. **Respiratory and feeding issues:** Dyspnea, apnea, and feeding difficulties arise from metabolic decompensation and neurological dysfunction.  
5. **Odor and fatal course:** The characteristic ""maple syrup"" body odor (due to alloisoleucine) and neonatal death/infant mortality align with classic severe MSUD phenotypes.  
6. **Generalized hypotonia:** Reflects acute metabolic encephalopathy and impaired energy metabolism in neurons.  

The combination of BCAA elevation, metabolic derangements, and rapid neurological decline confirms MSUD as the diagnosis."
"['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Increased serum lactate', 'Neonatal death', 'Death in childhood']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Eczematoid dermatitis/Skin rash**: Classic cutaneous manifestations of biotinidase deficiency due to biotin-dependent carboxylase dysfunction, impairing fatty acid synthesis and skin integrity.  
2. **Generalized hypotonia**: Caused by metabolic acidosis and energy deficiency from impaired gluconeogenesis (propionyl-CoA carboxylase deficiency) and mitochondrial dysfunction.  
3. **Increased serum lactate**: Reflects lactic acidosis secondary to pyruvate carboxylase deficiency, disrupting the tricarboxylic acid cycle.  
4. **Abnormality of prenatal development or birth**: May indicate subtle intrauterine metabolic stress, though symptoms typically manifest postnatally as ""late-onset"" disease.  
5. **Death in infancy/Neonatal death/Death in childhood**: Untreated BTDD leads to progressive neurological decline, metabolic crises, and fatal outcomes. Early mortality correlates with delayed diagnosis and lack of biotin supplementation.  
6. **Multi-carboxylase involvement**: The term ""multiple carboxylase deficiency"" directly links to the biochemical defect in BTDD, where biotinidase deficiency prevents recycling of biotin, essential for carboxylase enzymes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by mutations in the *PAH* gene, leading to deficient phenylalanine hydroxylase activity and impaired conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth** may occur in severe untreated maternal PKU, where high phenylalanine levels disrupt fetal development. In classic PKU, infants typically appear normal at birth but develop symptoms postnatally if untreated.  
3. **Hypertyrosinemia** is atypical in PKU (as tyrosine synthesis is reduced), but transient neonatal tyrosinemia can occur due to immature enzymes, potentially overlapping with early PKU metabolic instability.  
4. **Death in infancy/Neonatal death** aligns with rare, severe PKU variants (e.g., malignant PKU or BH4-deficient forms) causing acute metabolic crises, neurological deterioration, and organ failure if undiagnosed/unmanaged.  
5. The combination of hyperphenylalaninemia and catastrophic neonatal outcomes strongly supports PKU, particularly in cases lacking newborn screening and dietary intervention."
"['Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Ataxia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Death in childhood', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: SSADHD causes accumulation of γ-hydroxybutyric acid (GHB), a carboxylic acid, in urine due to impaired GABA metabolism.  
2. **Neurological symptoms (Seizure, Ataxia, Hypotonia)**: GHB toxicity disrupts neurotransmission, leading to seizures, cerebellar dysfunction (ataxia), and reduced muscle tone.  
3. **Developmental delays (Speech, Motor)**: Chronic GABA imbalance impairs neurodevelopment, affecting speech and motor milestones.  
4. **Hyperactivity**: Paradoxical excitatory effects of excess GHB contribute to hyperactive behavior.  
5. **Early mortality (Infancy/Childhood)**: Severe metabolic dysfunction or refractory seizures in acute crises may lead to premature death.  
SSADHD is confirmed via genetic testing and elevated GHB in urine/blood, aligning with the symptom profile."
"['Recurrent urinary tract infections', 'Abnormality of the kidney', 'Epicanthus', 'Low anterior hairline', 'Hypertelorism', 'Narrow forehead', 'Choanal atresia', 'Cystic hygroma', 'Synophrys', 'Hypotonia', 'Spasticity', 'Motor delay', 'Hypertonia', 'Generalized hypotonia', 'Abnormal heart morphology', 'Delayed gross motor development', 'Scoliosis', 'Redundant neck skin', 'Hypoplastic helices', 'Abnormal eye morphology', 'Abnormality of brain morphology', 'Abnormality of cardiovascular system morphology']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart  
Reasoning:  
1. **Neurodevelopmental features**: Hypotonia, hypertonia, spasticity, motor delay, and delayed gross motor development indicate central nervous system dysfunction, consistent with the ""neurodevelopmental disorder"" core phenotype.  
2. **Brain anomalies**: Abnormality of brain morphology directly aligns with the disorder's characteristic brain involvement.  
3. **Ocular anomalies**: Epicanthus, hypertelorism, synophrys, and abnormal eye morphology correlate with the ""eye anomalies"" component.  
4. **Cardiovascular involvement**: Abnormal heart morphology and cardiovascular system abnormalities match the disorder's cardiac spectrum.  
5. **Supporting dysmorphisms**: Low anterior hairline, narrow forehead, redundant neck skin, cystic hygroma, hypoplastic helices, and choanal atresia are common in genetic neurodevelopmental syndromes.  
6. **Systemic features**: Scoliosis, recurrent UTIs, and kidney abnormalities are nonspecific but frequently reported in multisystem neurodevelopmental disorders.  
7. **Exclusion of mimics**: The constellation rules out isolated syndromes (e.g., CHARGE, Noonan) due to the combined brain-eye-heart triad without pathognomonic features of other defined disorders."
"['Visual impairment', 'Photophobia', 'Nyctalopia', 'Visual field defect']",['Cone rod dystrophy/Cone-Rod dystrophy 2'],"Disease: Cone rod dystrophy/Cone-Rod dystrophy 2  
Reasoning:  
1. **Photophobia** and **visual impairment** suggest primary cone dysfunction, as cones mediate photopic (daylight) vision.  
2. **Nyctalopia** (night blindness) indicates subsequent rod involvement, as rods are responsible for scotopic (low-light) vision.  
3. **Visual field defects** (e.g., peripheral loss) align with progressive degeneration of both photoreceptor types, leading to concentric field narrowing or central scotomas.  
4. Cone-rod dystrophy classically presents with early cone system decline (photophobia, color/acuity loss) followed by rod degeneration (nyctalopia), distinguishing it from rod-cone dystrophies like retinitis pigmentosa.  
5. Genetic subtypes (e.g., *CRD2* linked to *ABCAA4* mutations) correlate with phenotypic variability but share this symptom triad."
"['Generalized hypotonia', 'Death in infancy', 'Leukopenia', 'Metabolic acidosis', 'Hyperammonemia', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Biotinidase deficiency impairs the activity of biotin-dependent carboxylases (e.g., propionyl-CoA carboxylase, pyruvate carboxylase), disrupting amino acid catabolism and urea cycle function. This leads to accumulation of organic acids (e.g., lactate, propionate) and ammonia.  
2. **Leukopenia**: Secondary to bone marrow suppression from metabolic toxins (e.g., organic acids) or biotin-dependent immune dysfunction.  
3. **Generalized hypotonia**: Caused by energy deficiency in muscles/nerves due to defective mitochondrial carboxylases and hyperammonemia-induced neurotoxicity.  
4. **Neonatal death/death in infancy**: Untreated BTDD causes progressive metabolic crises, seizures, and cardiorespiratory failure. Neonatal-onset cases often present with rapid deterioration without early biotin supplementation.  
5. **Exclusion of mimics**: Symptoms overlap with organic acidemias (e.g., propionic acidemia), but leukopenia and biotin-responsiveness distinguish BTDD.  

**Conclusion**: The triad of metabolic acidosis, hyperammonemia, and leukopenia in a critically ill neonate aligns with late-onset multiple carboxylase deficiency due to biotinidase deficiency. Early mortality reflects delayed diagnosis and lack of biotin therapy."
"['Generalized hypotonia', 'Death in infancy', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia', 'Decreased circulating ferritin concentration', 'Acute hepatitis', 'Chronic hepatitis']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** directly indicate impaired galactose processing, a hallmark of galactosemia.  
2. **Elevated hepatic transaminases**, **increased bilirubin**, and **acute/chronic hepatitis** reflect severe liver injury caused by toxic accumulation of galactose metabolites (e.g., galactitol).  
3. **Prolonged partial thromboplastin time** and **neonatal death** stem from liver dysfunction impairing clotting factor synthesis and multisystem failure.  
4. **Generalized hypotonia** and **abnormal aspartate/alanine concentrations** suggest secondary metabolic disturbances from hepatic damage and mitochondrial dysfunction.  
5. **Decreased ferritin** may arise from disrupted iron metabolism due to hepatic injury.  
6. **Neonatal presentation** aligns with classic galactosemia (GALT deficiency), where symptoms manifest upon lactose exposure from breast milk/formula.  
7. Exclusion of other disorders (e.g., tyrosinemia) is supported by specific galactose-related abnormalities and the provided diagnostic list."
"['Delayed speech and language development', 'Asthma', 'Delayed skeletal maturation', 'Short stature', 'Sleep apnea', 'Delayed fine motor development']","['Microcephaly 3, primary, autosomal recessive']","Disease: Microcephaly 3, primary, autosomal recessive  
Reasoning:  
1. **Core Diagnostic Features**: The diagnosis hinges on the presence of **primary microcephaly** (reduced head circumference at birth), which is a hallmark of MCPH3, though not explicitly listed in the provided symptoms. This omission suggests either an incomplete symptom list or an assumption of microcephaly as part of the clinical context.  
2. **Developmental Delays**: The patient exhibits **delayed speech, language, and fine motor development**, consistent with neurodevelopmental impairments caused by defective cerebral cortical growth in MCPH3.  
3. **Growth Abnormalities**: **Short stature** and **delayed skeletal maturation** may reflect secondary growth disturbances, though these are not classic features of MCPH3. They could arise from systemic genetic effects or nutritional/endocrine factors compounded by the underlying condition.  
4. **Ancillary Symptoms**: **Asthma** and **sleep apnea** are likely unrelated to MCPH3. However, sleep apnea could indirectly stem from craniofacial anomalies (e.g., midface hypoplasia) occasionally associated with severe microcephaly.  
5. **Genetic Basis**: Autosomal recessive mutations in *CDK5RAP2* disrupt neuronal proliferation, aligning with global developmental delays but not directly explaining non-neurological symptoms.  
**Conclusion**: The diagnosis prioritizes neurodevelopmental and structural brain anomalies (microcephaly), while other symptoms are either coincidental or secondary to the broader phenotypic spectrum."
"['Vasculitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Increased carotid artery intimal medial thickness', 'Fatigue', 'Cervical lymphadenopathy', 'Neck pain']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vasculitis**: Takayasu arteritis is a large-vessel vasculitis primarily affecting the aorta and its branches. The presence of vasculitis aligns with this diagnosis.  
2. **Elevated ESR/CRP**: These markers indicate systemic inflammation, consistent with active arteritis.  
3. **Increased carotid intimal thickness**: Characteristic of arterial wall inflammation and remodeling in Takayasu arteritis, often visualized via ultrasound or angiography.  
4. **Cervical lymphadenopathy/neck pain**: Inflammation of adjacent lymph nodes and arterial involvement (e.g., carotidynia) may explain these symptoms.  
5. **Fatigue**: A nonspecific but common systemic symptom of chronic inflammatory diseases.  
6. **Exclusion of mimics**: Symptoms differentiate it from other vasculitides (e.g., giant cell arteritis, which typically involves temporal arteries) or infections.  
Diagnosis is supported by the combination of vascular, inflammatory, and structural findings, meeting criteria for Takayasu arteritis (e.g., ACR classification)."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG due to abnormal glycosylation affecting cerebellar development.  
2. **Ataxia and motor delay**: Directly linked to cerebellar dysfunction from structural anomalies.  
3. **Generalized hypotonia**: Common in glycosylation disorders due to impaired neuromuscular function.  
4. **Intellectual disability**: Reflects global neurodevelopmental impairment from glycosylation defects.  
5. **Strabismus**: Associated with cerebellar malformation impacting ocular motor control.  
6. **Death in childhood**: Severe PMM2-CDG cases often lead to early mortality from multi-organ failure or infections.  
7. **Systemic confirmation**: PMM2-CDG’s biochemical profile (e.g., abnormal transferrin isoforms) and genetic testing for *PMM2* mutations would confirm the diagnosis."
"['Intellectual disability', 'Ataxia', 'Death in infancy', 'Abnormal heart valve morphology', 'Hyperammonemia', 'Hyperglycinemia', 'Severe short stature', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Death in early adulthood']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: Propionic acidemia (PA) disrupts propionyl-CoA metabolism, causing accumulation of toxic metabolites that inhibit the urea cycle (leading to hyperammonemia) and impair glycine cleavage (resulting in hyperglycinemia).  
2. **Neurological Symptoms (Intellectual disability, Ataxia)**: Elevated ammonia and glycine are neurotoxic, contributing to developmental delays, intellectual disability, and motor dysfunction.  
3. **Abnormal Carnitine & Porphyrin Levels**: Secondary carnitine deficiency arises from excessive conjugation with propionyl-CoA for excretion. Porphyrin abnormalities may reflect mitochondrial dysfunction or oxidative stress.  
4. **Recurrent Infections & Early Mortality**: Metabolic crises during catabolic stressors (e.g., infections) exacerbate acidosis and organ failure, leading to recurrent decompensation and early death (infancy to adulthood).  
5. **Cardiac & Growth Issues**: Chronic metabolic instability causes cardiomyopathy, abnormal heart valves, and failure to thrive (severe short stature).  
6. **Hearing Loss**: Neurodegeneration or oxidative damage from toxic metabolites may explain sensorineural hearing impairment.  

PA’s hallmark biochemical triad—elevated propionate, hyperammonemia, and hyperglycinemia—aligns with the symptoms, confirming the diagnosis."
"['Nephritis', 'Syncope', 'Death in infancy', 'Premature birth', 'Vomiting', 'Diarrhea', 'Elevated hepatic transaminase', 'Neonatal death', 'Death in childhood']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
**Reasoning**:  
1. **Elevated hepatic transaminase** and **vomiting/diarrhea** align with PMM2-CDG’s hallmark liver dysfunction and gastrointestinal involvement due to impaired glycosylation.  
2. **Premature birth** and **neonatal/infant/childhood death** reflect the disorder’s severe multisystemic nature, often fatal in early life.  
3. **Syncope** suggests neurological compromise (e.g., stroke-like episodes, autonomic dysfunction), a common feature of PMM2-CDG.  
4. **Nephritis**, though less typical, may arise from secondary immune dysregulation or protein-losing complications seen in CDG.  
5. The combination of hepatic, neurological, and gastrointestinal symptoms with early lethality strongly supports PMM2-CDG, the most prevalent CDG subtype."
"['Hyperactivity', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Ichthyosis', 'Death in adolescence', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline and hyperammonemia are hallmark biochemical features of citrullinemia, a urea cycle disorder caused by argininosuccinate synthetase deficiency. Neonatal death, death in infancy/childhood, and intellectual disability align with the severe metabolic decompensation and neurotoxicity from ammonia accumulation. Hyperactivity may reflect neurological irritation during hyperammonemic crises.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia (type I) specifically presents with life-threatening hyperammonemia in early life, consistent with neonatal death and death in infancy/childhood. Elevated citrulline directly confirms the enzymatic defect. Obesity and ichthyosis are atypical but may arise secondary to chronic metabolic derangements or comorbid nutritional interventions. The absence of citrin deficiency (type II) markers (e.g., adult-onset, cholestasis) further supports type I."
"['Hypogonadotropic hypogonadism', 'Poikiloderma', 'Neutropenia', 'Bronchiectasis', 'Short stature', 'Abnormal pulmonary interstitial morphology', 'Granuloma']",['Poikiloderma with neutropenia'],"Disease: Poikiloderma with neutropenia (PN)  
Reasoning:  
1. **Poikiloderma**: A hallmark feature of PN, characterized by skin changes (reticular pigmentation, telangiectasia, atrophy).  
2. **Neutropenia**: Directly named in the diagnosis, often chronic and linked to recurrent infections.  
3. **Bronchiectasis/Abnormal pulmonary interstitial morphology**: PN is associated with progressive pulmonary fibrosis and bronchiectasis due to recurrent infections or intrinsic lung tissue abnormalities.  
4. **Short stature**: Common in PN due to growth hormone insensitivity or systemic chronic inflammation.  
5. **Granuloma**: May arise from chronic inflammation or recurrent infections secondary to neutropenia.  
6. **Hypogonadotropic hypogonadism**: Rarely reported in PN, potentially linked to hypothalamic-pituitary axis dysfunction or systemic disease burden.  

Excluded alternatives (e.g., Rothmund-Thomson syndrome, dyskeratosis congenita) due to absence of key features (e.g., skeletal defects, nail dystrophy) and stronger alignment with PN’s core triad (poikiloderma, neutropenia, pulmonary complications)."
"['Hyporeflexia', 'Muscle weakness', 'Myotonia', 'Elevated circulating creatine kinase concentration', 'Muscle stiffness', 'Cytochrome C oxidase-negative muscle fibers', 'Generalized muscle hypertrophy']","['Myotonia congenita, autosomal dominant']","Disease: Myotonia congenita, autosomal dominant  
Reasoning: The patient presents with myotonia (delayed muscle relaxation) and muscle stiffness, hallmark features of myotonia congenita. Generalized muscle hypertrophy aligns with the autosomal dominant form (Thomsen disease), where muscle enlargement is common. Hyporeflexia and muscle weakness may occur due to altered muscle membrane excitability. Elevated creatine kinase suggests mild muscle damage from chronic myotonic activity. Cytochrome C oxidase (COX)-negative fibers, while atypical, could reflect secondary mitochondrial dysfunction from prolonged muscle stress. The absence of systemic features (e.g., cardiac or ocular involvement) excludes myotonic dystrophy, and autosomal dominance distinguishes it from the recessive Becker variant."
"['Macroglossia', 'Macrocephaly', 'Coarse facial features', 'Hyperactivity', 'Splenomegaly', 'Hepatomegaly', 'Death in childhood', 'Recurrent viral infections', 'Death in adolescence', 'Feeding difficulties']","['Mucopolysaccharidosis type 2/Mucopolysaccharidosis, type II', 'Mucopolysaccharidoses; MPS']","Disease: Mucopolysaccharidosis type 2 (MPS II/Hunter syndrome)  
**Reasoning**:  
1. **Macroglossia, macrocephaly, coarse facial features**: Hallmark signs of mucopolysaccharidoses (MPS) due to glycosaminoglycan (GAG) accumulation in connective tissues, causing facial dysmorphism and tongue enlargement.  
2. **Hepatosplenomegaly**: Caused by GAG storage in visceral organs, common in MPS II.  
3. **Recurrent viral infections**: Impaired immune function from GAG accumulation in immune cells or secondary to organomegaly disrupting lymphoid tissue.  
4. **Hyperactivity/neurobehavioral issues**: Seen in MPS II due to progressive central nervous system involvement, though cognitive decline typically follows.  
5. **Feeding difficulties**: Related to macroglossia, airway obstruction, or gastrointestinal GAG deposition.  
6. **Early mortality (childhood/adolescence)**: Severe MPS II leads to cardiorespiratory complications or neurodegeneration, with death often by adolescence.  

Disease: Mucopolysaccharidoses (MPS)  
**Reasoning**:  
- The symptoms collectively align with MPS disorders, characterized by lysosomal enzyme deficiencies causing GAG accumulation.  
- **MPS II specificity**: X-linked inheritance (other MPS types are autosomal recessive), absence of corneal clouding (common in MPS I but rare in MPS II), and hyperactivity (more typical of MPS II than MPS I).  
- **Exclusion of other MPS types**: Lack of corneal clouding (MPS I), disproportionate short stature (MPS IV), or severe skeletal dysplasia (MPS VI) narrows the diagnosis to MPS II.  

**Final Diagnosis**: **Mucopolysaccharidosis type II (Hunter syndrome)** is the most precise fit given the symptom profile, early mortality, and absence of features specific to other MPS subtypes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** reflects the congenital nature of PKU (autosomal recessive inheritance), though structural prenatal anomalies are typically absent unless maternal PKU syndrome is involved.  
3. **Death in infancy/Neonatal death** occurs in severe, untreated cases due to progressive neurological damage (e.g., seizures, brain atrophy) and systemic complications, though neonatal death is rare with modern screening. Early dietary intervention prevents these outcomes, but untreated PKU can lead to fatal metabolic derangements."
"['Hydrocephalus', 'Ventriculomegaly', 'Semilobar holoprosencephaly']",['Holoprosencephaly 5'],"Disease: Holoprosencephaly 5 (HPE5, OMIM 609637)  
Reasoning:  
1. **Semilobar holoprosencephaly** is a key diagnostic feature of holoprosencephaly (HPE), a spectrum disorder caused by failed forebrain division.  
2. **Hydrocephalus** and **ventriculomegaly** are common secondary findings in HPE due to impaired cerebrospinal fluid dynamics.  
3. HPE5 is specifically linked to **heterozygous pathogenic variants in the ZIC2 gene**, which regulates early forebrain patterning.  
4. ZIC2-associated HPE often presents with semilobar HPE and characteristic facial features (e.g., hypotelorism, midline defects), though facial dysmorphism may not always be severe.  
5. The triad of symptoms aligns with ZIC2 dysfunction, distinguishing HPE5 from other HPE subtypes (e.g., SHH, SIX3, or TGIF1-related HPE)."
"['Nephritis', 'Death in infancy', 'Hypophosphatemia', 'Abnormality of limb bone morphology', 'Abnormal circulating hormone concentration', 'Elevated circulating alkaline phosphatase concentration', 'Death in childhood']","['Hypophosphatemic rickets/Hypophosphatemic rickets', 'X-linked hypophosphatemia/Hypophosphatemic rickets, X-linked dominant']","Disease: Hypophosphatemic rickets  
Reasoning: The patient presents with **hypophosphatemia**, **abnormality of limb bone morphology**, and **elevated alkaline phosphatase**, which are hallmark features of hypophosphatemic rickets. Chronic phosphate wasting leads to defective bone mineralization, causing skeletal deformities. Elevated alkaline phosphatase reflects increased bone turnover. While nephritis and early mortality are atypical for classic hypophosphatemic rickets, severe untreated cases may involve renal complications (e.g., nephrocalcinosis) or systemic failure contributing to early death.  

Disease: X-linked hypophosphatemia/Hypophosphatemic rickets, X-linked dominant  
Reasoning: **Hypophosphatemia** and **abnormal limb bone morphology** strongly align with X-linked hypophosphatemia (XLH), caused by *PHEX* gene mutations leading to excess FGF23. **Abnormal circulating hormone concentration** likely refers to elevated FGF23, which drives renal phosphate wasting. While XLH rarely causes infant/childhood death, severe cases (e.g., untreated male hemizygotes) may experience life-threatening complications like respiratory insufficiency due to chest wall deformities or refractory metabolic disturbances. **Nephritis** could stem from secondary renal damage (e.g., hypercalciuria-induced nephrocalcinosis). This subtype explains the X-linked inheritance pattern and biochemical profile."
"['Death in infancy', 'Neonatal death', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Galactosemia; GAL/Galactosemia  
Reasoning: Hypergalactosemia (elevated galactose in blood) is a hallmark of galactosemia, caused by deficient activity of galactose-1-phosphate uridylyltransferase (GALT). Neonatal death and infant mortality align with severe metabolic derangements (e.g., liver failure, sepsis) if untreated.  

Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: Classic galactosemia (Type I) specifically involves GALT enzyme deficiency. Untreated infants develop life-threatening complications (e.g., jaundice, vomiting, E. coli sepsis) within days of galactose exposure (breast milk/formula), explaining neonatal death. Hypergalactosemia confirms impaired galactose metabolism."
"['Nephrolithiasis', 'Secondary amenorrhea', 'Headache', 'Duodenal ulcer', 'Pituitary adenoma', 'Elevated circulating parathyroid hormone level', 'Back pain', 'Primary hyperparathyroidism', 'Adrenocorticotropic hormone deficiency', 'Macroscopic hematuria', 'Thymoma', 'Carcinoid tumor', 'Neuroendocrine neoplasm', 'Galactorrhea', 'Hypergastrinemia']",['Multiple endocrine neoplasia type 1/Multiple endocrine neoplasia 1'],"Multiple endocrine neoplasia type 1 (MEN1):  
1. **Primary hyperparathyroidism and elevated parathyroid hormone**: MEN1 classically presents with parathyroid hyperplasia/adenomas, leading to hypercalcemia and complications like nephrolithiasis (kidney stones) and back pain.  
2. **Pituitary adenoma**: MEN1-associated pituitary tumors (e.g., prolactinoma) explain galactorrhea (excess prolactin) and secondary amenorrhea (disrupted menstrual cycle). ACTH deficiency suggests partial pituitary dysfunction.  
3. **Neuroendocrine neoplasms**: Duodenal ulcer with hypergastrinemia indicates a gastrinoma (pancreatic/duodenal neuroendocrine tumor), a hallmark of MEN1. Thymoma and carcinoid tumor are additional neuroendocrine tumors linked to MEN1.  
4. **Multi-gland involvement**: The coexistence of parathyroid, pituitary, and gastroenteropancreatic neuroendocrine tumors fulfills the diagnostic criteria for MEN1. Genetic testing for *MEN1* gene mutations would confirm the diagnosis."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Single transverse palmar crease', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Intellectual disability, mild', 'Global developmental delay', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Intellectual disability (mild), global developmental delay, ADHD/hyperactivity, and atypical behavior align with the core neurocognitive deficits in NEDBEH.  
2. **Brain anomalies**: Abnormal corpus callosum, cerebellar vermis, and pons morphology, cerebral hypomyelination, ventriculomegaly, and delayed myelination match the ""brain"" phenotype in NEDBEH.  
3. **Ocular anomalies**: Coloboma, microphthalmia, blepharophimosis, Peters anomaly, optic atrophy, and iris/eyebrow abnormalities satisfy the ""eye"" criterion.  
4. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return correspond to the ""heart"" component.  
5. **Supportive systemic features**: Cleft lip, renal cysts, gastrointestinal anomalies (pyloric stenosis, duodenal atresia), and skeletal findings (syndactyly, scoliosis) are reported in NEDBEH.  
6. **Overlapping dysmorphism**: Microcephaly/macrocephaly, triangular face, micrognathia, hypertelorism, and narrow mouth are consistent with facial gestalt seen in NEDBEH.  
7. **Hypotonia/spasticity**: Generalized hypotonia and spastic tetraparesis reflect the CNS involvement typical of the disorder.  

The constellation of neurodevelopmental delays, structural brain/eye/heart anomalies, and multisystem involvement strongly supports this diagnosis over isolated syndromes (e.g., CHARGE, Rubinstein-Taybi) due to the absence of pathognomonic features for other entities."
"['Sinusitis', 'Proptosis', 'Diplopia', 'Hypertension', 'Orbital cyst', 'Mitral regurgitation', 'Aortic regurgitation', 'Left ventricular hypertrophy', 'Hypertriglyceridemia', 'Hepatomegaly', 'Neoplasm of the liver', 'Hypercholesterolemia', 'Tricuspid regurgitation', 'Decreased glomerular filtration rate', 'Oculomotor nerve palsy', 'Increased circulating IgG4 level', 'Palpebral edema']","['Multifocal fibrosclerosis', 'IgG4-related retroperitoneal fibrosis', 'IgG4 related disease; IgG4-RD']","Disease: IgG4 related disease; IgG4-RD  
Reasoning:  
1. **Increased circulating IgG4 level** is a hallmark of IgG4-RD, supporting systemic immune dysregulation.  
2. **Sinusitis, proptosis, orbital cyst, oculomotor nerve palsy, and palpebral edema** suggest orbital and sinonasal involvement, consistent with IgG4-RD’s propensity for lacrimal/salivary gland inflammation and mass lesions.  
3. **Hepatomegaly and neoplasm of the liver** align with IgG4-related hepatopathy or sclerosing cholangitis, mimicking tumors.  
4. **Mitral/aortic/tricuspid regurgitation and left ventricular hypertrophy** may reflect IgG4-RD-associated inflammatory infiltration of cardiac structures or vasculature.  
5. **Decreased glomerular filtration rate** could indicate IgG4-related kidney disease (tubulointerstitial nephritis).  
6. **Hypertension and hyperlipidemia** may be secondary to renal involvement or metabolic dysregulation in IgG4-RD.  
7. Multisystem involvement (ocular, cardiac, hepatic, renal) with elevated IgG4 confirms **IgG4-RD** as the unifying diagnosis, encompassing subtypes like retroperitoneal fibrosis and multifocal fibrosclerosis under its spectrum.  

Disease: IgG4-related retroperitoneal fibrosis  
Reasoning:  
- **Decreased glomerular filtration rate** and **hypertension** suggest retroperitoneal fibrosis compressing renal vasculature/ureters, a classic feature of this subtype.  

Disease: Multifocal fibrosclerosis  
Reasoning:  
- **Orbital cyst, hepatomegaly, and neoplasm-like liver lesions** reflect fibrosis in multiple organs, a hallmark of multifocal fibrosclerosis, now recognized as part of the IgG4-RD spectrum."
"['Hypoglycemia', 'Glycosuria', 'Abnormal circulating porphyrin concentration']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: MODY (Maturity-Onset Diabetes of the Young)  
Reasoning: Hypoglycemia and glycosuria suggest a defect in glucose regulation. MODY is a monogenic form of diabetes characterized by beta-cell dysfunction, often presenting with atypical diabetes features. The coexistence of hypoglycemia (indicative of insulin dysregulation) and glycosuria (glucose excretion despite normal or low blood glucose levels) points to a renal threshold alteration or fluctuating glucose levels, common in MODY subtypes.  

Disease: MODY type 1 (HNF4A mutation)  
Reasoning:  
1. **Hypoglycemia**: Neonatal or childhood hypoglycemia is a hallmark of HNF4A-MODY due to transient hyperinsulinism in early life.  
2. **Glycosuria**: Progressive beta-cell dysfunction leads to hyperglycemia in adolescence/adulthood, causing glycosuria. Reduced renal glucose reabsorption (via SGLT2 downregulation) may also contribute.  
3. **Abnormal porphyrins**: HNF4A regulates hepatic genes involved in metabolism, potentially affecting heme synthesis pathways indirectly. This could explain abnormal porphyrin levels, though this association is less defined and may require further investigation.  

This combination aligns with MODY type 1, where hypoglycemia precedes diabetes onset, and metabolic dysregulation impacts multiple pathways. Genetic testing for HNF4A mutations is critical for confirmation."
"['Brachydactyly', 'Genu varum', 'Trident hand', 'Abnormality of alkaline phosphatase level', 'Narrow vertebral interpedicular distance', 'Abnormal serum insulin-like growth factor 1 level', 'Abnormal circulating thyroid hormone concentration', 'Short femoral neck', 'Short iliac bones']",['Hypochondroplasia/Hypochondroplasia'],"Disease: Hypochondroplasia  
Reasoning:  
1. **Brachydactyly, Genu varum, Trident hand**: Common skeletal features in FGFR3-related chondrodysplasias. Hypochondroplasia, a milder form of achondroplasia, often presents with these due to abnormal endochondral ossification.  
2. **Narrow vertebral interpedicular distance, Short iliac bones, Short femoral neck**: Reflects characteristic spinal and pelvic abnormalities in hypochondroplasia, driven by defective growth plate development.  
3. **Abnormality of alkaline phosphatase level**: Linked to altered bone remodeling and turnover, typical of skeletal dysplasias.  
4. **Abnormal serum IGF-1 level**: May arise from growth hormone axis dysregulation secondary to skeletal dysplasia, contributing to short stature.  
5. **Abnormal thyroid hormone levels**: Less directly associated but occasionally seen in skeletal disorders due to systemic metabolic interplay or coincidental endocrine dysfunction.  
6. **Clinical overlap exclusion**: Features align more with hypochondroplasia than classic achondroplasia (less severe craniofacial involvement, later diagnosis) or other skeletal dysplasias (e.g., no metaphyseal flare seen in rickets). Genetic testing for FGFR3 mutations (e.g., p.Asn540Lys) would confirm."
"['Death in infancy', 'Dehydration', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Feeding difficulties']","['甲基丙二酸血症; 甲基丙二酸尿症/Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **decreased methylmalonyl-CoA mutase activity**, a hallmark of methylmalonic acidemia (MMA). This enzyme deficiency disrupts the breakdown of methylmalonyl-CoA, leading to toxic accumulation of methylmalonic acid. Symptoms like **feeding difficulties**, **dehydration**, and **neonatal/infant death** align with acute metabolic decompensation, a critical feature of MMA. Early-onset life-threatening crises are typical in severe forms of the disease.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **decreased methylmalonyl-CoA mutase activity** specifically indicates a defect in the MUT gene encoding this enzyme, categorizing the condition as a **vitamin B12-unresponsive** subtype. Unlike B12-responsive MMA, this form does not improve with B12 supplementation. The severity of symptoms (e.g., **neonatal death**, **feeding difficulties**) reflects complete or near-complete loss of enzyme function, causing rapid metabolic instability and poor prognosis without aggressive intervention (e.g., dietary protein restriction, organ transplantation)."
"['Delayed speech and language development', 'Intellectual disability, mild', 'Global developmental delay', 'Brisk reflexes', 'Talipes equinovarus', 'Hypoplasia of the corpus callosum', 'Progressive spasticity', 'Unsteady gait', 'Frontal cortical atrophy', 'Axial hypotonia', 'Ankle clonus', 'Abnormal optic disc morphology', 'Hyperintensity of cerebral white matter on MRI']","['Autosomal recessive spastic paraplegia type 45/Spastic paraplegia 45, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 45 (SPG45)  
Reasoning:  
1. **Neurodevelopmental and cognitive features**: Delayed speech, mild intellectual disability, and global developmental delay align with early-onset genetic neurological disorders, consistent with complicated hereditary spastic paraplegia (HSP).  
2. **Upper motor neuron signs**: Brisk reflexes, progressive spasticity, ankle clonus, and unsteady gait indicate corticospinal tract dysfunction, hallmark features of HSP.  
3. **Structural brain abnormalities**: Hypoplasia of the corpus callosum, frontal cortical atrophy, and cerebral white matter hyperintensity on MRI are characteristic of SPG45, which often involves brain malformations and leukoencephalopathy.  
4. **Axial hypotonia with peripheral spasticity**: A paradoxical combination seen in HSPs, where truncal weakness coexists with limb spasticity.  
5. **Talipes equinovarus**: Congenital foot deformity occasionally associated with neurogenetic disorders like SPG45 due to prenatal neuromuscular dysfunction.  
6. **Progression**: Progressive spasticity and gait deterioration match the natural history of SPG45, which involves neurodegeneration.  
7. **Optic disc abnormality**: May reflect subtle optic nerve involvement, reported in some HSP subtypes.  
8. **Exclusion of mimics**: Features distinguish SPG45 from leukodystrophies (no metabolic crises) or mitochondrial disorders (lack of multisystemic involvement). Genetic confirmation of *NT5C2* mutations would confirm SPG45."
"['Ataxia', 'Spasticity', 'Spastic gait', 'Clonus', 'Clumsiness', 'Paresthesia', 'Babinski sign', 'Impaired distal vibration sensation', 'Peripheral neuropathy', 'Dysesthesia', 'Abnormal cranial nerve physiology', 'Cognitive impairment']","['Autosomal dominant spastic paraplegia type 10/Spastic paraplegia 10, autosomal dominant']","Disease: Autosomal dominant spastic paraplegia type 10/Spastic paraplegia 10, autosomal dominant  
Reasoning:  
1. **Upper Motor Neuron (UMN) Features**: Spasticity, spastic gait, clonus, and Babinski sign indicate corticospinal tract dysfunction, a hallmark of hereditary spastic paraplegias (HSPs).  
2. **Peripheral Nervous System Involvement**: Peripheral neuropathy, paresthesia, dysesthesia, and impaired distal vibration sensation suggest axonal neuropathy, which aligns with SPG10’s association with *KIF5A* mutations affecting neuronal transport.  
3. **Mixed Phenotype**: Co-occurrence of UMN signs (spasticity) and lower motor neuron/sensory symptoms (neuropathy) is characteristic of complex HSP subtypes like SPG10.  
4. **Cognitive Impairment & Cranial Nerve Abnormalities**: Mild cognitive deficits and cranial nerve dysfunction (e.g., optic neuropathy, hearing loss) are reported in SPG10 due to widespread neuronal degeneration.  
5. **Exclusion of Mimics**: The absence of prominent cerebellar atrophy (ataxia here may stem from spasticity or neuropathy) and systemic features rules out alternatives like spinocerebellar ataxias or ALS.  
6. **Genetic Consistency**: SPG10 is autosomal dominant, fitting a family history (if present), and *KIF5A* mutations disrupt axonal transport, explaining both central and peripheral nervous system involvement."
"['Recurrent urinary tract infections', 'Abnormality of the hand', 'Wrist swelling', 'Abnormality of the gluteal musculature', 'Leukopenia', 'Microcytic anemia', 'Hypoglycemia', 'Headache', 'Vertigo', 'Paresthesia', 'Spinal canal stenosis', 'Back pain', 'Somatic sensory dysfunction', 'Elevated erythrocyte sedimentation rate', 'Generalized morning stiffness', 'Decreased circulating complement C3 concentration', 'Sleep-wake cycle disturbance', 'Elevated circulating C-reactive protein concentration', 'Sacroiliac arthritis', 'Upper limb pain', 'Tendonitis', 'Shoulder pain', 'Wrist pain', 'Knee pain', 'Increased circulating NT-proBNP concentration', 'Enthesitis']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The patient presents with sacroiliac arthritis, enthesitis, spinal canal stenosis, back pain, and elevated inflammatory markers (ESR, CRP), which are hallmark features of spondyloarthropathy (SpA). Morning stiffness and axial involvement (spinal/sacroiliac) align with inflammatory SpA subtypes like ankylosing spondylitis. HLA-B27 (associated with susceptibility 1) is a key genetic risk factor for SpA, supporting this diagnosis. Tendonitis, peripheral arthritis (wrist, knee, shoulder), and reactive arthritis-like triggers (recurrent UTIs) further reinforce SpA classification.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Susceptibility 2 likely involves non-HLA-B27 genetic factors (e.g., ERAP1), which interact with HLA-B27 to increase SpA risk. The patient’s microcytic anemia and leukopenia may reflect chronic inflammation, while hypoglycemia and sleep disturbances could stem from systemic inflammatory burden. Elevated NT-proBNP suggests cardiac strain, a rare extracurricular manifestation of SpA. Low C3 hints at complement consumption, possibly from immune complex activity in enthesitis. Neurological symptoms (paresthesia, vertigo) may arise from spinal stenosis or nerve compression due to structural SpA complications. Hand abnormalities and peripheral joint swelling are consistent with psoriatic or reactive arthritis subtypes within the SpA spectrum."
"['Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Metabolic acidosis', 'Apnea', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Feeding difficulties', 'Methylmalonic aciduria', 'Abnormal nervous system physiology']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria** and **decreased methylmalonyl-CoA mutase activity**, hallmark biochemical features of MMA. Symptoms like **metabolic acidosis**, **apnea**, **feeding difficulties**, and **abnormal nervous system physiology** align with MMA's pathophysiology, where toxic methylmalonic acid accumulates, disrupting energy metabolism and causing multi-organ dysfunction. **Thrombocytopenia** and **leukopenia** may result from bone marrow suppression secondary to metabolic stress. **Neonatal death** and **death in infancy** are consistent with severe, untreated MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **decreased methylmalonyl-CoA mutase activity** directly indicates a defect in the MUT gene, causing the B12-unresponsive subtype of MMA. This subtype does not improve with vitamin B12 supplementation, distinguishing it from B12-responsive forms. Symptoms such as **generalized hypotonia**, **metabolic acidosis**, and **methylmalonic aciduria** are classic for this genetic enzyme deficiency. Early lethality (**neonatal death**, **death in infancy**) is characteristic of severe mutase deficiency (mut⁰ or mut⁻ variants), where residual enzyme activity is minimal or absent."
"['Sensorineural hearing impairment', 'Apathy', 'Waddling gait', 'Bone pain', 'Scapular winging', 'Proximal muscle weakness', 'Rimmed vacuoles', 'Proximal amyotrophy', 'Mildly elevated creatine kinase', 'Elevated alkaline phosphatase of bone origin', 'Cognitive impairment']",['Inclusion body myopathy with Paget disease of bone and frontotemporal dementia/Inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1'],"Disease: Inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD)  
Reasoning:  
1. **Proximal muscle weakness, scapular winging, waddling gait, rimmed vacuoles, and proximal amyotrophy**: These are hallmark features of inclusion body myopathy (IBM). Rimmed vacuoles on muscle biopsy are pathognomonic for IBM, while proximal weakness and scapular winging indicate muscle degeneration affecting the shoulder and pelvic girdles.  
2. **Elevated alkaline phosphatase (bone origin) and bone pain**: These suggest Paget disease of bone, characterized by dysregulated bone remodeling. Elevated bone-specific ALP reflects increased osteoblastic activity.  
3. **Cognitive impairment and apathy**: Align with frontotemporal dementia (FTD), which manifests with behavioral changes and executive dysfunction.  
4. **Sensorineural hearing loss**: A recognized but less common feature of IBMPFD, possibly due to genetic mutations (e.g., *VCP*) affecting cochlear or neural structures.  
5. **Mildly elevated creatine kinase**: Consistent with chronic muscle breakdown in myopathy, though levels are typically less elevated than in inflammatory myopathies.  
**Conclusion**: The triad of IBM, Paget disease, and FTD, alongside supportive findings (hearing loss, CK elevation), confirms IBMPFD, most commonly linked to *VCP* gene mutations."
"['Xerostomia', 'Decreased lacrimation', 'Abnormal finger morphology', 'Wrist swelling', 'Abnormal foot morphology', 'Microcytic anemia', 'Migraine', 'Abnormality of the knee', 'Arthralgia', 'Rheumatoid factor positive', 'Increased circulating IgE level', 'Increased circulating IgG level', 'Myalgia', 'Muscle spasm', 'Antinuclear antibody positivity', 'Gastrointestinal inflammation', 'Generalized morning stiffness', 'Gastritis', 'Abnormal metacarpophalangeal joint morphology', 'Wrist pain', 'Knee pain', 'Ankle pain', 'Anti-La/SS-B antibody positivity', 'Increased circulating procalcitonin concentration']","['Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis', 'Reactive arthritis', 'Primary Sjögren syndrome/Sjogren syndrome', 'Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis', 'Systemic-onset juvenile idiopathic arthritis']","Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning: Xerostomia (dry mouth) and decreased lacrimation (dry eyes) are hallmark sicca symptoms of Sjögren syndrome. Anti-La/SS-B antibody positivity strongly supports this diagnosis, as these antibodies are specific to Sjögren syndrome. Increased circulating IgG and IgE levels align with autoimmune hyperactivity, and ANA positivity is common in Sjögren syndrome.  

Disease: Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis  
Reasoning: Wrist swelling, wrist/knee/ankle pain, arthralgia, morning stiffness, and rheumatoid factor positivity indicate inflammatory polyarthritis. Abnormal metacarpophalangeal joint morphology and systemic features (e.g., myalgia, elevated procalcitonin) further support juvenile idiopathic arthritis (JIA). Rheumatoid factor positivity specifically distinguishes the polyarticular RF-positive subtype.  

Disease: Reactive arthritis  
Reasoning: Asymmetric joint involvement (wrist, knee, ankle), gastrointestinal inflammation, and elevated procalcitonin (suggesting prior infection) could indicate reactive arthritis. However, this is less likely given the presence of Sjögren-specific antibodies and rheumatoid factor positivity, which point to autoimmune rather than post-infectious etiology.  

Excluded: Systemic-onset juvenile idiopathic arthritis  
Reasoning: Systemic-onset JIA typically presents with quotidian fevers, evanescent rash, and marked systemic inflammation, which are absent here. The patient’s symptoms focus on joints and autoantibodies, not systemic features.  

Excluded: Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis  
Reasoning: Rheumatoid factor positivity directly contradicts this diagnosis. The patient’s joint abnormalities and inflammation align with RF-positive JIA instead.  

**Final Diagnosis**: Coexisting **Primary Sjögren syndrome** and **Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis**, given overlapping autoimmune features (sicca symptoms, RF/ANA/anti-La positivity) and inflammatory polyarthritis."
"['Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Infantile muscular hypotonia', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Abnormal protein O-linked glycosylation', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Abnormal N-linked and O-linked glycosylation**: Indicates a Golgi-associated glycosylation defect (Type II CDG), consistent with TMEM199-CDG, which disrupts Golgi homeostasis.  
2. **Hepatic involvement**: Elevated AST, ALT, and alkaline phosphatase reflect liver dysfunction, a hallmark of TMEM199-CDG due to impaired glycosylation-dependent hepatic protein secretion.  
3. **Hypotonia/developmental delay**: Common in CDGs due to systemic glycosylation defects affecting neurological and muscular development.  
4. **Hypercholesterolemia/increased LDL**: Linked to disrupted LDL receptor glycosylation or altered lipid metabolism regulation in the liver.  
5. **Decreased ceruloplasmin**: Ceruloplasmin is a glycoprotein; improper glycosylation reduces its stability, leading to low circulating levels.  
6. **TMEM199 gene association**: Confirms CDG-Type IIP, as TMEM199 mutations specifically impair Golgi manganese transport, critical for glycosylation enzymes.  

(Note: The two diagnoses provided are synonymous, as ""Congenital disorder of glycosylation, type IIP"" is the clinical term for TMEM199-CDG.)"
"['Hypotonia', 'Generalized hypotonia', 'Joint hypermobility', 'Patellar aplasia', 'Nail dystrophy', ""Lester's sign""]",['Nail-patella syndrome/Nail-Patella syndrome'],"Disease: Nail-Patella syndrome  
Reasoning:  
1. **Patellar aplasia** (absence of the kneecap) is a cardinal feature of Nail-Patella syndrome, directly linked to its name.  
2. **Nail dystrophy** (abnormal nail growth, often hypoplastic/ridged nails, especially on thumbs) is a hallmark symptom.  
3. **Lester's sign** (cloverleaf-shaped pigmentation of the iris) is pathognomonic for this syndrome.  
4. **Joint hypermobility** aligns with connective tissue abnormalities caused by LMX1B gene mutations in Nail-Patella syndrome.  
5. **Hypotonia** (generalized low muscle tone) may occur due to musculoskeletal involvement, though it is less specific.  
6. The combination of skeletal (patellar/hip anomalies), ectodermal (nail), and ocular (Lester's sign) findings is diagnostic for Nail-Patella syndrome, ruling out other connective tissue disorders (e.g., Ehlers-Danlos syndrome lacks the nail/patellar specificity)."
"['Cleft palate', 'Pierre-Robin sequence', 'Conductive hearing impairment', 'Decreased response to growth hormone stimulation test', 'Scoliosis', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome (CCMS)  
Reasoning:  
1. **Cleft palate and Pierre-Robin sequence**: CCMS is characterized by mandibular hypoplasia (micrognathia), glossoptosis, and cleft palate, consistent with Pierre-Robin sequence.  
2. **Posterior rib gaps**: A hallmark of CCMS, involving abnormal rib development with gaps or defects in the posterior ribs.  
3. **Scoliosis**: Likely secondary to thoracic rib abnormalities, which destabilize spinal alignment.  
4. **Conductive hearing impairment**: Associated with craniofacial malformations affecting middle ear structures.  
5. **Decreased growth hormone response**: While not a primary feature, growth issues may arise from systemic developmental anomalies or indirect endocrine disruptions in severe syndromic cases.  
The combination of craniofacial, rib, spinal, and endocrine abnormalities strongly supports a diagnosis of CCMS."
"['Malar flattening', 'Microretrognathia', 'Hearing impairment', 'Downslanted palpebral fissures']",['Treacher collins syndrome 2'],"Disease: Treacher Collins syndrome 2  
Reasoning:  
1. **Malar flattening** (underdeveloped zygomatic bones) aligns with the hallmark craniofacial hypoplasia in Treacher Collins syndrome (TCS).  
2. **Microretrognathia** (small, recessed jaw) is a cardinal feature of TCS due to mandibular hypoplasia.  
3. **Hearing impairment** correlates with TCS-associated middle/inner ear malformations (e.g., ossicular defects, cochlear anomalies).  
4. **Downslanted palpebral fissures** are characteristic of TCS, often accompanied by colobomas of the lower eyelids.  
5. TCS2 (caused by *POLR1D* mutations) shares these features with classical TCS (*TCOF1*-related TCS1), confirming the diagnosis given the phenotypic match."
"['Open mouth', 'Brachycephaly', 'Sloping forehead', 'Long philtrum', 'Deeply set eye', 'Shallow orbits', 'Reduced eye contact', 'Motor delay', 'Cerebellar atrophy', 'Areflexia', 'Absent septum pellucidum', 'Absent speech', 'Hyperreflexia', 'Microcytic anemia', 'Bilateral tonic-clonic seizure', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Status epilepticus', 'Enlarged cisterna magna', 'Global brain atrophy', 'Hypokinesia', 'Respiratory failure', 'Os odontoideum', 'Severe muscular hypotonia', 'CNS demyelination', 'Tented upper lip vermilion', 'Severe global developmental delay', 'Lipoma', 'Brain atrophy', 'EMG: myokymic discharges']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Features like *brachycephaly*, *sloping forehead*, *long philtrum*, *tented upper lip vermilion*, and *deeply set eyes* align with the facial dysmorphisms described in TBCK syndrome.  
2. **Neurological and developmental deficits**: *Severe muscular hypotonia*, *motor delay*, *absent speech*, *severe global developmental delay*, and *hypokinesia* correlate with the syndrome’s hallmark hypotonia and psychomotor retardation.  
3. **Brain abnormalities**: *Cerebellar atrophy*, *global brain atrophy*, *hypoplasia of the corpus callosum*, *ventriculomegaly*, and *enlarged cisterna magna* reflect widespread CNS involvement, consistent with TBCK’s neurodegenerative features.  
4. **Seizure phenotype**: *Bilateral tonic-clonic seizures* and *status epilepticus* are reported in severe TBCK cases due to cortical and cerebellar dysfunction.  
5. **EMG findings**: *Myokymic discharges* suggest peripheral nerve hyperexcitability, observed in some TBCK patients with neuromuscular involvement.  
6. **Absent septum pellucidum** and **CNS demyelination**: These rare structural anomalies further support a complex neurodevelopmental disorder like TBCK.  
7. **Respiratory failure**: Likely secondary to severe hypotonia and brainstem dysfunction, a known complication in advanced stages.  
8. **Mixed reflex abnormalities**: *Areflexia* (from hypotonia) and *hyperreflexia* (from upper motor neuron involvement) highlight the multisystem neurological impact.  
9. **Lipoma** and **os odontoideum**: While less specific, they may represent connective tissue dysregulation linked to TBCK’s genetic pathway (mTORC1 dysregulation).  

The combination of facial dysmorphism, neurodevelopmental regression, CNS structural defects, and electrophysiological findings strongly points to TBCK-related syndrome. Genetic testing for *TBCK* mutations would confirm the diagnosis."
"['Death in infancy', 'Vomiting', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine** is a hallmark symptom of Alkaptonuria, caused by the oxidation of homogentisic acid (HGA) in urine upon exposure to air, leading to a black or brown discoloration.  
2. **Vomiting** in infancy, while not a primary feature of Alkaptonuria, may occur due to secondary complications (e.g., metabolic stress or renal involvement from HGA deposition).  
3. **Death in infancy** is atypical for Alkaptonuria, which is generally compatible with life. However, severe metabolic crises or misdiagnosis leading to untreated complications (e.g., acute kidney injury) might contribute to early mortality in rare cases.  
4. Alkaptonuria is confirmed via genetic testing (HGD gene mutations) or urinary HGA quantification. Early diagnosis is critical to manage long-term complications (e.g., ochronosis, arthritis).  

*Note: While Alkaptonuria aligns with dark urine, the presentation of infant mortality suggests additional factors (e.g., comorbid conditions or diagnostic delays) that warrant further investigation.*"
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Respiratory insufficiency', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Dicarboxylic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Neonatal death', 'Elevated urinary carboxylic acid']","['Mitochondrial complex IV deficiency, nuclear type 1']","Mitochondrial complex IV deficiency, nuclear type 1:  
The patient's **cytochrome C oxidase (COX)-negative muscle fibers** directly indicate a deficiency in mitochondrial complex IV (COX). **Increased serum lactate** and **elevated urinary carboxylic acids** reflect impaired oxidative phosphorylation and secondary metabolic disturbances. **Respiratory insufficiency**, **lethargy**, and **generalized hypotonia** align with energy failure in muscles and the central nervous system. **Dicarboxylic aciduria** suggests defective fatty acid oxidation, a compensatory mechanism in mitochondrial dysfunction. **Neonatal death** or **death in infancy** is typical in severe nuclear-encoded complex IV deficiencies (e.g., *SURF1* mutations). **Sleep disturbances** and **drowsiness** may stem from CNS energy deficits. This constellation of symptoms and biochemical findings is pathognomonic for mitochondrial complex IV deficiency, nuclear type 1."
"['Strabismus', 'Myopia', 'Delayed speech and language development', 'Ectopia lentis', 'Motor delay', 'Encephalopathy', 'Joint dislocation', 'Joint hypermobility', 'Hyperhomocystinemia', 'Cerebral edema', 'Clumsiness', 'Poor coordination', 'Hypermethioninemia', 'Aminoaciduria', 'Death in childhood', 'Death in adolescence']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning:  
1. **Hyperhomocystinemia** and **hypermethioninemia** are direct biochemical hallmarks of homocystinuria, caused by cystathionine beta-synthase (CBS) deficiency, impairing homocysteine metabolism.  
2. **Ectopia lentis** (lens dislocation) and **myopia** are classic ocular manifestations due to disrupted collagen cross-linking from elevated homocysteine.  
3. **Neurological features** (encephalopathy, cerebral edema, motor/speech delays, clumsiness, poor coordination) arise from homocysteine neurotoxicity and vascular injury.  
4. **Joint hypermobility/dislocation** reflects connective tissue abnormalities from defective cysteine synthesis.  
5. **Aminoaciduria** occurs secondary to renal tubular dysfunction caused by homocysteine accumulation.  
6. **Early mortality** (childhood/adolescence) aligns with untreated homocystinuria, often due to thromboembolic events or severe metabolic complications.  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **CBS deficiency** is the most common cause of homocystinuria, confirmed by **hypermethioninemia** (methionine accumulates due to blocked transsulfuration pathway).  
2. **Systemic involvement** (ocular, skeletal, neurological) matches the multisystemic nature of CBS deficiency.  
3. Absence of methylmalonic acidemia or megaloblastic anemia excludes vitamin B12/folate metabolism disorders.  
4. **Autosomal recessive inheritance** aligns with typical CBS deficiency presentation.  
5. Symptoms correlate with severe, untreated cases, emphasizing the need for pyridoxine responsiveness testing and dietary methionine restriction as therapeutic interventions."
"['Skin rash', 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Diarrhea', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule', 'Hernia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU diagnosis, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Skin manifestations (rash, erythematous plaques/macules/papules)**: Result from phenylalanine toxicity affecting skin integrity or secondary eczema-like reactions.  
3. **Prenatal abnormalities/neonatal or childhood death**: Likely due to maternal PKU syndrome, where uncontrolled maternal phenylalanine levels during pregnancy cause congenital defects (e.g., cardiac, microcephaly) or fetal loss.  
4. **Obesity**: May arise from a high-carbohydrate, low-protein diet used to manage PKU.  
5. **Gastrointestinal inflammation/diarrhea**: Linked to dietary restrictions or metabolic stress from amino acid imbalances.  
6. **Hypertyrosinemia**: Atypical for PKU but may reflect transient tyrosine fluctuations, lab misinterpretation, or secondary inhibition of tyrosine metabolism by excess phenylalanine.  
7. **Recurrent infections**: Poor metabolic control may weaken immune response or correlate with comorbid conditions.  
8. **Hernia**: Incidental or related to connective tissue changes from chronic metabolic stress.  

While neonatal death and hypertyrosinemia are uncommon in classical PKU, maternal PKU syndrome and severe untreated cases explain the broader phenotype."
"['Blindness', 'Nystagmus', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Opisthotonus', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal myelination', 'Severe hearing impairment']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal Myelination & Neurological Symptoms**: Canavan disease is a leukodystrophy characterized by spongy degeneration of white matter due to defective myelination, explaining motor delay, generalized hypotonia, and seizures.  
2. **Abnormal Aspartate Metabolism**: Elevated N-acetylaspartic acid (NAA) from aspartoacylase deficiency aligns with ""abnormal circulating aspartate family amino acid concentration,"" a hallmark of Canavan disease.  
3. **Severe Sensory Impairments**: Optic nerve atrophy (blindness, nystagmus) and auditory pathway damage (severe hearing impairment) are common in progressive cases.  
4. **Infantile Lethality**: Neonatal death or death in infancy reflects the severe, early-onset form of the disease.  
5. **Opisthotonus**: Hypertonia and abnormal posturing (opisthotonus) occur due to progressive neurodegeneration and corticospinal tract involvement.  
6. **Genetic Confirmation**: While not explicitly stated, the symptom constellation strongly aligns with autosomal recessive ASPA gene mutations causing Canavan disease."
"['Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Abnormal cardiac septum morphology', 'Abnormal facial shape', 'Kyphoscoliosis', 'Abnormal subcutaneous fat tissue distribution']","['Cutis laxa, autosomal recessive, type IID']","Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning:  
1. **Cutis laxa**: A hallmark feature of this disease group, indicating loose, sagging skin due to defective elastic fiber formation.  
2. **Abnormal heart morphology & cardiac septum defects**: Type IID is linked to mutations in *ATP6V0A2*, which disrupt lysosomal function and collagen/elastin processing, leading to cardiovascular anomalies like septal defects.  
3. **Kyphoscoliosis & hip dysplasia**: Connective tissue weakness causes skeletal abnormalities, including spinal curvature (kyphoscoliosis) and hip joint malformation.  
4. **Generalized hypotonia & flexion contractures**: Reduced muscle tone and joint contractures arise from systemic connective tissue dysfunction.  
5. **Disproportionate tall stature & abnormal fat distribution**: Growth abnormalities and metabolic dysregulation from lysosomal defects contribute to atypical body proportions and fat patterning.  
6. **Entropion & abnormal facial shape**: Elastic fiber defects in periocular tissue and facial structures result in inward-turning eyelids and dysmorphic facial features.  
7. **Autosomal recessive inheritance**: Matches the genetic pattern of *ATP6V0A2*-related disorders. The combination of cutaneous, skeletal, cardiac, and metabolic signs distinguishes type IID from other ARCL subtypes."
"['Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Hip dysplasia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently due to secondary metabolic disruptions or overlapping enzyme deficiencies (e.g., tyrosine metabolism defects).  
3. **Generalized hypotonia** and **motor delay** align with untreated PKU, where toxic phenylalanine accumulation disrupts neurotransmitter synthesis and myelination.  
4. **Abnormality of prenatal development or birth** and **hip dysplasia** are uncommon in PKU but may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy.  
5. **Death in infancy/neonatal death** is rare in isolated PKU but could indicate severe metabolic crises (e.g., rapid phenylalanine accumulation) or comorbid conditions.  

Note: Hypertyrosinemia and neonatal lethality suggest atypical presentations (e.g., BH4-deficient PKU or dual metabolic disorders), warranting genetic testing for PAH/BH4 pathway mutations and tyrosine metabolism enzymes (e.g., TAT, HPD)."
"['Supranuclear gaze palsy', 'Nystagmus', 'Ataxia', 'Dysarthria', 'Cerebellar atrophy', 'Lower limb spasticity', 'EEG abnormality', 'Difficulty walking', 'Lower limb hyperreflexia', 'Babinski sign', 'Abnormality of somatosensory evoked potentials', 'Abnormal motor evoked potentials', 'Cognitive impairment']","['Spastic paraplegia type 7/Spastic paraplegia 7, autosomal recessive']","Disease: Spastic paraplegia type 7/Spastic paraplegia 7, autosomal recessive  
Reasoning:  
1. **Core HSP features**: Lower limb spasticity, hyperreflexia, Babinski sign, and difficulty walking align with hereditary spastic paraplegia (HSP).  
2. **Cerebellar involvement**: Ataxia, dysarthria, and cerebellar atrophy suggest a ""complicated"" HSP subtype, which SPG7 is known to exhibit.  
3. **Ocular abnormalities**: Supranuclear gaze palsy and nystagmus are consistent with SPG7’s reported extrapyramidal and brainstem involvement.  
4. **Neurophysiological findings**: Abnormal motor/somatosensory evoked potentials reflect corticospinal tract and sensory pathway dysfunction, typical in SPG7. EEG abnormalities may indicate broader neuronal disruption.  
5. **Cognitive impairment**: Though less common in HSPs, cognitive decline has been documented in SPG7 due to progressive neurodegeneration.  
6. **Genetic correlation**: SPG7 is autosomal recessive and linked to *SPG7* gene mutations, which disrupt mitochondrial function, explaining multisystem neurological degeneration.  
7. **Differential exclusion**: The combination of cerebellar atrophy, spasticity, and gaze palsy distinguishes SPG7 from other HSPs (e.g., SPG4/SPAST lacks cerebellar signs) and mimics like spinocerebellar ataxia (SCA)."
"['Hypertelorism', 'Low-set ears', 'Wide nasal bridge', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Excessive salivation', 'Neonatal death', 'Abnormal circulating acetylcarnitine concentration', 'Severe hearing impairment', 'Abnormal circulating creatine kinase concentration']",['Carnitine palmitoyl transferase 1A deficiency/Carnitine palmitoyltransferase I deficiency'],"Disease: Carnitine palmitoyl transferase 1A deficiency/Carnitine palmitoyltransferase I deficiency  
Reasoning:  
1. **Metabolic Abnormalities**: The patient’s abnormal circulating acetylcarnitine and creatine kinase concentrations strongly suggest a fatty acid oxidation disorder. CPT1A deficiency disrupts mitochondrial long-chain fatty acid transport, leading to accumulation of specific acylcarnitines (e.g., C16, C18:1) and secondary carnitine depletion, which may explain the abnormal acetylcarnitine profile. Elevated creatine kinase indicates muscle damage, consistent with metabolic crises.  
2. **Prenatal/Neonatal Severity**: ""Abnormality of prenatal development or birth,"" ""neonatal death,"" and ""death in infancy"" align with severe CPT1A deficiency, which can cause intrauterine metabolic stress, hypoglycemia, and lethal neonatal hepatic failure.  
3. **Neurological Manifestations**: Intellectual disability and motor delay result from recurrent hypoglycemic episodes and energy deficiency in the brain during critical developmental periods.  
4. **Dysmorphic Features**: Hypertelorism, low-set ears, and wide nasal bridge may reflect disrupted prenatal growth due to chronic metabolic instability, rather than primary structural anomalies.  
5. **Supporting Symptoms**: Excessive salivation (dysphagia/neurologic dysfunction) and severe hearing impairment (energy deficiency affecting cochlear function) are rare but plausible secondary effects of systemic metabolic dysfunction.  

**Note**: While craniofacial dysmorphism is atypical in CPT1A deficiency, the combination of metabolic lab findings, neonatal fatality, and neurological deficits provides a stronger diagnostic anchor, with dysmorphic features likely stemming from prenatal metabolic compromise."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: VLCADD disrupts mitochondrial β-oxidation of very long-chain fatty acids, leading to secondary carnitine deficiency due to increased acyl-carnitine excretion and reduced reabsorption.  
2. **Neonatal death/Death in infancy**: Severe VLCADD presents in infancy with hypoketotic hypoglycemia, cardiomyopathy, or hepatic encephalopathy during metabolic stress (e.g., fasting), often progressing to fatal metabolic crises.  
3. **Abnormality of prenatal development**: Severe cases may cause intrauterine growth restriction or structural anomalies (e.g., hypertrophic cardiomyopathy) due to impaired energy production during fetal development.  
4. **Key biochemical link**: Elevated C14:1 acylcarnitine on newborn screening supports VLCADD diagnosis, aligning with the observed carnitine abnormality and clinical outcomes.  

The combination of metabolic instability, carnitine dysregulation, and early lethality strongly aligns with the severe neonatal form of VLCADD."
"['Sensorineural hearing impairment', 'Rod-cone dystrophy', 'Cerebellar atrophy', 'Areflexia', 'Pes cavus', 'Hammertoe', 'Expressive language delay', 'Axonal loss', 'Somatic sensory dysfunction', 'Sensorimotor neuropathy', 'Progressive gait ataxia', 'Speech articulation difficulties', 'Peripheral demyelination', 'Peripheral retinal atrophy']",['Perrault syndrome 1'],"Disease: Perrault syndrome 1  
Reasoning:  
1. **Sensorineural hearing impairment** and **rod-cone dystrophy** are hallmark features of Perrault syndrome, particularly in subtypes with neurological involvement.  
2. **Cerebellar atrophy** explains **progressive gait ataxia** and **speech articulation difficulties**, aligning with neurological manifestations in Perrault syndrome type 1.  
3. **Areflexia**, **sensorimotor neuropathy**, **axonal loss**, and **peripheral demyelination** indicate peripheral neuropathy, consistent with the axonal and demyelinating neuropathies reported in HSD17B4-related Perrault syndrome.  
4. **Pes cavus** and **hammertoe** are secondary to chronic neuropathy, commonly seen in neurogenetic disorders affecting peripheral nerves.  
5. **Expressive language delay** and **somatic sensory dysfunction** correlate with cerebellar and sensory nerve dysfunction.  
6. **Peripheral retinal atrophy** complements **rod-cone dystrophy**, reinforcing the multisystem retinal involvement in this syndrome.  
7. While ovarian dysgenesis (typical in Perrault syndrome) is not explicitly listed, the combination of hearing loss, vision loss, cerebellar atrophy, and neuropathy strongly supports Perrault syndrome type 1 (HSD17B4 mutations), which can present with variable expressivity, including isolated neurological phenotypes."
"['Microcephaly', 'Global developmental delay', 'Motor delay', 'Absent speech', 'EEG abnormality', 'Intellectual disability, severe', 'Abnormality of brain morphology']","['Microcephaly, primary autosomal recessive, 6']","Disease: Microcephaly, primary autosomal recessive, 6 (MCPH6)  
Reasoning:  
1. **Microcephaly**: A hallmark of MCPH syndromes, reflecting reduced brain size due to impaired neurogenesis.  
2. **Global developmental delay/Motor delay/Absent speech/Severe intellectual disability**: Consistent with severe cortical malformations and neuronal dysfunction in MCPH6, caused by mutations in *CENPJ*, critical for centrosome and microtubule organization.  
3. **EEG abnormality**: Suggests cortical hyperexcitability or dysrhythmia, common in neurodevelopmental disorders with disrupted neuronal migration or connectivity.  
4. **Abnormality of brain morphology**: Likely simplified gyral patterns or cortical thinning, as seen in MCPH6 due to defective progenitor cell proliferation.  
5. **Autosomal recessive inheritance**: Matches the genetic etiology of MCPH6, requiring biallelic pathogenic variants in *CENPJ*.  
The constellation of severe neurological deficits, structural brain anomalies, and microcephaly prioritizes MCPH6 over other syndromic microcephalies."
"['Apathy', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hepatomegaly', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Enzyme Deficiencies**: The patient exhibits decreased pyruvate carboxylase activity and Propionyl-CoA carboxylase deficiency. Both enzymes require biotin as a cofactor, which is activated by holocarboxylase synthetase (HLCS). HLCS deficiency disrupts biotinylation, impairing all biotin-dependent carboxylases.  
2. **Metabolic Abnormalities**:  
   - **Metabolic acidosis** and **elevated serum lactate** stem from impaired gluconeogenesis (pyruvate carboxylase deficiency) and tricarboxylic acid cycle dysfunction.  
   - **Hyperammonemia** arises due to secondary urea cycle inhibition from accumulated organic acids (e.g., propionyl-CoA metabolites).  
   - **Elevated urinary carboxylic acids** (e.g., 3-hydroxypropionate, methylcitrate) reflect Propionyl-CoA carboxylase deficiency.  
3. **Dermatological Features**: **Eczematoid dermatitis** and **skin rash** are classic biotin-responsive manifestations due to defective fatty acid synthesis and keratinocyte dysfunction.  
4. **Systemic Symptoms**: **Apathy**, **hypotonia**, **feeding difficulties**, and **vomiting** result from metabolic decompensation and neurotoxicity (hyperammonemia, acidosis).  
5. **Hepatomegaly**: Linked to fatty infiltration or mitochondrial dysfunction from metabolic stress.  
6. **Aminoaciduria** and **abnormal glycine levels**: Secondary to renal tubular dysfunction and disrupted amino acid metabolism.  
7. **Early Mortality**: Untreated HLCS deficiency causes rapid metabolic crises, leading to **death in infancy**.  

This constellation of symptoms, enzyme deficiencies, and biochemical findings confirms HLCS deficiency as the diagnosis."
"['Tall stature', 'Bifid uvula', 'Dolichocephaly', 'Malar flattening', 'Hypertelorism', 'Downslanted palpebral fissures', 'Pectus excavatum', 'Striae distensae', 'Arachnodactyly', 'Mitral valve prolapse', 'Aortic root aneurysm', 'Scoliosis', 'Protrusio acetabuli', 'Tortuous cerebral arteries', 'Cervical spine instability', 'High myopia', 'Cystic medial necrosis', 'Dural ectasia']",['Loeys-Dietz syndrome/Loeys-Dietz syndrome 1'],"Loeys-Dietz syndrome 1:  
- **Craniofacial features**: Bifid uvula, hypertelorism, downslanted palpebral fissures, malar flattening, and dolichocephaly align with LDS1’s hallmark craniofacial abnormalities.  
- **Skeletal manifestations**: Tall stature, arachnodactyly, pectus excavatum, scoliosis, and protrusio acetabuli reflect connective tissue involvement.  
- **Cardiovascular abnormalities**: Aortic root aneurysm, mitral valve prolapse, tortuous cerebral arteries, and cystic medial necrosis indicate aggressive vascular pathology characteristic of LDS1.  
- **Connective tissue/systemic signs**: Striae distensae, cervical spine instability, high myopia, and dural ectasia further support TGF-β pathway dysregulation.  
- **Exclusion of mimics**: Bifid uvula and hypertelorism distinguish LDS1 from Marfan syndrome, while cervical instability and tortuosity differentiate it from Ehlers-Danlos syndromes. Genetic testing for TGFBR1/2 variants would confirm the diagnosis."
"['Strabismus', 'Myopia', 'Upslanted palpebral fissure', 'Synophrys', 'Anxiety', 'Delayed speech and language development', 'Brachydactyly', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Failure to thrive', 'Pes planus', 'Truncal obesity', 'Gastroesophageal reflux', 'Asthma', 'Spontaneous pneumothorax', 'Generalized non-motor (absence) seizure', 'Sleep disturbance', 'Downturned corners of mouth', 'Clinodactyly of the 5th finger', 'Short middle phalanx of the 5th finger', 'Short stature', 'Mild global developmental delay', 'Head-banging', 'Self-injurious behavior']",['Smith-Magenis syndrome/Smith-Magenis syndrome'],"Disease: Smith-Magenis syndrome  
Reasoning:  
1. **Facial features**: Upslanted palpebral fissures, synophrys (conjoined eyebrows), and downturned corners of the mouth align with the characteristic craniofacial dysmorphisms of SMS.  
2. **Developmental delays**: Intellectual disability, delayed speech, and mild global developmental delay are hallmark neurocognitive features of SMS.  
3. **Behavioral phenotype**: Self-injurious behavior (e.g., head-banging), anxiety, and sleep disturbances (e.g., inverted melatonin rhythm) are pathognomonic for SMS.  
4. **Skeletal anomalies**: Brachydactyly, clinodactyly of the 5th finger, and short middle phalanx of the 5th finger are common in SMS.  
5. **Growth/medical issues**: Hypotonia, failure to thrive in infancy, truncal obesity, and pes planus fit the SMS growth trajectory.  
6. **Neurological features**: Seizures (including absence seizures) and sleep disruption are frequently reported in SMS.  
7. **Supportive features**: Gastroesophageal reflux and asthma are common comorbidities, while spontaneous pneumothorax is a rare but documented association.  

The combination of distinct facial, behavioral, developmental, and skeletal features strongly supports SMS, typically caused by a *RAI1* gene mutation or 17p11.2 deletion."
"['Polyuria', 'Acne', 'Polydipsia', 'Headache', 'Abnormality of the knee', 'Arthralgia', 'Elevated circulating creatine kinase concentration', 'Generalized morning stiffness', 'Abnormal metacarpophalangeal joint morphology', 'Fatigue', 'Foot pain', 'Elbow pain', 'Wrist pain', 'Knee pain', 'Toe pain', 'Increased circulating IgG4 level']","['Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis', 'Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Reactive arthritis', 'Familial Mediterranean fever, AD', 'Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis', 'Systemic-onset juvenile idiopathic arthritis']","Disease: Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis  
Reasoning: The patient presents with polyarticular involvement (knee, elbow, wrist, toe, foot pain), morning stiffness, and abnormal metacarpophalangeal joint morphology—hallmarks of polyarticular JIA. Elevated IgG4 and creatine kinase may reflect systemic inflammation, though these are atypical for JIA. The absence of rheumatoid factor (RF) is inferred due to the lack of explicit mention of RF positivity and the inclusion of RF-negative JIA as a diagnostic option.  

Disease: Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis  
Reasoning: While similar to RF-negative JIA in joint symptoms, this diagnosis is listed as a potential option. However, RF positivity is typically associated with more severe erosive disease and specific autoantibodies, which are not detailed here. Its inclusion reflects diagnostic uncertainty without serologic data.  

Disease: Reactive arthritis  
Reasoning: Asymmetric joint pain (toe, foot) could suggest reactive arthritis, but the absence of preceding infection, urethritis, or conjunctivitis makes this less likely. Polyarticular upper-limb involvement and morning stiffness align better with JIA.  

Disease: Familial mediterranean fever (FMF), AR/AD  
Reasoning: FMF typically features recurrent fever and serositis, which are absent here. While arthralgia occurs in FMF, it is usually episodic and monoarticular. The chronic polyarticular pattern and lack of fever reduce suspicion for FMF, despite its inclusion in the options.  

Disease: Systemic-onset juvenile idiopathic arthritis  
Reasoning: Excluded due to the absence of hallmark systemic features (e.g., daily fevers, evanescent rash). The patient’s symptoms are confined to joints and lack systemic inflammatory signs.  

**Final Emphasis**: Rheumatoid factor-negative polyarticular JIA is the most consistent diagnosis given the clinical and laboratory findings. RF-positive JIA remains a possibility if serologic testing confirms RF, but the presentation leans toward RF-negative subtype. Other listed diseases lack sufficient supportive evidence."
"['Recurrent urinary tract infections', 'Purpura', 'Fever', 'Leukocytosis', 'Vasculitis', 'Pedal edema', 'Lower limb pain', 'Groin pain']",['Immunoglobulin A vasculitis'],"Disease: Immunoglobulin A vasculitis  
Reasoning:  
1. **Purpura**: A hallmark of IgA vasculitis, typically presenting as palpable purpura on the lower limbs and buttocks, aligning with the patient's symptom.  
2. **Vasculitis**: IgA vasculitis is a small-vessel vasculitis mediated by IgA immune deposits, directly confirmed in the patient's diagnosis.  
3. **Lower limb pain & Groin pain**: Consistent with arthralgia or inflammatory joint involvement, common in IgA vasculitis.  
4. **Pedal edema**: Suggests possible renal involvement (e.g., glomerulonephritis), a frequent complication of IgA vasculitis, which may also predispose to secondary infections.  
5. **Fever & Leukocytosis**: Reflect systemic inflammation, characteristic of active vasculitis.  
6. **Recurrent urinary tract infections**: May indicate renal compromise (e.g., proteinuria or hematuria) secondary to IgA vasculitis, creating a susceptibility to UTIs, or could represent overlapping inflammatory renal injury.  

The combination of purpura, vasculitis, systemic inflammation, and renal/articular manifestations strongly supports IgA vasculitis, despite atypical features like recurrent UTIs, which may require further nephrological evaluation."
"['High palate', 'Microcephaly', 'Epicanthus', 'Micrognathia', 'Intellectual disability', 'Motor delay', 'Hypertonia', 'Sleep disturbance', 'Lateral ventricle dilatation', 'Simplified gyral pattern']","['Microcephaly 5, primary, autosomal recessive']","Disease: Microcephaly 5, primary, autosomal recessive  
Reasoning:  
1. **Core Symptom Alignment**: The patient exhibits **primary microcephaly** (congenital small head size), a hallmark of MCPH5 caused by biallelic *ASPM* mutations.  
2. **Neurological Features**: **Simplified gyral pattern** and **lateral ventricle dilatation** reflect reduced cerebral cortex volume and impaired neuronal migration, consistent with ASPM-related brain malformations.  
3. **Developmental Delays**: **Intellectual disability** and **motor delay** correlate with cortical underdevelopment and disrupted neural connectivity.  
4. **Hypertonia**: Likely stems from corticospinal tract dysfunction due to abnormal cortical organization.  
5. **Craniofacial Findings**: **High palate**, **micrognathia**, and **epicanthus** are nonspecific but recurrently observed in syndromic microcephaly disorders, including MCPH5.  
6. **Sleep Disturbance**: May arise from dysregulation of sleep-wake cycles secondary to central nervous system abnormalities.  
7. **Exclusion of Alternatives**: Features align with MCPH5 rather than other microcephaly subtypes (e.g., no severe seizures or limb anomalies seen in MCPH2 or MCPH4). Autosomal recessive inheritance matches the genetic profile."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiency/multiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Elevated urinary carboxylic acid**: Biotinidase deficiency impairs biotin recycling, reducing activity of carboxylase enzymes (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). This disrupts organic acid metabolism, leading to urinary accumulation of carboxylic acids (e.g., 3-hydroxyisovaleric acid, lactic acid).  
2. **Seizures**: Biotin-dependent carboxylases are critical for fatty acid synthesis, gluconeogenesis, and neurotransmitter regulation. Deficiency causes metabolic acidosis and energy deficits, triggering neuroexcitability and seizures.  
3. **Generalized hypotonia**: Metabolic acidosis and disrupted mitochondrial energy production impair muscle function, manifesting as hypotonia.  
4. **Death in infancy**: Untreated biotinidase deficiency progresses to severe metabolic crises, respiratory failure, and neurological damage, often fatal within the first year without biotin supplementation.  
**Diagnostic confirmation**: Low serum biotinidase enzyme activity (<10% normal activity) and genetic testing for *BTD* gene mutations. Early biotin supplementation reverses symptoms, emphasizing urgency in diagnosis."
"['Hypertelorism', 'Micrognathia', 'Low-set ears', 'Oligodontia', 'Microdontia', 'Pectus excavatum', 'Hitchhiker thumb', 'Global developmental delay', 'Duplication of metatarsal bones', 'Chiari malformation', 'Kyphoscoliosis', 'Short nose', 'Short hallux', 'Talon cusp', 'Cutaneous syndactyly', 'Clinodactyly']",['Temtamy preaxial brachydactyly syndrome/Temtamy preaxial brachydactyly syndrome'],"Disease: Temtamy preaxial brachydactyly syndrome  
**Reasoning**:  
1. **Skeletal anomalies**: The presence of *preaxial brachydactyly* (evidenced by *Hitchhiker thumb* and *short hallux*), *duplication of metatarsal bones*, and *pectus excavatum* aligns with the syndrome's hallmark limb and chest abnormalities.  
2. **Dental features**: *Oligodontia* (few teeth) and *microdontia* (small teeth) are consistent with reported dental manifestations. The *talon cusp* further supports enamel developmental anomalies.  
3. **Craniofacial traits**: *Hypertelorism*, *low-set ears*, *short nose*, and *micrognathia* match characteristic facial dysmorphisms.  
4. **Neurological/Spinal involvement**: *Chiari malformation* and *kyphoscoliosis* correlate with spinal/cranial junction and vertebral defects seen in some cases.  
5. **Limb anomalies**: *Cutaneous syndactyly* (webbed digits) and *clinodactyly* (curved fingers) reinforce the diagnosis of a congenital limb patterning disorder.  
6. **Developmental delay**: *Global developmental delay* is reported in Temtamy syndrome, though severity varies.  
**Exclusion**: Overlap with syndromes like Rubinstein-Taybi or Greig cephalopolysyndactyly is ruled out by the absence of broad thumbs/polydactyly and the specific metatarsal duplication paired with dental findings."
"['Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Hypothermia', 'Apnea', 'Propionic acidemia', 'Neonatal death', 'Feeding difficulties', 'Fatigue']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Propionic acidemia (PA)** is an autosomal recessive disorder caused by defects in propionyl-CoA carboxylase, leading to toxic accumulation of propionic acid.  
2. **Feeding difficulties** and **fatigue** are early neonatal signs due to metabolic acidosis and hyperammonemia, impairing energy metabolism.  
3. **Generalized hypotonia** arises from muscle weakness secondary to energy depletion and acidosis.  
4. **Bradycardia** and **hypothermia** result from metabolic instability and impaired cardiac/thermoregulatory function during crises.  
5. **Apnea** occurs due to central nervous system depression from hyperammonemia or acidotic stress.  
6. **Death in infancy/neonatal death** reflects the severe, rapid progression of untreated PA, often triggered by catabolic states (e.g., fasting, infection).  
7. The explicit mention of **Propionic acidemia** in the symptom list aligns with biochemical confirmation (e.g., elevated propionylcarnitine on newborn screening, organic aciduria).  
8. All symptoms collectively match the acute neonatal-onset phenotype of PA, excluding other metabolic disorders (e.g., methylmalonic acidemia) via specificity of clinical and biochemical markers."
"['Abnormal saccadic eye movements', 'Cyanosis', 'Seizure', 'Death in infancy', 'Vomiting', 'Abnormal cerebral morphology', 'Dyspnea', 'Glutaric aciduria', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of glutaric acid accumulation, pathognomonic for GA-I due to **glutaryl-CoA dehydrogenase deficiency**.  
2. **Abnormal cerebral morphology**: Macrocephaly and striatal degeneration (e.g., basal ganglia atrophy) are hallmark neuroimaging findings in GA-I.  
3. **Seizures & abnormal saccadic eye movements**: Result from acute or chronic neurotoxicity caused by glutaric acid and 3-hydroxyglutaric acid, damaging neurons and disrupting neurotransmission.  
4. **Feeding difficulties & vomiting**: Common early signs of metabolic decompensation triggered by catabolic stress (e.g., infections, fasting).  
5. **Dyspnea & cyanosis**: May arise during metabolic crises due to acidosis or secondary respiratory complications from encephalopathy.  
6. **Death in infancy**: Untreated GA-I often leads to severe neurological injury or fatal metabolic crises in early life, consistent with the natural history of the disease.  
The combination of **neurodevelopmental regression**, **organic aciduria**, and **characteristic neuroimaging** strongly confirms GA-I. Early diagnosis is critical to prevent irreversible damage via dietary management (lysine/tryptophan restriction) and emergency protocols during metabolic stress."
"['Dolichocephaly', 'Astigmatism', 'Strabismus', 'Ptosis', 'Striae distensae', 'Arachnodactyly', 'Disproportionate tall stature', 'Mitral regurgitation', 'Aortic dissection', 'Tricuspid regurgitation', 'High myopia']","['Marfan syndrome', 'Marfan syndrome type 1']","Disease: Marfan syndrome  
Reasoning:  
1. **Skeletal Features**: Dolichocephaly (long skull), arachnodactyly (long fingers), and disproportionate tall stature align with Marfan syndrome’s skeletal manifestations due to connective tissue abnormalities.  
2. **Ocular Involvement**: Astigmatism, strabismus, ptosis, and high myopia are consistent with Marfan-related ocular defects, including lens dislocation risk and weakened ocular connective tissue.  
3. **Cardiovascular Abnormalities**: Mitral regurgitation, aortic dissection, and tricuspid regurgitation reflect hallmark cardiovascular complications of Marfan syndrome, driven by aortic root dilation and valvular insufficiency.  
4. **Cutaneous Findings**: Striae distensae (stretch marks) suggest connective tissue fragility, a common feature in Marfan syndrome.  

Disease: Marfan syndrome type 1  
Reasoning:  
- Marfan syndrome type 1 (MFS1) is the classic form caused by *FBN1* gene mutations. The listed symptoms (aortic dissection, mitral/tricuspid regurgitation, disproportionate tall stature, arachnodactyly) fulfill revised Ghent criteria for MFS1, which emphasizes aortic root aneurysm/dissection and systemic features. The overlap with type 1 confirms the diagnosis distinct from other fibrillinopathies.  

*Note: ""Marfan syndrome"" and ""Marfan syndrome type 1"" are often used interchangeably, but type 1 explicitly references the *FBN1*-linked classic form.*"
"['Hypothyroidism', 'Pruritus', 'Cholelithiasis', 'obsolete Mood changes', 'Dilated cardiomyopathy', 'Bradycardia', 'Acute pancreatitis', 'Weight loss', 'Macrocytic anemia', 'Leukocytosis', 'Nausea', 'Loss of speech', 'Incomprehensible speech', 'Vasculitis', 'Obstructive sleep apnea', 'Elevated circulating thyroid-stimulating hormone concentration', 'Abnormal EKG', 'Elevated circulating parathyroid hormone level', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Atrioventricular dissociation', 'Elevated gamma-glutamyltransferase level', 'Unhappy demeanor', 'Decreased circulating free T3', 'Perinuclear antineutrophil antibody positivity', 'Increased circulating IgG4 level', 'Carotid artery stenosis', 'Thyroiditis']","['Multifocal fibrosclerosis', 'IgG4-related retroperitoneal fibrosis', 'IgG4 related disease; IgG4-RD']","Disease: IgG4 related disease; IgG4-RD  
**Reasoning**:  
1. **Elevated IgG4 level** (Increased circulating IgG4 level) is a hallmark diagnostic criterion for IgG4-RD.  
2. **Multi-organ involvement**:  
   - **Thyroid**: Hypothyroidism, thyroiditis, elevated TSH, and low free T3 align with IgG4-related thyroid disease (e.g., Riedel’s thyroiditis).  
   - **Pancreas/biliary**: Acute pancreatitis, cholelithiasis, and elevated gamma-glutamyltransferase suggest IgG4-related autoimmune pancreatitis/sclerosing cholangitis.  
   - **Vascular**: Vasculitis, carotid stenosis, and antinuclear/ANCA positivity reflect systemic fibroinflammatory vasculopathy.  
3. **Inflammatory markers**: Elevated ESR, CRP, leukocytosis, and antinuclear antibody positivity support systemic inflammation.  
4. **Fibrosis**: Dilated cardiomyopathy (cardiac fibrosis), obstructive sleep apnea (airway fibrosis), and retroperitoneal fibrosis (linked to IgG4-RD spectrum).  
5. **Exclusion of mimics**: Macrocytic anemia and mood changes may arise from chronic inflammation, while antineutrophil antibodies and parathyroid hormone elevation are atypical but not contradictory in systemic autoimmune disorders.  

Disease: IgG4-related retroperitoneal fibrosis  
**Reasoning**:  
- A subset of IgG4-RD, retroperitoneal fibrosis explains **weight loss**, **nausea**, and potential ureteral obstruction (not explicitly listed but commonly associated).  
- Linked to elevated IgG4 levels and perivascular fibrosis (carotid stenosis, vasculitis).  

Disease: Multifocal fibrosclerosis  
**Reasoning**:  
- Historical term for IgG4-RD manifestations, encompassing fibrosis in **thyroid**, **pancreas**, **retroperitoneum**, and **vascular system** (carotid stenosis, AV dissociation from cardiac fibrosis).  
- Explains **dilated cardiomyopathy** (myocardial fibrosis) and **pruritus** (bile duct fibrosis/cholestasis).  

**Conclusion**: The patient’s multi-organ fibrosis, autoimmune features, and elevated IgG4 confirm **IgG4-RD** with retroperitoneal fibrosis and multifocal fibrosclerosis as overlapping phenotypes."
"['Death in infancy', 'Increased serum lactate', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Severe hearing impairment']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Metabolic acidosis**: Elevated serum lactate aligns with impaired mitochondrial energy production due to deficient carboxylases (e.g., pyruvate carboxylase), a hallmark of BTDD.  
2. **Neurological manifestations**: Opisthotonus (severe hypertonia) and feeding difficulties suggest neurological dysfunction from accumulated toxic metabolites (e.g., lactate, ammonia) or disrupted neurotransmitter synthesis.  
3. **Amino acid abnormalities**: Abnormal aspartate family amino acids (e.g., elevated aspartate) and alanine stem from defective amino acid metabolism via biotin-dependent enzymes (e.g., propionyl-CoA carboxylase).  
4. **Hearing impairment**: Cochlear dysfunction due to chronic metabolic stress or oxidative damage is a recognized feature of untreated BTDD.  
5. **Infantile lethality**: Untreated BTDD causes progressive metabolic crises, leading to early death.  
6. **Diagnostic confirmation**: BTDD explains all symptoms under the umbrella of ""late-onset multiple carboxylase deficiency,"" where biotin recycling failure triggers multi-system dysfunction. Biotin supplementation reverses symptoms if initiated early."
"['Megalocornea', 'Visual impairment', 'Deep anterior chamber', 'Abnormal intraocular pressure']","['MEGALOCORNEA', 'Isolated congenital megalocornea']","Disease: Isolated congenital megalocornea  
Reasoning:  
1. **Megalocornea**: Core diagnostic feature, defined as a corneal diameter >13 mm at birth, non-progressive, and bilateral.  
2. **Deep anterior chamber**: Consistent with anterior segment enlargement due to corneal stretching, without angle abnormalities (ruling out glaucoma-associated structural defects).  
3. **Visual impairment**: Likely secondary to refractive errors (e.g., myopia/astigmatism) from altered corneal curvature, rather than optic nerve or retinal pathology.  
4. **Abnormal intraocular pressure**: May reflect transient fluctuations or measurement artifacts; isolated congenital megalocornea typically maintains normal pressure, distinguishing it from congenital glaucoma (which causes persistent elevation and corneal edema).  
5. **Exclusion of alternatives**: No signs of systemic syndromes (e.g., Marfan), lens dislocation, or Haab’s striae (seen in glaucoma)."
"['Intellectual disability', 'Paresthesia', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Intellectual disability**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting brain development and function.  
3. **Paresthesia**: Chronic neurotoxicity from phenylalanine may cause peripheral neuropathy, manifesting as sensory disturbances.  
4. **Death in early adulthood**: Historically, untreated PKU results in severe neurological decline and systemic complications, though modern dietary management improves prognosis.  
5. **Acute/Chronic hepatitis**: Atypical for classic PKU. May suggest comorbid conditions (e.g., viral hepatitis, metabolic liver disease) or secondary effects from prolonged metabolic stress. PKU itself does not directly cause hepatitis, necessitating further investigation for liver-specific etiologies.  

Key PKU hallmarks (hyperphenylalaninemia, neurocognitive deficits) dominate the diagnosis, while liver abnormalities likely indicate a coexisting or unrelated condition."
"['Intellectual disability', 'Generalized hypotonia', 'Hyperreflexia', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Death in childhood', 'Abnormal myelination', 'L-2-hydroxyglutaric acidemia']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **L-2-hydroxyglutaric acidemia** is pathognomonic for L-2-hydroxyglutaric aciduria (L-2-HGA), a rare autosomal recessive neurometabolic disorder caused by mutations in the *L2HGDH* gene, leading to toxic accumulation of L-2-hydroxyglutaric acid.  
2. **Intellectual disability**, **generalized hypotonia**, and **hyperreflexia** align with the progressive neurological deterioration characteristic of L-2-HGA, affecting both cortical and subcortical structures.  
3. **Abnormal cerebral morphology** and **abnormal myelination** are consistent with leukoencephalopathy and cystic/white matter changes seen on neuroimaging in L-2-HGA.  
4. **Death in childhood** reflects the severe phenotype of the disease, often due to complications like seizures, respiratory infections, or metabolic crises.  
5. **Hyperammonemia**, though atypical, may occur secondary to mitochondrial dysfunction or intercurrent metabolic stressors in advanced disease.  
The combination of elevated L-2-hydroxyglutaric acid, neurodevelopmental regression, and neuroimaging abnormalities confirms the diagnosis."
"['Cataract', 'Hematuria', 'Hypoparathyroidism', 'Tetany', 'Malabsorption', 'Vertigo', 'Chronic mucocutaneous candidiasis', 'Hypocalcemia', 'Enamel hypoplasia', 'Primary adrenal insufficiency']","['Autoimmune polyendocrinopathy type 1/Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia']","Disease: Autoimmune polyendocrinopathy type 1 (APS-1/APECED)  
Reasoning:  
1. **Chronic mucocutaneous candidiasis**: A hallmark of APS-1, often presenting early in childhood.  
2. **Hypoparathyroidism and hypocalcemia**: Key features of APS-1, causing **tetany** (muscle spasms due to low calcium) and **enamel hypoplasia** (defective tooth enamel from calcium dysregulation).  
3. **Primary adrenal insufficiency (Addison’s disease)**: Completes the diagnostic triad of APS-1.  
4. **Cataracts**: Linked to chronic hypocalcemia from hypoparathyroidism.  
5. **Malabsorption**: May reflect autoimmune enteropathy, a recognized APS-1 manifestation.  
6. **Hematuria**: Could indicate autoimmune nephritis or nephrocalcinosis secondary to chronic hypocalcemia.  
7. **Vertigo**: Possibly related to electrolyte imbalances (e.g., hypocalcemia, adrenal crisis).  

The combination of mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency is pathognomonic for APS-1. Additional features align with multi-organ autoimmune involvement, confirming the diagnosis."
"['Delayed speech and language development', 'Global developmental delay', 'Bilateral tonic-clonic seizure', 'Frontal polymicrogyria']","['Bilateral frontoparietal polymicrogyria/Polymicrogyria, bilateral frontoparietal']","Disease: Bilateral frontoparietal polymicrogyria  
Reasoning:  
1. **Frontal polymicrogyria** is a hallmark feature, aligning with the brain malformation pattern seen in BFPP. The bilateral frontoparietal localization is pathognomonic.  
2. **Global developmental delay** and **delayed speech/language development** correlate with disrupted cortical organization in frontal and parietal regions, critical for cognitive and language functions.  
3. **Bilateral tonic-clonic seizures** are common due to abnormal cortical architecture predisposing to epileptogenic activity.  
4. BFPP is genetically linked to *ADGRG1* mutations, which disrupt neuronal migration and cortical layering. While genetic confirmation is ideal, the symptomatology and imaging findings strongly support this diagnosis over other polymicrogyria subtypes (e.g., perisylvian), which lack frontoparietal predominance."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** initially seems conflicting, as PAH deficiency typically reduces tyrosine levels. However, severe phenylalanine elevation may disrupt tyrosine metabolism or reflect a secondary metabolic disturbance.  
3. **Neonatal death/Death in infancy/childhood** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
4. **Abnormality of prenatal development** may stem from maternal PKU syndrome (untreated PKU in the mother during pregnancy), causing congenital anomalies in the fetus, though the patient’s own PKU manifests postnatally.  
5. The absence of early dietary intervention (low-phenylalanine diet) explains the fatal outcomes, emphasizing the critical need for newborn screening in PKU."
"['Microcephaly', 'Megalocornea', 'Optic disc pallor', 'Nystagmus', 'Global developmental delay', 'Cerebellar atrophy', 'Hypoplasia of the corpus callosum', 'Hyperintensity of cerebral white matter on MRI']",['Mucolipidosis type IV/Mucolipidosis IV'],"Disease: Mucolipidosis type IV/Mucolipidosis IV  
Reasoning:  
1. **Ocular Findings**: Megalocornea and optic disc pallor align with ML IV's hallmark corneal clouding/opacities and optic atrophy due to lysosomal accumulation in ocular tissues.  
2. **Neurological Features**: Cerebellar atrophy, hypoplasia of the corpus callosum, and cerebral white matter hyperintensity on MRI reflect progressive neurodegeneration and dysmyelination, consistent with ML IV's central nervous system involvement.  
3. **Developmental Delay**: Global developmental delay correlates with ML IV's early-onset psychomotor regression and intellectual disability.  
4. **Structural Brain Abnormalities**: Microcephaly and corpus callosum hypoplasia are recurrent findings in ML IV, linked to impaired neuronal migration and synaptic function.  
5. **Exclusion of Mimics**: The absence of coarse facial features, organomegaly, or skeletal dysplasia argues against other lysosomal disorders (e.g., mucopolysaccharidoses), while nystagmus and white matter changes differentiate it from isolated genetic microcephaly syndromes.  
6. **Pathophysiology**: ML IV is caused by *MCOLN1* mutations disrupting lysosomal TRP channel function, leading to abnormal storage material in brain and eyes—consistent with the patient's phenotype."
"['Sensorineural hearing impairment', 'Neonatal hypotonia', 'Muscle weakness', 'Craniosynostosis', 'Failure to thrive in infancy', 'Gastroesophageal reflux', 'Respiratory distress', 'Increased serum lactate', 'Increased CSF lactate', 'Elevated hepatic transaminase', 'Myopathy', 'Ragged-red muscle fibers', 'Generalized muscle weakness', 'Hyperalaninemia', 'Cytochrome C oxidase-negative muscle fibers', 'Feeding difficulties in infancy', 'Bronchiolitis', 'Elevated circulating acylcarnitine concentration']","['Combined oxidative phosphorylation deficiency 30', 'Combined oxidative phosphorylation defect type 30']","Disease: Combined oxidative phosphorylation deficiency 30 (COXPD30)  
Reasoning:  
1. **Mitochondrial Dysfunction Indicators**: Elevated serum/CSF lactate, ragged-red muscle fibers, and cytochrome C oxidase (COX)-negative fibers strongly suggest a mitochondrial disorder, specifically a defect in oxidative phosphorylation (OXPHOS).  
2. **Neuromuscular Symptoms**: Neonatal hypotonia, generalized muscle weakness, myopathy, and respiratory distress align with impaired mitochondrial energy production in muscles.  
3. **Metabolic Abnormalities**: Hyperalaninemia and elevated acylcarnitine indicate disrupted amino acid and fatty acid metabolism, common in OXPHOS defects due to secondary mitochondrial stress.  
4. **Multi-Organ Involvement**: Craniosynostosis (connective tissue/bone), hepatic transaminase elevation (liver), gastroesophageal reflux, and failure to thrive reflect systemic OXPHOS failure.  
5. **Genetic Link**: COXPD30 is caused by *MTFMT* mutations, disrupting mitochondrial translation and causing combined OXPHOS deficiencies (e.g., complexes I, IV). This matches the COX-negative fibers and overlapping symptoms.  
6. **Infantile Presentation**: Feeding difficulties, bronchiolitis, and failure to thrive in infancy are consistent with early-onset mitochondrial disorders like COXPD30.  

Disease: Combined oxidative phosphorylation defect type 30  
Reasoning:  
(This is the same entity as COXPD30; ""type 30"" refers to the specific genetic classification under combined OXPHOS deficiencies. The reasoning above applies here identically, as both terms describe the *MTFMT*-related disorder.)"
"['Thrombocytopenia', 'Increased mean platelet volume', 'Abnormal megakaryocyte morphology', 'Abnormal platelet aggregation', 'Platelet anisocytosis']","['Bleeding disorder, platelet-type, 15']","Disease: Bleeding disorder, platelet-type, 15  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with impaired platelet production or abnormal megakaryocyte function, a hallmark of GFI1B-related disorders like BDPLT15.  
2. **Increased mean platelet volume (MPV)**: Larger platelets suggest dysregulated megakaryopoiesis, consistent with GFI1B mutations disrupting cytoplasmic maturation.  
3. **Abnormal megakaryocyte morphology**: GFI1B is critical for megakaryocyte development; mutations cause small, hypolobated megakaryocytes with cytoplasmic abnormalities.  
4. **Abnormal platelet aggregation**: Platelet dysfunction due to GFI1B defects leads to impaired aggregation despite normal surface receptor expression.  
5. **Platelet anisocytosis**: Variability in platelet size reflects erratic thrombopoiesis from defective megakaryocyte fragmentation.  
The combination of quantitative (thrombocytopenia) and qualitative (aggregation defects, MPV elevation) platelet abnormalities, alongside megakaryocyte dysplasia, strongly supports a GFI1B mutation diagnostic of BDPLT15."
"['Seizure', 'Dystonia', 'Death in infancy', 'Glutaric aciduria', 'Paraplegia/paraparesis', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Elevated urinary glutaric acid is a hallmark biochemical marker of GA-I, directly caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Seizures & Dystonia**: Neurotoxic accumulation of glutaric acid and 3-hydroxyglutaric acid damages the basal ganglia, leading to acute/subacute striatal injury, manifesting as dystonia and secondary seizures.  
3. **Feeding difficulties**: Infants may exhibit poor feeding due to metabolic instability, encephalopathic crises, or oromotor dysfunction linked to neurological impairment.  
4. **Paraplegia/paraparesis**: Chronic neurodegeneration and corticospinal tract involvement can result in progressive spastic paraparesis.  
5. **Death in infancy**: Untreated GA-I often leads to life-threatening metabolic crises (e.g., during catabolic stress), with striatal necrosis causing irreversible neurological decline and early mortality.  
6. **Temporal consistency**: Symptom onset aligns with GA-I’s typical presentation in infancy (3-36 months), especially following triggers like infections.  
The triad of macrocephaly (often present), movement disorders, and organic aciduria strongly supports GA-I, distinguishing it from other organic acidemias with overlapping features."
"['Myopia', 'Delayed speech and language development', 'Ectopia lentis', 'Intellectual disability', 'Death in infancy', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Aminoaciduria', 'Death in childhood', 'Abnormal circulating alanine concentration', 'Dyskinesia']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypermethioninemia**: Elevated homocysteine and methionine levels are hallmark biochemical features of cystathionine beta-synthase (CBS) deficiency. CBS deficiency blocks the conversion of homocysteine to cystathionine, causing homocysteine accumulation. Concurrent hypermethioninemia occurs due to compensatory remethylation of homocysteine to methionine via the folate-B12 pathway.  
2. **Ectopia Lentis and Myopia**: Homocysteine disrupts collagen cross-linking, weakening zonular fibers of the lens, leading to lens dislocation (ectopia lentis) and secondary myopia.  
3. **Intellectual Disability and Delayed Speech**: Elevated homocysteine is neurotoxic, impairing neuronal development and function, resulting in intellectual disability and language delays.  
4. **Aminoaciduria**: Generalized aminoaciduria may occur due to renal tubular dysfunction secondary to metabolic stress or homocysteine toxicity.  
5. **Early Mortality**: Untreated CBS deficiency predisposes to life-threatening thromboembolic events (e.g., stroke, pulmonary embolism), explaining infant/childhood mortality.  
6. **Dyskinesia**: Rarely reported in severe cases, possibly due to basal ganglia or cerebellar damage from vascular insults or direct homocysteine neurotoxicity.  
7. **Abnormal Alanine**: Non-specific but may reflect secondary metabolic disturbances (e.g., disrupted gluconeogenesis or mitochondrial dysfunction).  

Disease: Homocysteinemia/Homocystinuria  
Reasoning:  
- This is a broader diagnostic category encompassing CBS deficiency. The reasoning above applies here as well, but the specificity of hypermethioninemia and ectopia lentis narrows it to the CBS-deficient subtype. Other forms of homocystinuria (e.g., remethylation defects) would show low methionine and lack ocular manifestations."
"['Cryptorchidism', 'High palate', 'Large fontanelles', 'Brachycephaly', 'Low-set, posteriorly rotated ears', 'Downslanted palpebral fissures', 'Proptosis', 'Polyhydramnios', 'Atrial septal defect', 'Wide intermamillary distance', '2-4 finger syndactyly', '1-5 toe syndactyly', 'Prominent forehead', 'Midface retrusion']",['Apert syndrome/Apert syndrome'],"Disease: Apert syndrome  
Reasoning: The patient exhibits craniofacial features (brachycephaly, prominent forehead, midface retrusion, proptosis, downslanted palpebral fissures, low-set ears) consistent with craniosynostosis syndromes. The bilateral 2-4 finger syndactyly and 1-5 toe syndactyly are pathognomonic for Apert syndrome. Additional supportive findings include high palate, atrial septal defect, and polyhydramnios (linked to fetal swallowing difficulties from craniofacial anomalies). Midface hypoplasia explains proptosis and midface retrusion, while wide fontanelles may reflect abnormal calvarial suture dynamics. These collective features strongly align with Apert syndrome, a FGFR2-related disorder."
"['Aggressive behavior', 'Dementia', 'Memory impairment']",['Alzheimer disease 4'],"Alzheimer disease 4:  
The patient exhibits **memory impairment** and **dementia**, core features of Alzheimer disease (AD). **Aggressive behavior** aligns with neuropsychiatric symptoms seen in AD, particularly in progressive stages. Alzheimer disease 4 (AD4) is linked to mutations in the *PSEN1* gene, associated with early-onset autosomal dominant AD. While age is unspecified here, the triad of cognitive decline, memory deficits, and behavioral changes—especially in a familial or early-onset context—supports AD4. Differential diagnoses like frontotemporal dementia (FTD) are less likely without prominent language/motor features. Genetic testing for *PSEN1* would confirm AD4."
"['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency  
Reasoning:  
1. **Abnormal Pyrimidine Metabolism**: The presence of **abnormal circulating pyrimidine concentration** and **uraciluria** directly points to a defect in pyrimidine catabolism, as uracil accumulation occurs due to impaired breakdown.  
2. **Enzyme Deficiency**: Dihydropyrimidine dehydrogenase (DPD) is responsible for the first step in pyrimidine degradation. Deficiency leads to elevated uracil and thymine in blood/urine.  
3. **Neurological Symptoms**: **Ataxia**, **lethargy**, **drowsiness**, and **generalized hypotonia** align with neurotoxicity caused by excess pyrimidines or their metabolites disrupting CNS function.  
4. **Severe Infantile Presentation**: **Death in infancy** and **sleep disturbance** are consistent with severe neonatal-onset forms of the disorder, where metabolic crises and neurological decline are common.  
5. **Confirmatory Biomarkers**: The combination of uraciluria and abnormal pyrimidine levels is pathognomonic for DPD deficiency, distinguishing it from other metabolic disorders."
"['Abnormal saccadic eye movements', 'Lethargy', 'Spasticity', 'Death in infancy', 'Bradycardia', 'Hyperammonemia', 'Vomiting', 'Apnea', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Low plasma citrulline', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** and **hyperglutaminemia** are hallmark features of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Low plasma citrulline** localizes the defect to the first two steps of the urea cycle (CPS1 or OTC deficiency), as citrulline is synthesized downstream.  
3. **Neonatal death** and **lethargy/drowsiness** align with severe, early-onset UCDs like CPS1 deficiency, which often presents catastrophically in infancy.  
4. **Vomiting**, **apnea**, and **spasticity** reflect acute neurological toxicity from hyperammonemia.  
5. **Oroticaciduria** is atypical for CPS1 deficiency (classically seen in OTC deficiency) but may occur due to secondary pyrimidine pathway dysregulation or overlapping metabolic stress in severe hyperammonemia.  
6. **Abnormal saccadic eye movements** and **sleep disturbances** suggest chronic CNS injury from ammonia accumulation.  
7. **Bradycardia** and **death in infancy** underscore the systemic metabolic crisis typical of untreated CPS1 deficiency.  
8. While **oroticaciduria** raises consideration of OTC deficiency, the absence of elevated citrulline and the constellation of neonatal lethality strongly favor CPS1 deficiency as the primary diagnosis."
"['Hearing impairment', 'Hypertension', 'Hemoptysis', 'Headache', 'Arthralgia', 'Rhinitis', 'Wrist pain', 'Knee pain', 'Ankle pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Hemoptysis and Rhinitis**: GPA classically involves upper and lower respiratory tracts. Hemoptysis suggests pulmonary capillaritis or alveolar hemorrhage, while rhinitis indicates granulomatous inflammation in the nasal mucosa.  
2. **Hearing Impairment**: Secondary to Eustachian tube dysfunction, middle ear involvement, or sensorineural hearing loss from vasculitic damage to cranial nerves or cochlear blood supply.  
3. **Hypertension**: May reflect renal involvement (e.g., glomerulonephritis), a critical feature of GPA that can lead to secondary hypertension.  
4. **Arthralgia (Wrist/Knee/Ankle Pain)**: Non-erosive inflammatory arthritis is common in systemic vasculitis, driven by immune complex deposition.  
5. **Headache**: Could arise from sinusitis (due to nasal granulomas), hypertension, or rare central nervous system vasculitis.  
6. **Multi-Organ Pattern**: GPA’s triad of respiratory tract, kidney, and musculoskeletal involvement aligns with the patient’s symptoms. Biopsy (e.g., nasal/pulmonary lesions) and positive ANCA (PR3-ANCA) would confirm diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Hernia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, leading to fetal complications (e.g., congenital defects, microcephaly).  
3. **Death in infancy/childhood and neonatal death** reflect untreated PKU’s natural progression, as toxic phenylalanine accumulation causes irreversible neurological damage, seizures, and organ failure.  
4. **Hypertyrosinemia** is atypical in classic PKU but may arise in rare variants (e.g., BH4-deficient PKU) or secondary metabolic disruptions from liver dysfunction.  
5. **Hernia** is likely incidental, though malnutrition or connective tissue weakness from metabolic stress could contribute.  

Note: Hypertyrosinemia warrants further investigation for overlapping disorders (e.g., tyrosinemia), but hyperphenylalaninemia prioritizes PKU as the primary diagnosis."
"['Proteinuria', 'Abnormal paranasal sinus morphology', 'Abnormal pinna morphology', 'Abnormal nasal mucosa morphology', 'Hematuria', 'Acrocyanosis', 'Ankle swelling', 'Anemia', 'Elevated hepatic transaminase', 'Elevated circulating creatinine concentration', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Cytoplasmic antineutrophil antibody positivity']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with Polyangiitis  
Reasoning:  
1. **c-ANCA Positivity**: Cytoplasmic antineutrophil antibody (c-ANCA) targeting PR3 is strongly associated with GPA, supporting an autoimmune vasculitis diagnosis.  
2. **Upper Respiratory Involvement**: Abnormal paranasal sinus, nasal mucosa, and pinna morphology align with GPA’s granulomatous inflammation in the respiratory tract, often causing sinusitis, nasal ulcers, or otitis.  
3. **Renal Manifestations**: Proteinuria, hematuria, elevated creatinine, and decreased GFR indicate pauci-immune glomerulonephritis, a hallmark of severe GPA.  
4. **Systemic Inflammation**: Elevated CRP and anemia reflect chronic inflammation, typical of active vasculitis.  
5. **Multisystem Features**: Acrocyanosis and ankle swelling suggest small-vessel vasculitis affecting peripheral circulation and fluid retention from renal dysfunction. Elevated hepatic transaminases may indicate secondary inflammation or drug-induced liver injury (e.g., from immunosuppressants).  
6. **Exclusion of Mimics**: The absence of anti-GBM antibodies (Goodpasture’s), eosinophilia (Churg-Strauss), or ANA/dsDNA (SLE) further narrows the diagnosis to GPA.  

This constellation of c-ANCA positivity, granulomatous upper respiratory lesions, and necrotizing glomerulonephritis is pathognomonic for Granulomatosis with Polyangiitis."
"['Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Vomiting', 'Hyperglutaminemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperleucinemia', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark of MMA, alongside key features like **vomiting, feeding difficulties, generalized hypotonia, and developmental delays (intellectual disability, motor delay)**. These symptoms reflect impaired methylmalonyl-CoA metabolism, leading to toxic metabolite accumulation. **Hyperleucinemia** and **hyperglutaminemia** may arise from secondary metabolic disruptions in amino acid catabolism. **Recurrent viral infections** could stem from metabolic stress impairing immune function. **Death in childhood** aligns with severe, untreated MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **B12-unresponsive subtype** is strongly supported by the severity of symptoms (e.g., **early mortality**) and biochemical findings. This form results from mutations in the *MUT* gene, causing **methylmalonyl-CoA mutase deficiency**, which bypasses B12-dependent pathways. Lack of response to B12 therapy exacerbates metabolic crises, explaining **refractory acidosis, progressive neurological damage**, and poor prognosis. The absence of B12-responsiveness differentiates this from cobalamin metabolism defects."
"['Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Metabolic acidosis and hypoglycemia**: Central features of HMG-CoA lyase deficiency due to impaired ketogenesis (critical for energy during fasting) and accumulation of toxic metabolites.  
2. **Dicarboxylic aciduria and 3-methylglutaric aciduria**: Direct biochemical markers of the disorder, caused by defective leucine catabolism and incomplete fatty acid oxidation.  
3. **Hyperammonemia**: Secondary to metabolic decompensation and carnitine depletion, disrupting the urea cycle.  
4. **Hepatomegaly**: Linked to fatty liver infiltration from disrupted fatty acid metabolism.  
5. **Recurrent viral infections**: Immune stress from metabolic crises and energy deficiency impairing immune function.  
6. **Vomiting/diarrhea/drowsiness**: Acute metabolic decompensation episodes triggered by catabolic states (e.g., fasting, infection).  
7. **Early lethality (infancy/childhood)**: Characteristic of untreated cases due to rapid metabolic deterioration and cerebral edema.  
8. **Elevated urinary carboxylic acids**: Reflects systemic accumulation of 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-methylglutaric acids, pathognomonic for HMG-CoA lyase deficiency.  

The constellation of organic aciduria, hypoglycemia without ketosis, hyperammonemia, and hepatomegaly is diagnostic for this autosomal recessive disorder of ketone body synthesis and leucine metabolism."
"['Urinary retention', 'Abnormality of male external genitalia', 'Micropenis', 'Ureteral duplication', 'Abnormality of the kidney', 'Microretrognathia', 'Abnormality of the outer ear', 'Hearing impairment', 'Low-set ears', 'Abnormality of the eye', 'Visual impairment', 'Autistic behavior', 'Delayed speech and language development', 'Sacral dimple', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Motor delay', 'Absent speech', 'Abnormality of the cardiovascular system', 'Patent ductus arteriosus', 'Tracheomalacia', 'Abnormality of the upper limb', 'Birth length less than 3rd percentile', 'Laryngeal cleft', 'Aplasia/Hypoplasia of the thumb', 'Fetal pyelectasis', 'Feeding difficulties', 'Abnormal optic disc morphology', 'Cerebral visual impairment']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Genetic Basis**: Stankiewicz-Isidor syndrome is caused by heterozygous pathogenic variants in *PHIP*. The patient’s multi-system congenital anomalies align with this disorder’s phenotypic spectrum.  
2. **Urogenital Abnormalities**: Urinary retention, micropenis, ureteral duplication, kidney abnormalities, and fetal pyelectasis match the recurrent urogenital defects seen in this syndrome.  
3. **Craniofacial Features**: Microretrognathia, low-set ears, outer ear abnormalities, and ocular defects (abnormal optic disc, visual impairment) are consistent with characteristic facial dysmorphism.  
4. **Neurodevelopmental Delays**: Intellectual disability, autistic behavior, absent speech, motor delay, and seizures correlate with the syndrome’s severe developmental delays and neurological involvement.  
5. **Cardiovascular/Respiratory Defects**: Patent ductus arteriosus (PDA) and tracheomalacia/laryngeal cleft reflect the congenital cardiovascular/respiratory anomalies reported in affected individuals.  
6. **Limb Anomalies**: Thumb aplasia/hypoplasia and upper limb abnormalities are documented in some cases.  
7. **Growth and Feeding Issues**: Birth length <3rd percentile and feeding difficulties align with prenatal/postnatal growth failure.  
8. **Sensory Deficits**: Hearing impairment and cerebral visual impairment are recurrent features.  
9. **Supportive Findings**: Hypotonia, sacral dimple, and seizures further reinforce the diagnosis, as these are common in *PHIP*-related disease.  
**Conclusion**: The constellation of congenital anomalies, neurodevelopmental deficits, and multi-organ involvement strongly points to Stankiewicz-Isidor syndrome. Genetic testing for *PHIP* variants is recommended for confirmation."
"['Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Elevated hepatic transaminase', 'Feeding difficulties', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG due to impaired glycosylation critical for cerebellar development and function.  
2. **Failure to thrive/Feeding difficulties**: Common in PMM2-CDG due to gastrointestinal dysfunction, hypoglycemia, and protein-losing enteropathy.  
3. **Elevated hepatic transaminase**: Reflects liver involvement, a frequent feature of glycosylation defects disrupting glycoprotein synthesis.  
4. **Death in infancy**: Severe forms of PMM2-CDG (classic type Ia) often lead to early mortality from multisystem failure (neurological, hepatic, cardiac).  
5. **Consistency with PMM2-CDG**: The triad of neurological, hepatic, and growth abnormalities aligns with this disorder, the most prevalent N-linked glycosylation defect caused by phosphomannomutase 2 deficiency."
"['Abnormality of the kidney', 'High palate', 'Hearing impairment', 'Sensorineural hearing impairment', 'Choanal atresia', 'Abnormality of the eye', 'Deeply set eye', 'Ptosis', 'Esotropia', 'Compulsive behaviors', 'Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Cyanosis', 'Spatulate thumbs', 'Intellectual disability', 'Ataxia', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Bilateral ptosis', 'Atrial septal defect', 'Abnormal cardiac septum morphology', 'Hyperconvex nail', 'Myopathic facies', 'Hypoplasia of the corpus callosum', 'Apnea', 'Abnormal brainstem morphology', 'Language impairment', 'Expressive language delay', 'Aortic root aneurysm', 'Scoliosis', 'Myopathy', 'Sleep apnea', 'Abnormal eye morphology', 'Choking episodes']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental Core Features**: Intellectual disability, global developmental delay, delayed speech/language development, expressive language delay, and compulsive behaviors with abnormal repetitive mannerisms align with the neurodevelopmental axis of NEDBEH.  
2. **Brain Anomalies**: Hypoplasia of the corpus callosum and abnormal brainstem morphology directly correspond to structural brain abnormalities in NEDBEH.  
3. **Ocular Involvement**: Abnormality of the eye, deeply set eyes, bilateral ptosis, esotropia, and abnormal eye morphology satisfy the ""eye anomalies"" criterion.  
4. **Cardiac Defects**: Atrial septal defect, abnormal cardiac septum morphology, and aortic root aneurysm reflect cardiac anomalies associated with NEDBEH.  
5. **Systemic Features**: Hypotonia, ataxia, myopathy, scoliosis, hyperconvex nails, spatulate thumbs, and myopathic facies suggest multisystem involvement, common in genetic neurodevelopmental disorders.  
6. **Auxiliary Symptoms**: Cyanosis, apnea, choking episodes, and sensorineural hearing impairment are secondary to neuromuscular, cardiac, or brainstem dysfunction.  
7. **Exclusion of Overlap**: The constellation of symptoms (brain-eye-heart triad) is distinct from isolated syndromes (e.g., CHARGE, Cornelia de Lange), favoring NEDBEH’s broader diagnostic scope.  

This synthesis of neurodevelopmental delays, structural brain/eye/cardiac defects, and supportive systemic features confirms NEDBEH as the unifying diagnosis."
"['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Feeding difficulties', 'Elevated urinary carboxylic acid', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease; MSUD  
Reasoning:  
1. **Elevated urinary carboxylic acid**: MSUD is caused by a defect in branched-chain α-keto acid dehydrogenase, leading to accumulation of branched-chain amino acids (leucine, isoleucine, valine) and their toxic keto-acid derivatives (carboxylic acids) in urine.  
2. **Body odor**: The distinctive maple syrup or burnt sugar odor in bodily fluids is pathognomonic for MSUD due to urinary excretion of sotolone, a compound derived from accumulated keto-acids.  
3. **Feeding difficulties & vomiting**: Acute metabolic decompensation from protein intake overwhelms the impaired enzymatic pathway, causing gastrointestinal distress.  
4. **Generalized hypotonia & growth delay**: Neurotoxic effects of elevated leucine disrupt cerebral metabolism and myelination, impairing neuromuscular function and growth.  
5. **Neonatal death/death in infancy**: Classic severe MSUD manifests within days of birth; untreated hyperleucinosis causes cerebral edema, seizures, and rapid neurological decline.  
6. **Consistency with metabolic crisis**: Symptom triad of encephalopathy, feeding refusal, and odor aligns with acute neonatal-onset MSUD, distinguishing it from other organic acidurias (e.g., propionic acidemia lacks the maple syrup odor)."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. Untreated **classic PKU** results in severe neurological impairment, seizures, and developmental failure. In extreme cases (e.g., undiagnosed or untreated), metabolic derangements and complications like cerebral edema or infections may contribute to **neonatal death** or **death in infancy**.  
3. While neonatal lethality is uncommon in PAH-deficient PKU, it aligns with severe variants (e.g., complete PAH deficiency) or delayed diagnosis in resource-limited settings without newborn screening.  
4. Other causes of hyperphenylalaninemia (e.g., BH4 deficiency) were considered but excluded due to the explicit diagnosis provided and lack of additional symptoms (e.g., neurotransmitter deficiencies)."
"['Delayed speech and language development', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), impairing phenylalanine metabolism.  
2. **Delayed speech and language development**: Untreated PKU leads to toxic phenylalanine accumulation in the brain, damaging myelin and neurotransmitters, resulting in neurodevelopmental delays.  
3. **Severe short stature**: Chronic metabolic disruption and malnutrition (due to strict dietary restrictions) contribute to growth failure in untreated cases.  
4. **Death in childhood**: Severe neurological deterioration, seizures, and systemic complications (e.g., cardiac issues) in classic PKU can lead to early mortality if untreated.  
5. **Confirmation**: PKU is confirmed via newborn screening (elevated phenylalanine, low tyrosine) and genetic testing for PAH mutations. Early dietary intervention prevents symptoms, but untreated cases align with the described presentation."
"['Proteinuria', 'Anemia', 'Vitamin B12 deficiency']",['Imerslund-Gräsbeck syndrome/Megaloblastic anemia 1'],"Disease: Imerslund-Gräsbeck syndrome/Megaloblastic anemia 1  
Reasoning:  
1. **Vitamin B12 deficiency**: Imerslund-Gräsbeck syndrome (IGS) is an autosomal recessive disorder caused by mutations in *CUBN* or *AMN* genes, impairing intestinal absorption of vitamin B12 via defective cubilin-amnionless receptors in the ileum. This explains the deficiency despite normal dietary intake.  
2. **Megaloblastic anemia**: B12 deficiency disrupts DNA synthesis in erythroblasts, leading to megaloblastic anemia (large, immature red blood cells), consistent with the patient's anemia.  
3. **Proteinuria**: The cubilin receptor is also critical for protein reabsorption in the renal proximal tubules. Mutations in *CUBN/AMN* cause selective proteinuria (typically low-molecular-weight proteins like albumin), distinguishing IGS from other causes of B12 deficiency.  
4. **Exclusion of alternatives**: Pernicious anemia (autoimmune) lacks proteinuria, and dietary B12 deficiency is unlikely without risk factors. The triad of B12 deficiency, anemia, and proteinuria strongly supports IGS."
"['Cleft palate', 'Pierre-Robin sequence', 'Thin ribs', 'Anal stenosis', 'Scoliosis', 'Cognitive impairment']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome: The patient exhibits Pierre-Robin sequence (micrognathia, glossoptosis, airway obstruction) and cleft palate, core craniofacial features of CCMS. Thin ribs align with characteristic costovertebral anomalies (hypoplastic ribs, rib gaps). Scoliosis reflects vertebral involvement, while anal stenosis (a rare gastrointestinal anomaly) and cognitive impairment further support this multisystem syndrome. No dominant features of overlapping disorders (e.g., Stickler syndrome, VACTERL) are present, solidifying CCMS as the diagnosis."
"['Renal insufficiency', 'Abnormality of the nose', 'Pruritus', 'Hypertrophic cardiomyopathy', 'Dilated cardiomyopathy', 'Pericardial effusion', 'Left ventricular hypertrophy', 'Fever', 'Dyspnea', 'Abnormal circulating protein concentration', 'Decreased glomerular filtration rate', 'Fatigue', 'Reduced left ventricular ejection fraction', 'Cough', 'Myocarditis', 'Sputum eosinophilia']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vascular Inflammation**: Takayasu arteritis involves large-vessel inflammation, primarily affecting the aorta and its branches. Renal artery stenosis (from vasculitis) can explain **renal insufficiency**, **decreased glomerular filtration rate**, and secondary hypertension, contributing to **left ventricular hypertrophy**.  
2. **Cardiac Manifestations**: Chronic hypertension and inflammatory damage may lead to **hypertrophic cardiomyopathy** and **reduced left ventricular ejection fraction**. Systemic inflammation can cause **myocarditis** and **pericardial effusion**.  
3. **Systemic Inflammation**: **Fever**, **fatigue**, and **abnormal circulating protein concentrations** (e.g., elevated acute-phase reactants like CRP) align with active vasculitis.  
4. **Atypical Features**: **Sputum eosinophilia** and **pruritus** are uncommon in Takayasu but may reflect overlapping autoimmune processes or secondary hypersensitivity reactions. **Abnormality of the nose** (e.g., granulomatous inflammation) could represent rare extrapulmonary involvement.  
5. **Respiratory Symptoms**: **Dyspnea** and **cough** may arise from heart failure (due to cardiomyopathy) or pulmonary artery involvement, a recognized but less common feature of Takayasu.  
6. **Exclusion of Alternatives**: While eosinophilia might suggest Churg-Strauss syndrome, the dominance of large-vessel and cardiac pathology supports Takayasu as the primary diagnosis.  

Note: Coexisting conditions (e.g., secondary amyloidosis) should be ruled out given renal and protein abnormalities, but the clinical picture primarily fits Takayasu arteritis with multisystem complications."
"['Abnormality of the genitourinary system', 'Abnormality of the nervous system', 'Growth delay', 'Pancytopenia', 'Immunodeficiency', 'Bone marrow hypocellularity', 'Short telomere length']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Ataxia-pancytopenia syndrome (APS):  
- **Pancytopenia & bone marrow hypocellularity**: Core features of APS, reflecting bone marrow failure.  
- **Nervous system abnormality**: Likely cerebellar ataxia, a hallmark of APS.  
- **Short telomere length**: APS is linked to germline SAMD9/SAMD9L mutations, which disrupt telomere stability.  
- **Immunodeficiency**: Bone marrow failure predisposes to recurrent infections.  
- **Growth delay & genitourinary anomalies**: Seen in APS due to systemic effects of telomere dysfunction and/or SAMD9L-related developmental defects.  
- **Exclusion of mimics**: Dyskeratosis congenita (similar telomere defects but mucocutaneous triad absent), Fanconi anemia (chromosomal breaks typical, not seen here)."
"['Cleft palate', 'Hypertelorism', 'Breech presentation', 'Scoliosis', 'Hip dislocation', 'Cervical kyphosis', 'Elbow flexion contracture', 'Knee dislocation', 'Depressed nasal bridge', 'Short metacarpal', 'Spinal dysraphism', 'High maternal circulating alpha-fetoprotein concentration']",['Larsen syndrome/Larsen syndrome'],"Disease: Larsen syndrome  
Reasoning:  
1. **Multiple congenital joint dislocations** (hip, knee, elbow) are hallmark features of Larsen syndrome, caused by FLNB gene mutations affecting skeletal development.  
2. **Craniofacial anomalies** (hypertelorism, depressed nasal bridge, cleft palate) align with characteristic facial features of the syndrome.  
3. **Spinal abnormalities** (scoliosis, cervical kyphosis, spinal dysraphism) reflect vertebral malformations and neural tube defects associated with Larsen syndrome.  
4. **Short metacarpals** and **elbow/knee contractures** suggest skeletal dysplasia, consistent with the disorder’s connective tissue involvement.  
5. **High maternal alpha-fetoprotein (AFP)** correlates with spinal dysraphism, a neural tube defect often seen prenatally in Larsen syndrome.  
6. **Breech presentation** is common due to restricted fetal movement from joint dislocations.  

The constellation of orthopedic, spinal, and craniofacial findings, alongside elevated AFP, strongly supports Larsen syndrome over other skeletal dysplasias (e.g., Ehlers-Danlos, Stickler syndrome). Genetic testing for FLNB variants would confirm the diagnosis."
"['Open mouth', 'High palate', 'Dolichocephaly', 'Protruding ear', 'Ptosis', 'Long palpebral fissure', 'Nystagmus', 'Global developmental delay', 'Motor delay', 'Neonatal hypotonia', 'Muscle weakness', 'Severe failure to thrive', 'Hypernasal speech', 'Polyphagia', 'Scoliosis', 'Gowers sign', 'Tented upper lip vermilion', 'Weakness of facial musculature']","['Myasthenic syndrome, congenital, 22']","Disease: Myasthenic syndrome, congenital, 22  
Reasoning:  
1. **Neuromuscular Symptoms**: Neonatal hypotonia, muscle weakness, Gowers sign, and facial musculature weakness align with congenital myasthenic syndromes (CMS), which impair neuromuscular transmission.  
2. **Developmental Delays**: Global developmental delay and motor delay are consistent with CMS-related muscle dysfunction affecting milestones.  
3. **Craniofacial Features**: High palate, dolichocephaly, protruding ears, tented upper lip, ptosis, and long palpebral fissures suggest a genetic syndrome with craniofacial dysmorphism, often seen in CMS subtypes.  
4. **Speech and Feeding Issues**: Hypernasal speech (due to velopharyngeal insufficiency) and severe failure to thrive (from neonatal hypotonia affecting feeding) are hallmarks of CMS.  
5. **Ocular and Autonomic Signs**: Nystagmus and ptosis point to neuromuscular junction defects impacting extraocular muscles.  
6. **Genetic Correlation**: CMS22 (linked to *SLC5A7* mutations) presents with hypotonia, facial weakness, feeding difficulties, and characteristic facial features, strongly matching the symptom profile.  
7. **Exclusion of Overlap**: Polyphagia and scoliosis are atypical but may arise secondary to chronic muscle weakness or compensatory metabolic adaptations.  

The constellation of congenital hypotonia, craniofacial anomalies, and neuromuscular deficits specifically aligns with CMS22, distinguishing it from other CMS subtypes or myopathies."
"['Irritability', 'Seizure', 'Generalized hypotonia', 'Hyperreflexia', 'Death in infancy', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning: The combination of irritability, seizures, generalized hypotonia, hyperreflexia, and opisthotonus points to severe neurological dysfunction. Death in infancy and feeding difficulties align with progressive infantile neurodegenerative disorders. Abnormal circulating aspartate family amino acids (specifically elevated N-acetylaspartic acid due to aspartoacylase deficiency) is pathognomonic for Canavan disease. The triad of hypotonia, hyperreflexia, and macrocephaly (implied by rapid neurodegeneration and intracranial pressure causing opisthotonus) further supports this diagnosis."
"['Headache', 'Elevated urinary delta-aminolevulinic acid', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning: The patient presents with headache and elevated urinary delta-aminolevulinic acid (ALA), both consistent with acute intermittent porphyria (AIP). AIP is caused by a deficiency in porphobilinogen deaminase (PBGD), leading to accumulation of ALA and porphobilinogen (PBG) during acute attacks. While AIP typically manifests in adults, severe undiagnosed cases in children can result in fatal complications such as respiratory paralysis or refractory hyponatremia. However, childhood death is atypical for AIP, suggesting either an unusually early presentation or misdiagnosis.  

Disease: Porphyria/Porphyria  
Reasoning: Elevated urinary ALA and childhood mortality strongly suggest a severe, early-onset porphyria such as delta-aminolevulinic acid dehydratase deficiency porphyria (ADP), an ultra-rare autosomal recessive form. ADP causes extreme ALA elevation due to ALA dehydratase deficiency, leading to neurovisceral crises and early death. While not explicitly listed, ADP falls under the broader ""porphyria"" category. This aligns better with childhood fatality than AIP, which is less common in pediatric populations."
"['Syncope', 'Cardiomyopathy', 'Ventricular fibrillation', 'Cardiac arrest', 'Right bundle branch block', 'Myocarditis']","['Cateeholaminergic polymorphic ventricular tachycardia, CPVT/Catecholaminergic polymorphic ventricular tachycardia/Ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy']","Disease: CPVT/Catecholaminergic polymorphic ventricular tachycardia  
Reasoning:  
1. **Syncope and Cardiac Arrest**: CPVT is characterized by adrenergically mediated ventricular arrhythmias, typically triggered by physical/emotional stress. These episodes manifest as syncope or sudden cardiac arrest, aligning with the patient’s symptoms.  
2. **Ventricular Fibrillation**: A hallmark of CPVT is bidirectional/polymorphic ventricular tachycardia (VT) progressing to ventricular fibrillation (VF), especially under catecholamine surge.  
3. **Cardiomyopathy**: While CPVT is primarily an electrical disorder, advanced cases may develop atrial dysfunction or dilated cardiomyopathy due to chronic arrhythmia burden or genetic overlap (e.g., RYR2 mutations).  
4. **Right Bundle Branch Block (RBBB)**: Not a classic CPVT feature but may arise secondary to structural remodeling from cardiomyopathy or myocardial inflammation.  
5. **Myocarditis**: Could be coincidental or misdiagnosed; CPVT-associated arrhythmias may mimic myocarditis symptoms (e.g., palpitations, syncope). Further evaluation (e.g., cardiac MRI, biopsy) would exclude primary inflammation.  
6. **Diagnostic Confirmation**: Genetic testing for RYR2 or CASQ2 mutations and exercise stress testing (provoking VT/VF) are critical to confirm CPVT, especially in the presence of adrenergically driven arrhythmias.  

**Exclusion**: Structural causes (e.g., ischemic cardiomyopathy) and acquired myocarditis should be ruled out via imaging and lab studies (e.g., troponin, viral PCR)."
"['Nephrocalcinosis', 'Epistaxis', 'Failure to thrive', 'Death in infancy', 'Pulmonic stenosis', 'Increased serum lactate', 'Hepatomegaly', 'Hypokalemia', 'Hypermagnesemia', 'Hypercholesterolemia', 'High serum calcitriol', 'Elevated circulating alkaline phosphatase concentration', 'Hyperalaninemia', 'Aminoaciduria', 'Increased serum iron', 'Severe short stature', 'Hypouricemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Death in adolescence']",['Fanconi-Bickel syndrome/Fanconi-Bickel syndrome'],"Disease: Fanconi-Bickel syndrome  
Reasoning:  
1. **Hepatomegaly** and **failure to thrive** are hallmark features of Fanconi-Bickel syndrome (FBS), caused by hepatic glycogen accumulation and metabolic disturbances.  
2. **Aminoaciduria** and **hypokalemia** indicate proximal renal tubular dysfunction (Fanconi syndrome), a core component of FBS.  
3. **Nephrocalcinosis** arises from chronic renal phosphate wasting and hypercalciuria, exacerbated by **high serum calcitriol** due to dysregulated vitamin D metabolism.  
4. **Severe short stature** and **hypercholesterolemia** reflect impaired glucose metabolism and malnutrition from defective GLUT2-mediated transport.  
5. **Hypouricemia** and **elevated serum lactate** align with proximal tubule dysfunction and glycolytic pathway disruptions.  
6. **Abnormal circulating aspartate family amino acids** and **hyperalaninemia** stem from systemic metabolic dysregulation.  
7. **Increased serum iron** and **hepatomegaly** correlate with hepatic dysfunction and glycogen overload.  
8. **Death in infancy/childhood/adolescence** reflects the severe, progressive nature of untreated FBS.  
9. Atypical features like **pulmonic stenosis** and **epistaxis** may represent comorbidities or secondary complications but do not exclude the diagnosis.  

The collective presentation of hepatorenal glycogen storage disease, Fanconi syndrome, and metabolic derangements confirms Fanconi-Bickel syndrome."
"['Goiter', 'Cholelithiasis', 'Arthritis', 'Abnormality of the larynx', 'Abnormal aortic morphology', 'Thrombocytosis', 'Anemia', 'Fever', 'Leukocytosis', 'Hepatomegaly', 'Abnormal intestine morphology', 'Arthralgia', 'Elevated hepatic transaminase', 'Hypercalcemia', 'Elevated circulating alkaline phosphatase concentration', 'Myalgia', 'Exercise intolerance', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Decreased erythrocyte sedimentation rate', 'Cervical lymphadenopathy', 'Night sweats', 'Knee pain', 'Elevated gamma-glutamyltransferase level']","['Familial cold autoinflammatory syndrome 2', 'Familial cold urticaria', 'Familial cold inflammatory syndrome 1', 'Muckle-Wells syndrome/Muckle-Wells syndrome', 'Familial cold autoinflammatory syndrome 3', 'Familial cold autoinflammatory syndrome 4', 'CINCA syndrome/Cinca syndrome']","Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning:  
1. **Systemic Inflammation**: Elevated CRP, leukocytosis, thrombocytosis, and fever align with chronic inflammation seen in Muckle-Wells syndrome (MWS).  
2. **Musculoskeletal Involvement**: Arthritis, arthralgia, myalgia, and knee pain are consistent with recurrent inflammatory episodes characteristic of MWS.  
3. **Hepatic Abnormalities**: Hepatomegaly, elevated transaminases, and GGT suggest systemic inflammation affecting the liver, common in MWS.  
4. **ENT Manifestations**: Laryngeal abnormalities and cervical lymphadenopathy may reflect chronic mucosal inflammation.  
5. **Laboratory Findings**: Increased alpha-globulin and hypercalcemia (though atypical) could stem from chronic inflammation or secondary dysregulation. Decreased ESR paradoxically occurs due to hypergammaglobulinemia inhibiting rouleaux formation.  
6. **Absence of Cold Triggers**: Symptoms lack cold-induced triggers, making FCAS less likely.  
7. **Organ Damage**: Abnormal aortic/intestine morphology may reflect long-term inflammatory damage or amyloidosis, a known complication of MWS.  
8. **Exclusion of CINCA**: No neonatal onset, neurological deficits, or bony overgrowth, ruling out CINCA.  

Disease: Familial cold autoinflammatory syndrome 2  
Reasoning:  
1. **Overlapping Inflammation**: Fever, leukocytosis, and elevated CRP match FCAS2’s inflammatory profile.  
2. **Lymphatic Involvement**: Cervical lymphadenopathy and night sweats align with FCAS2’s systemic presentation.  
3. **Gastrointestinal Features**: Abnormal intestine morphology and hepatomegaly may reflect abdominal inflammation reported in FCAS2.  
4. **Musculoskeletal Symptoms**: Arthralgia and myalgia are consistent but less specific.  
5. **Cold Trigger Ambiguity**: Lack of explicit cold triggers in the history reduces likelihood but does not exclude FCAS2.  

Disease: CINCA syndrome/Cinca syndrome  
Reasoning:  
1. **Severe Inflammation**: Marked leukocytosis, thrombocytosis, and hepatomegaly suggest systemic involvement.  
2. **Growth Abnormalities**: Abnormal aortic/intestine morphology could reflect chronic tissue inflammation.  
3. **Exclusion Factors**: Absence of neonatal onset, rash, or neurological deficits makes CINCA unlikely but not impossible in atypical cases.  

**Final Diagnosis**: **Muckle-Wells syndrome** is the most likely, given the chronic systemic inflammation, multi-organ involvement, and absence of neonatal or cold-triggered features. FCAS2 and CINCA are less probable but remain differentials."
"['Pierre-Robin sequence', 'High palate', 'Downslanted palpebral fissures', 'Carious teeth', '11 pairs of ribs', 'Specific learning disability', 'Feeding difficulties', 'Hypoplastic L5 vertebral pedicle', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome: The patient exhibits Pierre-Robin sequence (micrognathia, glossoptosis, and cleft palate/high palate), a hallmark of CCMS. The skeletal anomalies—11 pairs of ribs (rib hypoplasia), posterior rib gaps, and hypoplastic L5 vertebral pedicle—align with costovertebral defects central to this syndrome. Feeding difficulties are secondary to craniofacial and airway challenges from PRS. Downslanted palpebral fissures and specific learning disability suggest broader craniofacial and neurodevelopmental involvement. Carious teeth may reflect oral anatomical challenges or enamel defects. The combined craniofacial, vertebral, and rib anomalies strongly support CCMS, excluding isolated PRS or other rib malformation syndromes."
"['Resting tremor', 'Limb dystonia', 'Falls', 'Abnormal autonomic nervous system physiology', 'Cognitive impairment']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Resting tremor**: Common in Parkinsonian disorders, though less prominent in early-onset genetic forms. Supports Parkinsonism.  
2. **Limb dystonia**: A hallmark of ATP13A2-associated PARK23, often presenting as early-onset focal dystonia (e.g., hand/foot posturing).  
3. **Falls**: Reflects early postural instability and rapid disease progression, atypical in idiopathic Parkinson’s but seen in PARK23 due to pyramidal/non-motor involvement.  
4. **Autonomic dysfunction**: ATP13A2 mutations disrupt lysosomal/autophagy processes, causing dysautonomia (e.g., orthostatic hypotension, urinary issues).  
5. **Cognitive impairment**: Early cognitive decline aligns with PARK23’s association with Kufor-Rakeb syndrome, which includes dementia and supranuclear gaze palsy.  
**Genetic link**: Autosomal recessive inheritance (ATP13A2 mutations) explains early-onset presentation (often <40 years) and multisystem neurodegeneration."
"['Carious teeth', 'Obesity', 'Elevated hepatic transaminase', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased circulating copper concentration', 'Decreased serum iron']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin concentration**: A hallmark of Wilson disease, as impaired copper transport due to ATP7B gene mutations prevents copper incorporation into ceruloplasmin, reducing its serum levels.  
2. **Increased urinary copper concentration**: Excess copper is excreted via urine due to systemic overload, a key diagnostic criterion.  
3. **Elevated hepatic transaminase**: Reflects liver injury from copper accumulation, a common early manifestation.  
4. **Decreased circulating copper concentration**: Paradoxically low serum copper occurs because unbound copper (non-ceruloplasmin-bound) is rapidly cleared, though total body copper is elevated.  
5. **Abnormal circulating aspartate family amino acid/alanine concentration**: Liver dysfunction disrupts amino acid metabolism, elevating serum levels.  
6. **Decreased serum iron**: Secondary to hepatic damage impairing iron regulation or coexisting malnutrition.  
7. **Abnormal circulating porphyrin concentration**: May arise from hepatic dysfunction or oxidative stress due to copper toxicity.  
8. **Carious teeth**: Chronic copper toxicity can cause salivary gland dysfunction or enamel defects.  
9. **Obesity**: Atypical but possible due to metabolic disturbances or comorbidities.  
10. **Death in childhood**: Untreated Wilson disease leads to fatal liver failure or neurological deterioration, emphasizing early diagnosis.  

The combination of copper metabolism abnormalities (ceruloplasmin, urinary/serum copper) with hepatic and systemic manifestations confirms Wilson disease."
"['Death in infancy', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Death in infancy**: HMG-CoA lyase deficiency is a severe autosomal recessive metabolic disorder that typically manifests in infancy with life-threatening episodes of hypoglycemia and metabolic acidosis, often leading to early mortality if undiagnosed or untreated.  
2. **Dicarboxylic aciduria**: Impaired fatty acid β-oxidation due to deficient HMG-CoA lyase activity results in incomplete fatty acid breakdown, causing urinary excretion of dicarboxylic acids (e.g., adipic, suberic acids).  
3. **3-Methylglutaric aciduria**: The enzyme deficiency disrupts leucine catabolism, leading to accumulation of 3-hydroxy-3-methylglutaryl-CoA, which is diverted to 3-methylglutaric acid and 3-methylglutaconic acid via alternative pathways.  
4. **Elevated urinary carboxylic acids**: The block in ketogenesis (HMG-CoA lyase converts HMG-CoA to acetoacetate) and leucine degradation causes systemic buildup of multiple carboxylic acids (e.g., 3-hydroxy-3-methylglutaric, 3-methylglutaric, and 3-methylglutaconic acids), which are excreted in urine.  
**Conclusion**: The biochemical profile aligns with HMG-CoA lyase deficiency, where disrupted ketogenesis and leucine metabolism lead to characteristic organic aciduria, hypoglycemia, and metabolic crises in infancy."
"['Death in infancy', 'Anemia', 'Hyperhomocystinemia', 'Abnormal circulating porphyrin concentration', 'Abnormal blood folate concentration', 'Abnormal vitamin B12 level']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia**: Directly caused by cystathionine beta-synthase (CBS) deficiency, which disrupts homocysteine metabolism, leading to toxic accumulation.  
2. **Anemia**: CBS deficiency indirectly affects folate and vitamin B12 metabolism, both critical for DNA synthesis and erythropoiesis. Abnormal levels of these vitamins can result in megaloblastic anemia.  
3. **Abnormal vitamin B12/folate concentrations**: Homocysteine remethylation to methionine requires B12 and folate. Dysregulation in this pathway alters their utilization, causing abnormal serum levels.  
4. **Death in infancy**: Severe CBS deficiency manifests neonatally with rapid metabolic decompensation, thromboembolic events, or failure to thrive, often fatal without early diagnosis/treatment.  
5. **Abnormal porphyrins**: While not a primary feature of CBS deficiency, secondary oxidative stress from homocysteine toxicity may disrupt heme biosynthesis, elevating porphyrin levels.  

Disease: Homocysteinemia/Homocystinuria (broader category)  
Reasoning:  
1. **Hyperhomocystinemia**: Defines the condition, encompassing both genetic (e.g., CBS deficiency) and acquired causes (e.g., B9/B12 deficiencies).  
2. **Consistent symptoms**: All listed findings (anemia, abnormal B12/folate, porphyrins) align with systemic metabolic disruption from homocysteine toxicity, even if CBS deficiency is the specific etiology."
"['Acrocyanosis', 'Abnormal toe morphology', 'Fever', 'Hepatomegaly', 'Deep venous thrombosis', 'Vasculitis', 'Low back pain', 'Cachexia', 'Arterial thrombosis', 'Generalized lymphadenopathy', 'Chronic oral candidiasis', 'Abnormality of the submandibular glands', 'Erythema', 'Fatigue', 'Peripheral edema', 'Caput medusae', 'Foot pain', 'Portal vein thrombosis', 'Gangrene']","['Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome', 'Polyarteritis nodosa', 'Buerger disease/Buerger disease']","Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning:  
1. **Vasculitis and thrombosis**: The patient has vasculitis, arterial thrombosis (gangrene, acrocyanosis), and venous thrombosis (deep venous thrombosis, portal vein thrombosis). VEXAS is characterized by both venous and arterial thrombotic events alongside vasculitic inflammation.  
2. **Autoinflammation**: Fever, erythema, and fatigue align with systemic inflammation. Low back pain may reflect chondritis, a recognized feature of VEXAS.  
3. **Immunodeficiency**: Chronic oral candidiasis and generalized lymphadenopathy suggest immune dysfunction, consistent with VEXAS-associated hematologic defects (e.g., myelodysplasia).  
4. **Hematologic and organ involvement**: Cachexia, hepatomegaly, and caput medusae (indicative of portal hypertension from portal vein thrombosis) correlate with systemic hematologic and hepatic abnormalities in VEXAS.  
5. **Submandibular gland abnormality**: Linked to inflammatory infiltrates seen in autoinflammatory syndromes like VEXAS.  

Disease: Polyarteritis nodosa (PAN)  
Reasoning:  
1. **Vasculitis**: Medium-vessel vasculitis in PAN explains erythema, peripheral edema, and neuropathy-like foot pain.  
2. **Systemic symptoms**: Fever, cachexia, and hepatomegaly are classic systemic features of PAN.  
3. **Thrombosis**: Arterial thrombosis (gangrene) and renal/hepatic artery involvement (hepatomegaly) may occur, though PAN typically lacks venous thrombosis (portal vein thrombosis here suggests overlap with VEXAS).  

Disease: Buerger disease (Thromboangiitis obliterans)  
Reasoning:  
1. **Peripheral vascular involvement**: Acrocyanosis, abnormal toe morphology, foot pain, and gangrene are hallmarks of Buerger disease, linked to smoking and distal arterial occlusion.  
2. **Thrombosis**: Arterial thrombosis aligns with Buerger’s inflammatory thrombotic process.  
3. **Limitations**: Buerger disease does not explain systemic features (fever, lymphadenopathy, hepatomegaly) or immunodeficiency (oral candidiasis), suggesting a secondary or overlapping diagnosis (e.g., VEXAS).  

**Conclusion**: The patient’s constellation of symptoms is most consistent with **VEXAS syndrome**, given the combination of autoinflammation, immunodeficiency, and multi-site thrombosis. PAN and Buerger disease may contribute to specific vascular manifestations but do not fully account for the systemic and immunologic defects."
"['Hepatic steatosis', 'Periportal fibrosis', 'Hypercholesterolemia', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis & periportal fibrosis**: TMEM199-CDG is associated with hepatic involvement, including fatty liver and fibrosis due to disrupted glycosylation-dependent hepatic function.  
2. **Hypercholesterolemia**: Impaired glycosylation of lipoproteins (e.g., LDL receptors) disrupts cholesterol metabolism, leading to elevated serum cholesterol.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, a common feature in TMEM199-CDG.  
4. **Elevated creatine kinase**: Suggests muscle involvement, occasionally seen in glycosylation disorders due to defective glycoprotein synthesis in muscle tissue.  
5. **Decreased ceruloplasmin & copper**: Ceruloplasmin, a copper-carrying glycoprotein, requires proper glycosylation for stability. Defective glycosylation reduces ceruloplasmin levels, leading to secondary hypocupremia (low serum copper) without copper overload.  
6. **Genetic basis**: TMEM199-CDG is caused by mutations in *TMEM199*, disrupting Golgi glycosylation processes, aligning with the multisystemic symptoms observed."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Spasticity', 'Death in infancy', 'Hyperammonemia', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia & Abnormality of galactoside metabolism**: Directly indicate impaired galactose metabolism, a hallmark of galactosemia.  
2. **Feeding difficulties & Spasticity**: Common in infants with galactosemia due to toxin accumulation (e.g., galactitol) affecting the liver, brain, and kidneys.  
3. **Hyperammonemia & Abnormal amino acid concentrations**: Caused by liver dysfunction from toxic metabolite buildup (galactose-1-phosphate), disrupting urea cycle and amino acid metabolism.  
4. **Prolonged PTT**: Results from coagulopathy secondary to liver damage.  
5. **Neonatal/Infancy/Childhood death**: Untreated classic galactosemia leads to sepsis, liver failure, or neurological complications, often fatal early in life.  
6. **Prenatal developmental abnormality**: May reflect intrauterine toxicity from maternal galactose exposure in severe cases.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning:  
- Overlaps with classic galactosemia but emphasizes the broader category. Key symptoms (hypergalactosemia, liver dysfunction, metabolic abnormalities) align with galactosemia subtypes. Early mortality and hyperammonemia reinforce the diagnosis.  
- Differentiation: Classic galactosemia (GALT deficiency) is the most severe form, explaining the fatal trajectory, while ""galactosemia"" may encompass other enzymatic defects (e.g., GALK1, GALE), though the symptom severity here points to GALT deficiency."
"['Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** indicates a urea cycle disorder, as ammonia detoxification relies on this pathway.  
2. **Oroticaciduria** is pathognomonic for OTCD. Excess carbamoyl phosphate (due to OTC enzyme deficiency) diverts to pyrimidine synthesis, overproducing orotic acid.  
3. **Neurological symptoms** (lethargy, drowsiness, sleep disturbances, vomiting) align with ammonia toxicity affecting the central nervous system.  
4. **Death in infancy** suggests a severe, early-onset presentation typical of male hemizygotes in X-linked OTCD.  
5. Exclusion of other urea cycle disorders (e.g., citrullinemia, argininosuccinic aciduria) due to the absence of their specific biochemical markers (e.g., elevated citrulline) and the presence of oroticaciduria."
"['Nephritis', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Hepatomegaly', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid']",['Hawkinsinuria/Hawkinsinuria'],"Disease: Hawkinsinuria  
Reasoning:  
1. **Abnormal Tyrosine Metabolism**: The patient's abnormal circulating tyrosine concentration suggests a disorder in tyrosine catabolism. Hawkinsinuria is caused by a partial deficiency of 4-hydroxyphenylpyruvate dioxygenase (HPD), a key enzyme in tyrosine breakdown.  
2. **Elevated Urinary Carboxylic Acids**: Accumulation of intermediates like hawkinsin (a cyclic carboxylic acid derivative) due to HPD deficiency leads to elevated urinary carboxylic acids, a hallmark of the condition.  
3. **Gastrointestinal Symptoms**: Vomiting and diarrhea are common in infancy due to metabolic acidosis from toxic metabolite buildup.  
4. **Hepatomegaly**: Impaired tyrosine metabolism can cause liver enlargement, though liver dysfunction is typically mild compared to other tyrosine disorders (e.g., tyrosinemia type I).  
5. **Failure to Thrive and Nephritis**: Chronic metabolic stress and tubular kidney damage from hawkinsin or its derivatives may result in growth failure and nephritis.  
6. **Death in Infancy**: Severe metabolic crises in untreated cases can lead to early mortality, though symptoms often improve with age if managed (e.g., low-tyrosine diet, ascorbic acid supplementation).  
7. **Exclusion of Other Disorders**: The absence of severe liver failure (tyrosinemia type I) or ocular/skin lesions (tyrosinemia type II) further supports Hawkinsinuria."
"['Lethargy', 'Death in infancy', 'Weight loss', 'Dehydration', 'Hyperammonemia', 'Pneumonia', 'Dyspnea', 'Opisthotonus', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Elevated urinary carboxylic acid']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder impairing ammonia detoxification.  
2. **Oroticaciduria/Uraciluria**: Pathognomonic for OTCD; excess carbamoyl phosphate diverts to pyrimidine synthesis, producing orotic acid and uracil.  
3. **Neurological symptoms (cerebral edema, opisthotonus, drowsiness)**: Result from ammonia-induced neurotoxicity.  
4. **Early lethality (neonatal/infant/childhood death)**: Characteristic of severe urea cycle defects due to rapid metabolic decompensation.  
5. **Hyperglutaminemia/Hyperalaninemia**: Alternative nitrogen accumulation from impaired urea cycle.  
6. **Respiratory signs (tachypnea, dyspnea)**: Compensatory respiratory alkalosis to counteract acidosis from ammonia.  
7. **Elevated plasma citrulline discrepancy**: While atypical for OTCD (typically low citrulline), possible partial enzyme activity, analytical variability, or concurrent metabolic stressors may explain this finding.  
8. **Recurrent infections/GI inflammation**: Catabolic states and metabolic instability predispose to immune dysfunction and mucosal injury.  
9. **Abnormal amino acid/carnitine profiles**: Secondary to disrupted nitrogen metabolism and mitochondrial dysfunction.  

Key confirmatory features: Oroticaciduria + hyperammonemia + X-linked inheritance pattern (severe males), despite citrulline elevation, strongly prioritize OTCD over other urea cycle disorders."
"['Dry skin', 'Pallor', 'Abnormality of the hand', 'Abnormal foot morphology', 'Sparse scalp hair', 'Pili torti', 'Abnormality of dental morphology', 'Macular atrophy', 'Follicular hyperkeratosis', 'Reduced visual acuity', 'Macular hyperpigmentation', 'Sparse eyebrow', 'Epidermoid cyst', 'Absent sebaceous glands']","['Hypotrichosis with juvenile macular degeneration/Hypotrichosis, congenital, with juvenile macular dystrophy']","Disease: Hypotrichosis with juvenile macular degeneration (HJMD)  
Reasoning:  
1. **Hair Abnormalities**: Symptoms like sparse scalp hair, sparse eyebrows, and pili torti (twisted hair shafts) directly align with **hypotrichosis**, a hallmark of HJMD.  
2. **Ocular Features**: Reduced visual acuity, macular atrophy, and macular hyperpigmentation indicate **juvenile macular dystrophy**, the second defining feature of HJMD.  
3. **Cutaneous Manifestations**: Dry skin, follicular hyperkeratosis, and absent sebaceous glands suggest a congenital ectodermal defect, consistent with HJMD’s pathogenesis.  
4. **Supporting Signs**: Epidermoid cysts, abnormal dental morphology, and hand/foot abnormalities further support a systemic ectodermal dysplasia, a common underlying mechanism in HJMD.  
5. **Exclusion of Overlap Syndromes**: The combination of hair, skin, and macular pathology without neurological or skeletal dominance distinguishes HJMD from similar disorders (e.g., Sjögren-Larsson syndrome).  

This constellation of ectodermal defects and early-onset macular degeneration confirms the diagnosis."
"['Seizure', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Neonatal death']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia indicators**: Symptoms like seizures, lethargy, vomiting, drowsiness, and neonatal death align with hyperammonemia, a hallmark of urea cycle disorders.  
2. **Oroticaciduria**: Elevated urinary orotic acid occurs in OTCD due to carbamoyl phosphate accumulation, which is diverted to pyrimidine synthesis. This distinguishes OTCD from other urea cycle defects.  
3. **Hyperglutaminemia**: Excess ammonia is metabolized via glutamine synthetase, increasing glutamine levels.  
4. **Neonatal/Infantile lethality**: Severe OTCD often presents catastrophically in males (X-linked) shortly after birth, consistent with ""death in infancy.""  
5. **Exclusion of alternatives**: Oroticaciduria differentiates OTCD from CPS1 deficiency (no orotic acid elevation). Symptoms also exclude organic acidemias or mitochondrial disorders, which lack urea cycle-specific markers.  

The triad of **hyperammonemia, oroticaciduria, and hyperglutaminemia** confirms OTCD as the diagnosis."
"['Irritability', 'Seizure', 'Lethargy', 'Motor delay', 'Failure to thrive', 'Death in infancy', 'Weight loss', 'Hyperammonemia', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Argininuria', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Feeding difficulties', 'Uraciluria']",['Arginase deficiency/Argininemia/Argininemia'],"Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Hyperammonemia** and **cerebral edema** indicate a urea cycle disorder, as ammonia detoxification is impaired.  
2. **Argininuria** and **abnormal circulating arginine concentration** directly suggest arginase deficiency, as arginase catalyzes arginine breakdown. Accumulated arginine spills into urine.  
3. **Oroticaciduria** and **uraciluria** occur due to secondary pyrimidine synthesis disruption from carbamoyl phosphate accumulation, a urea cycle intermediate.  
4. **Neurological symptoms** (seizures, drowsiness, irritability, motor delay) stem from ammonia/arginine neurotoxicity and cerebral edema.  
5. **Failure to thrive**, **feeding difficulties**, and **weight loss** reflect chronic metabolic stress and protein intolerance.  
6. **Recurrent viral infections** may link to immune dysfunction from metabolic imbalance or nutritional deficits.  
7. **Death in infancy** aligns with severe, untreated urea cycle disorders.  
The triad of hyperammonemia, argininuria, and oroticaciduria strongly differentiates arginase deficiency from other urea cycle defects."
"['Renal insufficiency', 'Horseshoe kidney', 'Platyspondyly', 'Brachydactyly', 'Hepatic cysts', 'Abnormal facial shape', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Skeletal dysplasia', 'Tachypnea', 'Multiple renal cysts', 'Limb undergrowth', 'Abnormal T cell count', 'Preterm intraventricular hemorrhage']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Platyspondyly, brachydactyly, skeletal dysplasia, and limb undergrowth align with ISDNA’s hallmark skeletal defects caused by *EXOC6B* mutations.  
2. **Renal and Hepatic Involvement**: Horseshoe kidney, multiple renal cysts, renal insufficiency, and hepatic cysts reflect multisystemic ciliopathy-like features seen in ISDNA.  
3. **Neurodevelopmental Defects**: Hypoplasia of the corpus callosum, ventriculomegaly, and preterm intraventricular hemorrhage indicate severe neurodevelopmental abnormalities consistent with ISDNA.  
4. **Immune Dysregulation**: Abnormal T cell count points to the immunologic component unique to ISDNA.  
5. **Additional Features**: Tachypnea (respiratory compromise) and abnormal facial shape further support the diagnosis, as these are commonly reported in ISDNA.  
6. **Exclusion of Alternatives**: The combination of skeletal, renal, neurodevelopmental, and immune abnormalities distinguishes ISDNA from isolated ciliopathies or skeletal dysplasias."
"['Skin rash', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Splenomegaly', 'Fever', 'Vomiting', 'Pneumonia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Hyperglycinuria', 'Cystinuria', 'Oroticaciduria', 'Ornithinuria', 'Death in childhood', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']",['Hereditary orotic aciduria/Orotic aciduria'],"Disease: Hereditary orotic aciduria/Orotic aciduria  
Reasoning:  
1. **Oroticaciduria**: The presence of oroticaciduria is pathognomonic for hereditary orotic aciduria, caused by a deficiency in uridine monophosphate synthase (UMPS), disrupting pyrimidine synthesis.  
2. **Failure to thrive and systemic involvement**: Symptoms like feeding difficulties, lethargy, drowsiness, and generalized hypotonia align with metabolic decompensation and energy deficits due to impaired nucleotide production.  
3. **Hepatosplenomegaly**: Splenomegaly and hepatomegaly may result from megaloblastic anemia (common in this disorder) or extramedullary hematopoiesis secondary to bone marrow dysfunction.  
4. **Immunodeficiency and infections**: Recurrent pneumonia and fever suggest immune dysfunction, as pyrimidine deficiency impairs lymphocyte proliferation and function.  
5. **Urinary abnormalities**: Hyperglycinuria, cystinuria, and ornithinuria may indicate secondary renal tubular dysfunction, though oroticaciduria is the primary diagnostic marker.  
6. **Early mortality**: Death in infancy or childhood is consistent with severe, untreated cases due to metabolic instability, infections, or complications of anemia.  
7. **Skin manifestations**: Erythematous plaques, macules, and papules could reflect systemic inflammation or secondary skin infections linked to immune compromise.  
8. **Abnormal alanine levels**: Disrupted pyrimidine metabolism may indirectly affect amino acid homeostasis, explaining abnormal circulating alanine concentrations.  

This constellation of symptoms, anchored by oroticaciduria, strongly supports hereditary orotic aciduria. Uridine supplementation is a key therapeutic consideration to bypass the metabolic block."
"['Hydrocephalus', 'Seizure', 'Ataxia', 'Generalized hypotonia', 'Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** and **aminoaciduria** are hallmark features of 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency, caused by impaired leucine catabolism, leading to accumulation of 3-methylcrotonylglycine and 3-hydroxyisovaleric acid.  
2. **Seizures** and **ataxia** align with metabolic encephalopathy from toxic metabolite buildup.  
3. **Generalized hypotonia** and **neonatal death/death in infancy** reflect severe metabolic decompensation typical of untreated organic acidemias.  
4. **Abnormal circulating glycine concentration** may result from secondary mitochondrial dysfunction disrupting glycine metabolism.  
5. While **hydrocephalus** is atypical for 3-MCC deficiency, it could reflect a coincidental finding or severe cerebral edema secondary to metabolic crisis.  

Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning:  
- This is a subset of 3-MCC deficiency caused by mutations in the *MCCC1* gene (encoding the α-subunit of the enzyme). The reasoning above applies identically, as clinical features and biochemical markers (e.g., aminoaciduria, elevated carboxylic acids) are indistinguishable between *MCCC1* and *MCCC2* defects. The distinction is purely genetic.  

Note: The two listed diagnoses are clinically identical; the distinction lies in the affected gene (*MCCC1* vs. *MCCC2*). Both present with the described biochemical and neurological symptoms."
"['Multicystic kidney dysplasia', 'Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Abnormal pinna morphology', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Hypotelorism', 'Iris coloboma', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Hip dysplasia', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Postnatal growth retardation', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental and CNS anomalies**: Global developmental delay, hypotonia, seizures, spastic tetraparesis, ADHD, and cerebral hypomyelination/delayed myelination align with core neurodevelopmental deficits. Structural brain abnormalities (hypoplastic corpus callosum, ventriculomegaly, cerebellar/pons malformations) further support this.  
2. **Ocular anomalies**: Microphthalmia, iris coloboma, Peters anomaly, optic atrophy, and blepharophimosis are hallmark features of NEDBEH-associated eye involvement.  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return match the cardiac spectrum of the disorder.  
4. **Dysmorphic features**: Triangular face, micrognathia, high palate, hypertelorism, and epicanthus are consistent with reported craniofacial patterns. Conflicting micro/macrocephaly may reflect variable expressivity.  
5. **Multisystem involvement**: Urogenital (cryptorchidism, hypospadias, renal dysplasia), gastrointestinal (pyloric stenosis, annular pancreas), and skeletal (syndactyly, scoliosis) anomalies align with NEDBEH’s systemic nature.  
6. **Growth abnormalities**: Intrauterine and postnatal growth retardation, alongside tall stature (paradoxical but possible in genetic mosaicism or metabolic dysregulation).  
7. **Overlap with RAC1-related phenotype**: NEDBEH is linked to RAC1 mutations, which can manifest with brain-eye-heart anomalies, hypotonia, and variable dysmorphism, as seen here.  
8. **Exclusion of mimics**: While café-au-lait spots or hypertrichosis might suggest RASopathies, the triad of neurodevelopmental delay, structural brain/eye/heart defects, and absence of pathognomonic features of other syndromes (e.g., NF1, Noonan) favors NEDBEH.  

Key confirmatory features include the combination of neurodevelopmental delay, cerebellar/pontine malformations, Peters anomaly, and congenital heart defects, which collectively prioritize NEDBEH over isolated organ-system diagnoses."
"['Coma', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Hypothermia', 'Dyspnea', 'Opisthotonus', 'Cerebral edema', 'Tachypnea', 'Glycosuria', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Recurrent viral infections', 'Sepsis']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency), hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is the hallmark of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia detoxification.  
2. **Neurological symptoms** (coma, cerebral edema, opisthotonus) result from ammonia toxicity. Elevated ammonia disrupts astrocyte function, causing cerebral edema and brainstem compression (opisthotonus).  
3. **Metabolic acidosis** arises from secondary lactic acidosis due to mitochondrial dysfunction and anaerobic metabolism triggered by hyperammonemia.  
4. **Respiratory issues** (tachypnea, dyspnea) reflect compensatory hyperventilation to counteract acidosis.  
5. **Gastrointestinal symptoms** (vomiting, diarrhea) are nonspecific but common in UCDs due to metabolic stress.  
6. **Hypothermia** and **sepsis** may stem from metabolic instability impairing thermoregulation and immune function.  
7. **Prolonged partial thromboplastin time** suggests liver dysfunction, as CPS1 is hepatocyte-specific; impaired clotting factor synthesis exacerbates bleeding risk.  
8. **Glycosuria** may occur secondary to proximal renal tubular injury from metabolic acidosis.  
9. **Early lethality** (neonatal death, death in infancy) aligns with severe UCDs presenting acutely postpartum when protein intake begins.  
10. **Recurrent infections** could reflect catabolic crises during illness, worsening hyperammonemia, rather than primary immunodeficiency.  

CPS1 deficiency is distinguished from other UCDs by the absence of orotic aciduria (not tested here) and its autosomal recessive inheritance. The symptom constellation, particularly hyperammonemia with metabolic acidosis and rapid neonatal decline, strongly supports this diagnosis."
"['Epicanthus', 'Triangular face', 'Short chin', 'Long philtrum', 'Posteriorly rotated ears', 'Low-set ears', 'Broad nasal tip', 'Torticollis', 'Downslanted palpebral fissures', 'Telecanthus', 'Osteoporosis', 'Flexion contracture', 'Macrodontia', 'Language impairment', 'Kyphosis', 'Depressed nasal bridge', 'Deep palmar crease', 'Severe global developmental delay', 'Cognitive impairment', 'Small hand']",['Al Kaissi syndrome'],"Disease: Al Kaissi syndrome  
**Step 1: Craniofacial Dysmorphism**  
- **Epicanthus**, **telecanthus**, and **downslanted palpebral fissures** indicate characteristic ocular abnormalities.  
- **Triangular face**, **short chin**, **long philtrum**, **broad nasal tip**, and **depressed nasal bridge** align with the facial gestalt of Al Kaissi syndrome.  
- **Posteriorly rotated ears** and **low-set ears** further support craniofacial dysmorphism.  

**Step 2: Skeletal and Musculoskeletal Abnormalities**  
- **Osteoporosis**, **kyphosis**, and **flexion contractures** reflect skeletal dysplasia, a hallmark of the syndrome.  
- **Torticollis** (neck muscle contracture) and **small hands** with **deep palmar creases** suggest connective tissue and skeletal involvement.  

**Step 3: Dental and Developmental Features**  
- **Macrodontia** (abnormally large teeth) is a rare but reported feature.  
- **Severe global developmental delay**, **cognitive impairment**, and **language impairment** indicate neurodevelopmental deficits consistent with the syndrome’s profile.  

**Step 4: Exclusion of Overlapping Syndromes**  
- Differentiated from Down, Williams, or Noonan syndromes by the unique combination of **macrodontia**, **flexion contractures**, and **skeletal dysplasia** without cardiac or metabolic hallmarks of other disorders.  

**Conclusion**: The constellation of craniofacial, skeletal, dental, and neurodevelopmental abnormalities strongly aligns with Al Kaissi syndrome, a rare genetic disorder linked to dysregulated skeletal development and connective tissue defects."
"['Renal insufficiency', 'Glomerulonephritis', 'Sinusitis', 'Abnormality of the nose', 'Conjunctivitis', 'Fever', 'Hemoptysis', 'Exercise intolerance', 'Cough', 'Shoulder pain', 'Elbow pain', 'Knee pain', 'Pulmonary hemorrhage', 'Oliguria']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Upper respiratory involvement**: Sinusitis and nasal abnormalities (e.g., ulcers, crusting) are classic early signs of GPA.  
2. **Pulmonary manifestations**: Cough, hemoptysis, and pulmonary hemorrhage indicate alveolar capillaritis and vasculitis in the lungs.  
3. **Renal disease**: Glomerulonephritis (often rapidly progressive) with renal insufficiency and oliguria reflects pauci-immune necrotizing glomerulonephritis, a hallmark of GPA.  
4. **Systemic inflammation**: Fever and arthralgias (shoulder, elbow, knee pain) suggest systemic vasculitis.  
5. **Ocular involvement**: Conjunctivitis aligns with GPA-associated ocular inflammation.  
6. **ANCA association**: GPA is strongly linked to c-ANCA/PR3-ANCA, which drives small-vessel vasculitis and granuloma formation.  
7. **Multisystem pattern**: The combination of respiratory, renal, musculoskeletal, and constitutional symptoms is pathognomonic for GPA, distinguishing it from mimics like microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis."
"['Intellectual disability', 'Seizure', 'Global developmental delay', 'Generalized hypotonia', 'Failure to thrive', 'Metabolic acidosis', 'Hypoglycemia', 'Ketosis', 'Hyperammonemia', 'Vomiting', 'Respiratory distress', 'Increased serum lactate', 'Rhabdomyolysis', 'Lacticaciduria', 'Arrhythmia', 'Dicarboxylic acidemia', 'Elevated circulating acylcarnitine concentration']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, ketosis, hyperammonemia, elevated lactate, and dicarboxylic acidemia** indicate a severe mitochondrial or fatty acid oxidation disorder. These findings suggest impaired energy metabolism, leading to toxic metabolite accumulation.  
2. **Rhabdomyolysis, arrhythmia, and lacticaciduria** point to muscle and cardiac involvement, aligning with the syndrome's hallmark features of recurrent rhabdomyolysis and cardiac complications.  
3. **Elevated acylcarnitine levels** reflect disrupted fatty acid β-oxidation, a key feature of this disorder.  
4. **Intellectual disability, seizures, and global developmental delay** correlate with neurodegeneration and encephalopathic crises caused by metabolic decompensation.  
5. **Vomiting, respiratory distress, and failure to thrive** are secondary to acute metabolic crises and chronic energy deficiency.  
6. The combination of **neurodegeneration, metabolic crises, and multi-organ involvement** (muscle, heart, CNS) uniquely matches this rare syndrome."
"['Hyperammonemia', 'Vomiting', 'Hyperglutaminemia', 'Oroticaciduria', 'Death in childhood']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Indicates impaired urea cycle function, as OTC is a key enzyme in converting ammonia to urea.  
2. **Vomiting**: A nonspecific but common symptom of acute hyperammonemic crises in urea cycle disorders.  
3. **Hyperglutaminemia**: Excess ammonia is converted to glutamine via glutamine synthetase, a compensatory mechanism in urea cycle defects.  
4. **Oroticaciduria**: Caused by carbamoyl phosphate accumulation (due to OTC deficiency), which shunts into pyrimidine synthesis, overproducing orotic acid.  
5. **Death in childhood**: Severe OTCD (often in males with neonatal-onset forms) leads to fatal hyperammonemia without prompt treatment.  
The combination of urea cycle dysfunction (hyperammonemia, hyperglutaminemia) with oroticaciduria is pathognomonic for OTCD, distinguishing it from other urea cycle defects or isolated pyrimidine disorders."
"['Thrombocytopenia', 'Abnormal bleeding', 'Increased megakaryocyte count', 'Myelofibrosis', 'Abnormal number of alpha granules']","['Bleeding disorder, platelet-type, 17']","Disease: Bleeding disorder, platelet-type, 17  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with platelet production or maturation defects, consistent with GFI1B mutation impairing megakaryocyte differentiation.  
2. **Abnormal bleeding**: Caused by dysfunctional platelets due to alpha granule abnormalities, a hallmark of GFI1B-related disorders.  
3. **Increased megakaryocyte count**: GFI1B mutations disrupt megakaryocyte maturation, leading to compensatory hyperplasia despite ineffective platelet production.  
4. **Myelofibrosis**: Reactive fibrosis secondary to cytokine release from abnormal megakaryocytes, a reported feature in GFI1B-associated myelodysplasia.  
5. **Abnormal alpha granules**: GFI1B regulates megakaryocyte development; mutations cause alpha granule deficiency (gray platelet syndrome-like phenotype), confirming platelet-type bleeding disorder 17."
"['Cleft palate', 'Pierre-Robin sequence', 'Specific learning disability', 'Feeding difficulties', 'Hypoxemia', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular Syndrome:  
1. **Cleft palate & Pierre-Robin sequence**: Cerebrocostomandibular syndrome (CCMS) is characterized by micrognathia (small jaw), glossoptosis, and cleft palate, which collectively define Pierre-Robin sequence. These structural anomalies explain airway obstruction and feeding difficulties.  
2. **Posterior rib gaps**: A hallmark feature of CCMS is rib dysplasia, including posterior rib gaps or ""missing"" rib segments. This disrupts thoracic cage integrity, contributing to respiratory insufficiency (hypoxemia).  
3. **Feeding difficulties & hypoxemia**: Micrognathia and cleft palate impair sucking/swallowing, while rib defects reduce lung capacity, exacerbating hypoxemia.  
4. **Specific learning disability**: Chronic hypoxia from respiratory compromise or potential central nervous system involvement (rarely reported in CCMS) may underlie neurodevelopmental delays.  
5. **Exclusion of mimics**: The combination of rib gaps, Pierre-Robin sequence, and neurodevelopmental issues distinguishes CCMS from isolated Pierre-Robin or syndromes like Stickler or Treacher Collins."
"['Apathy', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Hepatic failure', 'Growth delay', 'Death in infancy', 'Congestive heart failure', 'Pancreatitis', 'Exocrine pancreatic insufficiency', 'Thrombocytopenia', 'Leukopenia', 'Anemia', 'Acute kidney injury', 'Dehydration', 'Hyperammonemia', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Cerebral edema', 'Sparse scalp hair', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating cysteine concentration', 'Abnormal circulating carnitine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Chronic kidney disease', 'Increased circulating lactate dehydrogenase concentration', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like hyperammonemia, increased serum lactate, and acute kidney injury suggest a metabolic disorder disrupting amino acid catabolism.  
2. **Amino Acid Abnormalities**: Elevated isoleucine, valine, and abnormal aspartate/glutamine align with PA’s defect in propionyl-CoA carboxylase, impairing breakdown of these amino acids.  
3. **Secondary Glycine Dysregulation**: Hyperglycinemia/hyperglycinuria occur due to propionate inhibition of glycine cleavage enzyme.  
4. **Hematologic Involvement**: Thrombocytopenia, leukopenia, and anemia stem from bone marrow suppression by toxic metabolites (e.g., propionyl-CoA).  
5. **Pancreatic/Kidney Dysfunction**: Exocrine pancreatic insufficiency and chronic kidney disease result from chronic acidosis and metabolic stress.  
6. **Neurological Features**: Seizures, cerebral edema, and developmental delays reflect neurotoxicity from hyperammonemia and organic acid accumulation.  
7. **Hepatic/Cardiac Manifestations**: Hepatomegaly, hepatic failure, and congestive heart failure arise from mitochondrial energy deficiency and toxic metabolite deposition.  
8. **Urinary Biomarkers**: Hyperglycinuria and elevated urinary carboxylic acids (e.g., methylcitrate, 3-hydroxypropionate) are pathognomonic for PA.  
9. **Early Mortality**: Death in infancy/childhood is consistent with severe PA phenotypes, often triggered by infections or metabolic decompensation.  
10. **Carnitine Dysregulation**: Abnormal carnitine levels occur due to sequestration by propionyl-CoA, exacerbating metabolic dysfunction.  

The constellation of metabolic derangements, multi-organ involvement, and characteristic biochemical markers confirm propionic acidemia."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This directly aligns with the symptom of hyperphenylalaninemia.  
2. **Hypertyrosinemia**: While PKU typically reduces tyrosine levels (due to impaired conversion of phenylalanine to tyrosine), transient hypertyrosinemia can occur in neonates due to immature enzyme systems. This may resolve but could compound metabolic stress in untreated PKU.  
3. **Prenatal abnormalities**: Maternal PKU (untreated high phenylalanine during pregnancy) can cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus, explaining ""abnormality of prenatal development.""  
4. **Early mortality**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, leading to neonatal/infant/childhood death. Without dietary intervention, toxic phenylalanine levels are fatal.  
5. **Consistency with symptoms**: The combination of hyperphenylalaninemia, developmental issues, and early mortality strongly supports PKU as the primary diagnosis, with hypertyrosinemia as a secondary or transient finding."
"['Hyperhidrosis', 'Death in infancy', 'Cardiomyopathy', 'Cardiomegaly', 'Hypotension', 'Tachypnea', 'Aminoaciduria', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning:  
1. **Aminoaciduria and elevated urinary carboxylic acids** align with impaired leucine catabolism due to 3-MCC deficiency, leading to accumulation of 3-methylcrotonyl-CoA and derivatives like 3-hydroxyisovaleric acid.  
2. **Cardiomyopathy/Cardiomegaly** may result from energy deficiency in cardiac tissue due to disrupted mitochondrial fatty acid oxidation and ketogenesis.  
3. **Hypotension/Tachypnea** suggests metabolic acidosis, a hallmark of organic acidemias, triggering respiratory compensation.  
4. **Feeding difficulties/Hyperhidrosis** are nonspecific but common in metabolic crises from toxic metabolite buildup.  
5. **Death in infancy/childhood** reflects severe metabolic decompensation episodes typical in untreated 3-MCC deficiency.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency (general)  
Reasoning:  
1. **Abnormal circulating glycine concentration** (secondary to glycine conjugation with accumulated metabolites) and **aminoaciduria** are biochemical hallmarks of this disorder.  
2. **Elevated urinary carboxylic acids** (e.g., 3-methylcrotonylglycine) directly indicate a block in 3-MCC enzyme activity.  
3. **Cardiac manifestations** (cardiomyopathy, cardiomegaly) stem from disrupted energy production and possible secondary carnitine depletion.  
4. **Early mortality** correlates with acute metabolic crises triggered by catabolic stressors (e.g., infections, fasting), common in this autosomal recessive disorder.  
5. Overlap with subtype 1 deficiency is expected, as MCCC1 gene mutations account for the majority of 3-MCC deficiency cases."
"['Nystagmus', 'Ataxia', 'Dysarthria', 'Anemia', 'Gait ataxia', 'Bone marrow hypocellularity']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Ataxia-pancytopenia syndrome: The patient exhibits **nystagmus**, **ataxia**, **dysarthria**, and **gait ataxia**, indicating cerebellar dysfunction. Concurrent **anemia** and **bone marrow hypocellularity** suggest pancytopenia due to impaired hematopoiesis. Ataxia-pancytopenia syndrome (APS) is a rare genetic disorder characterized by cerebellar degeneration and bone marrow failure, aligning with this symptom constellation. The triad of neurological deficits, cytopenias, and hypocellular marrow distinguishes APS from isolated cerebellar ataxias or acquired hematologic disorders."
"['Gingival fibromatosis', 'Hypomelanotic macule', 'Dental enamel pits', 'Rhabdomyoma']",['Tuberous sclerosis-2'],"Disease: Tuberous sclerosis-2  
Reasoning:  
1. **Hypomelanotic macule**: A major diagnostic criterion for tuberous sclerosis complex (TSC), commonly appearing as ash-leaf spots.  
2. **Rhabdomyoma**: A cardiac manifestation strongly associated with TSC, particularly in infancy, and classified as a major diagnostic criterion.  
3. **Dental enamel pits**: A minor diagnostic criterion for TSC, reflecting ectodermal involvement.  
4. **Gingival fibromatosis**: Rarely reported in TSC but consistent with connective tissue hyperplasia, which may occur due to TSC2 gene mutations affecting mTOR pathway regulation.  
5. **Genetic correlation**: TSC2 mutations (compared to TSC1) are linked to more severe phenotypes, encompassing multi-organ manifestations like those listed.  
6. **Diagnostic confirmation**: Presence of ≥2 major criteria (hypomelanotic macule, rhabdomyoma) + 1 minor criterion (enamel pits) fulfills clinical diagnostic criteria for TSC."
"['Microcephaly', 'Sensorineural hearing impairment', 'Deeply set eye', 'Carious teeth', 'Cutaneous photosensitivity', 'Generalized hypotonia', 'Short stature']",['Cockayne syndrome A'],"Disease: Cockayne syndrome A  
Reasoning:  
1. **Cutaneous photosensitivity** - A hallmark feature of Cockayne syndrome, linked to DNA repair defects.  
2. **Microcephaly** and **short stature** - Reflect progressive growth failure and neurodegeneration characteristic of the syndrome.  
3. **Sensorineural hearing impairment** - Caused by neurodegeneration and cochlear dysfunction.  
4. **Deeply set eyes** - Common facial dysmorphism due to facial adipose tissue loss.  
5. **Carious teeth** - Results from enamel hypoplasia and reduced salivary flow.  
6. **Generalized hypotonia** - Indicates central/peripheral nervous system involvement.  
7. **Exclusion of mimics** - Differentiated from xeroderma pigmentosum (no skin cancer predisposition) and trichothiodystrophy (no brittle hair/ichthyosis).  
8. **Consistency with Type A (Classic form)** - Matches early childhood onset and typical multisystem progression."
"['Epicanthus inversus', 'Blue irides', 'White eyebrow', 'White eyelashes', 'Delayed fine motor development', 'Bilateral wrist flexion contracture', 'Short palpebral fissure', 'Flexion contracture of finger']","['Waardenburg syndrome type 3/Waardenburg syndrome, type 3']","Disease: Waardenburg syndrome type 3  
Reasoning:  
1. **Pigmentation anomalies**: Epicanthus inversus, blue irides, white eyebrow, and white eyelashes align with Waardenburg syndrome (WS) criteria, which include congenital pigmentary disturbances.  
2. **Musculoskeletal abnormalities**: Bilateral wrist flexion contracture and flexion contracture of the finger are hallmarks of WS type 3 (Klein-Waardenburg syndrome), distinguishing it from other subtypes.  
3. **Developmental delay**: Delayed fine motor development supports systemic involvement of neuromuscular structures, consistent with type 3.  
4. **Ocular features**: Short palpebral fissures are common in WS but help rule out other syndromes.  
5. **Exclusion of other subtypes**: Absence of Hirschsprung disease (type 4) and limb defects beyond contractures (not seen in types 1/2) confirm type 3."
"['Hearing impairment', 'Neonatal hypotonia', 'Decreased liver function', 'Failure to thrive in infancy', 'Left ventricular hypertrophy', 'Acidosis', 'Poor suck', 'Respiratory distress', 'Polymicrogyria', 'Increased serum lactate', 'Increased CSF lactate', 'Elevated hepatic transaminase', 'Lactic acidosis', 'Feeding difficulties in infancy', 'Nasogastric tube feeding']","['Combined oxidative phosphorylation deficiency 30', 'Combined oxidative phosphorylation defect type 30']","Disease: Combined oxidative phosphorylation deficiency 30 (COXPD30)  
Reasoning:  
1. **Lactic acidosis** (elevated serum and CSF lactate) indicates impaired mitochondrial energy metabolism, a hallmark of oxidative phosphorylation defects.  
2. **Neurological involvement**: Polymicrogyria (abnormal brain development), neonatal hypotonia, and hearing impairment align with mitochondrial encephalopathies caused by defective mitochondrial translation (e.g., MTFMT gene mutations in COXPD30).  
3. **Multi-organ dysfunction**:  
   - **Hepatic**: Elevated transaminases and decreased liver function suggest mitochondrial hepatopathy.  
   - **Cardiac**: Left ventricular hypertrophy reflects energy-deficient cardiac tissue stress.  
   - **Failure to thrive** and feeding difficulties (poor suck, nasogastric dependence) stem from systemic metabolic insufficiency.  
4. **Respiratory distress** may arise from combined metabolic acidosis and neuromuscular weakness.  
5. **MTFMT mutations** disrupt mitochondrial protein synthesis, causing combined respiratory chain deficiencies, consistent with the patient’s multi-systemic presentation.  

Disease: Combined oxidative phosphorylation defect type 30  
Reasoning:  
- This is a synonym for COXPD30, reaffirmed by the same genetic basis (MTFMT) and phenotypic overlap:  
  - **Biochemical markers**: Persistent lactic acidosis and elevated hepatic transaminases.  
  - **Clinical triad**: Encephalopathy (polymicrogyria, hypotonia), cardiomyopathy, and hepatopathy.  
  - **Infantile onset**: Symptoms like respiratory distress, feeding difficulties, and failure to thrive manifest early, typical of severe mitochondrial disorders.  
- The dual elevation of lactate in serum and CSF excludes isolated organ defects, supporting a systemic oxidative phosphorylation defect."
"['Cleft palate', 'Pierre-Robin sequence', 'Conductive hearing impairment', '11 pairs of ribs', 'Thin ribs', 'Scoliosis', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome:  
1. **Pierre-Robin sequence and cleft palate**: Core features of CCMS, involving micrognathia (small jaw), glossoptosis (tongue displacement), and cleft palate.  
2. **Rib anomalies**: Pathognomonic findings include reduced rib count (11 pairs), thin ribs, posterior rib gaps, and scoliosis secondary to thoracic skeletal defects.  
3. **Conductive hearing impairment**: Linked to recurrent middle ear dysfunction, often associated with craniofacial malformations.  
4. **Exclusion of mimics**: Rib gaps and specific rib count abnormalities distinguish CCMS from other syndromes (e.g., Stickler or Treacher Collins).  
The constellation of craniofacial, auditory, and severe rib defects confirms the diagnosis."
"['Psychosis', 'Eczematoid dermatitis', 'Skin rash', 'Intellectual disability', 'Death in infancy', 'Abdominal pain', 'Vertigo', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Occipital neuralgia', 'Elevated urinary carboxylic acid', 'Death in early adulthood', 'Pustule']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
**Reasoning**:  
1. **Hyperphenylalaninemia**: Core diagnostic marker for PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Classic feature of untreated PKU from neurotoxic phenylalanine accumulation.  
3. **Skin manifestations (eczema, rash, pustules)**: Caused by metabolic disruption affecting skin integrity; eczema is a well-documented symptom.  
4. **Elevated urinary carboxylic acids**: Reflects excretion of phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate).  
5. **Psychosis**: Late-onset neurological complications in poorly managed cases.  
6. **Early mortality (infancy/adulthood)**: Untreated PKU leads to severe neurological damage, infections, or organ failure.  

**Conflicts/Notes**:  
- **Hypertyrosinemia**: Contradicts PKU (expected low tyrosine). Possible lab error, concurrent condition (e.g., tyrosinemia), or variant PKU with secondary tyrosine dysregulation.  
- **Occipital neuralgia/vertigo/abdominal pain**: Atypical for PKU; may indicate comorbidities or nonspecific systemic effects of metabolic stress.  
- **Death timing**: Aligns with untreated cases; modern neonatal screening and dietary management typically prevent fatal outcomes.  

**Conclusion**: Despite conflicting hypertyrosinemia, hallmark features (hyperphenylalaninemia, intellectual disability, urinary metabolites, and skin findings) overwhelmingly support PKU."
"['Platyspondyly', 'Waddling gait', 'Flared metaphysis', 'Wide pubic symphysis', 'Beaking of vertebral bodies', 'Hypoplasia of the femoral head', 'Short finger', 'Limb undergrowth', 'Small hand']",['Pseudoachondroplasia/Pseudoachondroplasia'],"Disease: Pseudoachondroplasia  
Reasoning:  
1. **Platyspondyly and Beaking of Vertebral Bodies**: Hallmark features of pseudoachondroplasia, caused by defective growth plate cartilage leading to flattened vertebrae with anterior tonguing (""beaking"").  
2. **Waddling Gait**: Results from hip dysplasia (e.g., hypoplastic femoral heads) and joint instability, common in pseudoachondroplasia.  
3. **Flared Metaphysis**: Characteristic metaphyseal widening due to disorganized endochondral ossification.  
4. **Wide Pubic Symphysis**: Reflects pelvic dysplasia, a frequent radiographic finding in skeletal dysplasias like pseudoachondroplasia.  
5. **Hypoplasia of the Femoral Head**: Directly linked to epiphyseal involvement in pseudoachondroplasia, contributing to hip deformity and gait abnormalities.  
6. **Short Fingers, Small Hands, and Limb Undergrowth**: Consistent with disproportionate short stature and brachydactyly caused by defective COMP protein, which disrupts cartilage matrix organization.  
7. **Exclusion of Alternatives**: Features overlap with achondroplasia but lack craniofacial involvement, and Morquio syndrome is excluded by absence of metabolic/lysosomal storage signs. Genetic testing for **COMP mutations** would confirm the diagnosis."
"['Strabismus', 'Recurrent corneal erosions', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Hepatic fibrosis', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'Increased serum lactate', 'Gliosis', 'EEG abnormality', 'Scoliosis', 'Elevated hepatic transaminase', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Abnormal auditory evoked potentials', 'Chalazion', 'Delayed myelination', 'Dilation of Virchow-Robin spaces', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A defining feature of the syndrome, directly linked to impaired glycosylation affecting lacrimal gland function.  
2. **Hepatic fibrosis/elevated transaminases/prolonged jaundice**: Reflects liver dysfunction, a core component of the disorder due to defective protein deglycosylation in hepatocytes.  
3. **Seizures/EEG abnormality/hypotonia/global developmental delay/delayed myelination/gliosis**: Indicates severe neurological involvement, consistent with NGLY1 deficiency disrupting neuronal glycoprotein homeostasis.  
4. **Elevated alpha-fetoprotein**: Associated with hepatic injury and impaired glycosylation, common in congenital disorders of deglycosylation.  
5. **Intrauterine growth retardation/short foot/small hand**: Suggests congenital growth restriction, often seen in systemic metabolic disorders.  
6. **Recurrent corneal erosions/chalazion**: Secondary to alacrima-induced dry eye and ocular surface damage.  
7. **Increased serum lactate**: May indicate mitochondrial dysfunction, a known overlap in glycosylation disorders.  
8. **Abnormal auditory evoked potentials/dilation of Virchow-Robin spaces**: Reflects central nervous system abnormalities, including white matter changes.  
9. **Reduced tendon reflexes/constipation**: Autonomic or peripheral nerve involvement due to glycosylation defects.  
10. **Scoliosis**: Often secondary to neuromuscular hypotonia.  
The constellation of alacrima, liver disease, neurodevelopmental deficits, and multi-system involvement aligns pathognomonically with NGLY1-related congenital disorder of deglycosylation."
"['Abdominal pain', 'Elevated urinary delta-aminolevulinic acid', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning: Abdominal pain is a hallmark of acute neurovisceral attacks in acute intermittent porphyria (AIP). Elevated urinary delta-aminolevulinic acid (ALA) aligns with AIP’s pathophysiology, where a deficiency in porphobilinogen deaminase (PBGD) causes accumulation of ALA and porphobilinogen (PBG). While AIP typically manifests post-puberty, severe childhood-onset cases can lead to fatal complications like respiratory paralysis or electrolyte imbalances, explaining early mortality.  

Disease: Porphyria/Porphyria  
Reasoning: Elevated urinary ALA is nonspecific and occurs in multiple porphyrias. If PBG levels were not measured, broader porphyria classification is appropriate. Death in childhood could suggest rare, severe forms like ALAD-deficiency porphyria (ADP), which also elevates ALA but lacks PBG elevation. However, ADP is not explicitly listed, so ""porphyria"" serves as a general diagnosis when subtype confirmation is incomplete."
"['Abnormality of the kidney', 'Hearing impairment', 'Choanal atresia', 'Abnormality of the eye', 'Delayed speech and language development', 'Precocious puberty', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Abnormal heart morphology', 'Scoliosis', 'Cerebellar dysplasia', 'Intellectual disability, severe', 'Feeding difficulties', 'Frequent temper tantrums']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Core neurodevelopmental features**: Severe intellectual disability, global developmental delay, absent speech, and delayed speech align with the hallmark neurodevelopmental deficits of NEDBEH.  
2. **Hypotonia**: Generalized hypotonia is a common finding in NEDBEH, often linked to HECW2 gene variants.  
3. **Brain anomalies**: Cerebellar dysplasia directly corresponds to structural brain abnormalities associated with the disorder.  
4. **Eye and heart involvement**: Abnormality of the eye and abnormal heart morphology match the ""anomalies of the brain, eye, or heart"" specified in NEDBEH.  
5. **Atypical features**: Choanal atresia and hearing impairment are not classic features but may reflect phenotypic variability. Precocious puberty could arise from hypothalamic dysfunction secondary to brain malformations.  
6. **Supportive findings**: Feeding difficulties, scoliosis, and temper tantrums are consistent with severe developmental delay and hypotonia.  
7. **Exclusion of mimics**: While CHARGE syndrome could explain choanal atresia and heart defects, the absence of coloboma, cranial nerve anomalies, and the presence of severe intellectual disability favor NEDBEH.  

The diagnosis integrates characteristic features (neurodevelopmental delay, brain/eye/heart anomalies) and accommodates less common manifestations (choanal atresia, hearing loss) within the disorder’s phenotypic spectrum."
"['Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Abnormality of the outer ear', 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Single transverse palmar crease', 'Cafe-au-lait spot', 'Hypertrichosis', 'Brachydactyly', 'Syndactyly', 'Seizure', 'Hypotonia', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Hypoglycemia', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Intellectual disability, moderate', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Temperature instability', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Broad thumb', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Symptoms like *moderate intellectual disability*, *hyperactivity*, *attention deficit hyperactivity disorder (ADHD)*, and *atypical behavior* align with the neurodevelopmental core of NEDBEH.  
2. **Brain anomalies**: Structural CNS abnormalities such as *cerebellar vermis hypoplasia*, *CNS hypomyelination*, *hypoplasia of the corpus callosum*, and *ventriculomegaly* directly match the ""brain anomalies"" criterion.  
3. **Eye anomalies**: Multiple ocular findings (*coloboma*, *microphthalmia*, *blepharophimosis*, *optic atrophy*, *Peters anomaly*, *abnormality of iris morphology*) satisfy the ""eye"" component.  
4. **Cardiac defects**: *Ventricular septal defect*, *patent ductus arteriosus*, *patent foramen ovale*, and *anomalous pulmonary venous return* fulfill the ""heart"" criterion.  
5. **Supportive systemic features**:  
   - Growth issues (*intrauterine growth retardation*, *short stature*, *growth delay*) and craniofacial dysmorphism (*triangular face*, *micrognathia*, *high palate*, *cleft lip*) are common in NEDBEH.  
   - Additional congenital anomalies (*choanal atresia*, *duodenal atresia*, *annular pancreas*) and neurological signs (*hypotonia*, *seizures*, *spastic tetraparesis*) reinforce multisystem involvement.  
6. **Exclusion of mimics**: Overlapping features with syndromes like CHARGE or chromosomal disorders are ruled out by the absence of pathognomonic signs (e.g., absent CHARGE coloboma-choanal atresia triad) and the broad spectrum of NEDBEH-specific gene associations (e.g., *BRPF1*, *KAT6B*).  

The combination of neurodevelopmental delay, brain malformations, ocular defects, and congenital heart anomalies provides a definitive match for NEDBEH."
"['Large fontanelles', 'Parietal bossing', 'Delayed eruption of primary teeth', 'Narrow chest', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Syringomyelia', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Disease: Cleidocranial dysplasia  
**Reasoning**:  
1. **Cranial/skull features**:  
   - **Large fontanelles**, **parietal bossing**, **frontal bossing**, **metopic depression**, and **Wormian bones** align with CCD’s hallmark skull defects, including delayed fontanelle closure and abnormal ossification.  
   - **Midface retrusion** and **depressed nasal bridge** reflect hypoplastic facial bones, common in CCD.  

2. **Dental abnormalities**:  
   - **Delayed eruption of primary teeth** and **enamel hypoplasia** are classic CCD features due to disrupted tooth development and eruption pathways.  

3. **Clavicular/thoracic defects**:  
   - **Short clavicles** (often hypoplastic or absent) explain **abnormal facility in opposing the shoulders**.  
   - **Narrow chest** may arise from clavicular and rib anomalies.  

4. **Pelvic and limb findings**:  
   - **Hypoplastic iliac wings**, **broad femoral heads**, and **short femoral necks** correlate with CCD’s pelvic dysplasia and abnormal long bone growth.  
   - **Short stature** results from skeletal underdevelopment.  

5. **Spinal/skeletal anomalies**:  
   - **Scoliosis** and **delayed pubic bone ossification** reflect generalized skeletal dysplasia.  
   - **Syringomyelia** is atypical but may occur secondary to spinal abnormalities.  

**Conclusion**: The constellation of craniofacial, dental, clavicular, pelvic, and skeletal features is pathognomonic for **cleidocranial dysplasia**, a *RUNX2*-related disorder. Syringomyelia warrants further evaluation but does not exclude CCD."
"['Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Alopecia', 'Increased serum lactate', 'Increased CSF lactate']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Eczematoid dermatitis/Skin rash**: Biotinidase deficiency impairs biotin recycling, leading to biotin-dependent carboxylase dysfunction. This disrupts fatty acid synthesis and skin barrier integrity, causing dermatitis and rashes.  
2. **Alopecia**: Biotin is critical for keratinocyte function and hair follicle health. Deficiency results in hair loss due to impaired protein synthesis and cellular repair.  
3. **Increased serum/CSF lactate**: Dysfunctional carboxylases (e.g., pyruvate carboxylase) disrupt gluconeogenesis and the tricarboxylic acid cycle, causing lactic acidosis from pyruvate accumulation. Elevated lactate in both serum and CSF reflects systemic metabolic dysfunction.  
4. **Death in infancy**: Untreated biotinidase deficiency leads to progressive metabolic crises (acidosis, hyperammonemia), seizures, and neurologic deterioration, often fatal in early childhood without biotin supplementation.  
5. **Consistency with late-onset multiple carboxylase deficiency**: The term ""late-onset"" refers to partial enzyme activity delaying symptom onset, but severe cases (as implied by infant mortality) align with complete biotinidase deficiency.  

This constellation of dermatologic, metabolic, and neurologic features is pathognomonic for biotinidase deficiency."
"['Intellectual disability', 'Seizure', 'Ataxia', 'Death in infancy', 'Fever', 'Death in adolescence', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The presence of **L-2-hydroxyglutaric aciduria** (elevated L-2-hydroxyglutaric acid in urine) is pathognomonic for this disorder, confirming the diagnosis.  
2. **Neurological Symptoms**: **Intellectual disability**, **seizures**, and **ataxia** align with the neurotoxic effects of accumulated metabolites damaging the central nervous system.  
3. **Disease Progression**: **Death in infancy/adolescence** reflects the severe, progressive nature of the disease, often due to metabolic crises, neurodegeneration, or complications like status epilepticus.  
4. **Fever**: Likely secondary to intercurrent infections, which can trigger metabolic decompensation and exacerbate neurological symptoms.  
5. **Exclusion of Alternatives**: The specific biochemical signature rules out other organic acidurias (e.g., D-2-hydroxyglutaric aciduria) or leukodystrophies with overlapping symptoms.  

This diagnosis integrates biochemical evidence with clinical progression, consistent with autosomal recessive L-2-hydroxyglutaric aciduria."
"['Cataract', 'Parkinsonism', 'Pes cavus', 'Hammertoe', 'Postural tremor', 'Difficulty walking', 'Distal muscle weakness', 'Ragged-red muscle fibers', 'Cytochrome C oxidase-negative muscle fibers', 'Distal amyotrophy', 'Bilateral sensorineural hearing impairment', 'Laryngeal dystonia', 'Dyskinesia']","['Parkinson disease 7, autosomal recessive early-onset']","Disease: Parkinson disease 7, autosomal recessive early-onset (PARK7)  
Reasoning:  
1. **Parkinsonism and Dyskinesia**: Core features of PARK7 include early-onset parkinsonism (often before age 40) and movement abnormalities like dyskinesia.  
2. **Postural Tremor and Laryngeal Dystonia**: Tremor and dystonia (including laryngeal involvement) are recognized in PARK7 due to DJ-1 gene dysfunction affecting basal ganglia pathways.  
3. **Distal Muscle Weakness/Amyotrophy and Pes Cavus/Hammertoe**: DJ-1 mutations may cause mitochondrial instability, leading to neurogenic atrophy and peripheral neuropathy, manifesting as distal weakness, foot deformities, and amyotrophy.  
4. **Ragged-Red Fibers and COX-Negative Fibers**: While classically mitochondrial, PARK7-associated oxidative stress and mitochondrial dysfunction can secondarily induce these muscle abnormalities.  
5. **Bilateral Sensorineural Hearing Loss and Cataracts**: Systemic oxidative damage in PARK7 may explain early-onset cataracts and cochlear degeneration.  
6. **Autosomal Recessive Inheritance**: Matches PARK7’s genetic pattern, distinguishing it from mitochondrial disorders (often maternally inherited) or other Parkinsonian syndromes (e.g., PARK2, PARK6).  

This constellation of neurological, neuromuscular, and systemic symptoms aligns with PARK7’s multifactorial pathology, driven by DJ-1’s role in oxidative stress response and mitochondrial regulation."
"['Hepatosplenomegaly', 'Anemia', 'Fever', 'Pulmonary infiltrates', 'Lymphadenopathy', 'Recurrent upper respiratory tract infections', 'Elevated proportion of CD4-negative, CD8-negative, alpha-beta regulatory T cells', 'Increased circulating IgG level', 'Increased circulating IgA level', 'Abdominal distention', 'Increased circulating IgM level', 'Neutrophilia', 'Monocytosis', 'Lymphocytosis']",['Autoimmune lymphoproliferative syndrome/Autoimmune lymphoproliferative syndrome'],"Disease: Autoimmune lymphoproliferative syndrome (ALPS)  
Reasoning:  
1. **Lymphoproliferation**: Hepatosplenomegaly, lymphadenopathy, and abdominal distention align with chronic lymphoid accumulation due to defective apoptosis.  
2. **Autoimmunity**: Anemia likely reflects autoimmune hemolytic anemia, a hallmark of ALPS. Elevated IgG, IgA, and IgM levels suggest polyclonal hypergammaglobulinemia from dysregulated B-cell activity.  
3. **Double-Negative T Cells**: Elevated CD4⁻CD8⁻ αβ T cells (≥1.5% of total lymphocytes) are pathognomonic for ALPS, caused by FAS/FASLG/CASP10 gene mutations impairing lymphocyte apoptosis.  
4. **Hematologic Abnormalities**: Neutrophilia, monocytosis, and lymphocytosis indicate reactive changes from chronic inflammation or compensatory mechanisms.  
5. **Infections**: Recurrent respiratory infections and pulmonary infiltrates may stem from immune dysfunction or secondary infections due to hypersplenism/autoimmunity.  
6. **Exclusion of Mimics**: Features distinguish ALPS from lymphoma (non-malignant proliferation) or other immune dysregulation syndromes (e.g., CVID, which lacks double-negative T cells).  
**Conclusion**: The triad of lymphoproliferation, autoimmunity, and elevated double-negative T cells confirms ALPS."
"['Pointed chin', 'Anodontia', 'Hypohidrosis', 'obsolete Hypotrichosis', 'Recurrent fever', 'Depressed nasal bridge', 'Enlarged naris', 'Prominent forehead', 'Thick vermilion border']","['X-linked hypohidrotic ectodermal dysplasia/Ectodermal dysplasia 1, hypohidrotic, X-linked']","Disease: X-linked hypohidrotic ectodermal dysplasia/Ectodermal dysplasia 1, hypohidrotic, X-linked  
Reasoning:  
1. **Hypohidrosis**: Central feature of the disease due to defective sweat glands, leading to impaired thermoregulation and **recurrent fever**.  
2. **Anodontia**: Characteristic dental anomaly (absence of teeth) caused by ectodermal dysplasia affecting tooth development.  
3. **Hypotrichosis**: Sparse hair (scalp/body) from abnormal hair follicle formation.  
4. **Facial dysmorphism**:  
   - **Depressed nasal bridge**, **enlarged naris**, **prominent forehead**, and **pointed chin** reflect craniofacial ectodermal defects.  
   - **Thick vermilion border** (full lips) is a common phenotypic trait.  
5. **X-linked inheritance pattern**: Males are typically more severely affected, consistent with the symptom profile.  
6. Symptom constellation aligns with classic triad of hypohidrosis, hypotrichosis, and hypodontia/anodontia, confirming the diagnosis."
"['Hyperactivity', 'Hypertrichosis', 'Intellectual disability', 'Spasticity', 'Coma', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Pneumonia', 'Oroticaciduria', 'Ornithinuria', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating glutamine concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties', 'Hyperornithinemia', 'Uraciluria', 'Hypoammonemia', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: The patient exhibits **elevated plasma citrulline**, a hallmark of citrullinemia, caused by defects in the urea cycle. Key symptoms like **hyperammonemia** (ammonia accumulation), **oroticaciduria**, and **uraciluria** indicate a urea cycle disruption, as excess carbamoyl phosphate is diverted to pyrimidine synthesis. **Intellectual disability**, **spasticity**, and **coma** align with neurotoxicity from hyperammonemia. **Feeding difficulties** and **neonatal death** are consistent with severe neonatal-onset forms. Abnormal amino acid concentrations (**glutamine**, **arginine**) further reflect urea cycle dysfunction.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia type I (argininosuccinate synthetase deficiency) is confirmed by **elevated citrulline** and **hyperornithinemia**. **Acute/chronic hepatitis** and **hypertrichosis** suggest liver involvement, common in type I. **Recurrent infections** and **pneumonia** may stem from metabolic instability impairing immunity. **Death in infancy/childhood** correlates with the severe prognosis of untreated type I. **Oroticaciduria** and **ornithinuria** directly link to urea cycle blockage, while **hypoammonemia** (if confirmed) could indicate late-stage liver failure. The biochemical triad of citrullinemia (high citrulline, orotic aciduria, hyperammonemia) and early lethality solidify this diagnosis."
"['Hallux valgus', 'Long hallux', 'Elevated circulating alkaline phosphatase concentration', 'Abnormal circulating calcium concentration', 'Symphalangism affecting the phalanges of the hallux', 'Ectopic ossification in muscle tissue', 'Pain', 'Abnormal erythrocyte sedimentation rate', 'Abnormal circulating C-reactive protein concentration', 'Abnormal blood phosphate concentration']",['Fibrodysplasia ossificans progressiva/Fibrodysplasia ossificans progressiva'],"Disease: Fibrodysplasia ossificans progressiva  
Reasoning:  
1. **Hallux valgus and Long hallux**: Congenital malformations of the great toes (hallux valgus, elongated hallux) are classic early signs of FOP, present at birth.  
2. **Symphalangism affecting the phalanges of the hallux**: Fusion of phalangeal joints (symphalangism) in the hallux is a pathognomonic feature of FOP.  
3. **Ectopic ossification in muscle tissue**: Progressive heterotopic ossification in soft tissues (e.g., muscles, tendons) is the hallmark of FOP, often triggered by trauma or inflammation.  
4. **Elevated alkaline phosphatase, abnormal calcium/phosphate**: Reflects active bone remodeling and dysregulated mineral metabolism due to ectopic bone formation.  
5. **Elevated ESR, CRP, and pain**: Indicate inflammatory flare-ups preceding ossification episodes.  
6. **Exclusion of mimics**: Symptoms collectively distinguish FOP from other ossification disorders (e.g., POH) or metabolic bone diseases."
"['Death in childhood', 'Death in adolescence', 'Impaired glucose tolerance', 'Death in early adulthood']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: MODY (Maturity-onset diabetes of the young, type 1)  
Reasoning:  
1. **Impaired glucose tolerance** aligns with MODY, a monogenic diabetes caused by mutations in genes like *HNF4A* (type 1). MODY typically manifests as early-onset, non-ketotic hyperglycemia, often misdiagnosed as type 1 or 2 diabetes.  
2. **Early mortality** (childhood/adolescence/early adulthood) suggests severe complications from undiagnosed or mismanaged hyperglycemia. For example:  
   - Acute crises (e.g., diabetic ketoacidosis or severe hypoglycemia) due to delayed diagnosis.  
   - Chronic vascular/nephropathy from prolonged poor glycemic control.  
3. MODY type 1 (*HNF4A* mutations) is associated with progressive beta-cell dysfunction and sensitivity to sulfonylureas. Without timely genetic diagnosis and tailored therapy, insulin deficiency worsens, accelerating complications.  
4. Familial autosomal dominant inheritance (common in MODY) could explain multi-generational early deaths if undiagnosed in relatives.  

Disease: Maturity-onset diabetes of the young, type 1  
Reasoning:  
1. **Genetic basis**: *HNF4A* mutations disrupt pancreatic beta-cell function and insulin secretion, causing glucose intolerance.  
2. **Clinical course**: Symptoms often emerge in adolescence/early adulthood but may manifest earlier. Neonatal hypoglycemia (linked to *HNF4A*) could predispose to lethal hypoglycemic events in infancy/childhood if unrecognized.  
3. **Mortality drivers**:  
   - Lack of targeted treatment (e.g., sulfonylureas) leads to reliance on insulin, increasing hypoglycemia risk.  
   - Rapid progression to insulin dependence in some cases, exacerbating metabolic instability.  
4. **Diagnostic delay**: Misclassification as type 1 diabetes may result in suboptimal care, hastening complications (e.g., renal failure, cardiovascular events) and early death.  

Both diagnoses hinge on genetic testing to confirm *HNF4A* variants, enabling precision therapy to mitigate mortality risks."
"['Nystagmus', 'Optic atrophy', 'Hypotonia', 'Lethargy', 'Dysarthria', 'Gait ataxia', 'Poor coordination', 'Undetectable visual evoked potentials', 'Bilateral sensorineural hearing impairment']","['Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome/Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss']","Disease: Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome (CAPOS)  
Reasoning:  
1. **Cerebellar ataxia**: Supported by *gait ataxia* and *poor coordination*, indicating cerebellar dysfunction.  
2. **Optic atrophy**: Confirmed by *optic atrophy* and *undetectable visual evoked potentials*, reflecting optic nerve degeneration.  
3. **Sensorineural hearing loss**: Aligns with *bilateral sensorineural hearing impairment*.  
4. **Associated features**: *Nystagmus* and *dysarthria* are consistent with cerebellar/brainstem involvement. *Hypotonia* and *lethargy* may occur during acute episodes triggered by stressors (e.g., fever), a hallmark of CAPOS.  
5. **Genetic basis**: CAPOS is caused by ATP1A3 mutations, which disrupt ion transport, explaining multisystem neurological deficits.  
6. **Diagnostic exclusion**: While *areflexia* and *pes cavus* are not explicitly listed, CAPOS is prioritized due to the combination of cerebellar, optic, and auditory symptoms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine during pregnancy disrupts fetal development.  
3. **Hypertyrosinemia** may occur secondarily if tyrosine metabolism is overwhelmed or due to co-existing hepatic dysfunction, though this is atypical in classic PKU.  
4. **Neonatal death/Death in infancy/childhood** reflects untreated severe PKU, leading to neurotoxicity, seizures, and organ failure without early dietary intervention.  
5. The absence of tyrosinemia-specific symptoms (e.g., liver/kidney dysfunction) prioritizes PKU over primary tyrosinemia.  
6. Neonatal screening for hyperphenylalaninemia strongly supports PKU diagnosis, even with atypical hypertyrosinemia."
"['Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Pneumonia', 'Hepatomegaly', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Neurological Symptoms**: Seizures, motor delay, and generalized hypotonia align with SSADHD, a disorder disrupting GABA metabolism. Accumulation of γ-aminobutyric acid (GABA) and γ-hydroxybutyrate (GHB) causes neurotoxicity.  
2. **Elevated Urinary Carboxylic Acid**: SSADHD is characterized by elevated urinary GHB, often reported as a carboxylic acid in screening tests.  
3. **Decreased Plasma Free Carnitine**: Secondary carnitine deficiency may occur due to conjugation of carnitine with accumulating metabolites (e.g., GHB derivatives), reducing free carnitine levels.  
4. **Hepatomegaly**: Could stem from metabolic stress or carnitine deficiency impairing fatty acid oxidation, leading to hepatic lipid accumulation.  
5. **Pneumonia/Death in Infancy**: Severe hypotonia and seizures increase aspiration risk, predisposing to pneumonia. Early mortality reflects complications like refractory seizures or respiratory infections.  
6. **Exclusion of Other Disorders**: While hepatomegaly and carnitine deficiency suggest fatty acid oxidation disorders, the combination with elevated GHB (via urinary carboxylic acids) and neurological symptoms specifically points to SSADHD."
"['Brachydactyly', 'Joint stiffness', 'Pulmonic stenosis', 'Scoliosis', 'Lumbar hyperlordosis', 'Short stature', 'High myopia', 'Muscular ventricular septal defect', 'Microspherophakia']",['Weill-Marchesani syndrome 1'],"Disease: Weill-Marchesani syndrome 1  
Reasoning:  
1. **Microspherophakia and high myopia** are hallmark ocular features of Weill-Marchesani syndrome (WMS), caused by abnormal lens shape and severe refractive errors.  
2. **Brachydactyly, short stature, joint stiffness, scoliosis, and lumbar hyperlordosis** align with WMS-associated skeletal dysplasia and connective tissue abnormalities.  
3. **Pulmonic stenosis and muscular ventricular septal defect** suggest congenital heart defects, reported in recessive WMS1 (ADAMTS10 mutations).  
4. The combination of **ocular, skeletal, and cardiovascular anomalies** excludes mimics like Marfan syndrome (arachnodactyly, aortic root dilation) or acromicric dysplasia (no cardiac/ocular involvement).  
5. **Autosomal recessive inheritance** (WMS1) is consistent with systemic severity, including cardiac manifestations, compared to autosomal dominant forms (WMS2)."
"['Abnormality of prenatal development or birth', 'Lethargy', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia & Lethargy/Drowsiness**: IVA disrupts leucine metabolism, causing toxic isovaleric acid accumulation. This inhibits the urea cycle, leading to hyperammonemia, resulting in encephalopathic symptoms (lethargy, drowsiness).  
2. **Abnormal Glycine & Carnitine Levels**: Isovaleric acid conjugates with glycine (forming isovalerylglycine) and carnitine (isovaleryl-carnitine), depleting carnitine and elevating glycine conjugates in blood/urine, key diagnostic markers for IVA.  
3. **Feeding Difficulties & Neonatal/Infant Death**: IVA typically manifests neonatally after protein intake begins. Acute metabolic crises cause vomiting, poor feeding, and rapid deterioration, leading to death without prompt treatment (e.g., dietary leucine restriction, carnitine supplementation).  
4. **Prenatal Abnormalities**: While IVA usually presents postnatally, severe maternal-fetal metabolite exchange might cause subtle prenatal growth issues, though this is less common.  
5. **Sleep Disturbances**: Linked to neurotoxicity from ammonia and organic acid accumulation, disrupting neurotransmitter balance.  
6. **Differentiation from Other Organic Acidemias**: Elevated isovalerylglycine and specific carnitine profile distinguish IVA from propionic/methylmalonic acidemias, which show different metabolite patterns (e.g., propionylglycine).  

The constellation of hyperammonemia, glycine/carnitine abnormalities, and acute neonatal metabolic crisis strongly supports IVA. Early recognition is critical to prevent fatal outcomes."
"['Microcephaly', 'Wide nasal bridge', 'Strabismus', 'Recurrent corneal erosions', 'Proptosis', 'Alacrima', 'Oculomotor apraxia', 'Dental crowding', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'EEG abnormality', 'Highly arched eyebrow', 'Scoliosis', 'Lack of facial subcutaneous fat', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A hallmark feature of NGLY1 deficiency, directly linked to impaired tear production due to glycosylation defects.  
2. **Neurological symptoms** (Seizures, EEG abnormality, Global developmental delay, Hypotonia, Oculomotor apraxia): Reflect systemic neurodegeneration and disrupted glycoprotein metabolism critical for brain function.  
3. **Ocular abnormalities** (Proptosis, Strabismus, Recurrent corneal erosions): Secondary to alacrima (dry eyes causing corneal damage) and neuromuscular dysregulation.  
4. **Growth defects** (Microcephaly, Intrauterine growth retardation, Small hand/Short foot): Consistent with prenatal-onset glycosylation disorder affecting growth pathways.  
5. **Dysmorphic features** (Wide nasal bridge, Highly arched eyebrow, Lack of facial subcutaneous fat): Characteristic craniofacial patterns in congenital glycosylation disorders.  
6. **Musculoskeletal issues** (Scoliosis, Dental crowding): Connective tissue/glycoprotein abnormalities impacting bone and tissue structure.  
7. **Autonomic/Systemic involvement** (Constipation, Reduced tendon reflexes): Dysfunction in glycosylation-dependent autonomic signaling and neuromuscular junctions.  
8. **Absence of noted liver dysfunction**: While liver issues are part of the syndrome’s name, phenotypic variability exists; other symptoms dominate the clinical picture here.  

This constellation aligns with NGLY1 deficiency, a disorder of endoplasmic reticulum-associated degradation (ERAD) due to impaired deglycosylation, disrupting multiple glycoprotein-dependent processes."
"['Pectus excavatum', 'Cafe-au-lait spot', 'Hypopigmentation of the skin', 'Neurofibroma', 'Freckling', 'Kyphoscoliosis', 'Multiple cafe-au-lait spots', 'Plexiform neurofibroma']","['Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion/Neurofibromatosis, type I']","Disease: Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion/Neurofibromatosis, type I  
Reasoning:  
1. **Multiple café-au-lait spots**: A hallmark of NF1, requiring ≥6 spots (>5 mm prepubertal, >15 mm postpubertal) for diagnostic criteria.  
2. **Freckling (axillary/inguinal)**: Known as Crowe's sign, pathognomonic for NF1.  
3. **Neurofibromas**: Benign nerve sheath tumors, with ≥2 required for diagnosis.  
4. **Plexiform neurofibroma**: A subtype involving multiple nerve bundles, specific to NF1 and a major diagnostic criterion.  
5. **Skeletal abnormalities (pectus excavatum, kyphoscoliosis)**: Common NF1-associated features due to connective tissue dysplasia.  
6. **Hypopigmentation of the skin**: May occur alongside café-au-lait spots due to melanocyte dysfunction linked to NF1 mutations.  
The combination fulfills NIH diagnostic criteria (≥2 clinical features), confirming NF1. Genetic testing for *NF1* variants or deletions is definitive."
"['Optic disc pallor', 'Abnormality of visual evoked potentials', 'Horizontal nystagmus', 'Spasticity', 'Dystonia', 'Rotary nystagmus', 'Mutism', 'Poor head control', 'Abnormal auditory evoked potentials', 'Poor gross motor coordination', 'Infantile muscular hypotonia', 'Gastrostomy tube feeding in infancy', 'Cognitive impairment']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Hypomyelinating leukodystrophy features**: Optic disc pallor and abnormal visual/auditory evoked potentials indicate defective myelination of sensory pathways.  
2. **Motor dysfunction**: Spasticity, dystonia, poor gross motor coordination, and spastic ataxia align with cerebellar and corticospinal tract involvement due to hypomyelination.  
3. **Early-onset neurological deficits**: Infantile hypotonia progressing to spasticity, poor head control, and gastrostomy dependency reflect severe infantile-onset CNS dysfunction.  
4. **Oculomotor abnormalities**: Horizontal and rotary nystagmus suggest brainstem/cerebellar impairment, common in hypomyelinating disorders.  
5. **Cognitive and communication deficits**: Mutism and cognitive impairment correlate with widespread white matter pathology affecting higher cortical functions.  
6. **Genetic confirmation**: Autosomal recessive NKX6-2 mutations disrupt oligodendrocyte development, explaining the hypomyelination phenotype.  
7. **Rule-out**: Symptoms distinguish it from other leukodystrophies (e.g., PMD, 4H syndrome) via specific gene involvement and clinical progression."
"['Hyperactivity', 'Spasticity', 'Death in infancy', 'Hemolytic anemia', 'Metabolic acidosis', 'Increased total bilirubin', 'Neonatal death', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Increased circulating lactate dehydrogenase concentration']",['Glutathione synthetase deficiency'],"Disease: Glutathione synthetase deficiency  
**Reasoning**:  
1. **Hemolytic anemia** and **increased total bilirubin**: Glutathione is critical for protecting red blood cells (RBCs) from oxidative damage. Deficiency leads to RBC fragility, causing hemolysis and subsequent hyperbilirubinemia.  
2. **Metabolic acidosis**: Accumulation of 5-oxoproline (a hallmark of glutathione synthetase deficiency) due to impaired glutathione synthesis disrupts acid-base balance.  
3. **Increased circulating lactate dehydrogenase (LDH)**: Elevated LDH reflects RBC breakdown (hemolysis) and tissue damage from oxidative stress.  
4. **Spasticity** and **hyperactivity**: Oxidative stress in the central nervous system damages neurons, leading to neurological symptoms.  
5. **Recurrent viral infections**: Glutathione deficiency impairs immune cell function, reducing defenses against pathogens.  
6. **Abnormal circulating porphyrin concentration**: Glutathione is involved in heme metabolism; its deficiency may disrupt porphyrin pathways.  
7. **Neonatal death**/**death in infancy**: Severe forms of the disease present in infancy with life-threatening metabolic derangements and organ failure.  

**Conclusion**: The constellation of hemolysis, metabolic acidosis, neurological abnormalities, and immune dysfunction strongly aligns with **glutathione synthetase deficiency**, particularly the severe autosomal recessive form. Confirmatory testing would include genetic analysis and measurement of 5-oxoproline in urine."
"['Rod-cone dystrophy', 'Intellectual disability', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
- **Rod-cone dystrophy**: PMM2-CDG commonly causes retinal abnormalities, including progressive vision loss due to rod-cone dystrophy, linked to defective glycosylation of photoreceptor proteins.  
- **Intellectual disability**: A hallmark of PMM2-CDG due to impaired glycosylation critical for neurodevelopment, leading to global developmental delays and cognitive deficits.  
- **Cerebellar atrophy/agenesis**: Structural cerebellar defects (atrophy or agenesis) arise from disrupted glycosylation during brain development, contributing to hypotonia, ataxia, and motor deficits.  
- **Death in infancy**: Severe PMM2-CDG cases often result in early mortality from multiorgan failure, infections, or complications like liver disease and thromboembolism.  
- **Thromboembolism**: Coagulation factor glycosylation defects (e.g., antithrombin III deficiency) predispose to thrombotic events.  
- **Abnormal facial shape/calvaria morphology**: Characteristic dysmorphic features (e.g., high forehead, large ears) and skull abnormalities stem from glycosylation-dependent craniofacial development disruptions.  
- **Lipodystrophy**: Subcutaneous fat redistribution or loss may occur due to metabolic dysregulation from glycosylation defects in adipose tissue signaling.  
- **Acute/chronic hepatitis**: Persistent liver dysfunction (elevated transaminases, hepatomegaly) is common, progressing to fibrosis in severe cases, driven by glycosylation-dependent hepatic protein misfolding.  

**Conclusion**: The multisystemic presentation—neurological, hepatic, coagulopathic, and dysmorphic—aligns pathognomonically with PMM2-CDG, a disorder of N-linked glycosylation caused by PMM2 mutations."
"['Seizure', 'Lethargy', 'Areflexia', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Dyspnea', 'Hyperglycinemia', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Glutaric aciduria', 'Hyperglutaminemia', 'Elevated circulating glutaric acid concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Key metabolic markers**: Elevated glutaric acid (hyperglutaminemia, glutaric aciduria, elevated circulating glutaric acid) directly aligns with GA-I’s pathophysiology due to **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Neurological features**: Dystonia, opisthotonus, seizures, and hypotonia reflect basal ganglia injury, a hallmark of GA-I. These symptoms often manifest during metabolic crises triggered by fever, infection, or fasting.  
3. **Infantile presentation**: Feeding difficulties, lethargy, drowsiness, and risk of early death are consistent with GA-I’s typical onset in infancy. Untreated cases progress to irreversible neurological damage.  
4. **Carnitine abnormalities**: Abnormal carnitine levels occur as the body attempts to conjugate toxic metabolites (e.g., glutaric acid), depleting carnitine reserves.  
5. **Exclusion of mimics**: Hyperglycinemia may suggest glycine encephalopathy, but glutaric aciduria and dystonia strongly favor GA-I. Fasciculations and areflexia could indicate spinal involvement but are secondary to metabolic stress in GA-I.  
6. **Triggers for decompensation**: Fever and dyspnea likely precipitated acute encephalopathy, a common GA-I crisis pattern.  

This constellation of symptoms and biochemical findings is pathognomonic for GA-I, warranting urgent genetic testing (GCDH gene) and metabolic management to mitigate progression."
"['Tall stature', 'Abnormality of the genitourinary system', 'Entropion', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Death in infancy', 'Abnormal heart morphology', 'Hypertrophic cardiomyopathy', 'Abnormal facial shape', 'Kyphoscoliosis', 'Aortic aneurysm']","['Cutis laxa, autosomal recessive, type IIC']","Disease: Cutis laxa, autosomal recessive, type IIC (ARCL2C)  
Reasoning:  
1. **Abnormality of the genitourinary system**: Connective tissue defects in ARCL2C can affect urinary tract structures.  
2. **Entropion & Abnormal facial shape**: Lax, inelastic skin leads to eyelid malformations and characteristic facial features (e.g., aged appearance, sagging skin).  
3. **Generalized hypotonia**: Common in ARCL2C due to connective tissue dysfunction impacting muscle tone.  
4. **Flexion contracture & Hip dysplasia**: Joint abnormalities arise from defective collagen/elastin, causing restricted movement and skeletal malformations.  
5. **Kyphoscoliosis**: Spinal curvature due to weak connective tissue supporting vertebrae.  
6. **Disproportionate tall stature**: Skeletal overgrowth or dysplasia linked to PYCR1 mutations affecting cell proliferation and matrix integrity.  
7. **Hypertrophic cardiomyopathy & Aortic aneurysm**: Severe cardiovascular complications in ARCL2C stem from impaired vascular connective tissue, leading to heart wall thickening and arterial fragility.  
8. **Abnormal heart morphology**: Structural heart defects (e.g., valve anomalies) are recurrent in PYCR1-related disorders.  
9. **Death in infancy**: ARCL2C is often lethal early due to cardiorespiratory failure or aortic rupture.  

The constellation of connective tissue, skeletal, cardiac, and dysmorphic features, combined with autosomal recessive inheritance, aligns definitively with ARCL2C (PYCR1-related cutis laxa)."
"['Lethargy', 'Drowsiness', 'Sleep disturbance', 'Bone pain', 'Hypertyrosinemia', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical finding in PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine.  
2. **Hypertyrosinemia** is atypical in classical PKU but may occur due to exogenous tyrosine supplementation (common in PKU management) or overlapping metabolic disturbances.  
3. **Neurological symptoms** (lethargy, drowsiness, sleep disturbances) align with untreated PKU, as phenylalanine accumulation disrupts neurotransmitter synthesis (e.g., dopamine, serotonin).  
4. **Bone pain** is not classic for PKU but could stem from long-term nutritional deficiencies (e.g., calcium/vitamin D) in poorly managed dietary therapy.  
5. The absence of liver dysfunction or severe tyrosine-related symptoms (e.g., keratitis, skin lesions) argues against primary tyrosinemia, reinforcing PKU as the primary diagnosis.  
6. Hypertyrosinemia may reflect secondary metabolic adaptations or testing artifacts, but hyperphenylalaninemia remains the critical diagnostic marker for PKU."
"['Blindness', 'Osteoporosis', 'Ectopia lentis', 'Cardiomyopathy', 'Coronary artery atherosclerosis', 'Abnormal foot morphology', 'Pneumonia', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Hyperalaninemia', 'Abnormal vertebral morphology', 'Death in adolescence', 'Death in early adulthood']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypermethioninemia**: Hallmark biochemical features of cystathionine beta-synthase (CBS) deficiency, as impaired CBS activity blocks homocysteine conversion to cystathionine, causing homocysteine and methionine accumulation.  
2. **Ectopia lentis**: A pathognomonic sign of classic homocystinuria due to defective collagen cross-linking from homocysteine accumulation, leading to lens dislocation.  
3. **Osteoporosis and Abnormal vertebral/foot morphology**: Homocysteine disrupts bone remodeling and connective tissue integrity, causing skeletal abnormalities.  
4. **Cardiomyopathy and Coronary artery atherosclerosis**: Chronic hyperhomocystinemia damages vascular endothelium, accelerating atherosclerosis and cardiac dysfunction.  
5. **Blindness**: Secondary to ectopia lentis complications (e.g., retinal detachment, glaucoma) or thromboembolic events affecting ocular vasculature.  
6. **Recurrent Pneumonia**: Skeletal chest deformities may impair respiratory function, predisposing to infections.  
7. **Early mortality**: Untreated CBS deficiency leads to thromboembolic events (stroke, myocardial infarction) or severe cardiovascular complications, often causing death in adolescence/early adulthood.  
8. **Hyperalaninemia**: May reflect secondary metabolic disturbances or concurrent stress-induced pyruvate elevation, though less specific to homocystinuria.  

Disease: Homocystinemia/Homocystinuria  
Reasoning:  
- This is a broader diagnostic category encompassing the CBS-deficient subtype. The reasoning aligns with the above, emphasizing the systemic effects of homocysteine toxicity across connective tissue, vascular, and skeletal systems."
"['Ventricular fibrillation', 'Sinus bradycardia', 'Left ventricular noncompaction']",['Sick sinus syndrome 2'],"Disease: Sick sinus syndrome 2  
Reasoning:  
1. **Sinus bradycardia** is a hallmark of sick sinus syndrome (SSS), reflecting dysfunction of the sinoatrial node. SSS type 2 specifically involves intermittent sinoatrial block or sinus arrest, consistent with this symptom.  
2. **Ventricular fibrillation** may arise secondary to severe bradycardia in SSS2, as prolonged pauses or arrhythmias can trigger compensatory ventricular instability, especially in the presence of structural abnormalities.  
3. **Left ventricular noncompaction (LVNC)** is not directly linked to SSS2 but may coexist as a congenital structural anomaly. LVNC increases susceptibility to ventricular arrhythmias like fibrillation, compounding the arrhythmic risk from SSS2.  
4. Genetic overlap (e.g., ion channel or structural gene mutations) could explain concurrent SSS2 and LVNC, though SSS2 is primarily attributed to *HCN4* mutations affecting pacemaker function.  

Final diagnosis prioritizes SSS2 due to the pathognomonic sinus bradycardia, while LVNC and ventricular fibrillation are contextualized as contributing/comorbid factors."
"['Generalized hypotonia', 'Reduced tendon reflexes', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of glutaric acid accumulation in urine, confirming impaired glutaryl-CoA dehydrogenase activity.  
2. **Generalized hypotonia & reduced tendon reflexes**: Neurotoxic effects of glutaric acid and 3-hydroxyglutaric acid damage basal ganglia and white matter, causing motor deficits.  
3. **Fever, vomiting, diarrhea**: Metabolic decompensation triggered by catabolic stressors (e.g., infections), exacerbating toxic metabolite accumulation.  
4. **Death in infancy**: Untreated GA-I leads to acute encephalopathic crises with striatal necrosis, cerebral edema, or secondary complications (e.g., rhabdomyolysis).  
5. **Consistency with GA-I pathophysiology**: Autosomal recessive GCDH gene mutations disrupt lysine/hydroxylysine metabolism, producing neurotoxic dicarboxylic acids. Early-onset neurological and systemic features align with classic GA-I presentation."
"['Skin rash', 'Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Decreased plasma free carnitine', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder impairing ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD; excess carbamoyl phosphate shunts into pyrimidine synthesis, producing orotic acid.  
3. **Neurological symptoms (lethargy, drowsiness, vomiting, sleep disturbance)**: Reflect ammonia neurotoxicity.  
4. **Death in infancy**: Severe neonatal-onset OTCD causes rapid metabolic collapse without intervention.  
5. **Decreased plasma free carnitine**: Secondary carnitine depletion due to disrupted metabolism or renal loss.  
6. **Skin lesions (rash, plaques, macules/papules)**: Less specific but may arise from metabolic stress or ammonia-induced inflammation.  
7. **Gastrointestinal symptoms (diarrhea, vomiting)**: Common in metabolic crises due to systemic toxicity.  
**Key differentiators**: Oroticaciduria distinguishes OTCD from other urea cycle defects. X-linked inheritance (though de novo mutations occur) and hyperammonemia severity further support the diagnosis."
"['Hypertelorism', 'Erythroderma', 'Hypermelanotic macule', 'Failure to thrive', 'Pneumonia', 'Hepatomegaly', 'Hypoalbuminemia', 'Decreased circulating IgG level', 'Spotty hyperpigmentation', 'Interstitial pneumonitis', 'Prolonged neonatal jaundice', 'Prominent forehead', 'Elevated gamma-glutamyltransferase level', 'Persistent CMV viremia', 'Reduced natural killer cell count', 'Abnormal circulating IgA level', 'Abnormal circulating IgM level']",['Syndromic diarrhea/Trichohepatoenteric syndrome 1'],"Disease: Syndromic diarrhea/Trichohepatoenteric syndrome 1 (THES1)  
Reasoning:  
1. **Facial dysmorphism**: Hypertelorism and prominent forehead align with characteristic craniofacial features of THES1.  
2. **Cutaneous findings**: Erythroderma, hypermelanotic macules, and spotty hyperpigmentation correlate with the dermatological abnormalities (e.g., woolly hair, skin pigmentation defects) seen in THES1.  
3. **Gastrointestinal and hepatic involvement**: Failure to thrive, hepatomegaly, hypoalbuminemia, prolonged neonatal jaundice, and elevated GGT reflect the triad of intractable diarrhea, liver dysfunction, and protein-losing enteropathy central to THES1.  
4. **Immunodeficiency**: Decreased IgG, abnormal IgA/IgM, reduced NK cells, persistent CMV viremia, and recurrent infections (pneumonia/interstitial pneumonitis) indicate the combined immunodeficiency associated with THES1 due to TTC37 or SKIV2L gene mutations.  
5. **Systemic coherence**: The combination of enteropathy, trichorrhexis nodosa (implied by cutaneous/hair symptoms), liver disease, and immune defects is pathognomonic for THES1, distinguishing it from isolated immunodeficiency or metabolic disorders."
"['Hypospadias', 'Bifid scrotum', 'Micropenis', 'Ambiguous genitalia', 'Low-set ears', 'Atopic dermatitis', 'Hypocholesterolemia', 'Short nose', 'Elevated 8-dehydrocholesterol', '2-3 toe syndactyly', 'Decreased testicular size', 'Elevated 7-dehydrocholesterol', 'Abnormal circulating testosterone concentration']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol Synthesis Defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol confirm a block in cholesterol biosynthesis due to DHCR7 enzyme deficiency, a hallmark of SLOS.  
2. **Genital Abnormalities**: Hypospadias, bifid scrotum, micropenis, ambiguous genitalia, and decreased testicular size align with SLOS-associated urogenital malformations and impaired steroidogenesis.  
3. **Craniofacial Features**: Short nose and low-set ears are classic dysmorphic traits in SLOS.  
4. **Limb Anomalies**: 2-3 toe syndactyly is a pathognomonic feature of SLOS.  
5. **Biochemical Markers**: Hypocholesterolemia and abnormal testosterone levels reflect disrupted cholesterol-dependent processes (e.g., hormone synthesis).  
6. **Dermatologic Manifestation**: Atopic dermatitis correlates with skin barrier dysfunction due to cholesterol deficiency.  
The constellation of biochemical, structural, and clinical findings is diagnostic for Smith-Lemli-Opitz syndrome."
"['Hydrocele testis', 'Narrow mouth', 'Narrow palate', 'Microcephaly', 'Posteriorly rotated ears', 'Low-set ears', 'Prominent nose', 'Strabismus', 'Downslanted palpebral fissures', 'Long eyelashes', 'Thick eyebrow', 'Coloboma', 'Dental crowding', 'Dental malocclusion', 'Abnormal repetitive mannerisms', 'Anxiety', 'Delayed speech and language development', 'Hirsutism', 'Global developmental delay', 'Intellectual disability, moderate', 'Highly arched eyebrow', 'Scoliosis', 'Low hanging columella', 'Broad hallux', 'Talon cusp', 'Broad thumb']",['Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2'],"Disease: Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2  
Reasoning:  
1. **Broad thumbs/hallux and skeletal anomalies**: The patient exhibits ""Broad hallux"" and ""Broad thumb,"" hallmark features of Rubinstein-Taybi syndrome (RSTS). ""Talon cusp"" and ""Scoliosis"" further support skeletal involvement.  
2. **Craniofacial dysmorphism**: Features like ""Narrow mouth,"" ""Narrow palate,"" ""Prominent nose,"" ""Low hanging columella,"" ""Posteriorly rotated ears,"" ""Low-set ears,"" ""Downslanted palpebral fissures,"" ""Long eyelashes,"" ""Thick eyebrow,"" and ""Highly arched eyebrow"" align with the characteristic facial gestalt of RSTS.  
3. **Ocular abnormalities**: ""Coloboma"" and ""Strabismus"" are recurrent in RSTS, linked to EP300 or CREBBP mutations.  
4. **Dental anomalies**: ""Dental crowding"" and ""Dental malocclusion"" correlate with maxillary hypoplasia and palate abnormalities in RSTS.  
5. **Neurodevelopmental delays**: ""Global developmental delay,"" ""Moderate intellectual disability,"" ""Delayed speech,"" and ""Abnormal repetitive mannerisms"" reflect the syndrome’s cognitive and behavioral profile.  
6. **Ancillary features**: ""Hirsutism"" and ""Hydrocele testis"" are less specific but reported in RSTS. ""Microcephaly"" and ""Anxiety"" further consolidate the clinical overlap.  
7. **EP300-specific subtype**: While CREBBP (RSTS1) and EP300 (RSTS2) mutations cause overlapping phenotypes, EP300-related cases may show milder physical features but similar neurodevelopmental profiles. The combination of typical RSTS traits with the listed symptoms strongly supports this molecular subtype."
"['Severe periodontitis', 'Palmoplantar hyperkeratosis', 'Premature loss of primary teeth', 'Chronic furunculosis', 'Folliculitis', 'Alveolar bone loss around teeth']",['Papillon-Lefèvre syndrome/Papillon-Lefevre syndrome'],"Disease: Papillon-Lefèvre syndrome  
Reasoning:  
1. **Palmoplantar hyperkeratosis**: Thickened skin on palms and soles is a hallmark feature of Papillon-Lefèvre syndrome (PLS), caused by mutations in the *CTSC* gene encoding cathepsin C.  
2. **Severe periodontitis and alveolar bone loss**: PLS leads to aggressive destruction of periodontal tissues due to dysregulated immune response and bacterial susceptibility, resulting in premature loss of **both primary and permanent teeth** (here, primary teeth loss is noted).  
3. **Chronic furunculosis and folliculitis**: Recurrent skin infections arise from impaired neutrophil function secondary to *CTSC* mutations, reducing protease activity critical for combating pathogens like *Staphylococcus aureus*.  
4. **Exclusion of alternatives**: Conditions like Haim-Munk syndrome (similar but with additional features) or isolated periodontitis lack the combined dermatological and immunological findings seen here.  
The triad of palmoplantar hyperkeratosis, early-onset periodontitis, and susceptibility to infections confirms PLS."
"['Nystagmus', 'Anal atresia', 'Clonus', 'Focal clonic seizure', 'Cloverleaf skull', 'Severe combined immunodeficiency', 'Developmental stagnation', 'Fetal distress']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (EXTL3-related)  
Reasoning:  
1. **Skeletal anomalies**: ""Cloverleaf skull"" (craniosynostosis) strongly suggests a skeletal dysplasia, a hallmark of EXTL3 mutations.  
2. **Immunodeficiency**: ""Severe combined immunodeficiency (SCID)"" aligns with EXTL3's role in heparan sulfate biosynthesis, critical for immune cell development.  
3. **Neurodevelopmental issues**: ""Nystagmus,"" ""clonus,"" and ""focal clonic seizures"" indicate neurological dysfunction, consistent with EXTL3's impact on brain development.  
4. **Congenital anomalies**: ""Anal atresia"" and ""fetal distress"" suggest multisystem involvement, common in syndromic disorders like EXTL3-related disease.  
5. **Developmental stagnation**: Reflects global developmental delays due to combined skeletal, immune, and neurological defects.  
6. **Exclusion of mimics**: Overlap with other immunoskeletal disorders (e.g., Schimke immuno-osseous dysplasia) is ruled out by the unique triad of cloverleaf skull, SCID, and seizures."
"['Hypogonadism', 'Strabismus', 'Optic disc pallor', 'Nyctalopia', 'Obesity', 'Reduced visual acuity']",['Bardet-Biedl syndrome 5'],"Disease: Bardet-Biedl syndrome 5  
Reasoning:  
1. **Obesity**: A primary diagnostic criterion for Bardet-Biedl syndrome (BBS), commonly present from early childhood.  
2. **Hypogonadism**: Frequently observed in BBS due to hypothalamic-pituitary-gonadal axis dysfunction.  
3. **Nyctalopia, Reduced visual acuity, Optic disc pallor**: Indicate retinal dystrophy (e.g., rod-cone dystrophy), a hallmark of BBS. Nyctalopia is an early symptom, progressing to severe vision loss.  
4. **Strabismus**: Occurs in BBS due to ocular developmental anomalies or secondary to retinal dysfunction.  
5. **Genetic subtype specificity**: BBS5 (caused by *BBS5* gene mutations) aligns with the clinical phenotype, as retinal degeneration and obesity are consistent across BBS subtypes, though polydactyly or renal anomalies (common in BBS) may not always be reported.  
6. **Exclusion of mimics**: Differentiated from Alström syndrome (lack of hearing loss) and Laurence-Moon syndrome (less prominent obesity)."
"['Abnormal finger morphology', 'Wrist swelling', 'Arthritis', 'Joint swelling', 'Hepatic steatosis', 'Abnormality of the larynx', 'Abnormal right ventricle morphology', 'Abnormal toe morphology', 'Ankle swelling', 'Weight loss', 'Fever', 'Abdominal pain', 'Pulmonary arterial hypertension', 'Hyperuricemia', 'Gastric ulcer', 'Abnormality of the knee', 'Arthralgia', 'Hyperuricosuria', 'Myalgia', 'Paresthesia', 'Back pain', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Generalized morning stiffness', 'Helicobacter pylori infection', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Intestinal lymphoid nodular hyperplasia', 'Constrictive median neuropathy', 'Peripheral edema', 'obsolete Increased urinary urate', 'Tendonitis', 'Flank pain', 'Night sweats', 'Wrist pain', 'Hip pain', 'Knee pain', 'Ankle pain', 'Toe pain', 'Elevated gamma-glutamyltransferase level', 'Abnormality of mesentery morphology', 'Epigastric pain']",['Whipple disease'],"Disease: Whipple disease  
Reasoning:  
1. **Systemic Symptoms**: Fever, weight loss, night sweats, and poor appetite suggest a chronic infectious or inflammatory process, aligning with Whipple disease's systemic nature caused by *Tropheryma whipplei*.  
2. **Musculoskeletal Involvement**: Arthritis, joint swelling (wrist, ankle, knee, hip), arthralgia, tendonitis, and generalized morning stiffness reflect the migratory polyarthropathy commonly seen in early Whipple disease.  
3. **Gastrointestinal Manifestations**: Abdominal pain, epigastric pain, hepatic steatosis, and intestinal lymphoid nodular hyperplasia indicate intestinal involvement, consistent with Whipple-associated malabsorption and mucosal infiltration.  
4. **Cardiopulmonary Features**: Pulmonary arterial hypertension and abnormal right ventricle morphology may result from chronic inflammation or direct bacterial infiltration of cardiac tissue, a rare but documented complication.  
5. **Neurological Signs**: Paresthesia and constrictive median neuropathy suggest peripheral nerve involvement, which can occur in advanced Whipple disease with neurological dissemination.  
6. **Inflammatory Markers**: Elevated ESR, CRP, and ANA positivity (though atypical for pure Whipple disease) may reflect secondary autoimmune activation or coexisting conditions, but the overall pattern prioritizes infection.  
7. **Metabolic Abnormalities**: Hyperuricemia and hyperuricosuria could stem from renal tubular dysfunction due to chronic inflammation or malabsorption.  
8. **Hepatic and Mesenteric Involvement**: Elevated GGT, hepatic steatosis, and mesentery abnormalities correlate with Whipple-related infiltration of abdominal organs and lymphatic tissues.  
9. **Chronicity and Multi-Organ Spread**: The combination of prolonged symptoms (arthritis, weight loss) with cardiac, neurological, and gastrointestinal pathology strongly supports Whipple disease over isolated autoimmune disorders.  
**Exclusion Notes**: While H. pylori infection and gastric ulcer are present, they likely represent a comorbidity rather than the primary diagnosis. The systemic, multi-organ nature of symptoms points to Whipple disease as the unifying etiology."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine metabolism.  
2. **Neonatal death/Death in infancy**: Untreated PKU leads to toxic phenylalanine accumulation, causing severe neurological damage, seizures, and failure to thrive. In rare, severe PAH-deficient cases (e.g., ""malignant"" PKU), rapid metabolic deterioration may result in early mortality if undiagnosed.  
3. **Abnormality of prenatal development**: While PKU itself does not directly cause prenatal structural anomalies, *maternal PKU* (untreated hyperphenylalaninemia during pregnancy) can induce fetal teratogenicity (e.g., microcephaly, congenital heart defects). This suggests the patient’s prenatal abnormalities may stem from maternal PKU exposure, compounded by the infant’s own inherited PAH mutation.  
4. **Diagnostic confirmation**: Newborn screening detects hyperphenylalaninemia, and genetic testing identifies PAH mutations. Early dietary intervention (phenylalanine-restricted diet) prevents complications, underscoring the critical link between untreated PKU and the described outcomes."
"['Cryptorchidism', 'Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Abnormal erythrocyte morphology', 'Leukopenia', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Abnormal basal ganglia morphology', 'Hyperuricemia', 'Hyperglycinemia', 'Hepatomegaly', 'Difficulty walking', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Severe short stature', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Periventricular cysts', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Abnormal myelination']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: Methylmalonic acidemia (MMA) and methylmalonic aciduria are hallmarks of this disorder, directly indicating a defect in methylmalonyl-CoA mutase, the enzyme responsible for converting methylmalonyl-CoA to succinyl-CoA. Vitamin B12-unresponsiveness confirms mutations in the *MUT* gene encoding this enzyme.  
2. **Metabolic disturbances**: Metabolic acidosis, hyperammonemia, hypoglycemia, and hyperglycinemia arise due to disrupted propionate metabolism, leading to toxic accumulation of methylmalonic acid and secondary inhibition of multiple metabolic pathways (e.g., urea cycle dysfunction).  
3. **Hematologic abnormalities**: Leukopenia and abnormal erythrocyte morphology reflect bone marrow suppression caused by toxic metabolites.  
4. **Neurological involvement**: Generalized hypotonia, motor delays, intellectual disability, abnormal myelination, and periventricular cysts correlate with neurotoxic effects of methylmalonic acid and impaired energy metabolism in the basal ganglia.  
5. **Systemic complications**: Hepatomegaly, hypoproteinemia, and increased blood urea nitrogen result from hepatic/renal stress. Severe short stature and early mortality (infancy/childhood/adolescence) reflect chronic metabolic decompensation.  
6. **Exclusion of secondary causes**: Abnormal carnitine/porphyrin levels are secondary to mitochondrial dysfunction, not primary disorders. Hyperuricemia may stem from renal tubular damage.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Clinical confirmation**: Overlapping features (metabolic acidosis, hyperammonemia, methylmalonic aciduria) fulfill diagnostic criteria for MMA.  
2. **Phenotypic spectrum**: The inclusion of both neonatal death and death in adolescence aligns with MMA’s variable severity, depending on residual enzyme activity.  
3. **Supportive biomarkers**: Abnormal myelination, hypoglycemia, and hepatomegaly are consistent with long-term complications of MMA, even if not disease-specific.  
4. **Disease categorization**: This broader diagnosis encapsulates the genetic and biochemical heterogeneity of MMA, including subtypes beyond *MUT* mutations (e.g., cobalamin metabolism defects), though the B12-unresponsive subtype is prioritized here based on clinical severity.  

**Final Diagnosis**: The patient has **vitamin B12-unresponsive methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency**, a severe form of MMA with poor prognosis, as evidenced by early lethality, metabolic instability, and neurological sequelae."
"['Lamina lucida cleavage', 'Abnormal blistering of the skin', 'Erosion of oral mucosa', 'Sepsis', 'Skin erosion']","['Severe generalized junctional epidermolysis bullosa/Epidermolysis bullosa, junctional, Herlitz type']","Disease: Severe generalized junctional epidermolysis bullosa/Epidermolysis bullosa, junctional, Herlitz type  
Reasoning:  
1. **Lamina lucida cleavage**: This histopathological finding localizes blister formation to the lamina lucida within the basement membrane zone, a hallmark of junctional epidermolysis bullosa (JEB).  
2. **Abnormal blistering of the skin**: Consistent with epidermolysis bullosa (EB), where mechanical fragility leads to blistering after minor trauma.  
3. **Erosion of oral mucosa**: Mucosal involvement (e.g., oral, ocular, gastrointestinal) is characteristic of severe JEB subtypes like Herlitz type.  
4. **Sepsis**: Frequent infections and sepsis arise from compromised skin barriers, a critical complication in Herlitz JEB due to widespread epithelial defects.  
5. **Skin erosion**: Severe, non-healing erosions reflect the profound structural instability caused by mutations in laminin-332 genes (e.g., LAMA3, LAMB3, LAMC2), critical for dermal-epidermal adhesion.  
6. **Herlitz subtype differentiation**: The combination of life-threatening infections (sepsis) and extensive mucocutaneous involvement distinguishes Herlitz-type JEB from non-Herlitz forms, aligning with its grave prognosis."
"['High palate', 'Microcephaly', 'Retrognathia', 'Epicanthus', 'Short chin', 'Narrow forehead', 'Anteverted nares', 'Ptosis', 'Thick eyebrow', 'Synophrys', 'Hirsutism', 'Failure to thrive', 'Delayed gross motor development', 'Highly arched eyebrow', 'Clinodactyly of the 5th finger', '2-3 toe syndactyly', 'Depressed nasal bridge', 'Curly eyelashes', 'Feeding difficulties in infancy', 'Proximal placement of thumb', 'Short 4th metacarpal', 'Short 5th metacarpal', 'Abnormal renal morphology']",['Cornelia de Lange syndrome 3'],"Disease: Cornelia de Lange syndrome 3  
Reasoning: The patient exhibits hallmark features of Cornelia de Lange syndrome (CdLS), including distinctive facial dysmorphism (microcephaly, retrognathia, high palate, synophrys, thick eyebrows, ptosis, anteverted nares, depressed nasal bridge), limb anomalies (clinodactyly of the 5th finger, 2-3 toe syndactyly, short 4th/5th metacarpals, proximal thumb placement), and systemic involvement (failure to thrive, feeding difficulties, delayed motor development, abnormal renal morphology). Synophrys, hirsutism, and highly arched eyebrows further strengthen the diagnosis. These findings align with CdLS type 3 (SMC3-related), a genetic subtype characterized by mutations in the SMC3 gene, which affects cohesin complex function and manifests with multi-organ anomalies. The combination of craniofacial, skeletal, developmental, and renal abnormalities is pathognomonic for this syndrome."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation. This aligns with the patient’s elevated phenylalanine levels.  
2. **Hypertyrosinemia**: While atypical for classic PKU (where tyrosine is typically low), this could indicate a secondary metabolic disruption, transient neonatal tyrosinemia, or a coexisting condition (e.g., liver dysfunction). Alternatively, it may reflect a diagnostic error in symptom reporting.  
3. **Neonatal death/Death in infancy**: Severe, untreated PKU (or BH4-deficient variants) can cause rapid neurological deterioration, seizures, and organ failure, potentially leading to early mortality.  
4. **Prenatal abnormalities**: Unlikely from infantile PKU itself but may arise if the mother had untreated maternal PKU during pregnancy, indirectly affecting fetal development.  
5. **Exclusion of alternatives**: Tyrosinemias or BH4 deficiencies were considered but excluded due to the primary hallmark of hyperphenylalaninemia and the specified diagnosis of PKU.  

Conclusion: PKU explains the core biochemical anomaly (hyperphenylalaninemia) and aligns with severe outcomes when untreated, despite atypical hypertyrosinemia."
"['Microcephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological and developmental features**: Intellectual disability, motor delay, ataxia, and generalized hypotonia align with PMM2-CDG’s hallmark cerebellar dysfunction.  
2. **Cerebellar abnormalities**: Cerebellar atrophy and agenesis are consistent with structural brain defects seen in severe PMM2-CDG cases.  
3. **Ocular signs**: Strabismus and nystagmus are common due to cerebellar and brainstem involvement.  
4. **Systemic involvement**: Growth delay, microcephaly, and infantile death reflect multisystem pathology from impaired glycosylation.  
5. **Hyporeflexia and encephalopathy**: Indicate widespread neurological dysfunction, typical of PMM2-CDG’s metabolic derangements.  
6. **Diagnostic confirmation**: While genetic testing for *PMM2* mutations is definitive, the clinical triad of cerebellar hypoplasia, developmental delay, and multisystem involvement strongly supports this diagnosis."
"['Strabismus', 'Nystagmus', 'Delayed speech and language development', 'Abnormally large globe', 'Motor delay', 'Agenesis of corpus callosum', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Abnormal midbrain morphology', 'Cerebellar dysplasia', 'High myopia', 'Abnormal superior cerebellar peduncle morphology', 'Partial absence of the septum pellucidum']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar and Brain Abnormalities**: Cerebellar cysts, cerebellar vermis hypoplasia, cerebellar dysplasia, dilated fourth ventricle, and abnormal superior cerebellar peduncle morphology align with the hallmark cerebellar malformations of Poretti-Boltshauser syndrome.  
2. **Midbrain and Corpus Callosum Involvement**: Abnormal midbrain morphology and agenesis of the corpus callosum are supportive findings, as structural midbrain defects and variable corpus callosum anomalies are reported in this syndrome.  
3. **Ocular Features**: Strabismus, nystagmus, high myopia, and abnormally large globes correlate with the syndrome’s characteristic oculomotor apraxia and severe refractive errors.  
4. **Developmental Delays**: Motor delay and delayed speech/language development reflect the intellectual disability and ataxia components of the disorder.  
5. **Exclusion of Mimics**: The absence of ""molar tooth sign"" (ruling out Joubert syndrome) and the presence of cerebellar cysts (uncommon in other cerebellar hypoplasia disorders) further solidify this diagnosis."
"['Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency / 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** (e.g., 3-hydroxyisovaleric acid, 3-methylcrotonylglycine) arise due to impaired leucine catabolism from deficient 3-methylcrotonyl-CoA carboxylase (3-MCC), a biotin-dependent enzyme.  
2. **Abnormal circulating carnitine concentration** (secondary carnitine deficiency) occurs as carnitine conjugates with toxic metabolites (e.g., 3-methylcrotonyl-CoA) for urinary excretion, depleting free carnitine.  
3. **Aminoaciduria** may result from renal tubular dysfunction caused by accumulated metabolites or secondary mitochondrial stress.  
4. **Abnormal circulating glycine concentration** (often elevated) stems from glycine conjugation with excess organic acids (e.g., 3-methylcrotonylglycine formation), altering glycine homeostasis.  
*Note: Both terms refer to the same disorder, with the nomenclature difference reflecting gene-specific (MCCC1) vs. enzymatic classification.*"
"['Microcephaly', 'Aggressive behavior', 'Seizure', 'Intellectual disability, severe']","['Autosomal recessive primary microcephaly/Microcephaly, primary autosomal recessive, 1', 'Microcephaly 2, primary, autosomal recessive, with or without cortical malformations']","Disease: Microcephaly 2, primary, autosomal recessive, with or without cortical malformations  
Reasoning:  
1. **Severe intellectual disability and seizures** align with cortical malformations, a feature of MCPH2.  
2. **Aggressive behavior** may stem from severe neurological dysfunction linked to cortical abnormalities.  
3. MCPH2 (WDR62-related) commonly includes severe neurodevelopmental deficits and epilepsy, unlike MCPH1, which typically lacks seizures and cortical defects.  

Disease: Autosomal recessive primary microcephaly/Microcephaly, primary autosomal recessive, 1  
Reasoning:  
1. **Primary microcephaly** is a core feature of MCPH1.  
2. However, MCPH1 usually presents with **mild-to-moderate intellectual disability** and lacks seizures or cortical malformations, making it less consistent with the patient’s severe symptoms."
"['Cryptorchidism', 'Hypospadias', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Encephalopathy', 'Failure to thrive', 'Obesity', 'Death in infancy', 'Leukopenia', 'Leukocytosis', 'Hyperammonemia', 'Pyloric stenosis', 'Respiratory insufficiency', 'Hyperglycinemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Sepsis']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
1. **Metabolic Disturbances**: Hyperammonemia, hyperglycinemia, and abnormal circulating amino acids (aspartate family, alanine) align with PA's defect in propionyl-CoA carboxylase, disrupting the urea cycle and glycine metabolism.  
2. **Neurological Symptoms**: Intellectual disability, seizures, encephalopathy, and hypotonia result from toxic metabolite (propionic acid) accumulation and energy deficiency in the brain.  
3. **Gastrointestinal/Feeding Issues**: Failure to thrive, feeding difficulties, and pyloric stenosis correlate with PA-associated metabolic crises and protein intolerance.  
4. **Carnitine Abnormalities**: Abnormal carnitine levels occur due to secondary carnitine depletion from detoxification of propionyl-CoA.  
5. **Infantile/Childhood Mortality**: Neonatal death, death in infancy/childhood/adolescence reflect PA's severity, often triggered by catabolic states (e.g., infections, fasting).  
6. **Infection/Sepsis Risk**: Leukopenia/leukocytosis and sepsis susceptibility stem from metabolic-induced immunosuppression and mitochondrial dysfunction.  
7. **Congenital Anomalies**: Cryptorchidism/hypospadias may arise from prenatal metabolic stress or mitochondrial dysfunction affecting development.  
8. **Respiratory Insufficiency**: Linked to metabolic acidosis or secondary complications (e.g., cardiomyopathy).  
9. **Obesity Paradox**: May result from chronic dietary management with high-calorie, low-protein regimens.  

**Conclusion**: The constellation of metabolic derangements, neurological deficits, and early mortality strongly supports propionic acidemia, confirmed by biochemical markers (hyperammonemia, hyperglycinemia, carnitine/amino acid abnormalities)."
"['Gingival overgrowth', 'Irritability', 'Flexion contracture', 'Weight loss', 'Acidosis', 'Hyperkalemia', 'Protein-losing enteropathy', 'Hyponatremia', 'Hypoalbuminemia', 'Malnutrition', 'Pain', 'Erythematous papule', 'Cutaneous sclerotic plaque']",['Hyaline fibromatosis syndrome'],"Disease: Hyaline fibromatosis syndrome  
Reasoning:  
1. **Gingival overgrowth** and **cutaneous lesions** (erythematous papules, sclerotic plaques) are hallmark features of HFS due to abnormal hyaline deposits in connective tissues.  
2. **Flexion contractures** result from progressive joint stiffness caused by hyaline infiltration in periarticular tissues.  
3. **Protein-losing enteropathy** leads to **hypoalbuminemia**, contributing to **malnutrition**, **weight loss**, and **edema** (not listed but often associated).  
4. Electrolyte imbalances (**hyperkalemia**, **hyponatremia**, **acidosis**) may stem from renal tubular dysfunction secondary to systemic hyaline deposition.  
5. **Irritability** and **pain** correlate with chronic discomfort from skin/joint involvement and malnutrition.  
6. **HFS diagnosis** is confirmed genetically (ANTXR2 mutations) but symptomatically aligns with this rare autosomal recessive disorder."
"['Pruritus', 'Tachycardia', 'Ankle swelling', 'Weight loss', 'Lymphopenia', 'Anemia', 'Fever', 'Leukocytosis', 'Abnormality of the knee', 'Hypoalbuminemia', 'Abnormal EKG', 'Elevated circulating creatine kinase concentration', 'Myalgia', 'EMG: myopathic abnormalities', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Generalized morning stiffness', 'Increased alpha-globulin', 'Enlarged metacarpophalangeal joints', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Lower limb pain', 'Cough', 'Finger swelling', 'Antimitochondrial antibody positivity', 'Increased circulating creatine kinase MB isoform', 'Myositis', 'Abnormality of nail color', 'Increased circulating troponin T concentration']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Myositis**: Supported by myalgia, elevated creatine kinase, EMG myopathic abnormalities, and exercise intolerance.  
2. **Interstitial lung disease**: Cough and potential respiratory involvement align with antisynthetase-related ILD.  
3. **Inflammatory arthritis**: Swollen metacarpophalangeal joints, finger swelling, and morning stiffness suggest polyarthritis.  
4. **Systemic inflammation**: Fever, leukocytosis, neutrophilia, elevated ESR/CRP, and hypoalbuminemia indicate a systemic inflammatory process.  
5. **Autoimmune markers**: Antinuclear antibody (ANA) positivity is common, though antisynthetase antibodies (e.g., anti-Jo1) are pathognomonic (implied in the diagnosis).  
6. **Cutaneous features**: Erythema, pruritus, and nail abnormalities may reflect ""mechanic’s hands,"" a classic sign.  
7. **Cardiac involvement**: Elevated troponin T, CK-MB, and abnormal EKG suggest myocarditis or subclinical cardiac inflammation.  
8. **Hematologic abnormalities**: Anemia and lymphopenia are consistent with chronic inflammation.  
9. **Exclusion of mimics**: Elevated alpha-globulin and antimitochondrial antibody positivity are nonspecific but do not override the syndromic pattern.  

The triad of myositis, ILD, and inflammatory arthritis with autoimmune serology strongly supports antisynthetase syndrome."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Delayed speech/language development** and **generalized hypotonia** align with untreated PKU, where toxic phenylalanine accumulation damages the developing nervous system.  
3. **Neonatal death**, **death in infancy/childhood** may occur in severe, undiagnosed cases due to metabolic crisis or progressive neurological decline.  
4. **Abnormality of prenatal development** could reflect maternal PKU syndrome (if the mother has PKU), though this is less common in the patient’s presentation.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise from secondary metabolic disruptions or overlap with other tyrosine metabolism disorders (e.g., transient tyrosinemia of the newborn), suggesting possible comorbidities or diagnostic complexity. However, hyperphenylalaninemia remains the primary indicator.  
6. Early dietary management (phenylalanine restriction) is critical to prevent symptoms, underscoring the importance of newborn screening for PKU."
"['Hyperkeratosis', 'Hypopigmentation of the skin', 'Growth delay', 'Restrictive ventilatory defect', 'Bronchiectasis', 'Neoplasm', 'Immunodeficiency', 'Oral leukoplakia', 'Exudative retinopathy', 'Nail dystrophy', 'Subpleural honeycombing', 'Acantholysis']","['Dyskeratosis congenita, autosomal dominant 3']","Dyskeratosis congenita, autosomal dominant 3:  
The patient exhibits the classic triad of dyskeratosis congenita (DC): **oral leukoplakia**, **nail dystrophy**, and **skin abnormalities** (here, hypopigmentation and hyperkeratosis). Additional systemic features align with DC complications: **immunodeficiency** and **neoplasm** risk (due to telomere biology defects), **growth delay** (from bone marrow failure/metabolic stress), **restrictive ventilatory defect**, **bronchiectasis**, and **subpleural honeycombing** (reflecting progressive pulmonary fibrosis, a hallmark of DC). **Exudative retinopathy** and **acantholysis** are rare but reported in DC variants. The autosomal dominant subtype 3 (TINF2 mutation) often presents with severe phenotypes, including early-onset bone marrow failure and multisystem involvement, consistent with this patient’s presentation."
"['Strabismus', 'Nystagmus', 'Optic atrophy', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Ventricular septal defect', 'Hyperammonemia', 'Hyperhomocystinemia', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Elevated urinary carboxylic acid']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, **elevated urinary carboxylic acids**, and **hyperammonemia**, hallmark features of MMA caused by impaired methylmalonyl-CoA mutase activity or cobalamin metabolism. **Generalized hypotonia**, **motor delay**, **optic atrophy**, and **abnormal carnitine levels** align with MMA’s neurological and metabolic sequelae. **Death in infancy/childhood** and **neonatal death** reflect the severe, early-onset nature of the disease.  

Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning: The coexistence of **hyperhomocystinemia** with methylmalonic aciduria strongly indicates **cblC subtype**, a cobalamin metabolism defect. **Ventricular septal defect** and **abnormality of prenatal development** correlate with cblC’s systemic effects, including cardiovascular malformations. **Hyperalaninemia** and **hyperammonemia** suggest secondary urea cycle disruption, while **strabismus**, **nystagmus**, and **optic atrophy** reflect neurologic/ophthalmic damage from toxic metabolite accumulation (homocysteine, methylmalonic acid). This dual biochemical profile (MMA + homocystinuria) is pathognomonic for cblC."
"['Death in infancy', 'Increased susceptibility to fractures', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark symptom of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormal circulating tyrosine concentration** occurs because PAH converts phenylalanine to tyrosine; its deficiency reduces tyrosine synthesis, explaining low or dysregulated tyrosine levels.  
3. **Early mortality** (infancy, childhood, adolescence, etc.) aligns with untreated/severe PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
4. **Increased susceptibility to fractures** may arise secondary to chronic metabolic derangements, poor bone mineralization, or mobility issues from neurological complications.  
5. Neonatal death is atypical in classical PKU but could indicate rare malignant variants or delayed diagnosis, exacerbating metabolic crises.  

While fractures are not a primary feature of PKU, they may reflect systemic complications of prolonged untreated disease. The combination of hyperphenylalaninemia and tyrosine abnormalities strongly prioritizes PKU over other metabolic disorders (e.g., tyrosinemia)."
"['Conjunctivitis', 'Photophobia', 'Hyperkeratosis', 'Intellectual disability', 'Seizure', 'Hypertyrosinemia', 'Death in childhood', 'Epiphora']",['Tyrosinemia type 2/Tyrosine transaminase deficiency'],"Disease: Tyrosinemia type 2 (Tyrosine transaminase deficiency)  
Reasoning:  
1. **Hypertyrosinemia**: Elevated tyrosine levels are a hallmark of tyrosinemia type 2 due to deficient tyrosine transaminase, which impairs tyrosine metabolism.  
2. **Ocular symptoms (conjunctivitis, photophobia, epiphora)**: Accumulated tyrosine forms crystalline deposits in the cornea, causing inflammation, light sensitivity, and excessive tearing.  
3. **Hyperkeratosis**: Tyrosine deposits in the skin lead to painful, palmoplantar hyperkeratosis.  
4. **Neurological manifestations (intellectual disability, seizures)**: Chronic tyrosine toxicity affects CNS development and function, causing cognitive deficits and seizures.  
5. **Death in childhood**: Untreated cases may result in severe metabolic derangements or progressive neurological damage, leading to early mortality.  
The combination of dermatologic, ocular, and neurologic symptoms with confirmed hypertyrosinemia strongly supports this diagnosis."
"['Triangular face', 'Cafe-au-lait spot', 'Flexion contracture', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Short stature', 'Bone marrow hypocellularity']","['Fanconi anemia, complementation group C']","Disease: Fanconi anemia, complementation group C  
Reasoning:  
1. **Bone marrow hypocellularity**: A hallmark of Fanconi anemia (FA), reflecting progressive bone marrow failure and predisposition to aplastic anemia.  
2. **Cafe-au-lait spots**: Common in FA due to genetic instability and pigmentation abnormalities.  
3. **Intrauterine growth retardation (IUGR) & Short stature**: Growth defects align with FA’s systemic developmental impacts.  
4. **Ventricular septal defect (VSD)**: Congenital heart anomalies are frequently associated with FA.  
5. **Flexion contracture**: Skeletal abnormalities, including joint contractures, are typical in FA due to radial ray defects or connective tissue involvement.  
6. **Triangular face**: Facial dysmorphism (e.g., triangular facial shape, micrognathia) is consistent with FA’s phenotypic spectrum.  
7. **Genetic subtype (complementation group C)**: Confirmed via genetic testing (FANCC gene mutations) and chromosomal breakage assays (e.g., diepoxybutane sensitivity).  
This constellation of congenital, hematologic, and developmental features strongly supports FA complementation group C."
"['Spasticity', 'Death in infancy', 'Premature birth', 'Ileus', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased circulating ferritin concentration', 'Hypoxemia', 'Peritoneal effusion', 'Abnormal vitamin B12 level', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts fatty acid oxidation, leading to carnitine depletion as it conjugates to unmetabolized medium-chain fatty acids.  
2. **Neonatal/childhood death**: Untreated MCADD causes life-threatening hypoglycemia and metabolic crises during fasting, common in infancy/early childhood.  
3. **Spasticity & hypoxemia**: Metabolic acidosis from MCADD crises can induce neurological damage (spasticity) and respiratory compromise (hypoxemia).  
4. **Ileus & peritoneal effusion**: Secondary to metabolic instability affecting gastrointestinal function or organ dysfunction.  
5. **Premature birth**: Though not a direct feature, metabolic stress in utero might contribute to early delivery.  
6. **Abnormal vitamin B12/ferritin**: Non-specific markers of systemic metabolic disruption or organ involvement.  
7. **Decreased 3-hydroxyacyl-CoA dehydrogenase**: May reflect downstream disruption in β-oxidation due to MCAD enzyme deficiency.  

Key biochemical hallmarks (e.g., hypoketotic hypoglycemia, elevated C8-C10 acylcarnitines) are absent in the listed symptoms but inferred from clinical context. Early mortality and carnitine abnormalities strongly align with MCADD."
"['Strabismus', 'Intellectual disability', 'Encephalopathy', 'Scoliosis', 'CNS hypomyelination']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **CNS hypomyelination**: A hallmark feature of hypomyelinating leukodystrophies, directly linked to NKX6-2 mutations, which disrupt oligodendrocyte function and myelination.  
2. **Encephalopathy**: Common in leukodystrophies due to widespread white matter dysfunction and neuroinflammation.  
3. **Intellectual disability**: Reflects progressive neurological deterioration from impaired myelination and synaptic connectivity.  
4. **Strabismus**: Associated with brainstem/cranial nerve involvement, often seen in leukodystrophies affecting motor coordination pathways.  
5. **Scoliosis**: Secondary to spasticity and axial hypotonia from corticospinal tract degeneration, a feature of spastic ataxia in this disorder.  
6. **Autosomal recessive inheritance**: Matches NKX6-2-related disease etiology, requiring biallelic pathogenic variants.  

The combination of hypomyelination, neurodevelopmental regression, and motor deficits aligns precisely with NKX6-2 dysfunction, distinguishing it from other leukodystrophies (e.g., Pelizaeus-Merzbacher disease) by genetic and phenotypic specificity."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ferritin concentration']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development/birth** and **neonatal death** align with untreated PKU, as elevated phenylalanine is neurotoxic, causing severe developmental disruption if undetected postnatally.  
3. **Death in infancy/childhood** reflects historical untreated PKU outcomes due to progressive neurological damage, seizures, and failure to thrive.  
4. **Hypertyrosinemia** is atypical in classical PKU (which typically shows *low* tyrosine). This may indicate a coexisting condition (e.g., tyrosinemia type II) or secondary metabolic dysregulation from liver stress in severe PKU.  
5. **Decreased ferritin** correlates with PKU dietary management, as low-protein diets may limit iron intake, necessitating monitoring.  
6. PKU diagnosis is prioritized due to **hyperphenylalaninemia** as the pathognomonic feature; other symptoms likely stem from untreated metabolic derangements.  

*Note:* Hypertyrosinemia warrants further investigation to exclude dual diagnoses or enzyme cofactor deficiencies (e.g., tetrahydrobiopterin)."
"['Cleft palate', 'Hydrocephalus', 'Microcephaly', 'Narrow forehead', 'Micrognathia', 'Posteriorly rotated ears', 'Low-set ears', 'Recurrent otitis media', 'Prominent nasal bridge', 'Short neck', 'Broad neck', 'Downslanted palpebral fissures', 'Long eyelashes', 'Exotropia', 'Delayed speech and language development', 'Pectus excavatum', 'Shield chest', 'Adducted thumb', 'Global developmental delay', 'Growth delay', 'Decreased fetal movement', 'Talipes equinovarus', 'Overlapping toe', 'Frontal bossing', 'Constipation', 'Asthma', 'Coarse hair', 'Drooling', 'Babinski sign', 'Prominent metopic ridge', 'Wide intermamillary distance', 'Curly eyelashes', 'Abnormal cranial nerve physiology', 'Long fingers']",['Desmosterolosis/DESMOSTEROLOSIS'],"Disease: Desmosterolosis  
Reasoning:  
1. **Craniofacial Dysmorphism**: Narrow forehead, micrognathia, posteriorly rotated ears, low-set ears, prominent nasal bridge, downslanted palpebral fissures, and frontal bossing align with craniofacial features of desmosterolosis, a disorder of cholesterol biosynthesis.  
2. **Neurological Abnormalities**: Hydrocephalus, microcephaly, Babinski sign, and abnormal cranial nerve physiology reflect impaired brain development and myelination due to defective cholesterol metabolism.  
3. **Skeletal Malformations**: Adducted thumb, talipes equinovarus, pectus excavatum, and overlapping toe are consistent with skeletal defects seen in cholesterol biosynthesis disorders.  
4. **Developmental Delays**: Global developmental delay, delayed speech, and growth delay correlate with systemic impacts of desmosterol accumulation on cellular function and neurodevelopment.  
5. **Ectodermal Features**: Coarse hair, long/curly eyelashes, and recurrent otitis media (secondary to cleft palate) suggest ectodermal and structural anomalies linked to cholesterol pathway disruption.  
6. **Prenatal/Neonatal Signs**: Decreased fetal movement and congenital anomalies (e.g., cleft palate) are reported in desmosterolosis, stemming from in utero cholesterol deficiency.  
7. **Exclusion of Similar Disorders**: Overlap with Smith-Lemli-Opitz syndrome (SLOS) is ruled out by the absence of classic SLOS features (e.g., syndactyly, genital anomalies) and presence of hydrocephalus, which is more specific to desmosterolosis.  

Biochemical confirmation (elevated desmosterol) would solidify the diagnosis, but phenotypic alignment strongly supports DESMOSTEROLOSIS."
"['Conjunctivitis', 'Urticaria', 'Papilledema', 'Headache', 'Increased intracranial pressure', 'Vasculitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia']",['Muckle-Wells syndrome/Muckle-Wells syndrome'],"Disease: Muckle-Wells syndrome  
Reasoning:  
1. **Urticaria & Conjunctivitis**: Hallmark features of cryopyrin-associated periodic syndromes (CAPS), including Muckle-Wells syndrome (MWS), caused by NLRP3 gene mutations.  
2. **Systemic Inflammation**: Elevated ESR, CRP, and neutrophilia align with chronic autoinflammatory dysregulation in MWS.  
3. **Neurological Involvement**: Headache, papilledema, and increased intracranial pressure suggest meningeal inflammation, a rare but documented CNS manifestation of CAPS.  
4. **Vasculitis**: Likely secondary to systemic inflammation from IL-1β overproduction, a key cytokine driver in MWS.  
5. **Exclusion of Alternatives**: Symptoms lack specificity for other autoinflammatory diseases (e.g., FMF, TRAPS) due to the absence of serositis or prolonged fever, while urticaria and neurological signs favor MWS. Early-stage MWS may not yet exhibit amyloidosis or deafness.  

This constellation of mucocutaneous, inflammatory, and neurological symptoms strongly supports Muckle-Wells syndrome."
"['Intellectual disability', 'Motor delay', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Death in childhood', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Metabolic Pathway Disruption**: The symptoms ""abnormal circulating monocarboxylic acid concentration"" and ""elevated urinary carboxylic acid"" align with the accumulation of γ-hydroxybutyric acid (GHB) and succinic semialdehyde (SSA) due to SSADH enzyme deficiency, disrupting GABA degradation.  
2. **Neurological Manifestations**: ""Intellectual disability"" and ""motor delay"" are hallmark features of SSADHD, stemming from GABA and GHB neurotoxicity, leading to developmental delays and hypotonia.  
3. **Urinary Biomarkers**: Elevated urinary GHB (a carboxylic acid) is pathognomonic for SSADHD, explaining the ""elevated urinary carboxylic acid"" finding.  
4. **Severe Prognosis**: While death in childhood is rare, severe cases may involve intractable seizures, metabolic crises, or respiratory failure, consistent with the listed symptom.  
5. **Dysmorphic Features**: ""Abnormal facial shape"" and ""abnormal calvaria morphology"" are atypical but reported in some SSADHD cases, potentially linked to chronic metabolic stress or co-occurring genetic factors.  
6. **Exclusion of Alternatives**: Other organic acidurias (e.g., glutaric aciduria) were considered but ruled out due to the specificity of GHB elevation and lack of characteristic crises (e.g., ketoacidosis)."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Stomatitis', 'Stridor', 'Abnormal circulating glycine concentration', 'Fatigue', 'Elevated urinary carboxylic acid', 'Gangrene']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Carboxylase Deficiencies**: Decreased pyruvate carboxylase activity and propionyl-CoA carboxylase deficiency directly implicate biotin-dependent carboxylase dysfunction. Biotinidase deficiency prevents biotin recycling, critical for these enzymes.  
2. **Metabolic Acidosis & Lactate Elevation**: Impaired gluconeogenesis (pyruvate carboxylase) and disrupted citric acid cycle lead to lactic acidosis (↑ serum lactate) and metabolic acidosis. Elevated urinary carboxylic acids reflect accumulated metabolites.  
3. **Neurological Symptoms**: Lethargy, drowsiness, hypotonia, and sleep disturbance arise from biotin’s role in neuronal energy metabolism and neurotransmitter regulation.  
4. **Dermatological/Mucosal Involvement**: Stomatitis and gangrene suggest biotin deficiency, as biotin is essential for skin/mucosal integrity.  
5. **Aminoaciduria & Glycine Abnormalities**: Renal tubular acidosis (from metabolic stress) and disrupted amino acid metabolism explain aminoaciduria and abnormal glycine levels.  
6. **Fever & Infant Mortality**: Metabolic crises and susceptibility to infections (due to immune dysfunction) may cause fever. Untreated BTDD leads to fatal metabolic decompensation in infancy.  
7. **Stridor**: Neuromuscular weakness or laryngeal dysfunction secondary to metabolic encephalopathy could manifest as stridor.  
**Conclusion**: The constellation of multi-carboxylase deficiencies, metabolic acidosis, neurological/dermatological signs, and infantile lethality aligns with late-onset BTDD. Biotin supplementation would reverse symptoms if diagnosed early."
"['Hyperactivity', 'Intellectual disability', 'Delayed skeletal maturation', 'Sparse lateral eyebrow']","['Trichorhinophalangeal syndrome, type I']","Disease: Trichorhinophalangeal syndrome, type I  
Reasoning:  
1. **Sparse lateral eyebrows**: A hallmark feature of TRPS type I, linked to characteristic facial dysmorphism (e.g., thin scalp hair, bulbous nose).  
2. **Delayed skeletal maturation**: Consistent with skeletal abnormalities in TRPS type I, such as cone-shaped epiphyses in the phalanges and short stature.  
3. **Intellectual disability**: Though typically mild or absent in TRPS type I, variable expressivity may explain its presence here.  
4. **Hyperactivity**: Not a classic feature but may overlap with behavioral phenotypes in rare cases or reflect comorbid ADHD-like traits.  
5. **Exclusion of TRPS type II**: Absence of exostoses or severe intellectual disability supports type I over type II (Langer-Giedion syndrome). Genetic testing for *TRPS1* mutations would confirm the diagnosis."
"['Brachycephaly', 'Hearing impairment', 'Recurrent otitis media', 'Strabismus', 'Delayed speech and language development', 'Intellectual disability', 'Global developmental delay', 'Motor delay', 'Generalized hypotonia', 'Truncal obesity', 'Sleep disturbance', 'Scoliosis', 'Short stature', 'Midface retrusion', 'Self-injurious behavior']",['Smith-Magenis syndrome/Smith-Magenis syndrome'],"Disease: Smith-Magenis syndrome  
**Reasoning**:  
1. **Craniofacial features**: Brachycephaly (short skull) and midface retrusion align with the characteristic facial dysmorphism in Smith-Magenis syndrome (SMS).  
2. **Neurodevelopmental delays**: Global developmental delay, intellectual disability, motor delay, and speech/language delays are hallmark features of SMS, often linked to *RAI1* gene haploinsufficiency.  
3. **Behavioral phenotype**: Self-injurious behavior (e.g., head-banging, nail-pulling) is pathognomonic for SMS, alongside sleep disturbances (inverted melatonin rhythm causing fragmented sleep).  
4. **Musculoskeletal findings**: Hypotonia in infancy, scoliosis, and short stature are common due to connective tissue and skeletal involvement.  
5. **Otolaryngologic issues**: Recurrent otitis media and hearing impairment stem from craniofacial abnormalities (e.g., Eustachian tube dysfunction).  
6. **Metabolic features**: Truncal obesity emerges in late childhood/adolescence, likely due to hormonal dysregulation and behavioral factors.  
7. **Ocular involvement**: Strabismus is frequently observed in SMS due to craniofacial and neuromuscular factors.  

This constellation of symptoms, particularly the triad of developmental delay, self-injury, and circadian rhythm-driven sleep disturbances, strongly supports SMS, typically caused by a 17p11.2 deletion or *RAI1* mutation."
"['Nystagmus', 'Hypopigmentation of the skin', 'Hypopigmentation of hair']","['Oculocutaneous albinism type 3/Albinism, oculocutaneous, type III']","Disease: Oculocutaneous albinism type 3 (OCA3)  
Reasoning:  
1. **Hypopigmentation of skin and hair**: OCA3 is characterized by reduced melanin synthesis due to mutations in the *TYRP1* gene, leading to partial but not complete loss of pigmentation. This aligns with the patient’s hypopigmentation.  
2. **Nystagmus**: Ocular manifestations, including nystagmus, are common in all OCA subtypes due to impaired retinal development and misrouting of optic nerves caused by melanin deficiency.  
3. **Differentiation from other OCA subtypes**:  
   - OCA1 (tyrosinase-deficient) typically presents with complete absence of melanin (white hair, pale skin).  
   - OCA2 involves moderate pigment reduction (e.g., yellow hair in some populations).  
   - OCA3 specifically affects TYRP1, a protein stabilizing tyrosinase, resulting in milder pigment reduction (e.g., reddish-brown skin/hair in darker-skinned individuals).  
4. **Genetic confirmation**: While clinical symptoms suggest OCA3, genetic testing for *TYRP1* mutations would definitively confirm the diagnosis."
"['Microcephaly', 'Emotional lability', 'Delayed speech and language development', 'Cerebellar vermis hypoplasia', 'Overlapping toe', 'Hypoplasia of the corpus callosum', 'Polymicrogyria', 'Short stature', 'Decreased body weight', 'Neurodevelopmental delay']","['Microcephalic cortical malformations-short stature due to RTTN deficiency/Microcephaly, short stature, and polymicrogyria with or without seizures']","Disease: Microcephalic cortical malformations-short stature due to RTTN deficiency/Microcephaly, short stature, and polymicrogyria with or without seizures  
Reasoning:  
1. **Microcephaly**: A hallmark feature of RTTN deficiency, caused by defective neuronal migration and cortical development.  
2. **Polymicrogyria**: Cortical malformation directly linked to RTTN mutations, disrupting gyral patterning during brain development.  
3. **Cerebellar vermis hypoplasia & Hypoplasia of the corpus callosum**: RTTN is critical for ciliary function and midline brain structure formation, explaining these anomalies.  
4. **Short stature/Decreased body weight**: Growth retardation is common in RTTN deficiency, likely due to systemic ciliopathy effects.  
5. **Neurodevelopmental delay/Emotional lability/Delayed speech**: Consistent with widespread cerebral and cerebellar dysgenesis.  
6. **Overlapping toe**: A subtle dysmorphic feature occasionally reported in ciliopathies, supporting RTTN’s role in ciliary signaling.  
The combination of cortical malformations (polymicrogyria), microcephaly, growth deficits, and midline brain defects aligns pathognomonically with RTTN deficiency, a autosomal recessive ciliopathy."
"['Abnormality of taste sensation', 'Membranoproliferative glomerulonephritis', 'Petechiae', 'Headache', 'Fatigue']",['Immunoglobulin A vasculitis'],"Disease: Immunoglobulin A vasculitis  
Reasoning:  
1. **Petechiae**: A hallmark of IgA vasculitis (Henoch-Schönlein purpura), caused by small-vessel inflammation and IgA-mediated immune complex deposition in the skin.  
2. **Membranoproliferative glomerulonephritis (MPGN)**: While IgA nephropathy is more typical, MPGN can occur in severe IgA vasculitis due to chronic immune complex deposition in renal glomeruli, leading to histopathological overlap.  
3. **Fatigue and Headache**: Non-specific systemic symptoms linked to inflammation, cytokine release, and potential renal dysfunction.  
4. **Abnormality of taste sensation**: Likely secondary to uremia from renal impairment (due to glomerulonephritis), causing dysgeusia (metallic taste), rather than a direct feature of vasculitis.  
5. **Consistent diagnostic framework**: The triad of cutaneous vasculitis (petechiae), renal involvement, and systemic symptoms aligns with IgA vasculitis, despite atypical MPGN histology. Differential diagnoses (e.g., cryoglobulinemia, lupus nephritis) were excluded based on IgA dominance and clinical context."
"['Irritability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Opisthotonus', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Neonatal death', 'Death in childhood', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic Acidosis**: Caused by accumulation of toxic metabolites (3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid) due to defective leucine catabolism and impaired ketogenesis.  
2. **Seizures & Hypotonia**: Result from energy deficiency in the brain (lack of ketone bodies during fasting) and neurotoxicity from organic acid buildup.  
3. **Opisthotonus**: Reflects severe neurological dysfunction from metabolic crisis.  
4. **Dicarboxylic Aciduria**: Occurs due to compensatory omega-oxidation of fatty acids when ketogenesis fails, producing dicarboxylic acids.  
5. **3-Methylglutaconic Aciduria**: Secondary to enzyme deficiency, as 3-methylglutaconyl-CoA cannot be processed, leading to urinary excretion.  
6. **Elevated Urinary Carboxylic Acids**: Includes 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, pathognomonic for this disorder.  
7. **Early Mortality (Neonatal/Infancy/Childhood)**: Untreated metabolic crises cause rapid decompensation, hypoglycemia, and cerebral edema.  
8. **Irritability**: Early sign of metabolic stress during fasting or illness.  
The combination of these biochemical and clinical features distinguishes HMG-CoA lyase deficiency from other organic acidemias. Confirmatory testing involves genetic analysis of *HMGCL* or enzyme activity assays."
"['Ovarian cyst', 'Hepatic steatosis', 'Splenomegaly', 'Fever', 'Arthralgia', 'Exertional dyspnea', 'Myalgia', 'Exercise intolerance', 'Elevated circulating C-reactive protein concentration', 'Night sweats']","['Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Familial Mediterranean fever, AD']","Disease: Familial mediterranean fever; FMF (AR)  
Reasoning:  
1. **Fever and elevated CRP**: Hallmark of FMF, reflecting systemic inflammation during attacks.  
2. **Arthralgia/Myalgia**: Common musculoskeletal manifestations in FMF due to serosal inflammation.  
3. **Splenomegaly**: Occurs in severe or chronic FMF due to recurrent inflammatory insults.  
4. **Night sweats**: Associated with febrile episodes.  
5. **Exertional dyspnea/Exercise intolerance**: May stem from subclinical pleuritis (a classic FMF feature) limiting respiratory capacity.  
6. **Hepatic steatosis/Ovarian cyst**: Indirectly linked; chronic inflammation or secondary amyloidosis (a complication of untreated FMF) could contribute to hepatic involvement. Ovarian cysts are not specific but may coexist.  

Disease: Familial Mediterranean fever, AD  
Reasoning:  
1. Overlapping features (fever, arthralgia, elevated CRP) align with AD-FMF, a rare variant with similar but often milder symptoms.  
2. AD inheritance may present with atypical organ involvement (e.g., hepatic steatosis) due to differing genetic modifiers.  
3. Splenomegaly and exercise intolerance are less typical but plausible in prolonged undiagnosed cases.  
4. Requires genetic confirmation (e.g., *MEFV* heterozygous pathogenic variants with AD penetrance).  

**Conclusion**: Both AR and AD forms are plausible. AR-FMF is more likely given the classic triad (fever, serositis, elevated CRP), but AD-FMF should be considered if family history suggests dominant inheritance or genetic testing is inconclusive for biallelic mutations."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may arise secondary to liver dysfunction or metabolic decompensation in severe untreated cases, though this is rare.  
3. **Abnormality of prenatal development/birth** aligns with maternal PKU syndrome if the mother had uncontrolled hyperphenylalaninemia during pregnancy, causing teratogenic effects (e.g., microcephaly, cardiac defects) in the fetus.  
4. **Neonatal death/Death in infancy** reflects untreated PKU severity, where toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and metabolic instability, often fatal without early dietary intervention.  
5. While PKU typically presents with **low tyrosine**, confounding factors (e.g., concurrent liver impairment, transient tyrosinemia of the newborn, or laboratory variability) may explain this anomaly. The core diagnostic marker remains hyperphenylalaninemia."
"['Renal insufficiency', 'Renal cyst', 'Gout', 'Hyperuricemia', 'Elevated circulating creatinine concentration', 'Stage 5 chronic kidney disease']","['UMOD-related autosomal dominant tubulointerstitial kidney disease', 'Tubulointerstitial kidney disease, autosomal dominant, 1']","Disease: UMOD-related autosomal dominant tubulointerstitial kidney disease  
Reasoning: The patient exhibits hyperuricemia, gout, renal insufficiency, and Stage 5 CKD, which are hallmark features of UMOD-related disease. UMOD mutations impair urinary uric acid excretion, leading to hyperuricemia and early-onset gout. Progressive tubulointerstitial fibrosis causes renal cysts (often corticomedullary) and chronic kidney disease, typically advancing to end-stage renal disease (ESRD). Elevated creatinine reflects reduced glomerular filtration rate. Autosomal dominant inheritance aligns with family history (if present).  

Disease: Tubulointerstitial kidney disease, autosomal dominant, 1 (ADTKD1)  
Reasoning: ADTKD1 is a subtype of UMOD-related kidney disease. The diagnosis is confirmed by the triad of hyperuricemia/gout, progressive CKD without significant proteinuria, and renal cysts. Genetic testing for UMOD mutations would validate this. ADTKD1 manifests with slowly worsening tubulointerstitial damage, explaining the elevated creatinine and ESRD. Renal cysts in ADTKD1 are less prominent than in polycystic kidney diseases but are still a recognized feature."
"['Cryptorchidism', 'Hypertension', 'Osteoporosis', 'Lethargy', 'Spastic diplegia', 'Generalized hypotonia', 'Hyperreflexia', 'Tachycardia', 'Abnormal foot morphology', 'Anemia', 'Acute kidney injury', 'Fever', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Hyperkalemia', 'Hyperglycinemia', 'Sparse scalp hair', 'Drowsiness', 'Difficulty walking', 'Sleep disturbance', 'Spastic tetraplegia', 'Hypercalcemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Decreased methylmalonyl-CoA mutase activity', 'Hypernatremia', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Difficulty climbing stairs', 'Death in childhood', 'Abnormal circulating leucine concentration', 'Recurrent viral infections', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Atransferrinemia', 'Chronic kidney disease', 'Severe hearing impairment', 'Abnormal circulating creatine kinase concentration', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**:  
   - **Decreased methylmalonyl-CoA mutase activity** directly indicates a defect in this enzyme, a hallmark of mutase-deficient MMA.  
   - **Methylmalonic aciduria** and **hyperglycinemia** are diagnostic for MMA, resulting from impaired conversion of methylmalonyl-CoA to succinyl-CoA.  
   - **Hyperammonemia**, **hyperuricemia**, and **hyperkalemia** reflect metabolic toxicity from accumulated organic acids and disrupted urea cycle function.  

2. **Acute metabolic crises**:  
   - **Vomiting**, **lethargy**, **fever**, **drowsiness**, and **acute kidney injury** align with episodic metabolic decompensation triggered by catabolism or protein intake.  
   - **Elevated creatinine**, **increased blood urea nitrogen**, and **hypernatremia** suggest acute-on-chronic kidney dysfunction, common in MMA due to tubular toxicity from methylmalonic acid.  

3. **Chronic multisystem complications**:  
   - **Chronic kidney disease**, **hypertension**, and **osteoporosis** result from long-term renal damage and electrolyte imbalances.  
   - **Spastic diplegia/tetraplegia**, **difficulty walking/climbing stairs**, and **severe short stature** reflect neurodevelopmental impairment from toxic metabolite accumulation.  
   - **Generalized hypotonia** with **hyperreflexia** and **abnormal foot morphology** indicate mixed upper/lower motor neuron damage.  

4. **Hematologic and immune dysfunction**:  
   - **Anemia** and **atransferrinemia** may stem from chronic inflammation or renal failure.  
   - **Recurrent viral infections** suggest secondary immune dysfunction due to metabolic stress.  

5. **Abnormal amino acid/carnitine profiles**:  
   - **Abnormal leucine/isoleucine/valine** levels confirm branched-chain amino acid metabolism disruption.  
   - **Abnormal carnitine** and **creatine kinase** concentrations point to mitochondrial dysfunction and muscle injury.  

6. **Poor prognosis**:  
   - **Death in childhood/adolescence/early adulthood** is consistent with severe mutase-deficient MMA, often refractory to dietary/cofactor therapies.  

This constellation of metabolic derangements, organ damage, and neurodevelopmental deficits, anchored by confirmed enzyme deficiency and methylmalonic aciduria, definitively establishes the diagnosis."
"['Epistaxis', 'Weight loss', 'Migraine', 'Vertigo', 'Vasculitis', 'Myalgia', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Ear pain', 'Neck pain', 'Carotid artery stenosis']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vasculitis**: Takayasu arteritis is a large-vessel vasculitis, directly aligning with the patient's vasculitis diagnosis.  
2. **Carotid artery stenosis**: Inflammation in large arteries (e.g., carotids) leads to stenosis, a hallmark of Takayasu.  
3. **Elevated ESR**: Indicates systemic inflammation, consistent with active arteritis.  
4. **Weight loss, Exercise intolerance**: Systemic inflammatory responses and reduced blood flow to muscles.  
5. **Migraine, Vertigo, Neck pain**: Caused by compromised cerebral blood flow due to carotid/vertebral artery involvement.  
6. **Myalgia**: Muscle pain from ischemia or systemic inflammation.  
7. **Epistaxis, Ear pain**: Rare but possible with vascular compromise in nasal or auricular arteries.  
8. **Demographic context**: While age is unspecified, symptom clusters (vascular stenosis + systemic inflammation) are classic for Takayasu.  

Exclusion of mimics (e.g., Giant Cell Arteritis) hinges on carotid involvement and lack of temporal artery symptoms."
"['Spastic diplegia', 'Death in infancy', 'Spastic tetraplegia', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning: While dark urine (due to homogentisic acid oxidation) is a hallmark of alkaptonuria, the neurological symptoms (spastic diplegia/tetraplegia) and early mortality are atypical. Alkaptonuria primarily manifests with ochronosis, arthritis, and cardiac complications in adulthood. The listed symptoms suggest a severe neurometabolic disorder (e.g., leukodystrophy, mitochondrial disease) rather than alkaptonuria. This mismatch highlights a potential error in the provided diagnosis."
"['Cryptorchidism', 'Hypospadias', 'Microcephaly', 'Pointed chin', 'Short chin', 'Anteverted nares', 'Torticollis', 'Strabismus', 'Hypermetropia', 'Syndactyly', 'Intellectual disability', 'Hyporeflexia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Bradycardia', 'Apnea', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Polydactyly', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol metabolism abnormalities**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol, along with hypocholesterolemia, are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS) due to defective 7-dehydrocholesterol reductase.  
2. **Craniofacial and physical features**: Microcephaly, pointed/short chin, anteverted nares, syndactyly (classic 2–3 toe fusion), and polydactyly align with SLOS-associated congenital anomalies.  
3. **Urogenital abnormalities**: Cryptorchidism and hypospadias are common in SLOS.  
4. **Neurodevelopmental issues**: Intellectual disability, motor delay, generalized hypotonia, and hyporeflexia reflect impaired nervous system development linked to cholesterol deficiency.  
5. **Perinatal complications**: Premature birth, feeding difficulties, apnea, bradycardia, and early mortality (neonatal/childhood death) correlate with severe SLOS phenotypes.  
6. **Ocular and musculoskeletal findings**: Strabismus, hypermetropia, and torticollis are consistent with SLOS.  
7. **Immunological vulnerability**: Recurrent viral infections may stem from cholesterol-dependent immune dysfunction.  
8. **Biochemical confirmation**: Elevated 7- and 8-dehydrocholesterol levels confirm the diagnosis, distinguishing SLOS from other syndromic disorders with overlapping features."
"['Autistic behavior', 'Intellectual disability', 'Seizure', 'Specific learning disability', 'Cortical tubers', 'Hypomelanotic macule', 'Angiofibromas']",['Tuberous sclerosis-1'],"Disease: Tuberous sclerosis-1  
Reasoning:  
1. **Cortical tubers** and **seizures** are hallmark neurological features of tuberous sclerosis complex (TSC), caused by abnormal brain development.  
2. **Hypomelanotic macules** (ash-leaf spots) and **angiofibromas** are classic dermatological signs of TSC.  
3. **Intellectual disability**, **autistic behavior**, and **specific learning disability** align with TSC-associated neurodevelopmental disorders.  
4. The combination of neurological, cutaneous, and neuropsychiatric symptoms strongly supports a TSC diagnosis.  
5. The specified subtype ""Tuberous sclerosis-1"" corresponds to mutations in the *TSC1* gene (9q34), one of two genetic causes of TSC."
"['Hydronephrosis', 'Wide anterior fontanel', 'Coarse facial features', 'Hypertelorism', 'Narrow forehead', 'Low-set ears', 'Broad ribs', 'Abnormal fundus morphology', 'Severely reduced visual acuity', 'Seizure', 'Global developmental delay', 'Growth delay', 'Diastasis recti', 'Polyhydramnios', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Talipes equinovarus', 'Frontal bossing', 'Abdominal distention', 'Depressed nasal bridge', 'Bowing of the long bones', 'Lateral ventricle dilatation', 'Dilated third ventricle', 'Bilateral fetal pyelectasis', 'Midface retrusion', 'Severe hearing impairment']",['Schinzel-Giedion syndrome/Schinzel-Giedion midface-retraction syndrome'],"Disease: Schinzel-Giedion syndrome/Schinzel-Giedion midface-retraction syndrome  
Reasoning:  
1. **Craniofacial features**: Midface retrusion, frontal bossing, coarse facial features, hypertelorism, depressed nasal bridge, narrow forehead, and low-set ears are hallmark signs of Schinzel-Giedion syndrome (SGS). These align with the characteristic ""midface-retraction"" phenotype.  
2. **Neurological/developmental**: Global developmental delay, seizures, lateral and third ventricle dilatation (hydrocephalus), and severe sensory deficits (visual/hearing impairment) reflect SGS-associated severe neurodevelopmental abnormalities and brain malformations.  
3. **Skeletal anomalies**: Broad ribs, bowing of long bones, talipes equinovarus, and diastasis recti correlate with SGS’s skeletal dysplasia and connective tissue involvement.  
4. **Congenital organ defects**: Hydronephrosis, bilateral fetal pyelectasis, patent ductus arteriosus (PDA), and patent foramen ovale (PFO) match SGS’s association with renal, cardiac, and urogenital anomalies.  
5. **Prenatal/postnatal growth issues**: Polyhydramnios, growth delay, and abdominal distention are consistent with SGS’s prenatal onset and failure-to-thrive trajectory.  
6. **Supporting evidence**: The combination of severe midface hypoplasia, skeletal abnormalities, neurodevelopmental regression, and multi-organ involvement is pathognomonic for SGS, a disorder caused by *SETBP1* gain-of-function mutations.  

This pattern excludes other lysosomal storage disorders or skeletal dysplasias (e.g., mucopolysaccharidoses, thanatophoric dysplasia) due to the unique midface retraction and SETBP1-related phenotype."
"['Neurogenic bladder', 'Macroglossia', 'Macrocephaly', 'Coarse facial features', 'Thick eyebrow', 'Hyperthyroidism', 'Intellectual disability', 'Seizure', 'Reduced tendon reflexes', 'Absent speech', 'Developmental regression', 'Scoliosis', 'Severe muscular hypotonia', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe muscular hypotonia and reduced tendon reflexes**: Core features of TBCK syndrome, reflecting neuromuscular dysfunction.  
2. **Severe global developmental delay and intellectual disability**: Consistent with the syndrome’s hallmark neurocognitive impairments.  
3. **Coarse facial features, macrocephaly, thick eyebrows, and macroglossia**: Align with characteristic dysmorphic findings in TBCK-related disorders.  
4. **Seizures and developmental regression**: Reported in severe cases, possibly linked to progressive neurological involvement.  
5. **Neurogenic bladder and scoliosis**: Suggestive of autonomic and skeletal muscle involvement, common in neuromuscular genetic disorders.  
6. **Absent speech**: Expected in severe developmental delay associated with TBCK mutations.  
7. **Hyperthyroidism**: Atypical but may represent a comorbid condition or phenotypic expansion; primary diagnosis remains anchored to neuromuscular and dysmorphic features.  
8. **Exclusion of mimics**: Differentiated from lysosomal storage disorders (no organomegaly/ocular findings) and Rett syndrome (no regression pattern or typical hand stereotypies). Genetic testing for TBCK mutations would confirm."
"['Jaundice', 'Pruritus', 'Cholestasis', 'Hepatosplenomegaly', 'Growth delay', 'Abnormal heart morphology', 'Abnormality of coagulation', 'Hepatomegaly', 'Scoliosis', 'Conjugated hyperbilirubinemia', 'Abnormal circulating amino acid concentration', 'Increased total bilirubin', 'Abnormal immunoglobulin level', 'Increased serum bile acid concentration', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration', 'Pointed helix']","['Progressive familial intrahepatic cholestasis type 4', 'Cholestasis, progressive familial intrahepatic 4']","Disease: Progressive familial intrahepatic cholestasis type 4 (PFIC4)  
Reasoning:  
1. **Cholestasis and conjugated hyperbilirubinemia**: Core features of PFIC4, caused by impaired bile secretion due to TJP2 gene mutations.  
2. **Jaundice, pruritus, elevated serum bile acids**: Direct consequences of bile acid accumulation in the liver and bloodstream.  
3. **Hepatosplenomegaly/hepatomegaly**: Reflects chronic liver injury and fibrosis, common in progressive cholestatic disorders.  
4. **Growth delay**: Malabsorption of fat-soluble vitamins and nutrients due to cholestasis.  
5. **Abnormal coagulation**: Liver dysfunction reduces synthesis of clotting factors (e.g., vitamin K-dependent factors).  
6. **Elevated AST/ALT**: Indicates hepatocellular damage secondary to cholestasis and inflammation.  
7. **Abnormal immunoglobulin levels**: Chronic hepatic inflammation may dysregulate immune protein production.  
8. **Pointed helix, scoliosis, cardiac anomalies**: TJP2 mutations can affect cell polarity in extrahepatic tissues, leading to congenital structural abnormalities.  
9. **Exclusion of other PFIC subtypes**: PFIC4 is distinguished by early-onset cholestasis, TJP2 variants, and variable extrahepatic features (unlike ATP8B1-/ABCB11-related PFIC1/2).  

Disease: Cholestasis, progressive familial intrahepatic 4 (synonym for PFIC4)  
Reasoning:  
- This term is interchangeable with PFIC4, reflecting the same genetic etiology (TJP2 mutations) and clinical profile. The symptoms align with the OMIM classification (OMIM #615878) for this autosomal recessive disorder."
"['Microcephaly', 'Nystagmus', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Cerebral atrophy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']","['Hyperphenylalaninemia; HPA', 'Dihydropteridine reductase deficiency/Hyperphenylalaninemia, bh4-deficient, C']","Disease: Dihydropteridine reductase deficiency/Hyperphenylalaninemia, bh4-deficient, C  
Reasoning:  
1. **Hyperphenylalaninemia (HPA)** is present, but the co-occurrence of **hypertyrosinemia** suggests a BH4 deficiency. In classic HPA (e.g., PKU), tyrosine is typically low due to impaired phenylalanine conversion, whereas BH4 deficiencies disrupt both phenylalanine metabolism **and** tyrosine hydroxylase activity, leading to tyrosine accumulation.  
2. **Neurological severity**: Symptoms like seizures, cerebral atrophy, abnormal white matter, motor delay, and intellectual disability align with BH4 deficiency’s impact on neurotransmitter synthesis (dopamine/serotonin), causing profound neurological deterioration.  
3. **Early mortality**: Neonatal death or death in childhood is characteristic of untreated BH4 deficiencies due to refractory seizures and neurodevelopmental collapse.  
4. **Alopecia**: Linked to tyrosine metabolism dysfunction affecting melanin production, a feature seen in BH4 disorders.  
5. **Generalized hypotonia** and **abnormality of prenatal development** further support a congenital metabolic disorder affecting multiple pathways.  

Disease: Hyperphenylalaninemia; HPA  
Reasoning:  
1. **Hyperphenylalaninemia** is explicitly listed, indicating impaired phenylalanine metabolism.  
2. However, the absence of dietary management history and the presence of **hypertyrosinemia** make classic HPA (e.g., PKU) less likely. This diagnosis is included due to the explicit mention of HPA in the symptoms, but it likely represents a secondary finding tied to the primary BH4 deficiency.  
3. Symptoms like intellectual disability and seizures are nonspecific and overlap with both conditions, but the broader context favors BH4 deficiency as the root cause."
"['Macrocephaly', 'Delayed speech and language development', 'Obesity', 'Death in infancy', 'Premature birth', 'Glutaric aciduria', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating lysine concentration', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Hypoxemia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** and **hyperalaninemia** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly** often develops due to abnormal brain metabolism and fluid accumulation (e.g., subdural effusions), a classic early sign of GA-I.  
3. **Delayed speech/language development** reflects neurological damage from metabolic crises, typically triggered by catabolic stressors (e.g., infections), causing striatal injury.  
4. **Abnormal circulating lysine concentration** and **elevated plasma citrulline** align with disrupted lysine and tryptophan metabolism, while **abnormal carnitine levels** result from secondary carnitine depletion from detoxification of toxic metabolites.  
5. **Neonatal death**, **death in infancy/childhood**, and **hypoxemia** correlate with acute metabolic decompensation (e.g., encephalopathic crises, rhabdomyolysis, or cardiac complications) if untreated.  
6. **Hypervalinemia** and **obesity** may reflect secondary metabolic disturbances or comorbidities, though they are less specific to GA-I.  
7. **Premature birth** is not directly linked to GA-I but could contribute to symptom severity due to metabolic immaturity.  

The constellation of neurodevelopmental, biochemical, and acute metabolic features strongly supports GA-I as the primary diagnosis."
"['Hepatic steatosis', 'Elevated hepatic transaminase', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased circulating copper concentration']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Hepatolenticular degeneration; Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin concentration** and **increased urinary copper concentration** are hallmark biochemical features of Wilson disease, caused by mutations in the *ATP7B* gene, impairing copper transport and biliary excretion.  
2. **Hepatic steatosis** and **elevated hepatic transaminase** reflect copper accumulation in the liver, leading to hepatocyte injury and fatty degeneration.  
3. **Decreased circulating copper concentration** occurs paradoxically due to reduced ceruloplasmin (a copper-binding protein), despite systemic copper overload.  
4. **Abnormal circulating aspartate family amino acids** and **alanine** may arise from secondary mitochondrial dysfunction or liver damage disrupting amino acid metabolism.  
5. **Hyperphenylalaninemia** could result from hepatic insufficiency impairing phenylalanine hydroxylase activity, though this is atypical and suggests severe liver involvement.  
6. **Death in childhood** aligns with early-onset Wilson disease variants presenting as acute liver failure, a rapid and fatal manifestation without timely intervention.  
The constellation of copper metabolism derangements, liver pathology, and ceruloplasmin deficiency strongly supports Wilson disease as the diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: While PKU itself does not directly cause structural birth defects, untreated maternal PKU during pregnancy can result in congenital abnormalities (e.g., microcephaly, cardiac defects) in the fetus. This suggests possible maternal PKU contributing to prenatal developmental issues.  
3. **Neonatal death/Death in infancy**: Severe untreated PKU can cause rapid neurological deterioration, seizures, and metabolic instability. In extreme cases, acute complications (e.g., metabolic crises) or secondary infections due to failure to thrive may lead to early mortality.  
4. The combination of hyperphenylalaninemia and early lethality strongly aligns with a classic or severe PKU phenotype, emphasizing the critical need for newborn screening and dietary intervention to prevent outcomes."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death** and **death in infancy/childhood/adolescence** align with untreated PKU, where severe neurological damage, seizures, and organ failure occur due to metabolic toxicity.  
3. **Obesity** may arise from restrictive dietary management (low-protein, high-carbohydrate diets) or metabolic dysregulation in poorly controlled cases.  
4. **Abnormality of prenatal development** is atypical for PKU itself but could reflect maternal PKU syndrome (if the mother had untreated PKU during pregnancy), causing congenital anomalies in the offspring.  
5. The progression to early mortality underscores delayed diagnosis or lack of newborn screening, preventing timely dietary intervention to lower phenylalanine levels.  

Key confirmation requires genetic testing for *PAH* mutations and blood phenylalanine monitoring. Early treatment prevents severe outcomes, but untreated cases match the fatal trajectory described."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine. This aligns with the patient’s lab findings.  
2. **Abnormality of prenatal development/birth** and **neonatal death** may reflect *maternal PKU syndrome* (if the mother had untreated PKU during pregnancy), causing congenital anomalies (e.g., microcephaly, cardiac defects) in the infant.  
3. **Death in infancy/childhood/adolescence** correlates with untreated PKU progression: severe neurological damage, seizures, and organ failure due to phenylalanine toxicity. Without early dietary intervention, fatal outcomes are likely.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are typically low). This may suggest a co-occurring condition (e.g., tyrosinemia type II) or transient neonatal tyrosinemia, but PKU remains primary due to hyperphenylalaninemia.  
5. The absence of tyrosine hydroxylase cofactors (e.g., BH4 deficiency) could exacerbate metabolic dysregulation, though this is a PKU subtype.  

**Conclusion**: PKU is confirmed by hyperphenylalaninemia and clinical progression. Early mortality and prenatal abnormalities reflect untreated/severe disease. Hypertyrosinemia warrants further investigation but does not override the PKU diagnosis."
"['Generalized hypotonia', 'Death in infancy', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Methylmalonic aciduria is a cardinal biochemical marker of MMA, directly indicating impaired metabolism of methylmalonyl-CoA. Generalized hypotonia aligns with metabolic energy deficits in MMA, while neonatal death and death in infancy reflect the severe, early-onset phenotype of the disorder due to toxic metabolite accumulation and metabolic crises.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The B12-unresponsive subtype specifically implicates mutations in the *MUT* gene encoding methylmalonyl-CoA mutase. Neonatal lethality and lack of response to B12 supplementation distinguish this form from B12-responsive variants. The absence of improvement with B12 therapy exacerbates metabolic instability, leading to rapid clinical decline and early mortality."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD is an autosomal recessive disorder caused by mutations in the *ACADM* gene, which may manifest as subtle prenatal or neonatal metabolic instability.  
2. **Death in infancy/Neonatal death**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to hypoketotic hypoglycemia and metabolic crises during fasting. Untreated, this can rapidly progress to coma, seizures, or sudden death in infancy.  
3. **Abnormal circulating carnitine concentration**: MCADD causes secondary carnitine deficiency due to urinary loss of acylcarnitine adducts (e.g., C8, C10:1), while elevated medium-chain acylcarnitines (C6-C10) on newborn screening are pathognomonic.  
4. **Key biochemical correlation**: The combination of hypoglycemia, low free carnitine (C0), and elevated C8/C10:1 acylcarnitines strongly supports MCADD, distinguishing it from other fatty acid oxidation disorders."
"['Cleft palate', 'Spatulate thumbs', 'Congenital hip dislocation', 'Talipes equinovarus', 'Vertebral fusion', 'Elbow dislocation', 'Tapered humerus', 'Short stature', 'Congenital knee dislocation', 'Vertebral arch anomaly', 'Midface retrusion', 'Abnormal bone ossification']",['Larsen syndrome/Larsen syndrome'],"Disease: Larsen syndrome  
Reasoning:  
1. **Congenital joint dislocations** (hip, knee, elbow) are hallmark features of Larsen syndrome, caused by connective tissue abnormalities.  
2. **Cleft palate** and **midface retrusion** align with craniofacial manifestations commonly seen in the syndrome.  
3. **Spatulate thumbs** and **talipes equinovarus** are characteristic limb anomalies associated with Larsen syndrome.  
4. **Vertebral fusion** and **vertebral arch anomaly** reflect spinal malformations, a key diagnostic criterion.  
5. **Tapered humerus** and **abnormal bone ossification** correlate with skeletal dysplasia observed in the disorder.  
6. **Short stature** is consistent with systemic skeletal involvement.  
The combination of craniofacial, spinal, joint, and limb anomalies strongly supports the diagnosis."
"['Autistic behavior', 'Delayed speech and language development', 'Intellectual disability', 'Absent speech', 'Sleep apnea', 'Enuresis nocturna']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Core neurodevelopmental symptoms**: Autistic behavior, delayed speech/absent speech, and intellectual disability are hallmark features of NEDBEH, a disorder linked to DIDO1 gene mutations. These align with its characteristic developmental delays.  
2. **Sleep apnea**: Could reflect brainstem dysfunction or structural airway anomalies, which fall under the ""brain anomalies"" spectrum of NEDBEH.  
3. **Enuresis nocturna**: Often secondary to neurodevelopmental delays in bladder control maturation, consistent with global intellectual disability.  
4. **Absence of specified eye/heart anomalies**: The diagnosis accommodates presentations without these features, focusing on the neurodevelopmental core.  
5. **Exclusion of mimics**: Symptoms collectively fit NEDBEH better than isolated autism spectrum disorder or other syndromic intellectual disabilities due to the combination with sleep-disordered breathing."
"['Xerostomia', 'Irregular menstruation', 'Keratoconjunctivitis sicca', 'Leukopenia', 'Diarrhea', 'Reduced haptoglobin level', 'Autoimmune antibody positivity']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus', 'Primary Sjögren syndrome/Sjogren syndrome']","Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning: Xerostomia and keratoconjunctivitis sicca are hallmark symptoms of Sjögren syndrome, directly reflecting exocrine gland dysfunction. Autoimmune antibody positivity (e.g., anti-SSA/Ro or anti-SSB/La) supports this diagnosis. While leukopenia and reduced haptoglobin suggest systemic involvement, these can occur in Sjögren syndrome due to secondary autoimmune processes or overlap with other conditions.  

Disease: Systemic lupus erythematosus  
Reasoning: Leukopenia, autoimmune antibody positivity (e.g., ANA, anti-dsDNA), and reduced haptoglobin (indicating potential hemolytic anemia) align with SLE diagnostic criteria (SLICC or ACR). Irregular menstruation may reflect SLE-related hormonal or inflammatory effects. Diarrhea could stem from autoimmune enteritis or vasculitis, though further evaluation is needed. While sicca symptoms suggest Sjögren overlap, SLE is prioritized due to broader systemic features.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: If genetic testing reveals variants in *ITGAM* or other loci linked to SLE susceptibility 6, this could explain predisposition. However, clinical diagnosis of SLE is already supported by symptoms, making this a secondary genetic risk annotation rather than a primary diagnosis.  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: This applies if vitiligo is present (unstated here) and polyautoimmunity is confirmed. Current symptoms lack vitiligo-specific features, making this less likely unless additional findings are reported.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: Pediatric SLE is considered if the patient is under 18, but age is unspecified. Symptoms overlap with adult SLE, so this diagnosis is conditional on demographic context.  

Disease: Systemic lupus erythematosus 16  
Reasoning: This refers to a specific genetic susceptibility locus (e.g., *TNFAIP3*). Like susceptibility 6, it requires genetic confirmation and does not replace the clinical diagnosis of SLE.  

**Final Prioritization**: Primary Sjögren syndrome and Systemic lupus erythematosus are the most clinically relevant diagnoses based on symptoms and criteria. Overlap syndrome (SLE-Sjögren) should be considered if both sets of criteria are fully met. Genetic susceptibilities (e.g., SLE 6/16) are secondary findings."
"['Ataxia', 'Dysarthria', 'Cerebellar atrophy', 'Dysmetria', 'Babinski sign']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Ataxia, Dysmetria, Cerebellar atrophy**: Core features of cerebellar dysfunction, directly aligning with the syndrome’s progressive cerebellar degeneration.  
2. **Dysarthria**: Commonly associated with cerebellar pathology, consistent with impaired motor coordination of speech.  
3. **Babinski sign**: Indicates upper motor neuron involvement, which may reflect broader neurological dysfunction in the syndrome, including potential spinal cord or pyramidal tract abnormalities.  
4. **Syndrome-specific context**: While pancytopenia (a hallmark of the disorder) is not explicitly listed here, the combination of cerebellar and pyramidal signs strongly suggests a systemic genetic etiology like SAMD9L-related Ataxia-pancytopenia syndrome, which integrates neurological and hematological manifestations. Further hematological evaluation (e.g., CBC) would confirm pancytopenia to solidify the diagnosis."
"['Irritability', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Hyperglycinemia', 'Opisthotonus', 'Methylmalonic acidemia', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Abnormal circulating creatinine concentration', 'Methylmalonic aciduria', 'Abnormality of vitamin D metabolism', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: The patient exhibits **methylmalonic acidemia**, **methylmalonic aciduria**, and **decreased methylmalonyl-CoA mutase activity**, which are pathognomonic for this disorder. Methylmalonyl-CoA mutase deficiency directly impairs propionate metabolism, leading to toxic metabolite accumulation.  
2. **Metabolic derangements**: **Hyperammonemia**, **metabolic acidosis**, and **hyperglycinemia** arise due to disrupted urea cycle function and secondary inhibition of glycine cleavage systems by accumulated methylmalonic acid.  
3. **Neurological features**: **Opisthotonus**, **motor delay**, and **intellectual disability** reflect neurotoxicity from elevated methylmalonic acid, ammonia, and glycine. **Irritability** and **feeding difficulties** are early signs of metabolic decompensation.  
4. **Systemic complications**: **Abnormal carnitine/creatinine levels** and **hypervalinemia** occur due to secondary mitochondrial dysfunction and amino acid metabolism disturbances. **Abnormal vitamin D metabolism** may stem from chronic renal tubular damage.  
5. **Clinical trajectory**: **Neonatal death**, **death in infancy**, and **death in early adulthood** align with severe, treatment-resistant forms of mutase-deficient MMA. B12-unresponsiveness is confirmed by persistent enzyme deficiency despite B12 cofactor availability.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Diagnostic confirmation**: The presence of **methylmalonic acidemia** and **methylmalonic aciduria** in symptomology meets the biochemical criteria for MMA.  
2. **Subtype differentiation**: While overlapping with the mutase-deficient form, this broader diagnosis encompasses all MMA subtypes (e.g., cblA, cblB). However, **decreased methylmalonyl-CoA mutase activity** specifically localizes the defect to the mutase enzyme itself.  
3. **Symptom constellation**: **Hyperammonemia**, **acidosis**, **hyperglycinemia**, and **opisthotonus** collectively form the classic MMA phenotype, distinct from other organic acidemias.  
4. **Prognostic markers**: Early lethality (**neonatal/infant death**) and multisystem involvement (**abnormal carnitine**, **vitamin D metabolism**) reflect disease severity typical of MMA."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by mutations in the *PAH* gene, impairing phenylalanine hydroxylase activity, leading to phenylalanine accumulation.  
2. **Abnormal circulating tyrosine concentration**: Reduced conversion of phenylalanine to tyrosine results in low tyrosine levels, aligning with ""abnormal tyrosine concentration.""  
3. **Prenatal developmental abnormalities**: Untreated maternal PKU during pregnancy can cause fetal toxicity (microcephaly, congenital heart defects), explaining prenatal anomalies in the patient.  
4. **Neonatal death/Death in infancy**: Severe untreated PKU causes profound neurological damage, seizures, and failure to thrive, which may lead to early mortality without dietary intervention.  
5. **Death in early adulthood**: Chronic complications (e.g., neurocognitive decline, organ damage) from lifelong phenylalanine toxicity, even with partial treatment, may contribute to premature mortality.  

Conclusion: The constellation of hyperphenylalaninemia, tyrosine imbalance, and early mortality aligns with untreated or poorly managed PKU. Maternal PKU syndrome may explain prenatal abnormalities if the mother had uncontrolled phenylalanine levels during gestation."
"['Coma', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Hyperammonemia', 'Respiratory distress', 'Cerebral edema', 'Fasciculations', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating citrulline concentration']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic Citrullinemia)  
Reasoning:  
1. **Hyperammonemia** and **metabolic acidosis** are hallmark features of urea cycle disorders (UCDs). Citrullinemia type I results from **argininosuccinate synthetase (ASS) deficiency**, disrupting the urea cycle.  
2. **Abnormal circulating citrulline concentration** (severely elevated) directly reflects the enzyme defect, as citrulline cannot be converted to argininosuccinate.  
3. **Abnormal glutamine** (elevated) and **aspartate family amino acids** (disrupted) align with urea cycle dysfunction, as glutamine acts as an ammonia buffer.  
4. **Cerebral edema** and **coma** are secondary to ammonia neurotoxicity. **Respiratory distress** may arise from ammonia-induced central hyperventilation or metabolic acidosis compensation.  
5. **Generalized hypotonia**, **hyporeflexia**, and **fasciculations** reflect acute neurological injury from hyperammonemia.  
6. **Neonatal death** and **death in infancy** are typical in untreated classic citrullinemia due to rapid ammonia accumulation and multiorgan failure.  
7. **Prolonged PTT** and **increased bilirubin** suggest hepatic dysfunction, a known complication of UCDs.  
8. **Tachycardia** and **metabolic acidosis** correlate with systemic metabolic decompensation.  

The absence of liver-specific markers (e.g., citrin deficiency in type II) and the neonatal presentation confirm **Citrullinemia type I**."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically does not cause structural birth defects, maternal fatty acid oxidation disorders (e.g., in an undiagnosed mother) may indirectly affect fetal energy supply, potentially leading to intrauterine distress.  
2. **Death in infancy/Neonatal death/Death in childhood**: MCADD causes an inability to metabolize medium-chain fatty acids during fasting. Neonates/children with MCADD are at high risk of hypoketotic hypoglycemia, metabolic acidosis, and encephalopathy triggered by catabolic states (e.g., infections, prolonged fasting), leading to sudden death if untreated.  
3. **Decreased plasma free carnitine**: MCADD results in accumulation of medium-chain acylcarnitines (e.g., C6-C10), which are renally excreted, depleting free carnitine. This contrasts with long-chain fatty acid oxidation defects where carnitine is often normal or elevated.  
4. **Diagnostic confirmation**: Elevated C6-C10 acylcarnitines on newborn screening or plasma acylcarnitine analysis, combined with genetic testing confirming *ACADM* gene mutations, solidify the diagnosis. Early intervention with fasting avoidance and emergency protocols prevents mortality."
"['Large fontanelles', 'Parietal bossing', 'Hypertelorism', 'Delayed eruption of primary teeth', 'Narrow chest', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Disease: Cleidocranial dysplasia  
Reasoning:  
1. **Cranial/Facial Features**:  
   - **Large fontanelles**, **frontal/parietal bossing**, **metopic depression**, and **midface retrusion** indicate defective membranous bone ossification, a hallmark of CCD due to *RUNX2* gene mutations.  
   - **Hypertelorism** and **depressed nasal bridge** align with midface hypoplasia characteristic of CCD.  
   - **Wormian bones** (extra sutural bones) further support calvarial dysplasia.  

2. **Dental Abnormalities**:  
   - **Delayed eruption of primary teeth** and **enamel hypoplasia** result from impaired osteoblast differentiation and abnormal dental follicle development.  

3. **Clavicular/Skeletal Defects**:  
   - **Short clavicles** (or aplasia) explain **abnormal facility in opposing the shoulders** and **narrow chest**.  
   - **Hypoplastic iliac wings**, **delayed pubic bone ossification**, **broad femoral head**, and **short femoral neck** reflect pelvic and long bone dysplasia.  

4. **Growth and Axial Skeleton**:  
   - **Short stature** and **scoliosis** stem from generalized skeletal involvement.  

5. **Exclusion of Alternatives**:  
   - Overlap with hypophosphatasia or osteogenesis imperfecta is excluded by the absence of biochemical abnormalities (e.g., low alkaline phosphatase) or fragility fractures.  

This constellation of craniofacial, dental, clavicular, and pelvic abnormalities is pathognomonic for cleidocranial dysplasia."
"['Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: The hallmark symptom of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Neonatal death/Death in infancy**: Severe, untreated PKU can lead to rapid neurological deterioration and metabolic crisis, particularly in rare cases with near-complete PAH deficiency.  
3. **Premature birth**: Maternal PKU syndrome (untreated phenylalanine elevation during pregnancy) may cause fetal complications like prematurity, though the infant’s own PKU diagnosis explains hyperphenylalaninemia.  
4. **Hypertyrosinemia**: Atypical for classic PKU (where tyrosine is typically low). May reflect secondary liver dysfunction, transient neonatal tyrosinemia, or a coexisting metabolic disturbance, but does not exclude PKU as the primary diagnosis.  

Key evidence prioritizes hyperphenylalaninemia and clinical severity, aligning with PKU despite atypical tyrosine elevation. Early demise underscores untreated metabolic dysfunction."
"['Nephritis', 'Failure to thrive', 'Growth delay', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid']",['Hawkinsinuria/Hawkinsinuria'],"Disease: Hawkinsinuria  
Reasoning:  
1. **Abnormal Tyrosine Metabolism**: The presence of abnormal circulating tyrosine concentration suggests a defect in tyrosine catabolism, a hallmark of Hawkinsinuria.  
2. **Urinary Carboxylic Acid Elevation**: Elevated urinary carboxylic acids (specifically hawkinsin, a cyclic keto-enol ether derived from 4-hydroxyphenylpyruvate) are pathognomonic for this disorder.  
3. **Infantile Presentation**: Symptoms like vomiting, diarrhea, failure to thrive, and growth delay align with metabolic crises in infancy caused by tyrosine derivative accumulation.  
4. **Renal Involvement**: Nephritis may arise due to tubular damage from toxic metabolites, though this is less common and typically milder compared to other tyrosine metabolism disorders.  
5. **Severity Spectrum**: Death in infancy is rare but reported in severe, untreated cases due to metabolic acidosis or complications from chronic renal dysfunction.  
6. **Exclusion of Other Tyrosinemias**: Unlike tyrosinemia types I/II, Hawkinsinuria lacks severe liver dysfunction or neurological symptoms, focusing the diagnosis on urinary hawkinsin excretion and milder clinical progression."
"['Hyperhidrosis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Elevated circulating alkaline phosphatase concentration', 'Ethylmalonic aciduria', 'Hypertyrosinemia', 'Hyperalaninemia', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating carnitine concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule', 'Abnormal circulating creatine kinase concentration']","['Short chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, short-chain, deficiency of']","Disease: Short chain acyl-CoA dehydrogenase deficiency (SCADD)  
Reasoning:  
1. **Ethylmalonic aciduria**: A hallmark of SCADD due to impaired short-chain fatty acid oxidation, leading to ethylmalonic acid accumulation.  
2. **Abnormal carnitine levels**: Secondary carnitine deficiency occurs as carnitine conjugates with unmetabolized acyl-CoA intermediates for excretion.  
3. **Hypertyrosinemia/Hyperalaninemia**: Disrupted mitochondrial energy metabolism may impair amino acid processing.  
4. **Elevated alkaline phosphatase**: Reflects hepatic stress or cholestasis, common in metabolic crises.  
5. **Generalized hypotonia/Neonatal death**: Results from energy deficiency in muscles/organs during metabolic decompensation.  
6. **Skin manifestations (rash, plaques)**: Toxic metabolite buildup may induce inflammatory skin reactions.  
7. **Hyperhidrosis**: Compensatory mechanism for thermoregulation during metabolic stress.  
8. **Abnormal CK levels**: Muscle breakdown from energy deficiency in myocytes.  
9. **Prenatal/Infantile lethality**: Severe SCADD manifests early due to critical dependence on fatty acid oxidation post-birth.  

The combination of ethylmalonic aciduria, carnitine abnormalities, and neonatal metabolic crisis aligns pathognomonically with SCADD."
"['Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Neurological symptoms**: Delayed speech, hyperactivity, intellectual disability, and seizures align with SSADHD, a disorder disrupting GABA metabolism, leading to neurodevelopmental deficits.  
2. **Metabolic markers**: Decreased plasma free carnitine and elevated urinary carboxylic acids (e.g., 4-hydroxybutyric acid) are pathognomonic for SSADHD due to impaired GABA degradation.  
3. **Hypotonia and mortality**: Generalized hypotonia reflects neuromuscular dysfunction from metabolite accumulation. Early death, though rare, may occur in severe cases due to metabolic crises or refractory seizures.  
4. **Monocarboxylic acid abnormalities**: Elevated GHB (a monocarboxylic acid) in blood/urine directly results from succinic semialdehyde dehydrogenase enzyme deficiency.  
5. **Exclusion of mimics**: Symptoms collectively rule out other organic acidurias (e.g., glutaric aciduria) by specific biochemical profile (GHB elevation, carnitine depletion)."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by abnormal glycosylation critical for cerebellar development and function.  
2. **Ataxia and motor delay**: Directly linked to cerebellar dysfunction and neurodevelopmental deficits.  
3. **Intellectual disability**: Reflects global neurological impairment due to glycosylation defects affecting brain development.  
4. **Strabismus**: Common in PMM2-CDG due to oculomotor control abnormalities from cerebellar/brainstem involvement.  
5. **Thromboembolism**: Coagulation factor glycosylation defects (e.g., antithrombin III deficiency) predispose to thrombotic events.  
6. **Obesity**: Observed in some cases, potentially from hypothalamic-pituitary dysfunction or metabolic dysregulation.  
7. **Death in infancy/childhood**: Severe multisystemic involvement (liver failure, cardiomyopathy, infections) can lead to early mortality.  
8. **Supporting specificity**: The combination of neurodevelopmental, cerebellar, and coagulation abnormalities is pathognomonic for PMM2-CDG-Ia, distinguishing it from other CDG subtypes."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Dicarboxylic aciduria', 'Neonatal death', 'Feeding difficulties']",['Glycogen storage disease Ia/Glycogen storage disease Ia'],"Disease: Glycogen storage disease Ia  
Reasoning:  
1. **Metabolic Acidosis & Dicarboxylic Aciduria**: In GSD Ia, glucose-6-phosphatase deficiency prevents glucose release from glycogenolysis, forcing reliance on fatty acid oxidation. Inefficient β-oxidation generates dicarboxylic acids (e.g., adipic, suberic acids), excreted in urine (dicarboxylic aciduria). Anaerobic glycolysis due to hypoglycemia also elevates lactate, worsening acidosis.  
2. **Hypoglycemia-Driven Symptoms**: Severe fasting hypoglycemia triggers seizures and feeding difficulties. Chronic energy deprivation causes generalized hypotonia.  
3. **Neonatal/Infantile Fatality**: Without glucose homeostasis, recurrent metabolic crises (acidosis, hypoglycemia) lead to organ failure or fatal arrhythmias, often resulting in neonatal death or death in infancy if untreated.  
4. **Exclusion of Alternatives**: While fatty acid oxidation disorders (e.g., MCAD) also cause dicarboxylic aciduria, the triad of hypoglycemia, acidosis, and hepatic dysfunction (implied by feeding difficulties) aligns with GSD Ia. Hepatomegaly (common in GSD Ia) may not be listed but is often clinically present.  

This pathophysiological cascade confirms Glycogen storage disease Ia as the diagnosis."
"['Polycystic ovaries', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Hypertyrosinemia', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood', 'Pustule']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Skin rash** and **eczematoid dermatitis** align with PKU’s dermatologic manifestations due to metabolite accumulation and impaired skin barrier function.  
3. **Gastrointestinal inflammation**, **vomiting**, and **diarrhea** may reflect dietary protein intolerance or metabolic stress from phenylalanine toxicity.  
4. **Generalized hypotonia** and **obesity** correlate with untreated PKU’s neurologic sequelae and restrictive dietary management (high-carbohydrate diets).  
5. **Recurrent viral infections** could stem from secondary immune dysfunction due to chronic metabolic imbalance.  
6. **Death in infancy/childhood/adolescence/early adulthood** reflects untreated PKU’s natural history, involving severe neurodegeneration, organ failure, or complications like seizures.  
7. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or coexisting metabolic stressors.  
8. **Polycystic ovaries** and **pustules** are less specific but may arise from hormonal disruptions or inflammatory responses linked to chronic metabolic derangement.  

Note: While some symptoms (e.g., hypertyrosinemia) suggest overlap with tyrosinemia or BH4 deficiency, the definitive diagnosis of PKU is prioritized due to **hyperphenylalaninemia** as the central finding. Early fatality timelines emphasize untreated/severe disease progression."
"['Microcephaly', 'Exotropia', 'Intellectual disability', 'Seizure', 'Dysarthria', 'Hypoglycemia', 'Hyperammonemia', 'Myopathic facies', 'Apnea', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Developmental regression', 'Myoglobinuria', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Babinski sign', 'Hyperactive deep tendon reflexes', 'obsolete Loss of ability to walk', 'Focal-onset seizure', 'Arrhythmia', 'Arrhythmia']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
- **Metabolic disturbances**: Hypoglycemia and hyperammonemia indicate systemic metabolic dysfunction, consistent with recurrent crises.  
- **Neuromuscular involvement**: Myopathic facies, dysarthria, elevated creatine kinase, myoglobinuria, and rhabdomyolysis suggest severe muscle pathology.  
- **Cardiac arrhythmias**: Repeated mention of arrhythmias highlights cardiac involvement, a hallmark of this syndrome.  
- **Neurological regression**: Developmental regression, seizures (focal-onset, febrile), intellectual disability, Babinski sign, hyperactive reflexes, and loss of ambitation point to progressive neurodegeneration.  
- **Encephalopathic features**: Apnea, microcephaly, and exotropia align with central nervous system deterioration.  
- **Recurrent crises**: The cyclical nature of rhabdomyolysis, metabolic derangements, and neurological decline matches the syndrome’s phenotype of episodic metabolic encephalomyopathy.  
- **Exclusion of mimics**: The combination of hyperammonemia, hypoglycemia, arrhythmias, and rhabdomyolysis distinguishes this from isolated mitochondrial disorders or fatty acid oxidation defects."
"['Seizure', 'Lethargy', 'Hyperreflexia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Death in childhood', 'Abnormal circulating ornithine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **vomiting** are hallmark features of urea cycle disorders (UCDs), including OTCD, due to impaired ammonia detoxification.  
2. **Oroticaciduria** is a critical clue: OTCD disrupts the urea cycle, causing carbamoyl phosphate accumulation, which shunts into pyrimidine synthesis, overproducing orotic acid.  
3. **Cerebral edema** and **seizures** result from ammonia neurotoxicity, exacerbated by **lethargy** and **drowsiness**.  
4. **Abnormal circulating ornithine concentration** aligns with OTCD pathophysiology, as ornithine is a substrate for the deficient OTC enzyme.  
5. **Hyperreflexia** and **sleep disturbances** reflect neurological dysfunction from hyperammonemia.  
6. **Death in childhood** is consistent with severe neonatal-onset OTCD if untreated.  
7. **Fever** may indicate metabolic decompensation triggered by catabolic stressors (e.g., infection), common in UCD crises.  

The absence of citrulline/arginine elevation and the presence of oroticaciduria distinguish OTCD from other UCDs (e.g., citrullinemia, arginase deficiency)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts medium-chain fatty acid β-oxidation, leading to secondary carnitine depletion as carnitine conjugates with accumulating toxic metabolites (e.g., medium-chain acylcarnitines).  
2. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: While MCADD primarily involves medium-chain acyl-CoA dehydrogenase (MCAD), impaired β-oxidation indirectly affects downstream enzymes like 3-hydroxyacyl-CoA dehydrogenase due to metabolic bottlenecking.  
3. **Vomiting, neonatal/infant death**: MCADD causes hypoglycemia and metabolic crises triggered by fasting (e.g., missed feeds), resulting in vomiting, encephalopathy, and rapid deterioration in neonates/infants.  
4. **Prenatal abnormalities**: Severe MCADD may manifest as intrauterine growth restriction or prematurity due to chronic energy deficiency from impaired fatty acid metabolism.  
5. **Diagnostic confirmation**: The clinical triad of hypoketotic hypoglycemia, elevated C6-C10 acylcarnitines, and genetic testing for *ACADM* mutations aligns with the symptoms and biochemical findings."
"['Secondary amenorrhea', 'Ventricular septal defect', 'Aortic regurgitation', 'Splenomegaly', 'Weight loss', 'Thrombocytosis', 'Microcytic anemia', 'Fever', 'Tubulointerstitial nephritis', 'Dyspnea', 'Arthralgia', 'Increased blood urea nitrogen', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Abnormal facility in opposing the shoulders', 'Right bundle branch block', 'Anterior uveitis', 'Decreased glomerular filtration rate', 'Upper limb pain', 'Mild proteinuria', 'Cough', 'Flank pain', 'Neck pain', 'Systolic heart murmur', 'Pollakisuria', 'Endocarditis']",['Tubulointerstitial nephritis and uveitis'],"Disease: Tubulointerstitial nephritis and uveitis (TINU syndrome)  
Reasoning:  
1. **Tubulointerstitial nephritis** and **anterior uveitis** are hallmark features of TINU syndrome, a rare autoimmune disorder.  
2. **Elevated ESR**, **fever**, **weight loss**, **arthralgia**, and **microcytic anemia** align with systemic inflammation, common in TINU.  
3. **Decreased GFR**, **increased blood urea nitrogen**, **mild proteinuria**, and **pollakisuria** reflect kidney dysfunction from tubulointerstitial injury.  
4. **Anterior uveitis** directly supports the ocular component of TINU.  
5. Secondary symptoms like **dyspnea**, **exercise intolerance**, and **splenomegaly** may stem from chronic inflammation or anemia.  
6. Cardiac findings (e.g., **ventricular septal defect**, **aortic regurgitation**, **endocarditis**) are likely unrelated congenital or acquired complications, as TINU primarily targets renal and ocular systems.  
7. **Thrombocytosis** and **flank/neck pain** could result from inflammatory or autoimmune processes.  

Disease: Infective endocarditis (complicating congenital heart defects)  
Reasoning:  
1. **Ventricular septal defect** (VSD) predisposes to **endocarditis**, explaining **systolic heart murmur**, **fever**, **weight loss**, and **splenomegaly**.  
2. **Aortic regurgitation** may arise from valve damage due to endocarditis or congenital anomalies.  
3. **Right bundle branch block** and **cough** could reflect cardiac strain or embolic events.  

*Note:* TINU syndrome is the primary diagnosis based on nephritis and uveitis. Cardiac abnormalities and endocarditis are likely separate, though VSD increases endocarditis risk."
"['Cerebellar atrophy', 'Encephalopathy', 'Death in infancy', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Neonatal death', 'Death in adolescence', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Neurological involvement**: Cerebellar atrophy/agenesis and encephalopathy are hallmark features of PMM2-CDG, reflecting severe central nervous system dysfunction due to impaired glycosylation.  
2. **Dysmorphic features**: Abnormal facial shape (e.g., inverted nipples, large ears, strabismus) and calvaria abnormalities (e.g., occipital prominence) are common phenotypic traits.  
3. **Early lethality**: Neonatal death, death in infancy, or adolescence align with the severe multisystemic nature of PMM2-CDG, often involving liver failure, coagulopathy, or infections.  
4. **Hepatic dysfunction**: Acute/chronic hepatitis correlates with the liver involvement seen in PMM2-CDG, including steatosis, fibrosis, and elevated transaminases.  
5. **Systemic manifestations**: The combination of neurological, hepatic, and dysmorphic symptoms strongly supports a glycosylation disorder, with PMM2-CDG (type Ia) being the most prevalent form."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormal foot morphology', 'Fever', 'Tachypnea', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: A hallmark of MCADD, as carnitine conjugates with unmetabolized medium-chain acyl-CoA derivatives, reducing free carnitine levels.  
2. **Metabolic instability in infancy/childhood**: Neonatal death, death in infancy, and childhood death align with MCADD's risk of fatal hypoglycemia and metabolic crisis during fasting or illness.  
3. **Acute symptoms (Fever, Tachypnea)**: Reflect metabolic decompensation, with tachypnea potentially secondary to metabolic acidosis.  
4. **Fatty acid oxidation defect**: MCADD impairs medium-chain fatty acid breakdown, leading to energy deficiency and toxic metabolite accumulation, especially under metabolic stress.  
5. **Prenatal/developmental abnormalities**: While less typical, prolonged intrauterine metabolic disturbances may contribute to developmental anomalies.  
6. **Exclusion of other disorders**: Symptoms prioritize MCADD over other fatty acid oxidation defects (e.g., VLCADD, LCHADD) due to medium-chain specificity and absence of cardiomyopathy/retinopathy.  
**Conclusion**: MCADD is the primary diagnosis, driven by carnitine deficiency, life-threatening metabolic crises, and hypoglycemia risk. Early recognition and fasting avoidance are critical to prevent mortality."
"['Intellectual disability', 'Motor delay', 'Cerebellar atrophy', 'Death in infancy', 'Hypoproteinemia', 'Hypocholesterolemia', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Intellectual disability & motor delay**: PMM2-CDG disrupts N-glycosylation, impairing neuronal development and cerebellar function, leading to neurodevelopmental deficits.  
2. **Cerebellar atrophy/agenesis**: Glycosylation defects cause structural brain abnormalities, particularly cerebellar hypoplasia/agenesis, a hallmark of PMM2-CDG.  
3. **Hypoproteinemia & hypocholesterolemia**: Impaired hepatic synthesis of glycosylated transport proteins (e.g., albumin, lipoproteins) reduces serum protein and cholesterol.  
4. **Lipodystrophy**: Abnormal fat distribution due to glycosylation-dependent adipocyte signaling and lipid metabolism dysfunction.  
5. **Acute/chronic hepatitis**: Liver involvement (elevated transaminases, steatosis) is common, progressing to fibrosis in severe cases.  
6. **Death in infancy**: Severe multisystemic disease (neurological, hepatic, and coagulopathic complications) often leads to early mortality in classical PMM2-CDG.  

The triad of **neurological impairment**, **protein-losing enteropathy/hypoalbuminemia**, and **hepatopathy** strongly supports PMM2-CDG. Confirmatory testing (phosphomannomutase 2 enzyme activity, genetic analysis for _PMM2_ variants) is required."
"['Blepharitis', 'Photophobia', 'Sparse eyelashes', 'Sparse body hair', 'Congenital ichthyosiform erythroderma', 'Sparse hair', 'Sparse eyebrow']","['Ichthyosis-hypotrichosis syndrome/Ichthyosis, congenital, autosomal recessive 11']","Disease: Ichthyosis-hypotrichosis syndrome/Ichthyosis, congenital, autosomal recessive 11  
Reasoning:  
1. **Congenital ichthyosiform erythroderma** is a hallmark of autosomal recessive congenital ichthyosis (ARCI), specifically linked to mutations in *ST14* (matriptase) in ARCI11.  
2. **Sparse hair, eyebrows, eyelashes, and body hair** align with the ""hypotrichosis"" component, indicating a systemic defect in hair follicle development/maintenance.  
3. **Blepharitis and photophobia** are secondary to eyelid margin inflammation (from scaling skin) and reduced ocular protection due to sparse lashes.  
4. The triad of **ichthyosis, hypotrichosis, and ocular involvement** is pathognomonic for ichthyosis-hypotrichosis syndrome.  
5. Exclusion of mimics (e.g., Netherton/KID syndromes) is supported by the absence of specific features like bamboo hair or keratitis."
"['Renal insufficiency', 'Proteinuria', 'Nephrotic syndrome', 'Hematuria', 'Membranoproliferative glomerulonephritis', 'Hypertension', 'Purpura', 'Splenomegaly', 'Ankle swelling', 'Metabolic acidosis', 'Nausea', 'Abdominal pain', 'Dyspnea', 'Abnormal lung lobation', 'Pulmonary infiltrates', 'Pleural effusion', 'Headache', 'Hypoalbuminemia', 'Elevated circulating creatinine concentration', 'Exercise intolerance', 'Decreased circulating IgG level', 'Abnormality of the pulmonary vasculature', 'Decreased circulating complement C3 concentration', 'Generalized lymphadenopathy', 'Elevated circulating C-reactive protein concentration', 'Increased circulating beta-2-microglobulin level', 'Ankle pain', 'Increased circulating NT-proBNP concentration', 'Parenchymal consolidation', 'Decreased circulating complement C4 concentration', 'Cryoglobulinemia']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Disease: Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed  
Reasoning:  
1. **Renal Involvement**: Membranoproliferative glomerulonephritis (MPGN) is a hallmark of cryoglobulinemic vasculitis. Proteinuria, hematuria, nephrotic syndrome, hypoalbuminemia, and elevated creatinine align with renal damage from cryoglobulin deposition and immune complex-mediated injury.  
2. **Cutaneous Manifestations**: Purpura is characteristic of small-vessel vasculitis driven by cryoglobulinemia.  
3. **Hypocomplementemia**: Decreased C3 and C4 levels indicate complement consumption due to immune complex formation, a key feature of cryoglobulinemia.  
4. **Systemic Inflammation**: Elevated C-reactive protein and generalized lymphadenopathy reflect chronic inflammatory activity.  
5. **Pulmonary Involvement**: Dyspnea, pulmonary infiltrates, pleural effusion, and abnormal vasculature suggest cryoglobulin-mediated vascular injury and inflammation in the lungs.  
6. **Cryoglobulinemia Confirmation**: Direct presence of cryoglobulins in the patient’s symptoms confirms the diagnosis.  
7. **Familial Component**: The ""familial mixed"" subtype implies genetic predisposition, though specific genetic markers (e.g., *CFHR5* mutations) may require further testing.  
8. **Secondary Features**: Hypertension, metabolic acidosis, and edema (ankle swelling) are consequences of renal dysfunction, while nausea and abdominal pain may arise from systemic vasculitis.  
9. **Immunologic Dysregulation**: Decreased IgG and elevated beta-2-microglobulin suggest chronic immune activation and possible underlying lymphoproliferative disorder, often associated with cryoglobulinemia.  
10. **Cardiac Stress**: Elevated NT-proBNP may indicate volume overload from nephrotic syndrome or cardiac strain secondary to hypertension.  

This pattern of multi-organ involvement (renal, cutaneous, pulmonary), hypocomplementemia, and cryoglobulin presence strongly supports familial mixed cryoglobulinemic vasculitis."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Abnormal cerebral morphology', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability & abnormal cerebral morphology**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting myelination and neurotransmitter synthesis, causing brain damage.  
3. **Hypertyrosinemia**: Secondary tyrosine elevation may occur due to metabolic dysregulation in PKU or overlapping enzyme deficiencies (e.g., transient tyrosinemia in neonates).  
4. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) are excreted as urinary carboxylic acids.  
5. **Neonatal/infant death or death in adolescence**: Severe untreated PKU causes progressive neurodegeneration, seizures, and multisystem failure; early mortality reflects delayed diagnosis or poor dietary compliance.  
6. **Obesity**: A complication of PKU management due to high-carbohydrate/low-protein diets required to restrict phenylalanine intake.  
7. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) causes fetal developmental defects, though this overlaps less with neonatal PKU presentation.  

PKU is the unifying diagnosis, with most symptoms explained by phenylalanine toxicity or dietary management challenges."
"['Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient's elevated urinary carboxylic acids (e.g., 3-hydroxyisovaleric acid and 3-methylcrotonylglycine) stem from a defect in leucine catabolism due to MCCC1 gene mutations. This disrupts 3-methylcrotonyl-CoA carboxylase activity, causing metabolite accumulation. Aminoaciduria arises from proximal tubule dysfunction secondary to toxic organic acids, while abnormal glycine levels may reflect increased conjugation with 3-methylcrotonyl-CoA, altering its circulating concentration.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: Broadly, this deficiency (encompassing MCCC1/MCCC2 mutations) disrupts leucine breakdown, leading to urinary excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine (explaining elevated carboxylic acids). Aminoaciduria occurs due to renal tubular damage from acidic metabolites. Glycine abnormalities may result from metabolic diversion to conjugate accumulated intermediates, reducing free glycine or altering its homeostasis."
"['Small face', 'Prominent supraorbital ridges', 'Strabismus', 'Shallow orbits', 'Eruption failure', 'obsolete Hypotrichosis', 'Alopecia', 'Frontal bossing', 'Severe short stature', 'Concave nasal ridge', 'Thick vermilion border']",['GAPO syndrome/GAPO syndrome'],"Disease: GAPO syndrome  
Reasoning:  
1. **Severe short stature**: Matches ""Growth retardation"" in GAPO (Growth Retardation, Alopecia, Pseudoanodontia, Optic atrophy).  
2. **Alopecia and Hypotrichosis**: Directly aligns with the ""Alopecia"" component of GAPO, involving hair loss.  
3. **Eruption failure**: Corresponds to ""Pseudoanodontia"" (failure of tooth eruption), a hallmark of GAPO.  
4. **Strabismus and Shallow orbits**: Suggests optic involvement, consistent with ""Optic atrophy"" (though atrophy may develop later; strabismus is a common early ocular finding).  
5. **Facial dysmorphism** (Small face, Prominent supraorbital ridges, Frontal bossing, Concave nasal ridge, Thick vermilion border): Characteristic craniofacial features reported in GAPO, including frontal bossing and midface hypoplasia.  
6. **Exclusion of alternatives**: Symptoms collectively fit GAPO’s triad (growth delay, alopecia, pseudoanodontia) with supporting ocular and facial signs, ruling out similar syndromes like ectodermal dysplasia or progeria."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, which impairs the conversion of phenylalanine to tyrosine. Elevated phenylalanine levels are diagnostic.  
2. **Hypertyrosinemia**: While atypical in classic PKU (where tyrosine is typically low/normal), this could result from **dietary management**. PKU treatment includes tyrosine supplementation to compensate for reduced endogenous synthesis. Excess supplementation or impaired tyrosine metabolism (e.g., secondary liver dysfunction from untreated PKU) might explain elevated tyrosine.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early death aligns with historical cases before newborn screening and dietary interventions.  

Note: The coexistence of hyperphenylalaninemia and hypertyrosinemia is unusual in PKU. Consider ruling out **BH4 deficiency** (a PKU mimic) or **tyrosinemia type I/II** (primary tyrosine disorders) if confirmatory testing (e.g., enzyme assays, genetic analysis) is available. However, the provided diagnosis prioritizes PKU as the primary condition."
"['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis and decreased methylmalonyl-CoA mutase activity are hallmark features of methylmalonic acidemia (MMA), an autosomal recessive disorder impairing methylmalonyl-CoA metabolism. Accumulation of methylmalonic acid leads to systemic toxicity, explaining early mortality. The presentation aligns with MMA’s severe neonatal/early infantile form, where rapid metabolic decompensation causes death in infancy or childhood if untreated.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Directly linked to the documented **decreased methylmalonyl-CoA mutase activity**, this subtype involves mutations in the *MUT* gene, rendering the enzyme nonfunctional. Unlike B12-responsive forms, supplementation is ineffective, resulting in refractory metabolic acidosis and poor prognosis. Early death reflects the severity of enzyme deficiency, as residual activity <1% is typically incompatible with long-term survival."
"['Broad philtrum', 'Long philtrum', 'Anteverted nares', 'Syndactyly', 'Generalized hypotonia', 'Death in infancy', 'Deep philtrum', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol biosynthesis markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) paired with hypocholesterolemia are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in the *DHCR7* gene, which disrupts cholesterol synthesis.  
2. **Craniofacial features**: Broad, long, and deep philtrum, along with anteverted nares, are classic dysmorphic findings in SLOS.  
3. **Limb anomalies**: Syndactyly (often of toes 2-3) is a hallmark congenital malformation in SLOS.  
4. **Neurological and systemic issues**: Generalized hypotonia and feeding difficulties align with the severe metabolic dysfunction and neurodevelopmental deficits seen in SLOS.  
5. **Lethality**: Neonatal death or death in infancy correlates with severe forms of SLOS, where cholesterol deficiency critically impacts organogenesis and cellular function.  

The combination of biochemical abnormalities (elevated 7-DHC/8-DHC), dysmorphic features, syndactyly, and life-threatening metabolic dysfunction confirms SLOS as the diagnosis."
"['Abnormality of the genitourinary system', 'Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Abnormal facial shape', 'Pneumothorax', 'Vascular dilatation', 'Kyphoscoliosis', 'Aortic aneurysm']","['Cutis laxa, autosomal recessive, type IIC']","Disease: Cutis laxa, autosomal recessive, type IIC  
Reasoning: The patient presents with cutis laxa, a hallmark of this disorder, alongside multisystemic manifestations. Generalized hypotonia and flexion contractures align with neuromuscular involvement. Kyphoscoliosis and hip dysplasia reflect skeletal abnormalities tied to connective tissue defects. Vascular dilatation, aortic aneurysm, and pneumothorax indicate severe vascular and pulmonary fragility, characteristic of ATP6V0A2 gene mutations. Abnormal heart morphology and facial shape, entropion, and genitourinary anomalies further support systemic connective tissue dysfunction. Disproportionate tall stature may arise from skeletal disproportions rather than growth acceleration, consistent with ARCL2C's phenotypic spectrum. This constellation of symptoms, particularly the combination of cutaneous, vascular, skeletal, and developmental features, strongly points to autosomal recessive cutis laxa type IIC."
"['Strabismus', 'Delayed speech and language development', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The explicit mention of ""L-2-hydroxyglutaric aciduria"" indicates elevated L-2-hydroxyglutaric acid in urine or blood, a hallmark of this autosomal recessive neurometabolic disorder.  
2. **Neurological Symptoms**: Strabismus and delayed speech/language development align with the disease’s typical neurological manifestations, including cerebellar dysfunction, intellectual disability, and motor deficits caused by toxic metabolite accumulation.  
3. **Prognosis**: ""Death in childhood"" reflects the severe progression of untreated cases, often due to neurodegeneration, seizures, or complications like respiratory infections.  
4. **Exclusion of Mimics**: Symptoms are consistent with L-2-hydroxyglutaric aciduria and not other organic acidurias (e.g., D-2-hydroxyglutaric aciduria), as the specific biochemical marker and clinical course differentiate it.  
5. **Confirmatory Testing**: Genetic testing for mutations in *L2HGDH* or MRI findings (e.g., leukoencephalopathy, basal ganglia changes) would solidify the diagnosis."
"['Proteinuria', 'Ascites', 'Acute pancreatitis', 'Splenomegaly', 'Pancytopenia', 'Fever', 'Diarrhea', 'Abdominal pain', 'Peritonitis', 'Arthralgia', 'Elevated circulating creatine kinase concentration', 'Generalized muscle weakness', 'Myalgia', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Hypovolemia', 'Fatigue', 'Increased circulating lactate dehydrogenase concentration', 'Hydrometrocolpos', 'Epigastric pain']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus']","Disease: Systemic lupus erythematosus  
Reasoning: The patient presents with multisystem involvement, including renal (proteinuria), hematologic (pancytopenia), musculoskeletal (myalgia, arthralgia, elevated creatine kinase), and immunologic (ANA positivity) manifestations. Fever, fatigue, and abdominal pain with serositis (ascites, peritonitis) further support SLE. Elevated LDH and muscle weakness may indicate lupus-related myositis or hemolysis. Acute pancreatitis and splenomegaly are rare but documented in SLE.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: While age is unspecified, symptoms like hydrometrocolpos (a congenital anomaly sometimes associated with pediatric autoimmune conditions) and pancytopenia could suggest early-onset SLE. Pediatric SLE often presents with severe renal and hematologic involvement, aligning with proteinuria and pancytopenia.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: Genetic susceptibility loci like SLEB6 (ITGAM gene) are linked to renal and hematologic phenotypes. Proteinuria, pancytopenia, and ANA positivity align with this genetic predisposition, though confirmatory testing would be required.  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: While vitiligo is not explicitly listed, overlapping autoimmune features (ANA positivity, pancreatitis, myositis) could suggest polyautoimmunity. However, this diagnosis is less definitive without vitiligo or confirmed genetic markers.  

Disease: Systemic lupus erythematosus 16  
Reasoning: Linked to DNASE1L3 mutations, causing severe renal and serosal inflammation (proteinuria, ascites, peritonitis). Elevated LDH and creatine kinase may reflect tissue damage from impaired apoptotic clearance, a hallmark of this subtype.  

**Note:** Hydrometrocolpos is an outlier; it may indicate a concurrent congenital anomaly (e.g., Müllerian duct obstruction) unrelated to SLE, necessitating further evaluation."
"['Spasticity', 'Pneumonia', '3-Methylglutaric aciduria', 'Death in childhood', 'Abnormality of acid-base homeostasis']","['3-methylglutaconic aciduria type 4/3-@methylglutaconic aciduria, type IV']","Disease: 3-methylglutaconic aciduria type IV  
Reasoning:  
1. **3-Methylglutaric aciduria**: Elevated 3-methylglutaric acid in urine suggests a defect in leucine metabolism, often linked to 3-methylglutaconic aciduria (3-MGA) disorders. While 3-methylglutaconic acid is the hallmark of 3-MGA, some subtypes (e.g., AUH deficiency) may also excrete 3-methylglutaric acid.  
2. **Spasticity**: Neurological involvement, such as spasticity, aligns with 3-MGA type IV, which can present with central nervous system abnormalities due to mitochondrial dysfunction or metabolic stress.  
3. **Abnormality of acid-base homeostasis**: Metabolic acidosis is common in organic acidurias due to toxic metabolite accumulation, disrupting mitochondrial energy production.  
4. **Pneumonia**: Aspiration pneumonia may occur secondary to dysphagia or muscle weakness caused by neurological deterioration.  
5. **Death in childhood**: Severe metabolic crises, progressive neurodegeneration, and respiratory complications in 3-MGA type IV often lead to early mortality.  
6. **Type IV classification**: This subtype encompasses heterogeneous presentations not fitting classical types I-III, often with variable neurological and metabolic features. The combination of acid-base disturbances, spasticity, and organic aciduria supports this diagnosis when genetic confirmation is pending."
"['Short neck', 'Intellectual disability', 'Kyphoscoliosis', 'Back pain', 'Vertebral segmentation defect', 'Disproportionate short-trunk short stature']","['Spondylocostal dysostosis, autosomal recessive 1']","Disease: Spondylocostal dysostosis, autosomal recessive 1  
Reasoning: The patient presents with vertebral segmentation defects and kyphoscoliosis, hallmark features of spondylocostal dysostosis (SCD). Disproportionate short-trunk short stature and a short neck align with axial skeletal involvement. Autosomal recessive type 1 (SCDO1), linked to *DLL3* mutations, is characterized by severe vertebral malformations and rib anomalies. While intellectual disability is atypical in isolated SCDO1, it may occur in syndromic overlaps or due to secondary complications (e.g., spinal cord compression). Back pain likely stems from structural spinal instability. The constellation of vertebral, thoracic, and growth defects strongly supports this diagnosis."
"['Abnormal vertebral morphology', 'Death in childhood', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine**: Alkaptonuria is caused by a deficiency of homogentisate 1,2-dioxygenase, leading to accumulation of homogentisic acid (HGA). HGA oxidizes in urine, causing it to darken upon exposure to air (a hallmark symptom).  
2. **Abnormal vertebral morphology**: Chronic HGA deposition in connective tissues (ochronosis) leads to cartilage degeneration, including intervertebral discs. Spinal deformities (e.g., kyphosis, disc calcification) may manifest early in severe cases.  
3. **Death in childhood**: While Alkaptonuria typically has a chronic course, rare severe forms with systemic ochronosis can cause early complications (e.g., cardiac valve calcification, renal failure) or susceptibility to infections, potentially leading to premature death.  

Note: Childhood mortality is atypical in Alkaptonuria and suggests an unusually aggressive presentation or comorbid conditions. Further genetic testing (HGD gene mutations) and urinary HGA quantification would confirm the diagnosis."
"['Polydipsia', 'Elevated hepatic transaminase', 'Decreased circulating ceruloplasmin concentration', 'Death in adolescence', 'Decreased circulating copper concentration']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin and copper concentrations**: Wilson disease is caused by ATP7B gene mutations, impairing copper transport and incorporation into ceruloplasmin, leading to low serum ceruloplasmin and copper levels.  
2. **Elevated hepatic transaminases**: Copper accumulation in the liver causes hepatocellular injury, manifesting as elevated liver enzymes.  
3. **Polydipsia**: Neurological involvement (e.g., hypothalamic dysfunction) or renal tubular acidosis (secondary to copper toxicity) may cause excessive thirst.  
4. **Death in adolescence**: Untreated Wilson disease progresses to liver failure, hemolytic crises, or neuropsychiatric complications, often fatal in adolescence/early adulthood without timely intervention.  
5. **Exclusion of mimics**: Symptoms align with Wilson disease’s triad (hepatic, neurologic, psychiatric) and biochemical profile, distinguishing it from other copper disorders (e.g., Menkes disease) or isolated liver pathologies."
"['Hyperactivity', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties', 'Abnormal myelination']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal myelination**: Canavan disease is a leukodystrophy caused by aspartoacylase deficiency, leading to defective myelin synthesis due to toxic accumulation of N-acetylaspartic acid (NAA) in the brain.  
2. **Abnormal circulating aspartate family amino acid concentration**: Elevated NAA in blood/urine is pathognomonic for Canavan disease, directly linked to the enzyme deficiency.  
3. **Feeding difficulties and death in infancy**: Early-onset symptoms (3–6 months) include hypotonia, poor feeding, and failure to thrive, progressing to severe neurodegeneration and typically fatal outcomes in infancy/early childhood.  
4. **Hyperactivity**: Neurological deterioration in Canavan disease may manifest as irritability or hyperexcitability due to cerebral dysfunction, though spasticity and developmental regression are more common.  
5. **Exclusion of other leukodystrophies**: The biochemical profile (NAA elevation) and clinical progression distinguish Canavan from other disorders like Tay-Sachs or Krabbe disease."
"['Vomiting', 'Abdominal pain', 'Death in childhood', 'Recurrent viral infections']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning:  
1. **Vomiting and abdominal pain**: Hallmark symptoms of acute porphyria attacks due to autonomic neuropathy and visceral involvement.  
2. **Death in childhood**: Uncommon in AIP (typically adult-onset), but severe cases with untreated neurovisceral crises (e.g., respiratory failure, arrhythmias) could lead to early mortality.  
3. **Recurrent viral infections**: Not classically linked to AIP. May suggest a secondary immunodeficiency or unrelated comorbidity, as porphyria does not directly impair antiviral immunity.  

Disease: Porphyria (General)  
Reasoning:  
1. **Recurrent viral infections**: Could align with congenital erythropoietic porphyria (CEP), a rare subtype causing chronic hemolysis and splenic dysfunction, increasing infection risk.  
2. **Death in childhood**: Severe porphyrias like CEP or ALA dehydratase deficiency porphyria (ADP) present early with multiorgan failure, photosensitivity, and anemia, potentially leading to childhood mortality.  
3. **Abdominal pain/vomiting**: Common to all acute hepatic porphyrias (e.g., AIP, VP, HCP) but less prominent in non-hepatic subtypes like CEP.  

**Conclusion**: Acute intermittent porphyria explains abdominal pain/vomiting but poorly aligns with recurrent infections or early death. A broader porphyria diagnosis (e.g., CEP or ADP) better accounts for childhood severity and infections but requires biochemical/histopathological confirmation (e.g., elevated porphyrins, enzyme assays)."
"['High palate', 'Muscle weakness', 'Flexion contracture', 'Hip dysplasia', 'Hypernasal speech', 'Broad-based gait', 'Scoliosis', 'Sensory axonal neuropathy', 'Increased variability in muscle fiber diameter', 'Type 1 muscle fiber predominance', 'Impaired proprioception', 'Feeding difficulties']","['Arthrogryposis, distal, with impaired proprioception and touch']","Disease: Arthrogryposis, distal, with impaired proprioception and touch  
Reasoning:  
1. **Distal joint contractures**: Flexion contracture aligns with ""distal arthrogryposis,"" which primarily affects extremities.  
2. **Sensory neuropathy**: Sensory axonal neuropathy and impaired proprioception directly correlate with the disease’s hallmark neurological involvement.  
3. **Musculoskeletal anomalies**: Hip dysplasia and scoliosis suggest congenital connective tissue/structural defects, common in syndromic arthrogryposis.  
4. **Neuromuscular features**: Muscle weakness, type 1 fiber predominance, and fiber size variability indicate mixed neuropathic/myopathic changes, consistent with the disease’s neuromuscular pathology.  
5. **Craniofacial involvement**: High palate and hypernasal speech point to velopharyngeal dysfunction, often seen in congenital syndromes.  
6. **Functional impairments**: Broad-based gait (due to proprioceptive loss) and feeding difficulties (linked to oropharyngeal weakness) further support systemic involvement.  
This constellation of distal contractures, sensory neuropathy, and multi-system features distinctively matches the rare diagnosis."
"['Abnormality of the eye', 'Arachnodactyly', 'Peripheral arterial stenosis', 'Death in adolescence', 'Abnormal nervous system physiology']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Abnormality of the eye**: Homocystinuria commonly causes ectopia lentis (dislocation of the ocular lens), leading to visual impairment.  
2. **Arachnodactyly**: Elevated homocysteine disrupts collagen cross-linking, resulting in Marfanoid habitus, including long, slender fingers.  
3. **Peripheral arterial stenosis**: Vascular damage from homocysteine-induced endothelial injury and thromboembolism predisposes to arterial stenosis and occlusion.  
4. **Death in adolescence**: Untreated homocystinuria carries high mortality from thromboembolic events (e.g., stroke, pulmonary embolism) or cardiovascular complications in early life.  
5. **Abnormal nervous system physiology**: Homocysteine neurotoxicity and thromboembolic strokes cause seizures, intellectual disability, or psychiatric manifestations.  

The combination of ocular, skeletal, vascular, and neurological features with early mortality strongly supports **cystathionine beta-synthase (CBS) deficiency**, the most common form of homocystinuria. Biochemical confirmation via elevated plasma homocysteine and methionine, with reduced cystathionine, would be definitive."
"['Hypertelorism', 'Micrognathia', 'Low-set ears', 'Otitis media', 'Cataract', 'Proptosis', 'Leukocoria', 'Shallow orbits', 'Delayed speech and language development', 'Joint hypermobility', 'Mitral valve prolapse', 'Thickened calvaria', 'Arthralgia', 'Hypoplasia of the odontoid process', 'Short stature', 'Limited elbow flexion', 'Delayed femoral head ossification', 'Midface retrusion', 'Submucous cleft of soft and hard palate']","['Stickler syndrome type 1/Stickler syndrome, type I']","Disease: Stickler syndrome type 1/Stickler syndrome, type I  
Reasoning:  
1. **Craniofacial features**: Midface retrusion, micrognathia, hypertelorism, low-set ears, and submucous cleft palate align with Stickler syndrome’s characteristic facial dysmorphism and palatal abnormalities (often clefting due to collagen defects).  
2. **Ocular manifestations**: Cataract, proptosis, leukocoria, and shallow orbits are hallmark findings in Stickler type 1, linked to COL2A1 mutations affecting vitreous and ocular structure.  
3. **Auditory issues**: Recurrent otitis media reflects predisposition to middle ear dysfunction from craniofacial and connective tissue abnormalities.  
4. **Skeletal/joint involvement**: Joint hypermobility, arthralgia, limited elbow flexion, delayed femoral head ossification, and hypoplasia of the odontoid process correlate with skeletal dysplasia and collagen-related joint instability.  
5. **Systemic features**: Short stature, mitral valve prolapse (connective tissue defect), and thickened calvaria (less common but reported) further support a collagenopathy.  
6. **Developmental delay**: Delayed speech/language development is secondary to hearing loss (chronic otitis) or cleft palate.  
7. **Exclusion of mimics**: Features distinguish Stickler type 1 (COL2A1) from type 2 (COL11A1, with sensorineural hearing loss) or Marshall syndrome (distinct vitreous changes, more severe skeletal dysplasia)."
"['Death in infancy', 'Respiratory insufficiency', 'Neonatal death', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency  
Reasoning:  
1. **Uraciluria** and **abnormal circulating pyrimidine concentration** are hallmark biochemical features of dihydropyrimidine dehydrogenase (DPD) deficiency, as the enzyme catalyzes the first step in pyrimidine degradation.  
2. DPD deficiency leads to accumulation of uracil and thymine in body fluids, which correlates with the observed metabolic abnormalities.  
3. **Respiratory insufficiency** and **neonatal death** are consistent with severe presentations of DPD deficiency, often due to neurological dysfunction or metabolic crises.  
4. **Death in infancy** aligns with the life-threatening nature of this autosomal recessive disorder, particularly in cases with complete enzyme deficiency.  
5. The combination of metabolic derangements and catastrophic early clinical course strongly supports this diagnosis over other rare pyrimidine metabolism disorders."
"['Death in infancy', 'Hyperammonemia', 'Oroticaciduria', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia conversion to carbamoyl phosphate, leading to toxic ammonia accumulation.  
2. **Neonatal death** and **death in infancy** align with severe UCDs like CPS1 deficiency, which often presents catastrophically within days of birth due to hyperammonemic coma if untreated.  
3. **Oroticaciduria** is atypical for CPS1 deficiency (typically seen in OTC deficiency). However, severe metabolic stress or liver dysfunction in CPS1 deficiency may secondarily elevate orotic acid via unclear mechanisms, or the finding could reflect a concurrent/overlapping pyrimidine metabolism disturbance.  
4. Key differentiation: CPS1 deficiency classically shows **low citrulline** and **absent oroticaciduria**. The presence of oroticaciduria here is unusual but does not exclude CPS1 deficiency if other features (e.g., hyperammonemia severity, timing) strongly align. Further testing (e.g., genetic analysis, enzyme assays) would confirm the diagnosis."
"['Abnormal repetitive mannerisms', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'Sleep disturbance', 'Bruxism', 'Secondary microcephaly', 'Hypoplasia of the frontal lobes', 'Feeding difficulties in infancy']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Secondary microcephaly** and **hypoplasia of the corpus callosum/frontal lobes** are hallmark neuroanatomical features of Rett syndrome (RTT), particularly in congenital variants where brain development anomalies are evident early.  
2. **Hypotonia** and **feeding difficulties in infancy** align with the congenital variant’s neonatal-onset hypotonia and failure to thrive.  
3. **Seizures** are common in RTT due to cortical hyperexcitability from MECP2 mutations or related genetic defects.  
4. **Abnormal repetitive mannerisms** (e.g., hand stereotypies) and **bruxism** are classic motor manifestations of RTT.  
5. **Sleep disturbances** correlate with autonomic dysfunction seen in RTT.  
6. The absence of a distinct regression phase (implied by congenital presentation) distinguishes this from typical RTT, fitting the *congenital variant* subtype (e.g., FOXG1-related or early-truncating MECP2 mutations).  
7. Structural brain abnormalities (corpus callosum/frontal hypoplasia) and early developmental stagnation further support this diagnosis over mimics like Angelman syndrome or CDKL5 deficiency disorder."
"['Seizure', 'Death in infancy', 'Metabolic acidosis', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with methylmalonic aciduria, metabolic acidosis, and life-threatening neonatal/infantile symptoms (seizures, neonatal death). These are hallmark features of methylmalonic acidemia (MMA), an autosomal recessive disorder caused by impaired metabolism of methylmalonyl-CoA. Accumulation of methylmalonic acid leads to metabolic acidosis and neurological toxicity, explaining seizures. Neonatal lethality reflects severe metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The presence of methylmalonic aciduria unresponsive to vitamin B12 therapy (implied by ""death in infancy"" despite likely standard care) points specifically to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme defect prevents isomerization of methylmalonyl-CoA to succinyl-CoA, causing irreversible accumulation of methylmalonic acid. B12-unresponsive forms are typically severe, manifesting in the neonatal period with rapid metabolic deterioration, consistent with the patient’s clinical course."
"['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Reduced tendon reflexes', 'Abnormal facial shape', 'Ventriculomegaly', 'Developmental regression', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Hypotonia and reduced tendon reflexes** are hallmark features of TBCK syndrome, reflecting neuromuscular involvement.  
2. **Severe global developmental delay** and **intellectual disability** align with the syndrome’s core neurocognitive phenotype.  
3. **Macrocephaly** and **ventriculomegaly** correlate with reported structural brain anomalies, including cortical atrophy or white matter changes.  
4. **Seizures** are commonly observed due to underlying neuronal dysfunction.  
5. **Abnormal facial shape** (e.g., coarse facies, hypertelorism, broad nasal tip) matches the characteristic dysmorphology.  
6. **Delayed speech/language development** and **developmental regression** (in some cases) reflect progressive neurological deterioration or static encephalopathy.  
7. Genetic confirmation would identify biallelic *TBCK* mutations, but clinical consistency suffices for preliminary diagnosis."
"['Abnormal mandible morphology', 'Ptosis', 'External ophthalmoplegia', 'Achilles tendon contracture', 'Myotonia', 'Distal amyotrophy', 'Neck flexor weakness', 'Pelvic girdle muscle weakness', 'Pelvic girdle muscle weakness', 'Facial paralysis', 'Distal lower limb muscle weakness', 'Abnormal nerve conduction velocity']","['Autosomal dominant centronuclear myopathy/Myopathy, centronuclear, autosomal dominant']","Disease: Autosomal dominant centronuclear myopathy/Myopathy, centronuclear, autosomal dominant  
Reasoning:  
1. **Oculomotor involvement**: Ptosis and external ophthalmoplegia are hallmark features of centronuclear myopathy (CNM), reflecting weakness in extraocular and levator palpebrae muscles.  
2. **Facial and bulbar weakness**: Facial paralysis and abnormal mandible morphology align with craniofacial muscle involvement typical in CNM.  
3. **Proximal and distal muscle weakness**: Pelvic girdle muscle weakness (repeated), neck flexor weakness, and distal lower limb weakness suggest a generalized myopathy pattern. Distal amyotrophy indicates chronic muscle atrophy.  
4. **Myotonia**: Though less common in CNM, overlapping features with myotonic disorders (e.g., DNM2-related CNM) may explain delayed muscle relaxation.  
5. **Tendon contractures**: Achilles tendon contracture reflects long-standing muscle fibrosis, a sequela of chronic myopathy.  
6. **Electrophysiological findings**: Abnormal nerve conduction velocity may mimic neuropathy but is consistent with myopathic changes affecting motor units.  
7. **Genetic correlation**: Autosomal dominant CNM (linked to DNM2 mutations) explains the phenotypic combination of facial, ocular, and axial/distal weakness without severe neonatal onset.  
8. **Exclusion of mimics**: Differentiated from myotonic dystrophy by the prominence of ophthalmoplegia and absence of systemic features (e.g., cardiac arrhythmia)."
"['Optic disc pallor', 'Seizure', 'Hypertonia', 'Generalized hypotonia', 'Myoclonus', 'Organic aciduria', 'Respiratory insufficiency', 'Increased serum lactate', 'EEG abnormality', 'Poor head control', 'Progressive muscle weakness', 'Hyperactive deep tendon reflexes', 'Frontotemporal cerebral atrophy', 'CNS demyelination', 'Nasogastric tube feeding in infancy', 'Hypoplastic hippocampus', 'Vegetative state', 'Enlarged sylvian cistern']",['Developmental and epileptic encephalopathy 28'],"Disease: Developmental and epileptic encephalopathy 28 (DEE28)  
Reasoning:  
1. **Seizures & EEG abnormalities**: Core features of epileptic encephalopathy, consistent with DEE28's presentation of early-onset refractory seizures. Myoclonus further supports a seizure spectrum disorder.  
2. **Neuromotor symptoms**: Hypertonia, hyperactive reflexes, and progressive muscle weakness suggest upper motor neuron degeneration. Generalized hypotonia and poor head control reflect severe developmental delay, typical of infantile-onset DEEs.  
3. **Neuroimaging findings**: Frontotemporal cerebral atrophy, CNS demyelination, hypoplastic hippocampus, and enlarged sylvian cistern align with progressive neurodegeneration and structural brain abnormalities seen in WDR45-related disorders (e.g., BPAN, a subtype of NBIA).  
4. **Developmental regression**: Nasogastric tube feeding in infancy and progression to a vegetative state indicate profound neurological deterioration, characteristic of DEE28's neurodegenerative course.  
5. **Metabolic disturbances**: Organic aciduria and elevated serum lactate may arise from mitochondrial dysfunction secondary to impaired autophagy (WDR45 mutation) or metabolic stress from recurrent seizures.  
6. **Respiratory insufficiency**: Likely due to combined effects of CNS dysfunction and progressive muscle weakness.  
7. **Consistency with WDR45 pathology**: While iron accumulation (a hallmark of NBIA) is not explicitly listed, the constellation of seizures, hypotonia-to-hypertonia progression, and cerebral atrophy strongly aligns with DEE28/BPAN phenotypes linked to WDR45 mutations."
"['Abnormality of male external genitalia', 'Hypospadias', 'Abnormality of the kidney', 'Horseshoe kidney', 'Ectopic kidney', 'Abnormal mandible morphology', 'Microretrognathia', 'Abnormality of the outer ear', 'Posteriorly rotated ears', 'Hearing impairment', 'Low-set ears', 'Abnormality of the eye', 'Strabismus', 'Nystagmus', 'Horizontal nystagmus', 'Atypical behavior', 'Delayed speech and language development', 'Intellectual disability', 'Hypotonia', 'Motor delay', 'Generalized hypotonia', 'Absent speech', 'Abnormality of the cardiovascular system', 'Ventricular septal defect', 'Atrial septal defect', 'Patent ductus arteriosus', 'Truncus arteriosus', 'Pneumonia', 'Abnormality of the upper limb', 'Crossed fused renal ectopia', 'Recurrent pneumonia', 'Aplasia/Hypoplasia of the thumb', 'Feeding difficulties', 'Hypoplastic aortic arch']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Urogenital and Renal Abnormalities**: Hypospadias, horseshoe kidney, ectopic kidney, and crossed fused renal ectopia align with the renal and genital anomalies commonly seen in Stankiewicz-Isidor syndrome (STISS), caused by mutations in *PSMD12*.  
2. **Craniofacial Features**: Microretrognathia, posteriorly rotated ears, low-set ears, and strabismus/nystagmus match the craniofacial dysmorphism and ocular abnormalities reported in STISS.  
3. **Developmental and Neurological Issues**: Intellectual disability, absent speech, motor delay, and generalized hypotonia are hallmark features of STISS, reflecting its neurodevelopmental impact.  
4. **Cardiovascular Defects**: Ventricular/atrial septal defects, patent ductus arteriosus, truncus arteriosus, and hypoplastic aortic arch are consistent with congenital heart defects observed in STISS.  
5. **Limb Anomalies**: Thumb hypoplasia/aplasia correlates with the upper limb malformations associated with STISS.  
6. **Systemic Complications**: Recurrent pneumonia and feeding difficulties likely stem from hypotonia, dysphagia, and aspiration risks, further supporting the diagnosis.  
7. **Exclusion of Overlapping Syndromes**: The constellation of symptoms (renal, cardiac, craniofacial, limb) differentiates STISS from similar syndromes (e.g., CHARGE, 22q11 deletion), which lack this specific combination.  

The diagnosis is strongly supported by the convergence of neurodevelopmental, cardiovascular, renal, craniofacial, and limb anomalies, characteristic of *PSMD12*-related Stankiewicz-Isidor syndrome."
"['Ataxia', 'Dystonia', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal myelination']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Directly links to GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Neurological symptoms (Ataxia, Dystonia)**: Toxic metabolites damage the basal ganglia and striatum, causing movement disorders.  
3. **Abnormal cerebral morphology**: Macrocephaly (often seen in infancy) and frontotemporal atrophy due to metabolic injury.  
4. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to glutaric acid for excretion.  
5. **Abnormal myelination**: Delayed or disrupted white matter development from neurotoxic metabolites.  
6. **Death in childhood**: Untreated GA-I leads to irreversible neurological damage, metabolic crises, and early mortality.  
7. **Consistency with GA-I**: Symptom constellation (organic aciduria, neurological deficits, imaging findings) is pathognomonic for this disorder."
"['Delayed speech and language development', 'Intellectual disability', 'Death in infancy', 'Hyperthreoninuria', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating tyrosine concentration', 'Galactosuria', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with key metabolic abnormalities indicative of galactose processing dysfunction, including hypergalactosemia, galactosuria, and abnormal galactoside metabolism. Classic galactosemia (GALT deficiency) disrupts the Leloir pathway, causing toxic accumulation of galactose-1-phosphate. This explains neonatal/childhood mortality due to fulminant liver failure, sepsis, or CNS complications. Abnormal amino acid concentrations (aspartate, alanine, tyrosine) reflect secondary hepatic dysfunction, while hyperthreoninuria may arise from proximal renal tubular damage from metabolite toxicity. Intellectual disability and speech delays align with long-term neurotoxic effects of untreated galactose metabolites. The constellation of life-threatening metabolic crises in infancy and specific biochemical markers strongly supports this diagnosis."
"['Microcephaly', 'Short neck', 'Shield chest', 'Global developmental delay', 'Hypertonia', 'Failure to thrive', 'Small for gestational age', 'Abnormal facial shape', 'Spondyloepiphyseal dysplasia', 'Delayed skeletal maturation', 'Recurrent upper respiratory tract infections', 'Elbow flexion contracture', 'Marked delay in bone age', 'Clinodactyly of the 5th finger', 'Decreased circulating antibody level', 'Short stature', 'Decreased proportion of CD4-positive helper T cells', 'Decreased proportion of CD8-positive T cells', 'Abnormal epiphysis morphology', 'Short 5th finger', 'Limb undergrowth', 'Epileptic spasm', 'Severe global developmental delay', 'Abnormal bone ossification', 'Overweight', 'Increased hepatic echogenicity']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Microcephaly, spondyloepiphyseal dysplasia, delayed skeletal maturation, clinodactyly of the 5th finger, short 5th finger, limb undergrowth, abnormal epiphysis morphology, and marked delay in bone age align with skeletal dysplasias characteristic of ISDNA.  
2. **Immunodeficiency**: Recurrent infections, decreased antibody levels, and reduced CD4+/CD8+ T cells indicate combined B- and T-cell dysfunction, a hallmark of ISDNA.  
3. **Neurodevelopmental Delays**: Severe global developmental delay, hypertonia, and epileptic spasms reflect central nervous system involvement, consistent with ISDNA’s neurodevelopmental phenotype.  
4. **Growth and Metabolic Features**: Short stature, small for gestational age, failure to thrive, and abnormal bone ossification further support a systemic disorder involving skeletal and metabolic pathways.  
5. **Exclusion of Alternatives**: Overlap with other immunooskeletal dysplasias (e.g., Schimke immunoosseous dysplasia) is ruled out by the absence of nephropathy and the presence of severe neurodevelopmental deficits, which are distinctive to ISDNA.  

The triad of skeletal dysplasia, immunodeficiency, and neurodevelopmental abnormalities confirms the diagnosis of ISDNA."
"['Triangular face', 'Posteriorly rotated ears', 'Sensorineural hearing impairment', 'Delayed speech and language development', 'Global developmental delay', 'Partial agenesis of the corpus callosum', 'Slender build', 'Asthma', '2-3 toe syndactyly', 'Hyperextensibility at elbow', 'Sparse eyebrow', 'Knee joint hypermobility', 'Arachnoid cyst']","['Chudley-Mccullough syndrome', 'Chudley-McCullough syndrome']","Disease: Chudley-McCullough syndrome  
**Reasoning**:  
1. **Sensorineural hearing impairment** and **partial agenesis of the corpus callosum** are hallmark features of Chudley-McCullough syndrome, a rare autosomal recessive disorder linked to mutations in the *GPSM2* gene.  
2. **Arachnoid cyst** and **global developmental delay** align with the neuroimaging findings and neurological manifestations typical of the syndrome.  
3. **Delayed speech and language development** correlates with both hearing loss and structural brain abnormalities.  
4. While **triangular face**, **posteriorly rotated ears**, and **2-3 toe syndactyly** are less specific, they may represent variable dysmorphic features occasionally reported in genetic syndromes affecting neurodevelopment.  
5. **Slender build**, **hyperextensibility at joints**, and **sparse eyebrow** are nonspecific but do not exclude the diagnosis, as phenotypic variability exists.  
6. **Asthma** is likely unrelated to the syndrome but noted as a comorbid condition.  

The combination of severe sensorineural hearing loss, corpus callosum anomalies, arachnoid cysts, and developmental delays strongly supports Chudley-McCullough syndrome. Genetic testing for *GPSM2* mutations is recommended for confirmation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had untreated PKU during pregnancy, causing congenital anomalies in the infant.  
3. **Death in infancy/childhood and neonatal death** correlate with severe, untreated PKU. Without dietary intervention, toxic phenylalanine levels cause irreversible neurological damage, seizures, and failure to thrive, often leading to early mortality.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually normal or low due to PAH deficiency). However, this could indicate a comorbid condition (e.g., transient tyrosinemia in newborns) or a secondary metabolic disruption from liver dysfunction in critical cases.  
5. The combination of hyperphenylalaninemia and early lethality strongly prioritizes PKU as the primary diagnosis, emphasizing the critical need for newborn screening and dietary management to prevent severe outcomes."
"['Apathy', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hypoglycemia', 'Leukocytosis', 'Hyperammonemia', 'Hypertriglyceridemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia**: MCADD impairs medium-chain fatty acid oxidation, critical during fasting, leading to glucose depletion.  
2. **Hypertriglyceridemia**: Inefficient fatty acid metabolism results in triglyceride accumulation.  
3. **Hyperammonemia**: Secondary urea cycle inhibition due to metabolic stress or accumulated toxic intermediates.  
4. **Abnormal carnitine levels**: Carnitine depletion occurs from excessive acylcarnitine formation (e.g., C8, C10 species) and urinary loss.  
5. **Seizures & hypotonia**: Energy deficiency in brain/muscle from impaired ketogenesis and ATP production.  
6. **Apathy**: Neurological dysfunction due to hypoglycemia and metabolic derangements.  
7. **Premature birth & severe short stature**: Intrauterine metabolic stress affecting growth; postnatal malnutrition exacerbates this.  
8. **Neonatal/childhood death**: Untreated MCADD causes lethal metabolic crises triggered by fasting or infection.  
9. **Recurrent infections**: Metabolic decompensation weakens stress responses, increasing infection susceptibility.  
10. **Amino acid abnormalities**: Disrupted gluconeogenesis (elevated alanine) and liver dysfunction alter aspartate metabolism.  
11. **Leukocytosis**: Stress response during acute metabolic decompensation.  

Key biochemical hallmarks (hypoglycemia, hyperammonemia, hypertriglyceridemia, acylcarnitine abnormalities) align with MCADD pathophysiology. Early fatality without intervention confirms severity typical of untreated cases."
"['Areflexia', 'Pes cavus', 'Decreased motor nerve conduction velocity', 'Decreased sensory nerve conduction velocity', 'Impaired distal tactile sensation', 'Distal upper limb muscle weakness', 'Anti-ganglioside antibody positivity']","['Hereditary neuropathy with liability to pressure palsies/Neuropathy, hereditary, with liability to pressure palsies']","Disease: Hereditary neuropathy with liability to pressure palsies (HNPP)  
Reasoning:  
1. **Areflexia**: Indicates peripheral neuropathy, consistent with HNPP, which disrupts nerve function.  
2. **Pes cavus**: Though more common in Charcot-Marie-Tooth disease (CMT), it can occur in HNPP due to chronic nerve damage and muscle imbalance.  
3. **Decreased motor/sensory nerve conduction velocity**: Demyelination (a hallmark of HNPP) slows conduction. HNPP often shows diffuse slowing with focal delays at compression sites.  
4. **Impaired distal tactile sensation and distal muscle weakness**: Distal nerve involvement aligns with HNPP’s predisposition to affect vulnerable nerve segments.  
5. **Anti-ganglioside antibody positivity**: Uncommon in HNPP but may represent a concurrent autoimmune process or incidental finding. HNPP is primarily genetic (PMP22 deletion), so clinical and electrophysiological features take precedence.  
6. Exclusion of mimics: Guillain-Barré syndrome (acute onset) and CMT (progressive course) are less likely. Recurrent pressure palsies and family history (implied by hereditary nature) further support HNPP.  

Final diagnosis hinges on hereditary pattern, electrophysiological findings, and structural nerve susceptibility, despite atypical anti-ganglioside antibodies."
"['Plantar hyperkeratosis', 'Localized epidermolytic hyperkeratosis', 'Palmar hyperkeratosis']","['Epidermolytic palmoplantar keratoderma/Palmoplantar keratoderma, epidermolytic']","Disease: Epidermolytic palmoplantar keratoderma/Palmoplantar keratoderma, epidermolytic  
Reasoning:  
1. **Plantar and palmar hyperkeratosis** indicates involvement of both soles and palms, characteristic of palmoplantar keratoderma (PPK).  
2. **Localized epidermolytic hyperkeratosis** suggests histopathological findings of epidermolysis (blistering) in the granular layer, a hallmark of epidermolytic PPK.  
3. The combination of palmoplantar hyperkeratosis with epidermolytic features aligns specifically with mutations in keratin genes (e.g., *KRT1* or *KRT9*), which disrupt epidermal integrity.  
4. Diffuse or focal PPK subtypes without epidermolysis (e.g., non-epidermolytic PPK) are excluded due to the presence of epidermolytic changes.  
5. Clinical and histopathological coherence confirms the diagnosis of epidermolytic PPK."
"['Congenital diaphragmatic hernia', 'Motor delay', 'Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Hiatus hernia', 'Lipodystrophy', 'Abnormal muscle physiology', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis and motor delay**: Hallmark neurological features of PMM2-CDG due to impaired glycosylation of proteins critical for cerebellar development and neuronal function.  
2. **Failure to thrive and death in infancy**: Common in severe PMM2-CDG cases due to multi-organ dysfunction, feeding difficulties, and metabolic instability.  
3. **Congenital diaphragmatic hernia (CDH) and hiatus hernia**: Rare but reported in PMM2-CDG, linked to abnormal connective tissue and muscle physiology from glycosylation defects.  
4. **Lipodystrophy and abnormal muscle physiology**: Reflect systemic metabolic disturbances caused by disrupted glycosylation of enzymes and structural proteins.  
5. **Consistent multisystem involvement**: Matches PMM2-CDG’s presentation, which combines neurological, gastrointestinal, musculoskeletal, and metabolic abnormalities.  

This pattern aligns with PMM2-CDG’s pathophysiology of defective N-glycosylation, confirmed by genetic testing for *PMM2* mutations."
"['Cerebellar atrophy', 'Generalized hypotonia', 'Tachycardia', 'Cardiac arrest', 'Skeletal muscle atrophy', 'Death in childhood', 'Recurrent viral infections', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Cerebellar agenesis', 'Increased urinary glycerol']",['Isolated glycerol kinase deficiency/Glycerol kinase deficiency'],"Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol** is pathognomonic for glycerol kinase deficiency (GKD), as the enzyme deficiency prevents glycerol metabolism, leading to its urinary excretion.  
2. **Skeletal muscle atrophy** and **generalized hypotonia** align with impaired energy production due to disrupted glycerol utilization in muscle tissue.  
3. **Aplasia/Hypoplasia of extremity musculature** suggests developmental metabolic dysfunction affecting muscle formation.  
4. **Cardiac arrest** and **tachycardia** may result from metabolic crises or cardiomyopathy secondary to energy deficits in cardiac tissue.  
5. **Recurrent viral infections** could reflect episodic metabolic decompensation weakening immune resilience.  
6. **Death in childhood** correlates with severe metabolic instability or cardiac complications in untreated GKD.  
7. **Cerebellar atrophy/agenesis** is atypical for isolated GKD but may represent a phenotypic variant or comorbid condition, though the primary diagnosis is anchored by urinary glycerol elevation and metabolic features."
"['Hypospadias', 'Vesicoureteral reflux', 'Renal insufficiency', 'Epicanthus', 'Low anterior hairline', 'Low-set ears', 'Preauricular skin tag', 'Short neck', 'Long eyelashes', 'Aggressive behavior', 'Delayed speech and language development', 'Hyperactivity', 'Global developmental delay', 'Atrial septal defect', 'Overlapping toe', 'Anal atresia', 'EEG abnormality', 'Short stature', 'Attention deficit hyperactivity disorder', 'Microtia', 'Partial duplication of thumb phalanx', 'Abnormality of brain morphology', 'Preaxial polydactyly']",['Townes-Brocks syndrome 1'],"Disease: Townes-Brocks syndrome 1  
Reasoning:  
1. **Core Triad Features**:  
   - **Anal atresia**: A hallmark feature of Townes-Brocks syndrome (TBS).  
   - **Ear anomalies**: Microtia, low-set ears, and preauricular skin tags align with TBS-associated ear malformations.  
   - **Thumb abnormalities**: Preaxial polydactyly and partial duplication of the thumb phalanx are characteristic limb defects in TBS.  

2. **Renal and Urological Involvement**:  
   - Vesicoureteral reflux and renal insufficiency correlate with TBS-related kidney dysfunction.  
   - Hypospadias further supports genitourinary anomalies linked to TBS.  

3. **Cardiac and Skeletal Features**:  
   - Atrial septal defect and overlapping toe are consistent with TBS-associated congenital anomalies.  

4. **Facial Dysmorphism**:  
   - Epicanthus, long eyelashes, short neck, and low anterior hairline match reported craniofacial traits in TBS.  

5. **Supportive Genetic Basis**:  
   - TBS1 is caused by pathogenic variants in *SALL1*, which explains multi-organ developmental defects.  

6. **Exclusion of Overlapping Syndromes**:  
   - Features like preaxial polydactyly and anal atresia distinguish TBS from VACTERL or Smith-Lemli-Opitz syndrome.  

7. **Neurodevelopmental Variability**:  
   - While developmental delay, ADHD, and EEG abnormalities are less typical, phenotypic variability in TBS can include mild neurocognitive involvement.  

Conclusion: The combination of anal, ear, thumb, renal, and cardiac anomalies strongly supports a diagnosis of Townes-Brocks syndrome 1."
"['Hearing impairment', 'Blue sclerae', 'Flexion contracture', 'Hepatosplenomegaly', 'Recurrent fractures', 'Abnormal echocardiogram', 'Elevated circulating alkaline phosphatase concentration', 'Short stature', 'Reduced bone mineral density']","['Osteogenesis imperfecta, type XI']","Disease: Osteogenesis imperfecta, type XI  
Reasoning:  
1. **Recurrent fractures** and **reduced bone mineral density** indicate a bone fragility disorder, common in Osteogenesis Imperfecta (OI).  
2. **Blue sclerae** are a hallmark of OI due to abnormal collagen affecting scleral thickness.  
3. **Short stature** aligns with skeletal deformities and growth deficiencies in severe OI subtypes.  
4. **Elevated alkaline phosphatase** reflects increased bone turnover from frequent fractures.  
5. **Flexion contractures** suggest Bruck syndrome overlap (OI type XI), linked to *FKBP10* mutations causing joint rigidity.  
6. **Hearing impairment** is seen in progressive OI subtypes due to ossicular chain abnormalities.  
7. **Abnormal echocardiogram** may indicate valvular or aortic root abnormalities, occasionally associated with collagen defects.  
8. **Hepatosplenomegaly** is atypical but reported in rare OI cases, possibly secondary to extramedullary hematopoiesis or metabolic stress.  

This constellation of symptoms, particularly fractures, contractures, and hearing loss, strongly supports OI type XI (Bruck syndrome type 2)."
"['Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Motor delay', 'Muscle weakness', 'Absent speech', 'Tachycardia', 'Torsade de pointes', 'Cardiac arrest', 'Hypoglycemia', 'Increased serum lactate', 'Myoglobinuria', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Generalized muscle weakness', 'Ventricular tachycardia', 'Prolonged QTc interval', 'Cardiorespiratory arrest', 'Lateral ventricle dilatation', 'Acute rhabdomyolysis', 'Arrhythmia']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Neurological/Developmental Symptoms**: Delayed speech, intellectual disability, motor delay, and absent speech indicate global developmental delay and neurodegeneration, consistent with encephalomyopathic involvement.  
2. **Metabolic Crises**: Hypoglycemia, increased serum lactate, and acute rhabdomyolysis (with myoglobinuria, elevated CK) suggest recurrent metabolic disturbances, a hallmark of the syndrome.  
3. **Muscle Pathology**: Generalized muscle weakness, rhabdomyolysis, and elevated creatine kinase point to myopathic processes and energy metabolism dysfunction.  
4. **Cardiac Arrhythmias**: Torsade de pointes, ventricular tachycardia, prolonged QTc interval, and cardiorespiratory arrest align with life-threatening arrhythmias characteristic of the syndrome.  
5. **Systemic Features**: Hypoglycemia and lactic acidosis further support a mitochondrial or metabolic etiology disrupting energy production.  
6. **Neuroimaging**: Lateral ventricle dilatation may reflect neurodegenerative changes or cerebral atrophy over time.  
7. **Syndrome Alignment**: The combination of recurrent metabolic crises, rhabdomyolysis, severe arrhythmias, and intellectual disability is pathognomonic for this rare disorder, distinguishing it from isolated metabolic or cardiac conditions."
"['Cleft palate', 'Hypertelorism', 'Triangular face', 'Broad forehead', 'Strabismus', 'Proptosis', 'Long eyelashes', 'Autistic behavior', 'Impaired social interactions', 'Reduced eye contact', 'Hypertrichosis', 'Prominent fingertip pads', 'Seizure', 'Hypotonia', 'Generalized hypotonia', 'Absent speech', 'Joint laxity', 'Macrodontia', 'Constipation', 'Sleep disturbance', 'Recurrent infections', 'Elbow hypertrichosis', 'No social interaction', 'Incisor macrodontia', 'Severe global developmental delay', 'Self-injurious behavior']",['Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities'],"Disease: Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities  
Reasoning:  
1. **Craniofacial dysmorphism**: The patient exhibits hypertelorism, triangular face, broad forehead, proptosis, and cleft palate, which are hallmark facial features of this disorder.  
2. **Neurodevelopmental/behavioral abnormalities**: Severe global developmental delay, absent speech, autistic behavior, impaired social interactions, and self-injurious behavior align with the disorder’s core neuropsychiatric profile.  
3. **Hypertrichosis and physical signs**: Elbow hypertrichosis, generalized hypertrichosis, and prominent fingertip pads are distinctive phenotypic markers.  
4. **Dental and systemic features**: Incisor macrodontia and recurrent infections suggest multisystem involvement, consistent with genetic etiologies linked to this diagnosis.  
5. **Neurological symptoms**: Hypotonia, seizures, and sleep disturbances further support a syndromic intellectual disability disorder.  
6. **Exclusion of mimics**: The constellation of features (e.g., macrodontia + hypertrichosis + cleft palate) differentiates this from similar syndromes like Wiedemann-Steiner or KBG, narrowing to the specified diagnosis."
"['Macrocephaly', 'Irritability', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Feeding difficulties', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Key Biochemical Markers**: Elevated glutaric aciduria and elevated circulating glutaric acid concentration are pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Neurological Symptoms**: Dystonia, dyskinesia, and generalized hypotonia align with basal ganglia damage, a hallmark of GA-I due to neurotoxic metabolite accumulation.  
3. **Macrocephaly**: Often presents pre-symptomatically in infancy, reflecting abnormal brain development or subdural effusions.  
4. **Metabolic Decompensation Episodes**: Vomiting, diarrhea, dehydration, fever, and lethargy during catabolic stress (e.g., infections) trigger acute crises, leading to irreversible neurological injury.  
5. **Carnitine Deficiency**: Decreased plasma free carnitine results from secondary carnitine depletion, as carnitine binds to glutaric acid for excretion.  
6. **Poor Prognosis Indicators**: Death in infancy/childhood and neonatal death (in severe cases) reflect untreated metabolic instability or encephalopathic crises.  
7. **Supportive Symptoms**: Irritability, drowsiness, hyperhidrosis, and feeding difficulties are consistent with chronic metabolic dysregulation and acute energy deficits.  
8. **Exclusion of Mimics**: Symptoms overlap with other organic acidemias, but glutaric acid elevation and specific neurological progression confirm GA-I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where uncontrolled maternal phenylalanine levels during pregnancy cause congenital anomalies.  
3. **Neonatal death/Death in infancy/Death in adolescence** reflects untreated PKU complications: severe neurotoxicity, seizures, and organ damage without dietary intervention.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low) but may indicate a concurrent condition, lab error, or severe metabolic dysregulation in terminal stages.  
5. The symptom constellation prioritizes PKU due to hyperphenylalaninemia, with early mortality explained by lack of treatment (e.g., phenylalanine-restricted diet).  

Note: Hypertyrosinemia warrants further investigation for overlapping disorders (e.g., tyrosinemia, BH4 deficiency), but PKU remains the primary diagnosis based on hyperphenylalaninemia and clinical context."
"['Nocturia', 'Renal cyst', 'Ovarian cyst', 'Hyperhidrosis', 'Facial erythema', 'Joint swelling', 'Hepatic steatosis', 'Ascites', 'Tachycardia', 'Acute pancreatitis', 'Abnormal toe morphology', 'Vomiting', 'Diarrhea', 'Nausea', 'Cerebral atrophy', 'Dyspnea', 'Pleuritis', 'Hyperuricemia', 'Hypertriglyceridemia', 'Pleural effusion', 'Hepatomegaly', 'Arthralgia', 'Neoplasm of the liver', 'Rheumatoid factor positive', 'Hypercholesterolemia', 'Hyperuricosuria', 'Increased circulating ferritin concentration', 'Myalgia', 'Back pain', 'Increased circulating IgM level', 'Exercise intolerance', 'Increased total bilirubin', 'Generalized morning stiffness', 'Abnormality of complement system', 'Enlarged metacarpophalangeal joints', 'Renal neoplasm', 'Peripheral neuropathy', 'Elevated circulating C-reactive protein concentration', 'obsolete Increased urinary urate', 'Increased circulating beta-2-microglobulin level', 'Neck pain', 'Shoulder pain', 'Finger pain', 'Elevated gamma-glutamyltransferase level', 'Perinephric fluid collection', 'Groin pain', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Abnormality of nail color', 'Insomnia', 'Increased hepatitis A virus antibody level']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Key Triad Features**:  
   - **Myositis**: Suggested by *myalgia* and *exercise intolerance* (common in muscle inflammation).  
   - **Interstitial Lung Disease (ILD)**: Supported by *dyspnea*, *pleural effusion*, and *pleuritis*.  
   - **Inflammatory Arthritis**: Evidenced by *joint swelling*, *arthralgia*, *enlarged metacarpophalangeal joints*, and *morning stiffness*.  

2. **Autoimmune Markers**:  
   - *Rheumatoid factor positive* and *elevated CRP* align with systemic inflammation.  
   - *Abnormality of complement system* and *increased IgG4/IgM* suggest immune dysregulation, though anti-synthetase antibodies (e.g., anti-Jo-1) are pathognomonic (not explicitly listed but inferred).  

3. **Overlapping Systemic Involvement**:  
   - *Hepatomegaly* and *hepatic steatosis* may reflect secondary metabolic dysfunction or inflammation.  
   - *Hyperuricemia* and *hypertriglyceridemia* could arise from systemic inflammation or comorbid metabolic syndrome.  

4. **Exclusions/Comorbidities**:  
   - *Renal cysts*, *neoplasms*, and *cerebral atrophy* are atypical for antisynthetase syndrome, suggesting comorbidities or alternative diagnoses (e.g., genetic disorders like HNF1B or VHL).  
   - *Acute pancreatitis* and *vitamin D deficiency* likely stem from metabolic disturbances rather than primary autoimmune pathology.  

5. **Supportive Findings**:  
   - *Facial erythema* and *abnormal nail color* may reflect vasculopathy or Raynaud’s phenomenon (common in overlap syndromes).  
   - *Peripheral neuropathy* and *fatigue* are nonspecific but compatible with chronic inflammatory states.  

Conclusion: The constellation of myositis, ILD, and inflammatory arthritis, alongside autoimmune markers, strongly supports antisynthetase syndrome. Further confirmation requires anti-synthetase antibody testing (e.g., anti-Jo-1) and imaging (e.g., HRCT for ILD)."
"['Membranoproliferative glomerulonephritis', 'Leukocytosis', 'Recurrent respiratory infections', 'Vasculitis', 'Increased circulating IgM level', 'Cryoglobulinemia']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed:  
1. **Cryoglobulinemia** is directly noted, a hallmark of the disease, where cryoglobulins precipitate in cold conditions, causing vascular inflammation.  
2. **Vasculitis** aligns with cryoglobulin-induced vascular damage, a core feature of cryoglobulinemic vasculitis.  
3. **Membranoproliferative glomerulonephritis (MPGN)** is a common renal manifestation of cryoglobulinemia due to immune complex deposition in glomeruli.  
4. **Increased circulating IgM** suggests type II cryoglobulinemia (mixed), where IgM acts as a rheumatoid factor, forming immune complexes.  
5. **Recurrent respiratory infections** may stem from immune dysfunction secondary to chronic immune complex deposition or complement consumption.  
6. **Leukocytosis** reflects systemic inflammation driven by vasculitis and recurrent infections.  
The familial form indicates a genetic predisposition, differentiating it from secondary causes (e.g., hepatitis C)."
"['Proteinuria', 'Abnormal vagina morphology', 'Abnormality of the dentition', 'Sinusitis', 'Abnormal nasal mucosa morphology', 'Agitation', 'Hypertension', 'Facial erythema', 'Gait disturbance', 'Abnormal hip joint morphology', 'Alopecia', 'Abnormality of the larynx', 'Ankle swelling', 'Fever', 'Polydipsia', 'Palpitations', 'Constipation', 'Gastroesophageal reflux', 'Abdominal pain', 'Headache', 'Vertigo', 'Arthralgia', 'Exertional dyspnea', 'Rheumatoid factor positive', 'Low back pain', 'Somatic sensory dysfunction', 'Antinuclear antibody positivity', 'Generalized morning stiffness', 'Swelling of proximal interphalangeal joints', 'Abnormality of hand joint mobility', 'Focal white matter lesions', 'Pedal edema', 'Abnormal metacarpophalangeal joint morphology', 'Pyuria', 'Decreased glomerular filtration rate', 'Erythema nodosum', 'Fatigue', 'Temporomandibular joint crepitus', 'Lower limb pain', 'Dysesthesia', 'Flank pain', 'Night sweats', 'Increased circulating insulin-like growth factor 1 concentration', 'Finger pain', 'Hip pain', 'Pruritis on hand', 'Flushing', 'Chest tightness', 'Groin pain', 'Jaw pain', 'Pollakisuria', 'Palpebral edema', 'Chest pain', 'Epigastric pain']","['Polymyositis', 'Localized scleroderma', 'Scleroderma, familial progressive', 'Scleroderma', 'Systemic sclerosi; SSc/Systemic sclerosis', 'Diffuse cutaneous systemic sclerosis', 'Limited cutaneous systemic sclerosis', 'CREST syndrome']","Disease: Systemic sclerosis (SSc)  
Reasoning: The patient presents with key features of systemic sclerosis including Raynaud's-like symptoms (flushing, finger pain), gastrointestinal involvement (GERD, constipation, abdominal pain), renal abnormalities (proteinuria, decreased GFR, hypertension suggestive of scleroderma renal crisis), and musculoskeletal issues (arthralgia, joint swelling, morning stiffness). Antinuclear antibody positivity and rheumatoid factor support autoimmune etiology. Skin and mucosal changes (facial erythema, pruritus, abnormal nasal/vaginal mucosa) align with sclerotic processes. Pulmonary symptoms (exertional dyspnea) may indicate interstitial lung disease or pulmonary hypertension.  

Disease: Diffuse cutaneous systemic sclerosis  
Reasoning: Renal crisis (hypertension, proteinuria, flank pain) and widespread organ involvement (GI, musculoskeletal, pulmonary) are hallmarks of diffuse cutaneous SSc. Skin abnormalities (hand pruritus, facial erythema) and somatic sensory dysfunction suggest extensive fibrosis.  

Disease: CREST syndrome (Limited cutaneous systemic sclerosis subset)  
Reasoning: GERD (esophageal dysmotility), telangiectasia (flushing, facial erythema), and potential sclerodactyly (abnormal hand joints) fit CREST criteria. Calcinosis is not explicitly listed but may correlate with joint pain. Antinuclear antibodies (often anticentromere in CREST) further support this subtype.  

Disease: Scleroderma (general)  
Reasoning: Broad scleroderma features include skin/mucosal abnormalities, fibrosis-related organ damage (renal, pulmonary), and autoimmune markers (ANA positivity). The absence of polymyositis-specific muscle weakness argues against overlap syndromes.  

Excluded: Polymyositis  
Reasoning: Lack of predominant proximal muscle weakness, elevated creatine kinase, or myositis-specific antibodies makes polymyositis less likely despite fatigue and exertional dyspnea. Symptoms align more with systemic sclerosis complications (e.g., ILD).  

Excluded: Localized scleroderma  
Reasoning: Localized forms (e.g., morphea) lack systemic involvement (renal, pulmonary, GI), which is prominent here.  

Key Clues: Multi-organ fibrosis (renal, GI, skin), autoantibodies, and CREST-like features differentiate systemic sclerosis subtypes. Renal crisis and diffuse symptoms prioritize diffuse cutaneous SSc, while esophageal and vascular symptoms support CREST."
"['Oral ulcer', 'Diplopia', 'Abnormal finger morphology', 'Syncope', 'Arthritis', 'Fever', 'Leukocytosis', 'Headache', 'Microscopic hematuria', 'Abnormal shoulder morphology', 'Genital ulcers', 'Myalgia', 'Paresthesia', 'Back pain', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Second degree atrioventricular block', 'Fatigue', 'Mesangial hypercellularity', 'Mild proteinuria', 'Finger pain', 'Aphthous ulcer', 'Increased circulating procalcitonin concentration']","['Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Familial Mediterranean fever, AD', 'Behçet disease/Behcet syndrome']","Disease: Behçet disease/Behcet syndrome  
Reasoning: The patient presents with key diagnostic criteria for Behçet disease, including recurrent oral ulcers (oral ulcer, aphthous ulcer) and genital ulcers. Additional supportive features include arthritis, neurological symptoms (headache, paresthesia, somatic sensory dysfunction), inflammatory markers (elevated ESR, CRP, leukocytosis), and possible ocular involvement (diplopia). While atypical, the second-degree AV block and renal findings (mesangial hypercellularity, mild proteinuria) could reflect rare vascular or renal complications of Behçet-related vasculitis. Fever and myalgia align with systemic inflammation.  

Disease: Familial Mediterranean fever, AR  
Reasoning: Symptoms such as recurrent fever, arthritis, elevated inflammatory markers (ESR, CRP, procalcitonin), and leukocytosis are consistent with FMF. Renal abnormalities (microscopic hematuria, mesangial hypercellularity) may suggest amyloidosis, a complication of untreated FMF. However, the absence of serositis (e.g., peritonitis/pleurisy), the presence of oral/genital ulcers, and neurological deficits are atypical for FMF, making this less likely unless overlapping with another condition.  

Disease: Familial Mediterranean fever, AD  
Reasoning: The autosomal dominant form of FMF shares features with the AR type, including fever, arthritis, and elevated acute-phase reactants. However, AD-FMF is rarer and often milder. The patient’s severe multisystem involvement (neurological, mucocutaneous ulcers) and lack of hallmark FMF features (self-limiting serosal attacks, colchicine responsiveness) make this diagnosis unlikely.  

**Final Diagnosis**: Behçet disease/Behcet syndrome is the most probable diagnosis, given the pathognomonic mucocutaneous ulcers and compatible systemic manifestations. FMF (AR/AD) is less likely due to inconsistent clinical features."
"['Macrocephaly', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** is a hallmark biochemical feature of GA-I, directly indicating a defect in glutaryl-CoA dehydrogenase, which disrupts lysine and tryptophan metabolism.  
2. **Macrocephaly** often presents in infancy due to abnormal accumulation of neurotoxic metabolites (glutaric acid, 3-hydroxyglutaric acid), causing frontotemporal atrophy.  
3. **Dystonia and dyskinesia** arise from striatal neurodegeneration, typically triggered by acute metabolic crises during infections or fever (aligned with **fever**, **vomiting**, and **diarrhea**).  
4. **Lethargy**, **drowsiness**, and **generalized hypotonia** reflect acute encephalopathic crises caused by metabolic acidosis and energy depletion in the brain.  
5. **Hyperhidrosis** and **sleep disturbance** are linked to autonomic nervous system dysfunction secondary to metabolic stress.  
6. **Dyspnea** may occur during metabolic decompensation due to respiratory compensation for acidosis or muscle weakness.  
7. **Death in infancy** underscores the severity of untreated GA-I, as crises lead to irreversible neurological damage or metabolic collapse.  
The combination of neurodevelopmental, metabolic, and autonomic symptoms, alongside biochemical evidence (glutaric aciduria), confirms GA-I."
"['Delayed speech and language development', 'Obesity', 'Death in infancy', 'Hyperalaninemia', 'Aminoaciduria', 'Increased total bilirubin', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating tyrosine concentration', 'Death in adolescence', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient exhibits hypergalactosemia and an abnormality of galactoside metabolism, directly implicating impaired galactose processing. Classic galactosemia (GALT deficiency) results in toxic accumulation of galactose-1-phosphate, leading to liver dysfunction (elevated bilirubin, hyperalaninemia, aminoaciduria) and metabolic derangements (abnormal tyrosine/aspartate family amino acids). Neonatal/infant mortality and adolescent death align with untreated cases due to liver failure, sepsis, or chronic complications. Delayed speech may reflect neurological damage from metabolite toxicity. Obesity is atypical but could arise from dietary adjustments or metabolic dysregulation.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning: This term encompasses broader galactose metabolism defects, including GALT, GALK1, or GALE deficiencies. The patient’s hypergalactosemia, galactoside metabolism abnormalities, and liver-related symptoms (increased bilirubin, aminoaciduria) are consistent with this category. Abnormal tyrosine/aspartate levels may reflect secondary disruptions in hepatic amino acid handling. Early mortality and developmental delays further support a severe, systemic galactosemia variant."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Thromboembolism', 'Reduced antithrombin III activity', 'Death in childhood', 'Lipodystrophy', 'Death in adolescence', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological involvement**: Ataxia, cerebellar atrophy/agenesis, motor delay, and intellectual disability align with PMM2-CDG’s hallmark cerebellar and developmental defects due to impaired glycosylation of neural proteins.  
2. **Hepatic manifestations**: Cirrhosis and hepatic fibrosis are consistent with multisystemic involvement, though liver disease is typically milder compared to other CDG subtypes.  
3. **Coagulopathy**: Reduced antithrombin III activity (a glycoprotein) explains thromboembolism, a recognized feature of glycosylation defects.  
4. **Early mortality**: Death in infancy/childhood/adolescence reflects severe phenotypic variability, with fatal outcomes in critical organ dysfunction.  
5. **Hypotonia and strabismus**: Common early signs due to neuromuscular and cranial nerve glycosylation deficits.  
6. **Lipodystrophy**: Rarely reported but plausible in PMM2-CDG, potentially linked to metabolic dysregulation from glycosylation errors.  
7. **Cerebellar agenesis**: Represents an extreme structural anomaly in severe cases, overlapping with cerebellar atrophy spectrum.  

PMM2-CDG is confirmed by genetic testing for *PMM2* mutations and abnormal transferrin glycosylation patterns."
"['Microcephaly', 'Seizure', 'Coma', 'Global developmental delay', 'Absent speech', 'Torsade de pointes', 'Hypoglycemia', 'Ketosis', 'Lower limb spasticity', 'Status epilepticus', 'Increased serum lactate', 'Myoglobinuria', 'Ketonuria', 'Elevated circulating thyroid-stimulating hormone concentration', 'Lactic acidosis', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Acute encephalopathy', 'Axial hypotonia', 'Arrhythmia', 'Brain atrophy', 'Dicarboxylic acidemia', 'Elevated circulating acylcarnitine concentration']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic Dysregulation**: Hypoglycemia, ketosis, ketonuria, dicarboxylic acidemia, and elevated acylcarnitine suggest impaired fatty acid oxidation and mitochondrial dysfunction.  
2. **Neurological Crises**: Acute encephalopathy, seizures, status epilepticus, coma, and lactic acidosis align with recurrent metabolic encephalopathic episodes.  
3. **Muscle Involvement**: Rhabdomyolysis, myoglobinuria, and elevated creatine kinase indicate severe myopathy, consistent with ""encephalomyopathic"" features.  
4. **Cardiac Arrhythmias**: Torsade de pointes and arrhythmia reflect systemic metabolic toxicity affecting cardiac ion channels.  
5. **Neurodegeneration**: Microcephaly, brain atrophy, global developmental delay, absent speech, axial hypotonia, and spasticity imply progressive neurodegeneration.  
6. **Thyroid Dysregulation**: Elevated TSH may indicate secondary endocrine disruption due to chronic metabolic stress.  
7. **Consistency with Syndrome**: The triad of recurrent encephalopathy, rhabdomyolysis, and arrhythmias, combined with neurodegeneration and metabolic biomarkers, uniquely matches this ultra-rare syndrome."
"['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Tachycardia', 'Anemia', 'Tachypnea', 'Neonatal death', 'Abnormal nervous system physiology', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease; MSUD  
Reasoning:  
1. **Elevated urinary carboxylic acids**: MSUD disrupts branched-chain amino acid (BCAA) metabolism, leading to accumulation of branched-chain keto acids (e.g., ketoisocaproic acid), which are carboxylic acids excreted in urine.  
2. **Abnormal nervous system physiology** and **generalized hypotonia**: Neurotoxicity from elevated BCAAs and their derivatives damages neurons, impairing motor function and muscle tone.  
3. **Tachycardia** and **tachypnea**: Metabolic acidosis triggers compensatory mechanisms (e.g., increased respiratory rate to expel CO₂, tachycardia to maintain circulation).  
4. **Growth delay** and **anemia**: Chronic metabolic stress and protein catabolism impair nutrient utilization, affecting growth and red blood cell production.  
5. **Neonatal death/death in infancy**: Untreated classic MSUD causes rapid metabolic decompensation, cerebral edema, and fatal outcomes without early intervention (e.g., dietary BCAA restriction).  
6. **Absence of maple syrup odor**: While a hallmark, this may not be immediately apparent in neonatal screening or masked by acute crisis management.  
Key biochemical confirmation involves detecting elevated plasma BCAAs (leucine, isoleucine, valine) and urinary branched-chain keto acids."
"['Coarse facial features', ""Widow's peak"", 'Recurrent otitis media', 'Bulbous nose', 'Autistic behavior', 'Anxiety', 'Delayed speech and language development', 'Brachydactyly', 'Prominent fingertip pads', 'Global developmental delay', 'Organic aciduria', 'Abnormal circulating amino acid concentration', 'Aminoaciduria', 'Short stature', 'Mucopolysacchariduria', 'Oligosacchariduria', 'Echolalia', 'Abnormal leukocyte count', 'Abnormal serum insulin-like growth factor 1 level', 'Small hand']","['Leukocyte adhesion deficiency type II/Congenital disorder of glycosylation, type IIc']","Disease: Leukocyte adhesion deficiency type II/Congenital disorder of glycosylation, type IIc (LAD II/CDG-IIc)  
**Reasoning**:  
1. **Glycosylation Defects**: Mucopolysacchariduria and oligosacchariduria indicate impaired glycosylation, a hallmark of congenital disorders of glycosylation (CDG).  
2. **Immune Dysfunction**: Recurrent otitis media and abnormal leukocyte count align with leukocyte adhesion deficiency (LAD II), a CDG-IIc-specific immune defect due to faulty fucose metabolism.  
3. **Developmental Delays**: Global developmental delay, speech delay, autistic behavior, and echolalia reflect neurological involvement common in CDG.  
4. **Skeletal Features**: Brachydactyly, small hands, prominent fingertip pads, and short stature correlate with skeletal dysplasia seen in CDG-IIc.  
5. **Metabolic Abnormalities**: Organic aciduria, aminoaciduria, and abnormal serum amino acids/IGF-1 levels suggest systemic metabolic disruption from glycosylation errors.  
6. **Dysmorphic Traits**: Coarse facial features, bulbous nose, and widow’s peak are consistent with CDG-IIc’s craniofacial phenotype.  

The integration of glycosylation defects (urinary metabolites), immune deficiency, neurodevelopmental delays, and skeletal anomalies confirms LAD II/CDG-IIc."
"['Strabismus', 'Apathy', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Abdominal distention', 'Propionyl-CoA carboxylase deficiency', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Key biochemical marker**: Propionyl-CoA carboxylase deficiency is a hallmark of biotinidase deficiency (BTDD), as biotin is a cofactor for multiple carboxylases, including propionyl-CoA carboxylase.  
2. **Metabolic abnormalities**: Elevated urinary carboxylic acids (e.g., propionate, 3-hydroxyisovalerate) and abnormal aspartate/alanine concentrations align with impaired carboxylase activity due to biotin depletion.  
3. **Dermatological features**: Alopecia (hair loss) is a classic sign of biotin deficiency, as biotin is critical for keratin synthesis.  
4. **Neurological symptoms**: Seizures, motor delay, apathy, and severe hearing impairment reflect biotin’s role in neuronal function and myelination. Untreated BTDD causes progressive neurodegeneration.  
5. **Immune dysfunction**: Recurrent viral infections may stem from biotin’s role in immune regulation and leukocyte function.  
6. **Early mortality**: Death in infancy/childhood is typical in severe, untreated cases due to metabolic crises or infections.  
7. **Abdominal distention**: Likely secondary to metabolic acidosis or hepatic dysfunction from toxic metabolite accumulation.  
8. **Late-onset presentation**: Symptoms like delayed speech and hypotonia manifest after the neonatal period, distinguishing BTDD from holocarboxylase synthetase deficiency (early-onset).  
**Conclusion**: The constellation of carboxylase deficiency, neurological decline, alopecia, and metabolic derangements confirms BTDD. Immediate biotin supplementation is critical to reverse symptoms."
"['Generalized hypotonia', 'Death in infancy', 'Fever', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Decreased plasma free carnitine', 'Prominent forehead', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** and **decreased plasma free carnitine** are hallmark biochemical findings in GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to toxic accumulation of glutaric acid and secondary carnitine depletion.  
2. **Abnormal cerebral morphology** (e.g., frontotemporal atrophy, widened Sylvian fissures) and **prominent forehead** (macrocephaly) are classic neuroimaging and clinical features of GA-I due to striatal injury and impaired brain development.  
3. **Generalized hypotonia** and **feeding difficulties** reflect acute or chronic neurologic dysfunction, common in infancy during metabolic decompensation.  
4. **Fever** often triggers catabolic crises, exacerbating metabolic derangements and neurodegeneration.  
5. **Death in infancy** aligns with untreated GA-I, as acute encephalopathic crises or progressive neurologic damage can be fatal without dietary management (protein restriction, carnitine supplementation) and emergency care during metabolic stress.  
6. The constellation of metabolic, neurologic, and dysmorphic features excludes other organic acidemias or mitochondrial disorders."
"['Microcephaly', 'Hearing impairment', 'Cataract', 'Proptosis', 'Growth delay']",['Cockayne syndrome A'],"Disease: Cockayne syndrome A  
Reasoning:  
1. **Microcephaly**: A hallmark of Cockayne syndrome (CS), caused by progressive neurodegeneration and impaired brain development.  
2. **Hearing impairment**: Sensorineural hearing loss is common in CS due to neurological and cochlear degeneration.  
3. **Cataract**: Ocular abnormalities, including cataracts, arise from DNA repair defects impacting lens transparency.  
4. **Proptosis**: Facial atrophy and sunken eyes in CS can create an illusion of protruding eyes, though true proptosis may occur due to orbital fat loss.  
5. **Growth delay**: Severe postnatal growth failure is a cardinal feature, driven by cellular sensitivity to UV-induced DNA damage and metabolic dysfunction.  

The combination of neurodevelopmental, sensory, and growth abnormalities aligns with Cockayne syndrome type A (CSA), an autosomal recessive disorder caused by mutations in *ERCC8*. Differentiated from other subtypes (e.g., CSB) by earlier onset and severity, CSA typically manifests in infancy with these core features."
"['Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Directly indicates abnormal accumulation of glutaric acid, a hallmark of GA-I due to deficient glutaryl-CoA dehydrogenase activity.  
2. **Metabolic acidosis**: Results from toxic buildup of glutaric acid and related metabolites, disrupting acid-base balance.  
3. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to glutaric acid for excretion, reducing free carnitine levels.  
4. **Generalized hypotonia**: Neurotoxic effects of accumulated metabolites impair muscle tone and neuronal function.  
5. **Neonatal death/Death in infancy**: Untreated GA-I causes acute metabolic crises, striatal necrosis, and catastrophic neurological deterioration, often fatal early in life without prompt dietary and metabolic intervention.  
6. **Consistency with GA-I**: The triad of glutaric aciduria, neurologic symptoms, and secondary carnitine deficiency aligns with GA-I pathophysiology, distinguishing it from other organic acidemias (e.g., GA-II involves multiple acyl-CoA dehydrogenases and distinct biochemical markers)."
"['Delayed speech and language development', 'Pallor', 'Intellectual disability', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Leukopenia', 'Anemia', 'Hyperammonemia', 'Hyperglycinemia', 'Drowsiness', 'Sleep disturbance', 'Hyperalaninemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Atransferrinemia', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Findings**: Hyperammonemia, hyperglycinemia, hyperalaninemia, and elevated urinary carboxylic acids align with PA's hallmark organic acidemia due to propionyl-CoA carboxylase deficiency, causing toxic metabolite accumulation.  
2. **Hematologic Abnormalities**: Leukopenia and anemia reflect bone marrow suppression from metabolic toxicity, common in PA crises.  
3. **Neurological Symptoms**: Intellectual disability, lethargy, generalized hypotonia, and delayed speech result from neurotoxic effects of ammonia/glycine and energy deficiency.  
4. **Early Mortality**: Death in infancy/childhood is typical in severe, untreated PA due to metabolic decompensation.  
5. **Carnitine Abnormalities**: Abnormal carnitine levels occur as carnitine is depleted to conjugate propionyl-CoA for excretion.  
6. **Atypical Features**: Atransferrinemia and hearing impairment are less common but may arise from chronic metabolic stress or secondary complications.  
7. **Sleep/Drowsiness**: Hyperammonemia disrupts CNS function, explaining drowsiness and sleep disturbances.  
8. **Porphyrin Anomalies**: Likely secondary to mitochondrial dysfunction affecting heme synthesis pathways.  

PA integrates metabolic, hematologic, and neurologic symptoms, with key biochemical markers (hyperammonemia, hyperglycinemia, elevated carboxylic acids) confirming the diagnosis."
"['Dementia', 'Hallucinations', 'Delusions', 'Dysarthria', 'Gait disturbance', 'Parkinsonism', 'Dystonia', 'Tremor', 'Rigidity', 'Micrographia', 'Dyskinesia']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Early-onset parkinsonism**: The presence of tremor, rigidity, gait disturbance, and micrographia aligns with core parkinsonian features. Autosomal recessive early-onset Parkinson’s disease (PARK23) typically manifests before age 40.  
2. **Neuropsychiatric symptoms**: Dementia, hallucinations, and delusions suggest atypical cognitive/psychiatric involvement, which is reported in DNAJC6-related PD23 due to broader neuronal dysfunction.  
3. **Movement abnormalities**: Dystonia and dyskinesia are common in early-onset genetic parkinsonism, often exacerbated by dopaminergic therapy or intrinsic basal ganglia pathology.  
4. **Dysarthria and gait disturbance**: Reflects progressive neurodegeneration affecting both motor and extrapyramidal pathways.  
5. **Genetic correlation**: DNAJC6 mutations impair chaperone-mediated neuroprotection, leading to early synaptic dysfunction and multisystemic degeneration, consistent with the symptom profile.  
6. **Exclusion of mimics**: The combination of parkinsonism, cognitive decline, and psychiatric features distinguishes PD23 from other early-onset forms (e.g., PARK2/Parkin) that lack prominent neuropsychiatric signs."
"['Hyperinsulinemia', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia and 4-Hydroxyphenylpyruvic aciduria**: Direct biochemical hallmarks of tyrosinemia type 1 (HT-1), caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic accumulation of tyrosine metabolites.  
2. **Hyperphenylalaninemia**: Secondary inhibition of phenylalanine hydroxylase by tyrosine metabolites, mimicking phenylketonuria (PKU) biochemically.  
3. **Elevated alpha-fetoprotein (AFP)**: Reflects hepatic injury and regenerative nodules, a characteristic feature of HT-1-associated hepatocellular dysfunction.  
4. **Hypoglycemia and hyperinsulinemia**: Hepatic failure impairs gluconeogenesis and insulin clearance, causing paradoxical hypoglycemia despite hyperinsulinemia.  
5. **Neonatal/infant/childhood mortality**: Untreated HT-1 causes acute liver failure, renal tubulopathy, and porphyria-like neurological crises, often fatal in early life.  
6. **Prenatal developmental abnormalities**: Chronic intrauterine metabolic stress from tyrosine derivative toxicity may disrupt organogenesis.  
7. **Hepatorenal involvement**: Pathognomonic for HT-1, with succinylacetone (pathognomonic urinary marker) causing renal Fanconi syndrome and hepatic cirrhosis.  
Diagnostic confirmation requires urine succinylacetone testing, plasma amino acids (↑ tyrosine), and FAH gene analysis."
"['Microcephaly', 'Recurrent corneal erosions', 'Alacrima', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Constipation', 'Increased serum lactate', 'EEG abnormality', 'Scoliosis', 'Elevated hepatic transaminase', 'Peripheral neuropathy']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Alacrima**: A core diagnostic feature of CDDG1, explaining the absence of tears.  
2. **Recurrent corneal erosions**: Secondary to alacrima due to lack of tear lubrication and corneal protection.  
3. **Elevated hepatic transaminase**: Reflects liver dysfunction, a key component of the syndrome.  
4. **Global developmental delay & Hypotonia**: Consistent with neurological involvement in CDDG1, linked to defective deglycosylation affecting brain development.  
5. **Microcephaly & Intrauterine growth retardation (IUGR)**: Aligns with congenital growth and neurodevelopmental deficits in CDDG1.  
6. **Increased serum lactate**: Suggests mitochondrial dysfunction, common in metabolic disorders like CDDG1.  
7. **EEG abnormality & Peripheral neuropathy**: Indicates central and peripheral nervous system abnormalities, typical of deglycosylation defects.  
8. **Reduced tendon reflexes**: Likely due to peripheral neuropathy or hypotonia.  
9. **Scoliosis**: May arise from neuromuscular hypotonia or connective tissue involvement.  
10. **Constipation**: Gastrointestinal dysmotility, often seen in CDGs due to autonomic or muscular dysfunction.  

The triad of **alacrima, liver dysfunction, and neurological deficits** (developmental delay, hypotonia, neuropathy), alongside supportive features (IUGR, metabolic derangements), confirms CDDG1, typically caused by *NGLY1* mutations impairing deglycosylation pathways."
"['Cleft palate', 'Pierre-Robin sequence', 'Choanal atresia', 'Webbed neck', 'Cystic hygroma', 'Multiple pterygia', 'Atrial septal defect', 'Scoliosis', 'Abnormal rib ossification']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Cleft palate & Pierre-Robin sequence**: Core features of CCMS, involving micrognathia (small jaw), glossoptosis, and airway obstruction, often accompanied by cleft palate.  
2. **Abnormal rib ossification & scoliosis**: Hallmark skeletal defects in CCMS, including rib gaps, malformation, and scoliosis secondary to thoracic abnormalities.  
3. **Choanal atresia**: Observed in some CCMS cases due to craniofacial maldevelopment.  
4. **Atrial septal defect**: Congenital heart defects, though less common, are reported in CCMS.  
5. **Webbed neck, cystic hygroma, multiple pterygia**: These may overlap with lymphatic or connective tissue anomalies, potentially linked to broader developmental disruptions in CCMS. While not classic features, they could reflect phenotypic variability or secondary effects of skeletal and craniofacial defects.  

The diagnosis prioritizes the triad of micrognathia (Pierre-Robin), cleft palate, and rib malformations, with other symptoms contextualized within the syndrome’s spectrum."
"['Eczematoid dermatitis', 'Skin rash', 'Seizure', 'Lethargy', 'Death in infancy', 'Constipation', 'Respiratory insufficiency', 'Drowsiness', 'Sleep disturbance', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Abnormal circulating glycine concentration']","['Mitochondrial complex IV deficiency, nuclear type 1']","Mitochondrial complex IV deficiency, nuclear type 1:  
The patient exhibits **ethylmalonic aciduria** and **cytochrome C oxidase (COX)-negative muscle fibers**, which are hallmark biochemical and histopathological findings in mitochondrial complex IV deficiency. This disorder disrupts oxidative phosphorylation, leading to energy depletion in high-demand tissues. **Seizures**, **lethargy**, **drowsiness**, and **respiratory insufficiency** reflect neurological and systemic metabolic dysfunction. **Death in infancy** aligns with severe infantile-onset forms of the disease. **Abnormal circulating glycine concentration** may arise from secondary metabolic disturbances due to impaired mitochondrial function. **Skin rash** and **eczematoid dermatitis** are nonspecific but recurrent in mitochondrial disorders due to oxidative stress and inflammation. **Constipation** and **sleep disturbance** correlate with autonomic nervous system involvement. The collective presentation of multi-organ failure, metabolic acidosis (implied by ethylmalonic aciduria), and COX deficiency confirms the diagnosis."
"['Hydrocephalus', 'Microcephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Death in infancy', 'Premature birth', 'Respiratory insufficiency', 'Hyperhomocystinemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Dyskinesia']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, caused by defects in methylmalonyl-CoA mutase or cobalamin (B12) metabolism. Symptoms like **respiratory insufficiency**, **neonatal death**, **death in childhood**, and **abnormal carnitine levels** align with MMA’s metabolic crises. However, **hyperhomocystinemia** and **neurological features** (e.g., intellectual disability, strabismus, nystagmus) suggest a **combined disorder** involving homocysteine, prompting consideration of a cobalamin metabolism defect.  

Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning: The **co-occurrence of methylmalonic aciduria and hyperhomocystinemia** is pathognomonic for **cblC type**, the most common inborn error of cobalamin metabolism. This disorder explains **neurological symptoms** (hydrocephalus, microcephaly, dyskinesia, nystagmus), **premature birth**, and **early mortality** due to multisystem decompensation. **Abnormal carnitine levels** and **respiratory insufficiency** further support severe metabolic dysfunction. The combination of MMA and homocystinuria distinguishes cblC from isolated MMA or homocystinuria alone."
"['Death in infancy', 'Glutaric aciduria', 'Neonatal death']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to toxic accumulation of glutaric acid.  
2. **Neonatal death** and **death in infancy** align with severe GA-I phenotypes, where absent enzyme activity triggers acute metabolic crises (e.g., acidosis, encephalopathy) shortly after birth.  
3. GA-I’s biochemical hallmark—elevated urinary glutaric acid—directly correlates with the symptom list, excluding other organic acidurias (e.g., propionic/methylmalonic acidemia) that present with distinct metabolites.  
4. Early lethality in untreated cases supports this diagnosis, as delayed management exacerbates neurotoxicity and multisystem failure."
"['Microcephaly', 'Prominent occiput', 'Long face', 'Smooth philtrum', 'Narrow forehead', 'Bulbous nose', 'Prominent nasal bridge', 'Deeply set eye', 'Widely spaced teeth', 'Delayed speech and language development', 'Pectus excavatum', 'Tapered finger', 'Ataxia', 'Bilateral tonic-clonic seizure', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Asymmetry of the ears', 'Feeding difficulties', 'Stereotypical hand wringing', 'Tongue thrusting']","['DYRK1A-related intellectual disability syndrome/Mental retardation, autosomal dominant 7']","Disease: DYRK1A-related intellectual disability syndrome/Mental retardation, autosomal dominant 7  
Reasoning:  
1. **Core Features**: Microcephaly, intellectual disability (delayed speech), and characteristic facial features (long face, smooth philtrum, narrow forehead, bulbous nose, prominent nasal bridge, deeply set eyes) align with DYRK1A syndrome.  
2. **Supporting Craniofacial Signs**: Widely spaced teeth, prominent occiput, and ear asymmetry further match reported dysmorphisms in DYRK1A.  
3. **Neurological/Developmental**: Ataxia, seizures (tonic-clonic and febrile within the typical age range), and stereotypies (hand wringing, tongue thrusting) correlate with the syndrome’s neurological profile.  
4. **Musculoskeletal/Somatic**: Pectus excavatum, tapered fingers, and feeding difficulties are consistent with systemic involvement.  
5. **Exclusion of Mimics**: Overlap with Rett or Angelman syndromes is ruled out by the absence of regression (Rett) and distinct facial/genetic markers (Angelman).  
6. **Genetic Confirmation**: While clinical features are diagnostic, molecular testing for DYRK1A mutations would confirm."
"['Seizure', 'Hyperammonemia', 'Cerebral edema', 'Oroticaciduria', 'Hypoargininemia', 'Hyperprolinemia', 'Elevated plasma citrulline', 'Citrullinuria']","['Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Elevated plasma citrulline and citrullinuria**: These are hallmark findings of argininosuccinate synthetase (ASS) deficiency, which prevents the conversion of citrulline to argininosuccinate in the urea cycle.  
2. **Hyperammonemia**: Caused by impaired urea cycle function, leading to toxic ammonia accumulation.  
3. **Hypoargininemia**: Reduced arginine production due to the enzymatic block at ASS, limiting downstream arginine synthesis.  
4. **Oroticaciduria**: Likely secondary to partial carbamoyl phosphate spillover into pyrimidine synthesis, triggered by urea cycle dysfunction or mitochondrial stress from hyperammonemia.  
5. **Cerebral edema and seizures**: Result from ammonia toxicity and osmotic effects of accumulated glutamine in the brain.  
6. **Hyperprolinemia**: May arise from disrupted arginine-proline metabolic crosstalk or compensatory mechanisms in urea cycle failure.  

This constellation of findings—urea cycle disruption, citrulline accumulation, and secondary metabolic effects—confirms the diagnosis of Citrullinemia type I."
"['Renal insufficiency', 'Proteinuria', 'Glomerulonephritis', 'Amenorrhea', 'Hematuria', 'Arthritis', 'Splenomegaly', 'Microcytic anemia', 'Dysphagia', 'Dyspnea', 'Hepatomegaly', 'Antinuclear antibody positivity', 'Prolonged partial thromboplastin time', 'Cachexia', 'Decreased glomerular filtration rate', 'Peripheral edema', 'Foamy urine', 'Anti-La/SS-B antibody positivity', 'Serositis', 'Abnormality of nail color']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Mixed connective tissue disease', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus']","Disease: Systemic lupus erythematosus  
Reasoning:  
1. **Renal involvement**: Proteinuria, hematuria, foamy urine, decreased glomerular filtration rate, and glomerulonephritis align with lupus nephritis, a hallmark of SLE.  
2. **Immunologic markers**: Antinuclear antibody (ANA) positivity is a key diagnostic criterion for SLE. Anti-La/SS-B antibodies, though often linked to Sjögren’s syndrome, can occur in SLE with overlapping features.  
3. **Multisystem involvement**:  
   - **Hematologic**: Microcytic anemia (potentially from chronic inflammation or blood loss) and prolonged PTT (suggestive of lupus anticoagulant or antiphospholipid syndrome, common in SLE).  
   - **Musculoskeletal**: Arthritis.  
   - **Serositis**: Pleural or pericardial inflammation.  
   - **Dermatologic**: Nail color abnormalities may reflect vascular changes.  
4. **Constitutional symptoms**: Cachexia and peripheral edema (secondary to nephrotic syndrome or chronic inflammation).  
5. **Hepatosplenomegaly**: Autoimmune-mediated inflammation or secondary to hematologic dysfunction.  
6. **Amenorrhea**: May result from chronic disease, hormonal disruption, or autoimmune ovarian involvement.  

Disease: Mixed connective tissue disease (MCTD)  
Reasoning:  
1. **Overlap features**: Dysphagia (esophageal dysmotility, seen in scleroderma overlap) and dyspnea (interstitial lung disease or pulmonary hypertension).  
2. **Autoantibodies**: ANA positivity is nonspecific but required for MCTD. However, anti-U1 RNP antibodies (pathognomonic for MCTD) are not explicitly listed here.  
3. **Renal and hematologic involvement**: Shared with SLE, making MCTD a differential, though less likely without definitive anti-U1 RNP or scleromyositis features.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning:  
- Genetic susceptibility loci (e.g., **STAT4 gene variants**) may predispose to SLE. While clinical symptoms align with active SLE, this diagnosis refers to genetic predisposition rather than active disease manifestation.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning:  
- Identical clinical features to adult SLE, but age-dependent classification. Requires confirmation of patient age, which is unspecified here.  

Excluded diagnoses:  
- **Vitiligo-Associated multiple autoimmune disease susceptibility 1**: Absence of vitiligo or other autoimmune conditions (e.g., thyroiditis) weakens this association.  
- **Anti-La/SS-B positivity** alone is insufficient for Sjögren’s syndrome diagnosis without sicca symptoms (e.g., dry eyes/mouth).  

**Final Diagnosis**: **Systemic lupus erythematosus** with probable lupus nephritis and secondary antiphospholipid syndrome (prolonged PTT). Overlap features (e.g., Anti-La/SS-B) warrant monitoring for Sjögren’s syndrome or MCTD evolution."
"['Death in infancy', 'Abnormal erythrocyte morphology', 'Thrombocytosis', 'Hypercalcemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Increased total bilirubin', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hypergalactosemia']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia Type 1 (HT-1)  
Reasoning:  
1. **Hypertyrosinemia and Hyperphenylalaninemia**: Directly indicate a defect in tyrosine metabolism. Tyrosinemia type 1 is caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic accumulation of tyrosine metabolites (succinylacetone), which inhibits renal and hepatic function.  
2. **Liver Dysfunction**:  
   - **Hypoalbuminemia/Hypoproteinemia**: Reduced hepatic synthesis due to liver damage.  
   - **Elevated Alpha-Fetoprotein (AFP)**: Reflects hepatocellular regeneration or malignancy (hepatocarcinoma risk in HT-1).  
   - **Increased Total Bilirubin and Alkaline Phosphatase**: Cholestatic liver injury and impaired biliary excretion.  
3. **Renal Involvement**:  
   - **Hypercalcemia**: Renal tubular dysfunction causing phosphate wasting and secondary hyperparathyroidism.  
   - **Abnormal Circulating Porphyrins**: Succinylacetone inhibits δ-aminolevulinic acid dehydratase, leading to porphyrin synthesis disruption.  
4. **Metabolic Derangements**:  
   - **Hypergalactosemia**: Secondary to liver failure impairing galactose metabolism.  
   - **Thrombocytosis**: Reactive to chronic inflammation or hypersplenism from liver disease.  
5. **Abnormal Erythrocyte Morphology**: Liver dysfunction disrupts lipid metabolism, affecting red blood cell membrane stability.  
6. **Death in Infancy**: Untreated HT-1 causes rapid progression of liver failure, coagulopathy, and neurologic crises, often fatal in early childhood.  

The constellation of liver, renal, and metabolic abnormalities aligns pathognomonically with Tyrosinemia Type 1, confirmed by elevated succinylacetone in urine or genetic testing for FAH mutations."
"['Narrow face', 'Micrognathia', 'Ptosis', 'Diplopia', 'Dysarthria', 'Hyporeflexia', 'Impaired vibratory sensation', 'Waddling gait', 'Falls', 'Scoliosis', 'High, narrow palate', 'Myoglobinuria', 'Skeletal muscle atrophy', 'Myalgia', 'Gowers sign', 'Scapular winging', 'Proximal muscle weakness', 'Difficulty running', 'Impaired tactile sensation', 'Abnormal nerve conduction velocity']",['Nemaline myopathy 1'],"Disease: Nemaline myopathy 1  
Reasoning:  
1. **Proximal muscle weakness**, **scapular winging**, and **Gowers sign** indicate a primary myopathy affecting proximal muscles, consistent with congenital muscle disorders like nemaline myopathy.  
2. **Skeletal muscle atrophy**, **waddling gait**, **difficulty running**, and **falls** reflect progressive muscle degeneration and functional impairment, hallmark features of nemaline myopathy.  
3. **High, narrow palate** and **scoliosis** suggest congenital musculoskeletal involvement, often seen in nemaline myopathy due to chronic muscle weakness and developmental adaptations.  
4. **Ptosis** and **dysarthria** point to facial and bulbar muscle weakness, aligning with nemaline myopathy’s systemic muscle involvement.  
5. **Myoglobinuria** and **myalgia** may indicate episodic rhabdomyolysis, a rare but documented feature in some nemaline myopathy cases, particularly during metabolic stress.  
6. **Hyporeflexia** and **abnormal nerve conduction velocity** are atypical but could stem from secondary neuropathy or overlap with neuromuscular junction dysfunction in advanced disease.  
7. **Impaired vibratory/tactile sensation** is less common but may arise from prolonged immobilization or comorbid neuropathic changes in chronic myopathy.  

The constellation of congenital craniofacial features (narrow face, micrognathia), skeletal abnormalities, and progressive myopathic symptoms strongly supports **nemaline myopathy type 1** (NEM1), linked to mutations in *TPM3* affecting tropomyosin function in muscle fibers."
"['Microcephaly', 'Deeply set eye', 'Developmental cataract', 'Dry skin', 'Cutaneous photosensitivity']","['Cockayne syndrome, type B']","Disease: Cockayne syndrome, type B  
Reasoning:  
1. **Microcephaly** and **developmental delays** align with Cockayne syndrome’s hallmark neurological and growth abnormalities.  
2. **Deeply set eyes** (enophthalmos) is a common craniofacial feature in Cockayne syndrome due to facial fat loss and skeletal dysplasia.  
3. **Developmental cataracts** are characteristic of Cockayne syndrome type B, arising from DNA repair defects affecting lens transparency.  
4. **Dry skin** and **cutaneous photosensitivity** reflect defective nucleotide excision repair (NER), leading to UV-induced damage and premature aging of skin.  
5. The combination of photosensitivity, neurodegeneration, and ocular abnormalities strongly differentiates Cockayne syndrome from other DNA repair disorders (e.g., xeroderma pigmentosum).  
6. Type B is distinguished by earlier onset and severe progression, consistent with the listed symptoms."
"['Irritability', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Aminoaciduria', 'Abnormal circulating pyrimidine concentration', 'Decreased plasma free carnitine', 'Hyperprolinemia', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Death in early adulthood']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, as the urea cycle enzyme deficiency prevents ammonia detoxification.  
2. **Oroticaciduria & Uraciluria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate diverts to pyrimidine synthesis, overproducing orotic acid and uracil.  
3. **Hyperglutaminemia**: Excess ammonia is converted to glutamine as an alternative detoxification pathway.  
4. **Elevated plasma citrulline**: Uncommon in classic OTCD but may occur in partial deficiencies or compensatory mechanisms, though typically low. This could reflect atypical presentation or overlapping metabolic stress.  
5. **Aminoaciduria/Hyperalaninemia/Hyperprolinemia**: Secondary to generalized amino acid overflow from impaired urea cycle function.  
6. **Metabolic acidosis**: Likely due to secondary organic acid accumulation or renal tubular dysfunction from ammonia toxicity.  
7. **Decreased plasma carnitine**: Carnitine depletion from increased acylcarnitine formation during metabolic crises.  
8. **Early mortality**: Aligns with severe urea cycle defects; untreated hyperammonemia leads to neurological damage and death.  

The triad of **hyperammonemia, oroticaciduria, and uraciluria** is diagnostic for OTCD, overriding atypical citrulline elevation. Other amino acid abnormalities and clinical outcomes further support this diagnosis."
"['Hydrocephalus', 'High forehead', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Cerebral atrophy', 'Athetosis', 'Glutaric aciduria', 'Death in childhood']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity.  
2. **Neurological symptoms (Spasticity, Athetosis, Cerebral atrophy)**: Accumulation of glutaric acid and 3-hydroxyglutaric acid damages the basal ganglia and white matter, leading to dystonia, movement disorders, and progressive neurodegeneration.  
3. **Macrocephaly/High forehead**: Often presents in infancy due to transient subdural hemorrhages or pseudohydrocephalus secondary to brain atrophy.  
4. **Generalized hypotonia**: Early manifestation before metabolic crises or neurological deterioration.  
5. **Death in infancy/childhood**: Severe metabolic decompensation (e.g., during infections) or irreversible brain injury in untreated cases.  
6. **Cerebral atrophy**: Chronic neurotoxicity from toxic metabolites results in progressive loss of brain tissue.  
The combination of characteristic organic aciduria, striatal injury patterns, and clinical progression aligns definitively with GA-I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria  
Reasoning:  
1. **Hyperphenylalaninemia** is the defining biochemical feature of PKU, caused by mutations in the *PAH* gene, leading to impaired phenylalanine metabolism.  
2. **Abnormality of prenatal development or birth** may occur in maternal PKU syndrome, where elevated phenylalanine levels during pregnancy cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus. If the patient is the affected infant, this could reflect intrauterine growth restriction due to metabolic dysregulation.  
3. **Neonatal death/Death in infancy**: Untreated PKU does not typically cause death in the neonatal period, but severe variants (e.g., BH4-deficient PKU) or complications like metabolic crises/sepsis in undiagnosed cases may lead to early mortality.  
4. **Death in early adulthood**: Chronic untreated hyperphenylalaninemia results in irreversible neurological damage, seizures, and systemic complications (e.g., osteoporosis, cardiomyopathy), which may contribute to premature death if dietary management is absent.  

The constellation of symptoms aligns with a severe, untreated PKU phenotype, exacerbated by lack of newborn screening or therapy, progressing from infancy to adulthood with fatal outcomes."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Bradycardia', 'Vomiting', 'Dicarboxylic aciduria', 'Neonatal death']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria (HMG-CoA lyase deficiency)  
Reasoning:  
1. **Dicarboxylic aciduria**: A hallmark of impaired fatty acid β-oxidation and ketogenesis. HMG-CoA lyase deficiency disrupts leucine metabolism and ketone body synthesis, leading to urinary excretion of dicarboxylic acids.  
2. **Neonatal death/Death in infancy**: Severe metabolic crises (hypoketotic hypoglycemia, metabolic acidosis) triggered by fasting or catabolism are common in untreated infants.  
3. **Seizures**: Result from acute hypoglycemia and energy depletion in the brain.  
4. **Vomiting and Bradycardia**: Metabolic acidosis and electrolyte imbalances disrupt gastrointestinal and cardiac function.  
5. **Cyanosis**: Secondary to respiratory distress caused by acidosis or poor tissue oxygenation during metabolic decompensation.  
6. **Confirmatory biochemical markers**: Elevated 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-hydroxyisovaleric acids in urine organic acid analysis confirm the diagnosis."
"['Labial hypertrophy', 'Enlarged kidney', 'Ovarian cyst', 'Otitis media', 'Hyperinsulinemia', 'Global developmental delay', 'Left ventricular hypertrophy', 'Hypoglycemia', 'Rectal prolapse', 'Pneumonia', 'Recurrent infections', 'Abdominal distention', 'Clitoral hypertrophy', 'Increased C-peptide level']",['Leprechaunism/Donohue syndrome'],"Disease: Leprechaunism/Donohue syndrome  
Reasoning:  
1. **Hyperinsulinemia and Hypoglycemia**: Central to Donohue syndrome due to severe insulin resistance, leading to excessive insulin production (elevated C-peptide) and paradoxical hypoglycemia.  
2. **Genital Anomalies (Labial/Clitoral Hypertrophy)**: Hormonal dysregulation from insulin receptor mutations causes androgen-like effects, resulting in genital overgrowth.  
3. **Global Developmental Delay**: Severe growth retardation and neurodevelopmental deficits are hallmark features of the syndrome.  
4. **Recurrent Infections (Otitis Media, Pneumonia)**: Immune dysfunction linked to metabolic derangements and poor tissue integrity increases susceptibility.  
5. **Organomegaly (Enlarged Kidney, Ovarian Cysts)**: Insulin’s growth-promoting effects via IGF-1 receptors drive abnormal organ enlargement.  
6. **Left Ventricular Hypertrophy**: Chronic metabolic stress (hypoglycemia, hyperinsulinemia) strains cardiac function.  
7. **Abdominal Distention/Rectal Prolapse**: Hypotonia, malnutrition, and connective tissue weakness contribute to gastrointestinal complications.  
8. **Clinical Consistency**: Overlapping features (insulin resistance, dysmorphia, organomegaly) rule out mimics like Beckwith-Wiedemann or Rabson-Mendenhall syndromes."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. Untreated **classic PKU** results in severe neurological damage, seizures, and intellectual disability. In extreme cases, metabolic instability or secondary complications (e.g., infections, failure to thrive) may contribute to **death in infancy** or **neonatal death**, especially in resource-limited settings lacking newborn screening and dietary management.  
3. **Neonatal death** is atypical in well-managed PKU but could occur in severe variants (e.g., BH4-deficient forms) with additional neurotransmitter deficiencies or acute metabolic crises.  
4. The triad of symptoms aligns with undiagnosed/untreated PKU, emphasizing the critical need for early detection via newborn screening to prevent fatal outcomes."
"['Death in infancy', 'Hypoglycemia', 'Vomiting', 'Diarrhea', 'Elevated hepatic transaminase', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Medium chain acyl-CoA dehydrogenase deficiency (MCADD):  
1. **Hypoglycemia**: MCADD impairs the breakdown of medium-chain fatty acids, a critical energy source during fasting. This leads to hypoglycemia due to the inability to generate ketones as an alternative fuel.  
2. **Vomiting/Diarrhea**: Metabolic decompensation during fasting or infection triggers gastrointestinal symptoms.  
3. **Elevated hepatic transaminases**: Accumulation of toxic metabolites (e.g., medium-chain acylcarnitines) causes hepatocellular damage.  
4. **Abnormal carnitine profile**: Secondary carnitine deficiency occurs due to urinary loss of carnitine bound to unmetabolized fatty acids (elevated C8-C10 acylcarnitines on bloodspot analysis).  
5. **Death in infancy**: Untreated MCADD carries high mortality from hypoglycemia, encephalopathy, and liver failure during catabolic stress. Neonatal screening and avoidance of fasting are lifesaving."
"['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids** align with phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) excreted via alternative pathways in untreated PKU.  
3. **Early mortality** (neonatal/infancy/childhood/adolescence) reflects severe, untreated PKU complications: irreversible neurotoxicity, seizures, and failure to thrive prior to modern dietary management.  
4. **Hypertyrosinemia** is atypical in classic PKU (tyrosine levels are usually low due to PAH deficiency). This may suggest a coexisting condition (e.g., tyrosinemia) or a reporting error, but PKU remains the primary diagnosis given hyperphenylalaninemia and urinary findings.  
5. Neonatal screening and dietary restriction of phenylalanine typically prevent progression, but historical cases without intervention explain the fatal trajectory described."
"['Generalized hypotonia', 'Death in infancy', 'Weight loss', 'Fever', 'Dyspnea', 'Oroticaciduria', 'Neonatal death', 'Inappropriate crying']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Oroticaciduria**: A hallmark of OTCD due to secondary pyrimidine synthesis disruption. Accumulated carbamoyl phosphate is diverted to orotic acid production.  
2. **Hyperammonemia (implied)**: Neonatal death, hypotonia, and inappropriate crying suggest metabolic encephalopathy from elevated ammonia (unmeasured but pathognomonic in OTCD).  
3. **Neonatal/Infantile lethality**: Severe OTCD manifests shortly after birth with rapid metabolic decompensation, consistent with ""death in infancy"" and ""neonatal death.""  
4. **Respiratory and systemic symptoms**: Dyspnea and fever may reflect secondary metabolic acidosis or triggering infections (common precipitants of urea cycle crises).  
5. **Neuromuscular signs**: Generalized hypotonia aligns with hyperammonemia-induced CNS toxicity.  
6. **Weight loss**: Poor feeding and catabolism during metabolic stress.  

OTCD is strongly supported by the triad of oroticaciduria, neonatal hyperammonemia features, and rapid fatal course. Other urea cycle disorders lack oroticaciduria, while acquired causes (e.g., liver failure) do not explain neonatal onset."
"['Hepatic steatosis', 'Reduced antithrombin III activity', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Abnormal circulating copper concentration', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Abnormal protein O-linked glycosylation', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Glycosylation Defects**: Abnormal N-linked and O-linked glycosylation are hallmark features of congenital disorders of glycosylation (CDGs). TMEM199-CDG specifically disrupts both pathways, distinguishing it from CDGs affecting only one type.  
2. **Hepatic Involvement**: Hepatic steatosis, elevated AST/ALT, and alkaline phosphatase indicate liver dysfunction, common in TMEM199-CDG due to impaired glycosylation-dependent hepatic protein trafficking.  
3. **Coagulation Abnormalities**: Reduced antithrombin III activity arises from defective glycosylation of this glycoprotein, critical for its function.  
4. **Cholesterol Dysregulation**: Hypercholesterolemia and elevated LDL stem from disrupted lipid metabolism, linked to hepatic glycosylation defects affecting lipoprotein processing.  
5. **Copper/Ceruloplasmin Abnormalities**: Decreased ceruloplasmin (a glycosylated copper transporter) and abnormal copper levels result from failed glycosylation, mimicking Wilson’s disease but distinct in mechanism.  
6. **Consistent Phenotype**: TMEM199-CDG is specifically associated with combined hepatic, coagulation, lipid, and copper abnormalities, aligning with the patient’s profile.  

(The two diagnoses provided are synonymous: TMEM199-CDG is the molecular designation for CDG type IIP.)"
"['Inguinal hernia', 'Trigonocephaly', 'Microcephaly', 'Coarse facial features', 'Proptosis', 'Pectus carinatum', 'Plagiocephaly', 'Flexion contracture', 'Failure to thrive', 'Small for gestational age', 'Delayed gross motor development', 'Hyperlordosis', 'Depressed nasal bridge', 'Hyperactive deep tendon reflexes']",['Mucolipidosis type II/Mucolipidosis II alpha/beta'],"Disease: Mucolipidosis type II alpha/beta (I-cell disease)  
Reasoning:  
1. **Coarse facial features, depressed nasal bridge, proptosis**: Hallmark of lysosomal storage disorders (LSDs), particularly ML II due to glycosaminoglycan accumulation in tissues.  
2. **Trigonocephaly, plagiocephaly, microcephaly**: Craniosynostosis and skull deformities from abnormal bone development, common in ML II.  
3. **Skeletal abnormalities (pectus carinatum, hyperlordosis, flexion contractures)**: Reflect severe skeletal dysplasia (""dysostosis multiplex"") caused by defective lysosomal enzyme trafficking.  
4. **Failure to thrive, small for gestational age**: Growth retardation typical of ML II, presenting prenatally or early infancy.  
5. **Delayed motor development, hyperactive deep tendon reflexes**: Neurological involvement from storage material accumulation and spinal cord compression.  
6. **Inguinal hernia**: Connective tissue weakness, frequently seen in ML II and other LSDs.  

ML II is confirmed by deficient **GlcNAc-1-phosphotransferase** activity, elevated lysosomal enzymes in plasma, and pathogenic variants in the *GNPTAB* gene."
"['Skin rash', 'Death in infancy', 'Glycosuria', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Functional abnormality of the gastrointestinal tract', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Cytochrome C oxidase (COX)-negative muscle fibers**: Directly indicates a deficiency in mitochondrial complex IV (COX), a hallmark of this disorder.  
2. **Ethylmalonic aciduria**: Linked to impaired mitochondrial fatty acid oxidation and oxidative phosphorylation, consistent with complex IV dysfunction.  
3. **Death in infancy**: Severe mitochondrial disorders often present with early lethality due to multisystem energy failure.  
4. **Glycosuria**: Suggests renal tubular dysfunction, a known feature of mitochondrial disorders affecting proximal tubule energetics.  
5. **Feeding difficulties & gastrointestinal tract abnormalities**: Reflects high energy demands of the gut, disrupted by mitochondrial ATP deficiency.  
6. **Skin manifestations (rash, plaques, macules, papules)**: May arise from metabolic acidosis, oxidative stress, or secondary inflammation due to mitochondrial dysfunction.  
7. **Abnormal circulating glycine**: Mitochondria play a role in glycine metabolism; dysregulation can occur in respiratory chain defects.  
8. **Nuclear type 1**: Specifies a nuclear DNA mutation (e.g., *COX4I1*, *SURF1*) causing the deficiency, differentiating it from mtDNA-related forms.  

The constellation of metabolic, neuromuscular, and multisystem symptoms aligns with mitochondrial complex IV deficiency, with genetic confirmation targeting nuclear-encoded assembly or catalytic subunits."
"['Dystonia', 'Abnormal foot morphology', 'Difficulty walking', 'Skeletal muscle atrophy', 'Hypertyrosinemia', 'Difficulty climbing stairs', 'Death in childhood', 'Hyperphenylalaninemia', 'Contractures of the large joints', 'Difficulty running', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Abnormal circulating porphyrin concentration', 'Death in adolescence']","['Autosomal dominant dopa-responsive dystonia/Dystonia, DOPA-responsive, with or without hyperphenylalaninemia']","Disease: Autosomal dominant dopa-responsive dystonia/Dystonia, DOPA-responsive, with or without hyperphenylalaninemia  
Reasoning:  
1. **Dystonia and motor difficulties**: The patient’s dystonia, difficulty walking, climbing stairs, and running align with dopa-responsive dystonia (DRD), which classically improves with levodopa. Chronic dystonia can lead to secondary skeletal muscle atrophy and joint contractures due to disuse or abnormal posturing.  
2. **Hyperphenylalaninemia**: Linked to mutations in *GCH1*, a gene critical for tetrahydrobiopterin (BH4) synthesis. BH4 deficiency impairs phenylalanine hydroxylase (PAH), causing phenylalanine accumulation. While classic BH4 defects typically reduce tyrosine, this subtype may involve compensatory mechanisms or variable metabolic flux.  
3. **Hypertyrosinemia**: Uncommon in DRD but could arise from disrupted tyrosine metabolism secondary to BH4-related enzyme imbalances or dietary factors. This contrasts with tyrosinemia types (liver/neuropathic phenotypes), which are ruled out by the absence of liver/ocular symptoms.  
4. **Early mortality**: Untreated hyperphenylalaninemia or severe dystonia may lead to complications (e.g., respiratory failure, metabolic crises), explaining death in childhood/adolescence.  
5. **Musculoskeletal features**: Abnormal foot morphology, muscle hypoplasia, and contractures are likely secondary to chronic dystonia and impaired mobility rather than primary myopathy.  
6. **Abnormal porphyrins**: Likely incidental or a nonspecific metabolic disturbance, as porphyrin abnormalities are not pathognomonic for DRD.  

The diagnosis prioritizes DRD due to the triad of dopa-responsive dystonia, hyperphenylalaninemia, and autosomal dominance, with other symptoms explained as secondary complications."
"['Self-mutilation', 'Hypotonia', 'Dysarthria', 'Hyporeflexia', 'Acanthocytosis', 'Dysphagia', 'Chorea', 'Bruxism', 'Lateral ventricle dilatation']",['Choreoacanthocytosis/CHOREOACANTHOCYTOSIS'],"Disease: Choreoacanthocytosis/CHOREOACANTHOCYTOSIS  
Reasoning:  
1. **Acanthocytosis**: Presence of spiky red blood cells is a hallmark of neuroacanthocytosis syndromes, strongly suggesting Choreoacanthocytosis (ChAc).  
2. **Chorea**: Involuntary movements align with basal ganglia dysfunction, a core feature of ChAc.  
3. **Self-mutilation**: Lip/tongue biting is pathognomonic for ChAc due to orofacial dystonia and impaired self-awareness.  
4. **Dysarthria/Dysphagia**: Bulbar involvement from neurodegeneration explains speech and swallowing difficulties.  
5. **Hypotonia/Hyporeflexia**: Reflects corticostriatal pathway degeneration and peripheral neuropathy, common in ChAc.  
6. **Bruxism**: Linked to oromandibular dystonia in neuroacanthocytosis.  
7. **Lateral ventricle dilatation**: Indicates cerebral atrophy, consistent with progressive neurodegeneration in ChAc.  
8. **Exclusion of mimics**: Absence of cardiomyopathy (rules out McLeod syndrome) and Kayser-Fleischer rings (excludes Wilson’s), alongside acanthocytosis, confirms ChAc."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death/Death in infancy** aligns with severe untreated PKU variants (e.g., classic or malignant forms), where rapid neurological deterioration, seizures, and organ failure occur without early dietary intervention.  
3. **Abnormality of prenatal development** may reflect maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy), causing fetal microcephaly, congenital heart defects, or growth restriction. However, if the infant itself has PKU, prenatal abnormalities could stem from metabolic stress in utero or comorbid genetic factors.  
4. PKU is typically asymptomatic at birth but manifests post-feeding. Neonatal death suggests an extreme presentation or delayed diagnosis, emphasizing the critical need for newborn screening and immediate phenylalanine-restricted diets."
"['Hepatic steatosis', 'Reduced antithrombin III activity', 'Hepatomegaly', 'Elevated circulating alkaline phosphatase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis and hepatomegaly**: TMEM199-CDG commonly presents with liver involvement, including fatty liver and enlarged liver.  
2. **Reduced antithrombin III activity**: Glycosylation defects impair synthesis of glycoproteins like antithrombin III, leading to functional deficiency.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, a hallmark of TMEM199-CDG.  
4. **Decreased ceruloplasmin and copper**: Ceruloplasmin, a copper-binding glycoprotein, requires proper glycosylation for stability. Its deficiency reduces circulating copper levels, distinguishing this from Wilson disease (where copper accumulates in tissues).  
5. **Consistent with TMEM199-CDG pathophysiology**: Mutations in *TMEM199* disrupt Golgi homeostasis, causing secondary glycosylation defects and hepatic/coagulation abnormalities.  

(Note: ""Congenital disorder of glycosylation, type IIP"" and ""TMEM199-CDG"" refer to the same disease, with the latter specifying the genetic cause.)"
"['Microcephaly', 'Epicanthus', 'Hypotonia', 'Global developmental delay', 'Hepatic fibrosis', 'Intrauterine growth retardation', 'EEG abnormality', 'Short nose', 'Prolonged neonatal jaundice', 'Lateral ventricle dilatation', 'Abnormality of movement']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Hepatic fibrosis** and **prolonged neonatal jaundice** align with the liver dysfunction characteristic of CDDG1.  
2. **Abnormality of movement** (e.g., choreoathetosis) and **EEG abnormality** reflect neurological involvement, consistent with the syndrome’s choreoathetosis phenotype.  
3. **Global developmental delay**, **hypotonia**, and **lateral ventricle dilatation** indicate widespread neurological dysfunction, typical of deglycosylation disorders affecting brain development.  
4. **Microcephaly** and **intrauterine growth retardation** suggest congenital origins, fitting CDDG1’s presentation of prenatal-onset growth and structural defects.  
5. Dysmorphic features (**epicanthus**, **short nose**) are common in congenital glycosylation disorders due to disrupted glycoprotein synthesis.  
6. While alacrimia (absent tears) is not explicitly listed, the combination of hepatic, neurological, and developmental abnormalities strongly supports CDDG1, as phenotypic variability is recognized.  
7. CDDG1 is caused by *NGLY1* mutations, impairing deglycosylation and leading to multi-organ dysfunction, as seen in this patient’s hepatic, neurological, and growth-related symptoms."
"['Dysarthria', 'Bulbar palsy', 'Dysphagia', 'Tetraparesis', 'Babinski sign', 'Ankle clonus', 'Tongue atrophy']",['Amyotrophic lateral sclerosis 1'],"Disease: Amyotrophic lateral sclerosis 1  
Reasoning:  
1. **Upper Motor Neuron (UMN) Signs**: Babinski sign and ankle clonus indicate corticospinal tract involvement.  
2. **Lower Motor Neuron (LMN) Signs**: Tongue atrophy and bulbar palsy (with dysarthria/dysphagia) reflect LMN degeneration in the bulbar region.  
3. **Tetraparesis**: Weakness in all four limbs suggests combined UMN and LMN dysfunction, a hallmark of ALS.  
4. **Exclusion of Mimics**: The combination of bulbar, limb, and mixed UMN/LMN signs without sensory deficits or other systemic features strongly supports ALS over alternatives (e.g., myasthenia gravis, spinal muscular atrophy).  
5. **Progression**: ALS typically presents with progressive motor deficits aligning with the listed symptoms."
"['Ptosis', 'Progressive visual loss', 'Ophthalmoplegia', 'Reduced tendon reflexes', 'Ragged-red muscle fibers', 'Generalized muscle weakness', 'Generalized amyotrophy', 'Acute hepatitis', 'Chronic hepatitis']",['Mitochondrial DNA depletion syndrome 3 (hepatocerebral type)'],"Disease: Mitochondrial DNA depletion syndrome 3 (hepatocerebral type)  
Reasoning:  
1. **Hepatocerebral involvement**: The coexistence of *acute hepatitis* and *chronic hepatitis* (liver dysfunction) with neurological symptoms (*ptosis*, *ophthalmoplegia*, *progressive visual loss*) aligns with the hepatocerebral phenotype of mitochondrial disorders.  
2. **Neuromuscular features**: *Generalized muscle weakness*, *generalized amyotrophy*, and *ragged-red muscle fibers* (observed on biopsy) are hallmark signs of mitochondrial myopathies caused by impaired oxidative phosphorylation due to mtDNA depletion.  
3. **Ocular manifestations**: *Ptosis* and *ophthalmoplegia* are classic findings in mitochondrial disorders like chronic progressive external ophthalmoplegia (CPEO), often linked to mtDNA defects.  
4. **Reduced tendon reflexes**: Suggests peripheral nerve or motor neuron involvement, consistent with multisystemic mitochondrial dysfunction.  
5. **Ragged-red fibers**: Pathognomonic for mitochondrial myopathy, caused by abnormal mitochondrial proliferation in muscle fibers.  
6. **Genetic confirmation**: Mitochondrial DNA depletion syndrome 3 is caused by *DGUOK* mutations, disrupting mitochondrial DNA maintenance and leading to combined hepatic, neurological, and muscular degeneration.  
This constellation of liver disease, progressive neuromuscular deterioration, and biopsy findings strongly supports the diagnosis of MDDS3."
"['Polyuria', 'Visual loss', 'Hematuria', 'Dry skin', 'Keratoconjunctivitis sicca', 'Tremor', 'Diarrhea', 'Constipation', 'Heat intolerance', 'Migraine', 'Exertional dyspnea', 'Myalgia', 'Exercise intolerance', 'Inflammatory abnormality of the skin', 'Fatigue', 'Cough', 'Abnormal systemic blood pressure', 'Increased circulating IgG4 level', 'Dyspepsia']","['Multifocal fibrosclerosis', 'IgG4-related retroperitoneal fibrosis', 'IgG4 related disease; IgG4-RD']","Disease: IgG4 related disease; IgG4-RD  
Reasoning: The patient exhibits elevated IgG4 levels, a hallmark of IgG4-RD, alongside multi-organ involvement. Ocular symptoms (visual loss, keratoconjunctivitis sicca) suggest lacrimal or orbital inflammation. Renal manifestations (polyuria, hematuria) may indicate tubulointerstitial nephritis or retroperitoneal fibrosis causing ureteral obstruction. Cutaneous (dry skin, inflammatory skin changes), respiratory (cough, exertional dyspnea), and gastrointestinal symptoms (dyspepsia, diarrhea/constipation) reflect systemic inflammation and fibrosis. Systemic features (fatigue, myalgia, exercise intolerance) align with chronic inflammatory states. Migraine and blood pressure abnormalities may arise from secondary effects of organ compression or systemic inflammation.  

Disease: IgG4-related retroperitoneal fibrosis  
Reasoning: A subtype of IgG4-RD, retroperitoneal fibrosis explains hematuria and polyuria via ureteral obstruction or renal parenchymal involvement. Abdominal symptoms (dyspepsia, constipation/diarrhea) could stem from retroperitoneal mass effects on adjacent organs. Elevated IgG4 levels and association with other IgG4-RD features (e.g., ocular, cutaneous) further support this diagnosis.  

Disease: Multifocal fibrosclerosis  
Reasoning: This term describes fibrosis across multiple sites, now recognized as part of the IgG4-RD spectrum. The patient’s diverse symptoms (ocular, renal, cutaneous, respiratory) indicate fibroinflammatory lesions in various organs. Increased IgG4 levels and systemic involvement confirm multifocal fibrosclerosis as a manifestation of underlying IgG4-RD."
"['Sinusitis', 'Eosinophilia', 'Dyspnea', 'Pulmonary infiltrates', 'Increased circulating IgE level', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Nasal polyposis']",['Eosinophilic granulomatosis with polyangiitis'],"Disease: Eosinophilic granulomatosis with polyangiitis (EGPA)  
Reasoning:  
1. **Sinusitis and Nasal Polyposis**: Common ENT manifestations in EGPA, reflecting granulomatous inflammation.  
2. **Eosinophilia**: A hallmark of EGPA, driven by eosinophil-rich tissue infiltration.  
3. **Dyspnea and Pulmonary Infiltrates**: Indicates asthma-like airway involvement and eosinophilic pneumonitis.  
4. **Nodular Pattern on HRCT**: Suggests granulomatous lesions or vasculitic damage in the lungs.  
5. **Increased IgE Levels**: Linked to allergic/atopic predisposition, often seen in EGPA.  
6. **Autoimmune Antibody Positivity**: ANCA (typically MPO-ANCA) may be present, supporting vasculitic pathology.  
7. **Triphasic Disease Progression**: Aligns with allergic, eosinophilic, and vasculitic phases typical of EGPA.  
**Exclusion**: Other eosinophilic disorders (e.g., ABPA) lack vasculitis, while GPA lacks prominent eosinophilia."
"['Difficulty walking', 'Myalgia', 'Difficulty climbing stairs', 'Episodic flaccid weakness', 'Death in childhood', 'Difficulty running', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating carnitine concentration', 'Abnormal circulating creatine kinase concentration', 'Episodic quadriplegia']","['Carnitine palmitoyl transferase II deficiency, myopathic form/Carnitine palmitoyltransferase II deficiency, myopathic, stress-induced']","Disease: Carnitine palmitoyl transferase II deficiency, myopathic form/Carnitine palmitoyltransferase II deficiency, myopathic, stress-induced  
Reasoning:  
1. **Episodic Muscle Weakness**: The patient’s episodic flaccid weakness and quadriplegia align with stress-induced attacks characteristic of CPT II deficiency, triggered by prolonged exercise, fasting, or infection.  
2. **Exercise Intolerance**: Difficulty walking, climbing stairs, and running reflect impaired fatty acid oxidation, leading to energy deficits in muscles during sustained activity.  
3. **Laboratory Abnormalities**:  
   - **Elevated Creatine Kinase (CK)**: Indicates recurrent muscle breakdown (rhabdomyolysis) during episodes.  
   - **Abnormal Carnitine Levels**: CPT II deficiency disrupts carnitine-dependent fatty acid transport, altering circulating carnitine.  
   - **Abnormal Aspartate Family Amino Acids**: Secondary metabolic derangements (e.g., hyperammonemia) during crises may perturb amino acid metabolism.  
4. **Death in Childhood**: Severe metabolic crises (e.g., renal failure from rhabdomyolysis) can lead to early mortality, though the myopathic form is typically less severe than infantile CPT II deficiency.  
5. **Exclusion of Alternatives**: Symptoms and labs rule out glycogenoses (e.g., McArdle disease) by the absence of ""second wind"" phenomenon and presence of lipid metabolism-specific abnormalities.  
6. **Genetic Confirmation**: While not stated, autosomal recessive mutations in *CPT2* would confirm the diagnosis."
"['Jaundice', 'Splenomegaly', 'Anemia', 'Reticulocytosis', 'Hepatomegaly', 'Elliptocytosis', 'Coombs-positive hemolytic anemia', 'Imbalanced hemoglobin synthesis', 'Conjunctival icterus', 'Abnormal glucose-6-phosphate dehydrogenase level in blood']",['Elliptocytosis 2'],"Disease: Elliptocytosis 2  
Reasoning:  
1. **Elliptocytosis**: Presence of elliptocytes on blood smear is a hallmark of hereditary elliptocytosis (HE), specifically type 2, linked to mutations in cytoskeletal proteins like spectrin or ankyrin.  
2. **Hemolytic anemia**: Reticulocytosis, anemia, and jaundice indicate compensatory bone marrow response to chronic hemolysis, consistent with HE.  
3. **Splenomegaly/Hepatomegaly**: Splenic sequestration of abnormal RBCs and extramedullary hematopoiesis from chronic hemolysis explain organ enlargement.  
4. **Conjunctival icterus/jaundice**: Elevated bilirubin from RBC breakdown aligns with hemolysis.  
5. **Imbalanced hemoglobin synthesis**: Chronic hemolysis disrupts erythropoiesis, leading to ineffective hemoglobin production.  
6. **Coombs-positive anomaly**: Uncommon in HE but may reflect concurrent autoimmune hemolysis or assay interference; primary diagnosis relies on structural RBC defects.  
7. **Abnormal G6PD level**: Likely incidental (e.g., heterozygous carrier or mild deficiency) but could exacerbate oxidative stress-induced hemolysis in HE.  

The combination of elliptocytes, hemolysis markers, and exclusion of primary enzymatic defects (despite G6PD anomaly) prioritizes hereditary elliptocytosis type 2 as the diagnosis."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), leading to the accumulation of phenylalanine in the blood. This directly explains the elevated phenylalanine levels.  
2. **Elevated urinary carboxylic acids**: In PKU, phenylalanine is metabolized via alternative pathways, producing phenylketones (e.g., phenylpyruvate, phenyllactate), which are carboxylic acids excreted in urine.  
3. **Death in infancy/childhood**: Untreated PKU results in severe neurological damage, seizures, and developmental failure, often leading to early mortality if dietary phenylalanine restriction is not implemented.  
4. **Hypertyrosinemia discrepancy**: Classic PKU typically causes *low* tyrosine due to blocked PAH activity. Hypertyrosinemia here may reflect a lab error, concurrent tyrosine supplementation, or an atypical presentation (e.g., transient tyrosinemia from liver dysfunction).  
5. **Recurrent viral infections**: Unrelated to PKU pathophysiology but could arise from secondary complications (e.g., malnutrition, immunosuppression due to systemic metabolic stress).  

Conclusion: Core symptoms (hyperphenylalaninemia, urinary phenylketones) align with PKU. Atypical features (hypertyrosinemia, infections) require further investigation but do not override the primary diagnosis."
"['Increased variability in muscle fiber diameter', 'Proximal muscle weakness', 'Mildly elevated creatine kinase', 'Weakness of facial musculature', 'Internally nucleated skeletal muscle fibers']",['Distal myotilinopathy/MYOTILINOPATHY'],"Disease: Distal myotilinopathy/MYOTILINOPATHY  
Reasoning:  
1. **Increased variability in muscle fiber diameter**: A hallmark of myofibrillar myopathies, including myotilinopathy, due to disorganization of sarcomeric proteins and degeneration of myofibrils.  
2. **Proximal muscle weakness**: Consistent with myotilinopathy, which can present with proximal or distal weakness, though facial involvement adds specificity.  
3. **Mildly elevated creatine kinase**: Reflects mild muscle damage, typical of myotilinopathy, unlike severe elevations seen in dystrophies.  
4. **Weakness of facial musculature**: A distinguishing feature, as facial weakness is uncommon in many myopathies but reported in MYOT-linked myotilinopathy.  
5. **Internally nucleated skeletal muscle fibers**: Indicates chronic myopathy and regeneration, characteristic of myofibrillar myopathies, including myotilinopathy.  
Genetic confirmation of a **MYOT gene mutation** would definitively diagnose myotilinopathy, but the clinical and histopathological findings strongly support this diagnosis."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Intellectual disability** arises from untreated phenylalanine toxicity, damaging brain development postnatally.  
3. **Hypertyrosinemia** is atypical in classic PKU (which typically causes *low* tyrosine). This may suggest a PAH deficiency variant, secondary metabolic disruptions, or a co-occurring tyrosinemia (e.g., type II), though PKU remains primary due to hyperphenylalaninemia dominance.  
4. **Neonatal death/Death in infancy/adolescence** reflects severe metabolic complications (e.g., seizures, organ failure) in untreated or late-diagnosed cases.  
5. **Abnormality of prenatal development** is inconsistent with isolated PKU (as fetal PAH is inactive; symptoms manifest postnatally). This may indicate maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy) affecting the fetus, aligning with the patient’s congenital anomalies.  

Note: Hypertyrosinemia and prenatal anomalies require further investigation for overlapping metabolic disorders, but hyperphenylalaninemia and clinical progression prioritize PKU as the primary diagnosis."
"['Strabismus', 'Intellectual disability', 'Seizure', 'Motor delay', 'Cerebellar atrophy', 'Death in infancy', 'Hepatomegaly', 'Hypoproteinemia', 'Hypocholesterolemia', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological involvement**: Cerebellar atrophy/agenesis, motor delay, seizures, and intellectual disability are hallmark features of PMM2-CDG, reflecting disrupted glycosylation critical for brain development and function.  
2. **Hepatic manifestations**: Hepatomegaly, acute/chronic hepatitis, hypoproteinemia, and hypocholesterolemia align with PMM2-CDG’s multisystemic impact, including liver dysfunction due to impaired glycoprotein synthesis.  
3. **Metabolic abnormalities**: Hypocholesterolemia and hypoproteinemia stem from defective glycosylation of apolipoproteins and transport proteins, while lipodystrophy reflects adipose tissue dysregulation.  
4. **Severe infantile course**: Death in infancy is consistent with the life-threatening complications (e.g., organ failure, severe infections) seen in classical PMM2-CDG type Ia.  
5. **Exclusion of mimics**: The combination of cerebellar defects, liver disease, and metabolic derangements distinguishes PMM2-CDG from other metabolic disorders (e.g., Niemann-Pick, peroxisomal disorders) that lack glycosylation-specific biomarkers (e.g., abnormal transferrin isoforms)."
"['Seizure', 'Death in infancy', 'Respiratory insufficiency', 'Opisthotonus', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Sepsis']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated branched-chain amino acids (Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia)**: MSUD is caused by a defect in the branched-chain alpha-keto acid dehydrogenase complex, leading to toxic accumulation of leucine, isoleucine, and valine. These lab findings are pathognomonic.  
2. **Neurological symptoms (Seizure, Opisthotonus)**: Excess leucine is neurotoxic, causing cerebral edema and severe neurological dysfunction, manifesting as seizures and abnormal posturing (opisthotonus).  
3. **Metabolic decompensation (Feeding difficulties, Respiratory insufficiency)**: Infants develop poor feeding, vomiting, and lethargy due to metabolic acidosis. Respiratory failure may arise from central nervous system depression or muscle weakness.  
4. **Early lethality (Neonatal death, Death in infancy)**: Untreated classic MSUD progresses rapidly to coma and death within weeks to months due to irreversible neurological damage.  
5. **Sepsis mimicry**: Metabolic crises in MSUD can mimic sepsis (lethargy, respiratory distress), and secondary infections may occur due to immune dysfunction from metabolic stress.  

The combination of BCAA elevation, acute neurological decline, and neonatal onset confirms MSUD as the diagnosis."
"['Cryptorchidism', 'Hypospadias', 'Microcephaly', 'Low-set ears', 'Strabismus', 'Ptosis', 'Hypermetropia', 'Eczematoid dermatitis', 'Skin rash', 'Syndactyly', 'Intellectual disability', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Vomiting', 'Constipation', 'Drowsiness', 'Sleep disturbance', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties', 'Hypoxemia', 'Severe hearing impairment']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Cholesterol biosynthesis defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) with hypocholesterolemia are pathognomonic for SLOS, caused by mutations in *DHCR7*, impairing 7-DHC reductase activity.  
2. **Congenital anomalies**: Syndactyly (especially 2nd–3rd toe), cryptorchidism, hypospadias, microcephaly, and low-set ears align with SLOS-associated malformations.  
3. **Neurodevelopmental features**: Intellectual disability, motor delay, generalized hypotonia, dystonia, and lethargy reflect disrupted cholesterol-dependent myelination and neuronal development.  
4. **Ocular findings**: Ptosis, strabismus, and hypermetropia are common in SLOS due to craniofacial dysmorphism and connective tissue abnormalities.  
5. **Gastrointestinal/dysautonomia symptoms**: Feeding difficulties, vomiting, constipation, and sleep disturbances correlate with autonomic dysfunction and gastrointestinal dysmotility.  
6. **Cutaneous manifestations**: Eczematoid dermatitis and skin rash result from defective epidermal barrier function due to cholesterol deficiency.  
7. **Severe outcomes**: Neonatal/childhood death, hypoxemia, and recurrent infections reflect multisystem failure and immune dysfunction from cholesterol insufficiency.  
8. **Supporting biochemical markers**: Elevated 7-DHC/8-DHC on sterol analysis confirms the diagnosis.  

This constellation of structural, metabolic, and developmental abnormalities is diagnostic of Smith-Lemli-Opitz syndrome."
"['Coma', 'Death in infancy', 'Premature birth', 'Metabolic acidosis', 'Hypoglycemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Death in adolescence', 'Hypoxemia']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia and metabolic acidosis**: MCADD impairs mitochondrial β-oxidation of medium-chain fatty acids, leading to insufficient ketone production during fasting. This results in hypoglycemia (due to reliance on glucose without alternative energy sources) and metabolic acidosis (from accumulating toxic metabolites like medium-chain acylcarnitines).  
2. **Decreased plasma free carnitine**: Unmetabolized medium-chain acyl-CoA intermediates bind to carnitine, forming acylcarnitines that accumulate and deplete free carnitine.  
3. **Life-threatening crises and early mortality**: Prolonged fasting or metabolic stress (e.g., infections) triggers acute decompensation, causing coma, hypoxemia (secondary to respiratory failure), and multi-organ dysfunction. Untreated cases often result in neonatal death or death in infancy/childhood/adolescence.  
4. **Gastrointestinal inflammation**: May arise during metabolic crises due to tissue hypoxia or direct toxicity from metabolites.  
5. **Premature birth**: Not a primary feature of MCADD but may reflect prenatal stress or comorbid factors contributing to early presentation.  

The constellation of hypoglycemia, metabolic acidosis, carnitine deficiency, and catastrophic outcomes aligns pathognomonically with MCADD, a disorder of fatty acid oxidation. Confirmatory testing would include plasma acylcarnitine profile (elevated C6-C10 species) and genetic analysis of *ACADM* gene variants."
"['Cleft palate', 'Broad philtrum', 'Long philtrum', 'Wide nasal bridge', 'Anteverted nares', 'Glaucoma', 'Cataract', 'Abnormal external genitalia', 'Syndactyly', 'Generalized hypotonia', 'Death in infancy', 'Deep philtrum', 'Vomiting', 'Pyloric stenosis', 'High, narrow palate', 'Hypocholesterolemia', 'Abdominal distention', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol biosynthesis defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in *DHCR7* leading to impaired cholesterol synthesis.  
2. **Craniofacial features**: Cleft palate, broad/deep philtrum, wide nasal bridge, anteverted nares, and high/narrow palate align with SLOS-associated dysmorphism.  
3. **Ocular anomalies**: Glaucoma and cataracts are linked to abnormal cholesterol-dependent eye development.  
4. **Genital/skeletal abnormalities**: Abnormal external genitalia and syndactyly (classically 2-3 toe syndactyly) are hallmark features.  
5. **Gastrointestinal issues**: Feeding difficulties, vomiting, pyloric stenosis, and abdominal distention reflect cholesterol-dependent digestive dysfunction.  
6. **Poor prognosis**: Neonatal death or death in infancy correlates with severe SLOS phenotypes.  
7. **Hypocholesterolemia**: Directly ties to the biochemical defect in cholesterol synthesis.  
8. **Generalized hypotonia**: Common in SLOS due to disrupted membrane cholesterol in neuromuscular function.  

The combination of sterol abnormalities, syndromic malformations, and metabolic features confirms SLOS."
"['Hypogonadotropic hypogonadism', 'Hyporeflexia', 'Cerebellar atrophy', 'Dysdiadochokinesis', 'Retinal pigment epithelial atrophy', 'Decreased circulating follicle stimulating hormone concentration', 'Decreased circulating luteinizing hormone level', 'Decreased serum testosterone concentration']",['Ataxia-hypogonadism-choroidal dystrophy syndrome/Boucher-Neuhauser syndrome'],"Disease: Ataxia-hypogonadism-choroidal dystrophy syndrome/Boucher-Neuhauser syndrome  
Reasoning:  
1. **Hypogonadotropic hypogonadism** (evidenced by low FSH, LH, and testosterone) aligns with the syndrome’s hallmark endocrine dysfunction due to impaired hypothalamic-pituitary-gonadal axis signaling.  
2. **Cerebellar atrophy** and **dysdiadochokinesis** indicate progressive cerebellar degeneration, a core neurological feature of the syndrome.  
3. **Retinal pigment epithelial atrophy** corresponds to choroidal dystrophy, a defining ocular manifestation.  
4. **Hyporeflexia** further supports cerebellar or spinocerebellar pathway involvement.  
5. The triad of **ataxia** (from cerebellar atrophy), **hypogonadotropic hypogonadism**, and **retinal/choroidal degeneration** is pathognomonic for Boucher-Neuhauser syndrome, distinguishing it from mimics like Gordon Holmes syndrome (which lacks retinal involvement)."
"['Conjunctivitis', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs in MCADD due to excess conjugation of carnitine to accumulating toxic medium-chain acyl metabolites (e.g., octanoylcarnitine).  
2. **Neonatal/Infancy/Childhood fatality**: MCADD causes life-threatening hypoglycemia and metabolic crises during fasting or illness, often presenting in infancy or early childhood if undiagnosed.  
3. **Prenatal abnormalities**: Though less common, intrauterine metabolic stress from MCADD may contribute to growth restriction or complications, particularly in severe cases.  
4. **Enzyme discrepancy**: The listed ""decreased 3-hydroxyacyl-CoA dehydrogenase level"" may reflect a misreporting. MCADD specifically involves *medium-chain acyl-CoA dehydrogenase* deficiency. If accurate, this could indicate a concurrent or overlapping disorder (e.g., trifunctional protein deficiency), but MCADD remains primary given clinical alignment.  
5. **Conjunctivitis**: Atypical for MCADD; possibly coincidental (e.g., infection) or misdocumented (retinopathy in LCHAD deficiency is a differential but excluded here).  
6. **Key biochemical link**: Hypoketotic hypoglycemia and elevated medium-chain acylcarnitines (C6-C10) on tandem mass spectrometry confirm MCADD, aligning with decreased free carnitine and clinical history."
"['Torticollis', 'Vertical supranuclear gaze palsy', 'Hypometric saccades', 'Supranuclear gaze palsy', 'Nystagmus', 'Ataxia', 'Dysarthria', 'Motor delay', 'Cerebellar atrophy', 'Dystonia', 'Morphological abnormality of the pyramidal tract', 'Spastic ataxia', 'Inability to walk', 'CNS hypomyelination', 'Somatic sensory dysfunction', 'Demyelinating peripheral neuropathy', 'Peripheral neuropathy', 'Abnormal involuntary eye movements', 'Titubation']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8  
Reasoning:  
1. **Hypomyelination**: The presence of **CNS hypomyelination** and **demyelinating peripheral neuropathy** indicates a leukodystrophy with combined central and peripheral nervous system involvement, a hallmark of NKX6-2-related disorders.  
2. **Spastic ataxia**: **Ataxia**, **spasticity**, **cerebellar atrophy**, and **morphological pyramidal tract abnormalities** align with the ""spastic ataxia"" phenotype linked to NKX6-2 mutations.  
3. **Oculomotor deficits**: **Vertical supranuclear gaze palsy**, **hypometric saccades**, and **abnormal eye movements** are consistent with brainstem and cerebellar dysfunction seen in this disorder.  
4. **Motor dysfunction**: **Inability to walk**, **dystonia**, **titubation**, and **motor delay** reflect progressive cerebellar and pyramidal tract degeneration.  
5. **Peripheral neuropathy**: **Somatic sensory dysfunction** and **peripheral neuropathy** support the dual central-peripheral hypomyelination pattern unique to NKX6-2-related disease.  
6. **Exclusion of mimics**: The combination of central hypomyelination, spastic ataxia, and peripheral neuropathy distinguishes this from other leukodystrophies (e.g., Pelizaeus-Merzbacher disease, 4H syndrome) or isolated spinocerebellar ataxias. Genetic confirmation of NKX6-2 mutations would be definitive."
"['Dementia', 'Skin rash', 'Spasticity', 'Areflexia', 'Death in infancy', 'Fever', 'Hyperammonemia', 'Diarrhea', 'Cerebral edema', 'Hepatomegaly', 'Progressive neurologic deterioration', 'Hyperlysinuria', 'Hypoargininemia', 'Abnormal circulating methionine concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating alanine concentration', 'Elevated plasma citrulline', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic)  
Reasoning:  
1. **Elevated plasma citrulline** and **hyperammonemia** are hallmark biochemical features of citrullinemia type I, caused by a deficiency in argininosuccinate synthetase (ASS1), a urea cycle enzyme.  
2. **Progressive neurologic deterioration**, **cerebral edema**, **spasticity**, and **dementia** align with ammonia neurotoxicity and urea cycle dysfunction.  
3. **Hypoargininemia** occurs due to impaired arginine synthesis in the urea cycle, while **hyperlysinuria** reflects secondary amino acid transport disruptions.  
4. **Hepatomegaly** and **abnormal circulating amino acids** (methionine, glutamine, alanine) suggest metabolic liver stress and secondary mitochondrial dysfunction.  
5. **Death in infancy** is consistent with the severe neonatal-onset form of classic citrullinemia.  
6. Cutaneous manifestations (**rash, erythematous plaques/macules/papules**) may result from metabolic acidosis or ammonia-induced inflammation.  
7. **Areflexia** and **fever** are nonspecific but compatible with acute metabolic decompensation.  

Disease: Citrullinemia type II (excluded)  
Reasoning:  
- Type II (citrin deficiency) typically presents later (adult/childhood) with **different amino acid abnormalities** (e.g., hyperthreonine, hypermethionine) and lacks classic neonatal lethality. Elevated citrulline is milder compared to type I."
"['Obesity', 'Abnormal foot morphology', 'Hyperammonemia', 'Death in childhood']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Hyperammonemia**: A hallmark of BTDD due to impaired urea cycle function from deficient carboxylases (e.g., propionyl-CoA carboxylase), leading to metabolic acidosis and ammonia accumulation.  
2. **Abnormal foot morphology**: Neuromuscular abnormalities (e.g., hypotonia, spasticity) in untreated BTDD may cause skeletal deformities, including foot malalignment or pes equinovarus.  
3. **Obesity**: Uncommon but plausible in chronic metabolic dysregulation; biotin-dependent enzymes regulate lipid metabolism, and dysfunction may alter energy homeostasis.  
4. **Death in childhood**: Untreated BTDD causes progressive neurological decline, respiratory failure, or metabolic crises, often fatal in early life without biotin supplementation.  
**Key Link**: The combination of hyperammonemia, neurological/skeletal defects, and early mortality aligns with BTDD’s multisystemic presentation. Obesity may reflect secondary metabolic disturbances rather than a primary feature."
"['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Drowsiness', 'Sleep disturbance', 'Abnormal cerebral white matter morphology', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria and elevated glutaric acid**: Direct biochemical markers of GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Neurological symptoms (ataxia, hypotonia, drowsiness)**: Accumulated glutaric acid and neurotoxic metabolites (e.g., 3-hydroxyglutaric acid) damage the basal ganglia and white matter, consistent with **abnormal cerebral white matter morphology** on imaging.  
3. **Feeding difficulties and lethargy**: Common early signs in infants with GA-I due to metabolic instability.  
4. **Acute crises and neurodegeneration**: Untreated GA-I leads to metabolic decompensation (often triggered by infections/stress), causing irreversible brain injury, **sleep disturbance**, and **death in childhood**.  
5. **Exclusion of mimics**: Symptoms align with GA-I’s hallmark triad (encephalopathy, movement disorders, white matter changes) and biochemical profile, distinguishing it from other organic acidemias."
"['Microcephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Small for gestational age', 'Death in infancy', 'Splenomegaly', 'Anemia', 'Acute kidney injury', 'Metabolic acidosis', 'Hypoglycemia', 'Dehydration', 'Fever', 'Hyperammonemia', 'Hypothermia', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Hepatomegaly', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating homocysteine concentration', 'Elevated circulating C-reactive protein concentration', 'Feeding difficulties', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Elevated urinary carboxylic acid']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Key biochemical markers**: Elevated methylmalonic acid in blood (methylmalonic acidemia) and urine (methylmalonic aciduria), decreased methylmalonyl-CoA mutase activity, hyperammonemia, metabolic acidosis, and increased serum lactate directly indicate a defect in methylmalonyl-CoA metabolism.  
2. **Clinical features**: Neonatal death, failure to thrive, intellectual disability, motor delay, and generalized hypotonia align with severe mitochondrial energy deficiency caused by MMA.  
3. **Metabolic instability**: Hypoglycemia, hyperuricemia, hyperglycinemia, and abnormal amino acid profiles (e.g., aspartate, alanine, homocysteine) reflect disrupted intermediary metabolism and secondary mitochondrial dysfunction.  
4. **Organ involvement**: Hepatomegaly, splenomegaly, acute/chronic kidney injury, and elevated creatinine/blood urea nitrogen suggest toxic metabolite accumulation (methylmalonic acid) damaging organs.  
5. **Systemic complications**: Feeding difficulties, gastrointestinal inflammation, and recurrent infections (pneumonia) are consistent with chronic metabolic stress and immune dysfunction.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Enzyme deficiency confirmation**: Decreased methylmalonyl-CoA mutase activity explicitly identifies the molecular defect, distinguishing it from B12-responsive forms (e.g., cblA/cblB defects).  
2. **B12-unresponsiveness**: Persistence of methylmalonic acidemia despite B12 supplementation (implied by classification) and severe phenotypes (neonatal death, death in childhood) are hallmarks of mutase deficiency.  
3. **Carnitine depletion**: Decreased plasma free carnitine occurs due to excessive conjugation with toxic metabolites (e.g., propionyl-CoA derivatives), exacerbating energy crisis.  
4. **Chronic multisystem disease**: Chronic kidney disease, severe short stature, and abnormal porphyrin metabolism indicate long-term sequelae of uncontrolled MMA.  
5. **Laboratory correlations**: Elevated CRP, hyperlactatemia, and abnormal urinary carboxylic acids further support chronic metabolic decompensation and oxidative stress.  

Both diagnoses are intrinsically linked, with the second specifying the mutase-deficient, B12-unresponsive subtype underlying the patient’s catastrophic clinical course."
"['Hyperglycemia', 'Maturity-onset diabetes of the young', 'Multiple renal cysts', 'Abnormal pancreas morphology', 'Anti-glutamic acid decarboxylase antibody positivity', 'Elevated hemoglobin A1c']",['HNF1B-related autosomal dominant tubulointerstitial kidney disease/Renal cysts and diabetes syndrome'],"Disease: HNF1B-related autosomal dominant tubulointerstitial kidney disease/Renal cysts and diabetes syndrome  
Reasoning:  
1. **Hyperglycemia & Elevated HbA1c**: Indicates diabetes, consistent with the ""diabetes"" component of Renal Cysts and Diabetes Syndrome (RCAD).  
2. **Maturity-Onset Diabetes of the Young (MODY)**: HNF1B mutations cause MODY type 5, characterized by early-onset, autosomal dominant inheritance, and atypical features like renal/pancreatic involvement.  
3. **Multiple Renal Cysts**: A hallmark of HNF1B-related disease, distinguishing it from other MODY subtypes (e.g., HNF1A/HNF4A) and aligning with RCAD.  
4. **Abnormal Pancreas Morphology**: HNF1B is critical for pancreatic development; structural anomalies (e.g., atrophy, cysts) are common in this syndrome.  
5. **Anti-GAD Antibody Positivity**: Though atypical for MODY, rare cases of HNF1B-MODY report autoimmune markers, possibly due to overlapping autoimmune mechanisms or incidental findings.  
6. **Exclusion of Alternatives**: The combination of diabetes, renal cysts, and pancreatic defects rules out other MODY subtypes (e.g., GCK, HNF1A) and isolated autoimmune diabetes (e.g., type 1).  
Conclusion: The constellation of symptoms strongly supports HNF1B-related disease, fulfilling both renal and pancreatic/diabetic criteria for RCAD."
"['Seizure', 'Lethargy', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Hypoglycemia', 'Vomiting', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Feeding difficulties', 'Elevated urinary 3-hydroxybutyric acid']","['Fructose-1,6-bisphosphatase deficiency/Fructose-1,6-bisphosphatase deficiency']","Disease: Fructose-1,6-bisphosphatase deficiency  
Reasoning:  
1. **Hypoglycemia**: Central feature of FBPase deficiency due to impaired gluconeogenesis during fasting.  
2. **Metabolic acidosis & elevated serum lactate**: Blocked gluconeogenesis causes accumulation of lactate (a gluconeogenic precursor), leading to lactic acidosis.  
3. **Elevated urinary 3-hydroxybutyric acid**: Compensatory fatty acid oxidation generates ketone bodies (e.g., 3-hydroxybutyrate) during hypoglycemia.  
4. **Tachycardia & tachypnea**: Compensatory responses to acidosis (e.g., respiratory alkalosis attempt) and hypoglycemia.  
5. **Seizures, lethargy, drowsiness**: Neurological effects of hypoglycemia and metabolic derangements.  
6. **Feeding difficulties, vomiting, death in infancy**: Infants rely on frequent feeding; fasting triggers metabolic crises, risking fatal hypoglycemia/acidosis if untreated.  
7. **Sleep disturbance**: May reflect recurrent hypoglycemic episodes disrupting normal cycles.  
Key exclusion: Symptoms align with gluconeogenesis defects (not glycolysis or mitochondrial disorders). Elevated lactate + ketones + hypoglycemia in infancy is pathognomonic for FBPase deficiency."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The presence of **hyperammonemia** and **elevated plasma citrulline** strongly indicates a urea cycle disorder. Citrullinemia type I (argininosuccinate synthetase deficiency) is characterized by severe neonatal hyperammonemia due to impaired citrulline-to-argininosuccinate conversion. This leads to rapid accumulation of ammonia and citrulline, causing neurological decline, **neonatal death**, or **death in infancy** if untreated. The absence of cholestasis or liver-specific symptoms aligns with classic urea cycle dysfunction rather than hepatic pathology.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: **Elevated citrulline** and **hyperammonemia** can also occur in citrin deficiency (type II citrullinemia). Neonatal intrahepatic cholestasis (NICCD) manifests with transient liver dysfunction and cholestasis (implied in the disease name), which may compound metabolic stress. While citrulline levels are typically lower than in type I, severe cases can lead to **death in infancy/childhood** due to liver failure or metabolic decompensation. **Abnormality of prenatal development** may reflect intrauterine growth restriction from mitochondrial energy deficits caused by citrin deficiency."
"['High palate', 'Everted lower lip vermilion', 'Triangular face', 'Hypoplasia of the maxilla', 'Narrow nose', 'Blepharophimosis', 'Thin ribs', 'Lateral clavicle hook', 'Arachnodactyly', 'Intellectual disability', 'Pes planus', 'Generalized joint laxity', 'Genu valgum', 'Elbow flexion contracture', 'Dislocated radial head', 'Depressed nasal bridge', 'Camptodactyly']",['Van den Ende-Gupta syndrome'],"Disease: Van den Ende-Gupta syndrome  
Reasoning:  
1. **Craniofacial features**: Triangular face, hypoplasia of the maxilla, high palate, narrow nose, everted lower lip vermilion, and depressed nasal bridge align with the characteristic facial dysmorphism seen in Van den Ende-Gupta syndrome (VDEGS).  
2. **Ocular findings**: Blepharophimosis (narrowed palpebral fissures) is a hallmark feature of VDEGS.  
3. **Skeletal anomalies**: Thin ribs, lateral clavicle hook, arachnodactyly, camptodactyly, elbow flexion contracture, dislocated radial head, pes planus, and generalized joint laxity match the syndrome’s skeletal phenotype.  
4. **Developmental involvement**: Intellectual disability is variably present in VDEGS, further supporting the diagnosis.  
5. **Exclusion of mimics**: The combination of blepharophimosis, skeletal features, and intellectual disability differentiates VDEGS from Marfan syndrome, Loeys-Dietz syndrome, or congenital contractural arachnodactyly, which lack this specific syndromic constellation.  
6. **Genetic confirmation**: While clinical findings are sufficient for provisional diagnosis, VDEGS is caused by biallelic variants in *SCARF2*, and genetic testing would confirm the diagnosis."
"['Acute myeloid leukemia', 'Abnormal dense granules', 'Abnormal platelet aggregation']","['Platelet disorder, familial, with associated myeloid malignancy']","Disease: Platelet disorder, familial, with associated myeloid malignancy  
Reasoning:  
1. **Acute Myeloid Leukemia (AML)**: The presence of AML indicates a myeloid lineage malignancy, a hallmark of this disorder. Familial platelet disorders with associated myeloid malignancy often progress to AML due to genetic predisposition (e.g., RUNX1 mutations).  
2. **Abnormal Dense Granules**: Dense granule defects in platelets are characteristic of inherited platelet disorders, such as those caused by mutations in genes like RUNX1, which impair granule biogenesis or secretion.  
3. **Abnormal Platelet Aggregation**: Dysfunctional platelet aggregation aligns with impaired dense granule function, as these granules store critical agonists (e.g., ADP) necessary for aggregation. This defect is consistent with familial platelet disorders.  
4. **Genetic Link**: The co-occurrence of AML and platelet abnormalities strongly suggests a germline mutation (e.g., RUNX1, ANKRD26, or ETV6), which predisposes to both hematologic malignancy and platelet dysfunction.  
5. **Diagnostic Confirmation**: Genetic testing for RUNX1 or related mutations would confirm the familial nature and solidify the diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with untreated maternal PKU, where high maternal phenylalanine levels disrupt fetal development, though neonatal PKU itself typically manifests postnatally.  
3. **Hypertyrosinemia** is atypical in classic PKU (which usually causes *hypo*tyrosinemia). This may suggest a concurrent metabolic defect (e.g., transient tyrosinemia in neonates or a secondary pathway disruption) or a severe PAH variant affecting tyrosine metabolism indirectly.  
4. **Neonatal death/Death in infancy** correlates with untreated or severe PKU variants, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
5. The combination of hyperphenylalaninemia and early lethality strongly prioritizes PKU, though hypertyrosinemia warrants investigation for comorbid conditions (e.g., tyrosinemia type II) or BH4 metabolism disorders.  

Note: Hypertyrosinemia is incongruent with classic PKU and may indicate a complex case requiring additional biochemical/genetic analysis (e.g., BH4 deficiency or dual enzyme defects). However, hyperphenylalaninemia remains the primary diagnostic anchor."
"['Carious teeth', 'Intellectual disability', 'Death in childhood', 'Hyperphenylalaninemia', 'Ichthyosis', 'Abnormal circulating tyrosine concentration', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Untreated PKU leads to neurotoxic phenylalanine accumulation, disrupting myelination and neurotransmitter synthesis.  
3. **Abnormal circulating tyrosine concentration**: Low tyrosine levels occur due to blocked conversion from phenylalanine, aligning with PKU biochemistry.  
4. **Carious teeth**: High-phenylalanine diets (used historically) or sugary substitutes in managed diets increase caries risk.  
5. **Early mortality (childhood/adolescence)**: Severe untreated PKU causes progressive neurological damage, seizures, and organ failure, leading to premature death.  
6. **Ichthyosis**: Atypical for classic PKU but may reflect comorbid conditions, misdiagnosed eczema (common in PKU), or rare PKU variants with secondary metabolic disruptions affecting skin integrity.  

Note: While ichthyosis is not a core PKU feature, the remaining symptoms strongly support this diagnosis. Further testing (e.g., genetic analysis for PAH mutations, tetrahydrobiopterin deficiency exclusion) would refine the evaluation."
"['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is a hallmark laboratory finding directly linked to GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Metabolic acidosis** aligns with organic acidemia pathophysiology due to toxic accumulation of glutaric acid and derivatives.  
3. **Neurological symptoms (Ataxia, Lethargy, Drowsiness, Generalized hypotonia)** reflect basal ganglia and white matter injury from metabolic crises, characteristic of GA-I.  
4. **Death in infancy** underscores the severe, early-onset nature of untreated GA-I, often triggered by catabolic stressors (e.g., infections).  
5. **Sleep disturbances** may arise from neurotoxicity or secondary complications (e.g., electrolyte imbalances).  
6. Symptom combination excludes other organic acidemias (e.g., GA-II) or mitochondrial disorders, as GA-I uniquely associates with glutaric aciduria and striatal degeneration."
"['Blindness', 'Motor delay', 'Hyperreflexia', 'Death in infancy', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal circulating aspartate family amino acid concentration**: Directly links to Canavan disease, a leukodystrophy caused by aspartoacylase deficiency, leading to elevated N-acetylaspartic acid (NAA).  
2. **Motor delay and hyperreflexia**: Reflects progressive white matter degeneration, causing spasticity and upper motor neuron dysfunction.  
3. **Blindness**: Optic nerve atrophy due to demyelination is common in Canavan disease.  
4. **Opisthotonus**: Severe neurological damage from toxic NAA accumulation leads to abnormal posturing.  
5. **Death in infancy**: While typically fatal in early childhood, severe infantile forms can result in earlier demise.  
6. **Exclusion of alternatives**: Symptoms align with Canavan’s biochemical profile (aspartate-related metabolic error), distinguishing it from other leukodystrophies or aminoacidopathies."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This defect results in phenylalanine accumulation, directly explaining hyperphenylalaninemia.  
2. **Hypertyrosinemia**: Classic PKU typically presents with **low/normal tyrosine levels** due to impaired PAH activity. However, this case’s hypertyrosinemia may suggest atypical factors, such as:  
   - Concurrent liver dysfunction (unrelated to PKU) impairing tyrosine metabolism.  
   - Dietary mismanagement (e.g., excessive tyrosine intake in a PKU-specific diet).  
   - A rare PKU variant with secondary metabolic disruptions.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early mortality aligns with untreated or poorly managed cases, compounded by potential complications from hypertyrosinemia (e.g., hepatic/renal stress).  

**Note**: Hypertyrosinemia is atypical for PKU and warrants investigation for comorbid conditions (e.g., tyrosinemia type II) or diagnostic reevaluation. However, hyperphenylalaninemia remains the hallmark feature, prioritizing PKU as the primary diagnosis."
"['Intellectual disability', 'Seizure', 'Ataxia', 'Tremor', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Biochemical Marker**: The presence of L-2-hydroxyglutaric aciduria in urine is pathognomonic for this disorder, confirming a defect in the L2HGDH gene, which disrupts lysine and tryptophan metabolism.  
2. **Neurological Symptoms**: Intellectual disability, seizures, ataxia, and tremor align with progressive neurodegeneration caused by toxic accumulation of L-2-hydroxyglutaric acid in the central nervous system.  
3. **Disease Progression**: Early-onset symptoms (e.g., developmental delay) progressing to severe neurological deterioration and death in childhood reflect the aggressive nature of the disorder.  
4. **Exclusion of Mimics**: Specific biochemical findings rule out other organic acidurias (e.g., D-2-hydroxyglutaric aciduria) or mitochondrial disorders with overlapping symptoms.  
5. **Genetic Confirmation**: While not explicitly stated here, the biochemical evidence (urinary acid elevation) is sufficient for clinical diagnosis, with genetic testing as confirmatory."
"['Cataract', 'Delayed speech and language development', 'Cholelithiasis', 'Intellectual disability', 'Spasticity', 'Failure to thrive', 'Death in infancy', 'Abnormal foot morphology', 'Vomiting', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Feeding difficulties', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient exhibits hypergalactosemia and abnormal galactoside metabolism, hallmark biochemical features of galactosemia. Symptoms like cataracts (galactitol accumulation), hepatomegaly, elevated hepatic transaminases, and cholelithiasis align with liver dysfunction caused by toxic galactose metabolites. Failure to thrive, vomiting, and feeding difficulties are common neonatal presentations. Intellectual disability, delayed speech, and spasticity reflect neurological damage from chronic toxicity. Elevated alkaline phosphatase and abnormal amino acid concentrations (aspartate/alanine) suggest secondary liver impairment. Early mortality (infancy/childhood/adolescence) underscores untreated disease severity, consistent with classic galactosemia caused by GALT deficiency."
"['Median cleft lip', 'Microcephaly', 'Depressed nasal tip', 'Diabetes insipidus', 'Absent nasal septal cartilage', 'Lobar holoprosencephaly', 'Median cleft palate']",['Holoprosencephaly 4'],"Disease: Holoprosencephaly 4 (HPE4)  
Reasoning:  
1. **Lobar holoprosencephaly** is a defining feature of HPE4, representing incomplete separation of the cerebral hemispheres.  
2. **Median cleft lip/palate** and **absent nasal septal cartilage** are midline facial defects, characteristic of HPE due to disrupted Sonic Hedgehog (SHH) signaling, which governs midline craniofacial development.  
3. **Microcephaly** aligns with impaired forebrain growth in HPE.  
4. **Depressed nasal tip** further supports midline structural abnormalities.  
5. **Diabetes insipidus** suggests hypothalamic-pituitary dysfunction, a known but less common feature of HPE4 linked to SHH mutations affecting neuroendocrine development.  
6. Genetic etiology: HPE4 is caused by heterozygous mutations in *SHH* (18q11.2), critical for forebrain and facial midline patterning. This gene’s role explains the syndromic combination of brain, facial, and endocrine anomalies."
"['Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Central features of HMG-CoA lyase deficiency, caused by impaired leucine catabolism and ketogenesis, leading to toxic accumulation of 3-hydroxy-3-methylglutaric acid and secondary urea cycle disruption.  
2. **Dicarboxylic aciduria and 3-methylglutaric aciduria**: Pathognomonic urinary biomarkers due to defective HMG-CoA lyase activity, which prevents cleavage of HMG-CoA into acetoacetate and acetyl-CoA, resulting in excretion of these metabolites.  
3. **Elevated urinary carboxylic acids**: Reflects systemic organic acidemia from blocked ketone body synthesis and mitochondrial energy dysfunction.  
4. **Abnormal circulating glycine**: Secondary glycine elevation occurs as glycine conjugation attempts to detoxify accumulating organic acids (e.g., 3-methylglutaconate).  
5. **Vomiting, fever, and infantile lethality**: Episodic crises triggered by catabolic stress (e.g., fasting, infection), causing acute metabolic decompensation. Untreated, this leads to rapid neurological decline and early mortality.  
6. **Exclusion of mimics**: The specific organic acid profile (3-methylglutaric aciduria) distinguishes it from other organic acidurias (e.g., propionic acidemia), which lack this marker."
"['Acne', 'Tachycardia', 'Left ventricular hypertrophy', 'Palpitations', 'Arthralgia', 'Abnormal EKG', 'Abnormality of galactoside metabolism', 'Edema of the dorsum of hands', 'Upper limb pain', 'Finger swelling', 'Finger pain', 'Knee pain', 'Ankle pain', 'Papule']",['Fabry disease/Fabry disease/Fabry disease'],"Disease: Fabry disease  
Reasoning:  
1. **Cardiac Manifestations**: Tachycardia, palpitations, left ventricular hypertrophy (LVH), and abnormal EKG align with Fabry disease's progressive cardiac involvement due to globotriaosylceramide (Gb3) accumulation in myocardial tissue, leading to arrhythmias and structural changes.  
2. **Neuropathic Pain**: Arthralgia, upper limb pain, finger/knee/ankle pain correlate with Fabry-associated acroparesthesias, characterized by episodic burning or tingling in extremities.  
3. **Metabolic Abnormality**: The explicit mention of ""abnormality of galactoside metabolism"" directly implicates alpha-galactosidase A deficiency, the enzymatic defect in Fabry disease.  
4. **Dermatologic Features**: Papules may represent angiokeratomas, a pathognomonic skin lesion of Fabry disease.  
5. **Edema and Swelling**: Edema of the hands and finger swelling may reflect vascular dysfunction or secondary renal impairment, though less typical, they reinforce multisystem involvement.  
6. **Exclusion of Alternatives**: Symptoms collectively point to a lysosomal storage disorder, with the metabolic clue excluding rheumatologic or isolated cardiac conditions."
"['Lens subluxation', 'Disproportionate tall stature', 'Aortic dissection', 'High myopia']","['Marfan syndrome', 'Marfan syndrome type 1']","Disease: Marfan syndrome  
Reasoning:  
1. **Lens subluxation**: A hallmark of Marfan syndrome due to defective fibrillin-1 (FBN1 gene), weakening zonular fibers that hold the lens.  
2. **Disproportionate tall stature**: Characterized by long limbs (arm span > height) and arachnodactyly, consistent with skeletal manifestations of Marfan.  
3. **Aortic dissection**: Caused by progressive aortic root dilation and connective tissue fragility, a life-threatening feature of Marfan syndrome.  
4. **High myopia**: Associated with elongation of the globe and structural weakness in the eye, common in Marfan-related ocular abnormalities.  

Disease: Marfan syndrome type 1  
Reasoning:  
1. **Genetic confirmation**: Type 1 specifically refers to classic Marfan syndrome caused by pathogenic FBN1 mutations, which explain all listed symptoms.  
2. **Systemic involvement**: The combination of ocular (lens subluxation, myopia), skeletal (tall stature), and cardiovascular (aortic dissection) features aligns with the multisystemic criteria for Marfan syndrome type 1.  
3. **Exclusion of overlap syndromes**: No features of Loeys-Dietz syndrome (e.g., hypertelorism, bifid uvula) or other fibrillinopathies, reinforcing the diagnosis of type 1."
"['Spastic diplegia', 'Death in infancy', 'Cerebral cortical atrophy', 'Opisthotonus', 'Athetosis', 'Spastic tetraplegia', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Elevated glutaric acid & Glutaric aciduria**: Direct biochemical markers of GA-I due to deficient glutaryl-CoA dehydrogenase enzyme activity, impairing lysine and tryptophan metabolism.  
2. **Decreased plasma free carnitine**: Secondary carnitine depletion occurs as carnitine binds to accumulating glutaric acid, forming glutarylcarnitine for excretion.  
3. **Cerebral cortical atrophy**: Neurotoxic effects of glutaric acid and its derivatives (e.g., 3-hydroxyglutaric acid) cause striatal and cortical neuronal damage.  
4. **Spastic diplegia/tetraplegia, Opisthotonus, Athetosis**: Result from basal ganglia and corticospinal tract injury, characteristic of GA-I-associated encephalopathic crises.  
5. **Death in infancy**: Untreated GA-I leads to acute metabolic decompensation (often triggered by infections), severe neurological damage, and early mortality.  
The triad of macrocephaly (not listed here but common), striatal necrosis, and organic acidemia strongly supports GA-I. Early-onset neurological deterioration with specific biochemical abnormalities confirms the diagnosis."
"['Abnormality of the genitourinary system', 'Hydrocephalus', 'Growth delay', 'Pancytopenia', 'Immunodeficiency', 'Bone marrow hypocellularity', 'Arachnoid cyst']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Pancytopenia & Bone Marrow Hypocellularity**: Core features of APS, caused by SAMD9L mutations disrupting hematopoiesis.  
2. **Immunodeficiency**: Secondary to pancytopenia (neutropenia, lymphopenia).  
3. **Hydrocephalus & Arachnoid Cyst**: Neurological structural anomalies (e.g., cerebellar defects, CSF flow issues) align with APS-associated CNS abnormalities.  
4. **Growth Delay**: Common in multisystem genetic disorders like APS.  
5. **Genitourinary Abnormalities**: Reported in some APS cases, though less typical, suggesting phenotypic variability.  
6. **Ataxia (implied)**: While not explicitly listed, hydrocephalus/cysts may indicate cerebellar dysfunction, a hallmark of APS.  

The constellation of hematologic, neurologic, and developmental symptoms strongly supports APS diagnosis."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Pustule']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning: Hyperphenylalaninemia is the defining biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine-to-tyrosine conversion.  
Reasoning: Untreated PKU leads to toxic phenylalanine accumulation, resulting in severe neurological damage, developmental failure, and early mortality (death in infancy/childhood).  
Reasoning: Hypertyrosinemia is atypical in classic PKU but may indicate a co-occurring BH4 deficiency (a PKU variant), where impaired tyrosine hydroxylase activity disrupts tyrosine metabolism, causing its accumulation.  
Reasoning: Pustules could reflect secondary skin manifestations from tyrosine-derived metabolites or oxidative stress due to systemic metabolic dysfunction."
"['Renal insufficiency', 'Proteinuria', 'Rod-cone dystrophy', 'Dental crowding', 'Diabetes mellitus', 'Postaxial hand polydactyly', 'Specific learning disability', 'Obesity', 'Postaxial polydactyly']",['Bardet-Biedl syndrome 2'],"Disease: Bardet-Biedl syndrome 2  
Reasoning:  
1. **Postaxial polydactyly** (hand) is a primary diagnostic feature of Bardet-Biedl syndrome (BBS).  
2. **Rod-cone dystrophy** (retinal degeneration) is a hallmark of BBS, typically leading to progressive vision loss.  
3. **Obesity** and **diabetes mellitus** align with metabolic abnormalities commonly seen in BBS.  
4. **Renal insufficiency** and **proteinuria** reflect renal involvement, a critical diagnostic criterion.  
5. **Specific learning disability** corresponds to cognitive impairments frequently associated with BBS.  
6. **Dental crowding** is a recognized orofacial manifestation of the syndrome.  
7. The combination of ≥4 major features (polydactyly, retinal dystrophy, obesity, renal anomalies, learning disability) and supportive findings (diabetes, dental anomalies) meets clinical diagnostic criteria for BBS.  
8. Subtype ""2"" refers to mutations in the *BBS2* gene, one of >25 known BBS-associated genes, confirmed via genetic testing."
"['Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hypothermia', 'Pneumonia', 'Hyperglycinemia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Elevated hepatic transaminase', 'Hyperglycinuria', 'Elevated circulating alkaline phosphatase concentration', 'Dicarboxylic aciduria', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Fatigue', 'Increased circulating lactate dehydrogenase concentration', 'Acute hepatitis', 'Chronic hepatitis']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **hepatic dysfunction** (elevated transaminases, hepatomegaly, acute/chronic hepatitis) indicate a urea cycle disorder (UCD).  
2. **Oroticaciduria** and **uraciluria** are pathognomonic for OTCD. Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, overproducing orotic acid and uracil.  
3. **Elevated plasma citrulline** may initially seem contradictory (classic OTCD features low citrulline), but partial enzyme activity or alternative metabolic stress (e.g., liver damage) can paradoxically elevate citrulline.  
4. **Hyperglutaminemia** and **hyperalaninemia** reflect nitrogen accumulation via alternative pathways, consistent with UCDs.  
5. **Metabolic acidosis**, **dicarboxylic aciduria**, and **elevated lactate dehydrogenase** suggest secondary mitochondrial dysfunction during metabolic crises.  
6. **Recurrent infections** and **prolonged PTT** align with hepatic synthetic failure (reduced clotting factors/immune proteins).  
7. **Early lethality** (infancy/childhood/adolescence) matches severe OTCD phenotypes, exacerbated by triggers like infection (pneumonia) or catabolism.  

Key differentiators from other UCDs (e.g., citrullinemia): Distinct **oroticaciduria** and **pyrimidine abnormalities** (uraciluria, abnormal circulating pyrimidines) are hallmark features of OTCD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), impairing phenylalanine metabolism.  
2. **Neonatal death/Death in infancy**: Untreated severe PKU can lead to toxic accumulation of phenylalanine, causing irreversible neurological damage, seizures, and failure to thrive, which may result in early mortality if undiagnosed and unmanaged.  
3. **Abnormality of prenatal development or birth**: Maternal PKU (untreated hyperphenylalaninemia during pregnancy) can cause fetal developmental abnormalities (e.g., microcephaly, congenital heart defects). However, if the infant itself has PKU, metabolic disruption post-birth may contribute to developmental issues.  
4. **Exclusion of BH4 deficiencies**: While hyperphenylalaninemia can also occur in tetrahydrobiopterin (BH4) deficiencies, the listed symptoms align more with classic PKU when neonatal screening/treatment is unavailable or delayed.  

Conclusion: The combination of hyperphenylalaninemia and early lethality strongly supports PKU, particularly in settings lacking newborn screening or dietary intervention."
"['Cleft palate', 'Pierre-Robin sequence', 'Cleft upper lip', 'Respiratory distress', 'Scoliosis', 'Posterior rib gap', '10 pairs of ribs']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Cleft palate, Pierre-Robin sequence, and cleft upper lip**: These craniofacial anomalies align with CCMS, which is characterized by mandibular hypoplasia (micrognathia, a key feature of Pierre-Robin sequence) and oral clefts.  
2. **Respiratory distress**: Likely secondary to micrognathia (obstructing the airway) and rib abnormalities impairing lung development/function.  
3. **Scoliosis and posterior rib gaps**: CCMS involves severe rib malformations, including posterior ""rib gaps"" (missing rib segments) and abnormal rib count.  
4. **10 pairs of ribs**: A hallmark of CCMS, as affected individuals often have fewer than the typical 12 pairs, with severe costal defects contributing to thoracic insufficiency.  
5. **Exclusion of alternatives**: While Pierre-Robin sequence and clefts occur in other syndromes (e.g., Stickler or Treacher Collins), the combination with rib gaps and rib count reduction is pathognomonic for CCMS."
"['Narrow face', 'Prominent nose', 'Dental malocclusion', 'Atypical behavior', 'Intellectual disability', 'Screwdriver-shaped incisors', 'Mulberry molar', 'Anteverted ears', 'Nuclear cataract']",['Nance-Horan syndrome/Nance-Horan syndrome'],"Disease: Nance-Horan syndrome/Nance-Horan syndrome  
Reasoning:  
1. **Nuclear cataract**: A defining feature of Nance-Horan syndrome, present in nearly all affected individuals.  
2. **Dental anomalies**: ""Screwdriver-shaped incisors"" and ""mulberry molar"" are pathognomonic dental findings in this syndrome.  
3. **Craniofacial features**: ""Narrow face,"" ""prominent nose,"" and ""anteverted ears"" align with the characteristic facial dysmorphism.  
4. **Intellectual disability and atypical behavior**: Common neurodevelopmental manifestations of the syndrome.  
5. **Dental malocclusion**: Secondary to abnormal tooth morphology and craniofacial structure.  
6. Exclusion of mimics: The combination of ocular, dental, and craniofacial abnormalities is distinct from other syndromes (e.g., Lowe syndrome, oculodentodigital dysplasia)."
"['Blue irides', 'Heterochromia iridis', 'White eyebrow', 'White eyelashes', 'Hypopigmentation of the fundus', 'Congenital sensorineural hearing impairment']",['Tietz syndrome/Tietz albinism-deafness syndrome'],"Disease: Tietz syndrome/Tietz albinism-deafness syndrome  
Reasoning:  
1. **Hypopigmentation features**: Blue irides, white eyebrows, white eyelashes, and hypopigmentation of the fundus align with Tietz syndrome, which causes generalized pigment deficiency affecting skin, hair, and eyes.  
2. **Congenital sensorineural hearing impairment**: A hallmark of Tietz syndrome, present from birth due to cochlear dysfunction.  
3. **Heterochromia iridis**: While less commonly reported, it may reflect variable melanin distribution in the irises, consistent with pigmentary abnormalities in Tietz syndrome.  
4. **Exclusion of differentials**: Waardenburg syndrome often includes dystopia canthorum or white forelock (distinct from white eyebrows/lashes), while oculocutaneous albinism lacks congenital deafness.  
5. **Genetic correlation**: Tietz syndrome is linked to mutations in *MITF*, critical for melanocyte and cochlear development, explaining both hypopigmentation and hearing loss."
"['Abnormal rib morphology', 'Osteoporosis', 'Scoliosis', 'Arthralgia', 'Hypercholesterolemia', 'Low alkaline phosphatase', 'Myalgia', 'Muscle spasm', 'Back pain', 'Antinuclear antibody positivity', 'Vertebral wedging', 'Increased HDL cholesterol concentration', 'Knee pain', 'Ankle pain']","['Hypophosphatasia; HPP/Hypophosphatasia', 'Hypophosphatasia, adult']","Disease: Hypophosphatasia, adult  
Reasoning:  
1. **Low alkaline phosphatase**: A hallmark of hypophosphatasia (HPP) due to ALPL gene mutations impairing tissue-nonspecific alkaline phosphatase (TNAP) activity.  
2. **Bone abnormalities**: ""Abnormal rib morphology,"" ""vertebral wedging,"" and ""osteoporosis"" align with HPP’s defective bone mineralization, leading to skeletal fragility and deformities.  
3. **Musculoskeletal pain**: ""Arthralgia,"" ""myalgia,"" ""back pain,"" ""knee pain,"" and ""ankle pain"" correlate with HPP-associated bone stress, microfractures, and musculoskeletal strain.  
4. **Scoliosis**: Secondary to vertebral instability and weakened spinal bones in adult HPP.  
5. **Hypercholesterolemia/Increased HDL**: May reflect metabolic adaptations to impaired TNAP function, though not pathognomonic.  
6. **ANA positivity**: Likely incidental (e.g., age-related autoimmunity) as HPP is not autoimmune.  
Exclusion of mimics (e.g., osteogenesis imperfecta, Paget’s disease) is supported by the combination of low ALP, skeletal features, and absence of classic collagenopathy signs."
"['Epididymitis', 'Conjunctivitis', 'Pericarditis', 'Splenomegaly', 'Weight loss', 'Fever', 'Leukocytosis', 'Diarrhea', 'Abdominal pain', 'Abnormality of the knee', 'Hypoalbuminemia', 'Generalized amyloid deposition', 'Elevated circulating creatinine concentration', 'Elevated erythrocyte sedimentation rate', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Intestinal lymphoid nodular hyperplasia', 'Fatigue', 'Moderate proteinuria', 'Heavy proteinuria', 'Night sweats', 'Hip pain', 'Abnormality of mesentery morphology', 'Periorbital edema']","['Tumor necrosis factor receptor 1 associated periodic syndrome/Periodic fever, familial, autosomal dominant']","Disease: Tumor necrosis factor receptor 1 associated periodic syndrome/Periodic fever, familial, autosomal dominant (TRAPS)  
Reasoning:  
1. **Systemic inflammation**: Fever, leukocytosis, elevated ESR, and CRP align with TRAPS’ hallmark of prolonged inflammatory episodes.  
2. **Mucocutaneous features**: Conjunctivitis and erythema reflect characteristic ocular/periocular inflammation and migratory rash in TRAPS.  
3. **Serositis**: Pericarditis matches recurrent serosal inflammation seen in TRAPS.  
4. **Amyloidosis**: Hypoalbuminemia, proteinuria, and generalized amyloid deposition indicate AA amyloidosis, a severe TRAPS complication from chronic inflammation.  
5. **Gastrointestinal involvement**: Abdominal pain, diarrhea, and mesenteric lymphoid hyperplasia suggest gut inflammation, consistent with TRAPS’ systemic effects.  
6. **Musculoskeletal symptoms**: Hip/knee pain and mesenteric morphology abnormalities (e.g., fat wrapping) correlate with TRAPS-associated arthralgia and tissue inflammation.  
7. **Periorbital edema**: A pathognomonic feature of TRAPS during flares.  
8. **Autosomal dominant pattern**: Familial periodic fever history (implied by diagnosis) supports genetic etiology of TNFRSF1A mutations.  
9. **Exclusion of mimics**: Symptoms overlap with other periodic fever syndromes (e.g., FMF, HIDS), but amyloidosis, prolonged attacks (>7 days), and periorbital edema favor TRAPS."
"['Obesity', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Death in adolescence']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: Biotinidase deficiency disrupts carboxylase function, leading to organic acid accumulation. This forces carnitine to conjugate with toxic metabolites, depleting carnitine stores and causing secondary deficiency.  
2. **Death in childhood/adolescence**: Untreated BTDD results in severe metabolic crises (e.g., ketoacidosis, hyperammonemia), neurological deterioration, and fatal outcomes without early biotin supplementation.  
3. **Obesity**: While atypical, disrupted fatty acid oxidation due to carnitine deficiency may impair energy production, shifting metabolism toward fat storage. Altered acetyl-CoA carboxylase activity (biotin-dependent) could further dysregulate lipid synthesis pathways.  
4. **Consistency with late-onset multiple carboxylase deficiency**: The phenotype aligns with delayed presentations, where partial enzyme activity permits survival into childhood/adolescence before metabolic decompensation occurs."
"['Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient presents with hyperammonemia, aminoaciduria, and elevated urinary carboxylic acids, indicative of a leucine metabolism disorder. Decreased plasma free carnitine aligns with secondary carnitine depletion due to conjugation with toxic metabolites like 3-methylcrotonylglycine. Neonatal death and growth issues correlate with metabolic crises from enzyme deficiency (MCCC1 gene), impairing 3-methylcrotonyl-CoA conversion.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: Symptoms overlap with the broader enzyme deficiency (MCCC1 or MCCC2 subunits). Elevated urinary 3-hydroxyisovaleric acid and abnormal glycine levels are hallmark biochemical findings. Death in infancy/childhood reflects acute decompensation episodes triggered by catabolic stressors. Small for gestational age suggests prenatal metabolic dysfunction. The combined features confirm disrupted branched-chain amino acid catabolism due to 3-MCC deficiency."
"['Renal cyst', 'Rod-cone dystrophy', 'Abnormal electroretinogram', 'Absent eyelashes', 'Abnormality of visual evoked potentials', 'Brachydactyly', 'Intellectual disability', 'Craniosynostosis', 'Alopecia', 'Absent eyebrow', 'Short stature', 'Ichthyosis', 'Severe global developmental delay', 'Feeding difficulties']",['Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies'],"Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Brachydactyly and Short Stature**: Core skeletal features of the syndrome, directly aligning with its diagnostic nomenclature.  
2. **Rod-Cone Dystrophy (Retinitis Pigmentosa)**: Confirmed by abnormal electroretinogram and visual evoked potential abnormalities, hallmark signs of retinal degeneration.  
3. **Ectodermal Abnormalities**: Absent eyelashes/eyebrows, alopecia, and ichthyosis suggest ectodermal dysplasia, which may occur in syndromic forms of retinitis pigmentosa.  
4. **Developmental and Intellectual Deficits**: Severe global developmental delay and intellectual disability are consistent with the syndrome’s potential neurodevelopmental involvement.  
5. **Renal Cyst**: May reflect broader systemic manifestations, as ciliopathies (often linked to retinal-skeletal syndromes) can involve renal pathology.  
6. **Craniosynostosis**: Though atypical for classic presentations, it could represent phenotypic variability or a rare association in severe cases.  
7. **Feeding Difficulties**: Commonly secondary to developmental delay or neuromuscular dysfunction in multisystem genetic disorders.  

The diagnosis is anchored by the triad of brachydactyly, short stature, and retinitis pigmentosa, with additional features reflecting the syndrome’s phenotypic spectrum."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Renal hypoplasia', 'Tall stature', 'Renal cyst', 'Hydronephrosis', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Abnormal pinna morphology', 'Prominent antihelix', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormal choroid morphology', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Abnormal thumb morphology', 'Hypotonia', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Hip dysplasia', 'Growth delay', 'Growth delay', 'Intrauterine growth retardation', 'Polyhydramnios', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Generalized non-motor (absence) seizure', 'Duodenal atresia', 'Tetraparesis', 'Hypoplastic nipples', 'Scoliosis', 'Neoplasm of the liver', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', '3-4 finger syndactyly', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormal choroid plexus morphology', 'Postnatal growth retardation', 'Anterior creases of earlobe', 'Abnormal fifth toe morphology', '1-2 finger syndactyly', 'Anomalous pulmonary venous return', 'Expanded terminal portion of crus of helix', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental/core features**: Global developmental delay, hypotonia, spastic tetraparesis, generalized non-motor seizures, ADHD, and cerebellar vermis hypoplasia align with central nervous system involvement. Delayed myelination, cerebral hypomyelination, and hypoplastic corpus callosum further support brain structural anomalies.  
2. **Ocular anomalies**: Microphthalmia, coloboma, Peters anomaly, optic atrophy, and abnormal iris morphology are hallmark eye abnormalities in NEDBEH.  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and abnormal cardiac septum morphology match the ""heart"" component of the disorder.  
4. **Craniofacial/Systemic dysmorphism**: Microcephaly/macrocephaly, triangular face, micrognathia, hypertelorism, smooth philtrum, and high palate are consistent with reported facial gestalt. Renal hypoplasia, hydronephrosis, and annular pancreas reflect multi-organ involvement.  
5. **Supportive features**: Growth retardation (pre/postnatal), sensorineural hearing impairment, limb anomalies (syndactyly, clinodactyly), and café-au-lait spots overlap with phenotypic variability in NEDBEH.  
6. **Exclusion**: While features like choanal atresia or duodenal atresia may suggest other syndromes (e.g., CHARGE), the combination of neurodevelopmental, eye, and heart anomalies without a primary skeletal dysplasia or metabolic disorder strongly favors NEDBEH.  

Key triad: Neurodevelopmental delay + structural brain/eye anomalies + congenital heart defects."
"['Lethargy', 'Generalized hypotonia', 'Tremor', 'Death in infancy', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Elevated urinary carboxylic acid', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Abnormal circulating leucine concentration**: MSUD is caused by a defect in the branched-chain alpha-keto acid dehydrogenase complex, leading to accumulation of branched-chain amino acids (BCAAs: leucine, isoleucine, valine). Elevated leucine is neurotoxic and a hallmark of MSUD.  
2. **Elevated urinary carboxylic acid**: Excess BCAAs are metabolized into ketoacids, which are excreted in urine as carboxylic acids (e.g., α-ketoisocaproic acid), detectable via urine organic acid analysis.  
3. **Body odor**: The presence of sotolon, a metabolite of isoleucine, produces a distinctive maple syrup or burnt sugar odor in bodily fluids.  
4. **Neurological symptoms (Lethargy, Hypotonia, Tremor, Opisthotonus, Drowsiness)**: Leucine toxicity disrupts neurotransmitter synthesis and cerebral energy metabolism, causing encephalopathy, hypotonia, and hypertonic posturing (opisthotonus).  
5. **Sleep disturbance, Neonatal/Infant death**: Untreated classic MSUD rapidly progresses to cerebral edema, seizures, coma, and death within weeks to months of birth due to metabolic crisis.  
6. **Early mortality**: Classic MSUD manifests neonatally; without dietary BCAA restriction and metabolic support, fatal outcomes are inevitable.  

The combination of metabolic derangements (leucine elevation, urinary ketoacids), neurotoxicity, and pathognomonic odor confirms MSUD."
"['Keratoconus', 'Dysarthria', 'Dysmetria', 'Lower limb spasticity', 'Gait ataxia', 'Limb ataxia', 'Upper limb spasticity']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Lower and upper limb spasticity**: Core features of hereditary spastic paraplegias (HSPs), including SPG76, caused by *CAPN1* mutations. Spasticity reflects corticospinal tract dysfunction.  
2. **Gait ataxia, limb ataxia, dysmetria**: Indicate cerebellar involvement, consistent with SPG76’s reported association with cerebellar degeneration.  
3. **Dysarthria**: Aligns with cerebellar or bulbar dysfunction, seen in complex HSP subtypes like SPG76.  
4. **Keratoconus**: Less typical but plausible in SPG76, as calpain dysfunction (from *CAPN1* mutations) may disrupt corneal structural integrity. Calpains regulate cytoskeletal proteins critical in corneal homeostasis.  
5. **Exclusion of mimics**: Other HSPs (e.g., SPG7) or ataxia syndromes lack this specific combination of spasticity, ataxia, and keratoconus. Genetic testing for *CAPN1* variants would confirm SPG76."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Death in infancy/childhood** aligns with untreated PKU, as elevated phenylalanine causes irreversible neurotoxicity, seizures, and failure to thrive.  
3. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low due to blocked PAH activity). This may suggest a secondary metabolic disturbance, comorbid tyrosinemia, or misdiagnosis of lab values.  
4. **Recurrent viral infections** are not characteristic of PKU and could indicate an unrelated immune disorder or complications from metabolic instability (e.g., malnutrition).  
5. The diagnosis prioritizes hyperphenylalaninemia and early lethality as primary PKU indicators, while acknowledging inconsistencies (hypertyrosinemia, infections) that warrant further investigation for overlapping disorders."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Symptoms of metabolic crisis**: Vomiting and diarrhea are common during acute episodes due to the inability to metabolize medium-chain fatty acids, leading to energy depletion and toxic metabolite accumulation.  
2. **Gastrointestinal inflammation**: Secondary to metabolic stress and mitochondrial dysfunction in gastrointestinal cells.  
3. **Abnormal carnitine levels**: MCADD causes secondary carnitine deficiency as carnitine conjugates with unmetabolized acyl-CoA intermediates (e.g., octanoylcarnitine) for urinary excretion.  
4. **Early mortality**: Neonatal/childhood death aligns with untreated MCADD, as prolonged fasting (e.g., during infections) triggers hypoglycemia, hepatopathy, and encephalopathy.  
5. **Prenatal/developmental abnormalities**: Subtle intrauterine metabolic stress may affect growth, though MCADD typically manifests postnatally.  
6. **Exclusion of other disorders**: Symptoms overlap with long-chain fatty acid oxidation defects (e.g., VLCAD), but gastrointestinal predominance and carnitine pattern favor MCADD.  
**Diagnostic confirmation**: Elevated C6-C10 acylcarnitines (especially C8) on newborn screening, genetic testing for *ACADM* mutations."
"['Mental deterioration', 'Slurred speech', 'Spastic tetraplegia', 'Dyskinesia']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Mental deterioration**: Observed in DNAJC6-related PARK23 due to rapid neurodegeneration and early cognitive decline.  
2. **Slurred speech**: Linked to dysarthria from basal ganglia dysfunction and possible pyramidal tract involvement.  
3. **Spastic tetraplegia**: Reflects pyramidal tract damage (spasticity), atypical in classic Parkinson’s but characteristic of PARK23’s broader neurological pathology.  
4. **Dyskinesia**: Arises from basal ganglia dysfunction and may occur earlier in genetic forms, independent of levodopa therapy.  
The combination of parkinsonism, pyramidal signs, cognitive decline, and dyskinesia aligns with PARK23’s phenotype caused by biallelic DNAJC6 mutations."
"['Intellectual disability, mild', 'Rectal prolapse', 'Wide pubic symphysis', 'Irregular iliac crest', 'Rhizomelia', 'Short metacarpal', 'Short metatarsal']",['Dyggve-Melchior-Clausen disease/Dyggve-Melchior-Clausen disease'],"Disease: Dyggve-Melchior-Clausen disease  
Reasoning:  
1. **Skeletal Dysplasia Indicators**: Rhizomelia (proximal limb shortening), short metacarpals/metatarsals, and pelvic abnormalities (wide pubic symphysis, irregular/lacy iliac crest) align with DMC’s hallmark skeletal features.  
2. **Intellectual Disability**: Mild cognitive impairment supports DMC, distinguishing it from Smith-McCort dysplasia (a phenocopy without intellectual disability).  
3. **Rectal Prolapse**: Likely secondary to pelvic connective tissue weakness or structural pelvic anomalies, a rare but plausible complication in DMC due to altered musculoskeletal integrity.  
4. **Exclusion of Alternatives**: Mucopolysaccharidoses or spondyloepiphyseal dysplasias lack the specific iliac crest irregularity and intellectual disability pattern seen here.  
5. **Genetic Confirmation**: Autosomal recessive *DYM* mutations confirm DMC, though clinical features alone strongly suggest the diagnosis."
"['Hyperactivity', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating creatine kinase concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Metabolic crisis indicators**: Hyperammonemia and abnormal amino acid concentrations (aspartate family, alanine) suggest a defect in fatty acid oxidation (FAO), leading to energy deficits and secondary metabolic disturbances.  
2. **Carnitine deficiency**: Decreased plasma free carnitine aligns with FAO disorders, as carnitine is required for long-chain fatty acid transport into mitochondria.  
3. **Muscle involvement**: Generalized hypotonia and elevated creatine kinase (muscle breakdown) reflect impaired energy production in muscles, a hallmark of VLCADD.  
4. **Neonatal/Infantile mortality**: Death in infancy/childhood and premature birth correlate with severe VLCADD presentations, including cardiomyopathy, hepatopathy, or hypoketotic hypoglycemia.  
5. **Hyperactivity**: May indicate neurological stress due to energy deprivation or toxic metabolite accumulation (e.g., long-chain acylcarnitines).  
6. **Specific biochemical profile**: VLCADD disrupts very long-chain fatty acid oxidation, distinguishing it from medium/short-chain FAO defects (e.g., MCADD). Confirmatory testing (acylcarnitine profile showing elevated C14:1, genetic analysis) would solidify the diagnosis."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids**: Reflects alternative metabolism of phenylalanine into phenylketones (e.g., phenylpyruvate, phenyllactate), which are excreted in urine.  
3. **Early mortality (infancy to adulthood)**: Untreated PKU causes severe neurological damage, seizures, and organ failure, often resulting in premature death without dietary intervention.  
4. **Obesity**: May arise from metabolic dysregulation or compensatory high-calorie diets low in phenylalanine.  
5. **Hypertyrosinemia**: Uncommon in classic PKU but could indicate a co-occurring tyrosinemia or secondary metabolic disruption from chronic phenylalanine toxicity.  
6. **Prenatal abnormalities**: Likely reflects maternal PKU syndrome (uncontrolled phenylalanine in a pregnant mother affecting fetal development), though not typical in the affected individual themselves.  

Note: While some symptoms (e.g., hypertyrosinemia) are atypical for isolated PKU, they may suggest complex metabolic interactions or comorbid conditions. The core diagnosis remains PKU due to hyperphenylalaninemia and urinary phenylketone derivatives."
"['Thin vermilion border', 'Abnormality of skull size', 'Long philtrum', 'Brachydactyly', 'Global developmental delay', 'Limited elbow extension', 'Bilateral ptosis', 'Polyhydramnios', 'Recurrent respiratory infections', 'Delayed skeletal maturation', 'Hypoplasia of the ulna', 'Limited knee extension', 'Short femur', 'Short stature', 'Short phalanx of finger', 'Short metacarpal']",['Geleophysic dysplasia 1'],"Disease: Geleophysic Dysplasia 1  
Reasoning:  
1. **Facial Features**: Thin vermilion border and long philtrum align with the characteristic ""happy-looking"" facies seen in geleophysic dysplasia.  
2. **Skeletal Abnormalities**: Brachydactyly, short metacarpals, short phalanx of finger, hypoplasia of the ulna, short femur, and delayed skeletal maturation are hallmark skeletal features of this disorder.  
3. **Growth Issues**: Short stature and prenatal polyhydramnios (often due to reduced fetal swallowing) are consistent with growth restriction patterns in geleophysic dysplasia.  
4. **Joint Limitations**: Limited elbow/knee extension and recurrent respiratory infections suggest connective tissue/joint contractures and potential tracheobronchial stenosis, common in this condition.  
5. **Developmental Delay**: Global developmental delay, though nonspecific, is reported in some cases, particularly due to systemic complications.  
6. **Ptosis**: Bilateral ptosis reflects craniofacial connective tissue involvement, a subtle but supportive feature.  
7. **Exclusion of Mimics**: Symptoms differentiate from similar disorders (e.g., acromicric dysplasia lacks recurrent infections; Myhre syndrome has distinct facial/skeletal features).  
Key genetic confirmation would involve *FBN1* or *ADAMTSL2* mutations, but clinical findings strongly prioritize geleophysic dysplasia 1."
"['Hypothyroidism', 'Splenomegaly', 'Lymphopenia', 'Microcytic anemia', 'Fever', 'Nausea', 'Dyspnea', 'Pleuritis', 'Pleural effusion', 'Hypocalcemia', 'Poor appetite', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Sinus tachycardia', 'Fatigue', 'Chills', 'Increased circulating lactate dehydrogenase concentration', 'Cervicitis', 'Chest pain']","['Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Familial Mediterranean fever, AD']","Disease: Familial Mediterranean fever, AR  
Reasoning:  
1. **Recurrent fever, chills, and systemic inflammation**: Elevated CRP and lactate dehydrogenase (LDH) align with FMF’s hallmark episodic inflammatory attacks.  
2. **Serositis manifestations**: Pleuritis, pleural effusion, and chest pain reflect pleural inflammation, a classic FMF feature. Dyspnea may arise from pleural effusion.  
3. **Splenomegaly and lymphopenia**: Common during acute FMF flares due to immune activation and cytokine release.  
4. **Microcytic anemia**: Likely secondary to chronic inflammation (anemia of chronic disease) rather than iron deficiency.  
5. **Hypocalcemia and abnormal sodium**: Electrolyte imbalances may occur due to transient renal dysfunction or inflammatory stress.  
6. **Absence of infectious etiology**: Fever, nausea, and fatigue are nonspecific but recurrent without clear infection (e.g., cervicitis could be coincidental).  
7. **Autosomal recessive (AR) inheritance**: FMF is predominantly AR (MEFV gene mutations); the AD form is exceedingly rare and less consistent with this presentation.  

Disease: Familial Mediterranean fever, AD  
Reasoning:  
1. **Overlap in inflammatory symptoms**: Fever, CRP elevation, and pleuritis are shared with AR-FMF.  
2. **Atypical features**: Cervicitis and hypothyroidism are not typical for FMF but might suggest comorbid autoimmune processes, which are less commonly associated with AD-FMF.  
3. **Limited evidence**: AD-FMF is poorly characterized compared to AR-FMF; this diagnosis is less likely unless family history strongly supports autosomal dominant transmission.  

**Final Diagnosis**: Familial Mediterranean fever, AR is the most probable diagnosis given the recurrent serositis, inflammatory markers, and population prevalence of AR inheritance. AD-FMF remains a differential but requires genetic confirmation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), leading to impaired conversion of phenylalanine to tyrosine. This results in toxic accumulation of phenylalanine in the blood, consistent with hyperphenylalaninemia.  
2. **Abnormal circulating tyrosine concentration**: Reduced PAH activity decreases tyrosine synthesis, explaining low tyrosine levels (""abnormal"" in this context).  
3. **Neonatal death/Death in infancy**: Untreated PKU causes severe neurological damage, seizures, and failure to thrive. Without early dietary intervention (low-phenylalanine diet), metabolic derangements and complications may lead to early mortality.  
4. **Abnormality of prenatal development or birth**: While PKU itself does not directly affect prenatal development, maternal PKU (untreated high phenylalanine during pregnancy) can cause congenital anomalies (e.g., microcephaly) in the fetus. If the patient’s mother had uncontrolled PKU, this could explain prenatal abnormalities.  
5. **Consistency with PKU**: The combination of metabolic findings (elevated phenylalanine, low tyrosine) and clinical outcomes aligns with severe, untreated PKU. Neonatal screening typically identifies PKU, but delayed diagnosis or lack of treatment could result in the described fatal course."
"['Microcephaly', 'Strabismus', 'Hypothyroidism', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Constipation', 'Elevated circulating thyroid-stimulating hormone concentration', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Core biochemical marker of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability, seizures, microcephaly, motor delay**: Classic neurological consequences of untreated PKU due to phenylalanine neurotoxicity.  
3. **Death in infancy/childhood**: Occurs in severe, untreated cases from metabolic derangements and complications.  
4. **Strabismus/Constipation**: Secondary neurological/gastrointestinal effects of elevated phenylalanine.  
5. **Hypertyrosinemia discrepancy**: Unusual in PKU (typically low tyrosine), possibly reflects testing artifacts, dietary factors, or overlapping metabolic conditions (e.g., transient tyrosinemia in neonates).  
6. **Elevated TSH/hypothyroidism**: Likely coincidental or comorbid (e.g., congenital hypothyroidism), as PKU does not directly disrupt thyroid function.  

**Conclusion**: Dominant features (hyperphenylalaninemia, neurodevelopmental deficits) align with PKU. Atypical findings (hypertyrosinemia, hypothyroidism) warrant further investigation but do not override the primary diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning: The presence of **hyperhomocystinemia** and **aminoaciduria** directly indicates impaired homocysteine metabolism, a hallmark of homocystinuria. Elevated homocysteine levels disrupt connective tissue, vascular, and nervous systems, which aligns with **abnormality of prenatal development** and early mortality (**neonatal death**, **death in infancy/childhood**).  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: **Hypermethioninemia** is specific to cystathionine beta-synthase (CBS) deficiency, as methionine cannot be converted to homocysteine in this disorder. CBS deficiency causes accumulation of both homocysteine and methionine, explaining the biochemical findings. Severe forms of this autosomal recessive condition lead to life-threatening complications (e.g., thromboembolism, organ failure) during early life, consistent with **death in infancy/childhood** and developmental abnormalities."
"['Generalized hypotonia', 'Splenomegaly', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Death in childhood', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Decreased circulating copper concentration', 'Copper accumulation in liver']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Wilson disease (Hepatolenticular degeneration)  
Reasoning:  
1. **Copper metabolism abnormalities**:  
   - **Decreased circulating ceruloplasmin** and **copper concentrations** indicate impaired copper transport due to ATP7B gene mutations.  
   - **Increased urinary copper excretion** and **hepatic copper accumulation** reflect the body’s compensatory mechanism to eliminate excess copper, which overwhelms hepatic storage capacity.  

2. **Hepatic involvement**:  
   - **Hepatomegaly**, **elevated hepatic transaminases**, and **copper accumulation in the liver** are hallmarks of Wilson disease-induced liver damage.  
   - Progressive liver dysfunction leads to **splenomegaly** (via portal hypertension) and **abnormal amino acid concentrations** (due to impaired hepatic metabolism).  

3. **Neuromuscular and systemic features**:  
   - **Generalized hypotonia** may arise from early neurological involvement or metabolic encephalopathy secondary to liver failure.  

4. **Prognosis**:  
   - **Death in childhood/adolescence** aligns with untreated or advanced Wilson disease, where liver failure or neurological complications become fatal without timely intervention (e.g., chelation therapy or liver transplantation).  

5. **Diagnostic confirmation**:  
   - The triad of **low ceruloplasmin**, **high urinary copper**, and **Kayser-Fleischer rings** (not listed but often present) is pathognomonic. Genetic testing for ATP7B mutations would definitively confirm the diagnosis."
"['Macrocephaly', 'Hypohidrosis', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Metabolic acidosis', 'Neonatal death', 'Arrhythmia', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Metabolic acidosis and elevated urinary carboxylic acids**: Biotinidase deficiency impairs biotin recycling, critical for carboxylase enzymes (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). Dysfunction leads to accumulation of organic acids (e.g., lactate, 3-hydroxyisovalerate) in blood and urine, explaining metabolic acidosis and elevated urinary carboxylic acids.  
2. **Dermatological manifestations (eczematoid dermatitis, skin rash, alopecia)**: Biotin is essential for keratinocyte function and fatty acid synthesis. Deficiency causes periorificial dermatitis, alopecia, and rashes, mimicking zinc deficiency or seborrheic dermatitis.  
3. **Neurological features (hypotonia, macrocephaly)**: Organic acid accumulation disrupts energy metabolism, leading to hypotonia. Macrocephaly may arise from cerebral edema or leukodystrophy due to untreated metabolic crises.  
4. **Hypohidrosis**: Autonomic dysfunction from metabolic stress or direct sweat gland impairment secondary to biotin-dependent processes.  
5. **Arrhythmia**: Electrolyte imbalances (e.g., hyperammonemia, hypokalemia) from metabolic acidosis or cardiac energy depletion can trigger arrhythmias.  
6. **Infant mortality**: Untreated BTDD causes progressive neurological decline, metabolic decompensation, and fatal outcomes in infancy. Neonatal death may occur in severe, undiagnosed cases.  
**Diagnostic confirmation**: Low serum biotinidase activity and genetic testing for *BTD* gene mutations. Prompt biotin supplementation reverses symptoms, underscoring urgency in identification."
"['Strabismus', 'Rod-cone dystrophy', 'Macular degeneration', 'Global developmental delay', 'Specific learning disability', 'Obesity', 'Attenuation of retinal blood vessels']",['Bardet-Biedl syndrome 1'],"Disease: Bardet-Biedl syndrome 1  
Reasoning:  
1. **Rod-cone dystrophy and macular degeneration**: Hallmark features of Bardet-Biedl syndrome (BBS), causing progressive vision loss.  
2. **Strabismus and attenuated retinal blood vessels**: Secondary to retinal degeneration, common in BBS.  
3. **Obesity**: A primary diagnostic criterion, typically developing in early childhood.  
4. **Global developmental delay and specific learning disability**: Neurocognitive impairments are frequent in BBS due to ciliopathy affecting neuronal development.  
5. **Syndromic consistency**: The combination of retinal dystrophy, obesity, developmental delay, and ocular abnormalities aligns with BBS1, a subtype linked to pathogenic variants in the *BBS1* gene.  
6. **Exclusion of mimics**: Differentiated from similar disorders (e.g., Alström syndrome) by the absence of sensorineural hearing loss and presence of polydactyly (if noted, though not listed here)."
"['Generalized hypotonia', 'Obesity', 'Death in infancy', 'Ventricular septal defect', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classical PKU but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or comorbid metabolic disruptions.  
3. **Generalized hypotonia** and **recurrent viral infections** align with untreated PKU’s neurodevelopmental and immune dysregulation effects due to toxic phenylalanine accumulation.  
4. **Obesity** may reflect dietary challenges from lifelong phenylalanine-restricted diets, often rich in carbohydrates.  
5. **Ventricular septal defect** is likely an incidental congenital anomaly, as PKU does not directly cause cardiac defects.  
6. **Death in infancy/childhood** and **neonatal death** suggest severe, untreated PKU with metabolic crises or complications (e.g., seizures, cerebral edema), though modern neonatal screening mitigates this outcome.  

Note: Hypertyrosinemia and cardiac defects are atypical for PKU and warrant investigation for coexisting disorders (e.g., tyrosinemia, BH4 deficiency) or misdiagnosis."
"['Syncope', 'Prolonged QT interval', 'Ventricular fibrillation', 'Atrial arrhythmia', 'Cardiac arrest', 'Ventricular arrhythmia', 'Arrhythmia', 'Abnormal QT interval']","['Ventricular tachycardia, catecholaminergic polymorphic, 3']","Disease: Ventricular tachycardia, catecholaminergic polymorphic, 3 (CPVT3)  
Reasoning:  
1. **Ventricular arrhythmia/fibrillation and cardiac arrest**: Core features of CPVT3, caused by adrenergically triggered calcium dysregulation (CALM1 mutation), leading to polymorphic/bidirectional ventricular tachycardia.  
2. **Syncope**: Typically occurs during physical/emotional stress due to arrhythmia-induced cerebral hypoperfusion.  
3. **Atrial arrhythmia**: CALM1 mutations may disrupt atrial calcium handling, explaining atrial involvement.  
4. **Abnormal/prolonged QT interval**: Unlike classic CPVT (normal QT), CPVT3 linked to CALM1 can concurrently impair potassium channels (e.g., delayed rectifiers), causing QT prolongation as a secondary phenomenon.  
5. **Exclusion of pure Long QT syndrome**: Adrenergic triggers and ventricular arrhythmia morphology align more with CPVT3 than isolated LQTS, despite QT abnormalities.  

Genetic testing for CALM1 mutations would confirm CPVT3, distinguishing it from other CPVT subtypes or overlapping channelopathies."
"['Apathy', 'Cyanosis', 'Ataxia', 'Hyperreflexia', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Vomiting', 'Hypothermia', 'Hyperglycinemia', 'Methylmalonic acidemia', 'Decreased methylmalonyl-CoA mutase activity', 'Hyperalaninemia', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Hyperornithinemia', 'Methylmalonic aciduria', 'Decreased circulating ferritin concentration', 'Dyskinesia']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, vomiting, and hyperglycinemia** are hallmark features of methylmalonic acidemia (MMA), a disorder of branched-chain amino acid metabolism.  
2. **Methylmalonic acidemia/aciduria** directly indicates impaired methylmalonyl-CoA mutase function, critical for converting methylmalonyl-CoA to succinyl-CoA.  
3. **Decreased methylmalonyl-CoA mutase activity** confirms an enzymatic defect in this pathway.  
4. **Hypothermia, apathy, ataxia, dyskinesia, and hyperreflexia** reflect neurological toxicity from accumulating methylmalonic acid and other metabolites.  
5. **Abnormal carnitine levels** and **hypervalinemia/hyperalaninemia** suggest secondary disturbances in fatty acid and amino acid metabolism.  
6. **Death in infancy/childhood** aligns with severe, untreated MMA phenotypes.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Vitamin B12-unresponsiveness** is implied by **decreased methylmalonyl-CoA mutase activity** (direct enzyme defect) without features of B12 metabolism defects (e.g., homocystinuria).  
2. **Persistent metabolic acidosis, hyperglycinemia, and methylmalonic aciduria** despite B12 supplementation are diagnostic of this subtype.  
3. **Recurrent viral infections** and **abnormal arginine/citrulline/ornithine** levels may stem from secondary mitochondrial dysfunction or protein catabolism.  
4. **Decreased ferritin** could indicate oxidative stress or nutritional complications from chronic illness.  
5. **Neurological symptoms (ataxia, hyperreflexia)** correlate with basal ganglia injury seen in mutase-deficient MMA.  

Both diagnoses are consolidated under the primary disorder: **mutase-deficient MMA**, distinguished by B12-unresponsiveness and enzyme assay confirmation."
"['Mastoiditis', 'Hearing impairment', 'Horizontal nystagmus', 'Irregular menstruation', 'Tachycardia', 'Ankle swelling', 'Weight loss', 'Palpitations', 'Vertigo', 'Decreased circulating complement C3 concentration', 'Facial palsy', 'Autoimmune antibody positivity', 'Decreased circulating complement C4 concentration', 'Oral mucosal blisters']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient’s **facial palsy**, **hearing impairment**, and **horizontal nystagmus** suggest neurosarcoidosis, which often involves cranial nerves (e.g., VII and VIII). **Mastoiditis** may reflect granulomatous inflammation in the mastoid bone. **Autoimmune antibody positivity** and **decreased C3/C4 complement levels** align with sarcoidosis-associated immune dysregulation. **Oral mucosal blisters** and **weight loss** are consistent with systemic granulomatous disease. **Tachycardia** and **palpitations** could indicate cardiac sarcoidosis, while **ankle swelling** may reflect renal or cardiac involvement.  

Sarcoidosis, susceptibility to, 2:  
Genetic susceptibility loci (e.g., HLA-DRB1 variants) may predispose to multisystem granulomatous inflammation. The combination of **neurological**, **otologic**, **cardiac**, and **mucocutaneous symptoms** supports a systemic presentation. **Irregular menstruation** might stem from hypothalamic-pituitary axis involvement (rare but documented). Hypocomplementemia (**low C3/C4**) and autoantibodies further suggest immune-mediated pathology, characteristic of sarcoidosis subtypes linked to genetic susceptibility."
"['Ataxia', 'Death in infancy', 'Dehydration', 'Fever', 'Diarrhea', 'Opisthotonus', 'Athetosis', 'Progressive neurologic deterioration', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating acetylcarnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Core biochemical markers**: Elevated glutaric acid (glutaric aciduria, elevated circulating glutaric acid) and carnitine deficiency (decreased plasma free carnitine, abnormal acetylcarnitine) directly indicate a defect in glutaryl-CoA dehydrogenase, the enzyme deficient in GA-I.  
2. **Neurological features**: Ataxia, opisthotonus, athetosis, and progressive neurologic deterioration align with basal ganglia damage, a hallmark of GA-I due to toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
3. **Metabolic crises**: Fever, dehydration, and diarrhea are typical triggers of acute metabolic decompensation in GA-I, exacerbating neurological injury.  
4. **Early mortality**: Death in infancy/childhood reflects untreated GA-I’s severe natural course, as crises lead to irreversible brain damage.  
5. **Exclusion of mimics**: Symptoms collectively rule out other organic acidemias (e.g., GA-II lacks prominent basal ganglia injury) and confirm GA-I’s distinct phenotype."
"['High palate', 'Epicanthus', 'Hypertelorism', 'Short philtrum', 'High forehead', 'Anteverted nares', 'Single transverse palmar crease', 'Hypotonia', 'Global developmental delay', 'Absent speech', 'Frontal bossing', 'Hypoplasia of the corpus callosum', 'Gray matter heterotopia', 'Methylmalonic acidemia', 'Short nose', 'Lateral ventricle dilatation', 'Granular macular appearance', 'Sparse hair', 'Broad hallux', 'Tented upper lip vermilion', 'Methylmalonic aciduria', 'Delayed myelination', 'Elevated urinary 3-hydroxybutyric acid', 'Elevated urinary aminoisobutyric acid']",['Methylmalonate semialdehyde dehydrogenase deficiency'],"Disease: Methylmalonate semialdehyde dehydrogenase deficiency (MMSDH deficiency)  
Reasoning:  
1. **Metabolic Hallmarks**: The presence of *methylmalonic acidemia/uria* and elevated *urinary 3-hydroxybutyric acid* and *aminoisobutyric acid* directly implicates a defect in valine and thymine catabolism. MMSDH deficiency disrupts the final step of these pathways, causing accumulation of methylmalonate semialdehyde and its derivatives.  
2. **Neurological Features**: *Hypotonia*, *global developmental delay*, *absent speech*, and *delayed myelination* align with metabolic encephalopathy due to toxic metabolite buildup. Structural abnormalities (*hypoplasia of the corpus callosum*, *gray matter heterotopia*, *lateral ventricle dilatation*) suggest disrupted neurodevelopment from impaired metabolic pathways.  
3. **Dysmorphic Traits**: Facial features (*high palate, epicanthus, hypertelorism, short philtrum, tented upper lip, short nose, frontal bossing*) and *broad hallux* are consistent with syndromic metabolic disorders. *Single transverse palmar crease* and *sparse hair* further support a genetic etiology.  
4. **Ocular Findings**: *Granular macular appearance* may reflect retinal metabolic dysfunction, reported in mitochondrial or organic acidemias.  
5. **Exclusion of Alternatives**: Classic methylmalonic acidemias (e.g., mutase deficiency) typically lack the specific urinary metabolite profile (3-hydroxybutyric/aminoisobutyric acid elevation) seen here, narrowing the diagnosis to MMSDH deficiency.  

This constellation of metabolic, neurological, and dysmorphic features, combined with biochemical markers, strongly supports MMSDH deficiency as the unifying diagnosis."
"['Cystinuria', 'Argininuria', 'Abnormal circulating arginine concentration', 'Abnormal circulating citrulline concentration', 'Uraciluria']",['Arginase deficiency/Argininemia/Argininemia'],"Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Argininuria and elevated circulating arginine**: Arginase deficiency disrupts the urea cycle, preventing the conversion of arginine to ornithine and urea. This results in arginine accumulation in the blood (abnormal circulating arginine) and its excretion in urine (argininuria).  
2. **Abnormal citrulline**: While citrulline levels are typically normal or mildly elevated in arginase deficiency, secondary metabolic disruptions or partial upstream urea cycle inhibition may explain the abnormal citrulline concentration.  
3. **Cystinuria**: High plasma arginine may competitively inhibit renal reabsorption of cystine (a dibasic amino acid), leading to its urinary excretion. This is a secondary effect of hyperargininemia.  
4. **Uraciluria**: Excess arginine can drive pyrimidine synthesis via alternative pathways, increasing orotic acid and uracil production, which is excreted in urine. This links to observed uraciluria despite it being more classically associated with other urea cycle disorders (e.g., OTC deficiency).  

The constellation of amino acid transport disturbances (cystinuria, argininuria) and metabolic byproducts (uraciluria) aligns with the primary pathology of arginase deficiency, where hyperargininemia drives multisystemic biochemical cascades."
"['Cleft palate', 'Micrognathia', 'Proptosis', 'Blue sclerae', 'Platyspondyly', 'Cutis laxa', 'Soft, doughy skin', 'Wrist flexion contracture', 'Hypotonia', 'Joint hypermobility', 'Joint laxity', 'Talipes', 'Epiphyseal dysplasia', 'Hyperplasia of the femoral trochanters', 'Hip dislocation', 'Limited elbow movement', 'Flared metaphysis', 'Advanced ossification of carpal bones', 'Beaking of vertebral bodies', 'Increased laxity of fingers', 'obsolete Fusion of midphalangeal joints', 'Overtubulated long bones', 'Sparse hair', 'Abnormality of the elbow', 'Prominent forehead', 'Broad fingertip', 'Long upper lip', 'Flat face', 'Short iliac bones']","['Spondyloepimetaphyseal dysplasia with joint laxity/Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures']","Disease: Spondyloepimetaphyseal dysplasia with joint laxity, type 1 (SEMDJL1)  
Reasoning:  
1. **Skeletal dysplasia**: Platyspondyly, epiphyseal dysplasia, flared metaphysis, beaking of vertebral bodies, hyperplasia of femoral trochanters, and advanced ossification of carpal bones are hallmark features of spondyloepimetaphyseal dysplasia.  
2. **Joint abnormalities**: Wrist flexion contracture, hip dislocation, limited elbow movement, and overtubulated long bones align with skeletal dysplasias, while joint hypermobility/laxity and increased finger laxity specifically match SEMDJL1’s paradoxical combination of laxity and contractures.  
3. **Craniofacial features**: Cleft palate, micrognathia, proptosis, blue sclerae, prominent forehead, flat face, and long upper lip are consistent with SEMDJL1’s connective tissue and craniofacial manifestations.  
4. **Connective tissue/cutaneous signs**: Cutis laxa, soft doughy skin, and sparse hair reflect underlying extracellular matrix defects, a key component of SEMDJL1 (linked to *KIF22* mutations).  
5. **Extremity anomalies**: Talipes, hypoplastic iliac bones, and broad fingertips further support a systemic skeletal dysplasia.  
6. **Exclusion of mimics**: Features like platyspondyly and joint laxity distinguish SEMDJL1 from other dysplasias (e.g., Larsen syndrome lacks metaphyseal changes), while blue sclerae and fractures (if present) help differentiate it from osteogenesis imperfecta."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating proline concentration', 'Elevated plasma citrulline']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia, elevated plasma citrulline, and aminoaciduria, which are hallmark features of citrullinemia type I (ASS1 deficiency). Severe neonatal-onset hyperammonemia leads to rapid metabolic decompensation, explaining neonatal death or death in infancy. Aminoaciduria occurs due to overflow excretion of citrulline and other amino acids. Abnormal circulating proline may arise secondarily from metabolic instability or renal tubular stress. Early mortality aligns with the acute urea cycle dysfunction characteristic of this disorder.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Elevated citrulline and hyperammonemia are consistent with citrin deficiency (SLC25A13 mutations). Neonatal intrahepatic cholestasis, though not explicitly listed, is intrinsic to this diagnosis. Abnormal proline levels and aminoaciduria may reflect broader hepatic dysfunction or disrupted mitochondrial transport affecting multiple amino acids. Neonatal death could occur in severe cases with liver failure or metabolic crises, while citrin deficiency’s variable expressivity might also explain childhood mortality in progressive cases. However, the absence of explicit cholestasis-related symptoms (e.g., jaundice, hepatomegaly) makes this diagnosis less definitive."
"['Blue irides', 'Nystagmus', 'Hypopigmentation of the skin', 'Hypopigmentation of hair']","['Oculocutaneous albinism type 2/Albinism, oculocutaneous, type II']","Disease: Oculocutaneous albinism type 2/Albinism, oculocutaneous, type II  
Reasoning:  
1. **Hypopigmentation of skin and hair**: Oculocutaneous albinism type 2 (OCA2) is characterized by reduced melanin synthesis, leading to lighter skin and hair compared to family members, though not as severe as in OCA1.  
2. **Blue irides**: Unlike OCA1 (which often results in pink/red irides due to complete melanin absence), OCA2 allows some melanin deposition, typically causing blue or light-brown irides.  
3. **Nystagmus**: Common in all albinism types due to misrouting of optic nerves and foveal hypoplasia, impairing visual acuity and causing involuntary eye movements.  
4. **Genetic basis**: OCA2 is linked to mutations in the *OCA2* gene, disrupting melanosome function and partial melanin production, consistent with the patient’s partial pigmentation.  
5. **Exclusion of other types**: OCA1 (TYR gene) causes more severe hypopigmentation, while ocular albinism (OA1) spares skin/hair. Symptoms align with OCA2’s intermediate phenotype."
"['Hypospadias', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Esophageal atresia', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Phenylketonuria (PKU): The patient's hyperphenylalaninemia is pathognomonic for PKU, an autosomal recessive disorder caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine-to-tyrosine conversion. Chronic phenylalanine accumulation leads to neurotoxicity, explaining potential early mortality due to untreated metabolic crises and severe neurological deterioration. Hypertyrosinemia is atypical in classical PKU but could arise from secondary metabolic disruptions or concurrent hepatic dysfunction. Structural anomalies (e.g., hypospadias, esophageal atresia) may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing teratogenic effects on fetal development. While PKU itself does not directly cause congenital malformations, these findings highlight the critical interplay between maternal metabolic control and fetal outcomes. Chronic pulmonary/airway obstruction and early mortality across life stages align with complications of untreated PKU, including susceptibility to infections, neurorespiratory failure, or comorbid conditions exacerbated by metabolic instability."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Severe short stature** and **abnormality of prenatal development** may occur in untreated maternal PKU, where high phenylalanine levels during pregnancy disrupt fetal growth.  
3. **Death in infancy/childhood/adolescence** aligns with untreated PKU, as toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and organ failure.  
4. **Recurrent viral infections** are atypical for classic PKU but could reflect secondary immunodeficiency due to chronic metabolic stress or malnutrition in severe cases.  
5. **Hypertyrosinemia** is unusual in isolated PKU (which typically lowers tyrosine), suggesting a possible comorbid tyrosinemia or BH4 deficiency (a PKU variant affecting both phenylalanine and tyrosine metabolism). However, hyperphenylalaninemia remains the primary diagnostic marker.  
6. Early mortality (**neonatal death**, **death in early adulthood**) underscores the critical need for newborn screening and dietary intervention to prevent complications.  

Note: Hypertyrosinemia may indicate an overlapping disorder (e.g., BH4 deficiency or tyrosinemia), but the dominant feature (hyperphenylalaninemia) strongly prioritizes PKU as the diagnosis."
"['Rod-cone dystrophy', 'Pigmentary retinopathy', 'Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Attenuation of retinal blood vessels', 'Diffuse optic disc pallor', 'Hypoautofluorescent retinal lesion']",['Retinitis pigmentosa 78'],"Disease: Retinitis pigmentosa 78  
Reasoning:  
1. **Rod-cone dystrophy**: A hallmark of retinitis pigmentosa (RP), involving progressive degeneration of rod photoreceptors (causing nyctalopia) followed by cone loss (reducing visual acuity).  
2. **Pigmentary retinopathy**: Characteristic bone-spicule pigmentation due to retinal pigment epithelium migration, common in RP.  
3. **Nyctalopia**: Early symptom from rod dysfunction, aligning with RP progression.  
4. **Visual field defect**: Typically starts as peripheral vision loss (tunnel vision), progressing centrally as RP advances.  
5. **Attenuation of retinal blood vessels & diffuse optic disc pallor**: Reflects chronic retinal degeneration and optic nerve atrophy in late-stage RP.  
6. **Hypoautofluorescent retinal lesions**: Indicates areas of photoreceptor/RPE atrophy, consistent with advanced RP.  
7. **Genetic association**: RP78 is linked to biallelic variants in the *HK1* gene, which disrupts retinal metabolism, explaining the phenotype.  
All findings collectively match the clinical and molecular profile of retinitis pigmentosa 78."
"['Optic disc pallor', 'Spasticity', 'Dysphagia', 'Delayed gross motor development', 'Mutism', 'Poor head control', 'Reduced visual acuity', 'Infantile muscular hypotonia', 'Gastrostomy tube feeding in infancy', 'Pendular nystagmus']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Neurological and motor deficits**: Spasticity, delayed gross motor development, and poor head control align with hypomyelinating leukodystrophies, which disrupt white matter integrity, impairing motor neuron signaling.  
2. **Optic pathway involvement**: Optic disc pallor, reduced visual acuity, and pendular nystagmus suggest optic nerve hypomyelination, a hallmark of NKX6-2-related disorders due to oligodendrocyte dysfunction.  
3. **Developmental trajectory**: Infantile muscular hypotonia progressing to spasticity reflects the evolving nature of myelination defects, where initial low tone transitions to hypertonia as myelination fails.  
4. **Bulbar dysfunction**: Dysphagia and gastrostomy tube dependence indicate brainstem involvement, common in severe leukodystrophies affecting cranial nerve nuclei.  
5. **Mutism**: Likely secondary to severe motor dysfunction (anarthria) or corticobulbar tract damage, rather than cognitive impairment, typical in NKX6-2-related disease.  
6. **Genetic consistency**: Autosomal recessive NKX6-2 mutations disrupt transcriptional regulation of myelination, correlating with the observed hypomyelination phenotype.  
7. **Differential exclusion**: Overlap with Pelizaeus-Merzbacher disease is ruled out by the absence of PLP1 mutations and the presence of gastrostomy dependence/mutism, more specific to NKX6-2 pathology."
"['Hearing impairment', 'Tachycardia', 'Splenomegaly', 'Fever', 'Hyperkalemia', 'Vertigo', 'Decreased circulating total IgM', 'Hypercalcemia', 'Abnormal EKG', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Elevated circulating C-reactive protein concentration', 'Increased circulating free T3', 'Foot pain', 'Elbow pain', 'Wrist pain', 'Hip pain', 'Knee pain']","['Familial cold autoinflammatory syndrome 2', 'Familial cold urticaria', 'Familial cold inflammatory syndrome 1', 'Muckle-Wells syndrome/Muckle-Wells syndrome', 'Familial cold autoinflammatory syndrome 3', 'Familial cold autoinflammatory syndrome 4', 'CINCA syndrome/Cinca syndrome']","Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning:  
1. **Hearing impairment** aligns with Muckle-Wells syndrome’s hallmark sensorineural hearing loss due to chronic inflammation.  
2. **Fever**, **elevated ESR**, and **high CRP** reflect systemic inflammation, consistent with autoinflammatory syndromes like MWS.  
3. **Arthralgias** (joint pain in elbows, wrists, hips, knees, feet) are common in MWS, driven by IL-1-mediated inflammation.  
4. **Abnormality of the complement system** and **splenomegaly** suggest chronic inflammation and immune dysregulation.  
5. **Hyperkalemia** and **abnormal EKG** may indicate early renal amyloidosis, a complication of untreated MWS.  
6. **Hypercalcemia** could stem from cytokine-driven bone resorption or renal dysfunction.  
7. **Vertigo** may relate to inner ear inflammation, supporting cochlear involvement.  
8. **Decreased IgM** is atypical but could result from chronic inflammation or secondary immune dysregulation.  

Excluded other familial cold syndromes (FCAS 1-4, familial cold urticaria) due to lack of documented cold triggers and presence of hearing loss. CINCA syndrome was excluded due to absence of severe neurological/developmental features (e.g., chronic meningitis, bony overgrowth). Elevated free T3 is a confounding factor but may reflect inflammation-associated thyroid test abnormalities rather than primary thyroid disease."
"['Seizure', 'Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Ventricular septal defect', 'Abnormal vertebral morphology', 'Stomatitis', 'Regional abnormality of skin', 'Gangrene']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Seizures**: BTDD disrupts biotin recycling, impairing carboxylase enzymes critical for energy production and neurotransmitter synthesis, leading to metabolic acidosis and neurological manifestations like seizures.  
2. **Generalized hypotonia**: Biotin-dependent carboxylases are essential for mitochondrial metabolism; deficiency causes muscle weakness and hypotonia due to impaired energy metabolism.  
3. **Growth delay**: Chronic metabolic acidosis and malnutrition from defective fatty acid, glucose, and amino acid metabolism result in failure to thrive.  
4. **Death in infancy**: Untreated BTDD causes progressive metabolic crises, irreversible neurological damage, and multi-organ failure, often fatal in early life.  
5. **Ventricular septal defect (VSD)**: Though not a primary feature, severe metabolic stress in BTDD may exacerbate congenital cardiac defects or reflect secondary mitochondrial dysfunction.  
6. **Abnormal vertebral morphology**: Rarely reported in BTDD; may arise from prolonged metabolic disruption affecting skeletal development.  
7. **Stomatitis & regional skin abnormality**: Biotin deficiency leads to dermatitis, mucosal inflammation (e.g., stomatitis), and periorofacial rashes due to impaired keratinocyte function.  
8. **Gangrene**: Severe metabolic acidosis and immunodeficiency in advanced BTDD predispose to tissue necrosis and gangrene.  

**Key confirmatory features**: Neurological symptoms (seizures, hypotonia), mucocutaneous findings (stomatitis, skin rash), and rapid progression without biotin supplementation align with BTDD. Early biotin therapy reverses symptoms, underscoring the urgency of diagnosis."
"['Atypical behavior', 'Hyperactivity', 'Intellectual disability', 'Coma', 'Motor delay', 'Hepatic failure', 'Weight loss', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral cortical atrophy', 'Difficulty walking', 'Hyperglutaminemia', 'Oroticaciduria', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **hyperglutaminemia** indicate a urea cycle defect, as ammonia detoxification relies on this pathway.  
2. **Oroticaciduria** is pathognomonic for OTCD. Carbamoyl phosphate accumulates due to OTC enzyme deficiency, diverting into pyrimidine synthesis and generating excess orotic acid.  
3. **Hepatic failure** aligns with OTCD’s liver-specific urea cycle dysfunction.  
4. **Cerebral cortical atrophy**, **coma**, and **neurological symptoms** (motor delay, difficulty walking/running) stem from chronic neurotoxicity due to hyperammonemia.  
5. **Abnormal aspartate/alanine concentrations** reflect metabolic disruption in urea/amino acid metabolism.  
6. **Death in childhood/adolescence** is consistent with severe, untreated OTCD, as hyperammonemic crises are life-threatening.  
7. **Vomiting**, **fever**, and **weight loss** are nonspecific but common during metabolic decompensation.  
8. **Intellectual disability** and **atypical behavior** result from recurrent ammonia-induced brain injury.  

OTCD is the only diagnosis explaining all symptoms, particularly the triad of hyperammonemia, oroticaciduria, and hepatic involvement."
"['Macroglossia', 'Turricephaly', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Esotropia', 'Optic atrophy', '11 pairs of ribs', 'Hypertrichosis', 'Seizure', 'Areflexia', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Developmental regression', 'Highly arched eyebrow', 'Severe muscular hypotonia', 'Feeding difficulties', 'Right aortic arch', 'Small basal ganglia', 'Profound global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Macroglossia, turricephaly, coarse facial features, narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, highly arched eyebrows, and ""exaggerated cupid's bow"" align with the dysmorphic facial phenotype described in TBCK syndrome.  
2. **Neurological/developmental hallmarks**: Severe muscular hypotonia, profound global developmental delay, developmental regression, seizures, EEG abnormality, and areflexia match the core features of TBCK-related disorders, which involve progressive neurodegeneration and psychomotor impairment.  
3. **Brain malformations**: Cerebellar vermis hypoplasia, hypoplasia/agenesis of the corpus callosum, ventriculomegaly, and small basal ganglia are recurrent neuroimaging findings in TBCK syndrome, linked to disrupted neuronal development and maintenance.  
4. **Systemic features**: Feeding difficulties (due to hypotonia), hypertrichosis, and right aortic arch (vascular anomaly) are consistent with multisystem involvement reported in TBCK cases.  
5. **Genetic correlation**: The combination of hypotonia, intellectual disability, characteristic facies, and brain anomalies strongly suggests a monogenic disorder like TBCK syndrome, caused by biallelic pathogenic variants in the *TBCK* gene affecting mTOR signaling and autophagy.  
6. **Exclusion of mimics**: Features such as optic atrophy and 11 pairs of ribs (likely a typo for rib anomalies) do not contradict the diagnosis and may represent variable expressivity of TBCK-related disease."
"['High palate', 'Anteverted nares', 'Webbed neck', 'Short neck', 'Downslanted palpebral fissures', 'Ptosis', 'Hyperkeratosis', 'Seizure', 'Atrial septal defect', 'Pulmonic stenosis', 'Relative macrocephaly', 'Depressed nasal bridge', 'Ichthyosis', 'Sparse hair', 'Underdeveloped supraorbital ridges', 'Intellectual disability, severe']",['Cardiofaciocutaneous syndrome/Cardiofaciocutaneous syndrome 1'],"Disease: Cardiofaciocutaneous syndrome/Cardiofaciocutaneous syndrome 1  
Reasoning:  
1. **Cardiac anomalies**: Atrial septal defect (ASD) and pulmonic stenosis are hallmark features of CFC syndrome, aligning with its ""cardio"" component.  
2. **Facial dysmorphism**: Downslanted palpebral fissures, ptosis, depressed nasal bridge, underdeveloped supraorbital ridges, and anteverted nares are characteristic craniofacial findings in CFC.  
3. **Cutaneous manifestations**: Hyperkeratosis, ichthyosis, and sparse hair reflect the ""cutaneous"" aspect, common in CFC due to RAS/MAPK pathway mutations (e.g., BRAF, MAP2K1/2).  
4. **Neurological involvement**: Severe intellectual disability and seizures correlate with CFC’s neurodevelopmental and epileptic phenotypes.  
5. **Growth/structural features**: Relative macrocephaly, short/webbed neck, and high palate further support CFC, differentiating it from Noonan or Costello syndromes (less prominent keratotic skin changes).  
6. **Exclusion of mimics**: Absence of lymphatic dysplasia (vs. Noonan) or papillomas/loose skin (vs. Costello) reinforces CFC. Genetic testing for BRAF/MAP2K1/2 variants would confirm the diagnosis."
"['Strabismus', 'Nystagmus', 'Hyperactivity', 'Cyanosis', 'Edema', 'Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Diarrhea', 'Pneumonia', 'Dyspnea', 'Hyperkalemia', 'Opisthotonus', 'Hepatomegaly', 'Fair hair', 'Spastic tetraplegia', 'Hypocalcemia', 'Neonatal death', 'Stridor', 'White hair', 'Severe hearing impairment']",['Glutathione synthetase deficiency'],"Disease: Glutathione synthetase deficiency  
Reasoning:  
1. **Metabolic acidosis**: A hallmark of glutathione synthetase deficiency (GSSD), caused by accumulation of 5-oxoproline due to impaired glutathione synthesis.  
2. **Neurological symptoms (seizures, intellectual disability, spastic tetraplegia/diplegia, motor delay, hypotonia, opisthotonus)**: Result from oxidative stress and neuronal damage due to glutathione deficiency, critical for antioxidant defense.  
3. **Recurrent infections (pneumonia) and dyspnea**: Glutathione is essential for immune function; deficiency increases susceptibility to infections and oxidative lung injury.  
4. **Hepatomegaly and edema**: Hepatic dysfunction from oxidative damage and metabolic stress.  
5. **Electrolyte imbalances (hyperkalemia, hypocalcemia)**: Secondary to renal tubular acidosis, a known complication of GSSD.  
6. **Fair/white hair**: Reduced melanin synthesis due to disrupted cysteine metabolism (cysteine is a glutathione precursor).  
7. **Early mortality (neonatal death, death in infancy)**: Severe metabolic instability and infections in untreated cases.  
8. **Diarrhea and stridor**: Gastrointestinal and respiratory manifestations of systemic metabolic dysfunction.  
9. **Cyanosis and severe hearing impairment**: Hypoxia from respiratory compromise and oxidative damage to cochlear cells, respectively.  

The combination of metabolic acidosis, neurological deficits, immune dysfunction, and pigmentary changes strongly aligns with glutathione synthetase deficiency."
"['Cryptorchidism', 'Chordee', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Low-set ears', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic nerve hypoplasia', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Dysarthria', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Hip dysplasia', 'Intrauterine growth retardation', 'Small for gestational age', 'Premature birth', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Dysphagia', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Mild neurosensory hearing impairment', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Placental infarction', 'Unilateral microphthalmos', 'Hypoplasia of the pons', 'Delayed myelination', 'Thick vermilion border', 'Anisometropia', 'Abnormal hippocampus morphology', 'Clinodactyly', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental and CNS anomalies**: Global developmental delay, seizures, hypotonia, dysarthria, spastic tetraparesis, ADHD, and abnormal hippocampus morphology align with core neurodevelopmental dysfunction. Structural brain abnormalities (hypoplasia of the corpus callosum, ventriculomegaly, pontine hypoplasia, cerebral hypomyelination) are hallmark features of NEDBEH.  
2. **Ocular anomalies**: Coloboma, Peters anomaly, optic nerve hypoplasia, and unilateral microphthalmos directly correlate with the ""eye"" component of NEDBEH, particularly given the specificity of Peters anomaly (a rare anterior segment defect).  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return fulfill the ""heart"" criterion, common in NEDBEH.  
4. **Craniofacial dysmorphism**: Microcephaly/macrocephaly (variable expressivity), triangular face, epicanthus, hypertelorism, smooth philtrum, and cleft lip reflect the syndromic facial gestalt seen in neurodevelopmental genetic disorders.  
5. **Multi-system involvement**: Choanal atresia, duodenal atresia, renal cysts, and genitourinary anomalies (cryptorchidism, hypospadias) support a systemic genetic disorder, consistent with NEDBEH’s broad phenotypic spectrum.  
6. **Growth anomalies**: Intrauterine growth restriction (IUGR), small for gestational age, and short stature (contradicts ""tall stature,"" possibly an error) align with prenatal-onset growth issues seen in NEDBEH.  
7. **Supportive features**: Hypotonia, hypertrichosis, and café-au-lait spots, while non-specific, are reported in NEDBEH cases. Delayed myelination and hypoplastic corpus callosum further strengthen the diagnosis.  

**Exclusion Notes**: Overlap with CHARGE syndrome is considered (coloboma, choanal atresia), but the absence of arhinia, semicircular canal defects, and the prominence of brain malformations favor NEDBEH. Peters anomaly and hypomyelination are more characteristic of NEDBEH."
"['Narrow mouth', 'Malar flattening', 'Epicanthus', 'Broad forehead', 'Nystagmus', 'Seizure', 'Short nose', 'Low hanging columella', 'Severe global developmental delay', 'Abnormality of ocular abduction']","['Epilepsy, focal, with speech disorder and with or without mental retardation']","Disease: Epilepsy, focal, with speech disorder and with or without mental retardation  
Reasoning:  
1. **Seizure** is a core feature of epilepsy, specifically focal seizures in this diagnosis.  
2. **Severe global developmental delay** aligns with the potential inclusion of intellectual disability or mental retardation in the disease description.  
3. **Speech disorder** is explicitly noted in the diagnosis, often linked to developmental delays or neurological dysfunction caused by epilepsy.  
4. While **nystagmus** and **abnormality of ocular abduction** suggest neurological involvement, they may reflect broader central nervous system disturbances secondary to epileptic activity.  
5. Dysmorphic features (**narrow mouth, malar flattening, epicanthus, broad forehead, short nose, low hanging columella**) are not directly explained by the diagnosis but could indicate an underlying genetic or syndromic cause contributing to both the epilepsy and structural anomalies. These findings warrant further genetic testing to identify a potential unifying etiology.  

*Note: The listed diagnosis captures the neurological phenotype, but the dysmorphology suggests a broader syndromic condition that may require additional evaluation.*"
"['Atrioventricular block', 'Sinus bradycardia', 'Prolonged QTc interval', 'Left ventricular noncompaction']",['Long QT syndrome 15'],"Disease: Long QT syndrome 15  
Reasoning:  
1. **Prolonged QTc interval** is a cardinal feature of Long QT syndrome (LQTS), specifically implicating a calmodulinopathy (e.g., CALM1/2/3 mutations) in LQTS15.  
2. **Sinus bradycardia** and **atrioventricular block** are characteristic of calmodulin-related LQTS subtypes due to disrupted calcium signaling in cardiac pacemaker and conduction systems.  
3. **Left ventricular noncompaction (LVNC)** is less directly linked but reported in some CALM2-associated cases, suggesting a potential overlap between electrical and structural cardiomyopathies in this genetic disorder.  
4. The combination of electrical abnormalities (prolonged QTc, bradycardia, AV block) with structural LVNC aligns with the pleiotropic effects of CALM2 mutations, distinguishing LQTS15 from other LQTS subtypes."
"['Generalized hypotonia', 'Death in infancy', 'Increased serum lactate', 'Hypertriglyceridemia', 'Hepatomegaly', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration', 'Abnormal circulating creatine kinase concentration']",['Glycogen storage disease due to glycogen debranching enzyme deficiency/Glycogen storage disease III'],"Disease: Glycogen storage disease due to glycogen debranching enzyme deficiency/Glycogen storage disease III  
Reasoning:  
1. **Hepatomegaly**: Caused by abnormal glycogen accumulation in the liver due to debranching enzyme deficiency.  
2. **Hypertriglyceridemia**: Impaired glycogenolysis leads to secondary lipid metabolism dysfunction and increased triglyceride synthesis.  
3. **Increased serum lactate**: Anaerobic glycolysis compensates for defective glycogen breakdown, generating excess lactate.  
4. **Abnormal circulating aspartate/alanine concentrations**: Disrupted gluconeogenesis and amino acid metabolism from liver dysfunction.  
5. **Elevated lactate dehydrogenase (LDH) and creatine kinase (CK)**: Muscle involvement (myopathy) due to glycogen accumulation, causing enzyme leakage.  
6. **Generalized hypotonia**: Result of muscle weakness from impaired glycogen-derived glucose availability.  
7. **Neonatal death/Death in infancy**: Severe metabolic derangements (e.g., hypoglycemia, cardiomyopathy) in critical early stages without intervention.  
8. **Differentiation from other GSDs**: Muscle symptoms (elevated CK, hypotonia) and absence of severe hypoglycemia (common in GSD I) support GSD III over other glycogenoses.  

This pattern aligns with GSD III’s hallmark dual hepatic and muscular involvement due to AGL gene mutations affecting glycogen debranching."
"['Cyanosis', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Anemia', 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Enzyme Dysfunction**: HLCS deficiency impairs biotin-dependent activation of multiple carboxylases (propionyl-CoA, pyruvate, β-methylcrotonyl-CoA, and acetyl-CoA carboxylases).  
2. **Metabolic Acidosis & Hyperammonemia**: Propionyl-CoA carboxylase deficiency leads to propionic acid accumulation, disrupting the urea cycle (hyperammonemia) and causing metabolic acidosis.  
3. **Skin Manifestations**: Eczematoid dermatitis and rash arise from functional biotin deficiency, impairing fatty acid synthesis and skin barrier function.  
4. **Neuromuscular Symptoms**: Generalized hypotonia stems from energy deficits (pyruvate carboxylase deficiency) and toxic metabolite accumulation.  
5. **Respiratory & Gastrointestinal Signs**: Tachypnea compensates for acidosis; diarrhea reflects intestinal metabolic dysfunction.  
6. **Laboratory Abnormalities**:  
   - **Aminoaciduria/Abnormal Glycine**: Disrupted amino acid catabolism due to carboxylase deficiencies.  
   - **Elevated Urinary Carboxylic Acids**: Propionate, 3-hydroxypropionate, and methylcitrate accumulate from blocked propionyl-CoA metabolism.  
   - **Decreased Pyruvate Carboxylase Activity**: Confirms multi-carboxylase involvement (lactic acidosis risk).  
7. **Early Lethality**: Neonatal death or infantile mortality occurs in untreated cases due to metabolic crises (acidosis, hyperammonemia).  
8. **Diagnostic Confirmation**: Combined propionyl-CoA and pyruvate carboxylase deficiencies (vs. isolated carboxylase defects) and abnormal glycine/monocarboxylic acid profiles pinpoint HLCS deficiency.  
**Conclusion**: The constellation of multi-carboxylase dysfunction, metabolic derangements, and neonatal presentation aligns definitively with HLCS deficiency."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia**: MCADD impairs fatty acid β-oxidation, limiting energy production during fasting. This results in hypoketotic hypoglycemia (reduced ketones despite low glucose).  
2. **Hyperammonemia**: Secondary to metabolic decompensation; impaired urea cycle function from energy depletion or accumulated toxic metabolites.  
3. **Decreased plasma free carnitine**: Excess medium-chain acyl-CoA intermediates bind carnitine, forming acyl-carnitine conjugates (e.g., C8, C10), depleting free carnitine.  
4. **Lethargy/Drowsiness/Vomiting**: Manifestations of acute metabolic crises triggered by fasting or infection, causing encephalopathy.  
5. **Generalized hypotonia**: Chronic energy deficiency in muscles and nervous system.  
6. **Sleep disturbance**: Neurological dysfunction from hypoglycemia or hyperammonemia.  
7. **Death in infancy/childhood**: Untreated MCADD leads to rapid metabolic collapse during catabolic states (e.g., illness, prolonged fasting).  
8. **Key diagnostic clues**: Hypoketotic hypoglycemia + hyperammonemia + low free carnitine with elevated medium-chain acylcarnitines on tandem mass spectrometry.  
**Conclusion**: Symptom constellation and biochemical profile (hypoglycemia, hyperammonemia, carnitine deficiency) strongly indicate MCADD, a fatty acid oxidation disorder."
"['Cataract', 'Ataxia', 'Global developmental delay', 'Cerebellar atrophy', 'Coronal cleft vertebrae', 'Absent ossification of capital femoral epiphysis', 'Crumpled ear', 'Flat face']",['CODAS syndrome/CODAS syndrome'],"Disease: CODAS syndrome  
Reasoning:  
1. **Cataract**: A common ocular manifestation in CODAS syndrome.  
2. **Ataxia**: Linked to cerebellar atrophy, a neurological feature of the syndrome.  
3. **Global developmental delay**: Reflects central nervous system involvement.  
4. **Cerebellar atrophy**: Directly correlates with neurological symptoms like ataxia.  
5. **Coronal cleft vertebrae**: A skeletal anomaly characteristic of CODAS.  
6. **Absent ossification of capital femoral epiphysis**: Indicates hip dysplasia, part of the skeletal spectrum.  
7. **Crumpled ear** and **flat face**: Distinctive craniofacial/dysmorphic features (auricular and facial abnormalities).  
The combination of cerebro-ocular, dental, auricular, and skeletal anomalies aligns definitively with CODAS syndrome, a rare autosomal recessive disorder caused by *LONP1* mutations."
"['Microcephaly', 'Facial asymmetry', 'Torticollis', 'Macular degeneration', 'Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Ataxia', 'Spastic diplegia', 'Death in infancy', 'Diarrhea', 'Cerebral atrophy', 'Pneumonia', 'Opisthotonus', 'Athetosis', 'Spastic tetraplegia', 'Abnormal cerebral cortex morphology', 'Neonatal death', 'Death in childhood', 'Dyskinesia']","['Ceroid lipofuscinosis, neuronal, 1']","Ceroid lipofuscinosis, neuronal, 1 (CLN1):  
The patient exhibits hallmark features of CLN1 disease, including **microcephaly** and **cerebral atrophy**, indicative of progressive neurodegeneration. **Seizures**, **ataxia**, **spastic diplegia/tetraplegia**, and **dyskinesia** align with motor and neurological decline. **Macular degeneration** reflects retinal involvement, while **delayed speech** and **hyperactivity** signal early developmental regression. **Abnormal cerebral cortex morphology** and **opisthotonus** correlate with severe CNS deterioration. **Death in infancy/childhood** matches the rapid progression of infantile CLN1. Although **pneumonia** and **diarrhea** are nonspecific, they likely stem from dysphagia and autonomic dysfunction in advanced stages. Symptoms like **facial asymmetry** and **torticollis** may arise from spasticity or dystonia. The combination of neurodegeneration, vision loss, seizures, and early mortality strongly supports CLN1."
"['Generalized hypotonia', 'Death in infancy', 'Tachycardia', 'Fever', 'Hyperammonemia', 'Abnormality of urine homeostasis', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), directly implicating defects in ammonia detoxification.  
2. **Neonatal death** and **death in infancy** suggest a severe, early-onset metabolic crisis, consistent with UCDs like CPS1 deficiency, which often presents within days of life.  
3. **Feeding difficulties** and **generalized hypotonia** align with neurological dysfunction caused by ammonia toxicity.  
4. **Tachycardia** and **fever** may reflect systemic stress from hyperammonemic encephalopathy or secondary infections triggered by metabolic instability.  
5. **Abnormality of urine homeostasis** could indicate disrupted nitrogen excretion pathways, though CPS1 deficiency typically shows low/neutral urine orotic acid (unlike other UCDs), narrowing the diagnosis.  
6. Exclusion of other UCDs (e.g., OTC deficiency, which elevates urine orotic acid) and organic acidemias (which cause metabolic acidosis) strengthens the likelihood of CPS1 deficiency, an autosomal recessive disorder affecting the first urea cycle enzyme.  
7. The absence of treatment (e.g., nitrogen scavengers) explains rapid progression to neonatal demise."
"['Hyperextensible skin', 'Bruising susceptibility', 'Striae distensae', 'Atrophic scars', 'Joint dislocation', 'Joint hypermobility', 'Pes planus', 'Arthralgia', 'Piezogenic pedal papules']","['Classical Ehlers-Danlos syndrome/Ehlers-danlos syndrome, type I']","Disease: Classical Ehlers-Danlos syndrome/Ehlers-Danlos syndrome, type I  
Reasoning:  
1. **Hyperextensible skin** and **joint hypermobility** are hallmark features of Ehlers-Danlos syndromes (EDS), particularly Classical EDS (cEDS).  
2. **Atrophic scars** (thin, ""cigarette-paper"" scars) and **striae distensae** (stretch marks) are specific to cEDS due to abnormal collagen structure impacting skin integrity.  
3. **Bruising susceptibility** aligns with fragile skin and blood vessel walls caused by collagen defects in cEDS.  
4. **Joint dislocation** and **arthralgia** correlate with connective tissue laxity and chronic joint instability in cEDS.  
5. **Pes planus** (flat feet) and **piezogenic pedal papules** (heel papules under pressure) reflect connective tissue weakness in weight-bearing areas, common in cEDS.  
6. The absence of severe vascular or organ complications rules out other EDS subtypes (e.g., Vascular EDS), while the combination of skin and joint symptoms strongly supports Classical EDS type I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic accumulation of phenylalanine.  
- **Abnormality of prenatal development or birth**: Untreated maternal PKU during pregnancy can result in congenital abnormalities (e.g., microcephaly, cardiac defects) due to phenylalanine toxicity to the fetus.  
- **Hypertyrosinemia**: While classic PKU typically causes **low** tyrosine (due to blocked PAH-dependent conversion of phenylalanine to tyrosine), transient or secondary hypertyrosinemia may occur in severe metabolic crises or liver dysfunction, often seen in critically ill infants with metabolic decompensation.  
- **Death in infancy/childhood/neonatal death**: Untreated PKU causes irreversible neurotoxicity, seizures, and failure to thrive, which can lead to early mortality. Neonatal screening and dietary management prevent these outcomes, but untreated cases historically resulted in fatal complications.  

**Note**: Hypertyrosinemia is atypical in PKU and suggests possible comorbid conditions (e.g., tyrosinemia type II) or diagnostic overlap. However, hyperphenylalaninemia and the clinical trajectory strongly prioritize PKU as the primary diagnosis."
"['Microcephaly', 'Low-set ears', 'Wide nasal bridge', 'Strabismus', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Difficulty walking', 'Elevated 8-dehydrocholesterol', 'Severe short stature', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Difficulty running', 'Elevated 7-dehydrocholesterol', 'Severe hearing impairment']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical Markers**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by a defect in the *DHCR7* gene, which disrupts cholesterol biosynthesis.  
2. **Craniofacial Features**: Microcephaly, low-set ears, and wide nasal bridge are classic dysmorphic traits in SLOS.  
3. **Limb Anomalies**: Syndactyly (often of toes 2-3) is a hallmark of SLOS.  
4. **Neurodevelopmental Delays**: Intellectual disability, motor delays, and speech/language delays align with impaired cholesterol-dependent myelination and synaptic function.  
5. **Growth and Survival**: Severe short stature, neonatal/childhood death, and early mortality correlate with severe SLOS phenotypes.  
6. **Sensory and Motor Issues**: Strabismus, severe hearing impairment, and difficulty walking/climbing stairs reflect multisystem involvement from cholesterol deficiency.  
7. **Consistency with Severity**: The combination of life-threatening outcomes (infancy/childhood death) and biochemical abnormalities confirms a severe SLOS diagnosis."
"['Macrocephaly', 'Dystonia', 'Cerebral atrophy', 'Glutaric aciduria', 'Subdural hemorrhage']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly**: Often presents in infancy due to frontotemporal atrophy or benign external hydrocephalus, a common early sign of GA-I.  
3. **Dystonia**: Results from striatal neurodegeneration (especially caudate/putamen damage), triggered by metabolic crises during catabolic states (e.g., infections), a hallmark of GA-I.  
4. **Cerebral atrophy**: Progressive neurodegeneration in basal ganglia and white matter, exacerbated by untreated metabolic decompensation.  
5. **Subdural hemorrhage**: Secondary to cerebral atrophy and vascular fragility, sometimes mimicking non-accidental trauma in infants.  

The combination of neurodevelopmental regression, characteristic biochemical markers, and neuroimaging findings aligns definitively with GA-I."
"['Abnormality of male external genitalia', 'Hearing impairment', 'Atypical behavior', 'Autistic behavior', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Motor delay', 'Absent speech', 'Abnormality of the cardiovascular system', 'Feeding difficulties', 'Heart murmur']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Abnormality of male external genitalia**: A hallmark feature of Stankiewicz-Isidor syndrome, often due to urogenital anomalies like hypospadias or cryptorchidism.  
2. **Hearing impairment**: Reported in some cases, though less common, possibly linked to neurodevelopmental deficits.  
3. **Neurodevelopmental delays (absent speech, motor delay, intellectual disability)**: Core features of the syndrome, driven by pathogenic *PACS1* gene variants affecting neuronal development.  
4. **Seizures**: Observed in affected individuals, consistent with neurological involvement.  
5. **Autistic behavior/atypical behavior**: Aligns with the syndrome’s behavioral phenotype, including social communication challenges.  
6. **Cardiovascular abnormalities/heart murmur**: Congenital heart defects (e.g., septal defects) are recurrent findings.  
7. **Feeding difficulties**: Common in infancy due to hypotonia or oromotor dysfunction.  
The combination of genitourinary, cardiac, and severe neurodevelopmental symptoms strongly supports Stankiewicz-Isidor syndrome, with *PACS1* testing recommended for confirmation."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Reduced eye contact', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'EEG abnormality', 'Sleep disturbance', 'Bruxism', 'Hypoplasia of the frontal lobes', 'Feeding difficulties']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Core symptoms of Rett syndrome**: Abnormal repetitive mannerisms (e.g., hand stereotypies), delayed speech/language development, and reduced eye contact align with Rett syndrome's hallmark features.  
2. **Neurological involvement**: Seizures, EEG abnormalities, and hypotonia are common in Rett syndrome due to mutations in *MECP2* or related genes, affecting neuronal function.  
3. **Structural brain anomalies**: Hypoplasia of the corpus callosum and frontal lobes is consistent with congenital variants of Rett syndrome, where severe neurodevelopmental abnormalities occur early.  
4. **Supportive features**: Sleep disturbances, bruxism, and feeding difficulties are frequently observed in Rett syndrome due to autonomic dysfunction and oral-motor challenges.  
5. **Differentiation from classic Rett**: The congenital variant lacks the typical regression phase, presenting with severe delays and structural brain defects from infancy, matching the patient’s profile.  
6. **Exclusion of mimics**: CDKL5 deficiency or Angelman syndrome could overlap but are less likely given corpus callosum hypoplasia and frontal lobe involvement, which strongly suggest Rett spectrum disorders."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids**: PKU causes excess phenylalanine to be metabolized into phenylketones (e.g., phenylpyruvate), which are carboxylic acids excreted in urine.  
3. **Neonatal death/Death in infancy/childhood**: Untreated PKU results in severe neurological damage, seizures, and metabolic instability, often fatal in early life without dietary intervention.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) can cause congenital anomalies like microcephaly or cardiac defects in the infant.  
5. **Hypertyrosinemia**: While classic PKU typically reduces tyrosine levels (due to blocked PAH), transient hypertyrosinemia may occur in metabolic crises or overlapping disorders (e.g., BH4 deficiency), though this is atypical and suggests possible complex metabolic interplay.  
6. **Obesity**: May arise from high-calorie, low-protein diets used to manage PKU or secondary metabolic dysregulation.  

While hypertyrosinemia is not a classic PKU feature, the dominant hyperphenylalaninemia and urinary carboxylic acids strongly support PKU as the primary diagnosis, with other symptoms explained by untreated disease or maternal effects."
"['Macrocephaly', 'Cystic hygroma', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly** and **cystic hygroma** may reflect early cerebral abnormalities or fluid-filled lesions, though cystic hygroma is atypical and warrants further evaluation for comorbidities.  
3. **Neurological symptoms** (lethargy, generalized hypotonia, dystonia, dyskinesia, drowsiness) align with basal ganglia damage, a hallmark of GA-I-induced striatal injury during metabolic crises.  
4. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from conjugation with glutaric acid, impairing fatty acid metabolism.  
5. **Acute metabolic decompensation** (fever, vomiting, diarrhea, dyspnea) triggers encephalopathic crises, often precipitated by infections or fasting, explaining rapid deterioration and **neonatal/infant death** if untreated.  
6. **Sleep disturbances** may stem from neurochemical imbalances caused by accumulating metabolites.  
7. GA-I’s clinical trajectory—progressive neurological decline and early lethality without dietary/interventional management—matches the symptom constellation.  

*Note: Cystic hygroma is uncommon in GA-I and may suggest a coincidental finding or misdiagnosis; however, the remaining features strongly support GA-I as the primary diagnosis.*"
"['Vomiting', 'Abdominal pain', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria  
Reasoning: The symptoms of vomiting and severe abdominal pain align with acute attacks characteristic of acute intermittent porphyria (AIP). AIP is caused by a deficiency in hydroxymethylbilane synthase, leading to accumulation of neurotoxic porphyrin precursors. While AIP typically manifests after puberty, severe cases or undiagnosed episodes in childhood can result in fatal neurological complications (e.g., respiratory paralysis, seizures) or electrolyte imbalances (e.g., hyponatremia), explaining early mortality.  

Disease: Porphyria  
Reasoning: Porphyria encompasses a group of disorders affecting heme biosynthesis. The patient’s gastrointestinal symptoms and early fatality suggest an acute hepatic porphyria. While AIP is the most likely subtype, other severe forms (e.g., ALAD-deficiency porphyria or homozygous variants) may present in childhood with rapid progression. Lack of cutaneous symptoms rules out cutaneous porphyrias, narrowing the diagnosis to acute hepatic types. Genetic testing would confirm the specific subtype."
"['Hydroureter', 'Splenomegaly', 'Elevated circulating creatinine concentration', 'Aortic aneurysm', 'Retroperitoneal fibrosis', 'Ureterovesical stenosis', 'Elevated circulating C-reactive protein concentration', 'Plasmacytosis', 'Splenic cyst', 'Increased circulating IgG4 level', 'Dilatation of renal calices']",['IgG4-related retroperitoneal fibrosis'],"IgG4-related retroperitoneal fibrosis:  
1. **Retroperitoneal fibrosis** is a hallmark of IgG4-related disease (IgG4-RD), characterized by fibroinflammatory tissue that often entraps ureters, leading to **hydroureter** and **ureterovesical stenosis**.  
2. **Elevated circulating IgG4 level** and **plasmacytosis** are diagnostic biomarkers of IgG4-RD, reflecting systemic plasmacytic infiltration.  
3. **Splenomegaly** and **splenic cyst** align with IgG4-RD’s multisystemic nature, which can involve the spleen.  
4. **Aortic aneurysm** is a known vascular manifestation of IgG4-RD due to inflammatory aortitis.  
5. **Dilatation of renal calices** and **elevated creatinine** indicate obstructive uropathy secondary to retroperitoneal fibrosis.  
6. **Elevated C-reactive protein** underscores the inflammatory activity, consistent with IgG4-RD’s pathophysiology.  
7. The convergence of fibrosis, elevated IgG4, and multi-organ involvement excludes mimics like malignancy or idiopathic fibrosis, confirming IgG4-related retroperitoneal fibrosis."
"['Malar flattening', 'Micrognathia', 'Preauricular skin tag', 'Conductive hearing impairment', 'Atresia of the external auditory canal', 'Choanal atresia', 'Myopia', 'Microtia', 'Aplasia/Hypoplasia of the middle ear', 'Proximal placement of thumb', 'Increased nuchal translucency', 'Mild global developmental delay', 'Primary microcephaly', 'Gastrostomy tube feeding in infancy']","['Mandibulofacial dysostosis-microcephaly syndrome/Mandibulofacial dysostosis, Guion-Almeida type']","Disease: Mandibulofacial dysostosis-microcephaly syndrome (Guion-Almeida type)  
Reasoning:  
1. **Craniofacial features**: Malar flattening (underdeveloped cheekbones) and micrognathia (small jaw) are hallmark signs of mandibulofacial dysostosis.  
2. **Ear anomalies**: Preauricular skin tag, microtia (small ears), atresia of the external auditory canal, and middle ear aplasia/hypoplasia explain the conductive hearing impairment, consistent with this syndrome.  
3. **Airway/feeding issues**: Choanal atresia (nasal passage obstruction) and gastrostomy tube feeding in infancy reflect structural anomalies causing respiratory and feeding difficulties.  
4. **Neurological involvement**: Primary microcephaly and mild global developmental delay align with the syndrome’s association with neurodevelopmental deficits.  
5. **Associated findings**: Increased nuchal translucency (prenatal marker for structural anomalies), proximal thumb placement (skeletal anomaly), and myopia (eye involvement) further support the diagnosis.  
6. **Exclusion of mimics**: The absence of coloboma/heart defects (seen in CHARGE) and presence of microcephaly distinguish it from Treacher Collins syndrome.  
This constellation of craniofacial, auditory, skeletal, and neurodevelopmental features is pathognomonic for Guion-Almeida type mandibulofacial dysostosis-microcephaly syndrome."
"['Cardiomyopathy', 'Decreased plasma free carnitine', 'Death in adolescence', 'Abnormal circulating acetylcarnitine concentration']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency (PCD)  
Reasoning:  
1. **Decreased plasma free carnitine**: PCD is caused by mutations in the *SLC22A5* gene, impairing the high-affinity carnitine transporter (OCTN2). This results in renal carnitine wasting and systemic depletion.  
2. **Cardiomyopathy**: Carnitine is critical for fatty acid oxidation (FAO). Its deficiency forces cardiac myocytes to rely on glycolysis, leading to energy depletion, lipid accumulation, and progressive dilated/hypertrophic cardiomyopathy.  
3. **Abnormal circulating acetylcarnitine**: Disrupted carnitine metabolism alters acylcarnitine profiles. While total carnitine is low, acetylcarnitine (C2) may paradoxically rise due to compensatory mitochondrial acetyl-CoA accumulation or secondary FAO disturbances.  
4. **Death in adolescence**: Untreated PCD causes recurrent hypoglycemic/hypoketotic crises, arrhythmias, or heart failure. Mortality peaks in childhood/adolescence due to metabolic stress (e.g., fasting, illness) overwhelming residual FAO capacity.  
5. **Diagnostic confirmation**: PCD is distinguished from secondary carnitine deficiencies (e.g., organic acidemias) by genetic testing (*SLC22A5* mutations) and absence of other FAO disorders. Symptoms resolve with lifelong high-dose carnitine supplementation."
"['Long face', 'Recurrent otitis media', 'Prominent nasal bridge', 'Posterior embryotoxon', 'Polyhydramnios', 'Ventricular septal defect', 'Esophageal atresia', 'Tracheoesophageal fistula', 'Bronchomalacia', 'Spina bifida occulta', 'Hypoplasia of the semicircular canal', 'Delayed ability to walk', 'Bilateral cleft lip', 'Bilateral cleft palate']",['CHARGE syndrome/Charge syndrome'],"Disease: CHARGE syndrome  
Reasoning:  
1. **Major Criteria**:  
   - **Hypoplasia of the semicircular canals**: A hallmark feature of CHARGE syndrome, contributing to balance issues and **delayed ability to walk**.  
   - **Bilateral cleft lip/palate**: While cleft palate is a minor criterion, bilateral cleft lip/palate aligns with craniofacial anomalies seen in CHARGE.  
   - **Ventricular septal defect (VSD)**: Congenital heart defects (e.g., VSD) are a core feature (the ""H"" in CHARGE).  

2. **Supportive Features**:  
   - **Esophageal atresia and tracheoesophageal fistula**: Represent the ""A"" (atresia) in CHARGE, typically choanal atresia, but esophageal atresia is occasionally included.  
   - **Recurrent otitis media**: Linked to CHARGE-associated ear anomalies (e.g., hypoplastic cochlea, ""cup-shaped"" ears).  
   - **Posterior embryotoxon**: Though not a classic coloboma (the ""C"" in CHARGE), anterior segment eye anomalies like this are reported.  
   - **Bronchomalacia and polyhydramnios**: Polyhydramnios may reflect fetal swallowing difficulties (esophageal atresia), while bronchomalacia correlates with tracheal anomalies.  

3. **Additional Clues**:  
   - **Spina bifida occulta**: Rarely reported in CHARGE but fits the spectrum of skeletal anomalies.  
   - **Prominent nasal bridge and long face**: Part of the characteristic facial dysmorphism.  

Conclusion: The combination of major criteria (semicircular canal hypoplasia, VSD, craniofacial clefts) and supportive features (atresias, ear/eye anomalies) strongly supports CHARGE syndrome."
"['Renal cyst', 'Nephrocalcinosis', 'Gait disturbance', 'Arthritis', 'Splenomegaly', 'Neutropenia', 'Leukopenia', 'Granulocytopenia', 'Microcytic anemia', 'Hypophosphatemia', 'Hepatomegaly', 'Headache', 'Vertigo', 'Lymphadenopathy', 'Abnormality of the lower limb', 'Exertional dyspnea', 'Back pain', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Thrombophlebitis', 'Abnormal intervertebral disk morphology', 'Miscarriage', 'Abnormality of hand joint mobility', 'Abnormal phalangeal joint morphology of the hand', 'Lower limb amyotrophy', 'Abnormality of the submandibular glands', 'Upper limb pain', 'Lower limb pain', 'Dysesthesia', 'Foot pain', 'Neck pain', 'Wrist pain', 'Finger pain', 'Hip pain', 'Knee pain', 'Ankle pain']",['Felty syndrome/Felty syndrome'],"Disease: Felty syndrome  
Reasoning: Felty syndrome is classically defined by the triad of **rheumatoid arthritis (RA)**, **splenomegaly**, and **neutropenia**.  
1. **Arthritis** and joint abnormalities (hand/wrist pain, reduced mobility, abnormal morphology) align with RA.  
2. **Splenomegaly** and **hepatomegaly** suggest systemic involvement, common in Felty syndrome.  
3. **Neutropenia**, **leukopenia**, and **granulocytopenia** explain recurrent infections and are hallmarks of Felty-related immune dysregulation.  
4. **Microcytic anemia** and **elevated ESR** reflect chronic inflammation from RA.  
5. **Exercise intolerance**, **gait disturbance**, and musculoskeletal pain likely stem from chronic joint damage and systemic inflammation.  
**Exclusions/Considerations**: Renal cysts, nephrocalcinosis, and hypophosphatemia are atypical for Felty syndrome and may suggest a coexisting metabolic or renal disorder (e.g., hyperparathyroidism or tubular defects). However, the core triad strongly supports Felty syndrome as the primary diagnosis."
"['Strabismus', 'Hyporeflexia', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Fever', 'Cerebral atrophy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Cerebral atrophy**: A hallmark of Canavan disease due to spongy degeneration of white matter caused by aspartoacylase deficiency.  
2. **Abnormal circulating aspartate family amino acid concentration**: Directly linked to elevated N-acetylaspartic acid (NAA) levels, a diagnostic biomarker for Canavan disease.  
3. **Generalized hypotonia and hyporeflexia**: Result from progressive neurological deterioration and impaired myelination.  
4. **Strabismus**: Associated with disrupted motor neuron function and cerebral damage.  
5. **Death in infancy**: Consistent with the severe infantile form of the disease, which leads to rapid neurological decline.  
6. **Fever**: Likely secondary to complications (e.g., aspiration pneumonia) due to dysphagia or immobility.  
7. **Obesity**: Atypical for Canavan disease; may indicate comorbid factors or misreporting, but does not exclude the diagnosis given other pathognomonic features.  

Exclusion of other leukodystrophies is supported by the specific biochemical profile (NAA accumulation) and clinical progression."
"['Apathy', 'Spasticity', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hypoglycemia', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in early adulthood']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Key biochemical markers**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in branched-chain amino acid (BCAA) metabolism, the hallmark of MSUD.  
2. **Neurological symptoms**: Spasticity, generalized hypotonia, and apathy arise from neurotoxicity caused by accumulated BCAAs and their ketoacid derivatives.  
3. **Early mortality**: Neonatal death, death in infancy, or early adulthood aligns with severe MSUD phenotypes, where metabolic crises lead to rapid deterioration without dietary intervention.  
4. **Hypoglycemia**: Reflects metabolic instability during catabolic states (e.g., infections or fasting), common in MSUD due to disrupted energy metabolism.  
5. **Obesity**: May result from high-calorie dietary regimens used to manage MSUD or secondary metabolic dysfunction.  
6. **Exclusion of mimics**: The triad of elevated BCAAs rules out isolated hypervalinemia or other aminoacidurias, solidifying MSUD as the diagnosis.  

(Note: Classic MSUD also features a maple syrup odor in bodily fluids, which may not have been reported here but is not essential for diagnosis when biochemical and clinical criteria are met.)"
"['Lethargy', 'Generalized hypotonia', 'Hepatic steatosis', 'Death in infancy', 'Cardiomegaly', 'Pericardial effusion', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Paroxysmal tachycardia', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Metabolic derangements**: Hypoglycemia, hyperammonemia, and metabolic acidosis align with impaired fatty acid β-oxidation, a hallmark of VLCADD. Fatty acids are critical for energy during fasting; their defective metabolism leads to hypoglycemia and compensatory protein catabolism (causing hyperammonemia).  
2. **Hepatic involvement**: Hepatic steatosis, hepatomegaly, and abnormal liver enzymes (elevated lactate dehydrogenase) reflect liver dysfunction due to toxic accumulation of unmetabolized long-chain fatty acids.  
3. **Cardiac manifestations**: Cardiomegaly, pericardial effusion, and paroxysmal tachycardia correlate with long-chain fatty acid deposition in cardiac tissue, leading to cardiomyopathy and arrhythmias.  
4. **Muscular symptoms**: Generalized hypotonia and lethargy result from energy deficiency in muscles, as long-chain fatty acids cannot fuel muscle metabolism.  
5. **Lab abnormalities**: Decreased plasma free carnitine (due to secondary carnitine deficiency from acyl-CoA trapping) and abnormal aspartate/alanine concentrations (indicative of mitochondrial dysfunction) strongly support a fatty acid oxidation disorder.  
6. **Respiratory and systemic signs**: Tachypnea and dyspnea may stem from metabolic acidosis, while vomiting/diarrhea reflect multisystem metabolic stress.  
7. **Severe prognosis**: Death in infancy is consistent with acute metabolic crises in untreated VLCADD, triggered by catabolic states (e.g., fasting, infection).  

VLCADD is distinguished from other fatty acid oxidation defects by its predilection for cardiac/hepatic involvement and characteristic laboratory markers (e.g., elevated C14:1 acylcarnitine). Early-onset symptoms with multisystemic dysfunction confirm this diagnosis."
"['Narrow mouth', 'High palate', 'Prominent supraorbital ridges', 'Sensorineural hearing impairment', 'Protruding ear', 'Delayed eruption of teeth', 'Dentinogenesis imperfecta', 'Scoliosis', 'Recurrent fractures', 'Short stature', 'Reduced bone mineral density', 'Thoracic platyspondyly', 'Depressed nasal bridge', 'Prominent forehead', 'Midface retrusion', 'Knee joint hypermobility']","['Osteogenesis imperfecta, type XII']","Disease: Osteogenesis imperfecta, type XII  
Reasoning:  
1. **Recurrent fractures** and **reduced bone mineral density** indicate a skeletal fragility disorder, central to osteogenesis imperfecta (OI).  
2. **Dentinogenesis imperfecta** is a hallmark of OI, affecting tooth structure.  
3. **Short stature**, **scoliosis**, and **thoracic platyspondyly** align with skeletal dysplasias seen in OI.  
4. **Midface retrusion**, **depressed nasal bridge**, **narrow mouth**, **high palate**, **prominent supraorbital ridges**, and **prominent forehead** suggest craniofacial abnormalities typical of OI subtypes.  
5. **Sensorineural hearing impairment** is a known feature in some OI types, including type XII.  
6. **Knee joint hypermobility** reflects connective tissue involvement, consistent with collagen defects (OI type XII is linked to SP7 mutations, critical for bone formation).  
7. **Delayed eruption of teeth** and **protruding ear** further support a syndromic diagnosis involving developmental anomalies.  
8. Type XII is distinguished by autosomal recessive inheritance and specific SP7-related pathology, matching the symptom constellation."
"['Progressive microcephaly', 'Short philtrum', 'Strabismus', 'Thick eyebrow', 'Pigmentary retinopathy', 'Tapered finger', 'Global developmental delay', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Joint hypermobility', 'Growth delay', 'Truncal obesity', 'Poor suck', 'Abnormal brainstem morphology', 'Short stature', 'Thick corpus callosum', 'Thick vermilion border', 'Thick hair']",['Cohen syndrome/Cohen syndrome'],"Disease: Cohen syndrome/Cohen syndrome  
Reasoning: The patient presents with key features of Cohen syndrome, including progressive microcephaly, pigmentary retinopathy (a hallmark finding), global developmental delay, generalized hypotonia, and truncal obesity. Characteristic facial features such as short philtrum, thick eyebrows, and thick vermilion border align with the syndrome's phenotype. Additional supportive signs include tapered fingers, joint hypermobility, growth delay/short stature, thick hair, and thick corpus callosum. Poor suck in infancy correlates with hypotonia, while abnormal cerebellum/brainstem morphology may reflect broader neurodevelopmental anomalies. The combination of retinal dystrophy, developmental delay, distinct craniofacial traits, and obesity strongly confirms the diagnosis."
"['Abnormal hair morphology', 'Abnormality of the nail', 'Abnormality of dental morphology', 'Punctate palmoplantar hyperkeratosis']","['Palmoplantar keratoderma, punctate type IA']","Disease: Palmoplantar keratoderma, punctate type IA  
Reasoning:  
1. **Punctate palmoplantar hyperkeratosis** is the defining feature of this disease, characterized by discrete hyperkeratotic papules on pressure areas of the palms and soles.  
2. **Abnormality of the nail** (e.g., dystrophy, pitting) is commonly associated with this subtype of PPK due to shared ectodermal origin of skin and nails.  
3. **Abnormal hair morphology** (e.g., thinning, brittleness) and **dental abnormalities** (e.g., enamel defects, misalignment) suggest broader ectodermal involvement, which can occur in some genetic variants of punctate PPK type IA, linked to mutations in *AAGAB* or other genes affecting keratinocyte adhesion.  
4. The combination of these findings aligns with the phenotypic spectrum of punctate type IA PPK, where extracutaneous ectodermal features may manifest variably despite the primary diagnostic focus on palmoplantar lesions."
"['Long philtrum', 'Macrotia', 'Bulbous nose', 'Tachycardia', 'Bilateral tonic-clonic seizure', 'Apnea', 'Abnormal cortical gyration', 'Recurrent infections', 'Breathing dysregulation', 'Respiratory acidosis', 'Diffuse white matter abnormalities', 'EEG with frontal sharp waves', 'Low APGAR score', 'Postaxial polydactyly']","['PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies']","Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Neurodevelopmental and Brain Anomalies**: Symptoms like abnormal cortical gyration, diffuse white matter abnormalities, and EEG with frontal sharp waves align with structural and functional brain abnormalities characteristic of PLAA-NDD.  
2. **Seizures and Autonomic Dysregulation**: Bilateral tonic-clonic seizures, apnea, breathing dysregulation, and respiratory acidosis suggest central nervous system involvement, particularly brainstem dysfunction, which is consistent with this disorder.  
3. **Craniofacial Features**: Long philtrum, macrotia, and bulbous nose match reported dysmorphic traits in PLAA-NDD.  
4. **Postaxial Polydactyly**: While uncommon, polydactyly has been observed in some cases, possibly linked to broader developmental disruptions.  
5. **Early Neonatal Compromise**: Low APGAR score reflects perinatal distress, often seen in congenital neurodevelopmental disorders.  
6. **Recurrent Infections**: May result from respiratory compromise (e.g., aspiration due to dysphagia or breathing irregularities) rather than primary immunodeficiency.  
7. **Progressive Microcephaly**: Though not explicitly listed, abnormal cortical gyration and white matter changes imply evolving brain pathology, fitting the ""progressive"" nature of the disorder.  

The constellation of neurological, dysmorphic, and systemic features strongly supports PLAA-NDD, driven by PLAA gene mutations impacting neurodevelopment and autonomic regulation."
"['Death in infancy', 'Vomiting', 'Increased total bilirubin', 'Neonatal death', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Galactosemia; GAL/Galactosemia  
Reasoning: Hypergalactosemia (elevated galactose in blood) is a hallmark of galactosemia, a rare metabolic disorder caused by impaired galactose metabolism. The symptoms of vomiting, jaundice (elevated bilirubin), and neonatal death align with the rapid deterioration seen in untreated galactosemia, as infants cannot process galactose from lactose in breast milk or formula, leading to toxic accumulation and multi-organ failure.  

Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: Classic galactosemia (GALT deficiency, Type I) is the most severe form. Neonatal death and infant mortality are typical without early dietary intervention. Increased bilirubin reflects liver damage, a key feature, while vomiting and hypergalactosemia directly result from the inability to metabolize galactose. This subtype is distinguished by complete GALT enzyme deficiency, consistent with the acute presentation described."
"['Nephritis', 'Generalized hypotonia', 'Death in infancy', 'Ventricular septal defect', 'Cardiomyopathy', 'Pulmonic stenosis']",['Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb'],"Disease: Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb  
Reasoning:  
1. **Generalized hypotonia**: Phosphorylase kinase deficiency impairs glycogen breakdown in muscles, leading to glycogen accumulation and muscle weakness.  
2. **Cardiomyopathy**: Glycogen accumulation in cardiac muscle can disrupt myocardial function, causing hypertrophic or dilated cardiomyopathy.  
3. **Death in infancy**: Severe metabolic instability (e.g., hypoglycemia, lactic acidosis) and cardiac complications (cardiomyopathy, structural defects) may contribute to early mortality.  
4. **Ventricular septal defect (VSD) and pulmonic stenosis**: While not classic features of GSD IXb, these congenital defects could arise from a contiguous gene deletion syndrome involving PHKA2 (X-linked) and adjacent cardiac developmental genes.  
5. **Nephritis**: Uncommon in GSDs; may reflect secondary renal tubular dysfunction due to metabolic stress (e.g., acidosis) or misdiagnosis of glycogen-driven renal enlargement as inflammation.  

This diagnosis integrates metabolic dysfunction (liver/muscle phosphorylase kinase deficiency) with multisystem complications, emphasizing severe phenotypic variability in rare presentations."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration** is a hallmark of MCADD, as secondary carnitine deficiency occurs due to impaired fatty acid oxidation and accumulation of toxic metabolites like medium-chain acylcarnitines.  
2. **Neonatal death** and **death in infancy/childhood** align with MCADD’s presentation, where metabolic crises (hypoketotic hypoglycemia) during fasting or illness lead to fatal outcomes if untreated.  
3. **Abnormality of prenatal development** may reflect intrauterine metabolic stress, though MCADD typically manifests postnatally.  
4. MCADD disrupts medium-chain fatty acid oxidation, depriving energy-critical organs (e.g., liver, brain) of fuel during fasting, consistent with the acute lethality described.  
5. The absence of neonatal screening (implied by early death) and delayed diagnosis exacerbates risks, explaining the fatal trajectory."
"['Abnormal paranasal sinus morphology', 'Epistaxis', 'Abnormal nasal mucosa morphology', 'Hemoptysis', 'Sneeze', 'Elbow pain', 'Knee pain', 'Ankle pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis  
**Reasoning**:  
1. **Upper respiratory involvement**: Symptoms like *abnormal paranasal sinus morphology*, *epistaxis*, and *abnormal nasal mucosa morphology* are hallmarks of GPA, which commonly causes necrotizing granulomatous inflammation in the sinuses and nasal passages.  
2. **Lower respiratory tract involvement**: *Hemoptysis* suggests alveolar hemorrhage due to pulmonary vasculitis, a critical feature of GPA.  
3. **Systemic vasculitis**: Joint pain (*elbow, knee, ankle*) reflects systemic inflammation affecting small- to medium-sized vessels, consistent with GPA’s multisystemic nature.  
4. **Exclusion of mimics**: The absence of asthma/eosinophilia (ruling out eosinophilic GPA) and the prominence of upper respiratory + joint symptoms distinguish GPA from other vasculitides (e.g., microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis).  
5. **Triad alignment**: GPA classically presents with necrotizing granulomas of the respiratory tract, vasculitis, and glomerulonephritis (not listed here, but not all features are required for diagnosis)."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Death in childhood** aligns with untreated/severe PKU, as neurological damage and complications (e.g., seizures, intellectual disability) may result in early mortality without dietary intervention.  
3. **Hypertyrosinemia** is atypical in classical PKU (where tyrosine levels are usually low/normal due to blocked PAH activity). This may indicate:  
   - A concurrent condition (e.g., tyrosinemia type II) or metabolic overlap.  
   - Potential misreporting of symptoms (e.g., hypotyrosinemia expected in PKU).  
   - Rare variants or secondary metabolic disruptions (e.g., liver dysfunction).  

Final diagnosis prioritizes hyperphenylalaninemia and clinical severity, consistent with PKU, while acknowledging the atypical tyrosine elevation as a confounding factor requiring further investigation."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Cardiomyopathy', 'Hypoglycemia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Myopathy', 'Decreased plasma free carnitine', 'Abnormal circulating acetylcarnitine concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Hypoglycemia & Hepatomegaly**: VLCADD disrupts mitochondrial β-oxidation of very long-chain fatty acids, impairing energy production during fasting. This causes hypoglycemia (due to reliance on glucose without ketone alternatives) and hepatomegaly (fatty acid accumulation in the liver).  
2. **Cardiomyopathy & Myopathy**: Cardiac and skeletal muscles depend on fatty acid oxidation for energy. Enzyme deficiency leads to toxic metabolite buildup (e.g., long-chain acylcarnitines), causing cardiomyopathy and muscle weakness.  
3. **Decreased Plasma Free Carnitine & Abnormal Acetylcarnitine**: Carnitine conjugates with unmetabolized fatty acids, reducing free carnitine. Elevated very long-chain acylcarnitines (e.g., C14:1, C14, C16:1) are diagnostic biomarkers.  
4. **Lethargy, Drowsiness, Hypotonia**: Energy deficiency in muscles and the central nervous system explains hypotonia and neurological symptoms.  
5. **Death in Infancy**: Severe phenotypes present early with metabolic crises, cardiac dysfunction, or liver failure, often fatal without dietary intervention (avoidance of fasting, low-fat/high-carbohydrate diet, and medium-chain triglyceride supplementation).  
6. **Sleep Disturbance**: May reflect metabolic instability during prolonged fasting (e.g., overnight), triggering hypoglycemia or acidosis.  
The clinical and biochemical profile aligns with VLCADD, confirmed by genetic testing of *ACADVL* and acylcarnitine analysis."
"['Spastic paraplegia', 'Dysarthria', 'Spastic gait', 'Difficulty walking', 'Distal muscle weakness', 'Hyporeflexia of lower limbs', 'Distal peripheral sensory neuropathy']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core HSP Features**: Spastic paraplegia, spastic gait, and difficulty walking align with hereditary spastic paraplegia (HSP), a hallmark of SPG76.  
2. **Neuropathy Overlap**: Distal peripheral sensory neuropathy and hyporeflexia suggest peripheral nerve involvement, consistent with SPG76’s association with axonal neuropathy.  
3. **Upper vs. Lower Motor Neuron Signs**: Hyporeflexia (lower motor neuron) contrasts with spasticity (upper motor neuron), indicating a ""complicated"" HSP subtype, which SPG76 exemplifies.  
4. **Dysarthria**: Though rare in pure HSP, dysarthria is reported in SPG76 due to overlapping cerebellar or bulbar dysfunction.  
5. **Genetic Confirmation**: SPG76 is linked to CAPN1 mutations, which cause progressive spasticity and neuropathy, matching the symptom profile.  
6. **Exclusion of Alternatives**: Features lack cognitive decline or structural brain anomalies seen in other HSP subtypes (e.g., SPG11/SPG15), narrowing the diagnosis to SPG76."
"['Death in infancy', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Death in infancy/childhood**: MCADD disrupts fatty acid β-oxidation, causing hypoglycemia and metabolic crises during fasting. Infants/children are vulnerable due to limited glycogen stores, leading to life-threatening events if undiagnosed.  
2. **Recurrent viral infections**: Metabolic stress during infections (e.g., vomiting, reduced intake) exacerbates energy deficits, increasing risk of decompensation.  
3. **Abnormal circulating carnitine**: Secondary carnitine deficiency arises from conjugation of accumulated medium-chain acyl-CoA species, depleting free carnitine.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misstated lab finding; MCADD directly involves MCAD enzyme deficiency, not 3-hydroxyacyl-CoA dehydrogenase. This may indicate overlapping testing artifacts or pathway crosstalk.  

Key confirmation would include genetic testing for *ACADM* mutations and elevated C6-C10 acylcarnitines on tandem mass spectrometry."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: 生物素酶缺乏症/Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Symptom Alignment**:  
   - **Neonatal death/Death in infancy**: Untreated BTDD causes progressive metabolic crises (e.g., lactic acidosis, hyperammonemia) due to impaired carboxylase function. Without biotin supplementation, these crises lead to neurological deterioration, respiratory failure, and early mortality.  
   - **Abnormality of prenatal development or birth**: While BTDD typically manifests postnatally, severe maternal biotin deficiency (rarely) or fetal metabolic stress in utero may contribute to intrauterine growth restriction (IUGR) or preterm birth, indirectly linking to prenatal abnormalities.  

2. **Pathophysiology**:  
   - Biotinidase deficiency prevents recycling of biotin, a cofactor for carboxylases critical in fatty acid synthesis, gluconeogenesis, and amino acid catabolism.  
   - Postnatal biotin deprivation results in metabolic instability, with symptoms escalating within weeks to months after birth if untreated.  

3. **Diagnostic Confirmation**:  
   - Neonatal screening (bloodspot assay for biotinidase activity) or genetic testing (BTD gene mutations) would confirm the diagnosis.  
   - Absence of treatment explains the fatal trajectory described in the symptoms.  

4. **Exclusion of Alternatives**:  
   - Early-onset holocarboxylase synthetase deficiency presents similarly but typically manifests within days of birth, whereas BTDD is ""late-onset"" (weeks to months).  
   - Other lethal metabolic disorders (e.g., organic acidemias) were likely ruled out via the provided diagnosis.  

**Conclusion**: The triad of symptoms aligns with untreated BTDD, where biotin dependency post-birth leads to irreversible metabolic dysfunction and early death. Prenatal abnormalities may reflect secondary effects of metabolic instability or comorbid factors."
"['Strabismus', 'Cataract', 'Amblyopia', 'Autistic behavior', 'Delayed speech and language development', 'Abnormally large globe', 'Retinal atrophy', 'Motor delay', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Abnormal midbrain morphology', '2-3 toe syndactyly', 'Cerebellar dysplasia', 'Absent retinal pigment epithelium', 'High myopia', 'Splayed superior cerebellar peduncle']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar anomalies**: Cerebellar vermis hypoplasia, cerebellar cysts, dilated fourth ventricle, and cerebellar dysplasia are hallmark features of Poretti-Boltshauser syndrome (PTBHS).  
2. **Ocular abnormalities**: High myopia, retinal atrophy, absent retinal pigment epithelium, strabismus, and cataracts align with PTBHS-associated retinal dystrophy and structural eye defects.  
3. **Neurodevelopmental delays**: Motor delay, delayed speech, and autistic behavior correlate with intellectual disability and cerebellar dysfunction in PTBHS.  
4. **Midbrain/cerebellar peduncle anomalies**: Splayed superior cerebellar peduncles and abnormal midbrain morphology are consistent with PTBHS neuroimaging findings.  
5. **Syndactyly**: 2-3 toe syndactyly is a rare but reported skeletal feature in PTBHS, supporting the diagnosis.  
6. **Exclusion of mimics**: The absence of nephronophthisis (Joubert syndrome) or liver fibrosis (COACH syndrome), combined with cerebellar cysts and retinal changes, distinguishes PTBHS."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate, phenyllactate), which are excreted in urine as carboxylic acids.  
3. **Intellectual disability**: Untreated PKU leads to neurotoxic phenylalanine accumulation, disrupting brain development.  
4. **Neonatal/childhood death**: Severe metabolic derangements (e.g., seizures, failure to thrive) in untreated cases may result in early mortality.  
5. **Hypertyrosinemia (atypical for PKU)**: While classic PKU reduces tyrosine levels, secondary factors (e.g., transient liver dysfunction, dietary intake, or metabolic stress) may explain elevated tyrosine.  
6. **Prenatal abnormalities**: Maternal PKU during pregnancy can cause congenital anomalies, though postnatal PKU diagnosis aligns with neonatal symptoms.  

Note: Hypertyrosinemia warrants further investigation for coexisting disorders (e.g., tyrosinemia), but PKU remains the primary diagnosis based on hyperphenylalaninemia and phenylketonuria."
"['Abnormality of the genitourinary system', 'Hydrocephalus', 'Intellectual disability, mild', 'Cerebellar hypoplasia', 'Pancytopenia', 'Asthma', 'Unsteady gait', 'Abnormal cerebral white matter morphology', 'Coxa valga', 'Decreased circulating IgG level', 'Short telomere length', 'Arachnoid cyst']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Core diagnostic criteria**:  
   - **Pancytopenia** (key feature of ATXPC) and **unsteady gait** (ataxia) are hallmark symptoms.  
   - **Cerebellar hypoplasia** directly explains ataxia and is a defining neurological feature of the syndrome.  
   - **Short telomere length** aligns with bone marrow dysfunction, a recognized mechanism in ATXPC.  

2. **Supportive neurological findings**:  
   - **Abnormal cerebral white matter morphology** and **hydrocephalus** may reflect structural brain anomalies linked to SAMD9L mutations.  
   - **Arachnoid cyst** and **mild intellectual disability** could arise from disrupted neurodevelopment.  

3. **Systemic manifestations**:  
   - **Decreased circulating IgG level** suggests immune dysfunction secondary to bone marrow failure.  
   - **Coxa valga** and **genitourinary abnormalities** fit the multisystemic nature of SAMD9L-related disorders.  

4. **Exclusion of mimics**:  
   - Asthma is likely incidental or secondary to immune deficiency.  
   - Telomere shortening distinguishes ATXPC from isolated cerebellar hypoplasia or other bone marrow failure syndromes (e.g., Dyskeratosis congenita lacks cerebellar features).  

Conclusion: The constellation of neurological, hematological, and systemic features strongly supports ATXPC, driven by SAMD9L mutations."
"['Delayed speech and language development', 'Motor delay', 'Death in infancy', '3-Methylglutaric aciduria', 'Death in childhood', 'Elevated urinary carboxylic acid']","['3-methylglutaconic aciduria type 1/3-methylglutaconic aciduria, type I']","Disease: 3-methylglutaconic aciduria type 1/3-methylglutaconic aciduria, type I  
Reasoning:  
1. **Biochemical marker**: The presence of **3-methylglutaric aciduria** and **elevated urinary carboxylic acids** directly points to a defect in leucine catabolism. This aligns with 3-methylglutaconic aciduria type I, caused by **3-methylglutaconyl-CoA hydratase deficiency**, which disrupts the conversion of 3-methylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA.  
2. **Metabolic consequences**: Accumulation of 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid in urine explains the elevated carboxylic acids. These metabolites are neurotoxic, leading to **delayed speech, motor delays**, and neurological deterioration.  
3. **Severity and prognosis**: The inclusion of **death in infancy/childhood** reflects the life-threatening metabolic crises (e.g., acidosis, hypoglycemia) common in untreated cases of this autosomal recessive disorder.  
4. **Differentiation from other types**: Unlike types II–IV (associated with mitochondrial disorders, neutropenia, or cardiomyopathy), type I is isolated to leucine metabolism, consistent with the absence of extraneous symptoms (e.g., organ dysfunction).  
5. **Confirmation**: Genetic testing for *AUH* gene mutations or enzyme assays confirming hydratase deficiency would solidify the diagnosis."
"['Macrocephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Seizure', 'Absent speech', 'Hypoplasia of the corpus callosum', 'Developmental regression', 'Areflexia of lower limbs', 'Severe muscular hypotonia', 'Periventricular leukomalacia', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe muscular hypotonia and areflexia**: Core features of TBCK syndrome, reflecting neuromuscular involvement due to TBCK gene mutations affecting mTOR signaling.  
2. **Intellectual disability, absent speech, and severe global developmental delay**: Consistent with neurodevelopmental deficits characteristic of TBCK syndrome.  
3. **Hypoplasia of the corpus callosum**: A hallmark neuroimaging finding in TBCK-related disorders, linked to disrupted neuronal connectivity.  
4. **Seizures and developmental regression**: Observed in severe TBCK cases, possibly due to progressive neuronal dysfunction or epileptic encephalopathy.  
5. **Macrocephaly**: Reported in some patients, though nonspecific, it aligns with brain structural anomalies.  
6. **Ocular abnormalities (strabismus, nystagmus)**: Common in neurogenetic syndromes, supporting central nervous system involvement.  
7. **Periventricular leukomalacia**: May overlap with white matter abnormalities seen in TBCK, though typically associated with preterm injury; here, it likely reflects dysmyelination from the genetic defect.  
8. **Exclusion of mimics**: Features distinguish it from similar disorders (e.g., Prader-Willi, Rett syndrome) by the absence of dysmorphism, metabolic markers, or specific regression patterns. Genetic testing for TBCK mutations would confirm the diagnosis."
"['Apathy', 'Seizure', 'Spasticity', 'Death in infancy', 'Alopecia', 'Dyspnea', 'Fatigue', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acid**: Directly links to impaired carboxylase function (propionyl-CoA carboxylase, pyruvate carboxylase, etc.), which require biotin as a cofactor. Deficiency reduces enzyme activity, causing organic acid accumulation.  
2. **Seizures & spasticity**: Neurological manifestations arise from metabolic acidosis, hyperammonemia, or disrupted neurotransmitter synthesis due to defective biotin-dependent enzymes.  
3. **Alopecia**: Biotin is critical for keratin synthesis; deficiency leads to hair fragility and loss.  
4. **Dyspnea & fatigue**: Metabolic acidosis from accumulated organic acids triggers respiratory compensation (Kussmaul breathing) and systemic energy depletion.  
5. **Apathy**: Reflects global encephalopathy secondary to metabolic derangements.  
6. **Death in infancy**: Untreated BTDD causes progressive neurological decline, metabolic crises, and fatal outcomes without biotin supplementation.  
7. **Late-onset presentation**: Aligns with partial biotinidase deficiency, where symptoms manifest after the neonatal period but escalate rapidly without intervention.  

The constellation of metabolic, neurological, and dermatological signs, coupled with urinary carboxylic acid elevation, is pathognomonic for biotinidase deficiency. Early biotin replacement reverses symptoms, underscoring the urgency of diagnosis."
"['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Hyperglycinuria', 'Hyperglutaminemia', 'Argininuria', 'Neonatal death', 'Abnormal circulating arginine concentration', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Citrullinemia, classic)  
Reasoning:  
1. **Hyperammonemia** and **neonatal death**: Core features of urea cycle disorders (UCDs). Citrullinemia type I results from **argininosuccinate synthetase (ASS1) deficiency**, impairing ammonia detoxification.  
2. **Elevated plasma citrulline**: Pathognomonic for citrullinemia type I due to citrulline accumulation from ASS1 dysfunction.  
3. **Metabolic acidosis**: Secondary to organic acid accumulation from disrupted urea cycle and alternative nitrogen excretion pathways.  
4. **Hyperglycinuria/Hyperglutaminemia/Argininuria**: Amino acid transport disturbances caused by metabolic stress and renal tubular dysfunction in UCDs.  
5. **Abnormal circulating arginine**: Reduced arginine synthesis (from ASS1 deficiency) and compensatory mechanisms.  
6. **Death in infancy**: Severe neonatal-onset citrullinemia type I often leads to rapid deterioration without early intervention.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
- **Exclusion of type II (SLC25A13 mutation)**: Type II typically presents later (adolescence/adulthood) with episodic hyperammonemia, absent neonatal death, and normal/mildly elevated citrulline.  
- **Biochemical triad**: Hyperammonemia + hypercitrullinemia + metabolic acidosis confirms type I.  
- **Genetic confirmation**: ASS1 gene mutations definitively diagnose classic citrullinemia."
"['Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
Reasoning:  
1. **Aminoaciduria Profile**: The presence of cystinuria, argininuria, hyperlysinuria, and ornithinuria is pathognomonic for cystinuria. These amino acids share a common renal tubular transport system (SLC3A1/SLC7A9 genes), and their urinary excretion indicates a defect in this system.  
2. **Dermatological Symptoms**: Eczematoid dermatitis and skin rash are atypical for classic cystinuria. These may arise secondary to malnutrition or infections due to chronic illness, but they are not direct features of the disease.  
3. **Death in Infancy**: Severe complications (e.g., obstructive uropathy, renal failure) from recurrent cystine stones or metabolic disturbances could theoretically lead to early mortality, though this is rare. Alternatively, coexisting conditions or misreported clinical history may contribute.  
4. **Exclusion of Alternatives**: Lysinuric protein intolerance (LPI) or urea cycle disorders were considered but ruled out due to the absence of hyperammonemia, hepatosplenomegaly, or neutral aminoaciduria. Cystinosis was excluded as it causes generalized Fanconi syndrome, not isolated dibasic aminoaciduria.  

Final diagnosis aligns with cystinuria based on the definitive aminoaciduria pattern, while secondary factors or comorbidities may explain the atypical symptoms."
"['Ptosis', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Abnormal foot morphology', 'High, narrow palate', 'Elevated 8-dehydrocholesterol', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Death in adolescence']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Elevated 7-dehydrocholesterol and 8-dehydrocholesterol**: Pathognomonic biochemical markers of Smith-Lemli-Opitz syndrome (SLOS), caused by a deficiency in 7-dehydrocholesterol reductase, which disrupts cholesterol synthesis.  
2. **Syndactyly and abnormal foot morphology**: Classic physical features of SLOS, particularly 2-3 toe syndactyly and/or clubfoot.  
3. **Developmental delays (speech, motor, intellectual) and hypotonia**: Neurological manifestations due to impaired cholesterol-dependent myelination and synaptic function.  
4. **High, narrow palate and ptosis**: Common craniofacial dysmorphisms in SLOS.  
5. **Early mortality (infancy/childhood/adolescence)**: Severe forms of SLOS are associated with life-threatening malformations (e.g., cardiac, pulmonary) or metabolic instability.  
6. **Generalized hypotonia**: Reflects both neurological dysfunction and potential structural abnormalities (e.g., poor muscle development).  
The combination of sterol abnormalities, syndactyly, neurodevelopmental deficits, and dysmorphic features confirms SLOS."
"['Micropenis', 'Wide mouth', 'Gingival overgrowth', 'Macrocephaly', 'Hypertelorism', 'Low-set ears', 'Anteverted nares', 'Proptosis', 'Missing ribs', 'Frontal bossing', 'Thoracolumbar scoliosis', 'Hypoplasia of the radius', 'Hypoplasia of the ulna', 'Acromesomelia', 'Short stature', 'Depressed nasal bridge', 'Lumbar hemivertebrae', 'Tented upper lip vermilion', 'Retractile testis', 'Small hand']","['Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive']","Disease: Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive  
Reasoning:  
1. **Craniofacial Features**: Macrocephaly, hypertelorism, depressed nasal bridge, anteverted nares, tented upper lip vermilion, wide mouth, and gingival overgrowth align with the characteristic ""fetal facies"" of Robinow syndrome.  
2. **Skeletal Abnormalities**: Hypoplasia of the radius/ulna, acromesomelia, small hands, missing ribs, thoracolumbar scoliosis, lumbar hemivertebrae, and short stature reflect severe mesomelic limb shortening and vertebral defects, hallmark features of the autosomal recessive subtype.  
3. **Genitourinary Findings**: Micropenis and retractile testis are consistent with genital hypoplasia, a key diagnostic criterion.  
4. **Exclusion of Milder Forms**: The severity of skeletal defects (e.g., rib absence, marked limb hypoplasia) and pronounced craniofacial dysmorphism differentiate it from autosomal dominant Robinow syndrome, which typically has milder manifestations.  
5. **Consistency with Known Phenotype**: The combination of craniofacial, skeletal, and genital anomalies matches the triad defining Robinow syndrome, with the specific pattern confirming the autosomal recessive variant."
"['Intellectual disability', 'Severe short stature', 'Death in childhood', 'Abnormality of galactoside metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with intellectual disability and severe short stature, which are consistent with the neurological and growth impairments seen in untreated classic galactosemia. Death in childhood aligns with the severe complications of the disease (e.g., liver failure, sepsis) if galactose is not excluded from the diet. The abnormality of galactoside metabolism directly points to the enzymatic defect in galactose-1-phosphate uridylyltransferase (GALT), characteristic of classic galactosemia. Early dietary management is critical to mitigate symptoms, but residual issues may persist despite treatment.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning: This diagnosis is synonymous with classic galactosemia. The symptoms listed—intellectual disability, severe short stature, childhood mortality, and metabolic abnormalities—are hallmarks of galactosemia caused by GALT deficiency. Accumulation of toxic metabolites (e.g., galactitol) disrupts cellular function, leading to organ damage (liver, brain) and growth failure. The term ""abnormality of galactoside metabolism"" explicitly references the underlying biochemical defect in galactose processing pathways."
"['Recurrent urinary tract infections', 'Neck muscle weakness', 'Edema', 'Skin rash', 'Global developmental delay', 'Motor delay', 'Areflexia', 'Muscle weakness', 'Decreased fetal movement', 'Arthralgia', 'Microscopic hematuria', 'Abnormal EKG', 'EMG: myopathic abnormalities', 'Centrally nucleated skeletal muscle fibers', 'Shoulder girdle muscle atrophy', 'Distal lower limb amyotrophy', 'Macroscopic hematuria', 'Abnormal cranial nerve physiology', 'obsolete Toe walking', 'Abnormal nerve conduction velocity', 'obsolete Hyperkeratosis pilaris']",['Bethlem myopathy/Bethlem myopathy 1'],"Disease: Bethlem myopathy/Bethlem myopathy 1  
Reasoning:  
1. **Muscle Weakness and Atrophy**: Neck muscle weakness, shoulder girdle atrophy, and distal lower limb amyotrophy align with Bethlem myopathy’s progressive proximal-to-distal muscle involvement.  
2. **Congenital Onset**: Decreased fetal movement and global/motor delays suggest early-onset muscle hypotonia, consistent with congenital myopathies like Bethlem.  
3. **Myopathic EMG and Muscle Biopsy**: EMG showing myopathic abnormalities and centrally nucleated skeletal muscle fibers indicate a congenital myopathy with regenerative changes, characteristic of collagen VI disorders.  
4. **Skin Involvement**: Skin rash (historically linked to hyperkeratosis pilaris) correlates with collagen VI defects affecting skin integrity.  
5. **Joint and Tendon Features**: Arthralgia and toe walking (Achilles contractures) reflect collagen VI’s role in connective tissue, leading to contractures.  
6. **Collagen VI Pathology**: Abnormal cranial nerve physiology and possible cardiac involvement (abnormal EKG) may stem from collagen VI’s extracellular matrix role, though typically less severe in Bethlem vs. Ullrich CMD.  
7. **Exclusion of Neuropathy**: Areflexia and abnormal nerve conduction velocity are atypical but may coexist due to secondary effects; primary myopathic features dominate.  
8. **Hematuria**: Unrelated to Bethlem but may indicate a separate renal issue, requiring further evaluation.  

The constellation of muscle, skin, and joint findings strongly supports a collagen VI-related disorder, specifically Bethlem myopathy 1 (COL6A1/A2/A3 mutations)."
"['Acne', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia**: Uncommon in classic PKU but may occur in atypical variants or secondary metabolic disruptions (e.g., tyrosine supplementation or overlapping enzyme deficiencies).  
3. **Neonatal death/Death in infancy/Death in adolescence**: Untreated PKU causes severe neurological damage, seizures, and organ failure, leading to early mortality in unscreened or unmanaged cases.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies, though this symptom is atypical for infantile PKU.  
5. **Acne**: May arise from tyrosine metabolism imbalances or secondary skin effects of chronic metabolic stress.  
6. **Diagnostic alignment**: While hypertyrosinemia and prenatal abnormalities are atypical, hyperphenylalaninemia and the mortality pattern strongly suggest PKU with severe complications from delayed diagnosis/treatment."
"['Kernicterus', 'Obesity', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Neonatal death', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation. While PKU classically presents with intellectual disability, seizures, and musty odor, severe untreated cases can result in **neonatal death** or **death in adolescence** due to profound neurological damage. **Obesity** may arise from a high-carbohydrate, low-protein diet used to manage PKU. However, **hypertyrosinemia** and **elevated urinary carboxylic acids** are atypical for PKU and suggest a coexisting metabolic disorder (e.g., tyrosinemia or organic acidemia). **Kernicterus** (bilirubin encephalopathy) and **recurrent infections** are not directly linked to PKU and may indicate additional hepatic or immune dysfunction. Further testing (e.g., BH4 responsiveness, tyrosine metabolites, urinary organic acids) is critical to address these inconsistencies."
"['Mandibular prognathia', 'Triangular face', 'Broad forehead', 'Protruding ear', 'Deeply set eye', 'Posterior embryotoxon', 'Jaundice', 'Dry skin', 'Xanthelasma', 'Global developmental delay', 'Cholestasis', 'Pulmonary hypoplasia', 'Hepatomegaly', 'Butterfly vertebrae', 'Acholic stools', 'Widened subarachnoid space', 'Heart murmur', 'Sparse eyebrow']",['Alagille syndrome/Alagille syndrome 1'],"Disease: Alagille syndrome/Alagille syndrome 1  
Reasoning:  
1. **Hepatobiliary Features**: Cholestasis, jaundice, acholic stools, and hepatomegaly are hallmark signs of Alagille syndrome (ALGS), caused by bile duct paucity leading to chronic liver dysfunction.  
2. **Cardiac Involvement**: Heart murmur aligns with ALGS-associated cardiovascular anomalies (e.g., peripheral pulmonary stenosis).  
3. **Facial Dysmorphism**: Triangular face, broad forehead, protruding ears, deeply set eyes, and sparse eyebrows are classic craniofacial features of ALGS.  
4. **Ocular Findings**: Posterior embryotoxon (a defining anterior segment eye anomaly) and xanthelasma (secondary to hyperlipidemia from cholestasis) support the diagnosis.  
5. **Skeletal Abnormalities**: Butterfly vertebrae (vertebral arch defects) are pathognomonic for ALGS.  
6. **Developmental Delay**: Global developmental delay and widened subarachnoid space may reflect multisystemic involvement or nutritional deficits from chronic cholestasis.  
7. **Cutaneous Features**: Dry skin and xanthelasma correlate with lipid metabolism disruption due to cholestasis.  
8. **Pulmonary Hypoplasia**: Rarely reported in ALGS but may occur secondary to severe thoracic skeletal anomalies.  

The combination of liver, cardiac, facial, ocular, and skeletal findings strongly confirms Alagille syndrome."
"['Hyperactivity', 'Lethargy', 'Coma', 'Encephalopathy', 'Abnormal cerebellum morphology', 'Dystonia', 'Tachycardia', 'Acute kidney injury', 'Fever', 'Leukocytosis', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Abnormality of extrapyramidal motor function', 'Hyperkalemia', 'Drowsiness', 'Sleep disturbance', 'Elevated hepatic transaminase', 'Hypernatremia', 'Death in childhood', 'Fatigue', 'Chronic kidney disease', 'Dyskinesia']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Hyperammonemia** and **encephalopathy**: Hallmark features of urea cycle disorders (UCDs). Citrullinemia type I (argininosuccinate synthetase deficiency) disrupts the urea cycle, leading to ammonia accumulation, neurotoxicity, and cerebral edema.  
2. **Neurological symptoms** (lethargy, coma, dystonia, dyskinesia, extrapyramidal abnormalities): Result from ammonia-induced neuronal damage, particularly in the basal ganglia and cerebellum, explaining **abnormal cerebral/cerebellar morphology**.  
3. **Acute/chronic kidney injury** and **hyperkalemia**: Metabolic acidosis and dehydration during hyperammonemic crises impair renal function. Chronic hyperammonemia may also cause tubular injury.  
4. **Elevated hepatic transaminases**: Secondary to metabolic stress or liver involvement in ammonia detoxification.  
5. **Hypernatremia**: Often due to dehydration during acute crises or inappropriate fluid management.  
6. **Death in childhood**: Untreated neonatal-onset citrullinemia type I is fatal within days to weeks without urgent ammonia-lowering therapy (e.g., dialysis).  
7. **Supporting features**: Leukocytosis and fever (inflammatory response to metabolic crisis), sleep disturbances, and fatigue (neurological dysfunction).  

Disease: Citrullinemia  
Reasoning:  
- This is the Chinese term for Citrullinemia type I. The reasoning aligns identically with the above, as it refers to the same disorder. The symptoms collectively match the classic presentation of this autosomal recessive urea cycle defect."
"['Inguinal hernia', 'Cryptorchidism', 'Tall stature', 'Abnormality of the genitourinary system', 'Entropion', 'Cutis laxa', 'Seizure', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Death in infancy', 'Abnormal heart morphology', 'Congestive heart failure', 'Abnormal cardiac septum morphology', 'Abnormal facial shape', 'Kyphoscoliosis', 'Aortic aneurysm', 'Abnormal subcutaneous fat tissue distribution']","['Cutis laxa, autosomal recessive, type IID']","Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning:  
1. **Cutis laxa** is a hallmark feature, involving loose, sagging skin, directly aligning with the diagnosis.  
2. **Abnormal cardiac septum morphology**, **aortic aneurysm**, and **congestive heart failure** indicate severe cardiovascular involvement, characteristic of type IID due to connective tissue defects.  
3. **Hip dysplasia**, **kyphoscoliosis**, and **flexion contractures** reflect skeletal abnormalities linked to systemic connective tissue dysfunction.  
4. **Abnormality of the genitourinary system** (e.g., cryptorchidism, inguinal hernia) and **abnormal facial shape** (entropion) are common in autosomal recessive cutis laxa subtypes.  
5. **Generalized hypotonia** and **seizures** suggest potential neurological compromise, reported in severe cases of type IID.  
6. **Disproportionate tall stature** and **abnormal subcutaneous fat distribution** further support a systemic connective tissue disorder.  
7. **Death in infancy** correlates with the severe prognosis of this subtype, driven by cardiovascular complications.  
The combination of cutaneous, cardiovascular, skeletal, and genitourinary anomalies with autosomal recessive inheritance confirms the diagnosis."
"['Hepatic steatosis', 'Fever', 'Leukocytosis', 'Gastroesophageal reflux', 'Hepatomegaly', 'Neoplasm of the liver', 'Elevated hepatic transaminase', 'Back pain', 'Exercise intolerance', 'Shortened PR interval', 'Generalized morning stiffness', 'Abnormal prostate morphology', 'Elevated circulating C-reactive protein concentration', 'Sacroiliac arthritis', 'Fatigue', 'Crackles', 'Elbow pain', 'Knee pain', 'Elevated gamma-glutamyltransferase level', 'Chest tightness', 'Decreased DLCO', 'Serositis', 'Chest pain', 'Skin erosion']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The presence of **sacroiliac arthritis**, **generalized morning stiffness**, **back pain**, and **elevated C-reactive protein** strongly suggests inflammatory spondyloarthropathy. Sacroiliitis is a hallmark of axial spondyloarthritis (e.g., ankylosing spondylitis). HLA-B27-associated susceptibility (common in spondyloarthropathies) aligns with genetic predisposition (susceptibility 1). Musculoskeletal symptoms (elbow/knee pain) and systemic inflammation (fever, leukocytosis) further support this diagnosis.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: **Serositis** (pleural/pericardial inflammation) and **decreased DLCO** (diffusing capacity of the lungs) indicate extra-articular manifestations, seen in broader autoimmune-driven spondyloarthropathy subtypes. **Skin erosions** and **abnormal prostate morphology** may reflect reactive arthritis or psoriatic spondyloarthropathy overlap, linked to alternative genetic loci (susceptibility 2). Hepatic involvement (steatosis, elevated transaminases) could stem from metabolic syndrome or drug-induced inflammation, common comorbidities in chronic inflammatory arthropathies."
"['Hyperactivity', 'Acne', 'Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Core diagnostic marker of PKU due to deficient phenylalanine hydroxylase (PAH), blocking phenylalanine conversion to tyrosine.  
2. **Intellectual disability and hyperactivity**: Untreated PKU causes toxic phenylalanine accumulation, impairing neurotransmitter synthesis and brain development.  
3. **Severe short stature and obesity**: Chronic metabolic disruption may alter growth hormone signaling and energy metabolism; obesity can arise from carbohydrate-heavy dietary management.  
4. **Death in childhood/adolescence/early adulthood**: Historically, untreated PKU leads to severe neurological decline, infections, or organ failure. Modern dietary interventions prevent this outcome.  
5. **Hypertyrosinemia discrepancy**: PKU typically causes *low* tyrosine (due to blocked PAH). Hypertyrosinemia suggests a comorbid or misdiagnosed condition (e.g., tyrosinemia type II) or lab error.  
6. **Acne**: Uncommon in PKU but may stem from hormonal imbalances or dietary factors (e.g., synthetic protein supplements).  

Note: Hypertyrosinemia and acne are atypical for PKU and warrant further investigation for overlapping disorders (e.g., BH4 deficiency or tyrosinemia)."
"['Spasticity', 'Dysarthria', 'Gait ataxia']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spasticity**: A hallmark of hereditary spastic paraplegias (HSPs), caused by progressive degeneration of corticospinal tracts. SPG76 specifically involves mutations in the *CAPN1* gene, leading to lower limb spasticity.  
2. **Dysarthria**: Indicates brainstem or cerebellar involvement, atypical in ""pure"" HSPs but seen in ""complex"" HSP subtypes like SPG76, where neurodegeneration extends beyond the spinal cord.  
3. **Gait ataxia**: Suggests cerebellar dysfunction, aligning with SPG76's reported phenotype of combined pyramidal (spasticity) and cerebellar (ataxia) features.  
4. **Exclusion of mimics**: Spinocerebellar ataxias (SCAs) were considered, but the triad of spasticity, ataxia, and dysarthria with autosomal recessive inheritance strongly favors SPG76. Genetic testing for *CAPN1* variants would confirm the diagnosis."
"['Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Death in early adulthood', 'Pustule']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid accumulation**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in the metabolism of valine, leucine, and isoleucine—the branched-chain amino acids (BCAAs). This triad is pathognomonic for MSUD, caused by a deficiency in the branched-chain α-keto acid dehydrogenase (BCKDH) complex.  
2. **Early mortality**: Death in infancy, childhood, adolescence, or early adulthood aligns with severe MSUD phenotypes (e.g., classic or intermediate forms). Untreated, toxic BCAA accumulation leads to metabolic decompensation, cerebral edema, and multisystem failure.  
3. **Gastrointestinal inflammation**: Metabolic crises in MSUD cause vomiting, feeding difficulties, and mucosal injury, explaining gastrointestinal symptoms.  
4. **Recurrent infections and pustules**: Chronic metabolic stress and ketoacidosis impair immune function, increasing susceptibility to infections. Skin pustules may arise from secondary bacterial infections or inflammatory responses to metabolic byproducts.  
5. **Neonatal death**: Severe MSUD manifests within days of birth if undiagnosed, as BCAA levels rise rapidly post-feeding, causing acute neurological decline.  

This constellation of symptoms and biochemical findings is specific to MSUD, with no other disorder combining these features."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death/Death in infancy** aligns with untreated severe PKU, where elevated phenylalanine levels cause irreversible neurological damage, seizures, and metabolic crises if undiagnosed and unmanaged (e.g., absent newborn screening).  
3. **Abnormality of prenatal development or birth** may reflect complications in maternal PKU (uncontrolled phenylalanine levels during pregnancy), but here it likely indicates postnatal developmental failure due to early metabolic dysfunction in the infant.  
4. PKU is typically asymptomatic at birth but manifests progressively after feeding; rapid deterioration without dietary intervention (low-phenylalanine diet) explains the fatal outcomes listed.  

*Note:* Confirmation requires genetic testing (PAH gene mutations) and newborn screening results (elevated phenylalanine with normal tyrosine). Early treatment prevents severe outcomes."
"['Slow saccadic eye movements', 'Dysarthria', 'Hypertonia', 'Spastic tetraparesis', 'Bilateral talipes equinovarus', 'Limb ataxia', 'Unsteady gait']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core spastic paraplegia features**: Spastic tetraparesis (spasticity in all four limbs) and hypertonia align with hereditary spastic paraplegia (HSP).  
2. **Cerebellar involvement**: Limb ataxia, dysarthria, and unsteady gait suggest cerebellar dysfunction, consistent with *complex HSP*.  
3. **Ocular abnormality**: Slow saccadic eye movements indicate brainstem/cerebellar pathology, reported in SPG76 due to CAPN1 mutations affecting neuronal signaling.  
4. **Congenital musculoskeletal anomaly**: Bilateral talipes equinovarus (clubfoot) may reflect early-onset neuromuscular dysfunction or developmental anomalies linked to SPG76.  
5. **Genetic confirmation**: Autosomal recessive inheritance matches SPG76’s etiology (CAPN1 mutations), which combines spasticity, ataxia, and variable neuro-ophthalmic signs.  
6. **Exclusion of mimics**: Symptoms differentiate SPG76 from pure HSP subtypes (no cerebellar signs) or spinocerebellar ataxias (less prominent spasticity)."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Fasciculations', 'Oroticaciduria', 'Low plasma citrulline', 'Neonatal death', 'Hypoargininemia']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** and **cerebral edema** are hallmarks of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia detoxification.  
2. **Low plasma citrulline** and **hypoargininemia** indicate a block early in the urea cycle, as citrulline and arginine are downstream metabolites not synthesized when CPS1 is deficient.  
3. **Neonatal death** and **death in infancy** align with the severe, early-onset presentation of CPS1 deficiency, as untreated hyperammonemia rapidly leads to neurological damage and mortality.  
4. **Seizures** and **fasciculations** result from ammonia-induced neurotoxicity and cerebral edema.  
5. **Cyanosis** may arise from metabolic acidosis or respiratory failure secondary to hyperammonemic crisis.  
6. **Oroticaciduria**, though classically linked to ornithine transcarbamylase (OTC) deficiency, can rarely occur in CPS1 deficiency due to compensatory metabolic stress or secondary pyrimidine pathway activation.  
7. The absence of elevated citrulline and arginine distinguishes CPS1 deficiency from later urea cycle defects (e.g., OTC or citrullinemia), solidifying the diagnosis."
"['Apathy', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Drowsiness', 'Sleep disturbance', 'Glycosuria', 'Death in childhood', 'Impairment of fructose metabolism']","['Fructose-1,6-bisphosphatase deficiency/Fructose-1,6-bisphosphatase deficiency']","Disease: Fructose-1,6-bisphosphatase deficiency  
Reasoning:  
1. **Hypoglycemia** and **metabolic acidosis** are hallmark features of fructose-1,6-bisphosphatase deficiency due to impaired gluconeogenesis, leading to glucose production failure during fasting and compensatory fat breakdown (causing ketosis and acidosis).  
2. **Impairment of fructose metabolism** arises because fructose ingestion exacerbates metabolic stress by depleting intracellular phosphate, worsening hypoglycemia and acidosis.  
3. **Glycosuria** may occur during metabolic crises, potentially from transient renal dysfunction or altered glucose homeostasis despite systemic hypoglycemia.  
4. **Lethargy**, **drowsiness**, **apathy**, and **sleep disturbances** reflect neurological impacts of hypoglycemia and acidosis.  
5. **Death in infancy/childhood** aligns with untreated metabolic decompensation during fasting or illness, which is life-threatening without prompt glucose supplementation and fructose/sucrose avoidance.  
6. Exclusion of hereditary fructose intolerance (HFI) is critical, as HFI primarily causes liver/kidney damage post-fructose ingestion but lacks fasting-induced hypoglycemia."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Intellectual disability** aligns with untreated PKU, as elevated phenylalanine levels are neurotoxic, impairing brain development.  
3. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, though this is not a direct symptom of the patient’s own PKU.  
4. **Early mortality** (infancy, childhood, adolescence) is atypical in modern managed PKU but reflects historical untreated cases, where toxic metabolite accumulation caused severe neurological decline, seizures, and organ failure.  
5. The absence of dietary management (low-phenylalanine diet) explains progression to lethal outcomes, emphasizing the critical role of newborn screening and early intervention in PKU.  

Note: The listed symptoms collectively describe a severe, untreated PKU presentation, historically common before widespread neonatal screening and dietary therapy."
"['Seizure', 'Death in infancy', 'Splenomegaly', 'Respiratory insufficiency']",['Cystinuria/Cystinuria'],"Cystinuria: Cystinuria is a genetic disorder characterized by impaired transport of cystine and other amino acids in the kidneys, leading to recurrent kidney stone formation. However, the listed symptoms—seizures, death in infancy, splenomegaly, and respiratory insufficiency—do not align with cystinuria. Cystinuria primarily manifests with urinary tract symptoms (e.g., nephrolithiasis, hematuria) and is not associated with neurological deficits, splenomegaly, or life-threatening respiratory failure in infancy. The diagnosis provided is inconsistent with the clinical presentation.  

**Likely Alternative Diagnosis (not cystinuria):**  
The symptoms suggest a severe metabolic or lysosomal storage disorder, such as:  
- **Niemann-Pick disease type A (ASMD):** Presents with hepatosplenomegaly, progressive neurodegeneration, seizures, and respiratory failure in infancy.  
- **Gaucher disease type 2:** Features splenomegaly, neurological deterioration, and respiratory complications, though seizures are less common.  
- **Mitochondrial respiratory chain disorders:** May cause multisystem involvement, including seizures, respiratory insufficiency, and organomegaly due to energy deficiency.  

**Conclusion:** The provided diagnosis of cystinuria is incorrect for this clinical scenario. Further evaluation (e.g., enzyme assays, genetic testing, imaging) is critical to identify the underlying condition."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative phenylalanine metabolism via transamination, a pathognomonic feature of PKU.  
3. **Neonatal death/Death in infancy/childhood** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurotoxicity, seizures, and organ failure without dietary intervention.  
4. **Hypertyrosinemia** may seem atypical (PAH deficiency typically reduces tyrosine), but secondary tyrosine elevation can occur due to metabolic stress or overlapping enzyme disruptions in severe cases.  
5. **Abnormality of prenatal development** could reflect maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy), causing fetal complications like microcephaly, though this is distinct from the infant’s own PKU diagnosis.  

Key confirmation: Hyperphenylalaninemia + phenylketonuria (via urinary carboxylic acids) are diagnostic for PKU. Early mortality underscores untreated disease severity."
"['Seizure', 'Cerebral cortical atrophy', 'Death in adolescence', 'Methylmalonic aciduria', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark biochemical finding of methylmalonic acidemia (MMA). MMA is an autosomal recessive disorder of branched-chain amino acid metabolism, caused by defects in methylmalonyl-CoA mutase or its cofactor adenosylcobalamin (vitamin B12). The presence of **seizures** and **cerebral cortical atrophy** aligns with chronic neurotoxicity from accumulated methylmalonic acid and metabolic instability, leading to progressive neurological damage. **Death in adolescence/early adulthood** reflects the severe natural history of untreated or unresponsive MMA, often due to metabolic crises, renal failure, or neurological complications.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the diagnostic term ""B12-unresponsive"") points specifically to mutations in the *MUT* gene encoding methylmalonyl-CoA mutase. This subtype accounts for ~60% of MMA cases and is associated with severe phenotypes. Cerebral cortical atrophy and seizures indicate irreversible neurological injury from chronic metabolite accumulation. Early mortality (adolescence/early adulthood) is typical in mutase-deficient MMA due to treatment-refractory metabolic decompensation, multiorgan dysfunction, and limited therapeutic options beyond supportive care."
"['Ventricular septal defect', 'Patent ductus arteriosus', 'Transposition of the great arteries', 'Complete atrioventricular canal defect', 'Asplenia', 'Single ventricle', 'Arrhinencephaly', 'Abdominal situs inversus', 'Pulmonary artery atresia', 'Pulmonary artery hypoplasia', 'Abnormal ciliary motility', 'Posteriorly placed anus']","['Heterotaxy, visceral, 1, X-linked']","Disease: Heterotaxy, visceral, 1, X-linked  
Reasoning:  
1. **Abdominal situs inversus**: Indicates abnormal visceral arrangement, a hallmark of heterotaxy syndromes.  
2. **Asplenia**: Common in heterotaxy (particularly right isomerism), associated with immune dysfunction and abnormal organ symmetry.  
3. **Complex congenital heart defects**:  
   - *Ventricular septal defect (VSD)*, *Patent ductus arteriosus (PDA)*, *Transposition of the great arteries (TGA)*, *Complete atrioventricular canal defect*, *Single ventricle*, *Pulmonary artery atresia/hypoplasia*: These defects reflect severe laterality disturbances during cardiac development, typical of heterotaxy.  
4. **Abnormal ciliary motility**: Implicates ciliary dysfunction, which disrupts left-right patterning in early embryogenesis (linked to ZIC3 mutations in X-linked heterotaxy).  
5. **Posteriorly placed anus**: Suggests midline developmental anomalies, consistent with heterotaxy-associated gastrointestinal malformations.  
6. **Arrhinencephaly**: Rarely reported in heterotaxy but may reflect broader dysregulation of embryonic midline signaling pathways.  

The combination of situs anomalies, complex cardiac defects, asplenia, and ciliary dysfunction aligns with *Heterotaxy, visceral, 1, X-linked* (OMIM #306955), caused by pathogenic variants in the ZIC3 gene critical for left-right axis determination."
"['Acute kidney injury', 'Methylmalonic acidemia', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Abnormal circulating creatinine concentration', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical findings**: Methylmalonic acidemia/aciduria confirms impaired methylmalonyl-CoA mutase function, a hallmark of MMA.  
2. **B12-unresponsiveness**: The diagnosis specifies a B12-unresponsive subtype, which aligns with a mutase (MUT gene) deficiency, as B12 supplementation cannot bypass the defective enzyme.  
3. **Renal complications**: Chronic kidney disease, acute kidney injury, and abnormal creatinine reflect long-term metabolic acidosis and hypermethylmalonic acid toxicity, common in severe, treatment-resistant MMA.  
4. **Carnitine deficiency**: Decreased plasma free carnitine occurs due to excessive urinary excretion of methylmalonyl-carnitine, a compensatory mechanism to eliminate toxic metabolites.  
5. **Early mortality**: Death in adolescence/early adulthood is typical in mutase-deficient MMA due to metabolic crises, renal failure, or secondary organ damage.  
6. **Porphyrin abnormalities**: Likely secondary to renal dysfunction or mitochondrial toxicity disrupting heme biosynthesis pathways.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Symptomatic confirmation**: The presence of methylmalonic acidemia and aciduria directly establishes the broad diagnosis of MMA.  
2. **Overlap with subtype**: This general diagnosis encompasses all forms of MMA, including the specific mutase-deficient subtype, which is further refined by the second diagnosis.  
3. **Metabolic derangements**: All listed symptoms (kidney injury, carnitine deficiency) are consistent with the systemic effects of MMA, regardless of subtype.  
4. **Terminology clarification**: ""Methylmalonic aciduria"" is synonymous with MMA, emphasizing urinary excretion of methylmalonic acid as a diagnostic feature.  

The two diagnoses are hierarchically linked: the second (mutase deficiency) specifies the etiology and subtype of the first (general MMA)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia**: Common in organic acidemias due to secondary inhibition of the urea cycle.  
2. **Abnormal carnitine**: IVA causes carnitine depletion via conjugation with isovaleric acid (isovalerylcarnitine excretion).  
3. **Abnormal glycine**: Excess isovaleric acid is detoxified via glycine conjugation (elevated isovalerylglycine in urine).  
4. **Neonatal/Infancy death**: Untreated IVA leads to metabolic crises, encephalopathy, and early mortality.  
5. **Prenatal abnormalities**: Severe metabolic stress may indirectly affect fetal development, though IVA typically manifests postnatally.  
6. **Exclusion of mimics**: Differentiated from other organic acidemias (e.g., propionic/methylmalonic acidemia) by specific biomarkers (isovalerylglycine, C5 acylcarnitine)."
"['Seizure', 'Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Alopecia', 'Fasciculations', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency  
Reasoning:  
1. **Seizures & Hypotonia**: Biotinidase deficiency disrupts biotin recycling, impairing carboxylase enzymes critical for energy metabolism and neurotransmitter synthesis, leading to neurological dysfunction.  
2. **Elevated Urinary Carboxylic Acids**: Biotin-dependent carboxylases (e.g., propionyl-CoA carboxylase) malfunction, causing organic acid accumulation (e.g., 3-hydroxyisovaleric acid), detectable in urine.  
3. **Alopecia**: Biotin is essential for keratin synthesis; deficiency results in hair loss.  
4. **Growth Delay & Death in Infancy**: Metabolic crises from untreated acidosis, hyperammonemia, and catabolism impair growth and are fatal without biotin supplementation.  
5. **Fasciculations**: Secondary to neuronal hyperexcitability from metabolic disturbances.  
6. **Diagnostic Confirmation**: The term ""late-onset multiple carboxylase deficiency"" refers to partial biotinidase deficiency, but severe infantile forms present acutely with this symptom cluster. Early biotin treatment reverses symptoms, underscoring urgency in diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to secondary carnitine depletion as carnitine conjugates with unmetabolized acyl-CoA intermediates (e.g., octanoylcarnitine), reducing free carnitine levels.  
2. **Neonatal death/Death in infancy**: MCADD typically manifests during fasting or metabolic stress (e.g., infections), causing hypoketotic hypoglycemia, encephalopathy, and hepatic dysfunction. Untreated, this rapidly progresses to coma or fatal metabolic crisis, especially in infancy.  
3. **Abnormality of prenatal development or birth**: While MCADD does not cause structural congenital anomalies, biochemical abnormalities (e.g., elevated C8-C10 acylcarnitines) may be detectable prenatally or at birth via newborn screening. Severe undiagnosed cases may present as sudden infant death syndrome (SIDS), aligning with ""abnormality of birth.""  
4. **Supporting evidence**: MCADD is included in newborn screening panels globally due to its preventable morbidity/mortality. The symptom constellation aligns with impaired energy metabolism during catabolic states, hallmark of fatty acid oxidation disorders."
"['Visual impairment', 'Rod-cone dystrophy', 'Optic atrophy', 'Delayed speech and language development', 'Intellectual disability', 'Truncal obesity', 'Retinal pigment epithelial mottling', 'Attenuation of retinal blood vessels', 'Polydactyly', 'Retinal thinning']",['Bardet-Biedl syndrome 4'],"Disease: Bardet-Biedl syndrome 4  
Reasoning:  
1. **Retinal abnormalities**: Rod-cone dystrophy, retinal pigment epithelial mottling, attenuation of retinal blood vessels, and retinal thinning are hallmark features of Bardet-Biedl syndrome (BBS), reflecting progressive retinal degeneration.  
2. **Visual impairment/Optic atrophy**: Secondary to advanced retinal dystrophy, consistent with BBS-associated ocular manifestations.  
3. **Polydactyly**: A primary diagnostic criterion for BBS, present in ~70% of cases.  
4. **Truncal obesity**: A core feature of BBS, typically emerging in early childhood.  
5. **Developmental delay/Intellectual disability**: Common neurocognitive features of BBS, particularly in speech and language domains.  
6. **Genetic subtype specificity**: BBS4 (linked to *BBS4* gene mutations) is distinguished by these classic features without atypical organ involvement, aligning with the patient’s phenotype.  
7. **Exclusion of mimics**: Laurence-Moon syndrome lacks polydactyly, while Alström syndrome lacks polydactyly and intellectual disability, further supporting BBS4."
"['Retrognathia', 'Hypomimic face', 'Low-set ears', 'Dysarthria', 'Gait disturbance', 'Hyperreflexia', 'Rigidity', 'Spastic gait', 'Bradykinesia', 'Short stature', 'Upgaze palsy', 'Dyskinesia']",['Kufor-Rakeb syndrome/Kufor-Rakeb syndrome'],"Disease: Kufor-Rakeb syndrome  
Reasoning:  
1. **Parkinsonian features** (rigidity, bradykinesia, hypomimic face, dyskinesia): Aligns with juvenile-onset Parkinsonism characteristic of Kufor-Rakeb syndrome, caused by ATP13A2 mutations.  
2. **Pyramidal signs** (hyperreflexia, spastic gait, gait disturbance): Reflects upper motor neuron involvement, consistent with spasticity seen in this syndrome.  
3. **Upgaze palsy**: A hallmark of supranuclear gaze abnormalities, a key diagnostic feature of Kufor-Rakeb syndrome.  
4. **Dysmorphic features** (retrognathia, low-set ears, short stature): May indicate a systemic genetic disorder; while not exclusive to Kufor-Rakeb, they support a syndromic diagnosis.  
5. **Dysarthria**: Common in neurodegenerative disorders with both pyramidal and extrapyramidal involvement.  
6. **Exclusion of mimics**: The combination of Parkinsonism, spasticity, and supranuclear gaze palsy distinguishes it from isolated juvenile Parkinson’s disease or other lysosomal storage disorders (e.g., Niemann-Pick type C lacks pyramidal signs here).  

Final diagnosis is strongly supported by the triad of early-onset Parkinsonism, spasticity, and vertical gaze palsy."
"['Nephrotic syndrome', 'Tremor', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **L-2-hydroxyglutaric aciduria** is explicitly listed as a biochemical finding, confirming excessive excretion of L-2-hydroxyglutaric acid in urine, a hallmark of this disorder.  
2. **Tremor** aligns with the neurological manifestations of L-2-HGA, which include ataxia, dystonia, and seizures due to cerebral organic acid accumulation.  
3. **Death in childhood** reflects the severe, progressive nature of the disease, often linked to neurodegeneration, metabolic crises, or complications like respiratory failure.  
4. **Nephrotic syndrome**, though atypical for classic L-2-HGA, may arise secondary to metabolic toxicity or mitochondrial dysfunction affecting renal podocytes, or indicate an overlapping/atypical variant of the disorder.  
The diagnosis prioritizes the biochemical marker (aciduria) and core neurological features, with nephrotic syndrome interpreted as a rare or comorbid complication in this case."
"['Recurrent urinary tract infections', 'Nephritis', 'Hematuria', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
Reasoning:  
1. **Cystinuria, argininuria, hyperlysinuria, and ornithinuria** indicate a defect in renal tubular reabsorption of dibasic amino acids (cystine, ornithine, lysine, arginine), a hallmark of cystinuria.  
2. **Recurrent urinary tract infections (UTIs), nephritis, and hematuria** arise from cystine stone formation in the urinary tract, causing obstruction, inflammation, and secondary infections.  
3. **Death in infancy** suggests a severe phenotype, potentially due to early-onset renal failure or complications from recurrent UTIs and nephritis in untreated cases.  
4. The combined aminoacidurias align with cystinuria’s pathophysiology (defect in SLC3A1/SLC7A9 genes), differentiating it from isolated amino acid transport disorders."
"['Increased circulating ferritin concentration', 'Abnormal circulating copper concentration', 'Increased circulating lactate dehydrogenase concentration', 'Hyperintensity of cerebral white matter on MRI', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']","['Hemophagocytic lymphohistiocytosis, familial, 2']","Disease: Hemophagocytic lymphohistiocytosis, familial, 2 (FHL2)  
Reasoning:  
1. **Increased ferritin**: A hallmark of HLH due to cytokine storm and macrophage activation.  
2. **Abnormal copper**: Secondary to liver dysfunction (common in HLH) or altered ceruloplasmin synthesis during inflammation.  
3. **Elevated LDH**: Reflects widespread tissue damage and cytolysis, typical in HLH.  
4. **Cerebral white matter hyperintensity**: Indicates CNS involvement, a known feature of advanced HLH.  
5. **Elevated AST/ALT**: Hepatic injury from immune-mediated inflammation or hemophagocytosis in the liver.  
6. **FHL2 specificity**: PRF1 mutations impair perforin function, leading to defective cytotoxic cell activity, triggering uncontrolled immune activation. The triad of cytopenia, fever, and organomegaly (implied by liver/CNS involvement) further supports HLH. Genetic testing for PRF1 would confirm FHL2."
"['Abnormal retinal morphology', 'Myopia', 'Oculomotor apraxia', 'Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Dilated fourth ventricle', 'Cerebellar dysplasia', 'Inferior cerebellar vermis hypoplasia']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar Abnormalities**: The presence of *dilated fourth ventricle*, *cerebellar dysplasia*, and *inferior cerebellar vermis hypoplasia* aligns with the hallmark cerebellar structural defects in Poretti-Boltshauser syndrome, often including cerebellar cysts or dysplasia.  
2. **Oculomotor Apraxia**: Directly matches the defining feature of the syndrome, explaining difficulties in initiating voluntary eye movements.  
3. **Neurodevelopmental Delays**: *Motor delay*, *delayed speech and language development*, and *generalized hypotonia* correlate with the intellectual disability and ataxia characteristic of the disorder.  
4. **Ocular Findings**: *Abnormal retinal morphology* and *myopia* are consistent with reported ocular anomalies linked to LAMA1 mutations, the genetic cause of the syndrome.  
5. **Exclusion of Alternatives**: The combination of cerebellar vermis hypoplasia, oculomotor apraxia, and retinal changes distinguishes it from similar disorders (e.g., Joubert syndrome, which typically shows a ""molar tooth sign"" absent here)."
"['Macrocephaly', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Athetosis', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
**Reasoning**:  
1. **Key biochemical markers**:  
   - **Glutaric aciduria** and **elevated circulating glutaric acid** directly indicate a defect in glutaryl-CoA dehydrogenase, the enzyme deficient in GA-I.  
   - **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from binding excess glutaric acid.  

2. **Neurological manifestations**:  
   - **Dystonia**, **dyskinesia**, and **athetosis** result from striatal injury and basal ganglia degeneration, classic in GA-I.  
   - **Generalized hypotonia** and **lethargy** are early signs of metabolic encephalopathy.  

3. **Acute metabolic crises**:  
   - **Vomiting**, **diarrhea**, **fever**, and **drowsiness** often precede or accompany acute crises triggered by catabolic stress (e.g., infections).  
   - **Dyspnea** may reflect metabolic acidosis or neurological respiratory control disruption.  

4. **Macrocephaly**:  
   - A hallmark of GA-I, caused by frontotemporal atrophy or delayed myelination, often evident before symptom onset.  

5. **Poor prognosis**:  
   - **Death in infancy/childhood** and **neonatal death** align with untreated GA-I, as crises cause irreversible neurological damage or cerebral edema.  

6. **Sleep disturbance**:  
   - Linked to basal ganglia dysfunction or neurochemical imbalances from accumulated metabolites.  

**Conclusion**: The triad of macrocephaly, movement disorders, and biochemical evidence (glutaric acid elevation, low carnitine) confirms GA-I. Acute crises exacerbate symptoms, leading to fatal outcomes without early intervention."
"['Delayed speech and language development', 'Hypothyroidism', 'Dysarthria', 'Spastic diplegia', 'Encephalopathy', 'Hyperreflexia', 'Spastic tetraplegia', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Death in adolescence', 'Death in early adulthood']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Ethylmalonic aciduria** and **cytochrome C oxidase-negative muscle fibers** are hallmark biochemical and histopathological findings in mitochondrial complex IV (cytochrome c oxidase) deficiency, directly implicating impaired oxidative phosphorylation.  
2. **Encephalopathy**, **hyperreflexia**, **spastic tetraplegia/diplegia**, and **dysarthria** reflect severe neurological dysfunction due to energy failure in neurons and corticospinal tract damage.  
3. **Delayed speech/language development** aligns with global neurodevelopmental delays caused by chronic cerebral energy deficits.  
4. **Hypothyroidism** and **recurrent viral infections** suggest multisystem involvement, as mitochondrial dysfunction affects thyroid metabolism and immune cell energetics.  
5. **Abnormal circulating glycine concentration** may arise from disrupted mitochondrial metabolism of amino acids.  
6. **Death in adolescence/early adulthood** is consistent with progressive neurodegeneration and multisystem failure in severe mitochondrial disorders.  
7. Nuclear type 1 (OMIM 220110) specifically involves mutations in *SURF1*, a gene critical for complex IV assembly, explaining the COX-negative fibers and systemic phenotype."
"['Hip dysplasia', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants or secondary metabolic disruptions (e.g., transient tyrosine elevation due to hepatic immaturity in premature infants).  
3. **Elevated urinary carboxylic acids** could reflect phenylalanine metabolites (e.g., phenylpyruvate) excreted in urine, misclassified as carboxylic acids.  
4. **Severe short stature** and **neonatal death** might indicate untreated or late-diagnosed PKU, leading to metabolic crises and growth failure.  
5. **Premature birth** and **hip dysplasia** are not directly linked to PKU but may coexist as unrelated complications or reflect syndromic forms (e.g., maternal PKU effects on fetal development).  
6. **Death in infancy/adolescence** aligns with severe metabolic derangements if phenylalanine-restricted diets are absent, causing neurodegeneration and multi-organ failure.  

*Note: Hypertyrosinemia and skeletal abnormalities (e.g., hip dysplasia) are atypical for PKU and suggest further investigation for coexisting disorders (e.g., tyrosinemia, skeletal dysplasias) or diagnostic inconsistencies.*"
"['Psychosis', 'Osteoporosis', 'Intellectual disability', 'Anemia', 'Hyperammonemia', 'Cerebral atrophy', 'Hyperglycinemia', 'Kyphoscoliosis', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Elevated urinary carboxylic acid', 'Death in early adulthood', 'Body odor']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic abnormalities**: Hyperammonemia, hyperglycinemia, hyperalaninemia, and elevated urinary carboxylic acids align with PA, a disorder of propionyl-CoA carboxylase deficiency. This causes accumulation of propionic acid derivatives (e.g., methylcitrate, 3-hydroxypropionate), disrupting amino acid metabolism and urea cycle function.  
2. **Neurological involvement**: Psychosis, intellectual disability, and cerebral atrophy result from neurotoxic effects of ammonia and organic acids, compounded by energy deficits in the brain.  
3. **Hematological/renal signs**: Anemia arises from bone marrow suppression by toxic metabolites. Elevated blood urea nitrogen (BUN) and creatinine reflect renal stress due to chronic metabolic acidosis.  
4. **Skeletal/growth issues**: Severe short stature, osteoporosis, and kyphoscoliosis stem from chronic protein catabolism, malnutrition, and metabolic bone disease.  
5. **Odor/abnormal metabolites**: Body odor (sweaty feet) and abnormal carnitine/porphyrin levels reflect disrupted fatty acid oxidation and heme synthesis secondary to propionyl-CoA accumulation.  
6. **Early mortality**: Death in adolescence/early adulthood is typical in severe PA due to metabolic crises, cardiac complications, or neurodegeneration.  
7. **Hyperglycinemia**: Propionyl-CoA inhibits glycine cleavage enzyme, leading to secondary glycine elevation.  
8. **Hearing impairment**: Sensorineural deafness may occur due to mitochondrial dysfunction in cochlear cells.  

PA explains all symptoms via defective propionate metabolism, mitochondrial toxicity, and multi-organ sequelae."
"['Apathy', 'Cyanosis', 'Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Hypoglycemia', 'Hyperammonemia', 'Dicarboxylic aciduria', 'Neonatal death']",['Carnitine-acylcarnitine translocase deficiency/Carnitine-acylcarnitine translocase deficiency'],"Carnitine-acylcarnitine translocase deficiency:  
1. **Hypoglycemia** and **dicarboxylic aciduria** indicate impaired fatty acid oxidation, as the body cannot utilize long-chain fatty acids for energy, leading to glucose depletion and alternative metabolism of fatty acids.  
2. **Hyperammonemia** arises due to secondary urea cycle dysfunction caused by accumulation of toxic acyl-CoA intermediates.  
3. **Bradycardia** and **cyanosis** result from cardiac energy deficiency and possible arrhythmias due to defective mitochondrial fatty acid transport.  
4. **Generalized hypotonia** and **apathy** reflect systemic energy failure, particularly in muscles and the central nervous system.  
5. **Neonatal death** or **death in infancy** aligns with the severe, rapid progression of metabolic crises in untreated CACT deficiency, often triggered by fasting or metabolic stress.  
6. The triad of **hypoglycemia, hyperammonemia, and dicarboxylic aciduria** is pathognomonic for fatty acid oxidation disorders, with CACT deficiency distinguished by neonatal onset and carnitine cycle involvement."
"['Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Hyperthreoninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hypervalinemia', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Decreased serum creatinine', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark of MMA, alongside metabolic crises (hyperammonemia, vomiting, feeding difficulties). Elevated branched-chain amino acid derivatives (hypervalinemia, abnormal isoleucine) align with impaired propionate metabolism due to defective methylmalonyl-CoA mutase or vitamin B12 metabolism. Neonatal/childhood death and hypotonia reflect severe enzymatic dysfunction, while hypoproteinemia and abnormal carnitine levels suggest secondary metabolic stress.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: **Recurrent viral infections** and **death in infancy** indicate a severe, B12-unresponsive subtype. Mutase deficiency prevents methylmalonyl-CoA conversion to succinyl-CoA, causing toxic metabolite accumulation (hyperammonemia, methylmalonic aciduria). **Decreased serum creatinine** and **increased blood urea nitrogen** point to renal dysfunction from metabolic acidosis. Neurological symptoms (intellectual disability, motor delay) and neonatal mortality are consistent with irreversible cellular damage from chronic toxicity."
"['Macrocephaly', 'Hypertelorism', 'Broad forehead', 'Low-set ears', 'Short neck', 'Broad neck', 'Downslanted palpebral fissures', 'Cafe-au-lait spot', 'Freckling', 'Bilateral ptosis', 'Growth delay', 'Cardiomyopathy', 'Low posterior hairline', 'Attention deficit hyperactivity disorder', 'Feeding difficulties']",['Noonan syndrome 6'],"Disease: Noonan syndrome 6  
Reasoning:  
1. **Facial features**: Hypertelorism, broad forehead, downslanted palpebral fissures, low-set ears, and bilateral ptosis align with classic Noonan syndrome craniofacial characteristics.  
2. **Neck anomalies**: Short/broad neck and low posterior hairline are consistent with Noonan-associated neck and lymphatic abnormalities.  
3. **Cardiac involvement**: Cardiomyopathy, though less common than pulmonary stenosis, is reported in Noonan syndrome, particularly linked to specific genetic subtypes like NS6 (LZTR1 mutations).  
4. **Growth/developmental delays**: Growth delay and feeding difficulties are hallmark features of Noonan syndrome. ADHD is a recognized neurodevelopmental component.  
5. **Cutaneous features**: Café-au-lait spots and freckling suggest overlap with RASopathy-associated skin manifestations. NS6 is tied to LZTR1 mutations, which may explain NF1-like pigmentation due to shared RAS/MAPK pathway dysregulation.  
6. **Genetic specificity**: NS6 (OMIM #613224) is distinguished by LZTR1 mutations, which can present with variable pigmentation anomalies alongside typical Noonan traits, ruling out other RASopathies like NF1 or LEOPARD syndrome."
"['Hypospadias', 'Microcephaly', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', '4-hydroxyphenylacetic aciduria', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1 (HT-1)  
Reasoning:  
1. **Metabolic abnormalities**: Hypertyrosinemia, 4-Hydroxyphenylpyruvic aciduria, and 4-hydroxyphenylacetic aciduria directly indicate a defect in tyrosine metabolism. These metabolites accumulate due to fumarylacetoacetate hydrolase (FAH) deficiency, a hallmark of HT-1.  
2. **Liver dysfunction**: Elevated alpha-fetoprotein (AFP) reflects hepatic damage, consistent with HT-1’s hepatotoxic effects, leading to neonatal liver failure and risk of early death (neonatal/infancy/childhood).  
3. **Neurological and developmental features**: Motor delay, hypotonia, and microcephaly may arise from toxic metabolite-induced neurotoxicity or prenatal metabolic disruption.  
4. **Prenatal/structural anomalies**: Hypospadias and prenatal developmental abnormalities could stem from intrauterine metabolic stress, though these are less typical and may suggest severe early-onset disease.  
5. **Mortality**: Early death aligns with untreated HT-1 progression, involving liver failure, renal disease, or neurological crises.  
6. **Hyperphenylalaninemia**: Likely secondary due to downstream tyrosine pathway disruption, though phenylalanine levels are less prominently elevated in HT-1 compared to phenylketonuria.  

Key confirmatory factors: Tyrosine metabolite elevation + AFP + clinical progression."
"['Cleft palate', 'Prominent occiput', 'Chorioretinal coloboma', 'Failure to thrive in infancy', 'Dehydration', 'Vomiting', 'Diarrhea', 'Hyponatremia', 'Decreased body weight', 'Preauricular pit', 'Hypovolemia', 'Nasogastric tube feeding in infancy', 'Cleft lip']","['Diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies']","Disease: Diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies  
Reasoning:  
1. **Core gastrointestinal features**: The patient exhibits chronic secretory diarrhea, vomiting, dehydration, hyponatremia, and hypovolemia, which are hallmark features of congenital sodium diarrhea (CSD). These symptoms stem from defective intestinal sodium-hydrogen exchange (e.g., SLC9A3 mutations), leading to impaired sodium absorption and osmotic diarrhea.  
2. **Failure to thrive and nutritional dependence**: Nasogastric tube feeding in infancy and decreased body weight align with severe malabsorption and electrolyte losses typical of CSD.  
3. **Congenital anomalies**: Cleft lip/palate, preauricular pit, and chorioretinal coloboma are structural defects associated with syndromic forms of CSD. These anomalies suggest a genetic etiology (e.g., SPINT2 mutations in some cases) affecting both enterocyte function and embryonic development.  
4. **Prominent occiput**: This may indicate craniofacial dysmorphism linked to an underlying genetic syndrome intersecting with CSD.  
5. **Exclusion of mimics**: The triad of congenital diarrhea, hyponatremia, and extraintestinal anomalies distinguishes CSD from other osmotic diarrheas or chloride-wasting disorders (e.g., CFTR-related disease). Genetic testing for SLC9A3 or SPINT2 would confirm the diagnosis."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Cerebellar atrophy/agenesis and ataxia**: PMM2-CDG is characterized by neurodevelopmental defects, including cerebellar hypoplasia/atrophy, leading to ataxia.  
2. **Neurological symptoms**: Intellectual disability, generalized hypotonia, and abnormal calvaria morphology align with multisystem neurological involvement in PMM2-CDG.  
3. **Dysmorphic features**: Abnormal facial shape and strabismus are common due to craniofacial and connective tissue glycosylation defects.  
4. **Severe infantile course**: Death in infancy correlates with severe PMM2-CDG subtypes, often from organ failure or infections.  
5. **Systemic involvement**: Glycosylation defects disrupt multiple organs, explaining the combination of CNS, skeletal, and dysmorphic features."
"['Motor delay', 'Obesity', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Motor delay** aligns with untreated PKU, as elevated phenylalanine disrupts myelination and neurotransmitter synthesis, leading to neurodevelopmental deficits.  
3. **Elevated urinary carboxylic acids** may reflect secondary metabolic disturbances from phenylalanine accumulation or dietary management (e.g., high protein substitutes).  
4. **Obesity** could arise from high-carbohydrate/low-protein diets used to manage PKU, promoting caloric imbalance.  
5. **Premature birth** and early mortality (**infancy/childhood/adolescence death**) suggest severe, untreated PKU with metabolic crises or complications like cerebral edema.  
6. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants or due to concurrent metabolic stress affecting tyrosine metabolism.  
7. **Recurrent viral infections** are not directly linked to PKU but may stem from compromised health in severe cases or nutritional deficiencies.  

**Note**: Hypertyrosinemia and elevated urinary carboxylic acids are unusual for classic PKU, suggesting possible comorbid conditions (e.g., tyrosinemia, organic acidemias) or atypical PKU variants. However, hyperphenylalaninemia remains the primary diagnostic anchor."
"['Seizure', 'Death in infancy', 'Alopecia', 'Death in childhood', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids**: Biotinidase deficiency impairs biotin recycling, reducing activity of biotin-dependent carboxylases (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). This disrupts fatty acid synthesis, gluconeogenesis, and amino acid catabolism, leading to urinary excretion of abnormal organic acids.  
2. **Seizures**: Biotin is critical for neuronal metabolism. Deficiency causes accumulation of neurotoxic metabolites (e.g., lactate, ammonia) and impaired energy production in the brain, triggering seizures.  
3. **Alopecia**: Biotin deficiency disrupts keratinocyte function and hair follicle integrity, resulting in hair loss.  
4. **Death in infancy/childhood**: Untreated BTDD causes progressive metabolic acidosis, hyperammonemia, and irreversible neurological damage (e.g., respiratory failure, coma). Neonatal-onset forms are often fatal within months without biotin supplementation.  

The term ""late-onset multiple carboxylase deficiency"" refers specifically to BTDD, distinguishing it from holocarboxylase synthetase deficiency (early-onset). Prompt biotin therapy reverses symptoms, emphasizing the urgency of early diagnosis."
"['Cerebellar atrophy', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy and agenesis**: PMM2-CDG is associated with structural cerebellar abnormalities, including hypoplasia (often misinterpreted as agenesis on imaging) and progressive atrophy due to impaired glycosylation, critical for cerebellar development and maintenance.  
2. **Death in childhood**: Severe PMM2-CDG cases involve multi-organ failure (hepatic, cardiac), recurrent infections, and coagulopathies, leading to early mortality.  
3. **Neurological hallmark**: The cerebellum is highly sensitive to glycosylation defects, explaining both developmental (agenesis-like hypoplasia) and degenerative (atrophy) features.  
4. **Exclusion of mimics**: Pontocerebellar hypoplasia or spinocerebellar ataxias lack the systemic manifestations (e.g., endocrine dysfunction, inverted nipples) typical of PMM2-CDG.  
5. **Diagnostic confirmation**: Elevated serum transferrin isoforms (via isoelectric focusing) and *PMM2* gene sequencing would validate the diagnosis."
"['Femoral bowing', 'Hypoplasia of the radius', 'Short tibia', 'Short humerus']","['Osteogenesis imperfecta, type VIII']","Disease: Osteogenesis imperfecta, type VIII  
Reasoning:  
1. **Femoral bowing**: A hallmark of severe osteogenesis imperfecta (OI) due to defective collagen leading to bone fragility and deformities. Type VIII OI is characterized by severe skeletal underdevelopment.  
2. **Hypoplasia of the radius**: Seen in recessive OI types (including type VIII) due to impaired bone growth and mineralization, resulting in underdeveloped or absent bones.  
3. **Short tibia and humerus**: Reflects rhizomelic (proximal) and mesomelic (middle-limb) shortening, consistent with type VIII OI’s severe growth deficiency and skeletal dysplasia.  
4. **Genetic correlation**: OI type VIII is linked to mutations in *P3H1* (LEPRE1), disrupting collagen prolyl hydroxylation, leading to extreme bone fragility and growth retardation. This matches the patient’s constellation of skeletal anomalies.  
5. **Exclusion of other OI types**: Type II/III OI typically involves fractures and blue sclera (not mentioned here), while type VIII presents with profound skeletal hypoplasia without these features."
"['Macrocephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Hepatomegaly', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Elevated plasma citrulline', 'Uraciluria']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Hyperammonemia** and **elevated plasma citrulline** are hallmark biochemical features of argininosuccinic aciduria (ASA), a urea cycle disorder caused by argininosuccinate lyase deficiency.  
2. **Aminoaciduria** (including **uraciluria**) and **abnormal circulating arginine/proline concentrations** reflect disrupted urea cycle metabolism and secondary effects on amino acid transport.  
3. **Neurological symptoms** (ataxia, opisthotonus, intellectual disability, motor/speech delays) result from chronic hyperammonemia and toxic metabolite accumulation.  
4. **Hepatomegaly** and **neonatal/childhood death** align with acute metabolic crises and multi-organ failure in severe ASA.  
5. **Prenatal abnormalities** and **macrocephaly** may stem from intrauterine ammonia toxicity or metabolic dysregulation.  
6. **Elevated citrulline** specifically differentiates ASA from other urea cycle defects (e.g., ornithine transcarbamylase deficiency), while **arginine/proline abnormalities** correlate with ASA’s unique biochemical profile."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in **tetrahydrobiopterin (BH4) deficiency**, a PKU variant. BH4 is a cofactor for PAH *and* tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, leading to dual accumulation.  
3. **Death in early adulthood** aligns with severe, untreated PKU or BH4 deficiency, where neurological damage, metabolic crises, or secondary complications (e.g., cardiac, hepatic) lead to premature mortality.  
4. The combined symptoms suggest **malignant PKU (BH4 deficiency)**, classified under PKU spectrum disorders due to shared hyperphenylalaninemia and clinical overlap.  

Disease: BH4 Deficiency (as a subtype of PKU)  
Reasoning:  
1. Directly links elevated phenylalanine *and* tyrosine via dual enzyme disruption (PAH and tyrosine hydroxylase).  
2. Explains rapid progression and early mortality due to neurotransmitter synthesis defects and systemic metabolic failure.  
3. Often grouped with PKU in diagnostic frameworks despite distinct molecular pathology.  

**Final Diagnosis**: PKU (with BH4 deficiency as the underlying subtype)."
"['Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Recurrent viral infections', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid and glutaric aciduria**: Direct biochemical markers of glutaryl-CoA dehydrogenase deficiency, which disrupts lysine and tryptophan metabolism.  
2. **Generalized hypotonia and feeding difficulties**: Common early signs of metabolic decompensation due to toxic metabolite accumulation.  
3. **Athetosis**: Reflects basal ganglia injury (e.g., striatal necrosis) from acute encephalopathic crises triggered by metabolic stressors like infections or fasting.  
4. **Death in infancy**: Untreated GA-I leads to irreversible neurological damage or fatal metabolic crises.  
5. **Recurrent viral infections**: Likely act as triggers for metabolic decompensation rather than indicating primary immune dysfunction.  
6. **Consistency with GA-I phenotype**: Macrocephaly, movement disorders, and episodic crises align with classic GA-I presentation, though immune dysfunction is not a core feature."
"['Hearing impairment', 'Intellectual disability', 'Seizure', 'Global developmental delay', 'Bicoronal synostosis']",['Muenke syndrome/Muenke syndrome'],"Disease: Muenke syndrome  
Reasoning:  
1. **Bicoronal synostosis**: A hallmark feature of Muenke syndrome, caused by the FGFR3 p.Pro250Arg mutation, which leads to premature fusion of both coronal sutures.  
2. **Hearing impairment**: Common in Muenke syndrome, often conductive or sensorineural hearing loss.  
3. **Intellectual disability/Global developmental delay**: Present in a subset of patients, though severity varies.  
4. **Seizure**: Rare but reported in some cases, possibly due to structural brain anomalies or secondary complications.  
5. **Exclusion of other craniosynostosis syndromes**: Features like severe midface hypoplasia (Pfeiffer/Crouzon) or limb anomalies (Apert) are absent, supporting Muenke syndrome. Genetic testing for FGFR3 mutation would confirm the diagnosis."
"['Delayed gross motor development', 'Gray matter heterotopia', 'Cerebellar dysplasia', 'Aplasia/Hypoplasia of the optic nerve']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Delayed gross motor development**: Common in Poretti-Boltshauser syndrome due to cerebellar dysfunction, which disrupts coordination and motor skill acquisition.  
2. **Gray matter heterotopia**: Reflects neuronal migration defects, a hallmark of neurodevelopmental disorders; while not pathognomonic, it aligns with the spectrum of brain malformations in this syndrome.  
3. **Cerebellar dysplasia**: A core feature of Poretti-Boltshauser syndrome, characterized by structural cerebellar abnormalities (e.g., cysts, dysplasia) contributing to ataxia and motor delays.  
4. **Aplasia/Hypoplasia of the optic nerve**: Observed in this syndrome due to congenital optic nerve defects, differentiating it from other cerebellar ataxias (e.g., Joubert syndrome, which typically involves retinal dystrophy instead).  
The combination of cerebellar dysplasia, optic nerve hypoplasia, and neurodevelopmental delays strongly supports this diagnosis, especially when genetic testing confirms pathogenic variants in *LAMA1* or *COL4A1*, genes implicated in the syndrome."
"['Hepatic steatosis', 'Periportal fibrosis', 'Hypercholesterolemia', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis & periportal fibrosis**: TMEM199-CDG is characterized by chronic liver disease, including steatosis and fibrosis, due to impaired glycosylation affecting hepatic function.  
2. **Hypercholesterolemia**: Glycosylation defects disrupt lipid metabolism pathways, leading to elevated cholesterol.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, common in TMEM199-CDG.  
4. **Elevated creatine kinase**: Suggests mild myopathy, occasionally observed in this disorder.  
5. **Low ceruloplasmin & copper**: TMEM199-CDG causes hypocupremia and hypoceruloplasminemia secondary to disrupted copper transport (likely via defective glycosylation of COMMD1, a copper metabolism regulator).  
6. **Exclusion of Wilson disease**: While low ceruloplasmin/copper mimic Wilson disease, the absence of neuropsychiatric symptoms and presence of hypercholesterolemia/liver fibrosis favor TMEM199-CDG. Genetic testing for TMEM199 variants confirms the diagnosis."
"['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Multiple carboxylase involvement**: Symptoms like decreased pyruvate carboxylase activity and propionyl-CoA carboxylase deficiency indicate a global defect in biotin-dependent carboxylases, which require holocarboxylase synthetase (HLCS) for activation.  
2. **Metabolic derangements**:  
   - **Hyperammonemia** and **metabolic acidosis** arise due to impaired urea cycle function (via propionyl-CoA accumulation) and excessive organic acids (e.g., lactic acid, 3-hydroxypropionic acid).  
   - **Elevated urinary carboxylic acids** and **aminoaciduria** reflect disrupted amino acid catabolism and mitochondrial dysfunction.  
3. **Biotin dependency**: HLCS deficiency prevents biotin incorporation into carboxylases, explaining the multi-enzyme dysfunction.  
4. **Neonatal severity**: Symptoms like **feeding difficulties**, **tachypnea** (compensatory respiratory alkalosis), and **neonatal death** align with the rapid metabolic decompensation seen in untreated HLCS deficiency.  
5. **Glycine abnormalities**: Propionyl-CoA accumulation inhibits glycine cleavage, leading to **abnormal circulating glycine**.  
6. **Exclusion of isolated deficiencies**: Concurrent pyruvate and propionyl-CoA carboxylase deficiencies rule out isolated defects (e.g., propionic acidemia), pointing to a shared biotinylation defect."
"['Keratitis', 'Conjunctivitis', 'Photophobia', 'Hyperkeratosis', 'Intellectual disability', 'Seizure', 'Hypertyrosinemia', 'Death in childhood', 'Epiphora']",['Tyrosinemia type 2/Tyrosine transaminase deficiency'],"Disease: Tyrosinemia type 2/Tyrosine transaminase deficiency  
Reasoning:  
1. **Hypertyrosinemia** is a hallmark biochemical feature of tyrosinemia type 2, caused by deficient tyrosine transaminase activity.  
2. **Ocular symptoms** (keratitis, conjunctivitis, photophobia, epiphora) arise from tyrosine crystal deposition in corneal epithelial cells, leading to inflammation and damage.  
3. **Hyperkeratosis** (palmar/plantar) occurs due to tyrosine accumulation in the skin, causing painful lesions.  
4. **Neurological involvement** (intellectual disability, seizures) may result from chronic tyrosine neurotoxicity or secondary metabolic disturbances.  
5. **Death in childhood** reflects severe untreated cases with complications like metabolic decompensation, infections, or neurological deterioration.  
6. **Consistency with phenotype**: The triad of dermatological, ocular, and neurological manifestations aligns with Richner-Hanhart syndrome (tyrosinemia type 2), distinguishing it from hepatic/renal-predominant tyrosinemia type 1."
"['Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Visual impairment', 'Seizure', 'Cerebellar vermis hypoplasia', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Highly arched eyebrow', 'Peripheral axonal neuropathy', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Dysmorphism**: ""Narrow forehead,"" ""Prominent nasal bridge,"" ""Anteverted nares,"" ""Exaggerated cupid's bow,"" and ""Highly arched eyebrow"" align with the characteristic facies of TBCK syndrome, which includes midface hypoplasia and distinct lip morphology.  
2. **Neurological Abnormalities**: ""Cerebellar vermis hypoplasia,"" ""Hypoplasia of the corpus callosum,"" and ""Small basal ganglia"" are consistent with brain malformations reported in TBCK-related disorders. ""Ventriculomegaly"" further supports structural CNS involvement.  
3. **Developmental and Motor Deficits**: ""Profound global developmental delay"" and ""Peripheral axonal neuropathy"" correlate with the syndrome’s hallmark hypotonia, psychomotor retardation, and progressive neurological decline.  
4. **Seizures/EEG Abnormalities**: ""Seizure"" and ""EEG abnormality"" match the epileptic phenotypes observed in TBCK patients, often linked to cortical dysfunction.  
5. **Systemic Involvement**: ""Feeding difficulties"" and ""Respiratory insufficiency"" reflect the multisystem impact of TBCK mutations, including bulbar weakness and respiratory muscle compromise.  
6. **Ocular and Genetic Consistency**: ""Visual impairment"" may stem from cortical or optic nerve abnormalities, while the genetic basis (biallelic TBCK loss) explains the syndromic clustering of these features.  
**Conclusion**: The constellation of craniofacial, neurological, and systemic findings strongly supports a diagnosis of TBCK-related intellectual disability syndrome."
"['Delayed speech and language development', 'Ataxia', 'Dysarthria', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Hyperreflexia', 'Growth delay', 'Death in infancy', 'Abnormal foot morphology', 'Diarrhea', 'Abnormal basal ganglia morphology', 'Increased serum lactate', 'Spastic tetraplegia', 'Ethylmalonic aciduria', 'Increased serum pyruvate', 'Cytochrome C oxidase-negative muscle fibers', 'Death in childhood', 'Death in adolescence']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Neurological and motor deficits**: Symptoms like spastic tetraplegia/diplegia, hyperreflexia, ataxia, dysarthria, and motor delays suggest upper motor neuron involvement and cerebellar dysfunction, consistent with mitochondrial encephalopathies.  
2. **Metabolic abnormalities**: Increased serum lactate and pyruvate, ethylmalonic aciduria, and cytochrome C oxidase (COX)-negative muscle fibers directly indicate a defect in mitochondrial energy metabolism, specifically complex IV (COX) deficiency.  
3. **Systemic manifestations**: Growth delay, diarrhea, and generalized hypotonia reflect multi-organ energy failure. Abnormal basal ganglia morphology aligns with mitochondrial dysfunction in brain regions sensitive to oxidative phosphorylation defects.  
4. **Fatal early course**: Death in infancy/childhood/adolescence is typical in severe mitochondrial disorders due to progressive metabolic crises and neurological decline.  
5. **Nuclear genetic origin**: The ""nuclear type 1"" designation implicates pathogenic variants in nuclear genes (e.g., *SURF1*) critical for COX assembly, distinguishing it from mitochondrial DNA-related complex IV defects.  

The combination of COX-negative fibers, ethylmalonic aciduria, and spasticity with early lethality is pathognomonic for this disorder."
"['Seizure', 'Coma', 'Hepatic steatosis', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Gastrointestinal hemorrhage', 'Hypokalemia', 'Elevated hepatic transaminase', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency (HMG-CoA lyase deficiency)  
Reasoning:  
1. **Hypoglycemia + Hyperammonemia + Hepatic steatosis**: Core triad of HMG-CoA lyase deficiency, caused by impaired ketogenesis and leucine catabolism, leading to energy deficits and toxic metabolite accumulation.  
2. **Dicarboxylic aciduria + 3-Methylglutaric aciduria**: Direct biochemical hallmarks due to defective breakdown of HMG-CoA into acetoacetate, resulting in elevated 3-hydroxy-3-methylglutaric, 3-methylglutaric, and dicarboxylic acids in urine.  
3. **Abnormal amino acids (glycine, aspartate family, alanine)**: Secondary to metabolic decompensation, disrupting amino acid homeostasis and urea cycle function.  
4. **Seizures + Coma + Death in infancy**: Result from severe hypoglycemia, hyperammonemia, and metabolic acidosis during metabolic crises, typical in untreated HMG-CoA lyase deficiency.  
5. **Elevated hepatic transaminases + GI hemorrhage**: Hepatic dysfunction from steatosis and metabolic stress, compounded by coagulopathy from hyperammonemia.  
6. **Hypokalemia**: Likely due to renal losses from acidosis or vomiting.  
7. **Abnormal porphyrins**: Possible secondary disruption of heme synthesis pathways during metabolic instability.  

The constellation of fatty acid oxidation defects, organic aciduria, and neonatal lethality confirms HMG-CoA lyase deficiency."
"['Hearing impairment', 'Epistaxis', 'Gait disturbance', 'Fever', 'Myalgia', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Lower limb pain', 'Ear pain', 'Cytoplasmic antineutrophil antibody positivity']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Cytoplasmic ANCA positivity**: Strongly associated with GPA (specifically c-ANCA/PR3), a hallmark for diagnosis.  
2. **Upper respiratory involvement**: Hearing impairment, ear pain, and epistaxis suggest granulomatous inflammation of the ears and nasal passages, common in GPA.  
3. **Systemic inflammation**: Fever, elevated CRP, fatigue, and myalgia align with systemic vasculitis.  
4. **Musculoskeletal/neurologic symptoms**: Gait disturbance and lower limb pain may reflect peripheral neuropathy, joint involvement, or vascular damage.  
5. **Exclusion of mimics**: Symptoms differentiate GPA from other ANCA-associated vasculitides (e.g., microscopic polyangiitis lacks prominent upper respiratory features; eosinophilic GPA typically includes asthma/eosinophilia).  
6. **Diagnostic consistency**: The triad of vasculitis, granulomatosis, and c-ANCA positivity supports GPA despite absent renal/pulmonary signs in this case."
"['Death in infancy', 'Cardiac arrest', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** directly indicates abnormal accumulation of glutaric acid, a hallmark of GA-I caused by **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Death in infancy** aligns with GA-I’s severe early-onset presentation, where metabolic crises (triggered by catabolic stress) lead to acute encephalopathy, striatal necrosis, and irreversible neurological damage, often fatal without prompt intervention.  
3. **Cardiac arrest** is atypical in GA-I but may occur secondary to severe metabolic acidosis or electrolyte imbalances during crises, disrupting cardiac function.  
4. The triad of symptoms suggests undiagnosed/untreated GA-I, where delayed management allows toxic metabolite buildup (glutaric acid, 3-hydroxyglutaric acid), causing multisystem failure.  
5. Differential exclusion: Cardiac arrest more commonly links to fatty oxidation disorders (e.g., GA-II), but glutaric aciduria and striatal pathology prioritize GA-I."
"['Abnormal saccadic eye movements', 'Abnormality of visual evoked potentials', 'Seizure', 'Spasticity', 'Death in infancy', 'Hypoglycemia', 'Fever', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine', 'Paraplegia/paraparesis', 'Elevated circulating acylcarnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Key biochemical markers**: Elevated glutaric acid (urine/blood) and glutarylcarnitine (acylcarnitine profile) directly result from glutaryl-CoA dehydrogenase deficiency, impairing lysine and tryptophan metabolism.  
2. **Carnitine abnormalities**: Decreased free carnitine and elevated acylcarnitine occur as carnitine conjugates with toxic metabolites (e.g., glutaric acid), leading to secondary deficiency.  
3. **Neurological manifestations**:  
   - **Abnormal cerebral morphology** (macrocephaly, frontotemporal atrophy) and **spasticity/paraparesis** stem from striatal degeneration and white matter damage.  
   - **Seizures** and **abnormal saccadic eye movements** reflect basal ganglia and cortical dysfunction.  
   - **Abnormal visual evoked potentials** suggest optic pathway involvement.  
4. **Metabolic crises**: Triggered by fever/infections, causing **hypoglycemia**, **hyperammonemia**, and encephalopathy due to energy depletion and metabolite accumulation.  
5. **Early lethality**: Untreated crises result in irreversible neurological damage or **death in infancy**.  
6. **Confirmatory findings**: **Glutaric aciduria** and genetic confirmation of GCDH mutations solidify the diagnosis.  

GA-I is distinguished from other organic acidemias by its specific metabolite profile (glutaric acid/glutarylcarnitine) and characteristic neuroimaging findings (striatal injury, frontotemporal atrophy)."
"['Seizure', 'Lethargy', 'Generalized hypotonia', 'Growth delay', 'Drowsiness', 'Sleep disturbance', 'Death in childhood', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine** is the hallmark symptom of Alkaptonuria, caused by the accumulation and oxidation of homogentisic acid (HGA) in urine. This symptom is often noticed in infancy or early childhood.  
2. **Growth delay** and **generalized hypotonia** may occur due to metabolic disruptions from chronic HGA accumulation, though these are less common and not well-documented in typical Alkaptonuria cases.  
3. **Seizures, lethargy, drowsiness, and sleep disturbances** are atypical for Alkaptonuria but could suggest secondary complications (e.g., metabolic acidosis or electrolyte imbalances) or comorbidities.  
4. **Death in childhood** is not characteristic of Alkaptonuria, which typically allows for a normal lifespan with progressive joint/connective tissue issues (e.g., ochronosis, arthritis) manifesting later in life. This may indicate a severe, atypical presentation or misattribution of symptoms.  
5. Despite inconsistencies, **dark urine** remains the critical diagnostic clue, prompting confirmatory testing (e.g., urinary HGA quantification, genetic analysis for *HGD* mutations)."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, along with **metabolic acidosis** caused by toxic accumulation of methylmalonic acid. **Seizures** and **generalized hypotonia** align with neurological complications of MMA. **Neonatal death** and **death in infancy** reflect the severe, early-onset nature of the disease due to metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The lack of response to vitamin B12 (implied by the absence of hematologic abnormalities and rapid progression) points to a **mutase deficiency subtype**. This subtype is caused by mutations in the *MUT* gene, leading to dysfunctional methylmalonyl-CoA mutase. The severity of symptoms (e.g., **neonatal death**) and metabolic instability are characteristic of this variant, which typically does not improve with B12 supplementation."
"['Hypospadias', 'Micropenis', 'Conjunctivitis', 'Large for gestational age', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Hyperkalemia', 'Hyponatremia', 'Hypercalcemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Feeding difficulties', 'Occipital neuralgia', 'Increased serum testosterone level', 'Elevated circulating 17-hydroxyprogesterone concentration']","['Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency/Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency']","Disease: Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency  
**Reasoning**:  
1. **Steroidogenesis disruption**: The enzyme 3β-HSD2 is critical for converting Δ5 steroids (pregnenolone, 17-hydroxypregnenolone, DHEA) to Δ4 steroids (progesterone, 17-hydroxyprogesterone, androstenedione). Deficiency causes accumulation of Δ5 steroids (e.g., elevated 17-hydroxyprogesterone via alternative pathways) and reduced cortisol, aldosterone, and active sex hormones.  
2. **Adrenal insufficiency**: Low cortisol and aldosterone explain **dehydration**, **hyponatremia**, **hyperkalemia**, and **hypercalcemia** (due to volume depletion), leading to **vomiting**, **diarrhea**, **fever**, and life-threatening crises (contributing to **death in infancy/childhood**).  
3. **Ambiguous genitalia in males**: Impaired testosterone synthesis (from DHEA) results in **micropenis** and **hypospadias** due to insufficient androgen exposure in utero. Paradoxically, **elevated testosterone** may occur postnatally from peripheral conversion of accumulated DHEA.  
4. **Salt-wasting crisis**: Electrolyte imbalances and adrenal failure drive neonatal mortality (**neonatal death**) without prompt treatment.  
5. **Feeding difficulties**: Poor oral intake secondary to metabolic stress and adrenal crisis.  
6. **Recurrent infections**: Chronic dehydration and metabolic instability may predispose to infections; however, immune dysfunction is not a primary feature, making **conjunctivitis**/viral infections likely coincidental or stress-triggered.  
7. **Occipital neuralgia**: Unrelated to 3β-HSD2 deficiency; consider incidental or secondary to dehydration/electrolyte shifts.  
8. **Large for gestational age**: Uncommon in 3β-HSD2 deficiency but may reflect transient prenatal hormonal effects or confounding factors.  

**Key biochemical clues**: Elevated 17-hydroxyprogesterone (due to alternative pathway activation) and hyperkalemia/hyponatremia distinguish this from other CAH forms (e.g., 21-hydroxylase deficiency typically shows higher 17-OHP and no hyperkalemia). Confirmatory testing would show elevated Δ5 steroids (17-hydroxypregnenolone, DHEA) and genetic analysis of *HSD3B2*."
"['Lethargy', 'Death in infancy', 'Clumsiness', 'Drowsiness', 'Sleep disturbance', 'Poor coordination', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Feeding difficulties']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient presents with lethargy, drowsiness, feeding difficulties, and decreased plasma free carnitine, consistent with a metabolic disorder. 3-Methylcrotonyl-CoA carboxylase (3-MCC) deficiency disrupts leucine catabolism, leading to toxic metabolite accumulation (e.g., 3-methylcrotonylglycine), which sequesters carnitine, causing secondary deficiency. Symptoms like poor coordination, clumsiness, and sleep disturbances align with metabolic encephalopathy. Severe forms can trigger life-threatening metabolic crises, explaining neonatal/childhood death if untreated.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis encompasses both MCCC1 and MCCC2 gene defects. The patient’s symptoms—lethargy, feeding difficulties, and early mortality—reflect acute metabolic decompensation. Decreased carnitine results from organic acid conjugation and renal loss. Neonatal death suggests a severe phenotype with rapid progression, often due to delayed diagnosis or metabolic stressors (e.g., fasting, infection). The clinical overlap between subtypes makes biochemical/genetic testing critical, but the symptom profile strongly supports 3-MCC deficiency as the underlying etiology."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by mutations in the *PAH* gene, leading to deficient phenylalanine hydroxylase activity and impaired phenylalanine metabolism.  
2. **Abnormality of prenatal development or birth**: While PKU itself does not cause structural birth defects, untreated maternal PKU during pregnancy can result in congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus. The symptom may reflect complications from maternal hyperphenylalaninemia affecting prenatal development.  
3. **Neonatal death/Death in infancy/Death in adolescence**: Severe, untreated PKU causes progressive neurotoxicity due to phenylalanine accumulation. Early death may occur from acute metabolic crises, seizures, or irreversible neurological damage. In classic PKU, death in adolescence is rare with modern screening and dietary management, but historically, untreated cases led to fatal outcomes.  

The constellation of symptoms aligns with severe, undiagnosed/untreated PKU, exacerbated by maternal PKU effects if applicable. Confirmation requires genetic testing and phenylalanine level analysis."
"['Petechiae', 'Thrombocytopenia', 'Leukocytosis', 'Headache', 'Vasculitis', 'Elevated hepatic transaminase', 'Smooth muscle antibody positivity', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Decreased circulating complement C3 concentration', 'Viral hepatitis', 'Peripheral neuropathy', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Lower limb pain', 'Foot pain', 'Antimitochondrial antibody positivity', 'Decreased circulating complement C4 concentration', 'Abnormality of nail color', 'Cryoglobulinemia']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Disease: Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed  
Reasoning:  
1. **Cryoglobulinemia**: Directly listed as a symptom, indicating abnormal immunoglobulin complexes precipitating in cold temperatures.  
2. **Vasculitis**: Present and central to the diagnosis; explains petechiae, peripheral neuropathy, and organ involvement (e.g., liver via elevated transaminases).  
3. **Complement consumption**: Decreased C3/C4 levels suggest immune complex deposition, a hallmark of cryoglobulinemic vasculitis.  
4. **Autoimmune markers**: Smooth muscle antibody (SMA), antinuclear antibody (ANA), and antimitochondrial antibody (AMA) positivity indicate autoimmune dysregulation, though AMA may overlap with viral hepatitis.  
5. **Viral hepatitis**: A common trigger for mixed cryoglobulinemia (often hepatitis C), linking liver injury and cryoglobulin production.  
6. **Inflammation**: Elevated ESR, CRP, leukocytosis, and fatigue align with systemic inflammation from vasculitis.  
7. **Cutaneous/neurologic involvement**: Petechiae, nail discoloration, peripheral neuropathy, and limb pain reflect small-vessel damage.  
8. **Familial component**: ""Familial mixed"" suggests genetic predisposition, though viral cofactors (hepatitis) may drive disease expression.  
9. **Renal/edema**: Pedal edema hints at possible renal involvement (glomerulonephritis) secondary to cryoglobulin deposition.  

The constellation of immune complexes, vasculitis, hepatitis, and complement abnormalities confirms **cryoglobulinemic vasculitis**, with familial mixed type indicating hereditary susceptibility."
"['Hyperammonemia', 'Hyperglycinemia', 'Hyperalaninemia', 'Decreased plasma free carnitine']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia/Propionic acidemia  
Reasoning:  
1. **Hyperammonemia**: Propionic acidemia disrupts the urea cycle due to accumulation of propionyl-CoA and its derivatives, impairing ammonia detoxification.  
2. **Hyperglycinemia**: Propionyl-CoA inhibits glycine cleavage enzyme activity, reducing glycine catabolism and elevating glycine levels.  
3. **Hyperalaninemia**: Secondary mitochondrial dysfunction and metabolic stress increase protein catabolism, releasing alanine as a byproduct.  
4. **Decreased plasma free carnitine**: Excess propionyl-CoA conjugates with carnitine (forming propionylcarnitine), depleting free carnitine reserves.  
5. **Pathogenic mechanism**: Biallelic mutations in *PCCA* or *PCCB* genes cause propionyl-CoA carboxylase deficiency, blocking valine, isoleucine, methionine, and odd-chain fatty acid metabolism. This results in toxic metabolite accumulation and secondary biochemical disturbances."
"['Death in infancy', 'Hyperammonemia', 'Increased total bilirubin', 'Neonatal death', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline directly indicates a urea cycle defect, specifically argininosuccinate synthetase (ASS1) deficiency, which defines citrullinemia. Hyperammonemia arises from impaired ammonia detoxification in the urea cycle. Neonatal death and infant mortality align with the severe, early-onset nature of this disorder. Increased bilirubin suggests secondary liver dysfunction due to metabolic crisis.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: The specificity of ""type I"" refers to the classic ASS1-deficient form (OMIM #215700), distinguishing it from type II (adult-onset citrullinemia II, SLC25A13-related). The neonatal presentation with hyperammonemia, citrulline elevation, and rapid progression to death is pathognomonic for type I. Elevated citrulline confirms the enzyme block at the ASS1 step, excluding other urea cycle defects (e.g., ornithine transcarbamylase deficiency)."
"['Delayed speech and language development', 'Hyporeflexia', 'Generalized hypotonia', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidinuria'],"Disease: Dihydropyrimidinuria  
Reasoning:  
1. **Uraciluria**: The presence of uracil in urine is a hallmark of dihydropyrimidinuria, caused by a deficiency in dihydropyrimidine dehydrogenase (DPD), which impairs pyrimidine catabolism.  
2. **Abnormal circulating pyrimidine concentration**: DPD deficiency leads to elevated levels of uracil and thymine in blood and urine due to blocked degradation.  
3. **Generalized hypotonia and hyporeflexia**: Accumulated pyrimidines may interfere with neuronal function or myelination, causing neuromuscular symptoms.  
4. **Delayed speech and language development**: Neurological dysfunction from metabolic disruption impacts cognitive and motor development.  
5. **Death in childhood**: Severe metabolic crises or complications (e.g., seizures, respiratory failure) in untreated cases lead to early mortality.  
6. **Exclusion of other disorders**: Symptoms align specifically with pyrimidine metabolism defects, ruling out mimics like orotic aciduria (which features orotic aciduria, not uraciluria)."
"['Intellectual disability', 'Coma', 'Motor delay', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Respiratory distress', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['β-ketothiolase deficiency; BKD; Mitochondrial acetoacetyl-CoA thiolase [3-oxothiolase] deficiency/Beta-ketothiolase deficiency/Alpha-Methylacetoacetic aciduria'],"β-ketothiolase deficiency; BKD; Mitochondrial acetoacetyl-CoA thiolase [3-oxothiolase] deficiency/Beta-ketothiolase deficiency/Alpha-Methylacetoacetic aciduria:  
1. **Metabolic acidosis, hypoglycemia, hyperammonemia**: BKD disrupts isoleucine catabolism and ketone metabolism, leading to toxic accumulation of methylacetoacetyl-CoA derivatives. This results in metabolic acidosis, while secondary mitochondrial dysfunction may cause hypoglycemia and mild hyperammonemia.  
2. **Elevated urinary carboxylic acids (e.g., alpha-methylacetoacetate, tiglylglycine, 2-methyl-3-hydroxybutyrate)**: Pathognomonic for BKD due to enzymatic block in isoleucine degradation.  
3. **Neurological symptoms (coma, dystonia, hypotonia, motor delay, intellectual disability)**: Acute metabolic crises cause energy failure and neurotoxicity, leading to coma. Chronic basal ganglia injury from recurrent crises explains dystonia and developmental delays.  
4. **Feeding difficulties, respiratory distress, early mortality**: Episodic decompensation triggered by catabolic stressors (e.g., fasting, infections) leads to vomiting, lethargy, and compensatory respiratory efforts. Untreated crises progress to multiorgan failure and death.  
5. **Abnormal glycine levels**: Secondary glycine elevation may occur due to competition for renal tubular reabsorption by accumulated organic acids."
"['Triangular face', 'Ventricular septal defect', 'Atrial septal defect', 'Patent ductus arteriosus', 'Neutropenia', 'Chiari malformation', 'Short thumb', 'Small pituitary gland', 'Chromosome breakage']","['Fanconi anemia, complementation group I']","Disease: Fanconi anemia, complementation group I  
Reasoning:  
1. **Chromosome breakage**: Hallmark of Fanconi anemia (FA), a DNA repair disorder. FA cells exhibit hypersensitivity to DNA crosslinking agents, leading to chromosomal instability.  
2. **Hematologic abnormalities (neutropenia)**: FA commonly causes bone marrow failure, resulting in cytopenias like neutropenia.  
3. **Congenital heart defects (VSD, ASD, PDA)**: Observed in some FA subtypes, particularly with mutations in genes like *FANCI* (complementation group I).  
4. **Radial ray anomalies (short thumb)**: Classic FA feature due to developmental defects; thumb/hand abnormalities are frequent.  
5. **Endocrine dysfunction (small pituitary gland)**: FA patients often exhibit endocrine deficiencies, including growth hormone insufficiency linked to pituitary anomalies.  
6. **Chiari malformation**: Rarely reported in FA but may reflect broader connective tissue/developmental instability.  
7. **Triangular facial shape**: A recognized craniofacial feature in FA, though nonspecific.  
8. **Genetic confirmation**: Complementation group I is defined by biallelic *FANCI* mutations, aligning with the clinical and cytogenetic profile.  

The combination of congenital anomalies, hematologic defects, and chromosomal fragility strongly supports FA. Subtyping to group I requires genetic testing but is consistent with the observed phenotype."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, leading to **ataxia** and **motor delay** due to impaired cerebellar function.  
2. **Intellectual disability**: Common in PMM2-CDG due to global neurodevelopmental deficits from abnormal glycosylation.  
3. **Strabismus**: Caused by cranial nerve dysfunction or cerebellar-related oculomotor coordination issues.  
4. **Thromboembolism**: Linked to hypoglycosylation of coagulation factors (e.g., antithrombin III deficiency), increasing clotting risk.  
5. **Early mortality (infancy/childhood)**: Severe PMM2-CDG cases involve multi-organ failure, infections, or thromboembolic events.  
6. **Obesity**: Less typical but possible due to endocrine dysregulation or hypothyroidism, which may occur in CDG.  
7. **Supporting evidence**: PMM2-CDG is the most prevalent CDG subtype, characterized by cerebellar abnormalities, neurodevelopmental deficits, and systemic complications. Isoelectric focusing of serum transferrin (abnormal glycosylation pattern) confirms diagnosis."
"['Ventricular fibrillation', 'Prolonged QTc interval', 'Myocarditis', 'Polymorphic ventricular tachycardia']",['Long QT syndrome 14'],"Disease: Long QT syndrome 14  
Reasoning:  
1. **Prolonged QTc interval**: A hallmark of Long QT syndrome (LQTS), indicating delayed ventricular repolarization.  
2. **Polymorphic ventricular tachycardia (e.g., torsades de pointes)**: Characteristic of LQTS, particularly in calmodulin-related subtypes like LQT14 due to severe electrical instability.  
3. **Ventricular fibrillation**: A life-threatening arrhythmia often triggered by untreated polymorphic VT, consistent with high-risk LQTS subtypes.  
4. **Myocarditis**: Overlaps with CALM1/2/3-associated LQTS (types 14-16), as calmodulin mutations may predispose to inflammation or mimic myocarditis via calcium signaling dysregulation.  
5. **Genetic basis**: LQT14 is linked to CALM1 mutations, disrupting calmodulin function critical for cardiac ion channels (e.g., L-type calcium channels), aligning with the arrhythmic and inflammatory phenotypes observed."
"['Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Severe hearing impairment']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hyperalaninemia**: Elevated alanine levels suggest disrupted amino acid metabolism, often secondary to energy crises from impaired fatty acid oxidation (FAO). MCADD disrupts medium-chain fatty acid breakdown, forcing reliance on glycolysis, increasing pyruvate (converted to alanine).  
2. **Abnormal circulating carnitine**: MCADD causes secondary carnitine deficiency due to accumulation of medium-chain acylcarnitines, which are excreted in urine, depleting free carnitine.  
3. **Neonatal/infant/childhood death**: MCADD presents with life-threatening hypoglycemia and metabolic decompensation during fasting (e.g., infections), leading to sudden death if untreated.  
4. **Small for gestational age (SGA)**: Impaired placental fatty acid metabolism in MCADD may restrict fetal energy supply, causing growth restriction.  
5. **Severe hearing impairment**: Rarely reported in MCADD but may occur due to metabolic acidosis or energy deficits affecting cochlear function during crises.  
6. **Exclusion of alternatives**: Symptoms align with FAO disorders (not urea cycle defects or mitochondrial diseases). MCADD is the most common FAO defect with this phenotype.  

Key diagnostic confirmation would require plasma acylcarnitine profiling (elevated C6-C10 species, especially C8) and genetic testing for *ACADM* mutations."
"['Macrocephaly', 'Cystic hygroma', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Key Biochemical Markers**: Elevated glutaric acid in urine (glutaric aciduria) and blood, combined with decreased plasma free carnitine, strongly suggest a defect in lysine, hydroxylysine, and tryptophan metabolism. GA-I is caused by mutations in the *GCDH* gene, leading to glutaryl-CoA dehydrogenase deficiency and subsequent toxic accumulation of glutaric acid.  
2. **Neurological Symptoms**: Macrocephaly (often due to frontotemporal atrophy), dystonia, dyskinesia, generalized hypotonia, and lethargy align with striatal degeneration caused by neurotoxic metabolites (e.g., glutaric acid, 3-hydroxyglutaric acid) during metabolic crises.  
3. **Acute Metabolic Crises**: Fever, vomiting, diarrhea, dyspnea, and metabolic acidosis are triggered by catabolic stressors (e.g., infections), characteristic of GA-I decompensation.  
4. **Poor Prognosis**: Neonatal death or death in childhood is common if untreated, as crises cause irreversible brain damage.  
5. **Supporting Features**: Hyperhidrosis and sleep disturbances may reflect autonomic dysfunction, while drowsiness and lethargy correlate with encephalopathic phases.  
6. **Exclusion of Cystic Hygroma**: While cystic hygroma is listed, it is likely incidental or a prenatal finding unrelated to GA-I, which primarily affects metabolic and neurological systems.  

The constellation of metabolic acidosis, glutaric acid accumulation, neurological deterioration, and carnitine deficiency confirms GA-I as the definitive diagnosis."
"['Microcephaly', 'Strabismus', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating glutamine concentration', 'Feeding difficulties']",['N-acetylglutamate synthase deficiency; NAGSD/Hyperammonemia due to N-acetylglutamate synthase deficiency/N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY'],"Disease: N-acetylglutamate synthase deficiency (NAGSD)  
Reasoning:  
1. **Hyperammonemia**: Central to NAGSD, as the enzyme deficiency disrupts the urea cycle, impairing ammonia detoxification.  
2. **Neurological symptoms (Seizures, Hypotonia, Motor/Speech Delay, Microcephaly)**: Chronic hyperammonemia causes neurotoxicity, leading to developmental delays, seizures, and structural brain abnormalities (e.g., microcephaly).  
3. **Premature birth & Neonatal death**: Severe urea cycle defects often manifest acutely in the neonatal period; untreated hyperammonemia rapidly progresses to metabolic crisis, coma, or death.  
4. **Feeding difficulties & Gastrointestinal inflammation**: Common in neonates with metabolic distress due to ammonia accumulation and systemic toxicity.  
5. **Abnormal glutamine levels**: Elevated glutamine is a biochemical hallmark of urea cycle dysfunction, as excess ammonia is shunted to glutamine synthesis.  
6. **Recurrent infections**: Indirectly linked to metabolic instability and catabolic stress during illnesses, which exacerbate hyperammonemia.  

NAGSD is distinguished by **direct disruption of N-acetylglutamate synthesis** (required for urea cycle initiation), differentiating it from other urea cycle disorders. Early recognition is critical due to rapid clinical deterioration."
"['Hematuria', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Diarrhea', 'Increased serum lactate', 'Increased CSF lactate', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The presence of **methylmalonic aciduria** directly indicates a defect in methylmalonyl-CoA metabolism. Combined with **metabolic acidosis**, **increased serum/CSF lactate**, and **feeding difficulties**, this aligns with MMA's hallmark metabolic decompensation. **Generalized hypotonia** and **death in infancy** reflect severe neurological and systemic involvement, while **diarrhea** and **hematuria** may stem from renal tubular dysfunction and metabolic stress.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The lack of vitamin B12 responsiveness points to a **mutase deficiency** (mut⁰ or mut⁻ subtypes). Elevated lactate in serum and CSF suggests impaired mitochondrial energy production due to dysfunctional methylmalonyl-CoA mutase. **Death in infancy** and severe acidosis are typical in B12-unresponsive forms, as residual enzyme activity is minimal. Genetic confirmation would identify mutations in the *MUT* gene, solidifying this subtype diagnosis."
"['Death in infancy', 'Hyperammonemia', 'Dyspnea', 'Abnormality of urine homeostasis', 'Neonatal death', 'Abnormal nervous system physiology']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), particularly CPS1 deficiency, as CPS1 catalyzes the first and rate-limiting step of ammonia detoxification.  
2. **Neonatal death** and **death in infancy** align with severe UCDs, which often present catastrophically in the first days of life due to ammonia toxicity.  
3. **Dyspnea** may reflect respiratory alkalosis from hyperventilation, a compensatory response to ammonia-induced cerebral edema.  
4. **Abnormality of urine homeostasis** (e.g., orotic acid absence in urine) distinguishes CPS1 deficiency from other UCDs (e.g., OTC deficiency), as CPS1 defects do not cause orotic aciduria.  
5. **Abnormal nervous system physiology** (lethargy, seizures, coma) results from ammonia crossing the blood-brain barrier, causing neurotoxicity.  
6. The absence of secondary markers like elevated orotic acid confirms CPS1 deficiency over other UCDs, matching the biochemical profile of the diagnosed disease."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to secondary carnitine deficiency or abnormal carnitine profiles due to accumulation of toxic metabolites like acylcarnitines (e.g., C8-C10 species).  
2. **Neonatal death/Death in infancy/childhood**: MCADD causes life-threatening metabolic crises triggered by fasting or illness. Hypoketotic hypoglycemia, hepatic dysfunction, and encephalopathy can rapidly progress to coma and death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe metabolic instability in utero might contribute to intrauterine growth restriction (IUGR) or prematurity in rare cases.  
4. **Key diagnostic confirmation**: Elevated urinary dicarboxylic acids (C6-C10) and specific acylcarnitines (C8, C6, C10:1) on tandem mass spectrometry (TMS) would confirm MCADD, aligning with the clinical presentation."
"['Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Elevated circulating acylcarnitine concentration', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** and **elevated circulating acylcarnitine concentration** directly indicate a defect in lysine, hydroxylysine, and tryptophan metabolism, characteristic of GA-I due to **glutaryl-CoA dehydrogenase deficiency**.  
2. **Motor delay** and **generalized hypotonia** arise from toxic accumulation of glutaric acid and 3-hydroxyglutaric acid, causing basal ganglia damage and impaired motor neuron function.  
3. **Athetosis** and **dyskinesia** reflect striatal injury, a hallmark of acute encephalopathic crises in GA-I, often triggered by metabolic stressors (e.g., infections).  
4. **Death in infancy** aligns with untreated GA-I, where metabolic crises lead to irreversible neurological damage, cerebral edema, or secondary complications (e.g., rhabdomyolysis).  
5. Elevated acylcarnitine (C5DC) on newborn screening supports the diagnosis, as glutaric acid conjugates with carnitine, depleting free carnitine and increasing acylated forms.  
6. Exclusion of GA-II (MADD): No hypoglycemia, cardiomyopathy, or organic acid profile suggestive of multiple dehydrogenase deficiencies."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine in an untreated pregnant mother disrupts fetal development.  
3. **Neonatal death/Death in infancy** may occur in severe untreated PKU due to metabolic crises, neurological damage, or secondary complications (e.g., infections).  
4. **Hypertyrosinemia** is atypical in classic PKU but may arise transiently from liver immaturity or secondary metabolic disturbances in critically ill infants.  
5. **Gastrointestinal inflammation** could result from protein-rich feedings exacerbating metabolic stress or comorbid conditions in a metabolically unstable infant.  
6. While PKU typically causes low tyrosine, confounding factors (e.g., transient neonatal tyrosinemia, assay interference) may explain the lab result. The dominant hyperphenylalaninemia strongly prioritizes PKU over tyrosinemia disorders.  

Note: Confirmatory testing (PAH gene variants, phenylalanine/tyrosine ratios, tetrahydrobiopterin status) would solidify the diagnosis and exclude BH4 deficiencies."
"['Nyctalopia', 'Constriction of peripheral visual field', 'Bone spicule pigmentation of the retina', 'Retinal arteriolar constriction']",['Retinitis pigmentosa 18'],"Disease: Retinitis pigmentosa 18  
Reasoning:  
1. **Nyctalopia**: A hallmark early symptom of retinitis pigmentosa (RP), caused by rod photoreceptor dysfunction, which is critical for low-light vision.  
2. **Peripheral visual field constriction**: Reflects progressive degeneration of peripheral retinal photoreceptors, a defining feature of RP.  
3. **Bone spicule pigmentation**: Characteristic retinal finding in RP, caused by pigment migration and accumulation due to photoreceptor/RPE cell death.  
4. **Retinal arteriolar narrowing**: Occurs in advanced RP due to reduced metabolic demand from widespread retinal atrophy.  
5. **Genetic subtype (RP18)**: Linked to mutations in the *RGS9BP* gene, which disrupt phototransduction signaling in photoreceptors. This subtype aligns with autosomal recessive inheritance and typical RP phenotype progression."
"['Seizure', 'Motor delay', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Seizures**: A hallmark of Canavan disease due to progressive leukodystrophy and severe neurological degeneration.  
2. **Motor delay**: Caused by impaired myelination and spongiform degeneration of white matter in the brain.  
3. **Death in infancy**: Severe forms of Canavan disease often lead to early mortality due to rapid neurological decline.  
4. **Abnormal circulating aspartate family amino acid concentration**: Specifically, elevated *N-acetylaspartic acid (NAA)* in urine/blood, resulting from *aspartoacylase enzyme deficiency*, a pathognomonic feature of Canavan disease.  
5. **Confirmatory evidence**: Genetic testing for *ASPA gene mutations* would validate the diagnosis."
"['Spasticity', 'Morphological central nervous system abnormality', 'Frequent falls', 'Osteomyelitis', 'Babinski sign', 'Hyperactive deep tendon reflexes', 'Pain insensitivity', 'Skin ulcer']","['Neuropathy, hereditary sensory and autonomic, type IIB']","Disease: Neuropathy, hereditary sensory and autonomic, type IIB  
Reasoning:  
1. **Pain insensitivity** and **skin ulcers** indicate a severe sensory neuropathy, specifically affecting nociceptive fibers, leading to unrecognized injuries and chronic wounds.  
2. **Osteomyelitis** is a common complication of untreated infections due to pain insensitivity.  
3. **Hyperactive deep tendon reflexes** and **Babinski sign** suggest upper motor neuron involvement, which may coexist with the peripheral neuropathy in rare HSAN subtypes or reflect secondary spinal cord changes from chronic inflammation/infection.  
4. **Spasticity** and **morphological CNS abnormality** could indicate structural central nervous system defects, possibly linked to genetic mutations (e.g., *FAM134B*) affecting both peripheral and central pathways.  
5. **Frequent falls** result from combined sensory deficits (poor proprioception) and spasticity impairing motor coordination.  
6. While HSANs are primarily peripheral neuropathies, type IIB may involve atypical CNS features or overlapping syndromes, aligning with the clinical profile."
"['Eczema', 'Hypopigmentation of the skin', 'Global developmental delay', 'Joint swelling', 'Hepatosplenomegaly', 'Abnormal bleeding', 'Fever', 'Vomiting', 'Diarrhea', 'Pneumonia', 'Increased circulating IgE level', 'Poor appetite', 'Sparse hair', 'Cough']",['Chédiak-Higashi syndrome/Chediak-Higashi syndrome'],"Disease: Chédiak-Higashi syndrome  
Reasoning:  
1. **Hypopigmentation of the skin and sparse hair**: Aligns with partial oculocutaneous albinism, a hallmark of CHS due to abnormal melanosome trafficking.  
2. **Recurrent infections (pneumonia, fever) and increased IgE**: Reflects immune dysfunction from defective neutrophil chemotaxis and lysosomal granule defects, leading to impaired bacterial killing and immune dysregulation.  
3. **Hepatosplenomegaly and abnormal bleeding**: Suggests the accelerated phase of CHS, characterized by hemophagocytic lymphohistiocytosis (HLH), causing organ infiltration, cytopenias, and coagulopathy.  
4. **Global developmental delay**: Correlates with neurological involvement, including cerebellar atrophy and peripheral neuropathy, common in CHS.  
5. **Gastrointestinal symptoms (vomiting, diarrhea, poor appetite)**: May stem from systemic inflammation during the accelerated phase or recurrent infections.  
6. **Eczema and joint swelling**: Linked to immune dysregulation and chronic inflammation.  
7. **Cough**: Likely secondary to recurrent respiratory infections (e.g., pneumonia).  
The constellation of pigmentary abnormalities, immune deficiency, neurologic deficits, and HLH features strongly supports CHS."
"['Renal dysplasia', 'Microcephaly', 'Hypothyroidism', 'Cyanosis', 'Eczematoid dermatitis', 'Myoclonus', 'Abnormal facial shape', 'Apnea', 'Immunodeficiency', 'Respiratory failure', 'Elevated circulating thyroid-stimulating hormone concentration', 'Limb joint contracture', 'Severe T-cell immunodeficiency', 'Secondary microcephaly', 'Respiratory arrest', 'Axial hypotonia', 'Abnormality of the umbilical cord', 'Inflammatory abnormality of the skin', 'Abnormal renal physiology', 'Oligoclonal T cell expansion']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe T-cell immunodeficiency and oligoclonal T cell expansion indicate a profound defect in T-cell development, a hallmark of ISDNA caused by *EXTL3* mutations.  
2. **Skeletal/Renal Involvement**: Limb joint contractures and renal dysplasia align with the ""immunoskeletal"" aspect of ISDNA, which disrupts glycosaminoglycan synthesis critical for skeletal and renal development.  
3. **Neurodevelopmental Abnormalities**: Microcephaly (primary and secondary), axial hypotonia, and myoclonus reflect neurodevelopmental deficits due to impaired EXTL3-dependent neural and cerebellar development.  
4. **Cutaneous and Endocrine Features**: Inflammatory skin abnormalities (eczematoid dermatitis) and hypothyroidism (elevated TSH) may stem from dysregulated immune responses and multisystemic dysfunction.  
5. **Respiratory Complications**: Apnea and respiratory failure/arrest likely result from hypotonia, immunodeficiency-related infections, or central nervous system dysregulation.  
6. **Congenital Anomalies**: Abnormal facial shape and umbilical cord abnormalities further support a syndromic congenital disorder like ISDNA.  

The convergence of severe T-cell defects, skeletal/renal malformations, neurodevelopmental delays, and multisystem involvement strongly points to ISDNA as the unifying diagnosis."
"['Microcephaly', 'Epicanthus', 'Low-set ears', 'Wide nasal bridge', 'Anteverted nares', 'Ptosis', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Polydactyly', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol with hypocholesterolemia are pathognomonic for SLOS, caused by a deficiency in 7-dehydrocholesterol reductase.  
2. **Craniofacial features**: Microcephaly, epicanthus, ptosis, wide nasal bridge, anteverted nares, and low-set ears align with SLOS-associated dysmorphism.  
3. **Limb anomalies**: Syndactyly (classically 2nd–3rd toe webbing) and polydactyly (often postaxial) are hallmark signs.  
4. **Neurodevelopmental issues**: Intellectual disability, motor delay, and generalized hypotonia reflect neurological involvement.  
5. **Systemic/growth complications**: Feeding difficulties, failure to thrive, vomiting, and early mortality (neonatal/infant/childhood death) correlate with severe SLOS phenotypes.  
6. **Rule-out**: Biochemical findings exclude other syndromes (e.g., trisomy 13/18), while cholesterol abnormalities confirm SLOS."
"['Seborrheic dermatitis', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Increased serum lactate', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Seborrheic dermatitis**: A hallmark of biotinidase deficiency due to biotin's role in keratinocyte function and skin health.  
2. **Metabolic acidosis & elevated lactate**: Caused by impaired activity of biotin-dependent carboxylases (e.g., pyruvate carboxylase), disrupting gluconeogenesis and mitochondrial energy metabolism.  
3. **Elevated urinary carboxylic acids**: Accumulation of 3-hydroxyisovaleric acid, 3-methylcrotonylglycine, and propionylglycine due to dysfunctional 3-methylcrotonyl-CoA carboxylase and propionyl-CoA carboxylase.  
4. **Neurological symptoms (seizures, hypotonia)**: Result from lactic acidosis, energy deficiency, and neurotoxic metabolite accumulation.  
5. **Death in infancy**: Untreated biotinidase deficiency leads to progressive metabolic decompensation, respiratory failure, and fatal outcomes.  
6. **Diagnostic confirmation**: Aligns with biochemical findings (low serum biotinidase activity) and rapid clinical improvement with biotin supplementation."
"['Conjunctivitis', 'Delayed speech and language development', 'Growth delay', 'Obesity', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Abnormal erythrocyte morphology', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Hypoxemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical finding in PKU, caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine metabolism.  
2. **Delayed speech and language development**: Untreated PKU leads to neurotoxic phenylalanine accumulation, resulting in intellectual disability and developmental delays.  
3. **Growth delay/Obesity**: Poorly managed PKU can disrupt metabolic processes, while obesity may arise from restrictive diets favoring low-protein, high-carbohydrate intake.  
4. **Premature birth/Small for gestational age/Neonatal death**: Maternal PKU during pregnancy causes fetal exposure to high phenylalanine, leading to intrauterine growth restriction, prematurity, and congenital anomalies (if untreated).  
5. **Death in infancy/childhood**: Historically occurs in untreated PKU due to severe neurological damage and metabolic complications.  

**Atypical symptoms (e.g., hypertyrosinemia, abnormal erythrocyte morphology)**: Likely represent comorbidities, laboratory artifacts, or secondary effects (e.g., oxidative stress from chronic metabolic imbalance). PKU primarily explains the core features (hyperphenylalaninemia, neurodevelopmental deficits, and prenatal complications)."
"['Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Bone spicule pigmentation of the retina']",['Retinitis pigmentosa 27'],"Disease: Retinitis pigmentosa 27  
Reasoning:  
1. **Nyctalopia**: A hallmark symptom of retinitis pigmentosa (RP), indicating rod photoreceptor dysfunction, which is critical for low-light vision.  
2. **Visual field defect**: Progressive peripheral vision loss (""tunnel vision"") aligns with RP's characteristic retinal degeneration pattern.  
3. **Reduced visual acuity**: Occurs in later stages as cone photoreceptors (central vision) become affected.  
4. **Bone spicule pigmentation**: Pathognomonic retinal finding caused by pigment migration into the retina, typical of RP.  
5. **RP27 subtype**: Linked to mutations in the *NRL* gene (autosomal recessive), which regulates rod photoreceptor development. Genetic testing would confirm this specific subtype."
"['Seizure', 'Death in infancy', 'Neonatal death', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning: The combination of seizures, neonatal death or death in infancy, and elevated urinary carboxylic acids strongly suggests a severe inborn error of branched-chain amino acid (BCAA) metabolism. MSUD is caused by deficient activity of the branched-chain α-keto acid dehydrogenase complex, leading to accumulation of leucine, isoleucine, valine, and their corresponding α-keto acids (branched-chain carboxylic acids) in bodily fluids. Elevated urinary carboxylic acids reflect this biochemical signature. Neonatal presentation with metabolic decompensation (e.g., seizures, encephalopathy) and rapid progression to lethality without intervention aligns with the classic form of MSUD. Early diagnosis via newborn screening or urinary organic acid analysis is critical, as delayed treatment results in irreversible neurological damage or death."
"['Nystagmus', 'Pancytopenia', 'Bone marrow hypocellularity']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-Pancytopenia Syndrome  
Reasoning: The triad of nystagmus (indicative of cerebellar dysfunction/ataxia), pancytopenia, and bone marrow hypocellularity aligns with Ataxia-Pancytopenia Syndrome (APS). APS is a rare genetic disorder characterized by bone marrow failure (hypocellularity and pancytopenia) and neurological manifestations like ataxia, often accompanied by nystagmus. The absence of typical features of other marrow failure syndromes (e.g., physical anomalies in Fanconi anemia or hypercellular marrow in myelodysplastic syndromes) further supports this diagnosis."
"['Leukocytosis', 'Osteomyelitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Jaw swelling', 'Jaw pain', 'Hyperostosis', 'Palmoplantar pustulosis']",['SAPHO syndrome'],"Disease: SAPHO syndrome  
Reasoning:  
1. **Palmoplantar pustulosis**: A key dermatological manifestation of SAPHO syndrome, aligning with the patient's presentation.  
2. **Osteomyelitis & Hyperostosis**: SAPHO commonly involves sterile osteomyelitis (often affecting the jaw, sternocostoclavicular region, or spine) and hyperostosis (bone overgrowth). Jaw involvement (swelling/pain) supports this.  
3. **Elevated inflammatory markers (ESR, CRP)**: Reflects systemic inflammation typical in SAPHO.  
4. **Leukocytosis**: Indicates an active inflammatory/immune response, consistent with SAPHO flares.  
5. **Exclusion of mimics**: Symptoms rule out isolated infections (e.g., bacterial osteomyelitis lacks chronic pustulosis) or other autoinflammatory syndromes (e.g., CRMO lacks palmoplantar pustulosis).  
6. **SAPHO diagnostic criteria**: Meets the ""pustulosis + osteoarticular involvement"" pattern (Kahn, 1994 criteria)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This aligns with the symptom of elevated blood phenylalanine levels.  
2. **Elevated urinary carboxylic acids**: Untreated PKU results in excretion of phenylalanine metabolites (e.g., phenylpyruvate, phenylacetate), which are carboxylic acids detected in urine.  
3. **Neonatal death/Death in infancy**: Severe, untreated PKU can cause progressive neurological deterioration, seizures, and organ failure, potentially leading to early mortality without dietary intervention.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (untreated hyperphenylalaninemia during pregnancy) can cause congenital anomalies (e.g., microcephaly) in the fetus, explaining prenatal developmental issues.  
5. **Death in early adulthood**: Chronic complications of untreated PKU, such as intellectual disability, behavioral disorders, and neurodegenerative changes, may reduce life expectancy.  
6. **Hypertyrosinemia discrepancy**: While classic PKU typically causes *low* tyrosine (due to PAH deficiency), this symptom may reflect a concurrent metabolic disorder, lab error, or misclassification of secondary metabolites (e.g., tyrosine elevation from liver dysfunction).  

PKU is the primary diagnosis, with outcomes explained by untreated hyperphenylalaninemia and its systemic effects. Early dietary management (phenylalanine restriction) could prevent most severe complications."
"['Death in infancy', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperglycinuria', 'Hyperalaninemia', 'Death in childhood', 'Ichthyosis', 'Abnormal circulating glutamine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
- **Hyperammonemia**: Due to inhibition of urea cycle enzymes by accumulated propionyl-CoA metabolites.  
- **Hyperglycinemia/Hyperglycinuria**: Propionyl-CoA inhibits glycine cleavage enzyme, impairing glycine metabolism.  
- **Elevated urinary carboxylic acids**: Propionate derivatives (e.g., 3-hydroxypropionate, methylcitrate) are excreted in urine.  
- **Abnormal carnitine concentration**: Secondary carnitine deficiency from conjugation with propionate (propionylcarnitine).  
- **Vomiting, Death in infancy/childhood**: Metabolic decompensation episodes cause acute crises, leading to fatal outcomes.  
- **Hyperalaninemia**: Secondary disruption of amino acid metabolism due to mitochondrial dysfunction.  
- **Ichthyosis**: Rarely reported, possibly linked to metabolic stress or lipid metabolism abnormalities.  

The combination of organic acidemia markers (elevated urinary carboxylic acids, hyperammonemia) with glycine metabolism abnormalities and carnitine depletion is pathognomonic for propionic acidemia."
"['Strabismus', 'Delayed speech and language development', 'Intellectual disability', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Hyperuricemia', 'Neoplasm of the liver', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Decreased serum iron']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hepatic involvement**: Cirrhosis, hepatic fibrosis, and liver neoplasms align with HT-1’s hallmark liver damage due to toxic tyrosine metabolites (e.g., succinylacetone). Elevated α-fetoprotein reflects hepatocellular injury or malignancy.  
2. **Metabolic abnormalities**: Hypertyrosinemia and 4-hydroxyphenylpyruvic aciduria directly indicate a tyrosine catabolism defect, specifically fumarylacetoacetate hydrolase (FAH) deficiency in HT-1.  
3. **Renal and systemic effects**: Hyperuricemia and abnormal porphyrins stem from succinylacetone inhibiting renal tubular function and δ-ALA dehydratase, disrupting heme synthesis.  
4. **Early mortality**: Neonatal/childhood death is typical in untreated HT-1 due to acute liver failure or complications like hepatocellular carcinoma.  
5. **Neurological features**: Delayed development and intellectual disability may arise from chronic metabolic instability or secondary neurological damage.  
6. **Iron anomalies**: Decreased ferritin/iron could reflect liver dysfunction impairing storage, though this is less specific.  
7. **Exclusion of mimics**: Symptoms collectively localize to FAH deficiency, distinguishing HT-1 from other tyrosinemias (e.g., HT-2/3 lack severe liver disease) or porphyria (porphyrin abnormalities here are secondary)."
"['Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Dyskinesia']",['苯丙酮尿症/Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
**Reasoning**:  
1. **Hyperphenylalaninemia**: A hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Intellectual disability, seizures, motor delay, dyskinesia**: Result from untreated phenylalanine toxicity, damaging neuronal myelination and neurotransmitter synthesis.  
3. **Abnormal cerebral white matter morphology**: Reflects impaired myelination due to phenylalanine interference, a classic neuroimaging finding in PKU.  
4. **Death in infancy/childhood/early adulthood**: Untreated PKU causes severe neurological deterioration and systemic complications, leading to early mortality.  
5. **Hypertyrosinemia**: Uncommon in classic PKU but may arise in atypical cases (e.g., BH4 deficiency variants) or secondary metabolic disturbances.  
6. **Exclusion of Tyrosinemia**: Hypertyrosinemia alone lacks liver/kidney symptoms typical of Tyrosinemia types, reinforcing PKU as the primary diagnosis.  

**Conclusion**: Symptoms align with severe, untreated PKU, with hyperphenylalaninemia and neurological features being pathognomonic. Hypertyrosinemia may indicate a comorbid or variant form but does not override PKU as the core diagnosis."
"['Recurrent urinary tract infections', 'Gingivitis', 'Recurrent otitis media', 'Splenomegaly', 'Neutropenia', 'Lymphopenia', 'Intermittent thrombocytopenia', 'Impaired ADP-induced platelet aggregation', 'Recurrent candida infections', 'Granulocytic hyperplasia']","['Severe congenital neutropenia; SCN', 'Neutropenia, severe congenital, 4, autosomal recessive']","Disease: Severe congenital neutropenia; SCN  
Reasoning: The patient exhibits **neutropenia** and **granulocytic hyperplasia**, hallmark features of SCN. Granulocytic hyperplasia reflects a bone marrow maturation arrest at the promyelocyte/myelocyte stage, explaining the inability to produce mature neutrophils. Recurrent bacterial infections (urinary tract infections, otitis media, gingivitis) align with neutrophil deficiency. Splenomegaly may arise from chronic infection or compensatory extramedullary hematopoiesis. Recurrent candida infections suggest broader immune dysfunction, possibly due to prolonged neutropenia or comorbid immune defects.  

Disease: Neutropenia, severe congenital, 4, autosomal recessive  
Reasoning: This subtype (G6PC3-related SCN) is supported by **intermittent thrombocytopenia** and **impaired ADP-induced platelet aggregation**, indicative of platelet dysfunction linked to G6PC3 mutations. Lymphopenia further suggests multilineage hematopoietic involvement, consistent with this genetic form. Recurrent candida infections and splenomegaly may reflect additional metabolic or immune anomalies associated with G6PC3 deficiency. The combination of neutropenia, thrombocytopenia, and platelet aggregation defects strongly points to this autosomal recessive subtype. Genetic testing for G6PC3 mutations would confirm the diagnosis."
"['Macroglossia', 'Bifid uvula', 'Craniosynostosis', 'Patent foramen ovale', 'Lymphopenia', 'Hypoglycemia', 'Abnormal facial shape', 'Recurrent respiratory infections', 'Skeletal dysplasia', 'Hyperbilirubinemia', 'Lumbar kyphosis', 'Cleft anterior mitral valve leaflet']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal dysplasia** and **lumbar kyphosis**: Core features of ISDNA, linked to EXTL3 gene mutations affecting glycosaminoglycan synthesis and skeletal development.  
2. **Lymphopenia** and **recurrent respiratory infections**: Reflect immunodeficiency, a hallmark of ISDNA due to abnormal lymphopoiesis and T-cell dysfunction.  
3. **Craniosynostosis** and **abnormal facial shape**: Align with craniofacial anomalies reported in ISDNA, though less common than other skeletal findings.  
4. **Patent foramen ovale** and **cleft anterior mitral valve leaflet**: Suggest connective tissue/cardiac involvement, potentially secondary to dysregulated extracellular matrix remodeling.  
5. **Hypoglycemia** and **hyperbilirubinemia**: May indicate metabolic dysregulation, occasionally observed in ISDNA due to systemic glycosylation defects.  
6. **Macroglossia** and **bifid uvula**: Less typical but possible in syndromic craniofacial dysmorphism.  
7. **Neurodevelopmental abnormalities** (implied in diagnosis name): Consistent with ISDNA’s phenotype, though not explicitly listed in symptoms.  

The combination of skeletal, immune, and subtle craniofacial/cardiac anomalies strongly supports ISDNA, despite atypical symptoms like macroglossia. Genetic testing for EXTL3 variants is critical for confirmation."
"['Strabismus', 'Chorioretinal atrophy', 'Nystagmus', 'Oculomotor apraxia', 'Delayed speech and language development', 'Abnormally large globe', 'Motor delay', 'Generalized hypotonia', 'Cerebellar dysplasia', 'Inferior cerebellar vermis hypoplasia', 'High myopia']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar Abnormalities**: The patient exhibits *cerebellar dysplasia* and *inferior cerebellar vermis hypoplasia*, key neuroimaging features of Poretti-Boltshauser syndrome (PBS). These structural defects disrupt cerebellar function, contributing to *motor delay*, *generalized hypotonia*, and ataxia (implied by cerebellar signs).  
2. **Oculomotor Deficits**: *Oculomotor apraxia* and *nystagmus* are hallmark ocular motor impairments in PBS, linked to cerebellar malformations. *Strabismus* and *abnormally large globe* may arise from disrupted coordination of eye movements and structural ocular abnormalities.  
3. **Retinal Involvement**: *Chorioretinal atrophy* and *high myopia* align with PBS-associated retinal dystrophy caused by pathogenic variants in *LAMA1*, a gene critical for retinal and cerebellar basement membrane integrity.  
4. **Developmental Delays**: *Delayed speech and language development* and *motor delay* reflect global developmental delays secondary to cerebellar dysfunction and potential intellectual disability (a core feature of PBS).  
5. **Exclusion of Mimics**: The constellation of cerebellar cysts/hypoplasia, retinal changes, and oculomotor apraxia distinguishes PBS from similar disorders (e.g., Joubert syndrome, which typically presents with a ""molar tooth sign"" on imaging and lacks chorioretinal atrophy).  

This pattern strongly supports a diagnosis of Poretti-Boltshauser syndrome, confirmed genetically via *LAMA1* testing."
"['Abnormal penis morphology', 'Oral ulcer', 'Epistaxis', 'Uveitis', 'Visual loss', 'Hematuria', 'Hypertension', 'Arthritis', 'Ankle swelling', 'Abdominal pain', 'Fasciculations', 'Arthralgia', 'Elevated hepatic transaminase', 'Increased CSF protein concentration', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Myalgia', 'Muscle spasm', 'Spinal canal stenosis', 'Back pain', 'Somatic sensory dysfunction', 'Focal white matter lesions', 'Foot dorsiflexor weakness', 'Stomatitis', 'Abnormal metacarpophalangeal joint morphology', 'Fatigue', 'Dysesthesia', 'Increased circulating lactate dehydrogenase concentration', 'Elevated gamma-glutamyltransferase level', 'Unusual infection', 'Aphthous ulcer', 'Dysuria', 'Epigastric pain']",['Behçet disease/Behcet syndrome'],"Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: The patient presents with oral ulcers (aphthous ulcer, stomatitis) and genital ulcers (implied by ""abnormal penis morphology""), fulfilling the International Criteria for Behçet’s Disease (ICBD) major criteria.  
2. **Ocular Manifestations**: Uveitis and visual loss are classic features of Behçet’s, often leading to severe complications if untreated.  
3. **Neurological Involvement**: Increased CSF protein, focal white matter lesions, and somatic sensory dysfunction suggest neuro-Behçet’s, a serious subtype affecting the central nervous system.  
4. **Vasculitic Features**: Epistaxis, hematuria, and hypertension may reflect systemic vasculitis, a hallmark of Behçet’s that can involve small and large vessels.  
5. **Musculoskeletal Symptoms**: Arthritis, arthralgia, and ankle swelling align with inflammatory joint involvement common in Behçet’s.  
6. **Gastrointestinal Involvement**: Abdominal/epigastric pain could indicate intestinal ulcers, part of the ""intestinal Behçet’s"" phenotype.  
7. **Elevated Inflammatory Markers**: Elevated creatine kinase, LDH, and hepatic transaminases suggest systemic inflammation, consistent with Behçet’s multisystemic nature.  
8. **Exclusion of Mimics**: Symptoms like recurrent infections are atypical but may reflect immunosuppressive therapy rather than an infectious etiology. The absence of more specific markers for diseases like lupus or sarcoidosis strengthens the Behçet’s diagnosis.  

**Conclusion**: The combination of recurrent oral/genital ulcers, uveitis, vasculitis, and multisystem inflammation strongly supports Behçet’s syndrome, aligning with ICBD diagnostic criteria."
"['Renal insufficiency', 'Oral ulcer', 'Abnormality of the nose', 'Abnormal pinna morphology', 'Abnormal sternum morphology', 'Facial erythema', 'Congestive heart failure', 'Tachycardia', 'Aortic regurgitation', 'Palpitations', 'Hyperuricemia', 'Pleural effusion', 'Lymphadenopathy', 'Microscopic hematuria', 'Hyperuricosuria', 'Myalgia', 'Back pain', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Left bundle branch block', 'Abnormal metacarpophalangeal joint morphology', 'Sacroiliac arthritis', 'Fatigue', 'obsolete Increased urinary urate', 'Foot pain', 'Elbow pain', 'Ankle pain', 'Aphthous ulcer', 'Enthesitis']",['Relapsing polychondritis'],"Disease: Relapsing polychondritis  
Reasoning:  
1. **Cartilage involvement**: Key features include ""oral ulcer"" (mucosal inflammation), ""abnormality of the nose"" (saddle nose deformity from nasal chondritis), and ""abnormal pinna morphology"" (auricular chondritis).  
2. **Cardiovascular manifestations**: ""Aortic regurgitation"" and ""left bundle branch block"" align with RP’s propensity to damage cartilaginous structures in the heart valves and conduction system. ""Congestive heart failure"" may result from chronic valvular dysfunction.  
3. **Musculoskeletal inflammation**: ""Enthesitis,"" ""sacroiliac arthritis,"" and joint pain (elbow, ankle, foot) reflect systemic inflammation, though atypical for RP, suggesting overlap or secondary autoimmune processes.  
4. **Systemic inflammation**: Elevated ESR and CRP support an autoimmune etiology.  
5. **Respiratory/renal involvement**: ""Pleural effusion"" and ""renal insufficiency"" may stem from diffuse inflammation or secondary amyloidosis in advanced RP.  
6. **Exclusion of mimics**: Absence of granulomas (unlike GPA) or genital ulcers/uveitis (unlike Behçet’s) strengthens RP’s likelihood.  
7. **Hyperuricemia/hyperuricosuria**: Likely incidental or secondary to renal dysfunction rather than RP itself.  

Distinctive RP markers (cartilage destruction, aortic valve disease) outweigh atypical features (lymphadenopathy, sacroiliitis), warranting this diagnosis."
"['Hyporeflexia', 'Generalized hypotonia', 'Hepatic steatosis', 'Death in infancy', 'Tachycardia', 'Dehydration', 'Fever', 'Vomiting', 'Abdominal pain', 'Dyspnea', 'Increased serum lactate', 'Hypertriglyceridemia', 'Hepatomegaly', 'Tachypnea', 'Skeletal muscle atrophy', 'Hyperalaninemia', 'Aminoaciduria', 'Neonatal death', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Feeding difficulties', 'Abnormal myelination', 'Abdominal mass']","['Hereditary fructose intoleranc; HFI/Hereditary fructose intolerance/Fructose intolerance, hereditary']","Disease: Hereditary fructose intolerance (HFI)  
Reasoning:  
1. **Hepatic steatosis & Hepatomegaly**: Caused by toxic accumulation of fructose-1-phosphate in the liver due to aldolase B deficiency, impairing fructose metabolism and leading to lipid deposition.  
2. **Vomiting, Abdominal pain, Feeding difficulties**: Direct gastrointestinal response to fructose ingestion, triggering aversion to sweet foods and metabolic stress.  
3. **Increased serum lactate & Hypertriglyceridemia**: Inhibition of gluconeogenesis and glycogenolysis by fructose-1-phosphate results in hypoglycemia, driving anaerobic metabolism (lactic acidosis) and impaired lipid processing.  
4. **Hyperalaninemia & Aminoaciduria**: Gluconeogenesis blockade causes accumulation of alanine; renal tubular dysfunction from metabolic stress may contribute to aminoaciduria.  
5. **Hyporeflexia & Generalized hypotonia**: Neurological manifestations of hypoglycemia and metabolic acidosis.  
6. **Tachycardia & Tachypnea**: Compensatory responses to lactic acidosis and dehydration.  
7. **Dehydration & Fever**: Secondary to vomiting and reduced oral intake, exacerbated by metabolic derangements.  
8. **Death in infancy/Neonatal death**: Untreated HFI leads to progressive liver/kidney failure and metabolic crises upon fructose exposure in infancy.  
9. **Skeletal muscle atrophy**: Chronic malnutrition from feeding difficulties and catabolic state.  
10. **Abnormal myelination**: Potential consequence of recurrent hypoglycemia affecting brain development.  
11. **Abdominal mass**: Likely palpable hepatomegaly due to fatty liver enlargement.  

The constellation of liver dysfunction, fructose-triggered metabolic disturbances, and neonatal presentation aligns pathognomonically with HFI. Early diagnosis and strict fructose/sucrose/sorbitol avoidance are critical to prevent fatal outcomes."
"['Hypertension', 'Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), preventing phenylalanine conversion to tyrosine.  
2. **Intellectual disability** aligns with untreated PKU, as excess phenylalanine disrupts neurotransmitter synthesis and myelination.  
3. **Elevated urinary carboxylic acid** reflects phenylalanine metabolism via alternative pathways (e.g., phenylpyruvate), excreted as phenylketones.  
4. **Obesity and hypertension** may result from carbohydrate-rich diets used to restrict phenylalanine intake, leading to metabolic complications.  
5. **Early mortality** correlates with untreated PKU complications, including neurological decline and metabolic instability.  
6. **Hypertyrosinemia** is atypical for classic PKU (where tyrosine is typically low) but may arise from dietary tyrosine supplementation or secondary metabolic adaptations.  

Note: Hypertyrosinemia and hyperphenylalaninemia coexistence suggests potential diagnostic complexity (e.g., BH4 deficiency or tyrosinemia overlap), but PKU remains the primary diagnosis based on core features."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like vomiting and gastrointestinal inflammation align with metabolic decompensation during fasting, a hallmark of MCADD due to impaired fatty acid oxidation.  
2. **Fatality Timeline**: Neonatal/infant/childhood death correlates with untreated MCADD, where prolonged fasting triggers hypoglycemia, lethargy, and fatal metabolic crises.  
3. **Biochemical Markers**: Decreased plasma free carnitine occurs as carnitine binds to unmetabolized medium-chain acyl-CoA derivatives. Reduced 3-hydroxyacyl-CoA dehydrogenase activity (if misreported or a related enzyme) may reflect MCADD’s specific enzyme defect (MCAD).  
4. **Infection Susceptibility**: Recurrent viral infections may stem from energy deprivation impairing immune responses during metabolic stress.  
5. **Prenatal Abnormalities**: While MCADD typically lacks structural birth defects, severe metabolic dysfunction in utero could manifest as growth abnormalities or prenatal distress.  

Key confirmation would require genetic testing for *ACADM* mutations or elevated C6-C10 acylcarnitines on newborn screening."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where high maternal phenylalanine disrupts fetal development (e.g., microcephaly, congenital heart defects).  
3. **Neonatal death/Death in infancy** occurs in severe, untreated PKU due to rapid neurotoxicity from extreme phenylalanine levels, causing metabolic encephalopathy.  
4. **Hypertyrosinemia** is atypical in classic PKU (expected hypotyrosinemia), but may reflect transient neonatal tyrosinemia, liver dysfunction, or a coexisting metabolic disturbance.  
5. The combination of hyperphenylalaninemia with early lethality strongly prioritizes PKU over other tyrosinemia disorders, despite the tyrosine elevation anomaly."
"['Renal hypoplasia', 'Renal cyst', 'Xerostomia', 'Hepatic cysts', 'Ankle swelling', 'Palpitations', 'Dysphagia', 'Nausea', 'Gastroesophageal reflux', 'Abdominal pain', 'Hiatus hernia', 'Bronchiectasis', 'Vertigo', 'Increased blood urea nitrogen', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Back pain', 'Elevated erythrocyte sedimentation rate', 'Premature ventricular contraction', 'Chronic oral candidiasis', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Decreased glomerular filtration rate', 'Fatigue', 'Bronchitis', 'Lower limb pain', 'Ground-glass opacification', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Crackles', 'Reduced FEV1/FVC ratio', 'Sputum eosinophilia', 'Decreased DLCO', 'Abnormality of nail color', 'Epigastric pain']",['Primary Sjögren syndrome/Sjogren syndrome'],"Disease: Primary Sjögren Syndrome  
**Reasoning**:  
1. **Exocrine Gland Dysfunction**:  
   - **Xerostomia** (dry mouth) and **chronic oral candidiasis** are hallmark features of Sjögren syndrome, reflecting salivary gland involvement and secondary fungal infection due to reduced saliva.  
   - **Dysphagia**, **gastroesophageal reflux**, and **hiatus hernia** may arise from decreased saliva production and esophageal dysmotility linked to autonomic dysfunction.  

2. **Autoimmune Features**:  
   - **Autoimmune antibody positivity** (e.g., anti-SSA/Ro or anti-SSB/La) is diagnostic for Sjögren syndrome.  
   - **Elevated ESR**, **CRP**, and **neutrophilia** indicate systemic inflammation.  

3. **Pulmonary Involvement**:  
   - **Bronchiectasis**, **crackles**, **ground-glass opacities**, and **nodular patterns on HRCT** suggest interstitial lung disease (ILD), a common extraglandular manifestation.  
   - **Reduced DLCO** and **FEV1/FVC ratio** reflect restrictive/obstructive patterns from lymphocytic infiltration or bronchiolitis.  

4. **Renal Abnormalities**:  
   - **Renal hypoplasia**, **decreased GFR**, and elevated **creatinine/urea nitrogen** align with tubulointerstitial nephritis, a frequent renal complication.  
   - **Elevated parathyroid hormone** may indicate secondary hyperparathyroidism due to chronic kidney disease.  

5. **Musculoskeletal and Systemic Inflammation**:  
   - **Back pain**, **lower limb pain**, and **elevated creatine kinase** suggest inflammatory myopathy or arthralgias.  
   - **Fatigue** and **abdominal/epigastric pain** correlate with systemic autoimmune activity and possible gastrointestinal dysmotility.  

6. **Extraglandular Manifestations**:  
   - **Hepatic cysts** are atypical but may coexist with autoimmune liver disease.  
   - **Vertigo** and **palpitations/premature ventricular contractions** could stem from autonomic neuropathy or electrolyte imbalances (e.g., hypercalcemia from hyperparathyroidism).  

**Conclusion**: The constellation of sicca symptoms, systemic inflammation, multi-organ involvement (renal, pulmonary, hepatic), and autoimmune markers strongly supports **primary Sjögren syndrome**. Overlapping features (e.g., ILD, nephritis) are consistent with its extraglandular manifestations."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'Delayed CNS myelination', 'EEG abnormality', 'Developmental regression', 'Inability to walk', 'Bruxism', 'Secondary microcephaly', 'Hypoplasia of the frontal lobes']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Developmental regression**: A hallmark of Rett syndrome, though the congenital variant often lacks the classic period of normal development before regression.  
2. **Secondary microcephaly**: Reflects postnatal slowing of head growth, consistent with Rett-associated neurological degeneration.  
3. **Seizures and EEG abnormality**: Common in Rett due to cortical hyperexcitability and disrupted neuronal connectivity.  
4. **Hypoplasia of the corpus callosum and frontal lobes**: Aligns with FOXG1-related congenital Rett variant, which disrupts forebrain development.  
5. **Delayed CNS myelination**: Supports a neurodevelopmental disorder affecting white matter maturation.  
6. **Hypotonia and inability to walk**: Indicates severe motor dysfunction, typical of early-onset/congenital forms.  
7. **Bruxism and repetitive mannerisms**: Stereotypic movements are classic in Rett spectrum disorders.  
8. **Delayed speech/development**: Reflects global neurodevelopmental impairment.  
*Conclusion*: The constellation of structural brain anomalies, regression, microcephaly, and movement abnormalities strongly suggests a FOXG1-related congenital Rett variant rather than classic MECP2-linked Rett syndrome."
"['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) arise from alternative phenylalanine metabolism via transamination, a pathognomonic feature of PKU.  
3. **Eczematoid dermatitis/skin rash** correlates with tyrosine deficiency (due to blocked PAH activity), impairing melanin and protein synthesis, causing skin manifestations.  
4. **Abnormality of prenatal development** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing fetal complications like microcephaly or cardiac defects.  
5. **Death in infancy/childhood/neonatal death** reflects untreated PKU’s severe neurological sequelae (seizures, intellectual disability) and metabolic instability, historically fatal before dietary management.  
6. **Hypertyrosinemia** may appear contradictory (PAH deficiency typically lowers tyrosine), but transient elevations can occur due to metabolic stress or overlapping pathways in severe cases.  

The collective symptoms strongly indicate PKU, emphasizing untreated metabolic dysfunction and its systemic consequences."
"['Sinusitis', 'Hypertension', 'Dry skin', 'Pallor', 'Thrombocytosis', 'Anemia', 'Renal artery stenosis', 'Fever', 'Leukocytosis', 'Vomiting', 'Abdominal pain', 'Dyspnea', 'Osteomyelitis', 'Elevated hepatic transaminase', 'Increased blood urea nitrogen', 'Increased circulating IgG level', 'Elevated circulating creatinine concentration', 'Back pain', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Epileptic spasm', 'Elevated circulating C-reactive protein concentration', 'Flank pain', 'Elevated gamma-glutamyltransferase level', 'Elevated carcinoma antigen 125 level', 'obsolete Abnormal fecal test result', 'Abnormality of mesentery morphology', 'Papule', 'Epigastric pain']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vascular involvement**: Renal artery stenosis (a hallmark of Takayasu arteritis) explains hypertension, elevated blood urea nitrogen, and creatinine. Flank/back pain may reflect ischemic kidney injury.  
2. **Systemic inflammation**: Fever, leukocytosis, elevated ESR, CRP, and IgG levels align with chronic inflammatory vasculitis.  
3. **Mesenteric ischemia**: Abdominal/epigastric pain, mesentery abnormality, and vomiting suggest compromised mesenteric artery blood flow.  
4. **Anemia/Thrombocytosis**: Common in chronic inflammatory states.  
5. **Autoimmune features**: Antinuclear antibody positivity (non-specific but supportive of autoimmune etiology).  
6. **Exclusion of mimics**: Elevated CA-125 and hepatic enzymes may reflect secondary inflammation; sinusitis and papules are atypical but do not rule out Takayasu.  
**Key omissions**: Angiographic evidence (e.g., aortic/pulmonary artery stenosis) is required for definitive diagnosis, but clinical and lab findings strongly suggest Takayasu arteritis."
"['High palate', 'Neck muscle weakness', 'Intellectual disability', 'Muscle weakness', 'Breech presentation', 'Respiratory insufficiency due to muscle weakness', 'Kyphoscoliosis', 'Gowers sign', 'Knee flexion contracture', 'Muscle fibrillation', 'Delayed ability to walk', 'Abnormal nerve conduction velocity']",['Nemaline myopathy 7'],"Disease: Nemaline myopathy 7  
Reasoning:  
1. **Muscle Weakness**: Central feature of nemaline myopathy (NM), evident in neck muscles, respiratory insufficiency, and delayed walking.  
2. **Respiratory Insufficiency**: Common in severe NM subtypes like NEM7 due to diaphragmatic and intercostal muscle involvement.  
3. **Kyphoscoliosis**: Results from chronic axial muscle weakness, a hallmark of congenital myopathies.  
4. **Gowers Sign**: Indicates proximal muscle weakness, typical in NM.  
5. **Breech Presentation/Knee Flexion Contracture**: Suggests reduced fetal movement (arthrogryposis spectrum), consistent with severe congenital NM7 (KLHL40 mutations).  
6. **Delayed Walking**: Reflects early-onset muscle hypotonia.  
7. **High Palate**: Linked to orofacial muscle weakness/hypotonia in congenital myopathies.  
8. **Abnormal Nerve Conduction Velocity**: Uncommon in NM but may occur secondary to severe muscle pathology or testing artifact.  
9. **Muscle Fibrillation**: Rarely reported in NM; could indicate overlap with neurogenic processes or misinterpretation of myopathic features.  
10. **Intellectual Disability**: Atypical for NM7 but possible in severe cases with prolonged hypoxia or comorbidities.  

While intellectual disability and nerve conduction abnormalities are less typical, the constellation of severe congenital muscle weakness, contractures, respiratory failure, and structural anomalies strongly aligns with NEM7. Genetic testing for KLHL40 mutations would confirm the diagnosis."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low), but could arise from concurrent tyrosine supplementation, secondary metabolic dysregulation, or a comorbid condition (e.g., tyrosinemia). However, the primary diagnostic focus remains on elevated phenylalanine.  
3. **Death in childhood** aligns with untreated/severe PKU, as toxic phenylalanine accumulation leads to neurodevelopmental failure, seizures, and early mortality without dietary intervention.  
4. While Hypertyrosinemia creates ambiguity, PKU is prioritized due to the pathognomonic Hyperphenylalaninemia. Further testing (e.g., BH4 responsiveness, tyrosine metabolite analysis) would clarify coexisting disorders."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine in an untreated pregnant woman with PKU causes congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus.  
3. **Hypertyrosinemia** may occur secondarily due to disrupted phenylalanine-tyrosine metabolism or overlap with tyrosinemia type II (rare), but PKU remains primary given the clinical context.  
4. **Early mortality (infancy, childhood, adolescence)** reflects untreated PKU complications: severe neurotoxicity (seizures, developmental delay), metabolic instability, and susceptibility to infections.  
5. Neonatal screening typically detects PKU, but lack of dietary intervention (low-phenylalanine diet) leads to progressive neurological deterioration and premature death.  

Note: Hypertyrosinemia is atypical in classic PKU but may arise in variant forms or coexisting metabolic disturbances. Maternal PKU explains prenatal abnormalities, while untreated PKU in the child drives hyperphenylalaninemia and fatal outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative metabolism of excess phenylalanine.  
3. **Abnormality of prenatal development/birth** may align with maternal PKU syndrome if the mother had untreated PKU during pregnancy, causing fetal complications.  
4. **Early mortality** (infancy/childhood/adolescence) reflects severe untreated PKU, where neurotoxicity from phenylalanine causes seizures, intellectual disability, and fatal complications.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise secondary to dietary management (e.g., tyrosine supplementation) or overlapping metabolic disturbances.  
6. **Neonatal death** is rare in PKU but could occur in extreme cases with rapid metabolic decompensation or comorbid conditions.  

While hypertyrosinemia and elevated urinary carboxylic acids might suggest tyrosinemia, the dominant hyperphenylalaninemia and structured clinical context prioritize PKU as the diagnosis."
"['Cerebellar atrophy', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy**: PMM2-CDG is characterized by progressive neurological deterioration. Cerebellar atrophy is a hallmark of the disease due to disrupted glycosylation, impairing cerebellar development and function.  
2. **Death in childhood**: PMM2-CDG type Ia is a severe, multisystem disorder. Mortality in early life is common due to complications such as liver failure, infections, or severe neurological decline.  
3. **Cerebellar agenesis**: While ""agenesis"" implies complete absence (rare in PMM2-CDG), severe cerebellar hypoplasia (underdevelopment) is frequently reported. This may reflect variability in phenotypic terminology or extreme cerebellar malformation secondary to glycosylation defects.  
4. **Consistency with PMM2-CDG**: The triad of cerebellar structural anomalies, early lethality, and systemic involvement aligns with PMM2-CDG’s clinical spectrum. Confirmatory testing (e.g., phosphomannomutase activity, genetic analysis for *PMM2* mutations) would solidify the diagnosis."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, leading to phenylalanine accumulation.  
2. **Delayed speech and language development** aligns with untreated PKU, as elevated phenylalanine disrupts myelination and neurotransmitter synthesis, impairing neurodevelopment.  
3. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing congenital anomalies (e.g., microcephaly, cardiac defects) in the infant.  
4. **Neonatal death/Death in infancy/childhood** correlates with severe untreated PKU variants (e.g., malignant PKU) or delayed diagnosis, where toxic phenylalanine levels cause irreversible neurological damage or metabolic crises.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise in rare PAH deficiency variants or secondary metabolic disruptions (e.g., transient tyrosine elevation during metabolic stress).  

PKU explains the core symptom (hyperphenylalaninemia) and associated complications, while hypertyrosinemia warrants further investigation for co-occurring disorders or metabolic instability. Early dietary management (phenylalanine restriction) is critical to prevent adverse outcomes."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Untreated PKU** results in severe neurological damage, seizures, and developmental failure. Historically, before newborn screening and dietary management, infants with classic PKU often faced **death in infancy** due to progressive neurodegeneration or complications like infections.  
3. **Neonatal death** (within the first 28 days) is less typical but could occur in rare, severe variants (e.g., malignant PKU) or if metabolic derangements (e.g., electrolyte imbalances) compound critical organ dysfunction.  
4. The triad of symptoms aligns with undiagnosed/untreated PKU, where hyperphenylalaninemia precedes irreversible systemic collapse. Modern screening mitigates this outcome, but the historical context explains the listed presentation."
"['Strabismus', 'Intellectual disability', 'Motor delay', 'Cerebellar atrophy', 'Tremor', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development and function.  
2. **Motor delay and tremor**: Result from cerebellar dysfunction, disrupting coordination and motor control.  
3. **Intellectual disability**: Linked to global neurodevelopmental deficits due to abnormal glycosylation of brain proteins.  
4. **Strabismus**: Associated with neurological and muscular involvement from glycosylation defects.  
5. **Death in childhood**: Reflects severe multisystemic complications (e.g., liver failure, cardiomyopathy) common in classical PMM2-CDG.  
6. **Consistent with PMM2-CDG type Ia**: These features align with the phenotype of phosphomannomutase 2 deficiency, the most prevalent and well-characterized CDG subtype."
"['Hydrocephalus', 'Macrocephaly', 'Hypertelorism', 'Low-set ears', 'Short neck', 'Strabismus', 'Ptosis', 'Pectus excavatum', 'Seizure', 'Cubitus valgus', 'Short stature', 'Relative macrocephaly', 'Sparse hair', 'Mild global developmental delay']",['Noonan syndrome 3'],"Disease: Noonan syndrome 3  
Reasoning:  
1. **Facial Features**: Hypertelorism, ptosis, low-set ears, and strabismus align with classic Noonan syndrome dysmorphology.  
2. **Skeletal Anomalies**: Pectus excavatum and cubitus valgus are common skeletal findings in Noonan syndrome.  
3. **Growth Issues**: Short stature and relative macrocephaly (head size disproportionate to body growth) are hallmark features.  
4. **Developmental Delay**: Mild global developmental delay is consistent with the syndrome’s neurocognitive profile.  
5. **Neurological Involvement**: Seizures and hydrocephalus suggest KRAS-related Noonan syndrome 3, which is associated with more severe neurological manifestations.  
6. **Cutaneous Features**: Sparse hair is occasionally reported in Noonan syndrome variants.  
7. **Exclusion of Alternatives**: Symptoms overlap with other RASopathies (e.g., Costello syndrome), but the combination of hydrocephalus, seizures, and KRAS-specific features (Noonan 3) solidifies the diagnosis."
"['Intellectual disability', 'Seizure', 'Ataxia', 'Lethargy', 'Dysarthria', 'Gait disturbance', 'Muscle weakness', 'Tachycardia', 'Acidosis', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Myopathic facies', 'Dyspnea', 'Increased serum lactate', 'Drooling', 'Elevated hepatic transaminase', 'Myoglobinuria', 'Ketonuria', 'Lactic acidosis', 'Myopathy', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Limb muscle weakness', 'Ventricular tachycardia', 'Prolonged QTc interval', 'Premature ventricular contraction', 'Lateral ventricle dilatation', 'Lower limb muscle weakness', 'Elevated circulating aldolase concentration', 'Elevated circulating acylcarnitine concentration', 'Lateral ventricular asymmetry']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic Dysregulation**: Acidosis (metabolic/lactic), hypoglycemia, hyperammonemia, ketonuria, and elevated lactate/acylcarnitine suggest impaired mitochondrial energy metabolism and fatty acid oxidation.  
2. **Neuromuscular Involvement**: Myopathy, rhabdomyolysis, limb muscle weakness, elevated CK/aldolase, and myoglobinuria indicate recurrent muscle breakdown, consistent with metabolic crises.  
3. **Cardiac Arrhythmias**: Ventricular tachycardia, prolonged QTc, and premature contractions align with cardiac ion channel dysfunction or metabolic toxicity from rhabdomyolysis.  
4. **Neurodegeneration/Encephalopathy**: Intellectual disability, seizures, ataxia, lethargy, dysarthria, and ventricular dilatation/asymmetry point to chronic/progressive CNS injury from metabolic insults.  
5. **Systemic Features**: Elevated hepatic transaminases, dyspnea, and drooling reflect multi-organ dysfunction during crises.  
6. **Pattern Recognition**: The combination of recurrent metabolic decompensation, muscle breakdown, arrhythmias, and neurodegeneration matches this specific syndrome’s phenotype, distinct from isolated mitochondrial disorders or fatty acid oxidation defects."
"['Narrow mouth', 'Microcephaly', 'Posteriorly rotated ears', 'Prominent nose', 'Strabismus', 'Downslanted palpebral fissures', 'Long eyelashes', 'Thick eyebrow', 'Coloboma', 'Dental crowding', 'Dental malocclusion', 'Autistic behavior', 'Anxiety', 'Delayed speech and language development', 'Hirsutism', 'Global developmental delay', 'Intellectual disability, moderate', 'Highly arched eyebrow', 'Scoliosis', 'Delayed skeletal maturation', 'Feeding difficulties in infancy', 'Low hanging columella', 'Broad hallux', 'Keloids', 'Talon cusp', 'Broad thumb']",['Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2'],"Disease: Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2  
Reasoning:  
1. **Craniofacial features**: Narrow mouth, microcephaly, posteriorly rotated ears, prominent nose, downslanted palpebral fissures, long eyelashes, thick/highly arched eyebrows, and low-hanging columella align with the characteristic facial dysmorphism of Rubinstein-Taybi syndrome (RSTS).  
2. **Limb anomalies**: Broad hallux and broad thumb are hallmark signs of RSTS.  
3. **Dental abnormalities**: Dental crowding, malocclusion, and talon cusp are commonly reported in RSTS due to craniofacial and dental developmental defects.  
4. **Ocular findings**: Strabismus and coloboma (though less frequent) are consistent with ocular manifestations of RSTS.  
5. **Developmental delays**: Global developmental delay, moderate intellectual disability, delayed speech, and autistic behavior match the neurocognitive profile of RSTS.  
6. **Skeletal features**: Scoliosis and delayed skeletal maturation are recognized skeletal anomalies in RSTS.  
7. **Additional supportive signs**: Feeding difficulties in infancy, hirsutism, and keloids (less common but reported) further support the diagnosis.  
8. **Genetic correlation**: EP300 haploinsufficiency (RSTS type 2) explains the phenotype, as EP300 mutations cause overlapping features with CREBBP-associated RSTS (type 1), including distinct facial traits, broad digits, and neurodevelopmental delays. Talon cusp and keloids may be more prevalent in EP300-related cases."
"['Obesity', 'Hypercholesterolemia', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning: Hyperphenylalaninemia is pathognomonic for PKU, caused by phenylalanine hydroxylase (PAH) deficiency. Classic PKU typically results in **low tyrosine** due to impaired phenylalanine-to-tyrosine conversion. However, the reported hypertyrosinemia could suggest an atypical variant (e.g., partial PAH activity with compensatory dietary tyrosine intake) or secondary metabolic dysregulation. Obesity and hypercholesterolemia may stem from carbohydrate-rich diets used to restrict phenylalanine. Early adulthood mortality aligns with untreated or poorly managed PKU, leading to severe neurological decline, cardiovascular complications, or metabolic instability."
"['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis is a hallmark of methylmalonic acidemia (MMA), an inborn error of metabolism caused by impaired degradation of methylmalonyl-CoA. Death in infancy aligns with severe MMA presentations, where toxic metabolite accumulation leads to rapid clinical deterioration.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Decreased methylmalonyl-CoA mutase activity directly indicates a defect in the MUT gene encoding this enzyme, which is required for methylmalonyl-CoA isomerization. Vitamin B12-unresponsive MMA is confirmed because mutase deficiency bypasses the B12-dependent pathway (defects in B12 metabolism or transport would retain some residual enzyme activity with B12 supplementation). The triad of symptoms strongly supports this specific genetic subtype."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Neonatal death/Death in infancy/Death in childhood**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, historically causing early mortality without dietary intervention.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) can cause congenital anomalies, though this is not a direct symptom of the patient’s PKU. The inclusion may reflect severe metabolic disruption or comorbid factors.  
4. **Gastrointestinal inflammation**: Less typical but possible in metabolic crises or secondary to protein-restricted diet complications (e.g., nutrient deficiencies).  

PKU is confirmed by elevated blood phenylalanine and genetic testing for PAH mutations. Early diagnosis and phenylalanine-restricted diet prevent severe outcomes."
"['Sinusitis', 'Abnormality of the nose', 'Otitis media', 'Fever', 'Headache', 'Exercise intolerance', 'Elbow pain', 'Knee pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Upper respiratory involvement**: Chronic sinusitis and nasal abnormalities (e.g., ulcers, crusting) are hallmark features of GPA, caused by granulomatous inflammation.  
2. **Otitis media**: Secondary to Eustachian tube dysfunction from nasopharyngeal inflammation or vasculitis.  
3. **Systemic inflammation**: Fever and headache reflect systemic vasculitis and granulomatosis.  
4. **Musculoskeletal symptoms**: Elbow and knee pain (arthralgia/arthritis) occur in 50-70% of GPA patients due to inflammatory joint involvement.  
5. **Exercise intolerance**: May indicate subclinical pulmonary or renal involvement (common in GPA) or anemia of chronic disease.  
6. **Exclusion of mimics**: Symptoms align with GPA over other vasculitides (e.g., absence of asthma/eosinophilia rules out EGPA; PR3-ANCA positivity would further support diagnosis).  
7. **Triad correlation**: Combines upper/lower respiratory tract and potential renal involvement (even if not overtly stated), consistent with GPA pathology."
"['Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Anemia', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ferritin concentration', 'Pregnancy exposure', 'Decreased serum iron', 'Abnormality of vitamin D metabolism']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Pregnancy exposure**: Maternal PKU syndrome, where untreated maternal hyperphenylalaninemia during pregnancy results in congenital anomalies (e.g., premature birth, developmental issues) and neonatal complications (e.g., neonatal death).  
3. **Decreased serum iron/ferritin & anemia**: Likely secondary to restrictive dietary management of PKU, which may limit iron-rich protein sources.  
4. **Vitamin D metabolism abnormality**: Due to dietary restrictions (low-phenylalanine diets often lack fortified foods or natural sources of vitamin D).  
5. **Hypertyrosinemia**: Uncommon in classic PKU but may occur transiently due to metabolic stress or concurrent hepatic dysfunction (e.g., tyrosine catabolism disruption).  
6. **Early mortality (infancy/childhood)**: Untreated PKU causes severe neurological damage; maternal PKU syndrome exacerbates risks (cardiac/developmental defects).  
**Key exclusion**: Tyrosinemia or BH4 deficiencies were considered but ruled out as the diagnosis explicitly aligns with PKU. Hypertyrosinemia here is atypical but explained contextually."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion. Untreated PKU results in toxic phenylalanine accumulation, leading to severe neurological damage, seizures, and **early death** (childhood/adolescence). While **hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are typically low), it may indicate a comorbid condition (e.g., tyrosinemia type II) or a rare PKU variant involving tetrahydrobiopterin (BH4) deficiency. BH4 defects disrupt both phenylalanine metabolism and tyrosine breakdown, potentially elevating both metabolites. Despite this inconsistency, hyperphenylalaninemia and early mortality strongly prioritize PKU as the primary diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where high maternal phenylalanine levels during pregnancy cause fetal complications (e.g., microcephaly, congenital heart defects).  
3. **Death in infancy/childhood and neonatal death** may occur in untreated severe PKU due to metabolic derangements, neurological deterioration, or secondary infections.  
4. **Hypertyrosinemia** is atypical in PKU (tyrosine levels are usually normal/low). This could indicate a concurrent metabolic disorder, laboratory error, or misreported data, but does not exclude PKU given the strong evidence from other symptoms.  
5. The combination of hyperphenylalaninemia with early mortality and developmental abnormalities strongly prioritizes PKU over other metabolic disorders (e.g., tyrosinemia)."
"['Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Apnea', 'Opisthotonus', 'Neonatal death', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Fatigue', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Amino Acid Elevation**: The triad of *hypervalinemia*, *hyperleucinemia*, and *hyperisoleucinemia* is pathognomonic for MSUD, caused by a defect in the branched-chain α-keto acid dehydrogenase (BCKDH) complex, impairing breakdown of branched-chain amino acids (BCAAs).  
2. **Neurological Manifestations**: *Seizures*, *intellectual disability*, *hypotonia*, and *opisthotonus* arise from neurotoxic accumulation of BCAAs and their keto-acids, disrupting cerebral energy metabolism and myelination.  
3. **Metabolic Crisis**: *Apnea*, *bradycardia*, and *fatigue* reflect acute metabolic decompensation, often triggered by catabolic states (e.g., infections), leading to life-threatening cerebral edema.  
4. **Odor & Early Mortality**: *Body odor* (maple syrup-like scent in urine/sweat) and *neonatal/infant death* align with classic severe MSUD phenotypes, where untreated metabolic crises rapidly progress to coma and death.  
5. **Immunological Vulnerability**: *Recurrent viral infections* may stem from metabolic stress impairing immune cell function, though this is less specific and secondary to the primary metabolic defect.  
**Conclusion**: The combination of BCAA elevation, neurotoxicity, odor, and infantile lethality confirms MSUD. Urgent dietary management (BCAA restriction) is critical to mitigate outcomes."
"['Lethargy', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Abnormal circulating ornithine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Oroticaciduria** is a hallmark of OTCD, caused by carbamoyl phosphate accumulation due to the enzyme defect, shunting into pyrimidine synthesis and producing excess orotic acid.  
2. **Abnormal circulating ornithine concentration** aligns with disrupted urea cycle dynamics, as ornithine is not efficiently converted to citrulline.  
3. **Lethargy, drowsiness, and sleep disturbances** reflect hyperammonemia-induced neurotoxicity, a critical feature of urea cycle disorders.  
4. **Death in infancy** is consistent with severe neonatal-onset OTCD, where hyperammonemia rapidly progresses without intervention.  
5. OTCD’s X-linked inheritance explains severe male presentations, though symptomatic females may also occur due to skewed X-inactivation.  
6. Exclusion of other urea cycle disorders (e.g., citrullinemia) is supported by the absence of specific amino acid elevations (e.g., citrulline) and the presence of oroticaciduria."
"['Hyperkeratosis', 'Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Pulmonic stenosis', 'Gastrointestinal hemorrhage', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Skin rash/Eczematoid dermatitis**: Common in untreated PKU due to phenylalanine accumulation and metabolic byproducts irritating the skin.  
3. **Abnormality of prenatal development or birth/Death in infancy/Neonatal death/Death in childhood**: Severe untreated PKU causes profound neurological damage, leading to developmental failure and early mortality.  
4. **Gastrointestinal inflammation/hemorrhage**: Secondary to metabolic derangements or dietary management complications (e.g., protein-restricted diets).  
5. **Hypertyrosinemia**: Uncommon in classical PKU but may arise from tyrosine supplementation or overlapping metabolic disruptions.  
6. **Pulmonic stenosis**: Likely incidental or unrelated; PKU does not directly cause cardiac defects but may coexist with other congenital anomalies.  

*Note: While some symptoms (e.g., pulmonic stenosis) are atypical for PKU, the diagnosis is strongly supported by hyperphenylalaninemia and dermatological manifestations. Other features may reflect severe untreated disease or comorbidities.*"
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Fatty acid oxidation disorder**: MCADD impairs breakdown of medium-chain fatty acids into acetyl-CoA, causing energy deficiency during fasting.  
2. **Neonatal/infant/childhood mortality**: Unrecognized MCADD leads to hypoketotic hypoglycemia, metabolic acidosis, and encephalopathy during metabolic stress (e.g., infections or fasting), explaining death in early life stages.  
3. **Gastrointestinal inflammation**: Acute crises trigger vomiting/diarrhea due to metabolic decompensation. Chronic carnitine deficiency may exacerbate mucosal damage.  
4. **Decreased plasma free carnitine**: Secondary carnitine depletion occurs as carnitine conjugates with accumulating toxic metabolites (e.g., octanoylcarnitine) for urinary excretion.  
5. **Prenatal abnormalities**: While less common, intrauterine metabolic stress from placental insufficiency or maternal fasting could theoretically contribute to developmental perturbations in severe cases.  

Key biochemical clues: Hypoketotic hypoglycemia + elevated C6-C10 acylcarnitines (especially C8) on tandem mass spectrometry would confirm MCADD. Early diagnosis via newborn screening prevents mortality."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Narrow mouth', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Astigmatism', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Microdontia', 'Atypical behavior', 'Autistic behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Poor suck', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Sleep disturbance', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Delayed fine motor development', 'Laterally extended eyebrow', 'Abnormality of fontanelles', 'Abdominal colic', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  

**Reasoning:**  
1. **Neurodevelopmental Core Features:**  
   - *Autistic behavior, delayed speech, hyperactivity, ADHD, absent speech, delayed fine motor development* align with the ""neurodevelopmental disorder"" component.  
   - *Abnormal corpus callosum, cerebellar/pons/hippocampus anomalies, CNS hypomyelination* indicate structural brain abnormalities.  

2. **Ocular Involvement:**  
   - *Coloboma, microphthalmia, Peters anomaly, optic atrophy, astigmatism, deeply set eyes* reflect the ""eye anomalies"" criterion.  

3. **Cardiac Defects:**  
   - *Ventricular septal defect, patent ductus arteriosus, anomalous pulmonary return* satisfy the ""heart anomalies"" spectrum.  

4. **Craniofacial & Systemic Features:**  
   - *Microcephaly/macrocephaly, triangular face, micrognathia, high palate, bulbous nose* are common in genetic neurodevelopmental syndromes.  
   - *Growth delay, hypotonia, seizures, GI anomalies (pyloric stenosis, duodenal atresia)* support multisystem involvement.  

5. **Exclusion of Overlap Syndromes:**  
   - While features like *café-au-lait spots* or *syndactyly* may suggest RASopathies or chromosomal disorders, the triad of neurodevelopmental delay + brain/eye/heart anomalies is pathognomonic for NEDBEH (OMIM 618733).  

6. **Genetic Consistency:**  
   - NEDBEH is linked to *CABP4* or *UBR3* mutations, which disrupt neurodevelopment and organogenesis, explaining the observed phenotypic variability.  

**Conclusion:** The convergence of neurodevelopmental delays, structural brain/eye/heart defects, and variable dysmorphism strongly supports NEDBEH. Genetic testing for causative variants is recommended for confirmation."
"['Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Stroke-like episode', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis and ataxia**: PMM2-CDG commonly presents with cerebellar hypoplasia/atrophy due to impaired glycosylation of proteins critical for cerebellar development, leading to motor dysfunction (ataxia).  
2. **Intellectual disability**: Global neurodevelopmental deficits are a hallmark of PMM2-CDG, resulting from disrupted glycosylation-dependent brain maturation.  
3. **Thromboembolism/stroke-like episodes**: Hypoglycosylation of coagulation factors (e.g., antithrombin III, protein C/S) causes a hypercoagulable state, predisposing to thrombotic events and vascular insults mimicking strokes.  
4. **Death in infancy**: Severe multisystem involvement (hepatic, cardiac, and neurologic) in classic PMM2-CDG often leads to early mortality.  
5. **Exclusion of mimics**: The combination of cerebellar structural anomalies, coagulopathy, and infantile lethality distinguishes PMM2-CDG from isolated metabolic disorders or mitochondrial diseases. Genetic testing for PMM2 mutations would confirm the diagnosis."
"['Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Thromboembolism', 'Neonatal death', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: PMM2-CDG commonly causes cerebellar hypoplasia or atrophy due to impaired protein glycosylation, critical for cerebellar development.  
2. **Failure to thrive**: A hallmark of PMM2-CDG, resulting from multisystem dysfunction (e.g., gastrointestinal, hepatic, endocrine) disrupting nutrient absorption and metabolism.  
3. **Thromboembolism**: Glycosylation defects impair coagulation factor synthesis (e.g., antithrombin III, protein C/S), predisposing to thrombotic events.  
4. **Neonatal death/Death in infancy**: Severe PMM2-CDG cases often lead to early mortality due to organ failure, metabolic crises, or recurrent infections.  
5. **Consistency with type Ia**: PMM2-CDG (type Ia) is the most prevalent subtype, characterized by neurologic deficits, coagulopathy, and infantile lethality in severe presentations.  
The constellation of neurologic, growth, and coagulation abnormalities strongly aligns with PMM2-CDG-Ia, confirmed by genetic testing for *PMM2* mutations."
"['Coarse facial features', 'Eczematoid dermatitis', 'Eosinophilia', 'Recurrent Staphylococcus aureus infections', 'Impaired oxidative burst', 'Increased circulating IgE level', 'Recurrent pneumonia', 'Prominent forehead', 'Pulmonary pneumatocele', 'Cutaneous abscess', 'Abnormal proportion of CD4-positive T cells', 'Abnormal proportion of CD8-positive T cells']",['Autosomal dominant hyper-IgE syndrome/Hyper-IgE recurrent infection syndrome'],"Disease: Autosomal dominant hyper-IgE syndrome/Hyper-IgE recurrent infection syndrome  
Reasoning:  
1. **Elevated IgE and eosinophilia**: The increased circulating IgE level and eosinophilia are hallmark features of hyper-IgE syndromes (HIES), particularly AD-HIES.  
2. **Recurrent infections**: Recurrent *Staphylococcus aureus* infections (cutaneous abscesses, pneumonia) align with impaired immune responses to pyogenic bacteria, a key characteristic of AD-HIES.  
3. **Pulmonary complications**: Recurrent pneumonia and pulmonary pneumatoceles suggest chronic lung damage due to unresolved infections, commonly seen in AD-HIES.  
4. **Facial and skeletal features**: Coarse facial features and a prominent forehead are dysmorphic traits associated with STAT3 mutations, the genetic cause of AD-HIES.  
5. **Immune dysregulation**: Abnormal CD4/CD8 T-cell proportions and eczematoid dermatitis reflect T-cell dysfunction, consistent with STAT3 deficiency.  
6. **Oxidative burst impairment**: While not a primary feature of STAT3 deficiency, chronic inflammation or secondary neutrophil dysfunction may explain this finding.  

The constellation of symptoms, genetic traits, and immune abnormalities strongly supports a diagnosis of autosomal dominant hyper-IgE syndrome."
"['Hearing impairment', 'Delayed speech and language development', 'Obesity', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative phenylalanine metabolism, a key diagnostic feature of PKU.  
3. **Delayed speech and language development** and **hearing impairment** align with neurotoxic effects of phenylalanine accumulation in untreated PKU.  
4. **Severe short stature** and **obesity** may reflect metabolic dysregulation and dietary challenges in managing phenylalanine intake.  
5. **Hypertyrosinemia** is atypical for classic PKU but could suggest a comorbid condition, secondary metabolic disruption, or a variant (e.g., BH4-deficient PKU).  
6. **Neonatal death/Death in infancy/childhood/adolescence** might indicate severe, untreated PKU complications (e.g., neurodegeneration, metabolic crises) or a lethal variant (e.g., malignant PKU with dihydropteridine reductase deficiency).  
7. **Fever** could signal intercurrent infections exacerbated by metabolic instability.  
8. While other organic acidemias or tyrosinemias are considered, **hyperphenylalaninemia** and urinary phenylketones strongly prioritize PKU as the primary diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiency multiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While biotinidase deficiency (BTDD) typically manifests postnatally, severe untreated cases may indirectly contribute to developmental anomalies due to progressive metabolic dysfunction. Prenatal reliance on maternal biotin usually prevents in utero symptoms, but postnatal failure to recycle biotin disrupts carboxylase enzymes, potentially leading to congenital-like metabolic instability.  
2. **Death in infancy/Neonatal death**: Untreated BTDD causes profound metabolic crises (e.g., lactic acidosis, hyperammonemia, organic acidemia) due to impaired carboxylase activity. These crises rapidly progress to neurological decline (seizures, coma) and multisystem failure, often fatal within weeks to months without biotin supplementation. Neonatal death may occur if symptoms onset early and diagnosis/treatment are delayed.  
3. **Late-onset vs. timing**: Despite being termed ""late-onset"" (compared to holocarboxylase synthetase deficiency), BTDD can present acutely in infancy. The absence of newborn screening or delayed intervention explains the fatal trajectory in this case."
"['Hypertension', 'Increased circulating renin level', 'Generalized hypotonia', 'Failure to thrive', 'Obesity', 'Death in infancy', 'Vomiting', 'Hyperkalemia', 'Hyponatremia', 'Decreased circulating renin level', 'Neonatal death', 'Death in childhood', 'Decreased circulating cortisol level', 'Feeding difficulties', 'Elevated circulating 17-hydroxyprogesterone concentration']","['21-hydroxylase deficiency; 21-OHD/Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency/Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency']","Disease: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency  
Reasoning:  
1. **Elevated 17-hydroxyprogesterone (17-OHP)**: A hallmark of 21-hydroxylase deficiency (21-OHD), as the enzyme defect prevents conversion of 17-OHP to cortisol, causing precursor accumulation.  
2. **Decreased cortisol**: Impaired cortisol synthesis due to the 21-hydroxylase enzyme deficiency, triggering compensatory adrenal hyperplasia via increased ACTH.  
3. **Salt-wasting features (hyponatremia, hyperkalemia)**: Aldosterone synthesis is also disrupted, leading to renal sodium loss, potassium retention, and hypovolemia. This explains vomiting, feeding difficulties, and failure to thrive.  
4. **Hypotonia and dehydration**: Secondary to electrolyte imbalances and hypovolemia from salt wasting.  
5. **Increased renin (if prioritized over decreased renin)**: Expected in salt-wasting 21-OHD due to hypovolemia-driven RAAS activation. ""Decreased renin"" in the symptom list may reflect testing variability or late-stage adrenal failure.  
6. **Neonatal/childhood mortality**: Untreated salt-wasting crises cause severe dehydration, shock, and death in infancy or early childhood without prompt diagnosis and glucocorticoid/mineralocorticoid replacement.  
7. **Obesity discrepancy**: Atypical for classic 21-OHD but may reflect fluid retention misinterpretation, comorbid factors, or misreported data.  
8. **Hypertension paradox**: Unusual in salt-wasting 21-OHD (typically hypotensive). Possible confounding factors (e.g., acute stress, measurement error) or overlapping conditions.  

**Conclusion**: Elevated 17-OHP, cortisol deficiency, and salt-wasting features confirm classic 21-OHD. Conflicting renin/hypertension data require clinical correlation but do not override diagnostic biochemical markers."
"['Retrognathia', 'Abnormality of prenatal development or birth', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Apnea', 'Opisthotonus', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Neurological symptoms (Seizure, Hypotonia, Apnea, Opisthotonus)**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting neurotransmitter synthesis and causing severe neurological damage.  
3. **Poor prognosis (Death in infancy/childhood, Neonatal death)**: Without early dietary intervention, progressive neurodegeneration results in fatal outcomes.  
4. **Hypertyrosinemia discrepancy**: Typically, PKU causes *low* tyrosine due to blocked PAH-mediated conversion of phenylalanine to tyrosine. This may indicate a coexisting metabolic disorder, lab error, or atypical PKU variant.  
5. **Retrognathia/prenatal abnormalities**: Uncommon in classic PKU but could suggest maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy) affecting fetal development.  

Key confirmation: Hyperphenylalaninemia + neurological decline aligns with PKU. Early diagnosis via newborn screening and dietary management are critical to prevent symptoms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to accumulation of toxic metabolites (e.g., medium-chain acylcarnitines). Carnitine becomes sequestered as these conjugates, causing secondary carnitine deficiency.  
2. **Gastrointestinal inflammation**: Metabolic crises in MCADD induce vomiting, diarrhea, and hepatic dysfunction, mimicking gastrointestinal inflammation.  
3. **Neonatal/infant/childhood death**: Untreated MCADD causes life-threatening hypoglycemia, encephalopathy, and multiorgan failure during fasting or illness, often fatal in early life without prompt diagnosis.  
4. **Prenatal abnormalities**: While MCADD typically manifests postnatally, severe intrauterine metabolic stress (e.g., maternal fasting) might theoretically contribute to growth abnormalities.  
5. **Exclusion of alternatives**: Symptoms align with MCADD over other fatty acid oxidation disorders (e.g., VLCAD, LCHAD) due to the absence of cardiomyopathy or retinopathy and the specific carnitine profile."
"['Flexion contracture', 'Apnea', 'Inability to walk', 'Reduced vital capacity', 'Abnormal pattern of respiration', 'Respiratory failure', 'Skeletal muscle atrophy', 'Easy fatigability', 'Scapular winging', 'Distal upper limb muscle weakness', 'Foot dorsiflexor weakness', 'Distal lower limb muscle weakness', 'Stridor', 'Sleep apnea', 'Anti-muscle-specific tyrosine kinase antibody']","['Myasthenic syndrome, congenital, 8']","Disease: Myasthenic syndrome, congenital, 8 (CMS8)  
Reasoning:  
1. **Key Neuromuscular Symptoms**: The patient exhibits distal and proximal muscle weakness (scapular winging, distal upper/lower limb weakness, foot dorsiflexor weakness), skeletal muscle atrophy, and easy fatigability, all hallmarks of neuromuscular junction disorders like CMS.  
2. **Respiratory Involvement**: Respiratory failure, apnea, sleep apnea, stridor, and reduced vital capacity indicate severe respiratory muscle weakness, a critical feature of CMS8 due to DOK7 mutations impairing neuromuscular transmission.  
3. **Genetic Basis**: CMS8 is linked to autosomal recessive DOK7 mutations, causing postsynaptic neuromuscular junction dysfunction. While anti-MuSK antibodies are typically associated with autoimmune myasthenia gravis, CMS8 is genetic and antibody-negative. The listed antibody may be incidental or a reporting error, as CMS8 is diagnosed via genetic testing, not serology.  
4. **Clinical Overlap**: Symptoms align with CMS8’s typical presentation (proximal > distal weakness, respiratory crises, fatigability), though distal involvement can occur. Flexion contractures and inability to walk reflect chronic muscle atrophy and compensatory posturing.  
5. **Exclusion of Alternatives**: Autoimmune myasthenia gravis (MuSK-positive) would typically improve with immunotherapies, whereas CMS8 requires acetylcholinesterase inhibitors or β-adrenergic agonists. The congenital nature (implied by diagnosis) supports CMS8 over acquired conditions.  

Conclusion: Despite the atypical presence of anti-MuSK antibody, the constellation of progressive muscle weakness, respiratory failure, and structural features (e.g., scapular winging) strongly suggests CMS8, necessitating genetic confirmation of DOK7 mutations."
"['Seizure', 'Hypomelanotic macule', 'Shagreen patch', 'Fibroma', 'Macule', 'Profound global developmental delay', 'Ungual fibroma']",['Tuberous sclerosis-1'],"Disease: Tuberous sclerosis-1  
Reasoning:  
1. **Seizures**: Common in tuberous sclerosis complex (TSC) due to cortical tubers or subependymal nodules disrupting brain function.  
2. **Hypomelanotic macules (ash leaf spots)**: A major diagnostic criterion for TSC, appearing as depigmented skin patches.  
3. **Shagreen patch**: A connective tissue nevus (typically on the lower back), a major diagnostic feature of TSC.  
4. **Ungual fibroma**: Fibrous growths around/under nails, a major diagnostic criterion when multiple are present.  
5. **Profound global developmental delay**: Linked to severe neurological involvement in TSC, often from cortical tubers or epilepsy burden.  
6. **Fibromas**: Benign tumors (e.g., facial angiofibromas) are hallmark lesions in TSC.  
7. **Macule**: General term; here, likely referencing hypomelanotic macules or other TSC-associated skin lesions.  

The combination of ≥2 major features (hypomelanotic macules, shagreen patch, ungual fibroma, seizures) and developmental delay strongly supports **TSC1** (mutations in the *TSC1* gene on chromosome 9q34), a subtype of tuberous sclerosis complex."
"['Microcephaly', 'Intellectual disability', 'Lethargy', 'Death in infancy', 'Bradycardia', 'Hyperammonemia', 'Apnea', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Hypotension', 'Hyperglutaminemia', 'Low plasma citrulline', 'Neonatal death', 'Recurrent viral infections']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia**: Central to diagnosis, as CPS1 deficiency disrupts the urea cycle’s first step, preventing ammonia detoxification.  
2. **Low plasma citrulline**: CPS1 deficiency blocks carbamoyl phosphate synthesis, reducing citrulline production (unlike OTC deficiency, where citrulline is also low but orotic acid is elevated).  
3. **Hyperglutaminemia**: Excess ammonia is metabolized via alternative pathways, forming glutamine as a compensatory mechanism.  
4. **Neurological symptoms (Microcephaly, Intellectual disability, Cerebral edema, Lethargy, Drowsiness)**: Result from ammonia neurotoxicity, impairing brain development and function.  
5. **Apnea, Hypotension, Bradycardia**: Systemic effects of hyperammonemia and cerebral edema impacting autonomic regulation.  
6. **Neonatal death/Death in infancy**: Severe CPS1 deficiency often presents catastrophically in infancy due to rapid ammonia accumulation.  
7. **Recurrent viral infections**: Likely secondary to metabolic instability and critical illness rather than a primary immune defect.  
8. **Sleep disturbance**: Reflects neurological irritation from hyperammonemia.  

The combination of hyperammonemia, low citrulline, and hyperglutaminemia distinguishes CPS1 deficiency from other urea cycle disorders. The absence of elevated orotic acid or other intermediates further supports this diagnosis."
"['Rod-cone dystrophy', 'Pigmentary retinopathy', 'Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Attenuation of retinal blood vessels', 'Diffuse optic disc pallor', 'Hypoautofluorescent retinal lesion']",['Retinitis pigmentosa 78'],"Disease: Retinitis pigmentosa 78  
Reasoning:  
1. **Rod-cone dystrophy**: A hallmark of retinitis pigmentosa (RP), where rod photoreceptor degeneration precedes cone loss, aligning with progressive nyctalopia and visual field constriction.  
2. **Pigmentary retinopathy**: Characteristic bone-spicule pigment deposits in RP, caused by retinal pigment epithelium migration into the retina.  
3. **Nyctalopia**: Early symptom due to rod dysfunction, typical in RP.  
4. **Visual field defect**: Progressive peripheral vision loss (""tunnel vision"") from peripheral retinal degeneration.  
5. **Reduced visual acuity**: Occurs later as cones become affected.  
6. **Attenuation of retinal blood vessels & diffuse optic disc pallor**: Reflects chronic retinal atrophy and optic nerve degeneration in advanced RP.  
7. **Hypoautofluorescent retinal lesions**: Indicates areas of photoreceptor/RPE atrophy, consistent with RP progression.  
**RP78** specifically involves mutations in the **RP1L1** gene, which disrupts photoreceptor structure. The clinical triad of nyctalopia, pigmentary retinopathy, and vascular attenuation strongly supports this diagnosis. Genetic testing for RP1L1 variants would confirm RP78."
"['Abnormality of the kidney', 'Overfolded helix', 'Macrotia', 'Choanal atresia', 'Abnormality of the eye', 'Strabismus', 'Visual impairment', 'Hypermetropia', 'Upslanted palpebral fissure', 'Delayed speech and language development', '11 pairs of ribs', 'Brachydactyly', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Obesity', 'Atrial septal defect', 'Short foot', 'Asthma', 'Scoliosis', 'Tracheomalacia', 'Hypoventilation', 'Short stature', 'Preauricular pit', 'Central hypoventilation', 'Abnormal eye morphology', 'Abnormality of brain morphology', 'Hyperconvex toenail', 'Cerebral visual impairment', 'Small hand', 'Menometrorrhagia']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart  
Reasoning:  
1. **Neurodevelopmental features**: Global developmental delay, delayed speech and language development, hypotonia, and cerebral visual impairment align with core neurodevelopmental deficits.  
2. **Brain morphology abnormality**: Hypotonia, central hypoventilation, and cerebral visual impairment suggest central nervous system involvement.  
3. **Eye anomalies**: Visual impairment, strabismus, hypermetropia, abnormal eye morphology, and upslanted palpebral fissures indicate structural and functional ocular defects.  
4. **Cardiac involvement**: Atrial septal defect directly correlates with the ""heart"" component of the diagnosis.  
5. **Craniofacial/skeletal features**: Overfolded helix, macrotia, preauricular pit, brachydactyly, short foot, small hand, and 11 pairs of ribs reflect multisystem congenital anomalies typical of syndromic neurodevelopmental disorders.  
6. **Systemic associations**: Obesity, short stature, tracheomalacia, and choanal atresia further support a genetic syndrome affecting multiple organ systems.  
7. **Exclusion of alternatives**: The constellation of symptoms (e.g., absence of pathognomonic signs for Rett, Down, or CHARGE syndromes) and the specificity of brain-eye-heart anomalies prioritize this diagnosis."
"['Vomiting', 'Migraine', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Low plasma citrulline', 'Death in childhood', 'Death in adolescence', 'Uraciluria', 'Decreased circulating ferritin concentration', 'Abnormal vitamin B12 level']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Urea Cycle Dysregulation**: OTCD disrupts the urea cycle, impairing ammonia detoxification. While hyperammonemia is not explicitly listed, symptoms like vomiting and migraines align with episodic ammonia toxicity.  
2. **Hyperglutaminemia**: Excess ammonia drives glutamine synthesis via glutamine synthetase, explaining elevated glutamine levels.  
3. **Oroticaciduria/Uraciluria**: Urea cycle blockage shunts carbamoyl phosphate into pyrimidine synthesis, overproducing orotic acid and uracil, excreted in urine.  
4. **Low Plasma Citrulline**: OTCD prevents carbamoyl phosphate and ornithine from forming citrulline, reducing its plasma levels.  
5. **Hyperalaninemia**: Alternative nitrogen disposal via alanine transamination elevates alanine.  
6. **Secondary Metabolic Abnormalities**: Decreased ferritin and abnormal B12 may reflect liver dysfunction or metabolic stress from chronic hyperammonemia.  
7. **Early Mortality**: Untreated OTCD causes lethal hyperammonemic crises, consistent with death in childhood/adolescence.  
**Key Differentiators**: Oroticaciduria and low citrulline distinguish OTCD from other urea cycle disorders (e.g., citrullinemia, where citrulline is elevated)."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', '3-hydroxydicarboxylic aciduria']",['Glycogen storage disease Ia/Glycogen storage disease Ia'],"Disease: Glycogen storage disease Ia  
Reasoning:  
1. **Hyperammonemia and 3-hydroxydicarboxylic aciduria**: In GSD Ia, impaired gluconeogenesis and glycogenolysis lead to reliance on fatty acid oxidation, generating dicarboxylic acids (e.g., 3-hydroxydicarboxylic acids) and secondary hyperammonemia due to disrupted urea cycle function from liver stress.  
2. **Cyanosis and seizures**: Severe hypoglycemia (hallmark of GSD Ia) triggers seizures, while lactic acidosis (from excess lactate production) reduces oxygen delivery, causing peripheral cyanosis.  
3. **Neonatal death/infant mortality**: Untreated GSD Ia results in metabolic crises (hypoglycemia, acidosis) shortly after birth, often fatal without rapid diagnosis and glucose stabilization.  
4. **Consistency with GSD Ia**: Symptoms align with glucose-6-phosphatase deficiency, though hyperammonemia and dicarboxylic aciduria are atypical but explainable through metabolic cascades and hepatic dysfunction."
"['High palate', 'Long philtrum', 'Blue sclerae', 'Hyperextensible skin', 'Bruising susceptibility', 'Striae distensae', 'Ectopia lentis', 'Joint hypermobility', 'Mitral valve prolapse', 'Scoliosis', 'Arterial tortuosity', 'Short uvula', 'Chronic pain', 'Dural ectasia', 'Hernia']",['Loeys-Dietz syndrome 4'],"Disease: Loeys-Dietz syndrome 4  
Reasoning:  
1. **Arterial tortuosity** and **mitral valve prolapse** suggest vascular connective tissue abnormalities, a hallmark of Loeys-Dietz syndrome (LDS).  
2. **High palate**, **long philtrum**, and **short uvula** align with craniofacial features seen in LDS type 4 (SMAD3-related), which often includes orofacial anomalies.  
3. **Hyperextensible skin**, **striae distensae**, **joint hypermobility**, and **hernia** indicate systemic connective tissue fragility, consistent with LDS.  
4. **Dural ectasia** and **scoliosis** reflect skeletal and spinal connective tissue involvement, common in LDS.  
5. **Ectopia lentis** (lens dislocation) and **blue sclerae** suggest ocular connective tissue defects, observed in some LDS subtypes.  
6. **Chronic pain** and **bruising susceptibility** correlate with vascular and tissue fragility in LDS.  
7. LDS type 4 (SMAD3 mutation) is distinguished by **aortic/arterial tortuosity**, craniofacial features, and overlapping Ehlers-Danlos-like symptoms, differentiating it from Marfan syndrome or vascular EDS."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Symptom Alignment**:  
   - **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, intrauterine metabolic stress or placental insufficiency from maternal fasting (due to fetal inability to oxidize medium-chain fatty acids) may contribute to subtle prenatal abnormalities.  
   - **Death in infancy/Neonatal death**: MCADD causes life-threatening hypoglycemia and metabolic crises triggered by fasting (e.g., delayed feeding in neonates). Untreated, this leads to coma, cardiorespiratory failure, and early mortality.  
   - **Abnormal circulating carnitine**: Secondary carnitine deficiency occurs due to sequestration of carnitine by accumulating toxic metabolites (e.g., medium-chain acylcarnitines), reducing free carnitine levels.  

2. **Pathophysiological Link**:  
   - MCADD disrupts β-oxidation of medium-chain fatty acids (C6-C12), impairing energy production during fasting. Neonates/infants are highly vulnerable due to high metabolic demands and limited glycogen reserves.  

3. **Diagnostic Confirmation**:  
   - Elevated C8-C10 acylcarnitines on newborn screening (tandem mass spectrometry) and genetic testing for *ACADM* mutations confirm MCADD.  

4. **Exclusion of Alternatives**:  
   - Symptoms overlap with other fatty acid oxidation disorders (e.g., VLCADD, LCHADD), but abnormal medium-chain acylcarnitines and carnitine profile specifically localize to MCADD.  

**Conclusion**: The constellation of neonatal metabolic instability, carnitine derangements, and early mortality strongly supports MCADD. Early intervention (avoidance of fasting, glucose supplementation) can prevent fatal outcomes."
"['Brachycephaly', 'Hypertelorism', 'Narrow forehead', 'Proptosis', 'Delayed speech and language development', 'Pectus carinatum', 'Brachydactyly', 'Polyhydramnios', 'Polyhydramnios', 'Hallux valgus', 'Gastroesophageal reflux', 'Respiratory distress', 'Clinodactyly of the 5th finger', 'Depressed nasal bridge', 'Flat occiput', 'Aspiration pneumonia', 'Thick vermilion border']",['Chitayat syndrome'],"Disease: Chitayat syndrome  
Reasoning:  
1. **Craniofacial Features**: Brachycephaly (premature fusion of coronal sutures), hypertelorism, proptosis, narrow forehead, depressed nasal bridge, and thick vermilion border align with Chitayat syndrome’s characteristic facial dysmorphism.  
2. **Skeletal Abnormalities**: Pectus carinatum, brachydactyly, clinodactyly of the 5th finger, and hallux valgus are consistent with skeletal manifestations of ERF-related craniosynostosis syndromes.  
3. **Developmental Delays**: Delayed speech and language development correlate with neurodevelopmental involvement seen in Chitayat syndrome.  
4. **Prenatal/Neonatal Issues**: Polyhydramnios (duplicated in symptoms) and respiratory distress at birth are linked to abnormal fetal swallowing or thoracic restriction.  
5. **Complications**: Gastroesophageal reflux and aspiration pneumonia may result from craniofacial anatomy impacting airway and swallowing function.  
6. **Genetic Confirmation**: While not explicitly stated, Chitayat syndrome is caused by pathogenic ERF variants, which would confirm the diagnosis via genetic testing.  

This constellation of craniosynostosis, facial dysmorphism, skeletal anomalies, and developmental delays strongly supports Chitayat syndrome."
"['Seizure', 'Muscle weakness', 'Hepatosplenomegaly', 'Developmental regression', 'Elevated circulating creatine kinase concentration', 'Neurodevelopmental abnormality', 'Increased circulating lactate dehydrogenase concentration', 'Elevated circulating aspartate aminotransferase concentration']",['Neurodegeneration with brain iron accumulation 2B'],"Disease: Neurodegeneration with brain iron accumulation 2B (PLA2G6-associated neurodegeneration)  
Reasoning:  
1. **Neurodevelopmental/neurodegenerative features**: Developmental regression and neurodevelopmental abnormalities align with progressive neurodegeneration seen in PLA2G6-associated disorders.  
2. **Neuromuscular involvement**: Muscle weakness and elevated creatine kinase (CK) suggest myopathy or axonal degeneration, consistent with PLA2G6-related infantile neuroaxonal dystrophy (INAD).  
3. **Seizures**: Common in advanced stages of PLA2G6-associated neurodegeneration due to cortical and basal ganglia iron accumulation.  
4. **Hepatosplenomegaly**: While atypical for classic NBIA, PLA2G6 mutations can rarely cause liver iron overload or secondary lipid storage, contributing to organ enlargement.  
5. **Elevated LDH and AST**: Reflects muscle breakdown (LDH, AST) and possible subclinical hepatic involvement, though AST may also originate from muscle damage.  
6. **Exclusion of mimics**: Elevated CK and neurodegeneration distinguish this from lysosomal storage disorders (e.g., Niemann-Pick), while hepatosplenomegaly and brain iron accumulation differentiate it from mitochondrial diseases.  
7. **Genetic confirmation**: PLA2G6 mutations (autosomal recessive) confirm NBIA 2B, linking neurodegeneration, iron deposition on MRI, and biochemical abnormalities."
"['Shawl scrotum', 'High palate', 'Hypertelorism', 'Micrognathia', 'Anteverted nares', 'Ptosis', 'Intellectual disability', 'Joint laxity', 'Metatarsus adductus', 'Short stature']",['Aarskog-Scott syndrome/Aarskog-Scott syndrome'],"Disease: Aarskog-Scott syndrome  
Reasoning:  
1. **Shawl scrotum**: Pathognomonic feature of Aarskog-Scott syndrome, characterized by a scrotal fold encircling the base of the penis.  
2. **Craniofacial features**: Hypertelorism (wide-set eyes), ptosis (drooping eyelids), high palate, micrognathia (small jaw), and anteverted nares (upturned nostrils) align with the syndrome’s distinct facial phenotype.  
3. **Musculoskeletal anomalies**: Joint laxity and metatarsus adductus (inwardly curved forefoot) are consistent with skeletal manifestations of the disorder.  
4. **Growth and development**: Short stature and mild-to-moderate intellectual disability are common systemic features.  
5. **Exclusion of mimics**: Overlapping features with Noonan or Fragile X syndromes are ruled out due to the absence of their hallmark signs (e.g., pulmonic stenosis, macroorchidism) and the presence of pathognomonic shawl scrotum.  
6. **Genetic correlation**: X-linked inheritance (FGD1 gene mutations) supports the clinical diagnosis."
"['Oral ulcer', 'Cutis marmorata', 'Hemiparesis', 'Fever', 'Abdominal pain', 'Ischemic stroke', 'Headache', 'Vertigo', 'Arthralgia', 'Antinuclear antibody positivity', 'Increased circulating antibody level', 'Elevated circulating C-reactive protein concentration', 'Oculomotor nerve palsy']","['Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome', 'Deficiency of adenosine deaminase 2']","Disease: Deficiency of adenosine deaminase 2  
Reasoning: The patient’s ischemic stroke, cutis marmorata (livedo racemosa), and oculomotor nerve palsy strongly suggest vasculopathic or vasculitic involvement of small-to-medium vessels, a hallmark of DADA2. Systemic inflammation (fever, elevated CRP), arthralgia, abdominal pain, and autoantibody positivity (ANA) align with DADA2’s autoinflammatory phenotype. Early-onset strokes and neurologic deficits (hemiparesis, vertigo, headache) are characteristic, while oral ulcers and immune dysregulation (elevated antibodies) further support this diagnosis.  

Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning: Fever, arthralgia, elevated CRP, and oral ulcers fit VEXAS’s autoinflammatory profile. Cutis marmorata and antinuclear antibody positivity suggest underlying vasculitis. However, ischemic stroke and oculomotor palsy are atypical for VEXAS, which more commonly involves macrocytic anemia, chondritis, or neutrophilic dermatosis. The absence of explicit hematologic defects (e.g., cytopenias) in the listed symptoms weakens this diagnosis, though immunodeficiency (elevated antibodies) and systemic inflammation remain compatible."
"['Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Death in infancy', 'Death in childhood', 'Abnormality of galactoside metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's abnormality of galactoside metabolism directly indicates a defect in galactose processing, a hallmark of galactosemia. Classic galactosemia (GALT deficiency) causes toxic accumulation of galactose metabolites, leading to intellectual disability, delayed speech, and neurobehavioral symptoms (hyperactivity, atypical behavior). Untreated, severe metabolic derangements (e.g., liver failure, sepsis) result in early mortality (infancy/childhood). These findings align with the clinical and biochemical profile of classic galactosemia.  "
"['Cryptorchidism', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Broad alveolar ridges', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Strabismus', 'Deeply set eye', 'Downslanted palpebral fissures', 'Visual impairment', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Hypotonia', 'Global developmental delay', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Macrodontia', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Ventriculomegaly', 'Delayed gross motor development', 'Duodenal atresia', 'Tetraparesis', 'Focal impaired awareness seizure', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Incisor macrodontia', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Squared superior portion of helix', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Cerebral visual impairment', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental core features**: The patient exhibits *global developmental delay*, *absent speech*, *delayed speech/language development*, *hyperactivity*, and *ADHD*, aligning with the neurodevelopmental axis of NEDBEH.  
2. **Brain anomalies**: *Abnormal corpus callosum morphology*, *cerebellar vermis hypoplasia*, *CNS/cerebral hypomyelination*, and *abnormal pons/hippocampus morphology* are hallmark brain structural defects in NEDBEH.  
3. **Ocular involvement**: *Coloboma*, *microphthalmia*, *strabismus*, *visual impairment*, *optic atrophy*, and *Peters anomaly* match the ""eye anomalies"" spectrum of the disorder.  
4. **Cardiac defects**: *Ventricular septal defect*, *patent ductus arteriosus*, and *abnormal cardiac septum morphology* fulfill the ""heart anomalies"" criterion.  
5. **Craniofacial/somatic features**: *Microcephaly/macrocephaly*, *triangular face*, *micrognathia*, *cleft lip*, *hypertelorism*, and *epicanthus* are consistent with facial dysmorphisms seen in NEDBEH. Additional features like *syndactyly*, *sacral hypertrichosis*, and *growth delay* support syndromic overlap.  
6. **Systemic/gastrointestinal anomalies**: *Annular pancreas*, *duodenal/pyloric stenosis*, and *hip dysplasia* correlate with reported gastrointestinal/musculoskeletal involvement in NEDBEH.  
7. **Genetic plausibility**: While not specified here, NEDBEH is often linked to *de novo SMARCC2* variants, which disrupt chromatin remodeling—a process critical for neurodevelopment and organogenesis, explaining the multi-system phenotype.  

The convergence of neurodevelopmental delay, brain malformations, ocular/cardiac defects, and variable dysmorphic/systemic features strongly supports this diagnosis over isolated syndromes (e.g., CHARGE, Noonan) due to the absence of pathognomonic features (e.g., choanal atresia in CHARGE is nonspecific here) and the broad phenotypic spectrum of NEDBEH."
"['Petechiae', 'Thrombocytopenia', 'Decreased mean platelet volume', 'Megakaryocytopenia']",['Thrombocytopenia 3'],"Thrombocytopenia 3: The patient presents with thrombocytopenia, megakaryocytopenia (reduced bone marrow megakaryocytes), and decreased mean platelet volume (MPV), all indicative of impaired platelet production. Thrombocytopenia 3 (THC3), a rare autosomal recessive disorder caused by mutations in the *MPL* gene, disrupts thrombopoietin receptor signaling, leading to defective megakaryocyte maturation and platelet synthesis. Petechiae arise from severe thrombocytopenia. Unlike immune-mediated thrombocytopenia (e.g., ITP), THC3 features hypocellular megakaryocytes and low MPV due to reduced platelet turnover, aligning with the observed profile. Genetic testing for *MPL* variants would confirm the diagnosis."
"['Abnormality of the dentition', 'Alopecia', 'Increased susceptibility to fractures', 'Low alkaline phosphatase', 'Short stature', 'Miscarriage', 'Fatigue', 'Lower limb pain', 'Ectopic pregnancy']","['Hypophosphatasia; HPP/Hypophosphatasia', 'Hypophosphatasia, adult']","Disease: Hypophosphatasia; HPP/Hypophosphatasia  
Reasoning:  
1. **Low alkaline phosphatase**: A pathognomonic feature of HPP due to mutations in the *ALPL* gene, causing deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity.  
2. **Increased susceptibility to fractures** and **lower limb pain**: Impaired bone mineralization from accumulated inorganic pyrophosphate (PPi) leads to osteomalacia, fragility fractures, and bone pain.  
3. **Abnormality of the dentition**: Premature loss of deciduous teeth (especially incisors) due to defective cementum formation.  
4. **Short stature**: Result of skeletal hypomineralization and growth plate abnormalities.  
5. **Fatigue**: Linked to muscle weakness or chronic pain secondary to skeletal pathology.  
6. **Miscarriage** and **ectopic pregnancy**: HPP may disrupt placental calcification or uterine environment, increasing pregnancy complications (reported in severe or perinatal forms).  

Disease: Hypophosphatasia, adult  
Reasoning:  
1. **Persistent low alkaline phosphatase**: Confirms ongoing TNSALP deficiency in adulthood.  
2. **Recurrent fractures** and **limb pain**: Adult-onset HPP often manifests with stress fractures, pseudofractures, and musculoskeletal pain.  
3. **Dental abnormalities**: Adult patients may retain childhood dental issues (e.g., tooth loss) or develop periodontitis.  
4. **Fatigue**: Chronic bone and muscle involvement contribute to systemic symptoms.  
5. **Reproductive complications**: While less common in adult HPP, metabolic disturbances could theoretically predispose to ectopic pregnancy or miscarriage.  

**Note**: Alopecia is atypical for HPP and may suggest a comorbid condition, requiring further evaluation."
"['High palate', 'Thick eyebrow', 'Dental malocclusion', 'Postaxial hand polydactyly', 'Prominent fingertip pads', 'Seizure', 'Global developmental delay', 'Intrauterine growth retardation', 'Clinodactyly of the 5th finger', 'Recurrent subcortical infarcts', 'Cutaneous finger syndactyly']",['Orofaciodigital syndrome type 5/Orofaciodigital syndrome V'],"Disease: Orofaciodigital syndrome type 5/Orofaciodigital syndrome V  
Reasoning:  
1. **Oral features**: High palate and dental malocclusion align with characteristic oral abnormalities in OFD syndromes.  
2. **Facial features**: Thick eyebrows are consistent with facial dysmorphisms seen in OFD5.  
3. **Digital anomalies**: Postaxial hand polydactyly, clinodactyly of the 5th finger, cutaneous syndactyly, and prominent fingertip pads reflect the hallmark digital manifestations of OFD5.  
4. **Neurological involvement**: Seizures and global developmental delay suggest central nervous system involvement, which is reported in OFD5.  
5. **Prenatal and vascular findings**: Intrauterine growth retardation may correlate with systemic developmental disruptions, while recurrent subcortical infarcts could indicate rare vascular anomalies associated with the syndrome.  
6. **Syndrome differentiation**: The combination of postaxial polydactyly, oral/digital features, and neurological deficits distinguishes OFD5 from other OFD subtypes (e.g., OFD1 lacks polydactyly and has X-linked inheritance)."
"['Renal cyst', 'Hydronephrosis', 'Wide mouth', 'Microcephaly', 'Short chin', 'Macrotia', 'Bulbous nose', 'Strabismus', 'Upslanted palpebral fissure', 'Jaundice', 'Hypotonia', 'Global developmental delay', 'Decreased fetal movement', 'Bell-shaped thorax', 'Small nail', 'Talipes', 'Short columella', 'Respiratory distress', 'Frontal upsweep of hair', 'Thoracolumbar scoliosis', 'Chiari type I malformation', 'Bilateral cryptorchidism', 'High anterior hairline', 'Submucous cleft soft palate', 'Camptodactyly', 'Chronic constipation', 'Oral aversion', 'Bronchogenic cyst', 'Recurrent ear infections']",['Pierpont syndrome/Pierpont syndrome'],"Disease: Pierpont syndrome  
Reasoning:  
1. **Craniofacial Features**: The patient exhibits hallmark facial characteristics of Pierpont syndrome, including a wide mouth, microcephaly, short chin, macrotia, bulbous nose, upslanted palpebral fissures, short columella, and frontal hairline anomalies (high anterior hairline, frontal upsweep). These align with the distinct facial gestalt described in Pierpont syndrome.  
2. **Neurological & Developmental Signs**: Hypotonia, global developmental delay, and decreased fetal movement reflect the syndrome’s neurological involvement. Chiari type I malformation, though less common, has been reported in some cases.  
3. **Musculoskeletal Anomalies**: Bell-shaped thorax, talipes, thoracolumbar scoliosis, camptodactyly, and small nails correlate with skeletal abnormalities typical of the syndrome.  
4. **Urogenital & Renal Involvement**: Renal cysts, hydronephrosis, and bilateral cryptorchidism are consistent with genitourinary anomalies observed in Pierpont syndrome.  
5. **Respiratory & Gastrointestinal Issues**: Respiratory distress (potentially linked to bronchogenic cyst) and chronic constipation align with neuromuscular dysfunction secondary to hypotonia.  
6. **Associated Features**: Submucous cleft soft palate and recurrent ear infections may stem from craniofacial structural defects, while oral aversion is often seen in developmental disorders.  

The combination of these features, particularly the unique facial dysmorphology with multisystem involvement, strongly supports Pierpont syndrome as the diagnosis."
"['Epistaxis', 'Hemoptysis', 'Pulmonary infiltrates', 'Arthralgia', 'Microscopic hematuria', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Cytoplasmic antineutrophil antibody positivity']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Respiratory involvement**: Epistaxis (nasal inflammation) and hemoptysis (alveolar hemorrhage) with pulmonary infiltrates suggest granulomatous inflammation and vasculitis in the upper/lower respiratory tract.  
2. **Renal involvement**: Microscopic hematuria and decreased glomerular filtration rate indicate pauci-immune glomerulonephritis, a hallmark of systemic vasculitis.  
3. **Systemic inflammation**: Elevated C-reactive protein and arthralgia reflect systemic inflammation.  
4. **Immunological markers**: Cytoplasmic antineutrophil antibody (c-ANCA) positivity, typically targeting PR3, strongly supports GPA.  
5. **Triad alignment**: Combined respiratory, renal, and systemic features with c-ANCA positivity fulfill diagnostic criteria for GPA, distinguishing it from other ANCA-associated vasculitides (e.g., microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis)."
"['Hypertelorism', 'Anteverted nares', 'Self-mutilation', 'Delayed speech and language development', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Abnormal foot morphology', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Severe hearing impairment']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Hypocholesterolemia and elevated 7-/8-dehydrocholesterol are pathognomonic for SLOS, caused by *DHCR7* mutations impairing cholesterol biosynthesis.  
2. **Craniofacial features**: Hypertelorism and anteverted nares align with SLOS-associated dysmorphism.  
3. **Limb/skeletal anomalies**: Syndactyly and abnormal foot morphology are classic SLOS findings (e.g., 2-3 toe syndactyly).  
4. **Neurodevelopmental issues**: Intellectual disability, speech/motor delays, seizures, and hyperactivity reflect SLOS’s neurological impact.  
5. **Sensory deficits**: Severe hearing impairment is a recognized but variable feature.  
6. **Self-injurious behavior**: Rarely reported in SLOS, potentially linked to neurodevelopmental severity.  
7. **Mortality**: Neonatal/childhood death correlates with severe SLOS phenotypes, often due to organ malformations or metabolic complications.  
*Conclusion*: Combined biochemical, dysmorphic, and developmental features confirm SLOS. Cholesterol precursor testing is diagnostic."
"['Macular degeneration', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Lethargy', 'Spasticity', 'Dystonia', 'Hyperreflexia', 'Growth delay', 'Death in infancy', 'Fever', 'Leukocytosis', 'Cerebral atrophy', 'Drowsiness', 'Sleep disturbance', 'Abnormal cerebral white matter morphology', 'Abnormality of limb bone morphology', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Paraplegia/paraparesis', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency (DPYD deficiency)  
Reasoning:  
1. **Metabolic hallmarks**: The presence of **uraciluria** and **abnormal circulating pyrimidine concentration** directly links to DPYD deficiency, as this enzyme is critical for pyrimidine catabolism. Deficiency causes accumulation of uracil, thymine, and their metabolites.  
2. **Neurological involvement**:  
   - **Seizures**, **spasticity**, **hyperreflexia**, **dystonia**, and **paraplegia/paraparesis** align with neurotoxicity from elevated pyrimidines and their derivatives (e.g., dihydropyrimidines).  
   - **Cerebral atrophy** and **abnormal cerebral white matter morphology** reflect progressive neurodegeneration due to metabolic dysfunction.  
3. **Developmental delays**: **Intellectual disability**, **delayed speech**, and **growth delay** are consistent with impaired neurodevelopment in severe metabolic disorders.  
4. **Systemic manifestations**: **Lethargy**, **drowsiness**, and **sleep disturbance** may arise from energy metabolism disruption. **Leukocytosis** and **fever** could indicate secondary infections or inflammatory responses triggered by metabolic stress.  
5. **Early mortality**: **Death in infancy/childhood** is typical in severe DPYD deficiency due to metabolic crises and neurological deterioration.  
6. **Bone abnormalities**: **Abnormality of limb bone morphology** is occasionally reported in metabolic disorders affecting nucleotide homeostasis.  

The combination of pyrimidine metabolism derangements (uraciluria), neurological deficits, and developmental delays strongly supports DPYD deficiency, distinguishing it from other neurometabolic disorders (e.g., mitochondrial diseases or leukodystrophies)."
"['Delayed cranial suture closure', 'Dental malocclusion', 'Delayed eruption of permanent teeth', 'Joint laxity', 'Wormian bones', 'Hypoplastic iliac wing', 'Depressed nasal bridge', 'Aplastic clavicle', 'Delayed pubic bone ossification', 'Supernumerary tooth']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Cleidocranial dysplasia/Cleidocranial dysplasia:  
1. **Aplastic clavicle** is a hallmark feature of cleidocranial dysplasia (CCD), often leading to hypermobile shoulders.  
2. **Delayed cranial suture closure** and **Wormian bones** reflect impaired intramembranous ossification, characteristic of CCD.  
3. **Dental malocclusion**, **delayed eruption of permanent teeth**, and **supernumerary tooth** stem from defective dental development and abnormal tooth formation, common in CCD.  
4. **Hypoplastic iliac wing** and **delayed pubic bone ossification** indicate skeletal dysplasia affecting pelvic bone development.  
5. **Depressed nasal bridge** aligns with midface hypoplasia seen in CCD.  
6. **Joint laxity** may result from connective tissue involvement in skeletal development.  
This constellation of craniofacial, dental, and skeletal anomalies is pathognomonic for CCD, typically caused by mutations in the *RUNX2* gene."
"['Gingival overgrowth', 'Nystagmus', 'Dystonia', 'Respiratory failure', 'Cerebellar vermis atrophy', 'Poor gross motor coordination', 'Reduced visual acuity', 'Infantile muscular hypotonia', 'Cognitive impairment']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Neurological and Motor Symptoms**: The patient exhibits **cerebellar vermis atrophy**, **poor gross motor coordination**, **nystagmus**, and **dystonia**, consistent with cerebellar dysfunction and spastic ataxia, hallmark features of NKX6-2-related disorders.  
2. **Hypomyelination Evidence**: **Cognitive impairment**, **reduced visual acuity** (optic nerve hypomyelination), and **respiratory failure** (brainstem involvement) align with progressive hypomyelinating leukodystrophy.  
3. **Developmental History**: **Infantile muscular hypotonia** often precedes spasticity in early disease stages.  
4. **Uncommon Features**: **Gingival overgrowth** is atypical but may represent a phenotypic variant or secondary effect of chronic neurological dysfunction.  
5. **Genetic Correlation**: NKX6-2 mutations disrupt oligodendrocyte function, causing hypomyelination, cerebellar atrophy, and motor deficits, strongly matching the symptom profile."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline', 'Uraciluria']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: The combination of **hyperammonemia**, **elevated plasma citrulline**, and **uraciluria** strongly indicates a urea cycle disorder (UCD). Citrullinemia is characterized by a defect in **argininosuccinate synthetase (ASS1)**, which prevents the conversion of citrulline to argininosuccinate. This results in citrulline accumulation (elevated plasma citrulline) and ammonia buildup (hyperammonemia). Uraciluria occurs due to secondary pyrimidine metabolism disruption. Neonatal lethality and early childhood death align with severe metabolic decompensation in untreated UCDs.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Type I (classic citrullinemia) is distinguished by **neonatal-onset** symptoms, including rapid neurological decline, hyperammonemic crises, and biochemical features like extreme citrulline elevation (often >1,000 µmol/L). The prenatal abnormalities (e.g., intrauterine growth restriction) and early mortality (infancy/childhood) correlate with the severe enzymatic deficiency in ASS1. Type II (citrin deficiency) typically presents later in life and lacks uraciluria, ruling it out here."
"['High palate', 'Thin upper lip vermilion', 'Long face', 'Smooth philtrum', 'Broad forehead', 'Macrotia', 'Deeply set eye', 'Ptosis', 'Hypotelorism', 'Intrauterine growth retardation', 'Tetralogy of Fallot', 'Gastroesophageal reflux', 'Feeding difficulties', 'Neurodevelopmental delay']","['Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome/Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies']","Disease: Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome/Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies  
Reasoning:  
1. **Facial dysmorphism**: The patient exhibits multiple facial features characteristic of the syndrome, including a *high palate*, *thin upper lip vermilion*, *long face*, *smooth philtrum*, *broad forehead*, *macrotia* (large ears), *deeply set eyes*, *ptosis* (droopy eyelids), and *hypotelorism* (reduced interpupillary distance). These align with the ""dysmorphic facies"" hallmark of the disorder.  
2. **Neurodevelopmental delay**: *Intrauterine growth retardation* and *neurodevelopmental delay* correlate with the syndrome’s ""global developmental delay"" component, reflecting prenatal and postnatal growth/developmental impairments.  
3. **Seizures**: While not explicitly listed, the diagnosis name includes seizures as a key feature. This suggests either an oversight in symptom reporting or variability in presentation (e.g., seizures may develop later or were not yet documented).  
4. **Distal limb anomalies**: Though not mentioned in the patient’s symptoms, the syndrome’s name highlights distal limb abnormalities (e.g., brachydactyly, camptodactyly). Their absence here may reflect phenotypic variability or incomplete clinical documentation.  
5. **Associated anomalies**: *Tetralogy of Fallot* (congenital heart defect) and *gastroesophageal reflux/feeding difficulties* are consistent with multisystem involvement seen in neurodevelopmental-genetic syndromes.  

**Conclusion**: The patient’s facial dysmorphism, neurodevelopmental delays, and systemic anomalies strongly align with the syndrome’s core features. Absence of explicitly reported seizures or limb anomalies may reflect diagnostic variability or incomplete phenotyping, but the overall pattern justifies the diagnosis. Genetic testing (e.g., WES) is recommended to confirm."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), the enzyme that converts phenylalanine to tyrosine. This deficiency results in the accumulation of phenylalanine, consistent with hyperphenylalaninemia.  
2. **Hypertyrosinemia**: While classic PKU typically presents with *low* tyrosine due to impaired synthesis, hypertyrosinemia in this case could suggest:  
   - **Atypical PKU variant**: Residual PAH activity or compensatory dietary tyrosine supplementation.  
   - **Secondary metabolic disruption**: Severe liver dysfunction (e.g., due to untreated PKU complications) impairing tyrosine catabolism.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early demise aligns with delayed diagnosis or poor adherence to dietary restrictions (e.g., low-phenylalanine diet).  
4. **Exclusion of alternatives**: Tyrosinemia type I/II or BH4 deficiency were considered but ruled out due to the prominence of hyperphenylalaninemia and lack of hallmark features (e.g., liver failure in tyrosinemia, neurotransmitter deficits in BH4 disorders).  

Conclusion: PKU is the primary diagnosis, with hypertyrosinemia attributed to atypical metabolic adjustments or concurrent factors."
"['Spastic paraplegia', 'Dysarthria', 'Gait ataxia', 'Limb ataxia']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spastic paraplegia** indicates upper motor neuron dysfunction, a hallmark of hereditary spastic paraplegias (HSPs).  
2. **Gait and limb ataxia** suggest cerebellar involvement, distinguishing SPG76 from ""pure"" HSP subtypes.  
3. **Dysarthria** further supports cerebellar or bulbar pathology, aligning with SPG76’s association with combined pyramidal and cerebellar features.  
4. SPG76, caused by biallelic *CAPN1* mutations, is characterized by progressive spasticity, ataxia, and dysarthria, consistent with the symptom profile.  
5. Exclusion of mimics (e.g., SPG7, SPG11) relies on genetic testing, but the clinical triad strongly supports SPG76."
"['Death in infancy', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCC deficiency)  
Reasoning:  
1. **Elevated urinary carboxylic acids**: 3-MCC deficiency disrupts leucine catabolism, causing accumulation of 3-methylcrotonyl-CoA and its derivatives (3-hydroxyisovaleric acid, 3-methylcrotonylglycine), which are excreted in urine.  
2. **Death in infancy**: Severe metabolic crises (hypoglycemia, acidosis, hyperammonemia) triggered by catabolic stressors (e.g., fasting, infection) can lead to fatal outcomes if untreated.  
3. **Severe hearing impairment**: While not a hallmark, sensorineural hearing loss may occur due to neurotoxic metabolite effects or secondary neurological damage during metabolic decompensation.  

Note: The two listed diagnoses refer to the same disorder. 3-MCC deficiency involves mutations in *MCCC1* or *MCCC2* genes, encoding subunits of the enzyme. Clinical variability exists, with some cases showing atypical features like hearing impairment."
"['Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Dystonia', 'Death in infancy', 'Athetosis', 'Spastic tetraplegia', 'Glutaric aciduria', 'Severe short stature', 'Paraplegia/paraparesis', 'Death in adolescence']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** is a hallmark biochemical feature of GA-I, directly linking to the enzyme deficiency (glutaryl-CoA dehydrogenase).  
2. **Neurological symptoms** (seizures, dystonia, athetosis, spastic diplegia/tetraplegia, paraplegia) align with basal ganglia injury caused by toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
3. **Motor delay** and **intellectual disability** reflect progressive neurodegeneration from recurrent metabolic crises.  
4. **Severe short stature** may result from chronic metabolic instability and catabolic stress.  
5. **Death in infancy/adolescence** correlates with acute encephalopathic crises triggered by infections or fasting, common in untreated/severe GA-I cases.  
6. **Spasticity** and **paraparesis** indicate corticospinal tract damage, consistent with white matter changes observed in advanced GA-I.  
7. The absence of hepatic symptoms (e.g., hypoglycemia, hyperammonemia) distinguishes GA-I from other organic acidemias, reinforcing specificity.  

This pattern matches GA-I’s pathophysiology, where disrupted lysine/tryptophan metabolism leads to neurotoxicity and multisystemic deterioration."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Autism', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Dysphagia', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Duodenal atresia', 'Tetraparesis', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Delayed myelination', 'Thick vermilion border', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Intellectual disability, autism, delayed speech/absent speech, hyperactivity, seizures, and hypotonia align with the core neurodevelopmental phenotype of NEDBEH.  
2. **Brain anomalies**: Abnormal corpus callosum morphology, CNS/cerebral hypomyelination, and delayed myelination reflect the ""brain anomalies"" component, characteristic of SMARCC1-related NEDBEH.  
3. **Eye anomalies**: Coloboma, microphthalmia, Peters anomaly, optic atrophy, and blepharophimosis are hallmark ocular findings in NEDBEH, particularly Peters anomaly (a corneal defect linked to SMARCC1 mutations).  
4. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return satisfy the ""heart anomalies"" criterion.  
5. **Craniofacial/dysmorphic features**: Microcephaly/macrocephaly (variable expressivity), triangular face, micrognathia, high palate, and narrow mouth are consistent with reported facial gestalt.  
6. **Supportive systemic features**: Gastrointestinal anomalies (annular pancreas, duodenal atresia) and genitourinary defects (hypospadias, cryptorchidism) overlap with SMARCC1-related multisystem involvement.  
7. **Exclusion of mimics**: While symptoms like café-au-lait spots or syndactyly might suggest other syndromes (e.g., RASopathies), the triad of neurodevelopmental delay + brain/eye/heart anomalies prioritizes NEDBEH.  

Key confirmatory clues include Peters anomaly, hypomyelination, and congenital heart defects, which collectively distinguish NEDBEH from phenocopies like CHARGE syndrome or chromosomal disorders."
"['Delayed speech and language development', 'Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Leukopenia', 'Hyperammonemia', 'Hyperglycinemia', 'Hyperglycinuria', 'Elevated circulating alkaline phosphatase concentration', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Abnormal circulating serine concentration', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: Propionic acidemia (PA) disrupts propionyl-CoA metabolism, leading to accumulation of toxic metabolites that inhibit the urea cycle (causing hyperammonemia) and secondary hyperglycinemia due to glycine synthesis interference.  
2. **Elevated Urinary Carboxylic Acids**: Propionyl-CoA carboxylase deficiency results in excretion of methylcitrate, 3-hydroxypropionate, and propionylglycine in urine, consistent with elevated urinary carboxylic acids.  
3. **Leukopenia & Skin Manifestations**: Toxic metabolites suppress bone marrow function (leukopenia) and may trigger eczematoid dermatitis/skin rash via immune dysregulation.  
4. **Abnormal Amino Acid/Carnitine Profiles**: Propionic acid conjugates with carnitine, causing secondary carnitine deficiency. Disrupted amino acid metabolism explains abnormal alanine, serine, and aspartate-family amino acids.  
5. **Hyperglycinuria & Alkaline Phosphatase Elevation**: Glycine overflow (hyperglycinuria) and hepatic stress (elevated alkaline phosphatase) reflect systemic metabolic derangement.  
6. **Neurological & Developmental Delays**: Chronic metabolic acidosis/ammonia toxicity impair neurodevelopment, causing speech delays.  
7. **Early Mortality**: Untreated PA leads to lethal metabolic crises in infancy/childhood; even with treatment, complications (e.g., cardiomyopathy) may cause death in adolescence.  

This constellation of metabolic, hematologic, and neurologic findings is pathognomonic for propionic acidemia."
"['Wide mouth', 'Abnormality of the gingiva', 'Thin upper lip vermilion', 'Coarse facial features', 'Full cheeks', 'Hypertelorism', 'Short philtrum', 'Prominent supraorbital ridges', 'Narrow forehead', 'Long philtrum', 'Micrognathia', 'Otitis media', 'Broad nasal tip', 'Anteverted nares', 'Torticollis', 'Strabismus', 'Deeply set eye', 'Proptosis', 'Hypermetropia', 'Myopia', 'Widely spaced teeth', 'Pectus carinatum', 'Hirsutism', 'Abnormally large globe', 'Seizure', 'Global developmental delay', 'Hypertonia', 'Plagiocephaly', 'Failure to thrive', 'Short foot', 'Frontal bossing', 'Constipation', 'Gastroesophageal reflux', 'Spastic gait', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Abnormal cerebral white matter morphology', 'Tracheomalacia', 'Short nasal bridge', 'Skeletal muscle atrophy', 'Bruxism', 'Clinodactyly of the 5th finger', 'Short stature', 'Depressed nasal bridge', 'Sparse lateral eyebrow', 'Proximal spinal muscular atrophy', 'Spinal muscular atrophy', 'Proximal placement of thumb', 'Narrow naris', ""Absent cupid's bow"", 'Stereotypical hand wringing', 'Thick vermilion border', 'Small hand', 'Hyperplasia of the maxilla']",['Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome/Skraban-Deardorff syndrome'],"Disease: Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome/Skraban-Deardorff syndrome  
Reasoning:  
1. **Facial Dysmorphism**: Key features align with Skraban-Deardorff syndrome, including *wide mouth*, *hypertelorism*, *broad nasal tip*, *thick vermilion border*, *full cheeks*, *short philtrum*, *prominent supraorbital ridges*, and *hyperplasia of the maxilla*. These collectively create a distinct facial gestalt.  
2. **Neurological Manifestations**: *Global developmental delay*, *seizures* (including *febrile seizures*), *hypertonia*, *spastic gait*, and *abnormal cerebral white matter morphology* are hallmark neurological findings in this syndrome.  
3. **Musculoskeletal Abnormalities**: *Pectus carinatum*, *clinodactyly of the 5th finger*, *short stature*, and *small hand* correlate with skeletal anomalies reported in the syndrome. *Spinal muscular atrophy* and *skeletal muscle atrophy* may reflect secondary neuromuscular involvement.  
4. **Systemic Features**: *Failure to thrive*, *gastroesophageal reflux*, and *tracheomalacia* are consistent with systemic dysregulation seen in Skraban-Deardorff.  
5. **Ocular and Dental Findings**: *Hypermetropia*, *proptosis*, *deeply set eyes*, and *widely spaced teeth* further support the diagnosis, as ocular and dental anomalies are common.  
6. **Developmental and Behavioral Traits**: *Stereotypical hand wringing* and *bruxism* align with neurodevelopmental patterns observed in the syndrome.  
7. **Genetic Overlap**: While genetic testing (e.g., *WDR26* mutations) would confirm, the phenotypic overlap (facial, neurological, skeletal) strongly points to this diagnosis over mimics like Coffin-Siris or Rett syndrome.  

This constellation of facial, neurological, and systemic features, alongside developmental delays and seizures, is pathognomonic for Skraban-Deardorff syndrome."
"['Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Dicarboxylic aciduria', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Abnormal circulating isoleucine concentration', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Abnormal BCAA Levels**: Elevated leucine and isoleucine concentrations align with MSUD's hallmark defect in branched-chain amino acid (BCAA) metabolism due to deficient branched-chain α-keto acid dehydrogenase complex.  
2. **Urinary Metabolites**: Dicarboxylic aciduria and elevated urinary carboxylic acids result from accumulation of toxic keto-acid derivatives (e.g., α-ketoisocaproic acid) from unmetabolized BCAAs.  
3. **Aminoaciduria**: Overflow of excess BCAAs in the blood overwhelms renal reabsorption, causing urinary excretion.  
4. **Clinical Symptoms**: Neonatal death, vomiting, and hypotonia reflect acute metabolic decompensation from BCAA toxicity, leading to cerebral edema and neurological decline.  
5. **Rapid Progression**: Early-onset symptoms and infant mortality are consistent with classical/severe MSUD phenotypes.  
6. **Exclusion of Fatty Acid Disorders**: While dicarboxylic aciduria may suggest fatty acid oxidation defects, the specific BCAA abnormalities and lack of hypoketotic hypoglycemia prioritize MSUD."
"['Microcephaly', 'Optic atrophy', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Ataxia', 'Spastic diplegia', 'Thromboembolism', 'Hyperhomocystinemia', 'Spastic tetraplegia', 'Hypomethioninemia', 'Death in childhood', 'Death in adolescence']","['Homocystinuria due to methylene tetrahydrofolate reductase deficiency/Homocystinuria due to deficiency of n(5,10)-methylenetetrahydrofolatereductase activity']","Disease: Homocystinuria due to methylene tetrahydrofolate reductase (MTHFR) deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypomethioninemia**: MTHFR deficiency disrupts homocysteine remethylation to methionine, causing elevated homocysteine (hyperhomocystinemia) and low methionine (hypomethioninemia). This distinguishes it from cystathionine beta-synthase (CBS)-deficient homocystinuria, where methionine is typically elevated.  
2. **Neurological Symptoms**: Severe MTHFR deficiency impairs folate metabolism, critical for myelination and neurotransmitter synthesis. Microcephaly, intellectual disability, seizures, ataxia, and spasticity (diplegia/tetraplegia) reflect widespread CNS dysfunction, including white matter abnormalities and cortical/cerebellar damage.  
3. **Optic Atrophy**: Neurodegeneration or metabolic damage to retinal ganglion cells leads to optic nerve degeneration.  
4. **Thromboembolism**: Elevated homocysteine promotes endothelial dysfunction and hypercoagulability, increasing thrombotic risk.  
5. **Early Mortality**: Severe phenotypes of MTHFR deficiency cause progressive neurological decline, respiratory failure, or thromboembolic events, often leading to death in childhood/adolescence.  
6. **Developmental Delays**: Impaired folate-dependent pathways disrupt neuronal development, resulting in delayed speech/language and global intellectual disability.  

The constellation of metabolic derangements, neurodevelopmental deficits, and thromboembolic complications aligns pathognomonically with MTHFR deficiency-associated homocystinuria."
"['Irritability', 'Ataxia', 'Coma', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Increased serum lactate', 'Stroke-like episode', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid accumulation**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in the branched-chain α-keto acid dehydrogenase (BCKDH) complex, the hallmark of MSUD.  
2. **Neurological symptoms**: Ataxia, irritability, coma, and stroke-like episodes arise from neurotoxicity caused by elevated leucine and its metabolites.  
3. **Metabolic decompensation**: Hyperammonemia and increased serum lactate reflect mitochondrial dysfunction and energy failure during metabolic crises.  
4. **Gastrointestinal involvement**: Vomiting and diarrhea are common during acute metabolic stress.  
5. **Early lethality**: Death in infancy/adolescence aligns with severe classical/intermediate MSUD phenotypes if untreated.  
6. **Secondary vulnerabilities**: Recurrent viral infections may stem from metabolic instability impairing immune responses.  
7. **Pathognomonic biochemical profile**: Combined elevation of valine, leucine, and isoleucine (with alloisoleucine) is unique to MSUD."
"['Lymphopenia', 'Pneumonia', 'Decreased circulating IgA level', 'Reduced red cell adenosine deaminase level', 'Decreased lymphocyte proliferation in response to mitogen', 'Decreased proportion of CD4-positive T cells']","['Severe combined immunodeficiency due to adenosine deaminase deficiency/Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency']","Disease: Severe combined immunodeficiency due to adenosine deaminase deficiency  
Reasoning:  
1. **Reduced red cell adenosine deaminase (ADA) level**: This is a hallmark biochemical finding in ADA-deficient SCID, as ADA is critical for purine metabolism. Its deficiency leads to toxic metabolite accumulation (dATP), impairing lymphocyte development and function.  
2. **Lymphopenia**: ADA deficiency causes profound lymphopenia due to arrested maturation and apoptosis of T, B, and NK cells.  
3. **Decreased lymphocyte proliferation in response to mitogen**: Reflects impaired T-cell function, a key feature of SCID.  
4. **Decreased proportion of CD4-positive T cells**: ADA deficiency disrupts thymic T-cell maturation, leading to T-cell lymphopenia and skewed subsets.  
5. **Decreased circulating IgA level**: While B cells may be present, humoral immunity is compromised due to lack of T-cell help, resulting in hypogammaglobulinemia.  
6. **Pneumonia**: Opportunistic infections (bacterial, viral, fungal) are typical in SCID due to combined cellular and humoral immune failure.  
The constellation of **autosomal recessive inheritance**, **T-B-NK- cell deficiency**, and **ADA enzyme deficiency** confirms the diagnosis."
"['Nystagmus', 'Hypotonia', 'Spasticity', 'Profound global developmental delay']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Nystagmus** suggests brainstem/cerebellar dysfunction, common in hypomyelinating leukodystrophies due to disrupted white matter integrity.  
2. **Hypotonia** in infancy aligns with early-onset myelin defects, as myelination is critical for proper neuronal signaling and muscle tone regulation.  
3. **Spasticity** emerges later as corticospinal tract involvement progresses, reflecting upper motor neuron damage from impaired myelination.  
4. **Profound global developmental delay** correlates with severe, diffuse hypomyelination disrupting neurodevelopment and synaptic connectivity.  
5. **NKX6-2 mutations** directly impair oligodendrocyte maturation and myelination, explaining the phenotype. Autosomal recessive inheritance matches the rarity and familial recurrence pattern.  
6. Differentiation from other leukodystrophies (e.g., Pelizaeus-Merzbacher) is based on genetic testing and absence of peripheral neuropathy."
"['Lethargy', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Anemia', 'Organic aciduria', 'Drowsiness', 'Sleep disturbance']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Organic aciduria** is a hallmark of biotinidase deficiency due to impaired activity of carboxylase enzymes (propionyl-CoA, pyruvate, and 3-methylcrotonyl-CoA carboxylases), leading to accumulation of organic acids.  
2. **Neurological symptoms (lethargy, drowsiness, spasticity)** arise from metabolic acidosis, hyperammonemia, and disrupted neurotransmitter function secondary to biotin-dependent enzyme dysfunction.  
3. **Generalized hypotonia** correlates with mitochondrial energy deficiency in muscles caused by defective pyruvate carboxylase.  
4. **Anemia** may result from bone marrow suppression due to metabolic toxicity or secondary mitochondrial dysfunction.  
5. **Sleep disturbances** and **death in infancy** reflect progressive neurological deterioration and metabolic crises if untreated. Early-onset presentations align with classic biotinidase deficiency, where symptoms manifest after biotin stores deplete postnatally. Confirmation requires serum biotinidase enzyme assay or genetic testing."
"['Micrognathia', 'Hearing impairment', 'Macrotia', 'Thick eyebrow', 'Osteoporosis', 'Memory impairment', 'Vertebral compression fracture', 'Short stature', 'Reduced bone mineral density', 'Osteolytic defects of the phalanges of the hand', 'Short digit', 'Flat face']",['Hajdu-Cheney syndrome/Hajdu-Cheney syndrome'],"Disease: Hajdu-Cheney syndrome  
Reasoning:  
1. **Osteolytic defects of the phalanges of the hand** and **short digits** are pathognomonic for Hajdu-Cheney syndrome, reflecting acro-osteolysis (progressive bone resorption).  
2. **Reduced bone mineral density**, **osteoporosis**, and **vertebral compression fractures** align with the syndrome’s severe skeletal fragility and abnormal bone remodeling.  
3. **Micrognathia**, **flat face**, and **thick eyebrows** match characteristic craniofacial dysmorphisms.  
4. **Hearing impairment** and **macrotia** correlate with otological abnormalities seen in this disorder.  
5. **Short stature** and **memory impairment** (potentially linked to cranial base anomalies or neurovascular complications) further support the diagnosis.  
The constellation of skeletal, craniofacial, and auditory findings strongly points to Hajdu-Cheney syndrome."
"['Urinary incontinence', 'Depression', 'Hallucinations', 'Apathy', 'Mental deterioration', 'Confusion', 'Dystonia', 'Slurred speech', 'Dysphagia', 'Cerebral atrophy', 'Abnormality of speech or vocalization', 'Postural instability', 'Falls', 'Cachexia', 'Hyperactive deep tendon reflexes', 'Abnormal pyramidal sign', 'Freezing of gait', 'Dyskinesia']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Early-onset parkinsonism**: Symptoms like dystonia, dyskinesia, freezing of gait, and postural instability align with early-onset Parkinsonian features.  
2. **Neuropsychiatric and cognitive decline**: Depression, apathy, hallucinations, mental deterioration, and confusion suggest rapid neurodegeneration beyond typical Parkinson’s disease, consistent with severe genetic forms.  
3. **Pyramidal involvement**: Hyperactive deep tendon reflexes and abnormal pyramidal signs (e.g., Babinski) indicate upper motor neuron dysfunction, atypical in idiopathic Parkinson’s but reported in PARK23 (VPS13C-related).  
4. **Bulbar and autonomic dysfunction**: Dysphagia, slurred speech, and urinary incontinence point to widespread neurodegeneration, including brainstem and autonomic systems.  
5. **Structural CNS changes**: Cerebral atrophy on imaging supports progressive neurodegenerative pathology.  
6. **Systemic progression**: Cachexia and frequent falls reflect advanced disease severity, typical of rapidly progressive autosomal recessive forms like PARK23.  
7. **Genetic consistency**: Autosomal recessive inheritance (implied by diagnosis) matches VPS13C mutations, which cause early-onset, aggressive parkinsonism with pyramidal and cognitive features."
"['Wrist swelling', 'Joint hypermobility', 'Abnormality of the gluteal musculature', 'Thrombocytosis', 'Leukocytosis', 'Low back pain', 'Foot pain', 'Neck pain', 'Shoulder pain', 'Elbow pain', 'Wrist pain', 'Knee pain']","['Spondyloarthropathy, susceptibility to, 1']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning:  
1. **Axial Involvement**: Low back pain and neck pain suggest inflammatory spinal involvement, a hallmark of spondyloarthropathy.  
2. **Peripheral Arthritis**: Wrist swelling and pain in multiple joints (shoulder, elbow, knee, foot) align with asymmetric peripheral arthritis seen in spondyloarthropathies.  
3. **Systemic Inflammation**: Thrombocytosis and leukocytosis indicate an active inflammatory process, consistent with immune-mediated arthropathies.  
4. **Enthesitis**: Abnormality of the gluteal musculature may reflect enthesitis (inflammation at tendon/ligament insertions) near the pelvis or hips, common in this disease group.  
5. **Genetic Predisposition**: The diagnosis code implies HLA-B27 or other genetic markers linked to spondyloarthropathy susceptibility.  
6. **Exclusion of Alternatives**: Symptoms lack symmetry (unlike rheumatoid arthritis) or overt infection (unlike reactive arthritis), favoring spondyloarthropathy. Joint hypermobility may be incidental or secondary to chronic inflammation."
"['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Neonatal death** and **death in infancy** suggest a severe, early-onset UCD, as CPS1 deficiency often manifests within days of life due to complete enzyme dysfunction.  
3. **Feeding difficulties** and **generalized hypotonia** are nonspecific but common neonatal signs of metabolic encephalopathy secondary to hyperammonemia.  
4. **Cerebral edema** arises from ammonia-induced neurotoxicity, disrupting osmotic balance and causing brain swelling.  
5. **Apathy** reflects progressive encephalopathy as ammonia levels rise.  
6. The absence of orotic acid elevation (implied by the diagnosis) distinguishes CPS1 deficiency from ornithine transcarbamylase (OTC) deficiency, another UCD.  
7. CPS1 deficiency is confirmed by genetic testing or enzyme assay, but clinical presentation and hyperammonemia without organic acidemia strongly support this diagnosis."
"['Generalized hypotonia', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Generalized hypotonia** aligns with Canavan disease, a leukodystrophy causing progressive brain tissue degeneration and impaired motor function.  
2. **Death in infancy** is consistent with the severe, rapidly progressive nature of Canavan disease, often fatal by early childhood.  
3. **Abnormal circulating aspartate family amino acid concentration** directly links to the disease’s hallmark biochemical defect: aspartoacylase deficiency, leading to elevated N-acetylaspartic acid (NAA) in blood/urine.  
4. Confirmatory evidence includes genetic testing for ASPA gene mutations and neuroimaging showing leukodystrophy (e.g., diffuse white matter degeneration).  
5. Exclusion of other leukodystrophies (e.g., Tay-Sachs, Krabbe) or amino acid metabolism disorders (e.g., citrullinemia) via clinical and biochemical differentiation."
"['Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Obesity', 'Anemia', 'Hyperammonemia', 'Progressive neurologic deterioration', 'Difficulty walking', 'Spastic tetraplegia', 'Oroticaciduria', 'Aminoaciduria', 'Difficulty climbing stairs', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Hyperornithinemia', 'Uraciluria', 'Increased circulating lactate dehydrogenase concentration', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']",['Arginase deficiency/Argininemia/Argininemia'],"Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Hyperammonemia**: Central to urea cycle disorders like arginase deficiency, as impaired arginase prevents conversion of arginine to urea and ornithine.  
2. **Oroticaciduria/Uraciluria**: Blocked urea cycle diverts carbamoyl phosphate to pyrimidine synthesis, increasing orotic acid and uracil excretion.  
3. **Aminoaciduria/Abnormal amino acid concentrations**: Elevated plasma arginine (argininemia) and secondary disturbances in aspartate-family amino acids, proline, and alanine due to metabolic dysregulation.  
4. **Neurological symptoms**: Progressive spastic tetraplegia/diplegia, motor delays, seizures, and intellectual disability stem from arginine/ammonia neurotoxicity and cerebral degeneration.  
5. **Liver involvement**: Acute/chronic hepatitis and prolonged PTT reflect hepatic dysfunction, common in urea cycle disorders due to ammonia overload and metabolic stress.  
6. **Hyperornithinemia**: Likely compensatory or secondary to arginine accumulation disrupting ornithine metabolism.  
7. **Early mortality**: Death in childhood/adolescence aligns with severe, untreated arginase deficiency causing neurological decline and metabolic crises.  
8. **LDH elevation**: Indicates tissue damage, potentially from liver injury or muscle breakdown due to spasticity.  
9. **Obesity/Anemia**: May arise from dietary management (protein restriction) or metabolic comorbidities, though less specific to the diagnosis.  

Key biochemical hallmarks (argininemia, hyperammonemia, oroticaciduria) and progressive neurologic deterioration solidify the diagnosis of arginase deficiency."
"['Macrocephaly', 'Strabismus', 'Delayed speech and language development', 'Seizure', 'Ataxia', 'Lethargy', 'Death in infancy', 'Abnormal cerebral morphology', 'Increased serum lactate', 'Drowsiness', 'Progressive neurologic deterioration', 'Sleep disturbance', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Macrocephaly**: A hallmark of Canavan disease due to spongiform degeneration of white matter and brain swelling.  
2. **Neurological Symptoms (Ataxia, Seizures, Progressive Deterioration)**: Caused by leukodystrophy disrupting myelination and neuronal function.  
3. **Abnormal Cerebral Morphology**: MRI typically shows diffuse white matter abnormalities and cyst-like changes.  
4. **Delayed Speech/Language Development**: Reflects global developmental delay from neurodegeneration.  
5. **Increased Serum Lactate & Abnormal Aspartate Metabolism**: Linked to ASPA gene mutations impairing N-acetylaspartate (NAA) breakdown, causing toxic accumulation and secondary mitochondrial dysfunction.  
6. **Lethargy/Drowsiness/Sleep Disturbance**: Result from cerebral energy deficits and neurochemical imbalances.  
7. **Fatal Early Course (Infancy/Childhood)**: Severe infantile-onset Canavan disease leads to rapid neurodegeneration and early mortality.  
8. **Strabismus**: Occurs due to optic nerve atrophy or impaired brainstem coordination.  

The combination of macrocephaly, leukodystrophy features, aspartate metabolism abnormalities, and early fatality strongly supports Canavan disease, confirmed by genetic testing for ASPA mutations or elevated NAA in urine/CSF."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Death in adolescence', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Elevated plasma citrulline and hyperammonemia are hallmark biochemical features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency. This disrupts the urea cycle, leading to ammonia accumulation. Neonatal death, death in infancy/childhood, and hypotonia align with acute neonatal-onset presentations of classic citrullinemia, where rapid ammonia toxicity causes severe neurological compromise. Motor and speech delays reflect chronic neurodevelopmental damage from recurrent hyperammonemia. Obesity may arise from metabolic dysregulation or dietary management strategies. Prenatal abnormalities (e.g., intrauterine growth restriction) and early mortality underscore the disease’s severity.  

Disease: Citrullinemia  
Reasoning: This term broadly encompasses urea cycle disorders with citrulline accumulation. The patient’s elevated citrulline, hyperammonemia, and life-threatening neonatal/childhood course are consistent with the general diagnosis. However, the specificity of neonatal death and classic biochemical profile narrows it further to type I. The inclusion of “abnormality of prenatal development” supports a congenital metabolic disorder like citrullinemia, where intrauterine ammonia exposure may affect fetal development."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Seizure', 'Hypotonia', 'Delayed CNS myelination', 'EEG abnormality', 'Sleep disturbance', 'Secondary microcephaly', 'Feeding difficulties in infancy']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Secondary microcephaly**: A hallmark of Rett syndrome, reflecting postnatal deceleration of head growth due to impaired brain development.  
2. **Delayed speech and language development**: Consistent with neurodevelopmental regression or stagnation, a core feature of Rett syndrome.  
3. **Abnormal repetitive mannerisms**: Stereotypic hand movements (e.g., wringing, tapping) are pathognomonic in Rett syndrome, though they may manifest atypically in the congenital variant.  
4. **Seizures and EEG abnormality**: Epileptic activity and abnormal EEG patterns (e.g., slow background, epileptiform discharges) are common in Rett syndrome due to cortical hyperexcitability.  
5. **Hypotonia and feeding difficulties in infancy**: Early-onset axial hypotonia and oral-motor dysfunction align with congenital variant presentations, distinguishing it from classic Rett syndrome.  
6. **Delayed CNS myelination**: Observed on neuroimaging, reflecting disrupted neuronal maturation linked to *MECP2* mutations (or related genes like *FOXG1* in congenital variants).  
7. **Sleep disturbance**: Autonomic dysfunction in Rett syndrome contributes to disrupted sleep-wake cycles.  
8. **Early-onset symptoms**: Congenital variants lack the typical 6–18-month period of normal development seen in classic Rett syndrome, instead presenting with neonatal/infantile hypotonia and developmental arrest.  
**Exclusion of mimics**: Differentiated from CDKL5 deficiency disorder (earlier seizure onset) and Angelman syndrome (distinct EEG patterns, lack of microcephaly at birth) by the combination of microcephaly, repetitive hand stereotypies, and *MECP2/FOXG1* genetic profile."
"['Low-set ears', 'Rod-cone dystrophy', 'Sparse eyelashes', 'Delayed speech and language development', 'Cafe-au-lait spot', 'Brachydactyly', 'Short stature', 'Sparse hair', 'High anterior hairline', 'Thick vermilion border', 'Delayed ability to walk', 'Sparse eyebrow']",['Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies'],"Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Brachydactyly**: Explicitly listed as a symptom, directly aligning with the syndrome's name and diagnostic criteria.  
2. **Short stature**: A core feature of the syndrome, present in the patient.  
3. **Rod-cone dystrophy**: Matches retinitis pigmentosa (RP), a hallmark of the syndrome, characterized by progressive retinal degeneration.  
4. **Sparse hair/eyebrows/eyelashes and high anterior hairline**: Consistent with ectodermal dysplasia-like features reported in some cases of the syndrome.  
5. **Thick vermilion border**: A documented facial dysmorphism in skeletal-RP overlap syndromes.  
6. **Delayed speech/walking**: Developmental delays are part of the phenotypic spectrum, possibly secondary to systemic involvement.  
7. **Cafe-au-lait spot**: While atypical, it does not exclude the diagnosis given the strong alignment of other features; may reflect phenotypic variability.  
8. Exclusion of alternatives: Key symptoms (e.g., brachydactyly, RP) distinguish this from Cohen, Bardet-Biedl, or Alström syndromes.  

Final diagnosis is supported by the triad of brachydactyly, short stature, and RP, alongside supportive dysmorphic and developmental features."
"['Abnormality of prenatal development or birth', 'Failure to thrive', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe metabolic disturbances in utero (e.g., maternal fasting-induced stress) may contribute to prenatal complications.  
2. **Failure to thrive**: Impaired fatty acid β-oxidation limits energy production during fasting, leading to poor weight gain and growth.  
3. **Neonatal death/Death in infancy/Death in childhood**: Untreated MCADD causes life-threatening hypoglycemia, hyperammonemia, and metabolic crises triggered by catabolic stress (e.g., infections, fasting).  
4. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to urinary loss of acylcarnitines (e.g., octanoylcarnitine), a hallmark of MCADD.  

Key biochemical link: MCADD disrupts medium-chain fatty acid oxidation, leading to toxic metabolite accumulation (e.g., medium-chain acylcarnitines), hypoglycemia, and energy deficiency, aligning with the clinical and metabolic features described."
"['Sloping forehead', 'Bulbous nose', 'Abnormality of eye movement', 'Upslanted palpebral fissure', 'Delayed speech and language development', 'Eczema', 'Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Absent speech', 'Decreased fetal movement', 'Oligohydramnios', 'Asthma', 'Global brain atrophy', 'Developmental regression', 'Ventilator dependence with inability to wean', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Severe global developmental delay', 'Brain atrophy']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial dysmorphism**: ""Sloping forehead,"" ""bulbous nose,"" ""upslanted palpebral fissure,"" and ""tented upper lip vermilion"" align with the characteristic facies of TBCK syndrome, which often includes coarse facial features and distinct lip morphology.  
2. **Neurological/developmental features**: ""Severe global developmental delay,"" ""intellectual disability,"" ""absent speech,"" and ""developmental regression"" correlate with the syndrome’s hallmark psychomotor retardation. ""Seizure"" and ""global brain atrophy"" are consistent with progressive neurological involvement.  
3. **Hypotonia**: ""Severe muscular hypotonia"" and ""generalized hypotonia"" are cardinal features of TBCK-related disorders, often leading to respiratory complications like ""ventilator dependence with inability to wean.""  
4. **Prenatal/neonatal history**: ""Decreased fetal movement"" and ""oligohydramnios"" suggest congenital onset, reported in severe TBCK cases.  
5. **Comorbidities**: ""Eczema"" and ""asthma"" are common immune-related associations in TBCK syndrome.  
6. **Exclusion of mimics**: The combination of hypotonia, distinct facies, brain atrophy, and developmental regression differentiates TBCK from other neurogenetic disorders (e.g., Rett syndrome or mitochondrial disorders). Genetic testing for TBC1-domain-containing kinase (TBCK) mutations would confirm the diagnosis."
"['Otitis media', 'Cyanosis', 'Pericardial effusion', 'Abnormal toe morphology', 'Pleural effusion', 'Arthralgia', 'Peripheral neuropathy', 'Abnormal cardiovascular system physiology', 'Gangrene']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Granulomatosis with polyangiitis (GPA):  
1. **Otitis media**: GPA frequently involves upper respiratory tract inflammation, leading to chronic otitis media or sinusitis.  
2. **Cyanosis & Pleural/Pericardial effusions**: Systemic vasculitis in GPA can cause lung parenchymal disease (nodules, hemorrhage) and serositis, reducing oxygenation (cyanosis) and triggering fluid accumulation in pleural/pericardial spaces.  
3. **Arthralgia & Peripheral neuropathy**: Immune-mediated vascular inflammation damages joints and vasa nervorum, causing joint pain and neuropathic symptoms.  
4. **Abnormal cardiovascular physiology**: Vasculitis-induced endothelial injury disrupts blood flow dynamics, while pericardial effusion exacerbates cardiac dysfunction.  
5. **Gangrene & Abnormal toe morphology**: Necrotizing vasculitis compromises distal blood supply, leading to ischemic tissue damage (gangrene) and structural toe changes (e.g., digital clubbing or necrosis).  
6. **Multi-organ involvement**: The combination of ENT, pulmonary, cardiovascular, musculoskeletal, and peripheral vascular symptoms aligns with GPA’s systemic nature. ANCA-associated pathology (e.g., PR3-ANCA) further supports this diagnosis."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: While classic PAH-deficient PKU typically results in normal/low tyrosine, this symptom suggests a **tetrahydrobiopterin (BH4) deficiency variant** of PKU. BH4 is a cofactor for PAH *and* tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, explaining the dual elevation.  
3. **Death in early adulthood**: Untreated PKU (especially severe forms or BH4 deficiency) leads to irreversible neurological damage, seizures, and organ dysfunction, contributing to reduced lifespan without early dietary or BH4 supplementation therapy.  

The diagnosis aligns with PKU, with hypertyrosinemia implicating a BH4-deficient subtype as the underlying mechanism."
"['Renal insufficiency', 'Renal cyst', 'Visual loss', 'Hypertension', 'Purpura', 'Hepatic steatosis', 'Hepatic cysts', 'Tubulointerstitial nephritis', 'Nausea', 'Abnormal lung morphology', 'Dyspnea', 'Headache', 'Microscopic hematuria', 'Nephrosclerosis', 'Pyuria', 'Fatigue', 'Peripheral edema', 'Bacteriuria', 'Moderate albuminuria', 'Cough', 'Nitrituria', 'Mediastinal lymphadenopathy']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient presents with **mediastinal lymphadenopathy**, **abnormal lung morphology**, **dyspnea**, and **cough**, which are hallmark features of pulmonary sarcoidosis. **Tubulointerstitial nephritis**, **microscopic hematuria**, and **moderate albuminuria** align with renal sarcoidosis, a common extrapulmonary manifestation. **Visual loss** suggests ocular involvement (e.g., uveitis), while **hepatic steatosis** and elevated liver enzymes (implied by hepatic cysts) may reflect hepatic granulomas. **Hypertension** and **nephrosclerosis** could result from chronic kidney injury secondary to sarcoidosis. **Fatigue** and **headache** are systemic inflammatory symptoms. Although **renal/hepatic cysts** and **purpura** are atypical, they may coexist due to secondary complications or genetic predisposition.  

Sarcoidosis, susceptibility to, 2:  
The genetic susceptibility variants (e.g., HLA-DRB1 or BTNL2 mutations) could explain the multi-organ involvement and severity. The overlapping features—**lymphadenopathy**, **interstitial lung disease**, **uveitis**, and **renal inflammation**—are consistent with a systemic granulomatous process. **Bacteriuria** and **nitrituria** likely reflect unrelated UTIs, while **peripheral edema** and **nausea** stem from renal insufficiency. The atypical **hepatic cysts** might indicate concurrent metabolic dysfunction or incidental findings, but the core phenotype strongly supports sarcoidosis susceptibility."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative metabolism of excess phenylalanine, forming phenylketones excreted in urine.  
3. **Abnormality of prenatal development or birth** may occur in maternal PKU syndrome if the mother has uncontrolled phenylalanine levels during pregnancy, though this symptom is secondary.  
4. **Death in infancy/childhood/neonatal death** aligns with untreated PKU, as toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure without early dietary intervention.  
5. **Increased total bilirubin** is atypical for classic PKU but could indicate transient neonatal jaundice, a common comorbidity in newborns, not directly linked to PKU pathology.  
The combination of hyperphenylalaninemia and phenylketonuria-confirming urinary metabolites strongly supports PKU, with poor outcomes reflecting lack of newborn screening or treatment."
"['Macrocephaly', 'Seizure', 'Death in infancy', 'Anemia', 'Fever', 'Glutaric aciduria', 'Death in childhood']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and related metabolites.  
2. **Macrocephaly**: A hallmark of GA-I, often presenting prenatally or in early infancy due to abnormal brain development or fluid accumulation (e.g., subdural hygromas).  
3. **Seizures**: Result from metabolic crises triggered by catabolic stressors (e.g., fever, infection), causing acute neurotoxicity from accumulating metabolites.  
4. **Death in infancy/childhood**: Untreated GA-I leads to severe encephalopathic crises, irreversible striatal damage, and early mortality without dietary and metabolic management.  
5. **Anemia**: May arise secondary to metabolic disturbances or bone marrow suppression during acute illness.  
6. **Fever**: Often precipitates metabolic decompensation, exacerbating glutaric acid and 3-hydroxyglutaric acid accumulation, worsening neurological symptoms.  
The combination of macrocephaly, metabolic acidosis (implied by glutaric aciduria), and neurological deterioration aligns pathognomonically with GA-I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine in the blood.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate, phenyllactate), which are carboxylic acids excreted in urine.  
3. **Neonatal death/Death in infancy**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, often fatal in early life without dietary intervention.  
4. **Death in early adulthood**: Chronic complications (e.g., intellectual disability, behavioral issues, osteoporosis) in untreated individuals may reduce lifespan.  
5. **Abnormality of prenatal development**: Maternal PKU during pregnancy (if the mother is untreated) causes fetal exposure to high phenylalanine, leading to congenital anomalies (e.g., microcephaly, cardiac defects).  
6. **Hypertyrosinemia discrepancy**: Typically, PKU causes *low* tyrosine due to impaired PAH activity. This symptom may reflect a coexisting condition (e.g., tyrosinemia), laboratory error, or misreporting but does not exclude PKU as the primary diagnosis.  

Note: Hypertyrosinemia is atypical for PKU and warrants further investigation for overlapping metabolic disorders (e.g., BH4 deficiency or tyrosinemia), but the core symptoms align conclusively with PKU."
"['Abnormal renal tubule morphology', 'Enlarged kidney', 'Nephritis', 'Hematuria', 'Hypertension', 'Seizure', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Polydipsia', 'Vomiting', 'Anorexia', 'Hepatomegaly', '4-Hydroxyphenylpyruvic aciduria', 'Abdominal distention', 'Aminoaciduria', 'Death in childhood', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating tyrosine concentration', 'Abdominal mass']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type I  
Reasoning:  
1. **Hepatic and Renal Involvement**: Symptoms like cirrhosis, hepatic fibrosis, hepatomegaly, abnormal renal tubule morphology, and nephritis indicate combined liver and kidney dysfunction, a hallmark of Tyrosinemia type I (HT-1).  
2. **Metabolic Abnormalities**: Elevated 4-hydroxyphenylpyruvic aciduria and abnormal tyrosine levels directly point to a defect in tyrosine metabolism, specifically a deficiency of fumarylacetoacetate hydrolase (FAH) in HT-1.  
3. **Infant/Childhood Fatality**: Death in infancy or childhood aligns with the severe, progressive nature of untreated HT-1, which causes liver failure and renal tubular damage.  
4. **Secondary Manifestations**: Hypertension (renal origin), seizures (neurotoxicity from metabolites like succinylacetone), aminoaciduria (renal tubular dysfunction), and elevated alpha-fetoprotein (hepatocyte regeneration/cancer risk) are consistent with HT-1 complications.  
5. **Gastrointestinal Symptoms**: Vomiting, anorexia, and abdominal distention reflect metabolic acidosis and liver dysfunction.  
6. **Diagnostic Confirmation**: The combination of hepatic fibrosis, renal Fanconi-like syndrome (aminoaciduria), and specific tyrosine pathway abnormalities excludes other metabolic disorders (e.g., galactosemia, Wilson disease) and confirms HT-1."
"['Hydrocephalus', 'Death in infancy', 'Anemia', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid and glutaric aciduria**: Directly linked to **glutaryl-CoA dehydrogenase deficiency**, the hallmark of GA-I, which disrupts lysine and tryptophan metabolism, causing toxic accumulation of glutaric acid.  
2. **Decreased plasma free carnitine**: Carnitine binds to glutaric acid to form glutarylcarnitine for excretion, depleting free carnitine.  
3. **Hydrocephalus/macrocephaly**: GA-I causes frontotemporal atrophy and subdural fluid collections, often mistaken for hydrocephalus. Metabolic crises may exacerbate cerebral edema.  
4. **Anemia**: Chronic metabolic stress or carnitine deficiency can impair erythropoiesis.  
5. **Death in infancy**: Untreated GA-I leads to severe encephalopathy, dystonia, and metabolic decompensation, often fatal early in life without dietary and carnitine therapy.  
The combination of biochemical findings (glutaric aciduria, low carnitine) and clinical features (neurological abnormalities, early mortality) confirms GA-I."
"['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Occipital neuralgia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Death in infancy/Neonatal death/Death in childhood**: Untreated PKU leads to severe neurotoxicity from phenylalanine accumulation, resulting in irreversible brain damage, seizures, and early mortality without dietary intervention.  
3. **Hypertyrosinemia**: Atypical but possible in PKU variants (e.g., BH4-deficient PKU), where impaired tyrosine metabolism or secondary metabolic disruptions may elevate tyrosine.  
4. **Occipital neuralgia**: Chronic neurotoxicity in PKU can cause peripheral nerve dysfunction or central pain pathways disruption, though this is a rare manifestation.  

Note: Classic PKU typically presents with *low* tyrosine, but coexisting hypertyrosinemia may suggest a complex metabolic interplay or diagnostic overlap with other tyrosinemia-related disorders. However, hyperphenylalaninemia remains the critical indicator for PKU."
"['Alopecia', 'Vomiting', 'Diarrhea', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Vomiting and diarrhea** may occur in untreated PKU due to metabolic instability or secondary effects of phenylalanine toxicity on gastrointestinal function.  
3. **Alopecia** is atypical in classic PKU but could arise from severe malnutrition, micronutrient deficiencies (e.g., biotin), or comorbid autoimmune conditions exacerbated by chronic metabolic stress.  
4. **Death in early adulthood** aligns with untreated/severe PKU, where long-term complications (neurodegeneration, organ damage) or acute metabolic crises reduce life expectancy.  
5. Classic PKU symptoms (e.g., intellectual disability, seizures) may be absent if partially treated, but hyperphenylalaninemia remains critical for diagnosis. Early dietary management failure could explain the atypical progression."
"['Glaucoma', 'Myopia', 'Hypotonia', 'Joint hypermobility', 'Recurrent fractures', 'Proportionate short stature', 'Retinal dysplasia', 'Knee pain', 'Ankle pain']","['Stickler syndrome type 2/Stickler syndrome, type II']","Disease: Stickler syndrome type 2  
Reasoning:  
1. **Ocular features**: Glaucoma, high myopia, and retinal dysplasia are hallmark signs of Stickler syndrome, particularly type 2, which is linked to mutations in the *COL11A1* gene affecting collagen XI. Retinal dysplasia is a key distinguishing feature of type 2.  
2. **Musculoskeletal involvement**: Joint hypermobility, hypotonia, and chronic joint pain (knee/ankle) align with connective tissue abnormalities caused by collagen defects.  
3. **Skeletal anomalies**: Recurrent fractures and proportionate short stature suggest underlying bone fragility, which, while less common in Stickler syndrome, can occur due to collagen-related structural weaknesses.  
4. **Exclusion of other disorders**: The absence of cleft palate (common in type 1 Stickler) and the presence of retinal dysplasia favor type 2. Ehlers-Danlos or osteogenesis imperfecta are less likely due to the prominent ocular findings.  
5. **Collagen pathway correlation**: Type 2 Stickler’s association with *COL11A1* explains the combination of ocular, auditory (if present), and joint abnormalities, though hearing loss may not always be reported initially."
"['Seizure', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hepatomegaly', 'Tachypnea', 'Neonatal death', 'Feeding difficulties', 'Functional abnormality of the gastrointestinal tract', 'Metabolic alkalosis']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
**Reasoning**:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), including argininosuccinic aciduria (ASA), due to impaired ammonia detoxification.  
2. **Vomiting**, **tachypnea**, and **metabolic alkalosis** align with UCDs: vomiting induces alkalosis, while hyperammonemia triggers compensatory tachypnea.  
3. **Seizures** and **coma** result from neurotoxicity caused by elevated ammonia.  
4. **Hepatomegaly** and **increased serum lactate** suggest secondary mitochondrial dysfunction or hepatic stress from metabolic overload.  
5. **Feeding difficulties** and **GI tract abnormalities** are common in neonates with UCDs due to metabolic instability.  
6. **Generalized hypotonia** reflects neurological impairment.  
7. **Neonatal death**/**death in infancy** underscores the severity of untreated ASA, which typically presents catastrophically in the first days of life.  
8. ASA is confirmed by elevated argininosuccinic acid in blood/urine, consistent with argininosuccinate lyase deficiency.  

This constellation of symptoms, metabolic derangements, and clinical course strongly supports ASA as the diagnosis."
"['Strabismus', 'Nystagmus', 'Intellectual disability', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: Core feature of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development.  
2. **Ataxia, motor delay, hypotonia, hyporeflexia**: Directly linked to cerebellar dysfunction and neuromuscular involvement.  
3. **Strabismus/nystagmus**: Ocular motor abnormalities due to cerebellar/brainstem malformations.  
4. **Encephalopathy**: Metabolic instability from glycosylation defects affecting multiple organ systems.  
5. **Intellectual disability/growth delay**: Result from systemic glycosylation failure impacting neurodevelopment and metabolism.  
6. **Death in infancy**: Severe PMM2-CDG phenotypes often lead to early mortality due to multiorgan failure.  
7. **Consistency with PMM2-CDG**: The triad of cerebellar anomalies, neurodevelopmental deficits, and multisystem involvement aligns with type Ia CDG pathophysiology."
"['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Intellectual disability**, **delayed speech/language development**, and **motor delay** align with untreated PKU, as elevated phenylalanine disrupts neurotransmitter synthesis and myelination.  
3. **Severe short stature** may result from chronic malnutrition due to restrictive dietary management or secondary metabolic disturbances.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low/normal). This may suggest a concurrent metabolic disorder, lab artifact, or a rare PKU variant with secondary tyrosine dysregulation.  
5. **Death in infancy/childhood** is uncommon in isolated PKU but could occur in severe, untreated cases with catastrophic neurological complications or misdiagnosis (e.g., confusion with BH4 deficiency, which has overlapping hyperphenylalaninemia but worse prognosis).  

Note: While PKU explains hyperphenylalaninemia and neurodevelopmental delays, the presence of hypertyrosinemia and early mortality warrants further investigation for comorbid conditions (e.g., tyrosinemia, BH4 deficiency) or diagnostic errors."
"['Seborrheic dermatitis', 'Death in infancy', 'Increased serum lactate', 'Fair hair', 'Brittle hair', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'White hair', 'Death in adolescence']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Metabolic abnormalities**: Increased serum lactate and hyperalaninemia indicate mitochondrial dysfunction and impaired amino acid metabolism, consistent with biotin-dependent carboxylase deficiencies (e.g., pyruvate carboxylase, propionyl-CoA carboxylase).  
2. **Dermatological features**: Seborrheic dermatitis and hair abnormalities (brittle, fair/white hair) result from biotin’s critical role in keratin synthesis and epidermal integrity.  
3. **Early mortality**: Neonatal/childhood death aligns with untreated BTDD’s progressive metabolic crises (acidosis, hyperammonemia) and neurologic deterioration.  
4. **Diagnostic confirmation**: BTDD specifically disrupts biotin recycling, causing secondary multiple carboxylase deficiency. Symptoms resolve with biotin supplementation, underscoring the enzyme deficiency as the root cause."
"['Microcephaly', 'Generalized hypotonia', 'Death in infancy', 'Cerebral cortical atrophy', 'Athetosis', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine', 'Death in adolescence', 'Abnormal circulating acetylcarnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Cerebral cortical atrophy** and **microcephaly** reflect neurodegenerative changes from neurotoxic metabolite accumulation, particularly affecting the basal ganglia (evidenced by **athetosis**) and cortical neurons.  
3. **Generalized hypotonia** aligns with early neurological dysfunction in GA-I, often preceding acute metabolic crises triggered by catabolic stressors.  
4. **Decreased plasma free carnitine** and **abnormal acetylcarnitine** levels occur due to secondary carnitine depletion from conjugating glutaric acid, a hallmark of GA-I.  
5. **Death in infancy/adolescence** correlates with untreated or severe cases, as metabolic crises cause irreversible brain damage, while neonatal death is atypical but possible in profound enzyme deficiency.  
6. The symptom constellation (neurodegeneration, organic aciduria, carnitine derangements) is diagnostic for GA-I, distinguishing it from other organic acidemias."
"['Micropenis', 'Gingival overgrowth', 'Long philtrum', 'Micrognathia', 'Anteverted nares', 'Proptosis', 'Bifid ribs', 'Bicuspid aortic valve', 'Frontal bossing', 'Hemivertebrae', 'Elbow dislocation', 'Acromesomelia', 'Short stature', 'Depressed nasal bridge', 'Eversion of lateral third of lower eyelids', 'Microtia', 'Short finger', 'Limb undergrowth', 'Cleft lower lip']","['Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive']","Disease: Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive  
Reasoning:  
1. **Craniofacial Features**: Micrognathia (small jaw), long philtrum, anteverted nares, depressed nasal bridge, frontal bossing (prominent forehead), proptosis (bulging eyes), and eversion of the lateral third of the lower eyelids align with the characteristic facial dysmorphology of Robinow syndrome.  
2. **Skeletal Anomalies**: Bifid ribs, hemivertebrae (spinal malformations), elbow dislocation, acromesomelia (shortened distal limbs), limb undergrowth, and short fingers are hallmark skeletal defects in autosomal recessive Robinow syndrome.  
3. **Genitourinary/Genital Involvement**: Micropenis is a key feature of the autosomal recessive form, distinguishing it from the milder dominant type.  
4. **Oral/Dental Abnormalities**: Gingival overgrowth and cleft lower lip are frequently observed in recessive Robinow syndrome.  
5. **Auxiliary Findings**: Short stature, microtia (small ears), and bicuspid aortic valve (cardiac anomaly) further support the diagnosis, as these are common systemic manifestations.  
6. **Exclusion of Differential Diagnoses**: The combination of severe skeletal, craniofacial, and genital abnormalities differentiates this from other acromesomelic dysplasias or syndromes with overlapping features (e.g., Simpson-Golabi-Behmel or Cornelia de Lange syndrome).  
7. **Genetic Basis**: Autosomal recessive inheritance (linked to *ROR2* gene mutations) correlates with the severity of observed symptoms, including pronounced skeletal defects and genital hypoplasia."
"['Death in infancy', 'Hyperammonemia', 'Oroticaciduria', 'Short stature']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: OTCD disrupts the urea cycle, impairing ammonia detoxification. This leads to toxic ammonia accumulation, a hallmark of urea cycle disorders.  
2. **Oroticaciduria**: The enzyme deficiency causes carbamoyl phosphate to divert into pyrimidine synthesis, overproducing orotic acid, which is excreted in urine.  
3. **Death in infancy**: Severe neonatal-onset OTCD often results in life-threatening hyperammonemic crises without prompt treatment.  
4. **Short stature**: Chronic metabolic stress and recurrent hyperammonemia impair growth and development over time.  
OTCD aligns uniquely with this symptom cluster, distinguishing it from other urea cycle defects (e.g., citrullinemia) through the presence of oroticaciduria."
"['Microcephaly', 'Carious teeth', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylpyruvate, phenyllactate, and phenylacetate, excreted in urine, aligning with PKU’s biochemical profile.  
3. **Neurological symptoms (Microcephaly, Delayed speech)**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, disrupting brain development and function.  
4. **Hypertyrosinemia**: Secondary tyrosine deficiency due to PAH dysfunction may alter tyrosine metabolism, though this is atypical and could indicate a comorbid metabolic disturbance or variant PKU.  
5. **Prenatal abnormalities/Death in infancy/childhood**: Severe untreated PKU causes progressive neurodegeneration, seizures, and early mortality. Maternal PKU during pregnancy can also induce congenital anomalies (e.g., microcephaly) in offspring.  
6. **Carious teeth**: Chronic metabolic imbalance or high-carbohydrate/low-protein diets (used to manage PKU) may predispose to dental decay.  
**Conclusion**: The constellation of hyperphenylalaninemia, urinary carboxylic acids, and neurodevelopmental deficits strongly supports PKU. Early mortality and prenatal issues reflect untreated or late-diagnosed cases."
"['Cryptorchidism', 'Hydronephrosis', 'High palate', 'Thin upper lip vermilion', 'Hypertelorism', 'Low-set ears', 'Downslanted palpebral fissures', 'Synophrys', 'Hyperextensible skin', 'Adducted thumb', 'Tapered finger', 'Generalized hypotonia', 'Talipes equinovarus', 'Arthrogryposis multiplex congenita', 'Finger joint hypermobility', 'Absent palmar crease']","['Musculocontractural Ehlers-Danlos syndrome/Ehlers-Danlos syndrome, musculocontractural type 1']","Disease: Musculocontractural Ehlers-Danlos syndrome, type 1 (mcEDS-1)  
Reasoning:  
1. **Major Diagnostic Criteria**:  
   - **Congenital Musculoskeletal Abnormalities**: Arthrogryposis multiplex congenita (multiple joint contractures), talipes equinovarus (clubfoot), and adducted thumbs align with hallmark contractures in mcEDS-1.  
   - **Characteristic Craniofacial Features**: Hypertelorism, low-set ears, downslanted palpebral fissures, synophrys (confluent eyebrows), high palate, and thin upper lip vermilion match the facial dysmorphism seen in mcEDS-1.  
   - **Cutaneous Features**: Hyperextensible skin and absent palmar crease reflect connective tissue fragility, a core feature of EDS subtypes.  

2. **Supportive Findings**:  
   - **Generalized Hypotonia**: Common in connective tissue disorders due to muscular and ligamentous laxity.  
   - **Tapered Fingers and Finger Joint Hypermobility**: Paradoxical hypermobility in some joints alongside contractures is typical in mcEDS-1.  
   - **Hydronephrosis**: May arise from connective tissue weakness in urinary tract structures.  
   - **Cryptorchidism**: Occasionally reported in mcEDS-1, possibly linked to developmental connective tissue defects.  

3. **Exclusion of Similar Disorders**:  
   - Overlap with other EDS subtypes (e.g., classical EDS) is ruled out by the presence of congenital contractures and distinct facial features.  
   - Differentiated from Loeys-Dietz syndrome or Marfan syndrome by the absence of aortic/arterial complications and specific gene associations (mcEDS-1 is linked to *CHST14* or *DSE* mutations).  

This constellation of congenital contractures, facial dysmorphism, cutaneous hyperextensibility, and systemic connective tissue involvement strongly supports mcEDS-1. Genetic testing for *CHST14* variants is recommended for confirmation."
"['Seizure', 'Flexion contracture', 'Fasciculations', 'Waddling gait', 'Scoliosis', 'Exertional dyspnea', 'Skeletal muscle atrophy', 'Progressive muscle weakness', 'Axial muscle weakness', 'Gowers sign', 'Fatigable weakness', 'Congenital bilateral ptosis', 'Distal lower limb amyotrophy', 'Sleep apnea', 'Tongue atrophy', 'Upgaze palsy', 'Anti-acetylcholine receptor antibody positivity']","['Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency']","Disease: Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency  
Reasoning:  
1. **Fatigable weakness** and **anti-acetylcholine receptor (AChR) antibody positivity**: Core features of neuromuscular junction dysfunction. While congenital myasthenic syndromes (CMS) are typically genetic (e.g., CHRNE mutations causing AChR deficiency), the presence of anti-AChR antibodies here may indicate a rare overlap or secondary autoimmunity, though CMS itself is not autoimmune.  
2. **Congenital bilateral ptosis** and **upgaze palsy**: Indicate lifelong ocular muscle weakness, aligning with CMS’s early-onset neuromuscular transmission defects.  
3. **Gowers sign**, **waddling gait**, and **axial/progressive muscle weakness**: Reflect proximal and truncal muscle involvement, consistent with AChR deficiency impairing synaptic transmission in skeletal muscles.  
4. **Scoliosis** and **flexion contractures**: Secondary to chronic axial and limb muscle weakness, leading to postural deformities.  
5. **Exertional dyspnea** and **sleep apnea**: Result from respiratory muscle fatigue and bulbar weakness (evidenced by **tongue atrophy**), common in severe CMS.  
6. **Distal amyotrophy** and **skeletal muscle atrophy**: Chronic denervation and disuse due to persistent neuromuscular signaling failure.  
7. **Fasciculations**: May arise from compensatory neuronal hyperexcitability or secondary neuropathy.  
8. **Seizures**: Atypical for CMS but could occur due to hypoxia from respiratory insufficiency or comorbid conditions.  

Though anti-AChR antibodies are classically linked to autoimmune myasthenia gravis, this diagnosis prioritizes the genetic AChR deficiency (CMS type 9) given congenital onset, structural myopathy signs, and systemic progression. Antibody positivity may reflect an atypical immune response to reduced receptor availability."
"['Nystagmus', 'Pancytopenia', 'Spinocerebellar tract degeneration', 'Decreased circulating IgA level', 'Decreased circulating total IgM', 'Decreased circulating IgG level', 'Cellular immunodeficiency', 'Bone marrow hypocellularity', 'Lower limb muscle weakness', 'Leg muscle stiffness']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Pancytopenia and bone marrow hypocellularity**: Central features of the syndrome, directly linked to bone marrow dysfunction.  
2. **Spinocerebellar tract degeneration**: Explains ataxia (implicit in the syndrome name) and neurological symptoms like nystagmus and lower limb muscle weakness/stiffness.  
3. **Immunodeficiency**: Decreased IgA, IgM, IgG levels and cellular immunodeficiency align with the syndrome’s hallmark humoral and T-cell defects.  
4. **Exclusion of mimics**: Lack of telangiectasia (rules out ataxia-telangiectasia) and absence of physical anomalies/DNA repair defects (rules out Fanconi anemia).  
5. **Symptom coherence**: The triad of ataxia, pancytopenia, and immunodeficiency is pathognomonic for APS."
"['Recurrent urinary tract infections', 'Gingivitis', 'Facial edema', 'Epistaxis', 'Hyperhidrosis', 'Abnormality of the larynx', 'Weight loss', 'Eosinophilia', 'Microcytic anemia', 'Hemoptysis', 'Pulmonary infiltrates', 'Hyperkalemia', 'Exertional dyspnea', 'Exercise intolerance', 'Adrenal hyperplasia', 'Abnormality of the submandibular glands', 'Facial palsy', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Peripheral edema', 'Cervical lymphadenopathy', 'Nodular pattern on pulmonary HRCT', 'Lagophthalmos', 'Elbow pain', 'Knee pain', 'Decreased thyroid-stimulating hormone level', 'Cutaneous abscess', 'Cytoplasmic antineutrophil antibody positivity', 'Neoplasm of the adrenal gland']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1: The patient exhibits multisystem granulomatous involvement, including pulmonary infiltrates, nodular HRCT patterns, cervical lymphadenopathy, and elevated CRP, all hallmarks of sarcoidosis. Facial palsy, lagophthalmos, and laryngeal abnormalities suggest neurosarcoidosis. Cutaneous abscesses, adrenal hyperplasia, and submandibular gland involvement align with extrapulmonary disease. Microcytic anemia, fatigue, and weight loss reflect chronic inflammation. Though cytoplasmic ANCA positivity is atypical, it may occur in overlap syndromes or as a false-positive. Eosinophilia and hyperkalemia could indicate adrenal dysfunction or renal involvement. Genetic susceptibility variants (e.g., HLA-DRB1) may underlie this presentation.  

Sarcoidosis, susceptibility to, 2: The phenotypic overlap with susceptibility type 1 is significant, but genetic distinctions (e.g., BTNL2 gene variants) may explain subtle differences in disease severity or organ tropism. The presence of exertional dyspnea, exercise intolerance, and hemoptysis emphasizes severe pulmonary involvement, potentially linked to specific genetic modifiers. Adrenal neoplasms, though rare in sarcoidosis, may arise from chronic hyperplasia. Persistent UTIs and gingivitis could reflect secondary immune dysregulation from granulomatous inflammation. Thyroid abnormalities (decreased TSH) may indicate concurrent autoimmune thyroiditis or hypothalamic-pituitary involvement."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently in neonates due to immature liver function or secondary metabolic disruptions from phenylalanine toxicity.  
3. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing fetal complications (e.g., congenital heart defects, microcephaly).  
4. **Upper airway obstruction** and **chronic pulmonary obstruction** are not direct features of PKU but could result from severe neurological impairment (e.g., hypotonia, poor swallowing) leading to aspiration or recurrent infections.  
5. **Neonatal death/Death in infancy** may occur in untreated/severe cases due to metabolic crises, neurological deterioration, or secondary complications (e.g., respiratory failure from aspiration).  

Note: While PKU explains hyperphenylalaninemia and prenatal abnormalities (via maternal PKU), hypertyrosinemia and airway/pulmonary symptoms suggest possible comorbidities (e.g., concurrent metabolic disorders or aspiration-related complications). Further testing (e.g., genetic analysis, BH4 responsiveness, tyrosine metabolite levels) is critical to confirm PKU and exclude overlapping conditions."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD is an autosomal recessive disorder affecting fatty acid oxidation, which can lead to intrauterine stress and developmental issues due to energy deficiency.  
2. **Neonatal/Infancy/Childhood death**: Untreated MCADD causes life-threatening hypoglycemia and metabolic crises during fasting, often fatal in early life without prompt diagnosis and management.  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to accumulation of toxic medium-chain acylcarnitines, which bind free carnitine, reducing its availability for fatty acid transport.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misinterpretation or mislabelling of enzyme testing. MCADD directly involves *medium-chain acyl-CoA dehydrogenase (MCAD)* deficiency, not 3-hydroxyacyl-CoA dehydrogenase. This discrepancy may stem from overlapping terminology or assay cross-reactivity in biochemical profiling.  

The constellation of early mortality, metabolic instability, and carnitine abnormalities strongly aligns with MCADD, a common fatty acid oxidation defect. Confirmatory testing would include genetic analysis of *ACADM* gene mutations and acylcarnitine profile showing elevated C6-C10 species."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Death in infancy/childhood/adolescence**: Untreated PKU leads to severe neurological damage, seizures, and failure to thrive, often resulting in early mortality without dietary intervention.  
3. **Elevated urinary carboxylic acids**: Phenylalanine derivatives like phenylpyruvate and phenyllactate (classic phenylketones) may be detected as urinary carboxylic acids.  

**Inconsistencies/Additional Considerations**:  
- **Hypertyrosinemia**: Not typical in PKU (tyrosine levels are usually low/normal). Suggests possible comorbid tyrosinemia or BH4 deficiency (a PKU variant).  
- **Recurrent viral infections**: Unrelated to classic PKU; may indicate immune dysfunction from malnutrition or a secondary disorder.  
- **Abnormal porphyrins/decreased ferritin**: Could reflect hepatic dysfunction or nutritional deficiencies due to restricted diets in PKU management.  

While PKU explains hyperphenylalaninemia and early mortality, hypertyrosinemia and immune issues warrant investigation for overlapping metabolic disorders (e.g., BH4 deficiency) or comorbidities."
"['Seizure', 'Coma', 'Fever', 'Vomiting', 'Tachypnea', 'Death in childhood', 'Hypervalinemia', 'Hyperisoleucinemia', 'Feeding difficulties']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Metabolic Abnormalities**: Hypervalinemia and hyperisoleucinemia indicate elevated branched-chain amino acids (BCAAs: valine, isoleucine, leucine), a hallmark of MSUD due to defective BCKD enzyme complex.  
2. **Neurological Symptoms**: Seizures, coma, and rapid neurological decline align with acute metabolic decompensation from toxic BCAA accumulation.  
3. **Systemic Manifestations**: Fever, vomiting, and tachypnea suggest metabolic acidosis and encephalopathy, common during crises.  
4. **Early Mortality**: Death in childhood is typical in untreated classical MSUD due to irreversible metabolic crises.  
5. **Feeding Difficulties**: Infants with MSUD struggle to tolerate protein intake, worsening BCAA accumulation.  
6. **Absence of Maple Syrup Odor Note**: While classic, this symptom may not always be reported or recognized, but biochemical findings confirm diagnosis."
"['Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Death in childhood', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADH deficiency)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: SSADH deficiency disrupts GABA metabolism, leading to accumulation of gamma-hydroxybutyric acid (GHB), a carboxylic acid excreted in urine.  
2. **Neurodevelopmental symptoms**: Delayed speech, hyperactivity, and intellectual disability align with GABAergic dysfunction, as GABA is critical for neuronal regulation and brain development.  
3. **Early mortality**: Severe cases may involve life-threatening complications (e.g., seizures, respiratory failure, or neuroregressive crises) contributing to death in childhood/adolescence.  
4. **Metabolic confirmation**: The triad of neurobehavioral abnormalities, elevated urinary GHB, and genetic testing confirms SSADH deficiency, distinguishing it from other organic acidurias."
"['Hypospadias', 'Low-set ears', 'Ptosis', 'Coloboma', 'Optic nerve hypoplasia', 'Iris coloboma', 'Diabetes mellitus', 'Hypertension', 'Cyanosis', 'Edema', 'Generalized hypotonia', 'Bilateral ptosis', 'Polyhydramnios', 'Ventricular septal defect', 'Atrial septal defect', 'Congestive heart failure', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Large forehead', 'Dyspnea', 'Apnea', 'Ventriculomegaly', 'Gray matter heterotopia', 'Bilateral choanal atresia', 'Right ventricular dilatation', 'Depressed nasal bridge', 'Redundant neck skin', 'Wide intermamillary distance', 'Ocular anterior segment dysgenesis', 'Corneal opacity', 'Microtia', 'Axial hypotonia', 'Infantile axial hypotonia', 'Maternal diabetes', 'Simplified gyral pattern', 'Prominent forehead', 'Flexion contracture of finger', 'Pulmonary edema']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental/Brain anomalies**: Simplified gyral pattern, gray matter heterotopia, ventriculomegaly, generalized hypotonia, and axial hypotonia indicate central nervous system involvement.  
2. **Ocular anomalies**: Coloboma (iris/optic nerve), optic nerve hypoplasia, corneal opacity, and anterior segment dysgenesis are hallmark eye findings in NEDBEH.  
3. **Cardiac defects**: Ventricular/atrial septal defects, patent foramen ovale, abnormal cardiac septum morphology, and congestive heart failure align with the cardiac spectrum of this disorder.  
4. **Supportive features**: Dysmorphic traits (low-set ears, depressed nasal bridge, microtia, redundant neck skin) and maternal diabetes (a known risk factor for congenital anomalies) further support the diagnosis.  
5. **Exclusion of mimics**: Choanal atresia and pulmonary edema may arise secondary to structural or functional abnormalities linked to the primary disorder. Polyhydramnios correlates with hypotonia-related fetal swallowing issues.  
6. **Syndromic coherence**: The triad of neurodevelopmental delay, brain/eye malformations, and congenital heart defects is pathognomonic for NEDBEH, often caused by de novo variants in genes like *BRD4* or *SMARCA2*."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Fatigue']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The patient exhibits key features of MCADD, including hypoglycemia due to impaired fatty acid oxidation during fasting, decreased plasma free carnitine (secondary to conjugation with unmetabolized medium-chain fatty acids), and gastrointestinal symptoms (vomiting, diarrhea, inflammation) triggered by metabolic stress. Neonatal/childhood death and dehydration align with acute metabolic crises, while fatigue reflects energy deficiency. Though MCADD does not directly cause prenatal abnormalities, early mortality and failure to thrive in infancy/childhood are hallmarks of untreated cases. The absence of ketosis during hypoglycemia (not explicitly listed but inferred) further supports this diagnosis."
"['Abnormality of the face', 'Hyperhidrosis', 'Pallor', 'Syncope', 'Weight loss', 'Leukocytosis', 'Vomiting', 'Nausea', 'Headache', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Fatigue', 'Pain', 'Chills', 'Jaw claudication']",['Giant cell arteritis/Temporal arteritis'],"Disease: Giant cell arteritis/Temporal arteritis  
Reasoning:  
1. **Jaw claudication** is a hallmark symptom of GCA due to ischemia of the masseter muscles caused by inflammation of the temporal arteries.  
2. **Headache** (often temporal) and **elevated ESR** strongly suggest systemic inflammation, consistent with GCA.  
3. **Weight loss**, **fatigue**, **chills**, and **pain** align with systemic inflammatory responses seen in GCA.  
4. **Syncope** and **exercise intolerance** may result from reduced blood flow or anemia (linked to **pallor**) secondary to chronic inflammation.  
5. **Leukocytosis** supports an inflammatory process, though less specific, it complements the elevated ESR.  
6. **Hyperhidrosis**, **nausea**, and **vomiting** are non-specific but may reflect autonomic dysregulation or systemic illness.  
7. GCA is a critical diagnosis due to the risk of irreversible complications (e.g., vision loss), necessitating prompt treatment with corticosteroids."
"['Coma', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Fever', 'Vomiting', 'Diarrhea', 'Increased serum lactate', 'Ketonuria', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid', 'Pustule']",['β-ketothiolase deficiency; BKD; Mitochondrial acetoacetyl-CoA thiolase [3-oxothiolase] deficiency/Beta-ketothiolase deficiency/Alpha-Methylacetoacetic aciduria'],"Disease: β-Ketothiolase Deficiency (Beta-ketothiolase deficiency)  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, and increased serum lactate**: Indicate a defect in mitochondrial energy metabolism, specifically in ketone body utilization and isoleucine catabolism, which are impaired in β-ketothiolase deficiency (BKD).  
2. **Ketonuria and elevated urinary carboxylic acids**: Result from the accumulation of ketones (acetoacetate, 3-hydroxybutyrate) and toxic metabolites like α-methylacetoacetate due to deficient mitochondrial acetoacetyl-CoA thiolase activity.  
3. **Abnormal circulating glycine and carnitine concentrations**: Secondary to metabolic decompensation; carnitine depletion occurs as it conjugates with toxic acyl-CoA intermediates for excretion.  
4. **Vomiting, diarrhea, and fever**: Common triggers of metabolic crises in BKD, often precipitated by infections or fasting, leading to catabolism and acute intoxication.  
5. **Coma and early mortality (infancy/childhood)**: Reflect severe metabolic derangements during crises, including hyperammonemia, cerebral edema, or energy failure.  
6. **Pustules**: May arise from secondary infections during catabolic stress or metabolic toxicity affecting immune responses.  
7. **Genetic confirmation**: Definitive diagnosis requires identification of *ACAT1* gene mutations or enzyme assay showing reduced thiolase activity.  

The constellation of episodic ketoacidosis, ketonuria, and characteristic organic aciduria aligns pathognomonically with BKD."
"['Platyspondyly', 'Hypoplastic ilia', 'Short tubular bones of the hand', 'Generalized hypotonia', 'Cerebellar hypoplasia', 'Atrioventricular block', 'Hypoplasia of the corpus callosum', 'Respiratory distress', 'Generalized myoclonic seizure', 'Flat acetabular roof', 'Narrow greater sciatic notch', 'Cupped metaphyses of hand bones', 'Abnormal intervertebral disk morphology', 'Simplified gyral pattern', 'Metaphyseal dysplasia']","['Spondylometaphyseal dysplasia, Sedaghatian type/Spondylometaphyseal dysplasia, Sedaghatian type']","Disease: Spondylometaphyseal dysplasia, Sedaghatian type  
Reasoning:  
1. **Skeletal Features**: Platyspondyly, hypoplastic ilia, flat acetabular roof, narrow greater sciatic notch, and cupped metaphyses of hand bones align with the ""spondylometaphyseal"" component, characteristic of skeletal dysplasia in this disorder.  
2. **Metaphyseal Dysplasia**: Short tubular bones of the hands and metaphyseal cupping confirm metaphyseal irregularities, a hallmark of the disease.  
3. **Neurological Involvement**: Cerebellar hypoplasia, simplified gyral pattern, and corpus callosum hypoplasia indicate severe central nervous system malformations, consistent with Sedaghatian type’s association with brain abnormalities.  
4. **Systemic Manifestations**: Generalized hypotonia, respiratory distress, and myoclonic seizures reflect neuromuscular and respiratory compromise, common in this lethal infantile form.  
5. **Cardiac Anomaly**: Atrioventricular block supports the diagnosis, as cardiac conduction defects are reported in Sedaghatian type.  
6. **Exclusion of Mimics**: The combination of severe skeletal, neurological, and cardiac features differentiates it from other spondylometaphyseal dysplasias lacking multisystem involvement."
"['Malar flattening', 'Conductive hearing impairment', 'Short neck', 'Angiokeratoma', 'Ataxia', 'Intellectual disability, mild', 'Hepatosplenomegaly', 'Aortic valve stenosis', 'Abnormality of extrapyramidal motor function', 'Tracheomalacia', 'Aminoaciduria', 'Short stature', 'Cherry red spot of the macula']",['Galactosialidosis/Galactosialidosis'],"Disease: Galactosialidosis  
Reasoning:  
1. **Cherry red spot of the macula**: A hallmark of lysosomal storage disorders, particularly sialidosis and galactosialidosis, caused by abnormal glycosphingolipid accumulation.  
2. **Angiokeratoma**: Common in lysosomal disorders like Fabry disease but also seen in galactosialidosis due to glycosphingolipid deposition in skin vasculature.  
3. **Hepatosplenomegaly**: Reflects systemic lysosomal storage, typical of galactosialidosis.  
4. **Aortic valve stenosis**: Associated with glycosaminoglycan deposition in cardiac tissue, a feature of late-onset galactosialidosis.  
5. **Ataxia & extrapyramidal motor dysfunction**: Indicates progressive neurodegeneration, consistent with the neurologic decline in galactosialidosis.  
6. **Conductive hearing impairment**: Linked to skeletal abnormalities (e.g., ossicle defects) and recurrent infections from immune dysfunction in lysosomal disorders.  
7. **Short stature, short neck, malar flattening**: Suggests skeletal dysplasia, common in lysosomal storage diseases due to impaired bone remodeling.  
8. **Mild intellectual disability**: Aligns with the slower progression of neurologic involvement in juvenile/adult-onset galactosialidosis.  
9. **Tracheomalacia**: Caused by connective tissue weakness from lysosomal accumulation, seen in systemic forms.  
10. **Aminoaciduria**: Renal tubular dysfunction due to lysosomal storage in kidney cells.  
Galactosialidosis is confirmed by combined β-galactosidase and neuraminidase deficiency, with protective protein/cathepsin A mutations, explaining the multisystemic presentation."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Respiratory distress', 'Apnea', 'Neonatal death', 'Respiratory acidosis', 'Elevated plasma citrulline', 'Hypoxemia']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia and markedly elevated plasma citrulline, hallmark features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency. Neonatal respiratory distress, apnea, and respiratory acidosis align with metabolic decompensation from ammonia toxicity, leading to neurological depression and respiratory failure. Premature birth and neonatal death are consistent with the severe, rapid progression of untreated urea cycle disorders.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: While cholestasis is not explicitly listed, citrin deficiency (type II) can present with neonatal hyperammonemia and elevated citrulline due to secondary urea cycle dysfunction. Respiratory distress and hypoxemia may reflect metabolic stress or hepatic involvement. Neonatal death and prematurity overlap with acute metabolic crises, though citrin deficiency often includes transient cholestasis or amino acid imbalances (e.g., high threonine), which may not be documented here. Differentiation from type I requires genetic testing or additional biomarkers (e.g., citrin protein analysis)."
"['Abnormality of prenatal development or birth', 'Ataxia', 'Obesity', 'Death in infancy', 'Apnea', 'Hypertyrosinemia', 'Paresthesia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth**: Untreated maternal PKU can lead to congenital anomalies due to phenylalanine toxicity during pregnancy.  
3. **Neurological symptoms (Ataxia, Paresthesia)**: Accumulated phenylalanine disrupts myelination and neurotransmitter synthesis, causing progressive neurological damage.  
4. **Obesity**: Managed PKU patients often consume low-protein, high-carbohydrate diets, which may contribute to weight gain.  
5. **Early mortality (Death in infancy/Neonatal death/Death in early adulthood)**: Untreated PKU results in severe intellectual disability, seizures, and systemic complications, leading to premature death without dietary intervention.  
6. **Apnea**: Rarely observed in severe neonatal cases due to metabolic instability or neurological dysfunction.  
7. **Hypertyrosinemia discrepancy**: Likely a typographical error; PKU typically causes *hypo*tyrosinemia (due to blocked phenylalanine conversion). If accurate, this could suggest a concurrent metabolic disorder (e.g., tyrosinemia) or a BH4-deficient PKU variant, though the primary diagnosis remains PKU.  

The constellation of hyperphenylalaninemia, neurodevelopmental deficits, and dietary management complications strongly aligns with PKU, despite atypical features like hypertyrosinemia requiring further investigation."
"['Triangular face', 'Underdeveloped nasal alae', 'Deeply set eye', 'Rieger anomaly', 'Delayed eruption of teeth', 'Short stature', 'Prematurely aged appearance', 'Lipodystrophy']",['SHORT syndrome/Short syndrome'],"Disease: SHORT syndrome  
Reasoning:  
1. **Short Stature**: A core feature of SHORT syndrome, aligning with the patient's short stature.  
2. **Rieger Anomaly**: A hallmark of SHORT syndrome, involving iris and anterior eye abnormalities, present in the patient.  
3. **Delayed Eruption of Teeth**: Matches the ""Teething delay"" component of the SHORT acronym.  
4. **Deeply Set Eyes (Ocular Depression)**: Corresponds to the ""Ocular depression"" in the syndrome’s acronym.  
5. **Triangular Face and Underdeveloped Nasal Alae**: Characteristic facial dysmorphisms seen in SHORT syndrome.  
6. **Lipodystrophy and Prematurely Aged Appearance**: Results from abnormal fat distribution, a common feature contributing to a progeroid phenotype.  
7. **Exclusion of Overlapping Syndromes**: Progeria lacks Rieger anomaly/dental delays, while Rieger syndrome does not include lipodystrophy/short stature. The combined features strongly support SHORT syndrome."
"['Hepatosplenomegaly', 'Neurodegeneration', 'Memory impairment', 'Psychomotor deterioration', 'Progressive encephalopathy', 'Falls', 'Neuronal loss in central nervous system', 'Central nervous system degeneration', 'Progressive forgetfulness', 'Progressive language deterioration', 'Social and occupational deterioration', 'Slowed slurred speech', 'Progressive psychomotor deterioration', 'Atrophy/Degeneration affecting the cerebrum']","['Niemann-Pick disease type C; NPD-C/Niemann-Pick disease type C/Niemann-pick disease, type C1']","Disease: Niemann-Pick disease type C (NPC1)  
Reasoning:  
1. **Hepatosplenomegaly**: A hallmark of NPC1 due to lysosomal accumulation of sphingolipids and cholesterol in visceral organs.  
2. **Neurodegenerative symptoms**: Progressive encephalopathy, memory impairment, psychomotor deterioration, and neuronal loss align with NPC1’s characteristic central nervous system (CNS) involvement, driven by lipid trafficking defects.  
3. **Speech and language decline**: Slurred speech and progressive language deterioration reflect cerebellar and cortical atrophy, common in NPC1.  
4. **CNS degeneration patterns**: Atrophy in the cerebrum and neuronal loss correlate with NPC1’s neuropathology, particularly in the thalamus, cerebellum, and cortex.  
5. **Progressive course**: Symptoms like occupational/social decline and worsening forgetfulness mirror NPC1’s insidious progression, often beginning with visceral symptoms before neurological decline.  
6. **Exclusion of mimics**: Symptoms overlap with other lysosomal disorders (e.g., Gaucher disease), but the combination of visceral and CNS features strongly supports NPC1."
"['Hearing impairment', 'Gait disturbance', 'Hepatic steatosis', 'Hepatic cysts', 'Pericardial effusion', 'Splenomegaly', 'Abnormal lung morphology', 'Hepatomegaly', 'Paraparesis', 'Somatic sensory dysfunction', 'Rhinitis', 'Lower limb pain', 'Splenic cyst', 'Cytoplasmic antineutrophil antibody positivity', 'Insomnia']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Cytoplasmic antineutrophil antibody (c-ANCA) positivity**: Highly specific for GPA, supporting an autoimmune vasculitis diagnosis.  
2. **Rhinitis and hearing impairment**: Reflect upper respiratory tract involvement, common in early GPA due to granulomatous inflammation.  
3. **Abnormal lung morphology**: GPA often causes pulmonary nodules, cavities, or infiltrates.  
4. **Paraparesis and somatic sensory dysfunction**: Indicates neurologic involvement, possibly from vasculitic neuropathy or CNS inflammation.  
5. **Pericardial effusion**: Suggests systemic vasculitis affecting serous membranes.  
6. **Hepatomegaly, hepatic steatosis, and splenomegaly**: Less common but documented in systemic GPA due to granulomatous infiltration or secondary inflammation.  
7. **Splenic/hepatic cysts**: Rare manifestations, potentially linked to chronic inflammation or ischemic injury.  
8. **Lower limb pain and gait disturbance**: May result from neuropathy, myositis, or joint involvement.  
9. **Insomnia**: Likely secondary to chronic pain or systemic illness.  

While hepatic/splenic cysts are atypical, the combination of c-ANCA positivity, multi-organ involvement (respiratory, renal, neurologic), and classic vasculitic features strongly aligns with GPA. Differential diagnoses (e.g., eosinophilic granulomatosis with polyangiitis) are less likely given the absence of eosinophilia or asthma."
"['Abnormality of the kidney', 'Hypertension', 'Seizure', 'Coma', 'Death in infancy', 'Cardiomyopathy', 'Thrombocytopenia', 'Leukopenia', 'Anemia', 'Leukocytosis', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Increased serum lactate', 'Hyperproteinemia', 'Hyperkalemia', 'Hyperglycinemia', 'Hypertriglyceridemia', 'Skeletal dysplasia', 'Tachypnea', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Hypercholesterolemia', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating parathyroid hormone level', 'Decreased methylmalonyl-CoA mutase activity', 'Hypernatremia', 'Hypermethioninemia', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Elevated systolic blood pressure', 'Elevated diastolic blood pressure', 'Abnormal circulating porphyrin concentration', 'Hyperhistidinemia', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties', 'Hyperornithinemia', 'Methylmalonic aciduria', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**:  
   - **Methylmalonic acidemia/aciduria** and **decreased methylmalonyl-CoA mutase activity** directly confirm a defect in the methylmalonyl-CoA mutase enzyme, critical for propionate metabolism.  
   - **Hyperammonemia**, **hyperuricemia**, **elevated lactate**, and **hyperglycinemia** reflect secondary metabolic disruptions from toxic metabolite accumulation.  

2. **Acute decompensation features**:  
   - **Seizures**, **coma**, **vomiting**, **tachypnea**, and **feeding difficulties** align with metabolic crises triggered by catabolic stress (e.g., infections, fasting).  
   - **Hyperkalemia**, **hypernatremia**, and **elevated blood urea nitrogen/creatinine** indicate renal dysfunction, a known complication of chronic methylmalonic acid toxicity.  

3. **Chronic multisystem involvement**:  
   - **Cardiomyopathy** and **hypertension** arise from metabolic stress and renal failure.  
   - **Skeletal dysplasia** and **severe short stature** result from chronic acidosis impairing bone mineralization.  
   - **Hematologic abnormalities** (anemia, leukopenia, thrombocytopenia) stem from bone marrow suppression by methylmalonic acid.  

4. **Early mortality**:  
   - **Neonatal death**, **death in infancy/childhood/adolescence**, and **death in early adulthood** reflect the severity of B12-unresponsive MMA, often fatal without aggressive management (dialysis, transplantation).  

5. **Supporting metabolic derangements**:  
   - **Abnormal carnitine**, **hypertriglyceridemia**, and **elevated citrulline/ornithine** highlight disrupted mitochondrial metabolism and urea cycle stress.  
   - **Elevated alkaline phosphatase/PTH** correlate with renal osteodystrophy from chronic kidney disease.  

This constellation of findings conclusively points to **methylmalonyl-CoA mutase deficiency**, a B12-unresponsive form of MMA, explaining both acute crises and progressive organ damage."
"['Irritability', 'Spasticity', 'Hyperreflexia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Neurological symptoms** (irritability, spasticity, hyperreflexia) arise from phenylalanine-induced brain damage in untreated cases.  
3. **Early mortality** (neonatal/infancy/childhood/adolescence death) aligns with severe untreated PKU variants or complications like metabolic crises or seizures.  
4. **Hypertyrosinemia inconsistency**: Typically, PKU causes *low* tyrosine (due to blocked PAH activity). This symptom suggests a possible comorbid condition (e.g., tyrosinemia type II) or diagnostic error.  
5. **Recurrent viral infections** are atypical for PKU and may indicate an unrelated immunodeficiency.  
6. PKU diagnosis is confirmed by elevated blood phenylalanine and genetic testing for *PAH* mutations, but conflicting hypertyrosinemia warrants further metabolic investigation.  

Note: Hypertyrosinemia and recurrent infections are not classic PKU features; additional workup is critical to rule out overlapping disorders (e.g., BH4 deficiencies, tyrosinemias)."
"['Seizure', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Fever', 'Vomiting', 'Drowsiness', 'Progressive neurologic deterioration', 'Sleep disturbance', 'Glutaric aciduria', '3-Methylglutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Metabolic acidosis and hypoglycemia**: Central features of HMGCLD due to impaired leucine catabolism and ketogenesis, leading to accumulation of toxic metabolites (e.g., 3-hydroxy-3-methylglutaric acid) and energy deficiency.  
2. **Glutaric aciduria and 3-methylglutaric aciduria**: Direct biochemical markers of HMG-CoA lyase deficiency, as the enzyme deficiency disrupts the breakdown of leucine and ketone body synthesis.  
3. **Seizures, lethargy, and progressive neurologic deterioration**: Result from neurotoxic effects of accumulated organic acids and recurrent metabolic crises.  
4. **Recurrent viral infections**: Metabolic decompensation often triggered by catabolic stressors like infections, which exacerbate energy deficits.  
5. **Abnormal glycine concentrations**: Secondary hyperglycinemia may occur as glycine conjugates with toxic metabolites to facilitate excretion.  
6. **Death in infancy/childhood**: Characteristic of untreated cases due to acute metabolic crises or irreversible neurological damage.  
7. **Elevated urinary carboxylic acids**: Reflects systemic spillage of incompletely metabolized intermediates (e.g., 3-hydroxy-3-methylglutarate, glutarate).  
8. **Hypoglycemia without ketosis**: Pathognomonic in HMGCLD, as the enzyme defect prevents ketogenesis during fasting."
"['Autistic behavior', 'Delayed speech and language development', 'Seizure', 'Global developmental delay', 'Nausea', 'Constipation', 'Reduced brain creatine level by MRS']",['X-linked creatine transporter deficiency/Cerebral creatine deficiency syndrome 1'],"Disease: X-linked creatine transporter deficiency/Cerebral creatine deficiency syndrome 1  
Reasoning:  
1. **Reduced brain creatine level by MRS** is a hallmark of cerebral creatine deficiency syndromes (CCDS), narrowing the diagnosis to AGAT, GAMT, or SLC6A8 (creatine transporter) deficiencies.  
2. **Neurological symptoms** (autistic behavior, delayed speech, seizures, global developmental delay) align with CCDS.  
3. **Gastrointestinal symptoms** (nausea, constipation) are more characteristic of SLC6A8 deficiency than AGAT/GAMT defects.  
4. **X-linked inheritance** (implied by the diagnosis) supports SLC6A8 deficiency, as AGAT/GAMT deficiencies are autosomal recessive.  
5. **Normal/high plasma creatine with low brain creatine** (not explicitly stated but inferred from MRS) suggests a transporter defect rather than a synthesis defect (AGAT/GAMT), where plasma creatine would be low.  
6. Confirmation would require genetic testing for *SLC6A8* mutations or elevated urinary creatine/creatinine ratio, consistent with transporter dysfunction."
"['Narrow mouth', 'Cataract', 'Thick eyebrow', 'Decreased response to growth hormone stimulation test', 'Delayed gross motor development', 'Genu valgum', 'Thoracic scoliosis', 'Severe short stature', 'Multiple skeletal anomalies', 'Distal peripheral sensory neuropathy', 'Bilateral sensorineural hearing impairment', 'Prominent forehead']","['Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome/Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia']","Disease: Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia (CGHS syndrome)  
Reasoning:  
1. **Cataract**: Present in the patient’s symptoms, aligning with the ocular manifestation of the syndrome.  
2. **Growth hormone deficiency**: Supported by the ""decreased response to growth hormone stimulation test"" and ""severe short stature,"" a hallmark of GH deficiency.  
3. **Sensory neuropathy**: Matches ""distal peripheral sensory neuropathy,"" indicating peripheral nerve involvement.  
4. **Sensorineural hearing loss**: Corresponds to ""bilateral sensorineural hearing impairment,"" a key auditory feature of the syndrome.  
5. **Skeletal dysplasia**: Explains ""multiple skeletal anomalies,"" including thoracic scoliosis, genu valgum, and severe short stature. Additional dysmorphic features (narrow mouth, thick eyebrows, prominent forehead) and delayed gross motor development further support skeletal and systemic involvement.  

This constellation of symptoms is pathognomonic for the rare autosomal recessive disorder caused by *PRDM5* gene mutations, which disrupt extracellular matrix integrity, leading to multi-systemic manifestations."
"['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Facial palsy', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Alkaptonuria:  
1. **Dark urine** is the hallmark symptom of alkaptonuria, caused by the accumulation and oxidation of homogentisic acid in urine. This is often the first sign noticed in infancy.  
2. **Generalized hypotonia** and **growth delay** may occur secondary to metabolic stress or systemic effects of chronic homogentisic acid accumulation, though these are not classic features of alkaptonuria and could indicate comorbid conditions.  
3. **Facial palsy** and **death in infancy** are atypical for alkaptonuria, which usually has a later-onset presentation (e.g., ochronosis, arthritis). These symptoms likely point to additional complications or misdiagnosis, but the presence of dark urine strongly prioritizes alkaptonuria as the primary diagnosis.  

*Note: While alkaptonuria explains the dark urine, the combination with severe infantile symptoms (e.g., death in infancy) suggests either an unusual presentation, coexisting disorders, or potential misalignment in the case details. Further testing for homogentisic acid in urine and genetic analysis for* HGD *gene mutations would confirm alkaptonuria.*"
"['Cryptorchidism', 'Micropenis', 'Microretrognathia', 'Incomplete partition of the cochlea type II', 'Retinal coloboma', 'Generalized hypotonia', 'Congestive heart failure', 'Dysphagia', 'Gastroesophageal reflux', 'Poor suck', 'Neonatal respiratory distress', 'Respiratory failure', 'Facial palsy', 'Aplasia of the semicircular canal']",['CHARGE syndrome/Charge syndrome'],"Disease: CHARGE syndrome/Charge syndrome  
Reasoning:  
1. **Coloboma**: Retinal coloboma is a hallmark feature of CHARGE syndrome, directly aligning with the ""C"" in the acronym.  
2. **Heart defects**: Congestive heart failure suggests congenital heart anomalies, corresponding to the ""H"" (Heart defects).  
3. **Genital hypoplasia**: Cryptorchidism and micropenis fulfill the ""G"" (Genital anomalies) criterion.  
4. **Ear abnormalities**: Incomplete partition of the cochlea type II and aplasia of the semicircular canal are characteristic inner ear malformations linked to the ""E"" (Ear anomalies).  
5. **Cranial nerve dysfunction**: Facial palsy and dysphagia/poor suck indicate cranial nerve involvement (CN VII, IX, X), common in CHARGE.  
6. **Multi-system involvement**: Neonatal respiratory distress, hypotonia, gastroesophageal reflux, and microretrognathia reflect the syndrome’s broad impact on respiratory, neuromuscular, and craniofacial systems.  
7. **Diagnostic criteria**: While choanal atresia (""A"") is not explicitly listed, the combination of major features (coloboma, semicircular canal hypoplasia) and minor features (heart defects, facial palsy) meets clinical diagnostic criteria for CHARGE syndrome."
"['Proteinuria', 'Retinopathy', 'Hypertension', 'Acute kidney injury', 'Chronic kidney disease', 'Elevated hemoglobin A1c', 'Death in early adulthood']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: Maturity-onset diabetes of the young, type 1 (MODY1/HNF4A)  
Reasoning:  
1. **Elevated hemoglobin A1c**: Indicates chronic hyperglycemia, a hallmark of MODY. MODY1 (HNF4A mutation) disrupts insulin secretion, leading to early-onset diabetes.  
2. **Retinopathy**: A microvascular complication of prolonged diabetes, consistent with poor glycemic control over time.  
3. **Hypertension**: Likely secondary to diabetic nephropathy or chronic kidney disease, exacerbated by diabetes-related vascular damage.  
4. **Proteinuria, Acute kidney injury (AKI), Chronic kidney disease (CKD)**: Diabetic nephropathy from long-standing hyperglycemia explains progressive kidney damage. MODY1 patients with suboptimal glycemic control are at risk for renal complications.  
5. **Death in early adulthood**: Severe renal failure (from CKD/AKI) or cardiovascular complications of uncontrolled diabetes and hypertension could lead to premature mortality.  
6. **MODY1 specificity**: While MODY5 (HNF1B) is classically linked to renal dysplasia, MODY1 can still manifest nephropathy due to diabetic damage. The absence of atypical features (e.g., cysts, genital anomalies) and presence of retinopathy favor MODY1 over other subtypes. Early death underscores aggressive complications from delayed diagnosis or inadequate management."
"['Coarse facial features', 'Strabismus', 'Pectus excavatum', 'Deformed rib cage', 'Hypotonia', 'Motor delay', 'Hepatic cysts', 'Omphalocele', 'Redundant skin', 'Mitral regurgitation', 'Abnormal facial shape', 'Spinal cord compression', 'Spondyloepimetaphyseal dysplasia', 'Coxa valga', 'Kyphoscoliosis', 'Radial head subluxation', 'Hypoplasia of the capital femoral epiphysis', 'Neonatal hyperbilirubinemia', 'Abnormality of the cervical spine', 'Short stature', 'Severe platyspondyly', 'Cervical instability', 'Abnormal pelvis bone morphology']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: The patient exhibits *spondyloepimetaphyseal dysplasia*, *severe platyspondyly*, *coxa valga*, and *abnormal pelvis bone morphology*, which are hallmark features of ISDNA. These align with the ""immunoskeletal"" component of the disease, reflecting dysostosis multiplex-like skeletal dysplasia.  
2. **Neurodevelopmental Delays**: *Hypotonia* and *motor delay* correlate with ISDNA-associated neurodevelopmental impairments, often linked to cerebellar hypoplasia or white matter changes.  
3. **Cervical Instability/Spinal Involvement**: *Cervical instability*, *spinal cord compression*, and *abnormality of the cervical spine* are critical findings in ISDNA due to defective bone maturation and ligamentous laxity.  
4. **Hepatic and Neonatal Features**: *Hepatic cysts* and *neonatal hyperbilirubinemia* suggest systemic involvement, consistent with ISDNA’s multisystemic nature. *Omphalocele* may reflect connective tissue dysfunction.  
5. **Dysmorphic Features**: *Coarse facial features*, *abnormal facial shape*, and *redundant skin* are seen in ISDNA, likely due to glycosylation defects or extracellular matrix disruption.  
6. **Cardiac and Ocular Manifestations**: *Mitral regurgitation* and *strabismus* align with connective tissue/craniofacial anomalies reported in ISDNA.  
7. **Genetic Link**: While not explicitly stated, ISDNA is caused by biallelic *EXOC6B* mutations, which disrupt exocytosis and glycosylation, explaining the skeletal, hepatic, and neurodevelopmental phenotypes.  

The constellation of severe skeletal dysplasia, neurodevelopmental delays, systemic involvement (hepatic/cardiac), and dysmorphism strongly supports ISDNA over other skeletal dysplasias (e.g., Morquio syndrome lacks neurodevelopmental features; COMP-associated disorders lack hepatic cysts)."
"['Apathy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Pneumonia', 'Hepatomegaly', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Abnormal circulating acetylcarnitine concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Metabolic acidosis**: Caused by accumulation of toxic metabolites (3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid) due to defective HMG-CoA lyase.  
2. **Hypoglycemia**: Impaired ketogenesis (HMG-CoA lyase is critical for ketone body synthesis) leads to energy deficits during fasting.  
3. **Hyperammonemia**: Secondary inhibition of the urea cycle by organic acid metabolites.  
4. **Hepatomegaly**: Fatty liver from disrupted lipid metabolism and mitochondrial dysfunction.  
5. **Dicarboxylic aciduria**: Increased fatty acid oxidation (compensatory energy pathway) produces dicarboxylic acids.  
6. **3-Methylglutaconic aciduria**: Direct result of HMG-CoA lyase deficiency, as 3-methylglutaconate cannot be metabolized to acetoacetate.  
7. **Decreased plasma free carnitine**: Carnitine is consumed conjugating toxic metabolites (e.g., 3-hydroxy-3-methylglutarate) for urinary excretion.  
8. **Abnormal acetylcarnitine**: Reflects disrupted mitochondrial acyl-CoA metabolism.  
9. **Elevated urinary carboxylic acids**: Excretion of 3-hydroxy-3-methylglutarate, 3-methylglutaconate, and other intermediates.  
10. **Apathy/Death in infancy**: Neurological sequelae of metabolic crises (hypoglycemia, acidosis) if untreated.  
11. **Vomiting/Pneumonia**: Common triggers (infection, fasting) for acute decompensation in metabolic disorders.  
12. **Abnormal glycine**: Potential secondary disturbance from mitochondrial dysfunction.  

**Conclusion**: The constellation of metabolic acidosis, hypoglycemia, hyperammonemia, specific urinary metabolites (3-methylglutaconic acid, dicarboxylic acids), and carnitine abnormalities is pathognomonic for HMG-CoA lyase deficiency."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: Severe, untreated maternal PKU can disrupt fetal development due to phenylalanine toxicity, though neonatal PKU itself typically manifests postnatally.  
3. **Hypertyrosinemia**: While PKU classically results in *low* tyrosine (due to impaired conversion of phenylalanine to tyrosine), transient hypertyrosinemia may occur in neonates with liver immaturity or secondary metabolic disturbances.  
4. **Neonatal death/Death in infancy**: Untreated PKU can cause rapid neurological deterioration, seizures, and failure to thrive, particularly in rare severe variants (e.g., ""malignant"" PKU with near-complete PAH deficiency).  
5. **Consistency with PKU**: The combination of hyperphenylalaninemia and severe early-life outcomes aligns with PKU, though hypertyrosinemia suggests possible comorbid factors (e.g., transient neonatal tyrosinemia) or misdiagnosis of lab values.  

**Note**: Hypertyrosinemia is atypical for classic PKU and warrants investigation for alternative/additional disorders (e.g., tyrosinemia types I–III, BH4 deficiencies) or confirmatory genetic testing for PAH mutations."
"['Apathy', 'Ataxia', 'Lethargy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Death in adolescence']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as the urea cycle enzyme deficiency causes impaired ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD due to carbamoyl phosphate shunting into pyrimidine synthesis, producing excess orotic acid.  
3. **Neurological symptoms** (Apathy, Ataxia, Lethargy, Drowsiness): Reflect hyperammonemic encephalopathy from ammonia neurotoxicity.  
4. **Gastrointestinal symptoms** (Vomiting): Common during metabolic decompensation episodes.  
5. **Sleep disturbance**: Linked to circadian disruption from ammonia accumulation.  
6. **Death in adolescence**: Consistent with late-onset OTCD complications if untreated (e.g., cerebral edema, coma).  

The triad of **hyperammonemia, oroticaciduria, and neurological decline** confirms OTCD, a urea cycle disorder with X-linked inheritance (though females may manifest due to skewed lyonization). Urgent ammonia reduction and long-term protein restriction/ammonia scavengers are critical."
"['Pallor', 'Death in infancy', 'Ascites', 'Thrombocytosis', 'Anemia', 'Hepatomegaly', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Aminoaciduria', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Pustule']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia & Aminoaciduria**: Direct biochemical hallmarks of tyrosinemia type 1 (HT-1), caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic tyrosine metabolite accumulation.  
2. **Hepatomegaly & Hypoalbuminemia/Hypoproteinemia**: Severe liver dysfunction due to tyrosine metabolite toxicity, impairing synthetic function and causing edema/ascites.  
3. **Elevated AFP**: Reflects hepatocyte regeneration or malignancy risk, a key marker in HT-1.  
4. **Abnormal circulating porphyrins**: Secondary to succinylacetone accumulation (a tyrosine metabolite), inhibiting δ-aminolevulinic acid dehydratase, disrupting heme synthesis.  
5. **Thrombocytosis & Anemia/Pallor**: Thrombocytosis may arise from splenic dysfunction or inflammation; anemia results from bone marrow suppression or bleeding complications.  
6. **Elevated alkaline phosphatase**: Indicates cholestatic liver injury.  
7. **Ascites**: Due to hypoalbuminemia and portal hypertension from cirrhosis.  
8. **Pustules**: Rare cutaneous manifestations of metabolic toxicity.  
9. **Death in infancy**: Untreated HT-1 causes acute liver failure, renal tubular dysfunction, and neurologic crises, often fatal in early childhood.  

The constellation of liver failure, tyrosine metabolism derangements, and secondary biochemical abnormalities confirms HT-1."
"['High palate', 'Microcephaly', 'Epicanthus', 'Micrognathia', 'Ptosis', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'Ventriculomegaly', 'Increased serum lactate', 'EEG abnormality', 'Abnormal midbrain morphology', 'Scoliosis', 'Short nose', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Alveolar ridge overgrowth', 'Peripheral neuropathy', 'Underdeveloped supraorbital ridges', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Alacrima**: A hallmark feature of CDDG1, directly listed in the patient’s symptoms.  
2. **Liver dysfunction**: Suggested by elevated alpha-fetoprotein (marker for hepatic issues) and prolonged neonatal jaundice.  
3. **Neurological involvement**: Global developmental delay, seizures, hypotonia, EEG abnormalities, and ventriculomegaly align with CDDG1’s neurodevelopmental deficits.  
4. **Craniofacial/skeletal anomalies**: Microcephaly, micrognathia, epicanthus, short nose, underdeveloped supraorbital ridges, small hands, short feet, and scoliosis reflect multisystem dysmorphism typical of glycosylation disorders.  
5. **Peripheral neuropathy**: Reduced tendon reflexes and peripheral neuropathy suggest nerve involvement, consistent with deglycosylation defects.  
6. **Metabolic markers**: Elevated serum lactate and abnormal midbrain morphology support mitochondrial or metabolic dysfunction seen in CDG disorders.  
7. **Supportive features**: Intrauterine growth retardation, constipation, and alveolar ridge overgrowth further correlate with systemic manifestations of CDDG1.  
8. **Exclusion of mimics**: While other CDG types (e.g., PMM2-CDG) share overlapping symptoms, the presence of alacrima and elevated AFP specifically points to CDDG1/NGLY1 deficiency."
"['Strabismus', 'Myopia', 'Nystagmus', 'Abnormally large globe', 'Motor delay', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Cerebellar dysplasia', 'Absent retinal pigment epithelium']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar anomalies**: Cerebellar vermis hypoplasia, dysplasia, cysts, and dilated fourth ventricle align with the hallmark cerebellar structural defects in Poretti-Boltshauser syndrome.  
2. **Ocular manifestations**: Strabismus, myopia, nystagmus, and absent retinal pigment epithelium reflect the syndrome’s retinal dystrophy and high myopia phenotype. The abnormally large globe (megalophthalmos) further supports congenital ocular abnormalities.  
3. **Neurological deficits**: Motor delay correlates with cerebellar dysfunction and ataxia, a core feature of the syndrome.  
4. **Exclusion of mimics**: The absence of ""molar tooth sign"" (Joubert syndrome), liver involvement (COACH syndrome), or severe muscular/lissencephaly findings (Walker-Warburg syndrome) strengthens the diagnosis.  
5. **Genetic confirmation**: While not explicitly stated, Poretti-Boltshauser syndrome is linked to LAMA1 mutations, which underlie the observed neuro-ocular developmental defects."
"['Abnormality of the kidney', 'Hypertelorism', 'Abnormal location of ears', 'Hearing impairment', 'Small earlobe', 'Prominent antihelix', 'Progressive sensorineural hearing impairment', 'Wide nasal bridge', 'Choanal atresia', 'Chorioretinal coloboma', 'Coloboma', 'Iris coloboma', 'Atypical behavior', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Flexion contracture', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Tachycardia', 'Respiratory distress', 'Difficulty walking', 'Developmental regression', 'Scoliosis', 'Thoracolumbar scoliosis', 'Difficulty standing', 'Short stature', 'Type I truncus arteriosus', 'Bilateral choanal atresia', 'Supraventricular tachycardia', 'Abnormal bone ossification', 'Flat face', 'Anisometropia']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental Features**: Intellectual disability, global developmental delay, absent speech, seizures, hypotonia, developmental regression, and atypical behavior align with the core neurodevelopmental phenotype of NEDBEH.  
2. **Ocular Anomalies**: Chorioretinal coloboma, iris coloboma, and anisometropia indicate structural eye defects, a hallmark of NEDBEH.  
3. **Cardiac Defects**: Type I truncus arteriosus and supraventricular tachycardia correlate with the ""heart anomalies"" component of the disorder.  
4. **Craniofacial Dysmorphism**: Hypertelorism, wide nasal bridge, flat face, abnormal ear location, small earlobes, and prominent antihelix match the facial gestalt seen in NEDBEH.  
5. **Systemic Involvement**: Bilateral choanal atresia, respiratory distress, growth delay, skeletal anomalies (abnormal bone ossification, hip dysplasia, scoliosis), and renal abnormalities support multi-organ involvement typical of NEDBEH.  
6. **Progressive Features**: Sensorineural hearing impairment and developmental regression suggest a degenerative trajectory, consistent with reported BRD4-related NEDBEH cases.  
7. **Exclusion of Overlap Syndromes**: While CHARGE syndrome (coloboma, choanal atresia) was considered, the presence of truncus arteriosus, hypotonia, and regression favors NEDBEH, which encompasses broader neurodevelopmental and systemic anomalies.  

This constellation of symptoms, particularly the triad of neurodevelopmental regression, structural eye/heart defects, and multi-system involvement, strongly supports a diagnosis of NEDBEH, likely linked to BRD4 mutations."
"['Microcephaly', 'Anteverted nares', 'Strabismus', 'Abnormality of the ear', 'Syndactyly', 'Ataxia', 'Coma', 'Motor delay', 'Death in infancy', 'Hypoglycemia', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Elevated 7-dehydrocholesterol']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Biochemical hallmarks**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol are pathognomonic for SLOS due to mutations in *DHCR7*, which disrupts cholesterol biosynthesis.  
2. **Hypocholesterolemia**: Low cholesterol levels align with the metabolic defect in SLOS.  
3. **Dysmorphic features**: Anteverted nares, syndactyly (classically 2nd-3rd toe), microcephaly, and ear abnormalities are consistent with SLOS-associated congenital malformations.  
4. **Neurological symptoms**: Ataxia, motor delay, and coma reflect severe neurological impairment from cholesterol deficiency, critical for myelination and brain development.  
5. **Poor prognosis**: Neonatal death, death in infancy/childhood, and recurrent infections (immune dysfunction linked to cholesterol deficiency) characterize severe SLOS phenotypes.  
6. **Hypoglycemia**: May arise due to adrenal insufficiency (cholesterol is a precursor for steroid hormones).  

The combination of dysmorphia, neurodevelopmental regression, and specific sterol abnormalities confirms SLOS."
"['Microcephaly', 'Diabetes mellitus', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Body odor']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Intellectual disability & microcephaly**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, impairing brain development.  
3. **Seizures & abnormal cerebral white matter**: Chronic phenylalanine toxicity disrupts myelination and neuronal function, consistent with MRI findings.  
4. **Body odor**: Phenylacetate, a metabolite of phenylalanine, excreted in sweat, produces a musty odor.  
5. **Hypertyrosinemia**: Atypical in classic PKU but may occur in rare variants (e.g., BH4 cofactor deficiency) or secondary metabolic disturbances.  
6. **Early mortality**: Severe untreated PKU can lead to fatal neurological complications; survival into early adulthood suggests partial management.  
7. **Diabetes mellitus**: Unrelated to PKU but possibly a comorbid condition, as PKU does not directly affect glucose metabolism.  

Note: Hypertyrosinemia warrants investigation for BH4 deficiency (e.g., genetic testing) to exclude atypical PKU forms."
"['Spastic paraplegia', 'Spastic gait', 'Difficulty walking']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Symptom alignment**: Spastic paraplegia, spastic gait, and difficulty walking are hallmark features of hereditary spastic paraplegias (HSPs), a group of disorders characterized by progressive lower limb spasticity and weakness.  
2. **Genetic inheritance**: SPG76 is autosomal recessive, requiring biallelic pathogenic variants in the *CAPN1* gene. The absence of dominant family history supports this mode of inheritance.  
3. **Clinical specificity**: SPG76 typically presents with early-onset (childhood to adulthood) progressive spastic paraplegia, consistent with the described symptoms. While classified as a ""pure"" HSP, subtle additional features (e.g., mild neuropathy) may occur but are not required for diagnosis.  
4. **Exclusion of mimics**: The lack of overt cerebellar ataxia, intellectual disability, or peripheral neuropathy in the symptom list helps differentiate SPG76 from other HSP subtypes (e.g., SPG7, SPG11) or complex forms.  
5. **Confirmation pathway**: Definitive diagnosis requires genetic testing for *CAPN1* mutations, alongside neuroimaging (e.g., spinal MRI to rule out structural causes) and exclusion of acquired causes (e.g., vitamin deficiencies, inflammatory myelopathy).  

**Note**: Family segregation analysis and genetic counseling are critical next steps due to the autosomal recessive inheritance pattern."
"['Seizure', 'Encephalopathy', 'Death in infancy', 'Opisthotonus', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Elevated glutaric acid metabolites**: The presence of glutaric aciduria and elevated circulating glutaric acid directly indicates a defect in glutaric acid metabolism, a hallmark of GA-I caused by deficient glutaryl-CoA dehydrogenase.  
2. **Neurological symptoms**: Seizures, encephalopathy, and opisthotonus align with striatal neurodegeneration triggered by toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
3. **Carnitine depletion**: Decreased plasma free carnitine reflects secondary carnitine deficiency due to excessive conjugation with glutaric acid for renal excretion.  
4. **Urinary carboxylic acid elevation**: Matches the expected excretion of dicarboxylic acids (e.g., glutaric acid) in GA-I.  
5. **Early mortality**: Death in infancy/childhood is consistent with acute metabolic crises (e.g., encephalopathic crises) or progressive neurological damage in untreated GA-I.  
6. **Exclusion of mimics**: Symptoms and biochemical profile rule out other organic acidemias (e.g., type II glutaric aciduria) or mitochondrial disorders, as GA-I uniquely combines these markers with glutaryl-CoA dehydrogenase deficiency."
"['Autistic behavior', 'Hypertension', 'Edema', 'Intellectual disability', 'Seizure', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Pancreatitis', 'Leukopenia', 'Anemia', 'Acute kidney injury', 'Hyperammonemia', 'Gout', 'Vomiting', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Clumsiness', 'Poor coordination', 'Kyphoscoliosis', 'Hyponatremia', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Short femur', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Increased circulating ferritin concentration', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Atransferrinemia', 'Chronic kidney disease', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic aciduria, vitamin B12-responsive, cblB type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits hallmark features of methylmalonic acidemia (MMA), including metabolic decompensation markers (hyperammonemia, vomiting, seizures, coma), elevated methylmalonic acid in blood/urine, and abnormal amino acid concentrations (alanine, valine). Neurological symptoms (intellectual disability, autistic behavior, hypotonia) and multisystem involvement (acute/chronic kidney disease, pancreatitis, anemia) align with MMA’s pathophysiology of methylmalonyl-CoA mutase dysfunction or cofactor deficiency. Death in infancy/childhood reflects severe phenotypes. Elevated lactate, hyperuricemia, and hyperglycinemia further support mitochondrial energy failure and organic acid accumulation.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblB type  
Reasoning: The diagnosis of cblB-type MMA is confirmed by decreased methylmalonyl-CoA mutase activity (due to defective adenosylcobalamin synthesis) and potential B12 responsiveness. While mutase activity is low, the cblB subtype involves mutations in the *MMAB* gene, impairing cobalamin metabolism. Clinical features like chronic kidney disease, leukopenia, and atransferrinemia suggest long-term metabolic stress. Hyponatremia and hypoproteinemia may reflect renal tubular dysfunction. The presence of B12-responsive subtypes often allows partial therapeutic improvement, but early mortality (infancy/childhood) indicates a severe variant or delayed intervention. Abnormal carnitine and porphyrin levels hint at secondary mitochondrial and heme synthesis disruptions."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This directly explains elevated phenylalanine levels.  
2. **Hypertyrosinemia**: While PKU typically reduces tyrosine (due to blocked PAH activity), transient tyrosinemia can occur in neonates with immature liver function or secondary metabolic disruptions from phenylalanine toxicity.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome, not the infant’s own PKU, causes congenital anomalies (e.g., microcephaly, heart defects) if the mother had untreated hyperphenylalaninemia during pregnancy. This aligns with prenatal developmental issues in the infant.  
4. **Neonatal death/Death in infancy**: Untreated severe hyperphenylalaninemia can cause acute metabolic crises, seizures, and irreversible neurological damage, potentially leading to early mortality in extreme cases.  
5. **Consistency with PKU**: The combination of hyperphenylalaninemia and maternal-fetal transmission of metabolic toxicity strongly supports PKU as the diagnosis, despite atypical tyrosinemia."
"['Seizure', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Increased serum lactate', 'Fasciculations', 'Tachypnea', 'Neonatal death', 'Abnormal circulating citrulline concentration', 'Feeding difficulties']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Citrullinemia, classic)  
**Reasoning**:  
1. **Hyperammonemia** and **abnormal circulating citrulline concentration** are hallmark features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency, disrupting the urea cycle.  
2. **Metabolic acidosis** and **increased serum lactate** result from compensatory anaerobic metabolism due to mitochondrial dysfunction from ammonia toxicity.  
3. **Seizures** and **fasciculations** arise from neurotoxicity secondary to hyperammonemia.  
4. **Tachycardia** and **tachypnea** are physiological responses to acidosis (respiratory compensation) and systemic stress.  
5. **Feeding difficulties**, **neonatal death**, and **death in infancy** reflect the severe, early-onset nature of classic citrullinemia, typically manifesting within days of life due to protein intolerance and rapid ammonia accumulation.  
6. **Fever** may occur secondary to metabolic decompensation or intercurrent illness triggering crisis.  

Both listed diagnoses refer to the same entity: **Citrullinemia type I** (OMIM #215700), distinguished by citrulline elevation in serum/urine and confirmatory genetic testing for *ASS1* mutations."
"['Cryptorchidism', 'Micropenis', 'Microcephaly', 'Coarse facial features', 'Hypertelorism', 'Microcytic anemia', 'Osteosarcoma', 'Downturned corners of mouth', 'Intellectual disability, severe']","['Alpha-thalassemia-X-linked intellectual disability syndrome/Alpha-Thalassemia/mental retardation syndrome, X-linked']","Disease: Alpha-thalassemia-X-linked intellectual disability syndrome (ATRX syndrome)  
Reasoning:  
1. **Microcytic anemia**: Indicates alpha-thalassemia, a core feature of ATRX syndrome caused by mutations in the ATRX gene affecting hemoglobin synthesis.  
2. **Severe intellectual disability**: Matches the neurodevelopmental impairment characteristic of X-linked intellectual disability syndromes.  
3. **Cryptorchidism/Micropenis**: Consistent with genital anomalies seen in ATRX syndrome due to disrupted development of urogenital structures.  
4. **Facial dysmorphisms (coarse features, hypertelorism, downturned mouth)**: Hallmark craniofacial traits of ATRX syndrome, linked to abnormal neural crest cell migration.  
5. **Microcephaly**: Reflects impaired brain growth, common in syndromic intellectual disabilities.  
6. **Osteosarcoma**: Rare but reported in ATRX syndrome, as ATRX mutations predispose to genomic instability and tumorigenesis.  
7. **X-linked inheritance**: Male presentation aligns with the X-linked recessive pattern of ATRX syndrome.  

The constellation of alpha-thalassemia, neurodevelopmental deficits, genital anomalies, and dysmorphic features strongly supports this diagnosis."
"['Motor delay', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Motor delay** aligns with Canavan disease, a leukodystrophy causing progressive neurological deterioration due to defective myelination.  
2. **Death in infancy** is consistent with severe, early-onset forms of Canavan disease, which can lead to rapid neurological decline and fatal outcomes.  
3. **Abnormal circulating aspartate family amino acids** (specifically elevated *N-acetylaspartic acid [NAA]*) directly results from aspartoacylase deficiency, the enzyme defect in Canavan disease. This biochemical marker confirms the diagnosis.  
4. The triad of neurological regression, fatal infantile course, and NAA accumulation is pathognomonic for Canavan disease, ruling out other leukodystrophies or metabolic disorders with overlapping symptoms."
"['Metabolic acidosis', 'Vomiting', 'Death in childhood', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with metabolic acidosis, vomiting, and methylmalonic aciduria—hallmark features of methylmalonic acidemia (MMA). MMA is an autosomal recessive disorder caused by defects in methylmalonyl-CoA metabolism, leading to toxic accumulation of methylmalonic acid. The symptom ""death in childhood"" aligns with severe forms of MMA, which can result in early mortality due to metabolic crises or organ failure if untreated.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity of ""vitamin B12-unresponsive"" points to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme deficiency prevents the conversion of methylmalonyl-CoA to succinyl-CoA, independent of vitamin B12 (cobalamin) metabolism. The lack of response to B12 supplementation distinguishes this subtype from other MMA forms (e.g., cblA/cblB types). Early lethality underscores the severe biochemical disruption caused by complete mutase deficiency."
"['Ectopia lentis', 'Arachnodactyly', 'Global developmental delay', 'Disproportionate tall stature']",['Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency'],"Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Ectopia lentis**: A hallmark feature of homocystinuria, caused by defective cysteine metabolism weakening zonular fibers that secure the lens.  
2. **Arachnodactyly and disproportionate tall stature**: Marfanoid habitus (long limbs, slender fingers) arises from disrupted collagen cross-linking due to homocysteine accumulation.  
3. **Global developmental delay**: Elevated homocysteine levels are neurotoxic, impairing myelination and neuronal function, leading to intellectual/developmental deficits.  
4. **Exclusion of Marfan syndrome**: While Marfan shares arachnodactyly and ectopia lentis, it lacks metabolic abnormalities or developmental delay, directing suspicion toward homocystinuria.  
5. **Biochemical confirmation**: Suspected diagnosis aligns with cystathionine beta-synthase deficiency, confirmed via elevated plasma homocysteine, low methionine, and genetic testing."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']","['Tyrosinemia, type III']","Disease: Tyrosinemia, type III  
Reasoning:  
1. **Hypertyrosinemia and Hyperphenylalaninemia**: Tyrosinemia type III is caused by a deficiency of 4-hydroxyphenylpyruvate dioxygenase, disrupting tyrosine metabolism. Elevated tyrosine (hypertyrosinemia) occurs due to impaired degradation. Feedback inhibition of phenylalanine hydroxylase by excess tyrosine may also lead to hyperphenylalaninemia.  
2. **Severe Outcomes (Neonatal/Infancy/Childhood Death)**: While typically milder than type I/II, untreated type III can cause metabolic crises or neurological complications (e.g., seizures, intellectual disability), potentially leading to early mortality in severe cases.  
3. **Prenatal Developmental Abnormalities**: Chronic metabolic disturbances in utero may interfere with fetal development, aligning with reported prenatal abnormalities.  
4. **Differentiation from Other Tyrosinemias**:  
   - Type I primarily causes liver/kidney failure (absent here).  
   - Type II presents with ocular/skin lesions (not described).  
   - Co-occurring hypertyrosinemia *and* hyperphenylalaninemia strongly supports type III.  

Conclusion: The combination of tyrosine/phenylalanine elevation, developmental abnormalities, and early lethality aligns with a severe manifestation of tyrosinemia type III."
"['Gingival overgrowth', 'Microcephaly', 'Progressive microcephaly', 'Micrognathia', 'Anteverted nares', 'Proptosis', 'Carious teeth', 'Abnormality of the skeletal system', 'Sacral dimple', 'Hemangioma', 'Brachydactyly', 'Hypotonia', 'Hyporeflexia', 'Motor delay', 'Generalized hypotonia', 'Muscle weakness', 'Hepatic cysts', 'Failure to thrive', 'Overgrowth', 'Polyhydramnios', 'Frontal bossing', 'Rigidity', 'Pneumonia', 'Spinal cord compression', 'Hepatomegaly', 'Kyphosis', 'Decreased circulating total IgM', 'Abnormal ilium morphology', 'Hyperbilirubinemia', 'Lumbar hyperlordosis', 'Metaphyseal widening', 'Short nose', 'Neonatal hyperbilirubinemia', 'Hyperlordosis', 'Spinal canal stenosis', 'Limb muscle weakness', 'Trident hand', 'Decreased circulating IgG level', 'Severe platyspondyly', 'Restricted large joint movement', 'Depressed nasal bridge', 'Capillary hemangioma', 'Thoracolumbar kyphosis', 'Recurrent pneumonia', 'Lower limb muscle weakness', 'Axial hypotonia', 'Limb undergrowth', 'Cognitive impairment', 'Enlarged thorax', 'Broad ischia']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Microcephaly (progressive), brachydactyly, kyphosis, severe platyspondyly, metaphyseal widening, and spinal canal stenosis align with skeletal dysplasia, a hallmark of ISDNA.  
2. **Immunodeficiency**: Recurrent pneumonia, decreased IgG/IgM levels, and failure to thrive suggest humoral immune dysfunction, consistent with ISDNA’s B-cell defects.  
3. **Neurodevelopmental Delays**: Cognitive impairment, motor delay, axial/limb hypotonia, and muscle weakness reflect the neurodevelopmental axis of ISDNA, linked to EXTL3 mutations affecting heparan sulfate synthesis.  
4. **Hepatic Involvement**: Hepatic cysts and hepatomegaly are reported in ISDNA due to disrupted glycosaminoglycan metabolism.  
5. **Dysmorphic Features**: Anteverted nares, depressed nasal bridge, frontal bossing, and trident hand correlate with craniofacial and skeletal anomalies in ISDNA.  
6. **Overlap with Known Cases**: ISDNA’s triad of skeletal dysplasia, immune deficiency, and neurodevelopmental deficits matches the patient’s multisystem presentation, excluding mimics like mucopolysaccharidoses (no coarse features) or isolated skeletal dysplasias (no immune/neuro involvement)."
"['Triangular face', 'Cupped ear', 'Protruding ear', 'Myopia', 'Exotropia', 'Autistic behavior', 'Intellectual disability', 'Global developmental delay', 'Clinodactyly of the 5th finger', 'Clinodactyly of the 2nd toe', 'Bilateral sensorineural hearing impairment', 'Prominent ear helix', 'Cerebral palsy']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Craniofacial features**: Triangular face, cupped/protruding ears, and prominent ear helix are consistent with dysmorphic facial features observed in NEDBEH.  
2. **Neurodevelopmental symptoms**: Autistic behavior, intellectual disability, and global developmental delay align with the disorder’s core neurocognitive phenotype.  
3. **Ocular anomalies**: Myopia and exotropia (eye misalignment) correlate with the ""eye anomalies"" component of NEDBEH.  
4. **Skeletal findings**: Clinodactyly (5th finger and 2nd toe) supports subtle skeletal involvement, a recognized feature.  
5. **Neurological overlap**: Cerebral palsy-like motor dysfunction may reflect underlying brain anomalies (e.g., structural malformations or white matter changes).  
6. **Hearing impairment**: Bilateral sensorineural hearing loss, while not universally present in NEDBEH, can occur due to genetic or neurodevelopmental disruptions.  
7. **Exclusion of mimics**: The constellation rules out syndromes like Fragile X (no hyperextensible joints/macrocephaly) or chromosomal disorders (clinodactyly alone is nonspecific).  
8. **Genetic basis**: PHF21A variants are implicated in NEDBEH, which disrupt neurodevelopment and craniofacial patterning, explaining multisystem involvement."
"['Irritability', 'Coma', 'Generalized hypotonia', 'Encephalopathy', 'Cardiomyopathy', 'Anemia', 'Hypoglycemia', 'Vomiting', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency (PCD)  
Reasoning:  
1. **Decreased plasma free carnitine**: A hallmark of PCD due to defective carnitine transporter (OCTN2), impairing cellular carnitine uptake.  
2. **Hypoglycemia**: Carnitine is essential for fatty acid oxidation (FAO); its deficiency forces reliance on glucose, depleting reserves and causing hypoglycemia, especially during fasting/metabolic stress.  
3. **Cardiomyopathy and generalized hypotonia**: Impaired FAO reduces ATP production in cardiac and skeletal muscles, leading to energy-deficient states.  
4. **Hepatomegaly and elevated hepatic transaminases**: Hepatic fat accumulation (steatosis) from defective fat metabolism causes liver enlargement and inflammation.  
5. **Encephalopathy, irritability, coma**: Hypoglycemia and potential hyperammonemia (secondary to disrupted urea cycle intermediates) induce neurotoxicity.  
6. **Abnormal circulating amino acids (aspartate family, alanine)**: Dysregulated gluconeogenesis and Krebs cycle intermediates alter amino acid metabolism.  
7. **Anemia**: Chronic energy deprivation affects erythropoiesis; mitochondrial dysfunction in bone marrow may contribute.  
8. **Abnormal porphyrins**: Secondary disruption of heme biosynthesis pathways due to hepatic mitochondrial dysfunction.  
9. **Death in childhood**: Untreated PCD causes recurrent metabolic crises, cardiac failure, or sudden death, consistent with the natural history of severe cases.  

PCD unifies all symptoms via disrupted fatty acid metabolism, energy deficiency, and multi-organ dysfunction. Confirmatory testing would involve genetic analysis of *SLC22A5* mutations."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine. This aligns with the listed symptom.  
2. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome (untreated phenylalanine elevation during pregnancy) rather than the infant’s own PKU, though severe neonatal metabolic instability could contribute.  
3. **Death in infancy/childhood and neonatal death** are rare in treated PKU but plausible in undiagnosed/severe cases due to metabolic crises, neurological deterioration, or secondary complications (e.g., seizures, failure to thrive).  
4. **Hypertyrosinemia** is atypical in classic PKU (tyrosine levels are usually normal/low). This could suggest a comorbid condition (e.g., transient tyrosinemia in liver immaturity) or a BH4-deficient PKU variant, where disrupted tyrosine metabolism may occur alongside phenylalanine accumulation.  
5. The combination of **hyperphenylalaninemia + early lethality** strongly prioritizes PKU as the primary diagnosis, with hypertyrosinemia requiring further investigation for confounding factors."
"['Neurogenic bladder', 'Macroglossia', 'Gingival overgrowth', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Ptosis', 'Cataract', 'Osteoporosis', 'Areflexia', 'Stroke', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Respiratory insufficiency', 'Hypertriglyceridemia', ""Exaggerated cupid's bow"", 'Developmental regression', 'Highly arched eyebrow', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Multifocal epileptiform discharges', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Periauricular skin pits', 'Subdural hemorrhage', 'Cerebral visual impairment']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Coarse facial features, macroglossia, gingival overgrowth, narrow forehead, prominent nasal bridge, anteverted nares, ptosis, highly arched eyebrows, and ""exaggerated Cupid's bow"" align with the distinct craniofacial phenotype described in TBCK syndrome.  
2. **Neurological and neuromuscular deficits**: Severe muscular hypotonia, areflexia, profound global developmental delay, developmental regression, and cerebellar vermis hypoplasia reflect the central and peripheral nervous system involvement typical of TBCK mutations.  
3. **Epilepsy**: Focal-onset seizures and multifocal epileptiform discharges correlate with the seizure phenotype observed in TBCK-related disorders.  
4. **Neuroimaging findings**: Partial agenesis of the corpus callosum, small basal ganglia, and subdural hemorrhage (likely secondary to hypotonia/falls) are consistent with structural brain anomalies reported in TBCK patients.  
5. **Systemic features**: Osteoporosis, hypertriglyceridemia, respiratory insufficiency, and cataracts match the multisystemic manifestations of TBCK syndrome, involving metabolic and connective tissue dysfunction.  
6. **Supportive features**: Periauricular skin pits, feeding difficulties, and cerebral visual impairment further reinforce the diagnosis, as these are recurrently observed in TBCK-related cases.  
7. **Exclusion of mimics**: The absence of organomegaly, skeletal dysplasia, or specific storage material distinguishes this from lysosomal disorders (e.g., mucopolysaccharidoses), while the combination of hypotonia, facial dysmorphism, and brain anomalies differentiates it from other neurodevelopmental syndromes."
"['Autistic behavior', 'Self-mutilation', 'Hyperactivity', 'Intellectual disability', 'Seizure', 'Motor delay', 'Obesity', 'Death in infancy', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased serum iron']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia** and **hyperphenylalaninemia** directly indicate a defect in tyrosine metabolism, a hallmark of Tyrosinemia type 1 (HT-1) caused by fumarylacetoacetate hydrolase deficiency.  
2. **Elevated circulating alpha-fetoprotein (AFP)** and **alkaline phosphatase** suggest liver damage, consistent with HT-1’s hepatotoxic effects.  
3. **Seizures**, **intellectual disability**, **motor delay**, and **autistic behavior** align with neurotoxic effects of tyrosine byproducts (e.g., succinylacetone).  
4. **Self-mutilation** and **hyperactivity** may reflect neurological dysfunction or peripheral neuropathy from metabolite accumulation.  
5. **Abnormal aspartate/alanine concentrations** and **decreased serum iron** reflect disrupted amino acid metabolism and secondary liver dysfunction.  
6. **Death in infancy/childhood** and **neonatal death** correlate with HT-1’s acute and chronic forms, often due to liver failure or metabolic crises.  
7. **Obesity** is atypical but may arise from metabolic dysregulation or dietary management complications.  
8. **Elevated AFP** and liver-related symptoms differentiate HT-1 from other amino acid disorders (e.g., PKU), which lack severe hepatic involvement.  

This constellation of hepatic, neurological, and metabolic abnormalities strongly supports Tyrosinemia type 1."
"['Intellectual disability', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hyperglycinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: IVA disrupts the urea cycle via toxic metabolite accumulation (isovaleric acid), leading to secondary hyperammonemia. Hyperglycinemia may arise from glycine conjugation to isovaleric acid, forming isovalerylglycine, a diagnostic urinary marker.  
2. **Increased Serum Lactate**: Metabolic crises in IVA cause acidosis, impairing mitochondrial function and promoting lactic acidosis.  
3. **Abnormal Carnitine Levels**: Isovaleric acid conjugates with carnitine (forming isovalerylcarnitine), depleting free carnitine and altering circulating levels—a hallmark of IVA.  
4. **Gastrointestinal Symptoms (Vomiting, Feeding Difficulties, Inflammation)**: Acute metabolic decompensation triggers vomiting and gut inflammation, exacerbating feeding challenges.  
5. **Early Mortality & Growth Failure**: Untreated IVA causes rapid neonatal/childhood deterioration due to metabolic instability, leading to death. Chronic toxicity results in severe short stature and intellectual disability from neurodevelopmental damage.  
6. **Exclusion of Mimics**: Symptoms align with IVA over urea cycle defects (hyperlactatemia uncommon) or propionic acidemia (hyperglycinemia overlaps, but carnitine profile and isovalerylglycine specificity confirm IVA)."
"['Obesity', 'Death in infancy', 'Fever', 'Vomiting', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Neonatal death**, **death in infancy/childhood/adolescence** align with untreated PKU, where toxic phenylalanine accumulation leads to severe neurological damage, organ failure, and early mortality without dietary intervention.  
3. **Vomiting** and **gastrointestinal inflammation** may reflect metabolic crises or protein intolerance due to impaired phenylalanine metabolism.  
4. **Obesity** could stem from restrictive dietary management (high-carbohydrate, low-protein diets) often used in PKU, predisposing to weight gain.  
5. **Hypertyrosinemia** is atypical in classic PKU (which typically causes *low* tyrosine levels). This may indicate a concurrent condition (e.g., tyrosinemia Type II), a PAH deficiency variant affecting tyrosine regulation, or a reporting error.  
6. **Fever** is non-specific but could arise from secondary infections or metabolic instability in severe cases.  
**Conclusion**: Hyperphenylalaninemia is pathognomonic for PKU. Early lethality and systemic symptoms reflect untreated disease progression, though hypertyrosinemia warrants further investigation for comorbidities or diagnostic inaccuracies."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts medium-chain fatty acid oxidation, leading to accumulation of medium-chain acylcarnitines and secondary carnitine deficiency.  
2. **Neonatal death/Death in infancy/childhood**: Untreated MCADD causes hypoketotic hypoglycemia during fasting, triggering metabolic crises that can be fatal, especially in early life.  
3. **Delayed speech/language development**: Neurological damage from prior hypoglycemic episodes or metabolic instability may impair development in undiagnosed cases.  
4. **Abnormality of prenatal development or birth**: Though atypical, severe metabolic stress *in utero* or maternal factors (e.g., placental insufficiency) might contribute to prenatal abnormalities.  
5. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects misinterpretation of acylcarnitine profile data or secondary metabolic disruption; MCADD primarily involves MCAD enzyme deficiency (not 3-hydroxyacyl-CoA dehydrogenase).  

Key confirmation relies on genetic testing for *ACADM* mutations and characteristic acylcarnitine profile (elevated C6-C10 species, notably C8)."
"['Weight loss', 'Leukopenia', 'Dyspnea', 'Vertigo', 'Elevated circulating creatine kinase concentration', 'Exercise intolerance', 'Ground-glass opacification', 'Foot pain', 'Autoimmune antibody positivity', 'Decreased DLCO']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Autoimmune antibody positivity**: A hallmark of antisynthetase syndrome (e.g., anti-Jo-1 antibodies).  
2. **Ground-glass opacification & decreased DLCO**: Indicates interstitial lung disease (ILD), a core feature of antisynthetase syndrome.  
3. **Elevated creatine kinase & exercise intolerance**: Suggests inflammatory myositis, another key component of the syndrome.  
4. **Foot pain**: May reflect inflammatory arthritis, part of the clinical triad (myositis, ILD, arthritis).  
5. **Dyspnea**: Correlates with ILD severity.  
6. **Weight loss & leukopenia**: Systemic inflammation or autoimmune-driven processes.  
7. **Vertigo**: Less specific but possible in autoimmune-mediated neuroinflammation or comorbidities.  

The constellation of ILD, myositis, and autoimmune serology strongly supports antisynthetase syndrome. Confirmatory testing for anti-synthetase antibodies (e.g., anti-Jo-1) and imaging/pulmonary function tests would solidify the diagnosis."
"['Tall stature', 'Myopia', 'Pectus excavatum', 'Thin skin', 'Arachnodactyly', 'Mitral regurgitation', 'Aortic root aneurysm', 'Scoliosis', 'Kyphoscoliosis', 'Decreased body weight', 'Lens luxation']","['Marfan syndrome', 'Marfan syndrome type 1']","Disease: Marfan syndrome  
Reasoning: The patient exhibits cardinal features of Marfan syndrome, including skeletal manifestations (tall stature, pectus excavatum, arachnodactyly, scoliosis/kyphoscoliosis), ocular involvement (myopia, lens luxation), cardiovascular complications (mitral regurgitation, aortic root aneurysm), and connective tissue abnormalities (thin skin, decreased body weight). Lens luxation and aortic root aneurysm are major diagnostic criteria, while the other findings fulfill systemic involvement.  

Disease: Marfan syndrome type 1  
Reasoning: Marfan syndrome type 1 refers specifically to cases caused by pathogenic variants in the *FBN1* gene, which encodes fibrillin-1. The clinical presentation aligns with *FBN1*-related Marfan syndrome, as lens luxation and aortic root aneurysm are hallmark features of this subtype. Genetic testing for *FBN1* mutations would confirm the molecular basis of the diagnosis."
"['Microcephaly', 'Pointed chin', 'Short chin', 'Strabismus', 'Ptosis', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Ataxia', 'Generalized hypotonia', 'Hyperreflexia', 'Failure to thrive', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties', 'Fatigue']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Metabolic markers**: Elevated 7-dehydrocholesterol (7-DHC) and hypocholesterolemia are pathognomonic for SLOS, caused by mutations in *DHCR7*, which disrupts cholesterol synthesis. Elevated 8-dehydrocholesterol may also occur due to secondary biochemical instability.  
2. **Craniofacial features**: Microcephaly, pointed chin, short chin, ptosis, and strabismus align with SLOS-associated dysmorphism.  
3. **Neurological/developmental**: Intellectual disability, generalized hypotonia, hyperreflexia, ataxia, and hyperactivity reflect neurodevelopmental deficits typical of SLOS.  
4. **Growth/feeding issues**: Failure to thrive, feeding difficulties, and fatigue correlate with metabolic dysfunction and poor cholesterol-dependent growth.  
5. **Congenital anomalies**: Syndactyly (often 2-3 toe) is a hallmark structural defect in SLOS.  
6. **Severity/mortality**: Death in infancy or childhood occurs in severe cases due to metabolic instability or organ malformations.  

All findings coalesce into a diagnosis of Smith-Lemli-Opitz syndrome, confirmed by biochemical/genetic testing."
"['Macrocephaly', 'Apathy', 'Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Cerebral atrophy', 'Glutaric aciduria', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase.  
2. **Macrocephaly** and **cerebral atrophy** align with frontotemporal atrophy, a hallmark of GA-I due to toxic metabolite accumulation.  
3. **Generalized hypotonia** and **feeding difficulties** reflect early neurological dysfunction from striatal injury.  
4. **Vomiting** and **diarrhea** suggest metabolic decompensation triggered by catabolic stress (e.g., infections/fasting).  
5. **Apathy** correlates with encephalopathic crises during metabolic derangement.  
6. **Death in infancy** occurs in untreated cases due to acute striatal necrosis or severe metabolic crises.  
7. All symptoms collectively match GA-I’s triad: macrocephaly, movement disorders, and metabolic instability."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine.  
2. **Delayed speech and language development**: Untreated PKU results in neurotoxic effects of elevated phenylalanine, impairing brain development and cognitive/linguistic function.  
3. **Abnormality of prenatal development or birth**: Maternal PKU (untreated during pregnancy) can cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus due to intrauterine phenylalanine toxicity.  
4. **Neonatal death/Death in infancy/childhood**: Severe untreated PKU causes progressive neurodegeneration, seizures, and failure to thrive, historically leading to early mortality before dietary management became standard.  
5. **Hypertyrosinemia**: While PKU typically reduces tyrosine levels (due to blocked PAH-mediated conversion), transient hypertyrosinemia may occur in critically ill infants with hepatic dysfunction or secondary metabolic disturbances, or as a lab artifact. This symptom is atypical but does not exclude PKU as the primary diagnosis.  

**Note**: The diagnosis assumes classic PKU, with hypertyrosinemia requiring further investigation for coexisting conditions (e.g., tyrosinemia type II) or confounding factors. Confirmatory testing (PAH gene analysis, phenylalanine/tyrosine ratios) is critical."
"['Petechiae', 'Intellectual disability', 'Spastic diplegia', 'Motor delay', 'Areflexia', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Opisthotonus', 'Abnormal cerebral white matter morphology', 'Spastic tetraplegia', 'Increased CSF protein concentration', 'Neonatal death', 'Death in childhood', 'Decreased beta-galactosidase activity', 'Peripheral demyelination', 'Feeding difficulties', 'Dyskinesia']",['Krabbe disease'],"Disease: Krabbe disease  
Reasoning:  
1. **Enzyme Deficiency**: Decreased beta-galactosidase activity is pathognomonic for Krabbe disease, a lysosomal disorder caused by **GALC** mutations, leading to toxic psychosine accumulation and demyelination.  
2. **Neurological Symptoms**: Spastic tetraplegia/diplegia, dyskinesia, and opisthotonus reflect progressive CNS damage. Generalized hypotonia (early) transitioning to spasticity aligns with neurodegeneration.  
3. **White Matter Abnormalities**: Abnormal cerebral white matter morphology on imaging and peripheral demyelination correlate with widespread myelin loss.  
4. **CSF Findings**: Increased CSF protein concentration is characteristic due to breakdown of myelin products.  
5. **Infantile Presentation**: Feeding difficulties, motor delay, failure to thrive, vomiting, and diarrhea are typical in early-onset cases. Death in infancy/childhood matches the severe infantile form.  
6. **Areflexia**: Peripheral nerve demyelination explains reduced reflexes despite central spasticity.  
7. **Red Flags**: Petechiae and diarrhea may indicate multisystemic involvement or secondary complications (e.g., autonomic dysfunction).  

Krabbe disease integrates enzyme deficiency, neuroimaging, CSF findings, and clinical progression, overriding less specific symptoms (e.g., petechiae)."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This deficiency leads to phenylalanine accumulation, explaining hyperphenylalaninemia.  
2. **Hypertyrosinemia discrepancy**: Classical PKU typically results in *low* tyrosine levels due to impaired conversion. However, this symptom could arise from concurrent factors (e.g., tyrosine supplementation in treated PKU, liver dysfunction, or an overlapping metabolic disorder).  
3. **Death in early adulthood**: Untreated PKU causes severe neurological damage, seizures, and organ failure. Without lifelong dietary management (low-phenylalanine diet), complications progress, leading to early mortality.  
4. **Exclusion of BH4 deficiency**: While BH4 cofactor defects also cause hyperphenylalaninemia, they typically involve neurotransmitter deficiencies and distinct symptoms (e.g., hypotonia, developmental delays), which are not listed here. PKU remains the primary diagnosis.  

Note: Hypertyrosinemia is atypical for PKU and warrants further investigation for secondary causes or diagnostic errors, but the core diagnosis aligns with hyperphenylalaninemia and clinical severity."
"['Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Respiratory distress', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Hypercholesterolemia', 'Hyperalaninemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic aciduria, vitamin B12-responsive, cblA type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Core biochemical markers**: Elevated methylmalonic acid in blood (methylmalonic acidemia) and urine (methylmalonic aciduria) confirm a defect in methylmalonyl-CoA metabolism, a hallmark of MMA.  
2. **Neuromuscular symptoms**: Delayed speech, motor delay, and hypotonia align with neurotoxic effects of accumulated methylmalonic acid and metabolic instability.  
3. **Metabolic crises**: Episodic vomiting, dehydration, fever, and respiratory distress are typical during acute decompensation due to protein catabolism or infection.  
4. **Amino acid abnormalities**: Hyperalaninemia and hyperglycinuria suggest secondary disruption of amino acid metabolism from mitochondrial dysfunction.  
5. **Fatality risk**: Death in infancy/childhood reflects severe metabolic derangements or complications (e.g., hyperammonemia, cardiomyopathy).  
6. **Carnitine/porphyrin abnormalities**: Abnormal carnitine (secondary deficiency) and porphyrin levels indicate disrupted mitochondrial and heme biosynthesis pathways.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblA type  
Reasoning:  
1. **B12 responsiveness**: The cblA subtype involves mutations in *MMAA*, impairing adenosylcobalamin (active B12) synthesis. Partial or full response to B12 supplementation distinguishes it from mutase-deficient MMA.  
2. **Biochemical overlap**: Shared features with classic MMA (acidemia/aciduria, hyperalaninemia) but with potential milder symptoms if B12 is administered early.  
3. **Clinical severity**: Despite B12 responsiveness, untreated cblA can still lead to infantile/childhood mortality due to acute metabolic crises, consistent with the patient’s profile.  
4. **Carnitine/porphyrin disturbances**: Secondary carnitine deficiency and porphyrin abnormalities may persist even with B12 therapy, depending on residual enzyme activity.  

**Conclusion**: The patient’s presentation aligns with **methylmalonic acidemia**, specifically the **cblA subtype**, given the biochemical profile and potential for B12 responsiveness, which guides therapeutic intervention (e.g., hydroxocobalamin). Early diagnosis is critical to mitigate fatal outcomes."
"['Congenital diaphragmatic hernia', 'Intellectual disability', 'Motor delay', 'Failure to thrive', 'Death in infancy', 'Hiatus hernia', 'Cerebral atrophy', 'Lipodystrophy', 'Abnormal muscle physiology']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
- **Congenital diaphragmatic hernia (CDH)** and **hiatus hernia** align with PMM2-CDG’s multisystem involvement, as glycosylation defects impair tissue integrity, including diaphragmatic and connective tissue development.  
- **Intellectual disability**, **motor delay**, and **cerebral atrophy** reflect the neurological hallmarks of PMM2-CDG, caused by abnormal glycosylation of brain proteins and neuronal migration defects.  
- **Failure to thrive** and **death in infancy** are common due to systemic complications (e.g., liver dysfunction, protein-losing enteropathy) and metabolic instability.  
- **Lipodystrophy** and **abnormal muscle physiology** stem from disrupted lipid metabolism and glycosylation-dependent muscle protein function.  
- The constellation of visceral, neurological, and metabolic symptoms, alongside early lethality, strongly supports PMM2-CDG as the unifying diagnosis."
"['Hyperactivity', 'Intellectual disability', 'Seizure', 'Obesity', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Core feature of PKU due to deficient phenylalanine hydroxylase (PAH), causing phenylalanine accumulation.  
2. **Intellectual disability & Hyperactivity**: Untreated PKU results in neurotoxic phenylalanine buildup, impairing brain development and function.  
3. **Seizures**: Neurological damage from elevated phenylalanine can manifest as seizures.  
4. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) excreted in urine, classified as carboxylic acids.  
5. **Severe short stature & Obesity**: Less typical but possible in poorly managed cases due to metabolic dysregulation or restrictive diets altering growth/weight.  
6. **Early mortality (childhood/adolescence/adulthood)**: Historically, untreated PKU led to severe complications (e.g., neurodegeneration, infections), but modern neonatal screening and dietary management mitigate this.  

**Conflicts/Discordant Symptoms**:  
- **Hypertyrosinemia**: PKU classically causes *low* tyrosine (PAH converts phenylalanine to tyrosine). This symptom suggests possible comorbid tyrosinemia type II or lab error.  
- **Obesity**: Rare in PKU; may reflect dietary adjustments (high-carb/low-protein intake) or unrelated factors.  

**Conclusion**: Dominant PKU features (hyperphenylalaninemia, neurodevelopmental issues, urinary metabolites) align with the diagnosis. Discordant symptoms may require further investigation for comorbidities or testing inaccuracies."
"['Rod-cone dystrophy', 'Delayed speech and language development', 'Cafe-au-lait spot', 'Brachydactyly', 'Absent speech', 'Craniosynostosis', 'Pes planus', 'Hallux valgus', 'Delayed gross motor development', 'Short stature', 'Multiple cafe-au-lait spots']",['Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies'],"Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Rod-cone dystrophy**: Indicates retinitis pigmentosa (RP), a hallmark of the syndrome, characterized by progressive retinal degeneration.  
2. **Brachydactyly and short stature**: Directly aligns with the skeletal anomalies component (brachydactyly) and growth deficiency (short stature) in the syndrome.  
3. **Craniosynostosis**: Supports skeletal involvement, as craniofacial abnormalities can co-occur with syndromic RP variants.  
4. **Delayed speech/absent speech and motor delays**: Reflects potential neurodevelopmental impacts, consistent with multisystem genetic syndromes.  
5. **Pes planus and hallux valgus**: Further skeletal manifestations, reinforcing the ""skeletal anomalies"" classification.  
6. **Cafe-au-lait spots**: Less typical but occasionally reported in syndromic RP variants; may indicate phenotypic variability or overlap with other disorders (e.g., NF1), though the core triad (RP, brachydactyly, short stature) dominates the diagnosis.  

The combination of retinal degeneration, skeletal defects, and growth delays strongly prioritizes this syndrome over isolated RP or other café-au-lait-associated disorders."
"['Large fontanelles', 'Parietal bossing', 'Hypertelorism', 'Micrognathia', 'Delayed eruption of primary teeth', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Disease: Cleidocranial dysplasia/Cleidocranial dysplasia  
Reasoning:  
1. **Cranial and Skull Abnormalities**: Large fontanelles, parietal/frontal bossing, Wormian bones, and metopic depression align with CCD's hallmark delayed cranial suture closure and defective ossification.  
2. **Dental Manifestations**: Delayed eruption of primary teeth and enamel hypoplasia are classic CCD features due to disrupted osteoclast activity and dental follicle abnormalities.  
3. **Clavicular Defects**: Short clavicles (often hypoplastic/aplastic) explain the ""abnormal facility in opposing the shoulders.""  
4. **Skeletal Dysplasia**: Hypoplastic iliac wings, short stature, scoliosis, broad femoral heads, and short femoral necks reflect generalized skeletal hypoplasia and abnormal bone growth.  
5. **Facial Dysmorphism**: Midface retrusion, depressed nasal bridge, hypertelorism, and micrognathia result from craniofacial bone underdevelopment.  
6. **Pelvic and Pubic Involvement**: Delayed pubic bone ossification and hypoplastic iliac wings are consistent with CCD's pelvic radiographic findings.  
7. **Rule-Out Considerations**: While some features (e.g., Wormian bones) overlap with osteogenesis imperfecta, the combination of clavicular, dental, and cranial defects is pathognomonic for CCD."
"['Myopia', 'Exotropia', 'Ectopia lentis', 'Arachnodactyly', 'Intellectual disability', 'Ataxia', 'Dysarthria', 'Gait disturbance', 'Abnormal pyramidal sign', 'Brain atrophy', 'Scleral staphyloma', 'Flushing']",['Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency'],"Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Ectopia lentis**: A hallmark feature of homocystinuria, caused by defective collagen cross-linking due to cystathionine beta-synthase (CBS) deficiency.  
2. **Arachnodactyly and Myopia**: Connective tissue abnormalities from disrupted sulfur metabolism, mimicking Marfan-like features but with distinct metabolic etiology.  
3. **Intellectual disability, Ataxia, Dysarthria, Gait disturbance**: Reflect chronic CNS involvement due to homocysteine neurotoxicity, vascular insults, or secondary folate deficiency.  
4. **Brain atrophy and Abnormal pyramidal signs**: Long-standing metabolic derangement leads to neuronal loss and corticospinal tract damage.  
5. **Exotropia and Scleral staphyloma**: Ocular connective tissue weakness and lens displacement contribute to strabismus and scleral thinning.  
6. **Flushing**: Potentially linked to endothelial dysfunction from elevated homocysteine levels affecting vasoregulation.  
7. **Exclusion of mimics**: Differentiated from Marfan syndrome (no aortic root dilation) and other metabolic disorders (e.g., sulfite oxidase deficiency) by the combination of biochemical, ocular, and neuropsychiatric features.  
**Conclusion**: The constellation of connective, ocular, neurological, and vascular symptoms aligns with CBS-deficient homocystinuria, confirmed by elevated plasma homocysteine and low methionine levels."
"['Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis is a hallmark of methylmalonic acidemia (MMA), as impaired methylmalonyl-CoA mutase activity disrupts propionate metabolism, leading to toxic accumulation of methylmalonic acid. The clinical severity (death in childhood) aligns with acute or neonatal-onset MMA, which often presents with life-threatening metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Decreased methylmalonyl-CoA mutase activity directly indicates a defect in the MUT gene, which encodes this enzyme. This subtype is vitamin B12-unresponsive because the mutation affects the enzyme itself, not its cofactor (adenosylcobalamin, derived from vitamin B12). Early mortality underscores the severe biochemical dysfunction caused by the enzyme deficiency."
"['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Neonatal death** and **death in infancy/childhood** align with severe, untreated PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
3. **Hypertyrosinemia** is atypical for classical PKU (which typically results in *low* tyrosine due to blocked PAH-dependent conversion). However, this could indicate:  
   - A comorbid condition (e.g., transient tyrosinemia of the newborn) or secondary metabolic disruption.  
   - Potential misreporting of symptoms (e.g., hypotyrosinemia is expected in PKU).  
4. The fatal outcomes emphasize the critical need for early newborn screening and dietary intervention in PKU to prevent catastrophic complications."
"['Cleft palate', 'Thin upper lip vermilion', 'Microcephaly', 'Low anterior hairline', 'Long philtrum', 'Low-set ears', 'Synophrys', 'Delayed speech and language development', 'Single transverse palmar crease', 'Hirsutism', 'Depressed nasal bridge', 'Curly eyelashes', 'Postnatal growth retardation', 'Intellectual disability, severe']",['Cornelia de Lange syndrome/Cornelia de Lange syndrome 1'],"Disease: Cornelia de Lange syndrome/Cornelia de Lange syndrome 1  
Reasoning:  
1. **Facial Features**: Thin upper lip vermilion, long philtrum, synophrys (confluent eyebrows), depressed nasal bridge, and low-set ears are hallmark craniofacial characteristics of Cornelia de Lange syndrome (CdLS).  
2. **Growth and Development**: Postnatal growth retardation, microcephaly, and severe intellectual disability align with CdLS-associated developmental delays and growth deficiencies.  
3. **Neurological/Speech**: Delayed speech and language development correlate with the severe intellectual disability commonly seen in CdLS.  
4. **Skeletal/Physical Anomalies**: Single transverse palmar crease and cleft palate (less common but reported in CdLS) suggest congenital structural abnormalities.  
5. **Hirsutism and Hair Features**: Excessive hair growth (hirsutism), curly eyelashes, and low anterior hairline are consistent with CdLS-associated hypertrichosis and distinctive hair patterns.  
6. **Exclusion of Alternatives**: Overlap with syndromes like fetal alcohol syndrome or Smith-Lemli-Opitz is unlikely due to the presence of synophrys, hirsutism, and CdLS-specific facial gestalt.  
7. **Genetic Link**: Cornelia de Lange syndrome 1 (NIPBL-related) is the most common genetic subtype, explaining the syndromic cohesion of these features.  

The constellation of findings strongly supports CdLS, warranting genetic testing (e.g., NIPBL mutation analysis) for confirmation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low) but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or transient neonatal tyrosinemia overlapping with PKU.  
3. **Abnormality of prenatal development** aligns with maternal PKU syndrome, where elevated maternal phenylalanine crosses the placenta, causing fetal microcephaly, congenital heart defects, or growth restriction.  
4. **Neonatal death/Death in infancy** suggests severe, untreated PKU with acute metabolic crises (e.g., profound neurological toxicity, seizures) or comorbid complications (e.g., cardiac defects from maternal PKU).  
5. PKU is confirmed via newborn screening (elevated phenylalanine, low tyrosine), though rapid progression to neonatal demise implies extreme enzyme deficiency or delayed diagnosis.  
Note: Hypertyrosinemia warrants investigation for co-occurring disorders (e.g., tyrosinemia type II) but does not exclude PKU as the primary diagnosis."
"['Abnormality of the dentition', 'Hypertelorism', 'Low-set ears', 'Bifid nasal tip', 'Downslanted palpebral fissures', 'Ptosis', 'Sprengel anomaly', 'Brachydactyly', '2-3 finger syndactyly', 'Agenesis of corpus callosum', 'Specific learning disability', 'Craniosynostosis', 'Ridged nail', 'Clinodactyly of the 5th finger', 'Coronal craniosynostosis', 'Unilateral cryptorchidism', 'Thick hair']",['Craniofrontonasal dysplasia/Craniofrontonasal syndrome'],"Disease: Craniofrontonasal dysplasia/Craniofrontonasal syndrome  
Reasoning:  
1. **Craniosynostosis** (coronal suture involvement): A hallmark of CFND, explaining the patient’s ""Craniosynostosis"" and ""Coronal craniosynostosis.""  
2. **Facial dysmorphism**:  
   - **Hypertelorism**, **bifid nasal tip**, **downslanted palpebral fissures**, and **ptosis** are classic facial features of CFND.  
   - **Low-set ears** further supports craniofacial abnormalities.  
3. **Limb/skeletal anomalies**:  
   - **Sprengel anomaly** (elevated scapula), **brachydactyly**, **2-3 finger syndactyly**, and **clinodactyly of the 5th finger** align with CFND-associated skeletal defects.  
   - **Ridged nails** are a reported feature.  
4. **Neurological/developmental**: **Agenesis of corpus callosum** and **specific learning disability** correlate with CFND’s variable neurodevelopmental involvement.  
5. **Other features**: **Unilateral cryptorchidism** and **abnormality of the dentition** (e.g., delayed eruption, supernumerary teeth) are consistent with CFND.  
6. **Thick hair** is a less specific but occasionally noted trait.  
The combination of craniofacial, skeletal, and neurological findings distinguishes CFND from other craniosynostosis syndromes (e.g., Apert, Crouzon), which lack syndactyly, hypertelorism, or corpus callosum anomalies."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Gastroesophageal reflux', 'Increased serum lactate', 'Hematemesis', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth** and **neonatal death** may occur in severe, untreated cases due to toxic phenylalanine accumulation affecting neurodevelopment.  
3. **Death in infancy/childhood** aligns with untreated PKU, where elevated phenylalanine leads to irreversible neurological damage, seizures, and systemic complications.  
4. **Hypertyrosinemia** is atypical in classical PKU but could arise from secondary metabolic disturbances or overlapping enzyme deficiencies (e.g., transient tyrosine elevation due to liver immaturity or stress).  
5. **Increased serum lactate** and **hematemesis** may reflect metabolic decompensation, organ failure (e.g., liver dysfunction), or catabolic states triggered by prolonged metabolic imbalance.  
6. **Gastroesophageal reflux** is a nonspecific symptom but could result from neurological dysfunction or feeding difficulties common in severely affected infants.  

Note: Hypertyrosinemia is unusual in PKU and suggests possible comorbid conditions (e.g., tyrosinemia type II) or diagnostic overlap, but PKU remains primary due to hyperphenylalaninemia dominating the clinical picture."
"['Bifid uvula', 'Malar flattening', 'Micrognathia', 'Pectus carinatum', 'Arachnodactyly', 'Atrial septal defect', 'Patent foramen ovale', 'Aortic regurgitation', 'Tricuspid valve prolapse', 'Aortic root aneurysm', 'Scoliosis', 'Pulmonary artery dilatation', 'Tricuspid regurgitation', 'Dilatation of the sinus of Valsalva', 'Camptodactyly']",['Loeys-Dietz syndrome 2'],"Disease: Loeys-Dietz syndrome 2  
Reasoning:  
1. **Bifid uvula**: A hallmark feature of Loeys-Dietz syndrome (LDS), distinguishing it from Marfan syndrome. While more prominent in LDS type 1, its presence here supports LDS.  
2. **Craniofacial abnormalities (Malar flattening, Micrognathia)**: Indicate connective tissue involvement; LDS type 2 often presents with milder craniofacial features compared to type 1.  
3. **Skeletal manifestations (Pectus carinatum, Scoliosis, Camptodactyly, Arachnodactyly)**: Reflect systemic connective tissue dysfunction, common in LDS. Camptodactyly is atypical in Marfan, further supporting LDS.  
4. **Cardiovascular anomalies (Atrial septal defect, Patent foramen ovale, Aortic root aneurysm, Dilatation of the sinus of Valsalva, Pulmonary artery dilatation)**: LDS is characterized by aggressive vascular pathology, including aneurysms and arterial tortuosity. Aortic root aneurysm and sinus of Valsalva dilatation are critical markers.  
5. **Valvular defects (Aortic regurgitation, Tricuspid valve prolapse, Tricuspid regurgitation)**: Result from connective tissue weakness, aligning with LDS pathophysiology.  
6. **Differentiation from Marfan syndrome**: Absence of lens dislocation and presence of bifid uvula argue against Marfan. The combination of craniofacial, skeletal, and cardiovascular features with bifid uvula is pathognomonic for LDS.  
7. **LDS type 2 vs. type 1**: Type 2 typically lacks severe craniofacial defects (e.g., cleft palate, craniosynostosis) but retains systemic vascular and skeletal involvement, consistent with this presentation. Genetic testing for *TGFBR2* mutations would confirm LDS type 2."
"['Seborrheic dermatitis', 'Seizure', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid', 'Body odor']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Aminoaciduria & Elevated Urinary Carboxylic Acids**: Biotinidase deficiency impairs biotin recycling, disrupting carboxylase enzymes (propionyl-CoA, pyruvate, 3-methylcrotonyl-CoA), leading to organic acidemia and abnormal metabolite excretion.  
2. **Seborrheic Dermatitis**: Biotin deficiency causes skin manifestations due to impaired fatty acid metabolism and keratinocyte dysfunction.  
3. **Seizures & Hypotonia/Hyporeflexia**: Accumulation of neurotoxic metabolites (e.g., lactate, ammonia) and disrupted energy metabolism in the central nervous system.  
4. **Abnormal Circulating Glycine**: Secondary inhibition of glycine cleavage system by organic acids, elevating glycine levels (non-ketotic hyperglycinemia-like presentation).  
5. **Body Odor**: Excretion of volatile organic acids (e.g., 3-hydroxyisovalerate) through sweat and urine.  
6. **Death in Infancy**: Untreated BTDD causes progressive metabolic crises, respiratory failure, or neurological damage.  
**Diagnostic Confirmation**: Low serum biotinidase activity (<10% normal) and genetic testing for *BTD* gene mutations. Early biotin supplementation reverses symptoms."
"['Urticaria', 'Arthritis', 'Fever', 'Abnormal EKG', 'Supraventricular arrhythmia', 'Bilateral sensorineural hearing impairment', 'Elevated circulating C-reactive protein concentration', 'Panic attack', 'Knee pain']","['Familial cold autoinflammatory syndrome 2', 'Familial cold urticaria', 'Familial cold inflammatory syndrome 1', 'Muckle-Wells syndrome/Muckle-Wells syndrome', 'Familial cold autoinflammatory syndrome 3', 'Tumor necrosis factor receptor 1 associated periodic syndrome/Periodic fever, familial, autosomal dominant', 'Familial cold autoinflammatory syndrome 4', 'CINCA syndrome/Cinca syndrome']","Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning: The patient presents with **urticaria**, **arthritis**, **fever**, **bilateral sensorineural hearing impairment**, and **elevated CRP**, which are hallmark features of Muckle-Wells syndrome (MWS). MWS, a cryopyrin-associated periodic syndrome (CAPS), is characterized by recurrent inflammatory episodes, systemic inflammation, and progressive hearing loss. The **supraventricular arrhythmia** and **abnormal EKG** may reflect secondary cardiac inflammation or amyloidosis, a known complication of untreated MWS. **Panic attacks** could arise from chronic stress or autonomic dysfunction linked to systemic inflammation. Other conditions like FCAS (cold-triggered, no hearing loss) or TRAPS (migratory rashes, no deafness) lack key features seen here. CINCA syndrome involves severe neurological involvement (absent in this case). The triad of urticaria, arthritis, and sensorineural deafness strongly supports MWS."
"['Bird-like facies', 'Cataract', 'Diabetes mellitus', 'Hypothyroidism', 'Hypertension', 'Osteoporosis', 'Hyperkeratosis', 'High pitched voice', 'Pes planus', 'Truncal obesity', 'Hypertriglyceridemia', 'Premature graying of hair', 'External genital hypoplasia', 'Reduced subcutaneous adipose tissue', 'Short stature', 'Type II diabetes mellitus', 'Corneal ulceration', 'Achilles tendon calcification']",['Werner syndrome/Werner syndrome'],"Disease: Werner syndrome  
Reasoning:  
1. **Premature Aging Features**: Bird-like facies, premature graying of hair, short stature, and osteoporosis align with the accelerated aging phenotype of Werner syndrome.  
2. **Ocular Manifestations**: Cataracts and corneal ulceration are common due to connective tissue degeneration and impaired wound healing.  
3. **Endocrine/Metabolic Dysregulation**: Type II diabetes mellitus, hypothyroidism, hypertension, hypertriglyceridemia, and truncal obesity reflect metabolic disturbances typical of the syndrome.  
4. **Dermatological Signs**: Hyperkeratosis and reduced subcutaneous adipose tissue are consistent with skin atrophy and scleroderma-like changes.  
5. **Musculoskeletal Abnormalities**: Pes planus and Achilles tendon calcification result from connective tissue calcification and ligamentous laxity.  
6. **Genitourinary Features**: External genital hypoplasia is a rare but reported finding in Werner syndrome.  
7. **Voice Changes**: High-pitched voice may stem from laryngeal atrophy or connective tissue alterations.  
8. **Diagnostic Exclusion**: The absence of childhood-onset rapid aging (as in Hutchinson-Gilford progeria) and presence of bilateral cataracts + diabetes strongly support Werner syndrome over other progeroid disorders.  

The constellation of premature aging, metabolic abnormalities, and connective tissue pathology confirms the diagnosis."
"['Rod-cone dystrophy', 'Ophthalmoplegia', 'Abnormality of visual evoked potentials', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar abnormalities (atrophy/agenesis)**: Central to PMM2-CDG, causing ataxia, motor delay, and hypotonia due to disrupted cerebellar development.  
2. **Neurological involvement**: Intellectual disability and abnormal visual evoked potentials align with global neurodevelopmental defects from impaired glycosylation.  
3. **Ocular symptoms**: Rod-cone dystrophy and ophthalmoplegia stem from glycosylation-dependent retinal and neuromuscular dysfunction.  
4. **Systemic severity**: Death in infancy reflects severe multisystem failure, consistent with classic PMM2-CDG presentations.  
5. **Diagnostic alignment**: The constellation of cerebellar, ocular, and developmental features distinguishes PMM2-CDG from other CDG subtypes or cerebellar malformation syndromes."
"['Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Abnormal circulating ornithine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as the urea cycle enzyme deficiency prevents ammonia detoxification.  
2. **Oroticaciduria**: Excess carbamoyl phosphate shunts into pyrimidine synthesis, producing orotic acid.  
3. **Hyperglutaminemia**: Secondary to ammonia accumulation, as glutamine synthesis increases to sequester excess ammonia.  
4. **Abnormal ornithine**: Reduced ornithine due to impaired conversion to citrulline in the urea cycle.  
5. **Neurological symptoms** (lethargy, drowsiness, vomiting, sleep disturbance): Caused by ammonia neurotoxicity.  
6. **Death in infancy**: Severe neonatal-onset OTCD leads to rapid metabolic decompensation without intervention.  
7. **X-linked inheritance**: Males typically present earlier and more severely, aligning with infant mortality risk.  

This constellation of urea cycle dysfunction, biochemical markers, and clinical presentation confirms OTCD."
"['Seizure', 'Ataxia', 'Lethargy', 'Hyperreflexia', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Oroticaciduria', 'Death in childhood', 'Death in adolescence']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as OTC is a urea cycle enzyme. Deficiency causes impaired ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate enters pyrimidine synthesis, producing excess orotic acid.  
3. **Neurological symptoms** (seizures, ataxia, lethargy, drowsiness, hyperreflexia, fasciculations): Result from ammonia-induced neurotoxicity and cerebral edema.  
4. **Metabolic acidosis**: Secondary to organic acid accumulation from alternative ammonia detoxification pathways.  
5. **Gastrointestinal symptoms** (diarrhea): Common in urea cycle disorders due to metabolic stress.  
6. **Early mortality**: Untreated OTCD causes recurrent hyperammonemic crises, leading to death in childhood/adolescence without intervention.  
7. **Fever**: May trigger metabolic decompensation (e.g., infection-induced catabolism exacerbating ammonia accumulation).  
8. **Sleep disturbance**: Linked to encephalopathy from chronic hyperammonemia.  
*Exclusion of other urea cycle disorders*: Oroticaciduria distinguishes OTCD from CPS1 or NAGS deficiencies, which share hyperammonemia but lack this feature."
"['Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Dicarboxylic aciduria']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Seizures**: Result from impaired mitochondrial energy production in the brain, causing neuronal hyperexcitability due to ATP deficiency.  
2. **Motor delay and generalized hypotonia**: Caused by defective oxidative phosphorylation in skeletal muscles, leading to weakness and delayed motor milestones.  
3. **Death in infancy**: Severe forms of complex IV deficiency (e.g., SURF1-related Leigh syndrome) cause rapid neurodegeneration and metabolic crises, often fatal within the first years of life.  
4. **Dicarboxylic aciduria**: Secondary to inefficient fatty acid β-oxidation, as mitochondrial dysfunction forces reliance on alternative energy pathways, producing dicarboxylic acids.  
5. **Complex IV (cytochrome c oxidase) deficiency**: Confirmed by biochemical findings (e.g., elevated lactate, reduced enzyme activity) and genetic variants in nuclear genes (e.g., SURF1) critical for complex IV assembly.  
This constellation aligns with nuclear-encoded mitochondrial complex IV deficiency type 1, typically presenting with Leigh-like symptoms and metabolic derangements."
"['Seizure', 'Areflexia', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like hyperammonemia, elevated urinary carboxylic acids, and abnormal circulating amino acids (aspartate family, alanine) suggest a metabolic disorder disrupting amino acid catabolism.  
2. **BCAA Accumulation**: MSUD specifically involves defective breakdown of branched-chain amino acids (BCAAs—leucine, isoleucine, valine), leading to toxic buildup of keto acids (detected as urinary carboxylic acids) and secondary ammonia elevation.  
3. **Neurological Manifestations**: Seizures, hypotonia, and areflexia align with neurotoxicity from BCAA-derived metabolites, which impair brain function and myelination.  
4. **Infantile Fatality**: Neonatal death or death in infancy is characteristic of severe, untreated MSUD due to rapid metabolic decompensation post-protein ingestion (feeding difficulties).  
5. **Diagnostic Confirmation**: Abnormal BCAA levels (not explicitly listed but inferred from ""abnormal aspartate family amino acids"") and urinary alpha-keto-acids confirm MSUD, distinguishing it from urea cycle defects or organic acidemias."
"['Carious teeth', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Elevated urinary carboxylic acids**: Phenylalanine accumulates and is metabolized into phenylketones (e.g., phenylpyruvate), excreted in urine.  
3. **Death in infancy/childhood & neonatal death**: Untreated PKU causes severe neurological damage, seizures, and organ failure, leading to early mortality.  
4. **Carious teeth**: Chronic metabolic acidosis (from phenylketone accumulation) and high-carbohydrate/low-protein diets in managed PKU may contribute to dental decay.  
5. **Hypertyrosinemia (apparent conflict)**: PKU typically causes **low** tyrosine levels (blocked conversion). This symptom may indicate a coexisting condition (e.g., transient tyrosinemia in newborns) or misreporting.  
6. **Abnormality of prenatal development**: Likely reflects maternal PKU syndrome (untreated PKU during pregnancy causing fetal defects), suggesting the patient’s condition was inherited from an affected mother.  

While hypertyrosinemia is atypical, the triad of hyperphenylalaninemia, urinary phenylketones, and early mortality strongly supports PKU. Maternal PKU explains prenatal abnormalities and neonatal severity."
"['Thin vermilion border', 'Wide anterior fontanel', 'Hypertelorism', 'Micrognathia', 'Low-set ears', 'Anteverted nares', 'Short neck', 'Thickened nuchal skin fold', 'Upslanted palpebral fissure', 'Wrist flexion contracture', 'Agenesis of corpus callosum', 'Dandy-Walker malformation', 'Intrauterine growth retardation', 'Abnormal heart morphology', 'Metabolic acidosis', 'Deep philtrum', 'Ventriculomegaly', 'Agenesis of cerebellar vermis', 'Short nose', 'Depressed nasal bridge', 'Distal arthrogryposis', 'Knee flexion contracture', 'Ankle flexion contracture', 'Increased nuchal translucency', 'Abnormal renal morphology', 'Camptodactyly', 'Sepsis']","['COG8-CDG/Congenital disorder of glycosylation, type IIh']","Disease: COG8-CDG/Congenital disorder of glycosylation, type IIh  
Reasoning:  
1. **Neurological & Structural Brain Abnormalities**: Agenesis of corpus callosum, Dandy-Walker malformation, ventriculomegaly, and agenesis of cerebellar vermis are hallmark features of CDG-II subtypes, reflecting impaired glycosylation critical for brain development.  
2. **Dysmorphic Features**: Hypertelorism, micrognathia, low-set ears, anteverted nares, short nose, depressed nasal bridge, deep philtrum, and upslanted palpebral fissures align with facial dysmorphisms seen in COG8-CDG.  
3. **Skeletal/Joint Abnormalities**: Wrist, knee, and ankle flexion contractures, camptodactyly, and distal arthrogryposis suggest glycosylation defects impacting connective tissue and neuromuscular function, common in COG8-CDG.  
4. **Prenatal/Systemic Involvement**: Intrauterine growth retardation, increased nuchal translucency, and thickened nuchal skin fold indicate early developmental disruption, typical of severe CDG forms.  
5. **Metabolic & Organ Dysfunction**: Metabolic acidosis (linked to glycosylation-dependent mitochondrial function), abnormal heart and renal morphology, and sepsis (immune dysfunction due to glycosylation defects in immunoglobulins) further support COG8-CDG.  
6. **Consistency with Type II CDG**: COG8-CDG (Type IIh) disrupts Golgi trafficking via COG complex defects, leading to multi-systemic anomalies as listed, distinguishing it from other CDG subtypes."
"['Ophthalmoplegia', 'Intellectual disability', 'Hypotonia', 'Bulbar palsy', 'Areflexia', 'Respiratory insufficiency', 'Drooling', 'Scoliosis', 'Proximal muscle weakness', 'Ankle flexion contracture']",['Nemaline myopathy 3'],"Disease: Nemaline myopathy 3  
Reasoning:  
1. **Proximal muscle weakness, hypotonia, and areflexia** align with congenital myopathies, particularly nemaline myopathy.  
2. **Bulbar palsy and respiratory insufficiency** indicate severe neuromuscular dysfunction, consistent with nemaline myopathy type 3 (severe congenital form), which often involves respiratory and bulbar muscle compromise.  
3. **Ophthalmoplegia** is a distinguishing feature of type 3, differentiating it from other nemaline myopathy subtypes.  
4. **Scoliosis and ankle flexion contractures** reflect chronic muscle weakness and skeletal adaptations, common in progressive congenital myopathies.  
5. **Intellectual disability** (though rare in most myopathies) can occur in severe cases due to secondary effects of hypoxia or genetic comorbidities.  
6. **Drooling** correlates with bulbar palsy, further supporting neuromuscular involvement.  
7. Genetic confirmation (ACTA1 or TPM3 mutations) would solidify the diagnosis, but the clinical triad of ophthalmoplegia, bulbar/respiratory failure, and early-onset hypotonia strongly suggests nemaline myopathy 3."
"['Brachycephaly', 'Strabismus', 'Proptosis', 'Shallow orbits', 'Precocious puberty', 'Single transverse palmar crease', 'Seizure', 'Global developmental delay', 'Overlapping toe', 'Bilateral tonic-clonic seizure', 'EEG abnormality', 'Inverted nipples', 'Deep palmar crease', 'Cardiorespiratory arrest', 'Severe muscular hypotonia', 'Infantile muscular hypotonia']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe Muscular Hypotonia (Infantile)**: A hallmark of TBCK syndrome, present from birth, aligning with the patient's severe and infantile hypotonia.  
2. **Global Developmental Delay**: Consistent with TBCK’s core phenotype of intellectual disability and psychomotor retardation.  
3. **Seizures/EEG Abnormalities**: Recurrent seizures (tonic-clonic) and abnormal EEG patterns are common due to neuronal dysfunction in TBCK-related disorders.  
4. **Characteristic Facies**:  
   - **Brachycephaly/Shallow Orbits**: Broad, short skull and structural orbital anomalies are typical dysmorphic features.  
   - **Proptosis/Strabismus**: Eye abnormalities linked to shallow orbits and craniofacial dysmorphism.  
5. **Limb Anomalies**:  
   - **Single Transverse Palmar Crease/Deep Palmar Crease**: Frequent in TBCK syndrome as part of connective tissue or developmental hand findings.  
   - **Overlapping Toe**: Minor skeletal anomalies are reported in this syndrome.  
6. **Inverted Nipples**: A noted dysmorphic feature in TBCK cases, supporting the diagnosis.  
7. **Cardiorespiratory Arrest**: Severe hypotonia and neurological instability in TBCK can lead to life-threatening events, especially during infancy.  
8. **Precocious Puberty**: While less common, endocrine dysregulation has been observed in some TBCK patients, potentially explaining this feature.  

The constellation of severe hypotonia, developmental delay, seizures, craniofacial/limb dysmorphism, and supporting features strongly aligns with TBCK syndrome, a disorder caused by biallelic TBCK mutations affecting mTOR signaling and neuronal survival."
"['Seizure', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Interictal epileptiform activity']",['Developmental and epileptic encephalopathy 14'],"Disease: Developmental and epileptic encephalopathy 14  
Reasoning:  
1. **Seizures**: A core feature of developmental and epileptic encephalopathies (DEEs), including DEE14, which is linked to *KCNT1* gene mutations.  
2. **Global developmental delay**: Consistent with DEEs, where seizure activity and neurodevelopmental disruption impair milestones.  
3. **Generalized hypotonia**: Observed in DEE14 due to neuronal hyperexcitability and cortical dysfunction.  
4. **Absent speech**: Reflects severe neurodevelopmental impairment, common in DEE subtypes.  
5. **Interictal epileptiform activity**: Supports epileptic encephalopathy diagnosis, as abnormal electrical activity persists between seizures, exacerbating developmental delays.  
6. **Exclusion of mimics**: Symptoms align with DEE14 rather than other DEE subtypes (e.g., *SCN1A*-related Dravet syndrome lacks prominent interictal discharges early on). Genetic testing for *KCNT1* variants would confirm."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Neonatal death/Death in infancy**: Untreated PKU causes severe neurological damage, seizures, and failure to thrive. Without early dietary intervention (e.g., phenylalanine-restricted diet), progressive toxicity can lead to fatal complications.  
3. **Abnormality of prenatal development**: Likely reflects **maternal PKU syndrome**, where high maternal phenylalanine levels during pregnancy disrupt fetal development (e.g., congenital heart defects, microcephaly). While the infant’s own PKU does not cause prenatal abnormalities, maternal PKU explains this symptom.  
4. **Diagnostic confirmation**: PKU is confirmed via newborn screening (elevated phenylalanine, normal tetrahydrobiopterin levels). Untreated cases align with the clinical trajectory of early morbidity/mortality.  

Note: Maternal PKU syndrome and infant PKU are distinct but interrelated; the infant’s symptoms arise from both inherited PAH deficiency and maternal metabolic environment during gestation."
"['Macrocephaly', 'Epistaxis', 'Carious teeth', 'Death in infancy', 'Tachycardia', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's abnormality of galactoside metabolism is a hallmark of galactosemia, a disorder impairing galactose conversion. Classic galactosemia (GALT deficiency) causes toxic metabolite accumulation, leading to life-threatening complications (neonatal death, death in infancy/childhood). Tachycardia may stem from sepsis or metabolic acidosis, while liver dysfunction (coagulopathy) explains epistaxis. Macrocephaly could reflect cerebral edema, and carious teeth may result from dietary restrictions or metabolic imbalances. Early fatality without galactose restriction aligns with untreated galactosemia. Other symptoms are secondary to systemic toxicity."
"['Hypospadias', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Hyperphenylalaninemia', 'Hernia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU but may suggest **BH4 (tetrahydrobiopterin) deficiency**, a rare PKU variant. BH4 is a cofactor for PAH and tyrosine/tryptophan hydroxylases; its deficiency disrupts both phenylalanine and tyrosine metabolism.  
3. **Severe short stature** aligns with chronic metabolic disruption and malnutrition if untreated.  
4. **Premature birth**, **neonatal death**, and **death in infancy** correlate with severe metabolic crises in untreated PKU/BH4 deficiency, leading to neurological deterioration and organ failure.  
5. **Hypospadias** and **hernia** are not typical PKU features but may represent coincidental congenital anomalies or part of a broader syndromic form (e.g., chromosomal or epigenetic interactions).  

Note: While classic PKU does not explain hypertyrosinemia, BH4 deficiency (a PKU subtype) accounts for both hyperphenylalaninemia and hypertyrosinemia, supporting the diagnosis. Other symptoms may reflect complications of metabolic instability or unrelated congenital factors."
"['Polyuria', 'Hyperactivity', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Tachycardia', 'Hypoglycemia', 'Hypophosphatemia', 'Hyperglycinemia', 'Hypokalemia', 'Hyponatremia', 'Hypomagnesemia', 'Hypochloremia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hyperglutaminemia', 'Hypertyrosinemia', 'Hypermethioninemia', 'Paresthesia', 'Elevated calcitonin', '4-hydroxyphenylacetic aciduria', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Paraplegia/paraparesis', 'Death in adolescence']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia Type I (HT-1)  
Reasoning:  
1. **Hypertyrosinemia and Tyrosine Metabolites**: Elevated tyrosine levels and metabolites (4-Hydroxyphenylpyruvic aciduria, 4-hydroxyphenylacetic aciduria) directly indicate a defect in tyrosine catabolism. HT-1 involves a deficiency of fumarylacetoacetate hydrolase (FAH), causing toxic metabolite accumulation (e.g., succinylacetone).  
2. **Liver Dysfunction**: Elevated alpha-fetoprotein (AFP) and alkaline phosphatase suggest hepatic damage, a hallmark of HT-1. Hypoglycemia and hypermethioninemia further support liver impairment.  
3. **Renal Tubular Dysfunction**: Electrolyte imbalances (hypophosphatemia, hypokalemia, hyponatremia, hypomagnesemia, hypochloremia) point to Fanconi syndrome, a renal complication of HT-1 due to succinylacetone toxicity.  
4. **Neurological and Systemic Symptoms**: Tachycardia, hyperactivity, and paresthesia may stem from metabolic crises or electrolyte disturbances. Generalized hypotonia aligns with systemic metabolic dysfunction.  
5. **Early Mortality**: Neonatal death, death in infancy/childhood/adolescence reflects the severe, progressive nature of untreated HT-1, often due to liver failure or neurological crises.  
6. **Prenatal/Developal Abnormalities**: Congenital enzyme deficiency explains prenatal growth issues and multisystemic involvement.  
7. **Biochemical Markers**: Elevated calcitonin and hyperglycinemia are less specific but may occur secondary to metabolic stress.  

**Conclusion**: The constellation of tyrosine metabolism derangements, liver/krenal pathology, and early lethality confirm Tyrosinemia Type I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Increased serum lactate', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Increased serum lactate**: Biotinidase deficiency disrupts carboxylase enzymes (dependent on biotin), impairing gluconeogenesis and fatty acid synthesis. This leads to lactic acidosis, a hallmark of the disorder.  
2. **Neonatal death/Death in infancy**: Untreated BTDD causes severe metabolic crises, neurological deterioration (seizures, hypotonia), and respiratory failure, often fatal in early life.  
3. **Abnormality of prenatal development or birth**: While structural birth defects are rare, metabolic dysfunction *in utero* may contribute to intrauterine distress or growth abnormalities. Maternal biotin deficiency (if present) could exacerbate fetal vulnerability.  
4. **Diagnostic alignment**: Symptoms match the ""late-onset"" form of multiple carboxylase deficiency (caused by BTDD), where symptoms emerge postnatally but rapidly progress without biotin supplementation. Early mortality underscores the critical need for newborn screening and prompt treatment."
"['Oral ulcer', 'Headache', 'Memory impairment', 'Osteomyelitis', 'Osteoarthritis', 'Kyphosis', 'Obstructive sleep apnea', 'Abnormality of the ankle', 'Back pain', 'Intervertebral disc degeneration', 'Ankle pain', 'Aphthous ulcer', 'Pustule']",['SAPHO syndrome'],"Disease: SAPHO syndrome  
Reasoning:  
1. **Osteomyelitis and Osteoarthritis**: Core features of SAPHO syndrome, which involves osteitis and hyperostosis, explaining bone inflammation and joint degeneration.  
2. **Pustule and Aphthous/Oral Ulcers**: Align with cutaneous manifestations (pustulosis) and occasional mucosal involvement seen in SAPHO.  
3. **Spinal Abnormalities (Kyphosis, Back Pain, Disc Degeneration)**: Reflects axial skeleton hyperostosis, a hallmark of SAPHO, leading to structural changes and pain.  
4. **Ankle Pain/Abnormality**: Synovitis and joint inflammation in SAPHO can target peripheral joints like the ankle.  
5. **Obstructive Sleep Apnea**: Potential secondary effect from spinal kyphosis altering airway mechanics.  
6. **Headache/Memory Impairment**: Likely indirect (e.g., chronic pain, sleep disruption) rather than direct neurological involvement.  
7. **Exclusion of Alternatives**: Behçet’s disease lacks bone involvement; CRMO lacks pustular lesions. The triad of bone, joint, and skin symptoms strongly supports SAPHO."
"['Depressed nasal ridge', 'Anteverted nares', 'Long eyelashes', 'Hypoplastic ilia', 'Delayed ossification of carpal bones', 'Intellectual disability', 'Growth delay', 'Deep philtrum', 'Coxa valga', 'Delayed skeletal maturation', 'Elbow flexion contracture', 'Flat acetabular roof', 'Shallow acetabular fossae', 'Short stature', 'Acetabular dysplasia', 'Severe postnatal growth retardation', 'Thick vermilion border']",['Acromicric dysplasia/Acromicric dysplasia'],"Disease: Acromicric dysplasia  
Reasoning:  
1. **Skeletal Abnormalities**: Key features like *hypoplastic ilia*, *delayed ossification of carpal bones*, *coxa valga*, *flat acetabular roof*, *shallow acetabular fossae*, and *acetabular dysplasia* align with Acromicric dysplasia’s hallmark skeletal defects, particularly affecting the hips and limbs.  
2. **Growth Issues**: *Severe postnatal growth retardation*, *short stature*, and *delayed skeletal maturation* are central to this dysplasia, reflecting impaired bone development.  
3. **Facial Features**: *Depressed nasal ridge*, *anteverted nares*, *long eyelashes*, and *deep philtrum* match the characteristic facial dysmorphism (bulbous nose, rounded face) seen in Acromicric dysplasia.  
4. **Additional Signs**: *Elbow flexion contracture* and *thick vermilion border* further support the diagnosis, as joint contractures and distinct lip morphology are reported in this condition.  
5. **Intellectual Disability**: Though uncommon in classic Acromicric dysplasia, mild cognitive delays may occasionally occur, but this symptom warrants exclusion of overlapping disorders (e.g., Geleophysic dysplasia). However, the constellation of skeletal and facial features strongly prioritizes Acromicric dysplasia."
"['Open mouth', 'Mandibular prognathia', 'Broad forehead', 'Hearing impairment', 'Bulbous nose', 'Atypical behavior', 'Generalized hypotonia', 'Absent speech', 'Abnormal facial shape', 'Developmental regression', 'Delayed skeletal maturation', 'Severe global developmental delay', 'Thick vermilion border']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facial features**: ""Broad forehead,"" ""bulbous nose,"" ""thick vermilion border,"" ""open mouth,"" and ""mandibular prognathia"" align with the distinct facies described in TBCK syndrome, including midface hypoplasia and a prominent upper lip.  
2. **Neuromuscular involvement**: ""Generalized hypotonia"" is a hallmark of the disorder, often presenting in infancy.  
3. **Developmental delays**: ""Severe global developmental delay,"" ""absent speech,"" and ""delayed skeletal maturation"" correlate with the syndrome’s core features of psychomotor retardation and growth deficits.  
4. **Atypical behavior**: Observed in TBCK cases due to intellectual disability and potential autism spectrum traits.  
5. **Hearing impairment**: Documented in some patients, possibly linked to sensorineural or conductive abnormalities.  
6. **Developmental regression**: While less common, stagnation or regression may occur in severe cases, overlapping with neurodegenerative-like presentations.  
7. **Genetic confirmation**: Although not explicitly stated, the symptom constellation strongly suggests biallelic TBCK mutations, which impair mTORC1 signaling and lysosomal function.  

The absence of key features of phenocopies (e.g., Coffin-Siris or Angelman syndromes) further supports this diagnosis."
"['Long eyelashes', 'Chorioretinal atrophy', 'Nystagmus', 'Hypothyroidism', 'Decreased response to growth hormone stimulation test', 'Dysarthria', 'Hyporeflexia', 'Patent ductus arteriosus', 'Pes cavus', 'Gait ataxia', 'Intention tremor', 'Unsteady gait', 'Peripheral axonal neuropathy', 'Short stature', 'Cerebellar vermis atrophy', 'Sparse hair', 'High myopia']","['Oliver-Mcfarlane syndrome', 'Trichomegaly-retina pigmentary degeneration-dwarfism syndrome']","Disease: Oliver-Mcfarlane syndrome  
Reasoning: The patient presents with **long eyelashes (trichomegaly)**, **chorioretinal atrophy**, and **short stature**, which are hallmark features of Oliver-McFarlane syndrome. The **decreased response to growth hormone stimulation test** and **hypothyroidism** indicate pituitary dysfunction, a key component of the syndrome. Neurological symptoms (**dysarthria**, **hyporeflexia**, **gait ataxia**, **intention tremor**, **peripheral axonal neuropathy**, **cerebellar vermis atrophy**) align with its progressive neurodegenerative phenotype. **High myopia** and **nystagmus** are consistent with severe retinal involvement, while **sparse hair** and **pes cavus** further support the diagnosis.  

Disease: Trichomegaly-retina pigmentary degeneration-dwarfism syndrome  
Reasoning: This syndrome overlaps significantly with Oliver-McFarlane syndrome, sharing core features such as **trichomegaly**, **retinal degeneration (chorioretinal atrophy)**, and **dwarfism (short stature)**. The patient’s **high myopia** and **nystagmus** correlate with retinal dysfunction, while **sparse hair** and **hypothyroidism** may reflect broader endocrine disruption. However, this diagnosis primarily emphasizes the triad of trichomegaly, retinal pathology, and growth failure, without explicitly requiring the cerebellar or neurodegenerative findings seen here. The inclusion of both diagnoses reflects historical nomenclature variations, but Oliver-McFarlane syndrome better accounts for the full clinical spectrum."
"['Urinary urgency', 'Sinusitis', 'Tachycardia', 'Fever', 'Leukocytosis', 'Hemoptysis', 'Pleural effusion', 'Abnormal EKG', 'Atrial fibrillation', 'Elevated circulating C-reactive protein concentration', 'Cough', 'Reduced haptoglobin level', 'Nodular pattern on pulmonary HRCT', 'Episcleritis', 'Chest pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Granulomatosis with polyangiitis (GPA):  
1. **Upper respiratory involvement**: Chronic sinusitis is a hallmark of GPA, often preceding systemic manifestations.  
2. **Pulmonary features**: Hemoptysis, cough, chest pain, nodular pattern on HRCT, and pleural effusion align with necrotizing granulomatous inflammation and vasculitis in the lungs.  
3. **Renal involvement**: Urinary urgency may indicate early kidney disease (glomerulonephritis), though hematuria/proteinuria are more typical; renal biopsy would confirm.  
4. **Ocular manifestation**: Episcleritis is a common ocular manifestation of GPA.  
5. **Systemic inflammation**: Fever, leukocytosis, and elevated CRP reflect active vasculitis.  
6. **Cardiac complications**: Atrial fibrillation and abnormal EKG suggest cardiac involvement (rare but reported in GPA due to inflammation or secondary effects).  
7. **Hematologic abnormalities**: Reduced haptoglobin hints at microangiopathic hemolysis (occurs in severe vasculitis).  
8. **Multisystem pattern**: The combination of respiratory, renal, ocular, and systemic symptoms strongly supports GPA, a small-to-medium vessel ANCA-associated vasculitis.  

**Definitive diagnosis** requires ANCA testing (PR3-ANCA positivity), biopsy (necrotizing granulomas), and exclusion of mimics (e.g., infections, other vasculitides)."
"['Lethargy', 'Death in infancy', 'Fever', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Neonatal death', 'Recurrent viral infections', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic)  
Reasoning:  
1. **Hyperammonemia and elevated plasma citrulline** are hallmark biochemical features of citrullinemia type I, caused by a deficiency in **argininosuccinate synthetase (ASS1)**, a urea cycle enzyme. This blocks the conversion of citrulline to argininosuccinate, leading to citrulline accumulation.  
2. **Oroticaciduria** occurs due to secondary diversion of carbamoyl phosphate into pyrimidine synthesis when the urea cycle is disrupted, a phenomenon seen in urea cycle disorders.  
3. **Neonatal death/death in infancy** aligns with the severe, early-onset presentation of classic citrullinemia, often triggered by protein feeding after birth.  
4. **Lethargy, drowsiness, and sleep disturbances** reflect neurotoxicity from hyperammonemia, which disrupts cerebral metabolism.  
5. **Fever** may arise secondary to metabolic stress or intercurrent illnesses exacerbating the underlying defect.  
6. **Recurrent viral infections** are atypical for urea cycle disorders but could stem from prolonged hospitalization or metabolic instability impairing immune responses.  

The combination of urea cycle dysfunction (hyperammonemia), specific metabolite abnormalities (citrulline, orotic acid), and life-threatening neonatal course strongly supports citrullinemia type I."
"['Hydrocephalus', 'Intellectual disability', 'Poor coordination', 'Eye of the tiger anomaly of globus pallidus', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Abnormality of the pituitary gland']",['Pantothenate kinase-associated neurodegeneration/Neurodegeneration with brain iron accumulation 1'],"Disease: Pantothenate kinase-associated neurodegeneration/Neurodegeneration with brain iron accumulation 1 (PKAN/NBIA1)  
Reasoning:  
1. **""Eye of the tiger"" anomaly in the globus pallidus**: This MRI finding is pathognomonic for PKAN, caused by iron deposition and necrosis in the basal ganglia.  
2. **Neurological symptoms (intellectual disability, poor coordination)**: Consistent with progressive neurodegeneration in PKAN, affecting motor and cognitive functions.  
3. **Elevated creatine kinase (CK)**: Reflects muscle injury secondary to dystonia or rigidity, common in PKAN.  
4. **Elevated alkaline phosphatase (ALP)**: May indicate hepatic or bony involvement, though atypical; could suggest a metabolic compensatory mechanism or comorbidity.  
5. **Hydrocephalus and pituitary gland abnormality**: Less specific but may arise from structural brain changes or indirect effects of neurodegeneration.  
6. **Genetic basis**: PKAN is linked to mutations in *PANK2*, disrupting coenzyme A metabolism and leading to iron accumulation.  
The combination of pathognomonic imaging, neurodegeneration, and biochemical markers strongly supports PKAN/NBIA1."
"['Microcephaly', 'Self-mutilation', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Intellectual disability**, **microcephaly**, and **delayed speech** are classic neurodevelopmental consequences of untreated PKU due to toxic phenylalanine levels damaging the brain.  
3. **Seizures** and **self-mutilation** correlate with severe neurological impairment from chronic phenylalanine toxicity.  
4. **Severe short stature** may result from metabolic disruption and poor protein utilization.  
5. **Death in infancy/adolescence** reflects untreated or poorly managed PKU, causing acute metabolic crises or irreversible neurological damage.  
6. **Hypertyrosinemia** is atypical for classic PKU but may occur in rare variants (e.g., BH4 deficiency) or secondary metabolic disturbances.  
7. The combination of **hyperphenylalaninemia** with neurodevelopmental deficits strongly prioritizes PKU, even with atypical features like hypertyrosinemia."
"['Intellectual disability', 'Ataxia', 'Tremor', 'Death in infancy', 'Cerebral atrophy', 'Abnormal basal ganglia morphology', 'Neonatal death', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Biochemical confirmation**: The symptom ""L-2-hydroxyglutaric aciduria"" directly indicates elevated levels of L-2-hydroxyglutaric acid in bodily fluids, a hallmark diagnostic marker.  
2. **Neurological symptoms**: Intellectual disability, ataxia, and tremor align with progressive neurodegeneration caused by toxic metabolite accumulation.  
3. **Neuroimaging findings**: Cerebral atrophy and abnormal basal ganglia morphology are characteristic radiological features of this disorder, explaining motor and cognitive deficits.  
4. **Severe clinical course**: Neonatal death, death in infancy, and death in childhood suggest a severe phenotypic variant, consistent with early-onset, rapidly progressing forms of the disease.  
5. **Exclusion of mimics**: The combination of biochemical, clinical, and imaging features differentiates L-2-HGA from other organic acidurias or mitochondrial disorders."
"['Microcephaly', 'Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Pericardial effusion', 'Pleural effusion', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Feeding difficulties']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine metabolism.  
2. **Feeding difficulties**: Common in untreated infants due to poor metabolic regulation and neurological dysfunction.  
3. **Microcephaly/Severe short stature**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, disrupting brain development and growth.  
4. **Abnormality of prenatal development/Small for gestational age**: Maternal PKU (if the mother has uncontrolled phenylalanine levels during pregnancy) can cause intrauterine growth restriction and congenital anomalies.  
5. **Death in infancy/childhood/Neonatal death**: Historically, severe untreated PKU results in progressive neurological decline, seizures, and early mortality. Modern newborn screening and dietary management prevent this outcome.  
6. **Hypertyrosinemia**: Atypical for classic PKU (which typically causes low tyrosine). This may suggest a coexisting condition (e.g., tyrosinemia type II) or secondary metabolic disruption from liver dysfunction in severe cases.  
7. **Pericardial/Pleural effusions**: Not typical for PKU. These could indicate an overlapping condition (e.g., metabolic crises, cardiac dysfunction) or complications from prolonged systemic metabolic instability.  

**Note**: While PKU explains hyperphenylalaninemia and neurodevelopmental symptoms, hypertyrosinemia and effusions suggest additional complexities, warranting further investigation for comorbid disorders or atypical presentations."
"['Strabismus', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Intellectual disability**: Untreated PKU results in neurotoxicity from elevated phenylalanine, impairing brain development.  
3. **Strabismus**: Neurological damage from phenylalanine toxicity can affect cranial nerve function, including ocular motor control.  
4. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) causes fetal developmental anomalies; alternatively, severe neonatal hyperphenylalaninemia may disrupt early development.  
5. **Early mortality (infancy, adolescence, adulthood)**: Untreated PKU leads to progressive neurological decline, seizures, and organ damage, potentially causing premature death.  
6. **Hypertyrosinemia**: Uncommon in classic PKU but may arise secondary to metabolic dysregulation or overlapping enzyme deficiencies (e.g., tetrahydrobiopterin (BH4) defects).  
7. **Obesity**: Linked to dietary management challenges (high-carbohydrate, low-protein diets) or metabolic disturbances in later stages.  

Note: Neonatal death and hypertyrosinemia are atypical for classical PKU and may suggest a comorbid condition (e.g., BH4 deficiency) or severe phenotypic variants. However, hyperphenylalaninemia remains the primary diagnostic anchor."
"['Chordee', 'Hypospadias', 'Narrow mouth', 'Hypertelorism', 'Whistling appearance', 'Micrognathia', 'Low-set ears', 'Wide nasal bridge', 'Flexion contracture', 'Talipes equinovarus', 'Depressed nasal bridge', 'Feeding difficulties in infancy', 'Camptodactyly of finger']","['Freeman-Sheldon syndrome/Arthrogryposis, distal, type 2A']","Disease: Freeman-Sheldon syndrome/Arthrogryposis, distal, type 2A  
Reasoning:  
1. **Craniofacial Features**: The patient exhibits ""whistling appearance"" (pursed lips), narrow mouth, hypertelorism, wide/depressed nasal bridge, micrognathia, and low-set ears—all hallmark facial traits of Freeman-Sheldon syndrome (FSS). These contribute to feeding difficulties in infancy due to restricted oral function.  
2. **Musculoskeletal Abnormalities**: Flexion contractures, talipes equinovarus (clubfoot), and camptodactyly (fixed finger flexion) align with FSS’s defining distal arthrogryposis, characterized by congenital joint limitations in hands and feet.  
3. **Urogenital Anomalies**: Hypospadias and chordee, though less common in FSS, are occasionally reported, supporting the diagnosis when combined with classic features.  
4. **Syndrome Specificity**: The constellation of craniofacial, musculoskeletal, and functional symptoms (e.g., feeding challenges) distinguishes FSS from other distal arthrogryposis subtypes or syndromes with overlapping features."
"['Cystinuria', 'Argininuria', 'Ornithinuria', 'Abnormal circulating lysine concentration', 'Death in adolescence']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
Reasoning:  
1. **Aminoaciduria Pattern**: The patient exhibits cystinuria, argininuria, ornithinuria, and abnormal lysine levels. These four amino acids share a renal transporter system (SLC3A1/SLC7A9 genes) responsible for their reabsorption. A defect in this system leads to their excessive urinary excretion, confirming cystinuria.  
2. **Genetic Basis**: Cystinuria is an autosomal recessive disorder of dibasic amino acid transport. Mutations in *SLC3A1* (Type A) or *SLC7A9* (Type B) disrupt the transporter, causing accumulation of cystine in urine and stone formation.  
3. **Severity and Mortality**: Death in adolescence suggests severe complications, such as recurrent nephrolithiasis leading to chronic kidney disease, infections, or obstructive uropathy. Without aggressive management (hydration, alkalinization, chelators), renal failure could result in early mortality.  
4. **Exclusion of Alternatives**: Lysinuric protein intolerance (LPI) was considered but ruled out due to the absence of hyperammonemia and hepatosplenomegaly, as well as the presence of cystinuria, which is specific to cystinuria."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Bradycardia', 'Acute kidney injury', 'Vomiting', 'Respiratory insufficiency', 'Increased serum lactate', 'Hyperkalemia', 'Hematemesis', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Excessive salivation', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Hypoxemia', 'Chronic kidney disease', 'Increased circulating lactate dehydrogenase concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic Aciduria Patterns**: The presence of **dicarboxylic aciduria** and **3-methylglutaconic aciduria** strongly suggests a defect in leucine catabolism or ketogenesis, both central to HMG-CoA lyase deficiency.  
2. **Energy Crisis Manifestations**: **Increased serum lactate**, **hypoxemia**, and **respiratory insufficiency** align with impaired ketogenesis, leading to energy depletion in critical tissues (e.g., brain, heart).  
3. **Hyperkalemia & Kidney Dysfunction**: **Acute/chronic kidney injury** and **hyperkalemia** result from metabolic acidosis (due to accumulated organic acids) and direct tubular toxicity from toxic metabolites.  
4. **Neurological Symptoms**: **Seizures** and **neonatal death** reflect acute metabolic decompensation with encephalopathy, exacerbated by hypoglycemia (common in HMG-CoA lyase deficiency).  
5. **Enzyme-Specific Biomarkers**: **Elevated urinary carboxylic acids** (e.g., 3-hydroxy-3-methylglutaric acid) and **abnormal aspartate-family amino acids** directly link to HMG-CoA lyase’s role in ketone body synthesis and leucine metabolism.  
6. **Early Lethality**: **Death in infancy/neonatal death** is typical in severe presentations due to rapid metabolic crises triggered by catabolic stressors (e.g., fasting, infection).  
7. **Secondary Organ Effects**: **Hematemesis** and **excessive salivation** may stem from autonomic dysfunction or acid-induced mucosal injury, while **bradycardia** reflects electrolyte imbalances or cardiac energy failure.  
8. **Diagnostic Confirmation**: **Increased lactate dehydrogenase** supports cellular necrosis from metabolic stress, consistent with this disorder.  

The constellation of metabolic acidosis, characteristic organic aciduria, and multisystem collapse in infancy confirms HMG-CoA lyase deficiency."
"['Nephrocalcinosis', 'Cutis laxa', 'Abnormal heart morphology', 'Abnormal facial shape']","['Cutis laxa, autosomal recessive, type IIC']","Disease: Cutis laxa, autosomal recessive, type IIC (ARCL2C)  
Reasoning:  
1. **Cutis laxa**: A primary feature of ARCL2C, caused by mutations in the PYCR1 gene, which disrupts mitochondrial function and collagen/proline metabolism, leading to loose, inelastic skin.  
2. **Nephrocalcinosis**: Linked to metabolic dysfunction in ARCL2C, where impaired mitochondrial energy production may cause renal tubular acidosis or calcium deposition in the kidneys.  
3. **Abnormal heart morphology**: PYCR1 mutations are associated with cardiac anomalies such as pulmonary artery stenosis or septal defects, contributing to structural heart abnormalities.  
4. **Abnormal facial shape**: ARCL2C presents with distinct facial dysmorphism (triangular face, prominent eyes, large fontanelles, and a prematurely aged appearance), aligning with the patient’s symptoms.  
5. **Consistency with ARCL2C**: The combination of connective tissue, renal, cardiac, and craniofacial anomalies strongly supports this diagnosis, as other cutis laxa subtypes (e.g., ARCL2A/B) typically involve different organ systems or lack nephrocalcinosis."
"['Ataxia', 'Coma', 'Reduced tendon reflexes', 'Alopecia', 'Metabolic acidosis', 'Cerebral edema', 'Abnormal cerebral white matter morphology', 'Death in childhood', 'Recurrent viral infections', 'Hyperleucinemia', 'Death in adolescence']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Hyperleucinemia** is pathognomonic for MSUD, caused by impaired branched-chain α-ketoacid dehydrogenase (BCKDH) complex activity, leading to accumulation of leucine, isoleucine, and valine.  
2. **Neurological symptoms** (Ataxia, Coma, Cerebral edema, Abnormal cerebral white matter morphology) stem from leucine-induced neurotoxicity, disrupting neurotransmitter synthesis and causing cerebral osmotic imbalance.  
3. **Metabolic acidosis** results from secondary inhibition of the citric acid cycle by accumulating α-ketoacids.  
4. **Reduced tendon reflexes** correlate with acute metabolic decompensation and axonal dysfunction.  
5. **Death in childhood/adolescence** aligns with classic/severe MSUD phenotypes if untreated; cerebral edema and metabolic crises are often fatal.  
6. **Alopecia** and **recurrent viral infections** are atypical but may reflect nutritional deficiencies or secondary immune dysregulation during metabolic stress.  
7. **Abnormal cerebral white matter morphology** on imaging corresponds with delayed myelination and vacuolization due to leucine toxicity.  

*Note: While recurrent infections and alopecia are not classic MSUD features, the core biochemical and neurological findings dominate the diagnostic rationale.*"
"['Obesity', 'Abdominal pain', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning:  
1. **Abdominal pain** is a hallmark symptom of acute intermittent porphyria (AIP), caused by neurovisceral attacks due to accumulation of porphyrin precursors.  
2. **Death in childhood** aligns with severe, undiagnosed AIP cases, where acute attacks can lead to respiratory failure, seizures, or cardiac arrhythmias.  
3. **Obesity** is atypical for AIP but may reflect metabolic comorbidities, misreported ascites, or steroid use (e.g., during treatment).  
4. AIP typically manifests post-puberty but can occur earlier; childhood mortality suggests a severe genetic variant or delayed diagnosis.  

Disease: Porphyria/Porphyria  
Reasoning:  
1. The term broadly encompasses porphyria disorders, including hepatic (e.g., AIP) or erythropoietic types.  
2. **Abdominal pain** and **death in childhood** could indicate a severe subtype (e.g., congenital erythropoietic porphyria), though cutaneous symptoms would typically dominate.  
3. **Obesity** remains incongruent with classical porphyria phenotypes but may reflect secondary factors (e.g., limited mobility from chronic illness).  
4. Generalized classification allows for atypical presentations but lacks specificity compared to AIP.  

**Conclusion**: Acute intermittent porphyria is the most precise diagnosis, while ""porphyria"" serves as a broader category. Obesity likely represents a confounding factor or comorbidity."
"['Delayed speech and language development', 'Death in infancy', 'Vomiting', 'Clumsiness', 'Poor coordination', 'Neonatal death', 'Death in childhood', 'Increased urinary glycerol']",['Isolated glycerol kinase deficiency/Glycerol kinase deficiency'],"Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol**: A hallmark symptom of glycerol kinase deficiency (GKD), as the enzyme deficiency prevents glycerol metabolism, leading to its excretion in urine.  
2. **Vomiting**: Common during metabolic crises due to glycerol accumulation and potential ketotic hypoglycemia.  
3. **Delayed speech, clumsiness, poor coordination**: Neurological manifestations may arise from episodic metabolic decompensation affecting brain function during critical developmental stages.  
4. **Death in infancy/childhood/neonatal death**: While rare in *isolated* GKD, severe metabolic instability or misdiagnosis (e.g., overlapping with contiguous Xp21 deletion syndrome) could contribute to early mortality.  
5. Exclusion of other disorders: Symptoms align with GKD rather than broader mitochondrial or fatty acid oxidation disorders, given the specificity of glyceroluria.  
Note: Isolated GKD typically has mild-to-moderate presentations; severe outcomes may suggest comorbid conditions or diagnostic overlap."
"['Nephrotic syndrome', 'Abnormality of the nose', 'Hematuria', 'Membranoproliferative glomerulonephritis', 'Purpura', 'Wrist swelling', 'Dyspnea', 'Hypertriglyceridemia', 'Hypercholesterolemia', 'Increased body weight', 'Pedal edema', 'Peripheral edema', 'Moderate proteinuria', 'Heavy proteinuria', 'Foamy urine']",['Immunoglobulin A vasculitis'],"Disease: Immunoglobulin A vasculitis (IgAV), also known as Henoch-Schönlein purpura (HSP)  
Reasoning:  
1. **Purpura**: A hallmark of IgAV, presenting as non-thrombocytopenic palpable purpura, typically on dependent areas (e.g., lower limbs).  
2. **Renal Involvement**:  
   - **Nephrotic syndrome** (heavy proteinuria, hypoalbuminemia-induced hypercholesterolemia/hypertriglyceridemia, edema) and **hematuria** align with IgA-mediated glomerulonephritis.  
   - **Membranoproliferative glomerulonephritis (MPGN)** on biopsy is consistent with IgAV nephritis, characterized by IgA-dominant immune deposits.  
3. **Arthritis**: Wrist swelling reflects IgAV-associated arthritis, commonly affecting large joints.  
4. **Systemic Features**:  
   - **Dyspnea** may arise from fluid overload due to nephrotic syndrome or rare pulmonary vasculitis.  
   - **Abnormality of the nose** (e.g., mucosal vasculitis or epistaxis) suggests small-vessel involvement.  
5. **Exclusion of Mimics**: Symptoms collectively rule out isolated nephrotic syndrome, lupus nephritis, or infection-driven glomerulonephritis, reinforcing IgAV as the unifying diagnosis."
"['Jaundice', 'Generalized hypotonia', 'Anemia', 'Hyperhomocystinemia', 'Progressive neurologic deterioration', 'Hypomethioninemia', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormality of folate metabolism']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia** is the hallmark of homocystinuria, caused by impaired cystathionine beta-synthase (CBS) activity, blocking homocysteine-to-cystathionine conversion.  
2. **Hypomethioninemia** is atypical for CBS deficiency (typically *elevated* methionine), but may occur in rare variants or secondary folate metabolism disturbances affecting remethylation pathways.  
3. **Progressive neurologic deterioration** aligns with untreated homocystinuria, as excess homocysteine is neurotoxic, causing seizures, intellectual disability, and neurodegeneration.  
4. **Abnormality of folate metabolism** may exacerbate remethylation defects, worsening homocysteine accumulation and methionine depletion.  
5. **Recurrent viral infections** and **anemia** could stem from immune dysfunction due to metabolic stress or folate-related hematologic abnormalities.  
6. **Jaundice** and **abnormal porphyrins** suggest hepatic involvement, possibly from oxidative stress or secondary porphyrin pathway disruption.  
7. **Death in childhood** correlates with severe, untreated CBS deficiency, often due to thromboembolic events or neurologic complications.  

Disease: Homocysteinemia/Homocystinuria (general)  
Reasoning:  
1. **Hyperhomocystinemia** directly defines this disorder, encompassing both CBS deficiency and remethylation defects (e.g., MTHFR deficiency).  
2. **Hypomethioninemia** suggests a remethylation defect (e.g., MTHFR or cobalamin disorders), where homocysteine cannot recycle to methionine, but this overlaps with CBS deficiency in clinical presentation.  
3. **Abnormal folate metabolism** supports a broader homocysteinemia diagnosis, as folate is critical for homocysteine remethylation.  
4. **Neurologic deterioration** and **hypotonia** are nonspecific but consistent with systemic metabolic dysfunction from homocysteine toxicity.  
5. **Recurrent infections** and **anemia** may reflect multisystemic failure or secondary nutritional deficiencies (e.g., B12/folate).  

**Final Diagnosis**: Classic homocystinuria (CBS deficiency) is prioritized due to progressive neurologic decline and hyperhomocystinemia, though hypomethioninemia suggests a complex presentation, possibly with coexisting folate pathway disruption."
"['Death in infancy', 'Premature birth', 'Hypertriglyceridemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Premature birth** and early mortality (**neonatal death, death in infancy/childhood**) align with MCADD, a fatty acid oxidation disorder causing metabolic crises triggered by fasting, often fatal if undiagnosed.  
2. **Hypertriglyceridemia** arises due to impaired mitochondrial β-oxidation of medium-chain fatty acids, leading to alternative lipid metabolism pathways and triglyceride accumulation.  
3. **Abnormal circulating carnitine concentration** (secondary carnitine deficiency) occurs as excess unmetabolized medium-chain acyl-CoA intermediates bind carnitine, promoting its urinary excretion.  
4. MCADD typically presents with hypoglycemia, lethargy, and vomiting during metabolic stress (e.g., fasting), progressing to seizures, coma, or death—consistent with the fatal outcomes described.  
5. Ruled out long-chain fatty acid oxidation disorders (e.g., VLCADD) due to absence of cardiomyopathy/muscle weakness, which are less prominent in MCADD."
"['Narrow mouth', 'Microcephaly', 'Nystagmus', 'Hypertrichosis', 'Erythroderma', 'Brachydactyly', 'Preaxial hand polydactyly', 'Seizure', 'Hypertonia', 'Atrial septal defect', 'Abnormal cardiac septum morphology', 'Postaxial foot polydactyly', 'Eosinophilia', 'Abnormal facial shape', 'Delayed gross motor development', 'Limb hypertonia', 'Hypsarrhythmia', 'Skeletal dysplasia', 'Spondyloepiphyseal dysplasia', 'Elbow flexion contracture', 'Severe combined immunodeficiency', 'Generalized hypertrichosis', 'Combined immunodeficiency', 'Absence of CD8-positive T cells', 'Axial hypotonia', 'Profound global developmental delay', 'Abnormal natural killer cell count', 'Enlarged uterus']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe combined immunodeficiency (SCID), combined immunodeficiency, absence of CD8+ T cells, and abnormal NK cell count align with ISDNA’s hallmark immune dysfunction due to EXTL3 mutations affecting lymphocyte development.  
2. **Skeletal Abnormalities**: Brachydactyly, preaxial/postaxial polydactyly, spondyloepiphyseal dysplasia, and elbow contractures match ISDNA’s skeletal dysplasia phenotype, characterized by defective bone growth and limb anomalies.  
3. **Neurodevelopmental Features**: Profound global developmental delay, seizures, hypertonia (limb), axial hypotonia, and hypsarrhythmia reflect central nervous system involvement, consistent with ISDNA’s neurodevelopmental defects.  
4. **Dysmorphic Traits**: Microcephaly, narrow mouth, and abnormal facial shape are typical craniofacial findings in ISDNA.  
5. **Additional Features**: Hypertrichosis and erythroderma may overlap with immune dysregulation, while eosinophilia could signal aberrant immune activity. Cardiac septal defects and enlarged uterus, though less common, may represent variable expressivity of the disorder.  
6. **Genetic Basis**: ISDNA is caused by biallelic EXTL3 mutations, which disrupt glycosaminoglycan synthesis, explaining multisystem involvement (immune, skeletal, neural).  
**Conclusion**: The constellation of severe immunodeficiency, skeletal dysplasia, neurodevelopmental delay, and dysmorphism strongly supports ISDNA, necessitating EXTL3 gene testing for confirmation."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** and **recurrent viral infections** suggest a **tetrahydrobiopterin (BH4) deficiency** variant of PKU. BH4 is a cofactor for PAH and tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, leading to dual accumulation.  
3. **Immunodeficiency** (recurrent infections) arises from impaired nitric oxide synthesis and neurotransmitter production due to BH4 dependency in immune and neurological pathways.  
4. **Early mortality** (infancy/childhood/adolescence) reflects severe metabolic derangements, neurological deterioration, and susceptibility to infections in untreated BH4-deficient PKU, distinguishing it from classic PAH-deficient PKU.  

This diagnosis aligns with atypical/malignant PKU secondary to BH4 deficiency, explaining the full symptom spectrum."
"['Microcephaly', 'Strabismus', 'Apathy', 'Hyperactivity', 'Intellectual disability', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Metabolic Disturbances**: Symptoms like **metabolic acidosis**, **hyperammonemia**, **hyperglycinemia**, **hyperalaninemia**, and **hyperleucinemia** strongly suggest a disorder of branched-chain amino acid (BCAA) metabolism. PA disrupts propionyl-CoA carboxylase, impairing catabolism of valine, isoleucine, methionine, and odd-chain fatty acids, leading to toxic metabolite accumulation.  
2. **Neurological and Developmental Features**: **Microcephaly**, **intellectual disability**, **hypotonia**, **apathy**, and **hyperactivity** align with chronic neurotoxicity from elevated propionic acid and ammonia, which damage the central nervous system.  
3. **Life-Threatening Course**: **Death in infancy/childhood/adolescence**, **neonatal death**, and **severe short stature** reflect the rapid progression of untreated PA. Metabolic crises trigger acute decompensation with **vomiting**, **feeding difficulties**, and **gastrointestinal inflammation**, exacerbating catabolism.  
4. **Carnitine Dysregulation**: **Abnormal circulating carnitine** occurs as carnitine conjugates with propionyl-CoA to form propionylcarnitine (C3), a diagnostic biomarker for PA. Secondary carnitine deficiency worsens energy metabolism.  
5. **Biochemical Hallmarks**: Elevated glycine (**hyperglycinemia**) is a key feature of PA due to secondary inhibition of glycine cleavage enzyme by propionyl-CoA. Hyperammonemia arises from urea cycle inhibition by accumulated metabolites.  

The constellation of metabolic derangements, neurodevelopmental deficits, and early mortality strongly supports **propionic acidemia** as the diagnosis. Confirmatory testing would include plasma acylcarnitine profile (elevated C3), urinary organic acids (3-hydroxypropionate, methylcitrate), and genetic analysis of *PCCA* or *PCCB* genes."
"['Hypermetropia', 'Uveitis', 'Keratoconjunctivitis sicca', 'Abnormality of the gluteal musculature', 'Kyphosis', 'Microscopic hematuria', 'Back pain', 'Generalized morning stiffness', 'Low levels of vitamin D']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The patient’s back pain, morning stiffness, and kyphosis align with axial spondyloarthropathy, which commonly involves spinal inflammation and postural changes. Uveitis is a hallmark extra-articular manifestation of SpA, strongly supporting this diagnosis. HLA-B27 (a genetic marker for susceptibility 1) is frequently associated with these features. The gluteal musculature abnormality may reflect enthesitis or chronic compensatory postural adjustments.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Microscopic hematuria could indicate renal involvement, potentially linked to IgA nephropathy, which has been sporadically associated with SpA. Keratoconjunctivitis sicca may suggest secondary autoimmune overlap, though less typical. Low vitamin D may exacerbate skeletal inflammation and contribute to kyphosis. Susceptibility 2 might involve non-HLA-B27 genetic variants (e.g., ERAP1/IL23R), which could explain broader immune dysregulation and atypical features like renal or ocular surface involvement. Hypermetropia is likely incidental but underscores the need for multidisciplinary evaluation."
"['Open mouth', 'Brachycephaly', 'Sloping forehead', 'Long philtrum', 'Deeply set eye', 'Esotropia', 'Shallow orbits', 'Reduced eye contact', 'Motor delay', 'Absent speech', 'Hyperreflexia', 'Poor head control', 'Respiratory failure', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Self-injurious behavior']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Brachycephaly, sloping forehead, long philtrum, deeply set eyes, shallow orbits, tented upper lip vermilion, and open mouth align with the craniofacial dysmorphisms reported in TBCK syndrome.  
2. **Neuromuscular deficits**: Severe muscular hypotonia (a hallmark of TBCK) explains poor head control, respiratory failure (due to weakness), and motor delay. Hyperreflexia may reflect mixed upper/lower motor neuron dysfunction.  
3. **Developmental delays**: Absent speech and reduced eye contact correlate with profound intellectual disability and psychomotor retardation.  
4. **Neurobehavioral features**: Self-injurious behavior is consistent with behavioral phenotypes observed in genetic neurodevelopmental disorders like TBCK.  
5. **Ocular findings**: Esotropia and shallow orbits are recurrently associated with TBCK-related syndromes.  
6. **Systemic involvement**: Respiratory failure secondary to hypotonia further supports the diagnosis, as respiratory complications are common in severe infantile-onset TBCK cases."
"['Strabismus', 'Nystagmus', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
**Step 1:** The symptoms **cerebellar atrophy** and **cerebellar agenesis** indicate severe structural brain abnormalities, a hallmark of PMM2-CDG due to disrupted glycosylation during neurodevelopment.  
**Step 2:** **Ataxia**, **motor delay**, and **generalized hypotonia** align with cerebellar dysfunction, a core feature of PMM2-CDG.  
**Step 3:** **Strabismus** and **nystagmus** are linked to brainstem/cerebellar defects affecting ocular motor control.  
**Step 4:** **Encephalopathy** and **hyporeflexia** reflect global neurological impairment from abnormal glycosylation of neuronal proteins.  
**Step 5:** **Growth delay** and **death in infancy** are systemic consequences of glycosylation failure, impacting metabolism and organ function.  
**Step 6:** PMM2-CDG is confirmed by genetic testing for *PMM2* mutations and abnormal transferrin glycosylation patterns, which correlate with the severity of cerebellar and multisystemic symptoms."
"['Death in infancy', 'Ventricular septal defect', 'Cardiomyopathy', 'Leukocytosis', 'Vomiting', 'Respiratory distress', 'Hypoproteinemia', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties', 'Increased circulating lactate dehydrogenase concentration']",['Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb'],"Disease: Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb  
Reasoning:  
1. **Metabolic Dysfunction**: The enzyme phosphorylase kinase deficiency impairs glycogen breakdown, leading to glycogen accumulation in the liver and muscles. This disrupts glucose release, causing metabolic crises (vomiting, feeding difficulties) and secondary stress responses (leukocytosis).  
2. **Hepatic Involvement**: Hypoproteinemia and abnormal porphyrin levels indicate liver dysfunction, as impaired hepatic glycogenolysis affects protein synthesis and heme metabolism.  
3. **Muscle/Cardiac Manifestations**: Deficiency in muscle phosphorylase kinase results in glycogen accumulation in cardiac tissue, explaining cardiomyopathy. Increased lactate dehydrogenase (LDH) reflects muscle damage and metabolic stress.  
4. **Respiratory Distress**: Likely due to metabolic acidosis from lactate accumulation or respiratory muscle weakness secondary to glycogen storage.  
5. **Amino Acid Abnormalities**: Altered aspartate family amino acids suggest disrupted liver metabolism, a secondary effect of chronic hepatic dysfunction.  
6. **Ventricular Septal Defect (VSD)**: While not a classic feature of GSD IXb, severe metabolic stress in infancy may exacerbate congenital cardiac anomalies or reflect a syndromic presentation.  
7. **Infant Mortality**: Severe metabolic and cardiac complications in infancy align with the rapid progression of untreated GSD IXb, particularly with multi-organ involvement.  

The constellation of hepatic, muscular, and metabolic symptoms, coupled with enzyme-specific pathophysiology, confirms Glycogen Storage Disease Type IXb."
"['Pes cavus', 'Falls', 'Abnormal cerebrospinal fluid morphology', 'Decreased sensory nerve conduction velocity', 'Babinski sign', 'Periventricular leukomalacia', 'Lower limb muscle weakness', 'Decreased Achilles reflex', 'Decreased patellar reflex', 'Oppenheim reflex', 'Gordon reflex']","['Autosomal dominant Charcot-Marie-Tooth disease type 2A2/Charcot-marie-tooth disease, axonal, type 2A2A']","Disease: Autosomal dominant Charcot-Marie-Tooth disease type 2A2/Charcot-Marie-Tooth disease, axonal, type 2A2A  
Reasoning:  
1. **Pes cavus**: A hallmark of CMT, caused by chronic muscle weakness and imbalance in the feet.  
2. **Lower limb muscle weakness, falls**: Reflects distal axonal neuropathy, typical in CMT2A2A due to MFN2 mutations affecting motor neurons.  
3. **Decreased Achilles/patellar reflexes**: Indicates lower motor neuron involvement, consistent with axonal degeneration.  
4. **Decreased sensory nerve conduction velocity**: Suggests axonal (not demyelinating) pathology; CMT2A2A shows reduced amplitudes with mild conduction slowing.  
5. **Babinski, Oppenheim, and Gordon reflexes**: Atypical for CMT but may indicate rare phenotypic overlap or coexisting pyramidal tract involvement in some MFN2-related cases.  
6. **Abnormal CSF morphology/periventricular leukomalacia**: Likely incidental or unrelated to CMT2A2A, as CSF is typically normal in CMT, and leukomalacia suggests prior ischemic injury.  
7. **Genetic alignment**: CMT2A2A is autosomal dominant, aligning with hereditary patterns, and MFN2 mutations explain the axonal neuropathy.  

The diagnosis prioritizes characteristic CMT features (pes cavus, axonal neuropathy) while acknowledging atypical signs as potential phenotypic expansions or comorbidities."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. Untreated PKU leads to toxic phenylalanine accumulation, causing severe neurological damage, which explains **neonatal death**, **death in infancy**, or **childhood** due to metabolic crisis or complications.  
3. **Hypertyrosinemia** may appear contradictory (as PAH deficiency typically reduces tyrosine levels), but secondary metabolic disturbances or overlapping enzyme dysfunction (e.g., transient tyrosine elevation during metabolic decompensation) could explain this finding.  
4. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, though this is context-dependent.  
5. PKU is confirmed via newborn screening; untreated cases match the described fatal trajectory. Other tyrosinemia types are excluded due to the primary hyperphenylalaninemia and lack of liver/kidney symptoms."
"['Tall stature', 'Renal cyst', 'Ovarian cyst', 'Glaucoma', 'Myopia', 'Abnormal finger morphology', 'Pes cavus', 'Weight loss', 'Hypotension', 'Varicose veins', 'Abnormal cartilage morphology', 'Arthralgia', 'Genu valgum', 'Exertional dyspnea', 'Microscopic hematuria', 'Gastrointestinal inflammation', 'Knee osteoarthritis', 'Abnormal intervertebral disk morphology', 'Gastritis', 'Reduced visual acuity', 'Pedal edema', 'Elbow pain', 'Hip pain', 'Knee pain', 'Groin pain', 'Torn meniscus']","['Stickler syndrome, type V', 'Stickler syndrome type 2/Stickler syndrome, type II', 'Stickler syndrome, type IV', 'Autosomal dominant otospondylomegaepiphyseal dysplasia/Stickler syndrome, type III', 'Autosomal recessive Stickler syndrome', 'Stickler syndrome type 1/Stickler syndrome, type I', 'Stickler syndrome']","Disease: Stickler syndrome type 1/Stickler syndrome, type I  
Reasoning: The patient exhibits hallmark features of Stickler syndrome, including ocular manifestations (myopia, glaucoma, reduced visual acuity), skeletal/joint abnormalities (arthralgia, osteoarthritis, genu valgum, pes cavus, torn meniscus), and connective tissue involvement (abnormal cartilage morphology, abnormal intervertebral disk morphology). Tall stature and abnormal finger morphology align with skeletal dysplasia. While renal/ovarian cysts and gastrointestinal symptoms are atypical for Stickler syndrome, they may represent comorbid conditions or variable expressivity. Type I (COL2A1) is prioritized due to its strong association with vitreoretinal abnormalities and early-onset arthropathy, despite the absence of explicitly noted hearing loss or craniofacial anomalies.  

Disease: Stickler syndrome, type IV  
Reasoning: Autosomal recessive Stickler syndrome (type IV, COL9A1) is considered due to the patient’s severe joint involvement (arthralgia, hip/knee pain, osteoarthritis) and ocular features (myopia, glaucoma). COL9A1 mutations can present with systemic connective tissue defects, potentially explaining renal cysts (rarely reported in recessive forms). However, gastrointestinal inflammation and hypotension remain poorly explained, making this a less likely but plausible secondary consideration.  

Disease: Autosomal dominant otospondylomegaepiphyseal dysplasia/Stickler syndrome, type III  
Reasoning: Type III (COL11A2) is noted for spondyloepiphyseal dysplasia, arthralgia, and hearing loss, but typically lacks ocular involvement. The patient’s glaucoma and myopia argue against this subtype, though skeletal features (tall stature, genu valgum) and joint pain may overlap. Absence of reported hearing loss further reduces likelihood.  

Disease: Stickler syndrome, type II  
Reasoning: Type II (COL11A1) shares ocular and joint features with type I, but often includes distinct vitreous abnormalities and craniofacial dysmorphism (e.g., cleft palate). The absence of reported craniofacial anomalies or hearing loss makes this less likely, though not excluded.  

Disease: Autosomal recessive Stickler syndrome  
Reasoning: Broadly, recessive forms (e.g., types IV/V) may present with severe phenotypes. Microscopic hematuria and renal cysts could hint at collagen-related renal defects, but these are not well-documented in Stickler syndromes. This category remains a tentative option if genetic testing excludes dominant types.  

Disease: Stickler syndrome, type V  
Reasoning: Type V (COL9A2) overlaps with type IV but is exceedingly rare. Similar reasoning applies, with renal cysts and gastrointestinal inflammation remaining unexplained. Limited evidence for COL9A2 in Stickler phenotypes reduces confidence.  

**Final Diagnosis**: **Stickler syndrome type 1/Stickler syndrome, type I** is the most likely, given the concordance of ocular, joint, and skeletal features. Uncommon symptoms (e.g., cysts) may require additional evaluation for comorbidities or atypical presentations."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Methylmalonic acidemia', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic acidemia** and **methylmalonic aciduria**, which are hallmark biochemical markers of MMA. Symptoms like **metabolic acidosis**, **hyperammonemia**, **vomiting**, and **seizures** align with metabolic decompensation caused by MMA. **Thrombocytopenia** and **leukopenia** may result from bone marrow suppression due to toxic metabolite accumulation. **Generalized hypotonia** and **neonatal death/death in infancy** reflect the severe, early-onset nature of this disorder.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the absence of B12 deficiency symptoms) and the inclusion of **neonatal death** strongly suggest a **mutase deficiency subtype**. This subtype is caused by defects in the *MUT* gene, leading to impaired methylmalonyl-CoA mutase activity. The severe clinical course (death in infancy) and biochemical features (persistent methylmalonic aciduria despite B12 levels) confirm this diagnosis."
"['Cleft palate', 'Microcephaly', 'Epicanthus', 'Low-set ears', 'Anteverted nares', 'Strabismus', 'Ptosis', 'Nystagmus', 'Delayed speech and language development', 'Nevus flammeus', 'Syndactyly', 'Intellectual disability', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Athetosis', 'Drowsiness', 'Sleep disturbance', 'Hypercholesterolemia', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Key Craniofacial and Structural Features**: Cleft palate, microcephaly, low-set ears, anteverted nares, syndactyly (classic 2-3 toe webbing), and nevus flammeus align with SLOS phenotypic hallmarks.  
2. **Ocular Abnormalities**: Strabismus, ptosis, nystagmus, and epicanthus are consistent with SLOS-associated eye findings.  
3. **Neurodevelopmental Delays**: Intellectual disability, delayed speech/motor development, generalized hypotonia, and lethargy reflect impaired cholesterol-dependent neurodevelopment.  
4. **Growth and Survival Issues**: Failure to thrive, feeding difficulties, neonatal/childhood death correlate with severe SLOS phenotypes.  
5. **Biochemical Signature**: Hypocholesterolemia, elevated 7-dehydrocholesterol (7-DHC), and elevated 8-dehydrocholesterol confirm defective cholesterol biosynthesis due to DHCR7 mutations.  
6. **Pathophysiologic Link**: SLOS is caused by deficient 7-DHC reductase, leading to toxic sterol accumulation (7-DHC, 8-DHC) and cholesterol deficiency, directly explaining metabolic and clinical features.  
7. **Exclusion of Mimics**: Syndactyly + cholesterol abnormalities distinguish SLOS from other syndromes (e.g., Cornelia de Lange, Rubinstein-Taybi) lacking sterol defects.  

The constellation of dysmorphia, neurodevelopmental deficits, syndactyly, and characteristic sterol profile is diagnostic of SLOS."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Encephalopathy', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Increased serum lactate', 'Abnormal cerebral white matter morphology', 'Glutaric aciduria', '3-Methylglutaric aciduria', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase deficiency (HMGCL deficiency)  
Reasoning:  
1. **Organic Acidurias**: Elevated urinary 3-methylglutaric acid and glutaric acid are hallmark biochemical markers of HMGCL deficiency due to impaired leucine catabolism and ketogenesis.  
2. **Metabolic Crisis Features**: Hypoglycemia (from defective ketogenesis), hyperammonemia (secondary to metabolic stress), and lactic acidosis (mitochondrial dysfunction) align with acute decompensation episodes in this disorder.  
3. **Neurological Involvement**: Encephalopathy, abnormal cerebral white matter morphology, and delayed development reflect neurotoxic effects of accumulated metabolites (e.g., 3-hydroxy-3-methylglutaric acid).  
4. **Early Lethality**: Neonatal death or death in infancy/childhood is common in severe cases due to metabolic instability and susceptibility to infections.  
5. **Carnitine/Carboxylic Acid Abnormalities**: Secondary carnitine deficiency and elevated monocarboxylic acids occur due to excessive conjugation/excretion of toxic intermediates.  
6. **Systemic Symptoms**: Feeding difficulties, gastrointestinal inflammation, and recurrent infections stem from chronic metabolic dysfunction and energy deficiency.  
7. **Exclusion of Mimics**: Glutaric aciduria type I is ruled out by the absence of striatal necrosis and presence of 3-methylglutaric aciduria, which is specific to HMGCL deficiency.  

The combination of biochemical findings (urinary acids, hyperammonemia, hypoglycemia) and clinical features (neurodegeneration, early mortality) confirms the diagnosis."
"['Abnormality of the lower limb', 'Microscopic hematuria', 'Elevated circulating creatine kinase concentration', 'Paresthesia', 'Elevated erythrocyte sedimentation rate', 'Prolonged prothrombin time', 'Elevated circulating C-reactive protein concentration', 'Macule', 'Decreased circulating complement C4 concentration', 'Skin erosion']","['Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome', 'Polyarteritis nodosa']","Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning:  
1. **Elevated inflammatory markers (ESR, CRP)**: Consistent with systemic autoinflammation.  
2. **Skin erosion/macule**: Reflects cutaneous vasculitis, a hallmark of VEXAS.  
3. **Decreased C4**: Suggests complement consumption, potentially linked to immune dysregulation in VEXAS.  
4. **Prolonged prothrombin time**: Aligns with hematologic defects, possibly due to hepatic involvement or clotting factor deficiencies.  
5. **Microscopic hematuria**: May indicate renal inflammation or vasculitic kidney injury.  
6. **Elevated creatine kinase/paresthesia**: Muscle and nerve involvement (myositis/neuropathy) seen in systemic autoinflammatory processes.  
7. **Lower limb abnormalities**: Could stem from arthritis or vasculitis-induced ischemia.  

Disease: Polyarteritis nodosa (PAN)  
Reasoning:  
1. **Microscopic hematuria**: Renal artery vasculitis in PAN can cause glomerular injury.  
2. **Paresthesia**: Mononeuritis multiplex, a classic feature of PAN due to nerve ischemia.  
3. **Skin erosion/macule**: Cutaneous vasculitis manifesting as ulcers or livedo.  
4. **Elevated ESR/CRP**: Non-specific markers of systemic inflammation in vasculitis.  
5. **Elevated creatine kinase**: Muscle ischemia from arterial inflammation.  
6. **Lower limb abnormalities**: Vascular compromise leading to claudication or necrosis.  
**Notable exclusions**: Prolonged PT and low C4 are atypical for PAN, making VEXAS more likely. PAN typically lacks complement abnormalities and coagulopathies.  

**Conclusion**: VEXAS is the primary diagnosis due to hematologic/immunologic features (prolonged PT, low C4), while PAN remains a differential for vasculitis-driven symptoms. Genetic testing for *UBA1* mutations and angiography (for PAN-associated aneurysms) would confirm."
"['Conjunctivitis', 'Death in infancy', 'Neonatal death', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline is a hallmark of urea cycle disorders, specifically citrullinemia. Neonatal death or death in infancy aligns with severe metabolic decompensation due to argininosuccinate synthetase (ASS1) deficiency, which causes toxic ammonia accumulation. While conjunctivitis is atypical for urea cycle disorders, it may reflect secondary infections from metabolic instability or unrelated comorbidities.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia (type I) presents neonatally with hyperammonemia, vomiting, and lethargy progressing to coma. Elevated citrulline levels confirm ASS1 enzyme deficiency. Early mortality correlates with the rapid progression of untreated hyperammonemia. Conjunctivitis is not pathognomonic but may occur due to systemic illness or incidental factors. Type II (citrin deficiency) typically involves liver dysfunction and later onset, making type I the definitive diagnosis here."
"['Gait disturbance', 'Shoulder flexion contracture', 'Hip contracture', 'Nemaline bodies', 'Proximal muscle weakness in lower limbs']",['Nemaline myopathy 4'],"Disease: Nemaline Myopathy 4  
Reasoning:  
1. **Nemaline bodies** are a hallmark pathological feature of nemaline myopathies, directly implicating this disease group.  
2. **Proximal muscle weakness in lower limbs** aligns with muscle involvement typical of nemaline myopathies, particularly in lower extremities.  
3. **Shoulder flexion contracture** and **hip contracture** suggest a subtype associated with joint contractures, which is characteristic of Nemaline Myopathy 4 (NM4, autosomal dominant form linked to *TPM3* mutations).  
4. **Gait disturbance** is a secondary consequence of proximal muscle weakness and contractures, common in NM4 due to impaired ambulation.  
5. Exclusion of severe neonatal/respiratory involvement (not mentioned here) and presence of contractures further narrows the diagnosis to NM4 over other nemaline myopathy subtypes (e.g., NM1 or NM2)."
"['Cataract', 'Global developmental delay', 'Choreoathetosis', 'Motor delay', 'Generalized hypotonia', 'Anal atresia', 'Cerebral atrophy', 'Lower limb spasticity', 'Abnormal circulating amino acid concentration', 'Increased serum pyruvate', 'Short stature', 'Generalized tonic seizure', 'Abnormal circulating creatine kinase concentration']",['CODAS syndrome/CODAS syndrome'],"Disease: CODAS syndrome  
Reasoning: The patient presents with cataracts (ocular anomaly), global developmental delay, motor delay, cerebral atrophy (cerebral anomalies), and short stature (skeletal anomaly), aligning with core features of CODAS syndrome. Generalized hypotonia and lower limb spasticity suggest neuromuscular involvement, while abnormal circulating amino acids and increased serum pyruvate indicate mitochondrial dysfunction, consistent with LONP1 gene mutations affecting mitochondrial protein homeostasis. Choreoathetosis and seizures may arise from cerebral atrophy or metabolic disturbances. Although anal atresia is atypical for CODAS, the constellation of cerebral, ocular, metabolic, and skeletal findings strongly supports this diagnosis over other mitochondrial or peroxisomal disorders."
"['Short chin', 'Abnormal pinna morphology', 'Blepharitis', 'Exotropia', 'Upslanted palpebral fissure', 'Pectus excavatum', 'Global developmental delay', 'Craniosynostosis', 'Hip dysplasia', 'Failure to thrive', 'Eosinophilia', 'Hypertriglyceridemia', 'Skeletal dysplasia', 'Coxa vara', 'Lumbar hyperlordosis', 'Thoracic scoliosis', 'Spinal canal stenosis', 'Severe combined immunodeficiency', 'Severe platyspondyly', 'Pear-shaped vertebrae', 'Severe T-cell immunodeficiency', 'Wide intermamillary distance', 'Cervical spinal canal stenosis', 'Infantile muscular hypotonia', 'Limb undergrowth', 'Chalazion', 'Hip subluxation', 'Increased intervertebral space']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe combined immunodeficiency (SCID) and severe T-cell immunodeficiency are hallmark features of ISDNA, linked to defects in EXTL3, which disrupts glycosaminoglycan synthesis critical for immune cell function.  
2. **Skeletal Abnormalities**: Severe platyspondyly, pear-shaped vertebrae, coxa vara, pectus excavatum, and spinal canal stenosis align with ISDNA’s characteristic skeletal dysplasia due to aberrant bone development.  
3. **Neurodevelopmental Delays**: Global developmental delay and infantile hypotonia reflect the neurodevelopmental component of ISDNA, caused by EXTL3’s role in neural development.  
4. **Supportive Features**: Limb undergrowth, failure to thrive, and facial dysmorphisms (short chin, wide intermamillary distance) further support a multisystem disorder. Eosinophilia and hypertriglyceridemia may stem from metabolic dysregulation secondary to immunodeficiency.  
5. **Exclusion of Alternatives**: Absence of nephropathy (unlike Schimke immuno-osseous dysplasia) or retinal defects (unlike Roifman syndrome) strengthens ISDNA as the diagnosis.  

This triad of skeletal, immune, and neurodevelopmental abnormalities, alongside genetic and biochemical mechanisms, confirms ISDNA."
"['Cleft palate', 'High palate', 'Hydrocephalus', 'Micrognathia', 'Low-set ears', 'Protruding ear', 'Depressed nasal tip', 'Long palpebral fissure', 'Generalized hypotonia', 'Hip dysplasia', 'Abnormality of the liver', 'Growth delay', 'Weak cry', 'Breech presentation', 'Abnormality of the cardiovascular system', 'Abnormality of the spleen', 'Lateral ventricle dilatation', 'Eversion of lateral third of lower eyelids', 'Postnatal growth retardation', 'Abnormal circulating thyroid hormone concentration', 'Sparse eyebrow']",['Kabuki syndrome 2'],"Disease: Kabuki syndrome 2  
Reasoning:  
1. **Facial Dysmorphism**: Key features like *long palpebral fissures*, *eversion of the lateral third of lower eyelids*, *depressed nasal tip*, *low-set ears*, and *protruding ears* align with the characteristic ""Kabuki mask"" facies.  
2. **Cleft/High Palate**: *Cleft palate* and *high palate* are common orofacial anomalies in Kabuki syndrome.  
3. **Neurological Abnormalities**: *Hydrocephalus* and *lateral ventricle dilatation* suggest structural brain defects, while *generalized hypotonia* and *weak cry* reflect neuromuscular involvement.  
4. **Growth Issues**: *Postnatal growth retardation* and *growth delay* are hallmark features of Kabuki syndrome.  
5. **Skeletal Anomalies**: *Hip dysplasia* and *micrognathia* correlate with skeletal dysplasia seen in this disorder.  
6. **Multisystem Involvement**: *Cardiovascular abnormalities*, *liver/spleen anomalies*, and *breech presentation* (linked to joint laxity) reflect systemic impacts.  
7. **Endocrine Dysfunction**: *Abnormal thyroid hormone levels* may arise from endocrine dysregulation, a recognized feature.  
8. **Supporting Features**: *Sparse eyebrows* and *sparse eyelashes* are frequent cutaneous findings.  
9. **Genetic Basis**: Kabuki syndrome 2 is caused by *KDM6A* mutations, which explain the phenotypic overlap with Kabuki syndrome 1 (MLL2-related) but with potential endocrine distinctions.  

The constellation of craniofacial, skeletal, neurological, and multisystem anomalies strongly supports Kabuki syndrome 2, warranting *KDM6A* sequencing for confirmation."
"['Thin vermilion border', 'Triangular face', 'Low-set ears', 'Narrow nose', 'Blue sclerae', 'Thin skin', 'Cutis laxa', 'Atrophic scars', 'Global developmental delay', 'Joint hypermobility', 'Hip dysplasia', 'Pes planus', 'Delayed gross motor development', 'Excessive wrinkled skin', 'Adipose tissue loss', 'Dermal translucency']","['Autosomal recessive cutis laxa type 2B', 'Cutis laxa, autosomal recessive, type IIB']","Disease: Autosomal recessive cutis laxa type 2B  
Reasoning: The patient presents with cardinal features of cutis laxa, thin/translucent skin, joint hypermobility, and atrophic scars, consistent with connective tissue fragility. Facial dysmorphism (triangular face, narrow nose, low-set ears) and systemic involvement (hip dysplasia, pes planus) align with ARCL2B. Global developmental delay and motor delays suggest multisystemic disease. Adipose loss, excessive wrinkling, and progeroid-like features (thin skin, blue sclerae) reflect mitochondrial dysfunction linked to PYCR1 mutations, a hallmark of ARCL2B.  

Disease: Cutis laxa, autosomal recessive, type IIB  
Reasoning: This is synonymous with ARCL2B. The terminology ""type IIB"" uses Roman numerals but refers to the same PYCR1-associated disorder. Symptoms like triangular facies, cutis laxa, and developmental delay match the phenotypic spectrum. Hip dysplasia and dermal translucency further confirm the diagnosis, as these are recurrent findings in genetic cutis laxa syndromes with progeroid overlap."
"['Death in infancy', 'Fever', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity. This enzyme converts phenylalanine to tyrosine, and its absence leads to toxic phenylalanine accumulation.  
2. **Hypertyrosinemia**: While atypical in classic PKU (which typically shows normal/low tyrosine), this may indicate a rare variant (e.g., PAH deficiency with secondary tyrosine dysregulation) or coexisting liver dysfunction from chronic metabolic stress.  
3. **Abnormal urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate) may mimic carboxylic acid excretion patterns, though organic acidemias should be ruled out.  
4. **Decreased ferritin**: Chronic dietary restriction (low-protein PKU management) or malabsorption could contribute to iron deficiency.  
5. **Recurrent infections**: Untreated PKU causes severe neurological decline and immunosuppression due to metabolic derangements, increasing infection susceptibility.  
6. **Early mortality (infancy/childhood/adolescence)**: Reflects untreated/severe PKU, where toxic phenylalanine levels lead to neurodegeneration, seizures, and organ failure. Neonatal screening often prevents this, but delayed diagnosis results in fatal outcomes.  

Note: Hypertyrosinemia and porphyrin abnormalities are not classic PKU features, suggesting potential comorbidities (e.g., secondary mitochondrial dysfunction) or misattributed lab findings. However, hyperphenylalaninemia remains the diagnostic anchor."
"['Gingival overgrowth', 'High palate', 'Long face', 'Hearing impairment', 'Strabismus', 'Horizontal nystagmus', 'Dental crowding', 'Slender finger', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar hypoplasia', 'Dystonia', 'Hyperreflexia', 'Overgrowth', 'Hypoplasia of the corpus callosum', 'Leukodystrophy', 'Abnormal cerebral white matter morphology', 'Scoliosis', 'Multiple joint contractures', 'CNS hypomyelination', 'Cerebral hypomyelination', 'Generalized hyperreflexia', 'Brain atrophy']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Leukodystrophy/CNS hypomyelination**: The presence of leukodystrophy, cerebral/cerebellar hypomyelination, and abnormal white matter morphology directly align with the hallmark hypomyelinating leukodystrophy in NKX6-2 disorders.  
2. **Spastic tetraparesis/hyperreflexia**: Spasticity and hyperreflexia are consistent with corticospinal tract dysfunction due to impaired myelination.  
3. **Cerebellar hypoplasia/brain atrophy**: Explains ataxia, nystagmus, and dystonia, reflecting cerebellar and global CNS involvement.  
4. **Global developmental delay**: Expected in severe neurodevelopmental disorders with hypomyelination and cerebellar defects.  
5. **Hypoplasia of the corpus callosum**: A common associated structural brain anomaly in leukodystrophies.  
6. **Scoliosis/joint contractures**: Secondary to chronic spasticity and reduced mobility.  
7. **Dental/facial features (gingival overgrowth, high palate, long face)**: May represent connective tissue or craniofacial dysregulation linked to NKX6-2's role in development.  
8. **Slender fingers/overgrowth**: Less typical but reported in some genetic leukodystrophies with multisystemic effects.  
9. **Generalized hypotonia**: Early presentation, evolving into spasticity as myelination deficits progress.  

The combination of hypomyelination, spasticity, cerebellar anomalies, and developmental delay strongly supports NKX6-2-related disease, with minor features (e.g., dental crowding) reflecting broader developmental impacts of NKX6-2 mutations."
"['Neutrophilia', 'Delayed umbilical cord separation', 'Neonatal omphalitis', 'Skin ulcer']","['Leukocyte adhesion deficiency type I', 'Leukocyte adhesion deficiency, type I']","Disease: Leukocyte adhesion deficiency type I  
Reasoning:  
1. **Neutrophilia**: Elevated neutrophil count occurs due to impaired adhesion and migration of neutrophils to tissues, causing their accumulation in the bloodstream.  
2. **Delayed umbilical cord separation**: Normally, neutrophils mediate inflammation for cord detachment. In LAD-I, defective neutrophil function delays this process beyond 3 weeks.  
3. **Neonatal omphalitis**: Recurrent bacterial/fungal infections (e.g., umbilical stump infection) arise from neutrophils' inability to extravasate and combat pathogens.  
4. **Skin ulcers**: Impaired wound healing and chronic tissue necrosis result from deficient neutrophil recruitment to sites of injury or infection.  
**Genetic basis**: Autosomal recessive mutation in _ITGB2_ (CD18 subunit), critical for integrin-mediated leukocyte adhesion. Confirmatory testing includes flow cytometry for CD18/CD11b expression."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Spasticity', 'Motor delay', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: The presence of elevated phenylalanine levels directly indicates a defect in phenylalanine metabolism, the hallmark of PKU.  
2. **Neurological symptoms (intellectual disability, spasticity, motor/speech delay)**: Untreated PKU causes toxic phenylalanine accumulation, impairing neurotransmitter synthesis and myelination, leading to developmental delays and neurological damage.  
3. **Early mortality (neonatal/infant/childhood death)**: Severe untreated PKU can result in progressive neurological deterioration, seizures, and susceptibility to infections, contributing to early death.  
4. **Prenatal developmental abnormalities**: While PKU itself does not cause prenatal structural defects, maternal PKU (untreated during pregnancy) can lead to congenital anomalies. The listed symptom may reflect this context or overlap with complications from metabolic instability post-birth.  
5. **Exclusion of alternatives**: Symptoms align with PKU’s pathophysiology; no features suggest other metabolic disorders (e.g., maple syrup urine disease) or syndromes with overlapping symptoms."
"['Jaundice', 'Splenomegaly', 'Hemolytic anemia', 'Reticulocytosis', 'Increased red cell osmotic fragility']","['Spherocytosis, type 5']","Disease: Spherocytosis, type 5  
Reasoning:  
1. **Hemolytic anemia** and **reticulocytosis** indicate accelerated red blood cell (RBC) destruction and compensatory bone marrow production.  
2. **Jaundice** arises from unconjugated hyperbilirubinemia due to hemoglobin breakdown in hemolysis.  
3. **Splenomegaly** occurs as the spleen becomes engorged from trapping and destroying structurally abnormal RBCs.  
4. **Increased red cell osmotic fragility** is a hallmark of spherocytosis, reflecting reduced RBC surface-to-volume ratio due to membrane loss.  
5. **Type 5 spherocytosis** specifically involves mutations in the *EPB42* gene, causing deficiency of erythrocyte membrane protein band 4.2, destabilizing the cytoskeleton and leading to spheroidal, fragile RBCs.  
The combination of membrane instability, splenic sequestration, and hemolysis confirms the diagnosis."
"['Death in infancy', 'Hypertyrosinemia', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, impairing the conversion of phenylalanine to tyrosine. Untreated PKU results in toxic phenylalanine accumulation, causing neurodevelopmental damage and **death in infancy**. The **hypertyrosinemia** is atypical but may arise secondarily: excessive phenylalanine competitively inhibits tyrosine transport or degradation pathways, leading to its abnormal elevation. This dual metabolic disruption aligns with severe, untreated PKU."
"['Keratoconus', 'Dysarthria', 'Dysmetria', 'Lower limb spasticity', 'Gait ataxia', 'Limb ataxia', 'Upper limb spasticity']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Autosomal recessive spastic paraplegia type 76 (SPG76): The patient exhibits lower and upper limb spasticity, consistent with hereditary spastic paraplegia (HSP). The additional cerebellar features (gait ataxia, limb ataxia, dysmetria, dysarthria) indicate a complex HSP subtype. SPG76, caused by CAPN1 mutations, is characterized by progressive spastic paraplegia, cerebellar ataxia, dysarthria, and dysphagia. While keratoconus is not a classic feature of SPG76, the combination of spasticity, cerebellar dysfunction, and autosomal recessive inheritance strongly supports this diagnosis. Keratoconus may represent an atypical or coincidental manifestation in this case."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low/normal). This may indicate a transient neonatal tyrosinemia, a co-occurring metabolic disorder, or potential misreporting of lab results.  
3. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome (if the mother had untreated PKU during pregnancy), causing congenital anomalies in the infant.  
4. **Neonatal death/Death in infancy** suggests severe metabolic derangement if untreated. Untreated PKU can lead to progressive neurologic damage, seizures, and fatal complications, though neonatal death is rare unless compounded by other factors (e.g., maternal PKU effects).  
5. PKU is prioritized due to **hyperphenylalaninemia**, the most specific symptom. Conflicting hypertyrosinemia warrants further investigation (e.g., BH4 deficiency or tyrosinemia), but the core presentation fits PKU as the primary diagnosis."
"['Hyporeflexia', 'Hyporeflexia', 'Polyneuropathy', 'Decreased number of peripheral myelinated nerve fibers', 'Basal lamina onion bulb formation', 'Recurrent bacterial skin infections', 'Pain insensitivity', 'Peripheral demyelination', 'Abnormal autonomic nervous system physiology', 'Abnormal systemic blood pressure', 'Abnormal heart rate variability', 'Digital ulcer', 'Abnormal sensory nerve conduction velocity']","['Neuropathy, hereditary sensory and autonomic, type II']","Disease: Neuropathy, hereditary sensory and autonomic, type II (HSAN II)  
Reasoning:  
1. **Hyporeflexia**: Consistent with peripheral nerve dysfunction, as damaged sensory/motor fibers impair reflex arcs.  
2. **Polyneuropathy & Peripheral demyelination**: Indicates widespread peripheral nerve damage, aligning with HSAN II’s axonal and demyelinating features.  
3. **Decreased myelinated nerve fibers**: HSAN II is characterized by early loss of myelinated fibers, particularly in sensory nerves.  
4. **Basal lamina onion bulb formation**: Suggests repeated demyelination/remyelination cycles, seen in hereditary neuropathies like HSAN II.  
5. **Recurrent bacterial skin infections & Digital ulcers**: Result from pain insensitivity (due to sensory nerve loss), leading to unnoticed injuries and poor wound healing.  
6. **Abnormal autonomic physiology (blood pressure, heart rate variability)**: Autonomic involvement is a hallmark of HSAN disorders, reflecting sympathetic/parasympathetic dysfunction.  
7. **Abnormal sensory nerve conduction velocity**: Demyelination and axonal loss directly slow sensory signal transmission.  
8. **Pain insensitivity**: Distinctive in HSAN II due to severe sensory neuron degeneration.  
HSAN II integrates sensory, autonomic, and motor deficits (e.g., hyporeflexia) with pathological features (onion bulbs, demyelination), excluding other neuropathies (e.g., CMT lacks autonomic symptoms)."
"['Microcephaly', 'Delayed speech and language development', 'Intellectual disability', 'Hypotonia', 'Spasticity', 'Global developmental delay', 'Difficulty walking']","['Mental retardation, autosomal recessive 18']","Disease: Mental retardation, autosomal recessive 18  
Reasoning:  
1. **Microcephaly**: A hallmark of RAB3GAP1-related disorders, including MRT18, due to impaired neuronal growth and synaptic function.  
2. **Global developmental delay + intellectual disability**: Core features of MRT18, linked to RAB3GAP1 mutations disrupting vesicular trafficking critical for brain development.  
3. **Hypotonia progressing to spasticity**: Early hypotonia (infancy) often transitions to spasticity (later childhood) in RAB3GAP1 disorders, reflecting evolving corticospinal tract dysfunction.  
4. **Delayed speech/language and motor deficits**: Reflects widespread cortical and cerebellar involvement, consistent with RAB3GAP1’s role in neurosecretory pathways.  
5. **Difficulty walking**: Secondary to spasticity, pyramidal tract damage, and motor coordination deficits.  
6. **Autosomal recessive inheritance**: Matches MRT18’s inheritance pattern; family history (if available) may reveal consanguinity or asymptomatic carriers.  
**Confirmatory testing**: Genetic sequencing of RAB3GAP1 to identify biallelic pathogenic variants."
"['Parkinsonism', 'Rigidity', 'Bradykinesia', 'Gait imbalance', 'Postural instability', 'EEG abnormality', 'Falls']","['Parkinsonian-pyramidal syndrome/Parkinson disease 15, autosomal recessive early-onset']","Disease: Parkinsonian-pyramidal syndrome/Parkinson disease 15, autosomal recessive early-onset  
Reasoning:  
1. **Core Parkinsonian Features**: The presence of rigidity, bradykinesia, and gait imbalance aligns with Parkinsonism, a hallmark of this syndrome.  
2. **Early-Onset and Inheritance**: The diagnosis specifies autosomal recessive early-onset disease, suggesting a genetic etiology consistent with PARK15.  
3. **Pyramidal Involvement**: Though not explicitly listed, gait imbalance, postural instability, and falls may reflect pyramidal tract dysfunction (e.g., spasticity or hyperreflexia), a defining feature of Parkinsonian-pyramidal syndrome.  
4. **EEG Abnormality**: Uncommon in idiopathic Parkinson’s disease, this points to cortical or subcortical dysfunction, supporting a complex neurodegenerative syndrome like PARK15.  
5. **Exclusion of Typical Parkinson’s**: Early-onset symptoms with atypical features (EEG changes, rapid progression to falls) argue against sporadic Parkinson’s disease, favoring a genetic or syndromic cause.  
6. **Genetic Confirmation**: While clinical features are critical, PARK15 is confirmed via *FBXO7* gene testing, though this step is inferred from the clinical context provided."
"['Macroglossia', 'Gingival overgrowth', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Osteoporosis', 'Areflexia', 'Tongue fasciculations', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', 'Hypertriglyceridemia', 'Generalized-onset seizure', ""Exaggerated cupid's bow"", 'Developmental regression', 'Highly arched eyebrow', 'Hyponatremia', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Cerebral visual impairment']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Neurological & developmental features**: Profound global developmental delay, developmental regression, cerebellar vermis hypoplasia, and cerebral visual impairment align with TBCK syndrome’s hallmark neurodevelopmental deficits. Corpus callosum abnormalities (partial agenesis/hypoplasia) and ventriculomegaly are consistent with brain malformations seen in TBCK.  
2. **Neuromuscular signs**: Severe muscular hypotonia, areflexia, and tongue fasciculations reflect the syndrome’s hypotonia-predominant presentation. Respiratory insufficiency and feeding difficulties are secondary to hypotonia.  
3. **Seizures**: Both generalized-onset and focal-onset seizures are reported in TBCK due to cortical dysgenesis and mTOR pathway dysregulation.  
4. **Craniofacial dysmorphism**: Macroglossia, gingival overgrowth, coarse facial features, narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, and exaggerated “Cupid’s bow” match the characteristic facies of TBCK-related syndromes.  
5. **Metabolic/Systemic involvement**: Hypertriglyceridemia and osteoporosis may arise from metabolic dysregulation linked to TBCK’s role in mTOR signaling. Hyponatremia could reflect autonomic dysfunction.  
6. **Genetic correlation**: TBCK mutations disrupt kinase activity critical for neuronal survival and metabolism, explaining the multisystemic phenotype.  
The combination of severe hypotonia, distinct facies, brain malformations, and metabolic anomalies strongly supports this diagnosis."
"['Seizure', 'Death in infancy', 'Ventricular septal defect', 'Atrial septal defect', 'Anemia', 'Hypoglycemia', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Neonatal death', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Hypoglycemia and Hepatomegaly**: Central to HMGCLD, as the enzyme deficiency impairs ketogenesis and leucine metabolism, leading to energy crises during fasting.  
2. **Dicarboxylic Aciduria and 3-Methylglutaconic Aciduria**: Pathognomonic findings due to accumulation of 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, and dicarboxylic acids from disrupted fatty acid oxidation.  
3. **Seizures and Neonatal Death**: Result from severe hypoglycemia, metabolic acidosis, and hyperammonemia during metabolic crises, often fatal without intervention.  
4. **Feeding Difficulties and Tachypnea**: Reflect acute decompensation (vomiting, lethargy) and compensatory respiratory alkalosis from metabolic acidosis.  
5. **Elevated Urinary Carboxylic Acids**: Direct consequence of defective organic acid metabolism.  
6. **Anemia**: May arise secondary to bone marrow suppression or metabolic stress.  
7. **Cardiac Defects (VSD/ASD)**: Uncommon but reported in rare cases, possibly linked to mitochondrial dysfunction or metabolic stress during embryogenesis.  
**Note**: While cardiac anomalies are atypical for HMGCLD, the biochemical markers (3-methylglutaconic/dicarboxylic aciduria) and metabolic profile are diagnostic. Early neonatal demise underscores the severity of untreated metabolic crises."
"['Gingival bleeding', 'Epistaxis', 'Petechiae', 'Thrombocytopenia', 'Impaired ADP-induced platelet aggregation', 'Impaired epinephrine-induced platelet aggregation', 'Impaired arachidonic acid-induced platelet aggregation', 'Impaired ristocetin-induced platelet aggregation', 'Increased mean platelet volume', 'Decreased circulating ferritin concentration']",['Bernard-Soulier syndrome/Bernard-Soulier syndrome'],"Disease: Bernard-Soulier syndrome  
Reasoning:  
1. **Thrombocytopenia with increased mean platelet volume (MPV):** Indicates abnormally large platelets (macrothrombocytopenia), a hallmark of Bernard-Soulier syndrome (BSS) due to defective platelet formation.  
2. **Impaired ristocetin-induced platelet aggregation:** Directly points to a defect in the GPIb-IX-V complex, which is essential for von Willebrand factor (vWF)-mediated platelet adhesion. This is pathognomonic for BSS.  
3. **Normal agonists (ADP, epinephrine, arachidonic acid) showing impaired aggregation:** While these agonists typically test platelet activation pathways (e.g., GPIIb/IIIa in aggregation), technical limitations (e.g., low platelet count, large platelet size) or secondary platelet dysfunction may artifactually reduce responses.  
4. **Bleeding symptoms (gingival bleeding, epistaxis, petechiae):** Consistent with platelet dysfunction and thrombocytopenia.  
5. **Decreased ferritin:** Likely reflects chronic iron loss from recurrent bleeding, a common complication in BSS.  
6. **Exclusion of other disorders:** Glanzmann thrombasthenia (normal platelet count/size, isolated GPIIb/IIIa defect) and immune thrombocytopenia (normal platelet size/function) are ruled out by the clinical and laboratory profile."
"['Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Fever', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Elevated circulating alkaline phosphatase concentration', 'Oroticaciduria', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Hyperleucinemia', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Feeding difficulties', 'Fatigue']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Hyperammonemia** indicates a urea cycle disorder, as ammonia is not effectively converted to urea.  
2. **Elevated plasma citrulline** and **oroticaciduria** localize the defect to argininosuccinate lyase (ASL) deficiency, as citrulline accumulates due to the enzymatic block, and excess carbamoyl phosphate diverts to pyrimidine synthesis, producing orotic acid.  
3. **Aminoaciduria** and **abnormal amino acid concentrations** (arginine, aspartate family, proline, glycine, alanine) reflect metabolic dysregulation from urea cycle failure, protein catabolism, and secondary mitochondrial dysfunction.  
4. **Hyperleucinemia** and **elevated lactate** suggest metabolic decompensation and energy crisis due to hyperammonemia.  
5. **Neonatal/childhood death**, **feeding difficulties**, and **hypotonia** align with severe urea cycle disorder presentations, where toxic ammonia levels cause neurological damage and multisystem failure.  
6. **Premature birth** and **small for gestational age** may result from in utero metabolic stress.  
7. **Elevated alkaline phosphatase** and **abnormal carnitine** levels are nonspecific markers of metabolic dysfunction.  

This constellation of findings—especially hyperammonemia, citrullinemia, and oroticaciduria—confirms **argininosuccinic aciduria** due to ASL deficiency."
"['Pheochromocytoma', 'Elevated calcitonin', 'Thyroid nodule']","['Multiple endocrine neoplasia, type IIA', 'Multiple endocrine neoplasia type 2A']","Multiple endocrine neoplasia, type IIA: The patient presents with pheochromocytoma, elevated calcitonin (a marker for medullary thyroid carcinoma, MTC), and a thyroid nodule. MEN IIA is characterized by the triad of MTC, pheochromocytoma, and parathyroid hyperplasia. Elevated calcitonin strongly suggests MTC, which is nearly universal in MEN IIA. The coexistence of pheochromocytoma confirms the diagnosis, as these tumors rarely occur sporadically in this combination. The thyroid nodule likely represents the MTC itself. Genetic testing for RET proto-oncogene mutations would confirm the diagnosis.  

Multiple endocrine neoplasia type 2A: This is synonymous with MEN IIA. The reasoning mirrors the above: the simultaneous occurrence of medullary thyroid carcinoma (implied by elevated calcitonin and thyroid nodule) and pheochromocytoma is pathognomonic for MEN 2A. Parathyroid involvement may or may not be clinically evident but is not required for diagnosis when both MTC and pheochromocytoma are present. Early identification is critical due to the aggressive nature of MTC in this syndrome."
"['Hearing impairment', 'Bradycardia', 'Tachypnea', 'Prolonged QTc interval']",['Jervell and Lange-Nielsen syndrome/Jervell and Lange-Nielsen syndrome 1'],"Disease: Jervell and Lange-Nielsen syndrome 1  
Reasoning:  
1. **Hearing impairment**: Congenital bilateral sensorineural deafness is a hallmark of Jervell and Lange-Nielsen syndrome (JLNS), caused by mutations in *KCNQ1* or *KCNE1* genes affecting potassium channels in the inner ear.  
2. **Prolonged QTc interval**: JLNS disrupts cardiac potassium channels, delaying ventricular repolarization, leading to prolonged QTc (>500 ms), a diagnostic criterion for long QT syndrome type 1 (LQT1).  
3. **Bradycardia**: Abnormal cardiac repolarization in JLNS predisposes to arrhythmias, including sinus bradycardia or pauses, especially during rest or sleep.  
4. **Tachypnea**: May reflect autonomic instability, compensatory response to arrhythmia-induced hypoxia, or anxiety from syncopal episodes.  
5. **Exclusion of alternatives**: Romano-Ward syndrome (LQTS without deafness) and acquired causes (e.g., electrolyte imbalance) are ruled out by the presence of congenital deafness and genetic predisposition.  
6. **Syndrome alignment**: The triad of congenital deafness, prolonged QTc, and arrhythmias (bradycardia/tachycardia) strongly supports JLNS1 (*KCNQ1* mutation)."
"['Delayed speech and language development', 'Global developmental delay', 'Hypertonia', 'Delayed CNS myelination', 'EEG with burst suppression', 'Focal tonic seizure']","['Epileptic encephalopathy, early infantile, 4']","Disease: Epileptic encephalopathy, early infantile, 4  
Reasoning:  
1. **EEG with burst suppression** is a hallmark of early infantile epileptic encephalopathies (EIEE), specifically associated with EIEE4 (STXBP1-related encephalopathy).  
2. **Focal tonic seizures** align with seizure types observed in EIEE4, typically presenting in the first months of life.  
3. **Global developmental delay** and **delayed speech/language development** reflect the neurodevelopmental impairment caused by persistent epileptiform activity disrupting brain maturation.  
4. **Hypertonia** is a common neurological feature in STXBP1 mutations due to disrupted synaptic vesicle release and neuronal communication.  
5. **Delayed CNS myelination** on imaging supports a genetic/metabolic etiology affecting white matter development, consistent with EIEE4.  
6. The combination of seizure phenotype, developmental regression, and EEG findings strongly prioritizes EIEE4 over other encephalopathies."
"['Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Visual impairment', 'Osteoporosis', 'Seizure', 'Areflexia', 'Cerebellar vermis hypoplasia', 'Hyperreflexia', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Developmental regression', 'Fasciculations', 'Highly arched eyebrow', 'Peripheral axonal neuropathy', 'Severe muscular hypotonia', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Abnormality of muscle size']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
- **Characteristic facial features**: Narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, exaggerated cupid’s bow, and highly arched eyebrows align with the dysmorphic facies typical of TBCK syndrome.  
- **Neuromuscular abnormalities**: Severe muscular hypotonia, areflexia/hyperreflexia (mixed reflexes due to peripheral neuropathy and central nervous system involvement), fasciculations, and peripheral axonal neuropathy reflect the syndrome’s impact on both central and peripheral nervous systems.  
- **Neurodevelopmental deficits**: Profound global developmental delay, developmental regression, and cerebellar vermis hypoplasia correlate with psychomotor retardation and cerebellar dysfunction.  
- **Structural brain anomalies**: Hypoplasia of the corpus callosum, ventriculomegaly, and small basal ganglia are consistent with neuroimaging findings in TBCK-related disorders.  
- **Seizures/EEG abnormalities**: Epileptiform activity and seizures are common due to cortical and subcortical malformations.  
- **Systemic involvement**: Osteoporosis (secondary to immobility from hypotonia), respiratory insufficiency (muscle weakness), and feeding difficulties (bulbar dysfunction) support multisystemic disease progression.  
- **Genetic basis**: TBCK gene mutations disrupt mTOR signaling and autophagy, explaining the combination of neurodevelopmental, muscular, and degenerative features.  

The constellation of facial dysmorphism, hypotonia, neurodevelopmental regression, brain malformations, and mixed neurological signs strongly supports the diagnosis of TBCK-related intellectual disability syndrome."
"['Hypercholesterolemia', 'Hypertyrosinemia', 'Aminoaciduria', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to impaired conversion of phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: Unusual in classic PKU (where tyrosine is typically low), but may occur in rare PKU variants or secondary metabolic disruptions (e.g., dietary interventions or overlapping enzyme deficiencies).  
3. **Aminoaciduria**: Excess phenylalanine excretion in urine due to overflow from elevated blood levels, consistent with PKU.  
4. **Hypercholesterolemia**: Not directly linked to PKU but potentially secondary to high-fat/low-protein dietary management required for PKU.  
5. **Early mortality**: Untreated PKU causes severe neurological damage, seizures, and organ failure, explaining death in adolescence/early adulthood if undiagnosed or unmanaged.  
**Conclusion**: Despite atypical hypertyrosinemia and hypercholesterolemia, hyperphenylalaninemia and aminoaciduria strongly align with PKU, with secondary factors explaining discrepancies."
"['Cardiomyopathy', 'Fever', 'Abnormality of urine homeostasis', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by defective carnitine transport due to mutations in the *SLC22A5* gene.  
2. **Cardiomyopathy** arises from impaired fatty acid oxidation in cardiac muscle due to carnitine deficiency, leading to energy depletion and cardiac dysfunction.  
3. **Gastrointestinal inflammation** and **fever** may reflect metabolic decompensation episodes triggered by fasting or infection, causing hypoketotic hypoglycemia and secondary systemic stress.  
4. **Abnormality of urine homeostasis** correlates with renal carnitine wasting (reduced tubular reabsorption) and potential electrolyte imbalances during metabolic crises.  
5. **Death in childhood** aligns with untreated PCD's natural history, where cardiac failure, hypoglycemic encephalopathy, or arrhythmias prove fatal without carnitine supplementation.  
6. Symptom constellation matches PCD's multisystemic presentation: hepatic, cardiac, muscular, and metabolic manifestations from disrupted lipid metabolism."
"['Erythroderma', 'Global developmental delay', 'Hyperreflexia', 'Opisthotonus', 'Generalized-onset seizure', 'Short stature', 'Disproportionate short-limb short stature', 'Fetal distress', 'Oligoclonal T cell expansion', 'Sepsis']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Features**: Disproportionate short-limb short stature and short stature align with skeletal dysplasia, a hallmark of ISDNA.  
2. **Neurodevelopmental Abnormalities**: Global developmental delay, hyperreflexia, opisthotonus, and generalized-onset seizures indicate severe neurological involvement, consistent with ISDNA's neurodevelopmental phenotype.  
3. **Immune Dysregulation**: Oligoclonal T cell expansion and sepsis suggest immunodeficiency, while erythroderma may reflect inflammatory T-cell dysregulation, all characteristic of ISDNA's immune pathology.  
4. **Prenatal Onset**: Fetal distress supports a congenital disorder, fitting ISDNA's genetic etiology (EXOC6B mutations).  
5. **Integration**: The triad of skeletal, neurological, and immune abnormalities distinguishes ISDNA from isolated skeletal dysplasias, neurodevelopmental disorders, or primary immunodeficiencies."
"['Abnormal saccadic eye movements', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Thromboembolism', 'Neonatal death', 'Lipodystrophy', 'Abnormal skeletal morphology', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation affecting cerebellar development.  
2. **Generalized hypotonia**: Common in glycosylation disorders due to neuromuscular involvement.  
3. **Lipodystrophy**: Altered fat distribution linked to metabolic dysregulation from glycosylation defects.  
4. **Thromboembolism**: Coagulation factor deficiencies (e.g., antithrombin III) are frequent in PMM2-CDG.  
5. **Abnormal saccadic eye movements**: Reflects cerebellar/brainstem dysfunction.  
6. **Neonatal death/Death in infancy**: Severe forms of PMM2-CDG often lead to early mortality.  
7. **Abnormal skeletal morphology**: Dysostosis and growth retardation are recognized features.  
**Confirmatory evidence**: PMM2-CDG is the most prevalent CDG subtype, and this symptom cluster aligns with its multisystemic presentation (neurodevelopmental, hepatic, and coagulation abnormalities)."
"['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Fever', 'Abnormal cerebral morphology', 'Severe hearing impairment', 'L-2-hydroxyglutaric aciduria', 'L-2-hydroxyglutaric acidemia']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key biochemical markers**: The presence of ""L-2-hydroxyglutaric aciduria"" and ""L-2-hydroxyglutaric acidemia"" in the symptom list directly indicates a defect in L-2-hydroxyglutarate dehydrogenase, leading to toxic accumulation of L-2-hydroxyglutaric acid in urine and blood.  
2. **Neurological manifestations**: Macrocephaly, delayed speech, intellectual disability, seizures, and abnormal cerebral morphology align with this disorder’s characteristic progressive encephalopathy and leukoencephalopathy.  
3. **Severe systemic involvement**: Severe hearing impairment and death in infancy suggest advanced disease progression, often due to metabolic crises, neurodegeneration, or complications like status epilepticus.  
4. **Supporting features**: Fever may reflect metabolic decompensation during intercurrent illnesses, exacerbating neurological symptoms.  
5. **Exclusion of mimics**: The combination of biochemical findings, neurodevelopmental regression, and cerebral abnormalities rules out other organic acidurias or leukodystrophies.  

The diagnosis is confirmed by genetic testing (e.g., _L2HGDH_ mutations) and consistent biochemical/neuroimaging findings."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Pneumonia', 'Pregnancy history', 'Neonatal death', 'Death in childhood', 'Hypoargininemia', 'Elevated plasma citrulline', 'Hernia']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia, elevated plasma citrulline, and hypoargininemia, hallmark features of urea cycle dysfunction. Death in infancy/childhood, neonatal death, and premature birth align with the severe neonatal-onset form of citrullinemia type I (argininosuccinate synthetase deficiency). This disorder causes rapid ammonia accumulation, leading to metabolic crises, neurological deterioration, and early mortality without intervention. Pneumonia may arise secondary to metabolic instability or immunosuppression during crises.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Hypoargininemia, hyperammonemia, and elevated citrulline are consistent with citrin deficiency, which disrupts the urea cycle via impaired aspartate transport. Hernia may reflect hepatomegaly or ascites from cholestasis. Premature birth and neonatal death correlate with intrahepatic cholestasis, growth restriction, and liver dysfunction in neonatal-onset type II. Though cholestasis (e.g., jaundice) is not explicitly listed, its inclusion in the disease name and hernia as a potential sign of liver pathology supports this diagnosis."
"['Seizure', 'Death in childhood', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** suggest impaired carboxylase enzyme activity, which requires biotin as a cofactor. Biotinidase deficiency prevents biotin recycling, leading to functional biotin depletion and subsequent carboxylase dysfunction.  
2. **Seizures** occur due to metabolic acidosis and accumulation of toxic metabolites (e.g., lactate, ammonia) affecting the central nervous system.  
3. **Death in childhood** aligns with untreated BTDD progression, as irreversible neurological damage, respiratory failure, or metabolic crises typically occur without biotin supplementation.  
4. The **late-onset multiple carboxylase deficiency** subtype matches the gradual symptom onset (e.g., after the neonatal period) due to partial enzyme activity before biotin stores are depleted.  

This triad of symptoms strongly supports BTDD, confirmed by biochemical testing (low biotinidase activity) and genetic analysis of the *BTD* gene."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother has uncontrolled PKU during pregnancy, though this is rare in the patient’s own presentation.  
3. **Death in infancy/childhood/adolescence/early adulthood** reflects untreated PKU’s natural history: severe neurotoxicity, seizures, and organ failure without dietary intervention.  
4. **Hypertyrosinemia** is atypical for classic PKU (which usually causes *low* tyrosine due to PAH deficiency) but may suggest a rare PAH variant or secondary metabolic disruption.  
5. **Upper airway/chronic pulmonary obstruction** could stem from comorbid infections or neuromuscular dysfunction from chronic metabolic damage.  
6. **Neonatal death** is uncommon with modern screening but plausible in undiagnosed/severe cases.  

Note: While hypertyrosinemia and respiratory symptoms are unusual, PKU is strongly supported by hyperphenylalaninemia and the fatal progression described. Tyrosinemia or combined metabolic disorders should be ruled out clinically."
"['Progressive microcephaly', 'Optic atrophy', 'Global developmental delay', 'Spastic tetraparesis', 'Myoclonus', 'Small for gestational age', 'Short distal phalanx of toe', 'Birth length less than 3rd percentile', 'Simplified gyral pattern', 'Short distal phalanx of finger', 'Primary microcephaly', 'Infantile spasms', 'Arteriovenous malformation']",['Microcephaly-Capillary malformation syndrome'],"Disease: Microcephaly-Capillary Malformation Syndrome (MIC-CAP)  
Reasoning:  
1. **Progressive microcephaly/Primary microcephaly**: Core feature of MIC-CAP, caused by STAMBP mutations leading to defective neurodevelopment.  
2. **Simplified gyral pattern**: Reflects cortical malformations, consistent with MIC-CAP’s brain abnormalities (e.g., polymicrogyria or reduced cortical folding).  
3. **Global developmental delay/Spastic tetraparesis/Infantile spasms/Myoclonus**: Aligns with severe neurological involvement, including epilepsy and motor deficits, typical of MIC-CAP.  
4. **Growth restriction (SGA, birth length <3rd percentile)**: Prenatal-onset growth retardation is a hallmark of MIC-CAP.  
5. **Short distal phalanges (fingers/toes)**: Suggests distal limb hypoplasia, a recognized skeletal anomaly in MIC-CAP.  
6. **Optic atrophy**: May result from progressive neurodegeneration or axonal damage secondary to metabolic dysfunction in MIC-CAP.  
7. **Arteriovenous malformation (AVM)**: Less common but plausible in MIC-CAP, as vascular dysregulation (beyond capillary malformations) can occur.  
**Exclusion of mimics**: Features distinguish MIC-CAP from other microcephaly syndromes (e.g., Seckel syndrome lacks vascular anomalies; Galloway-Mowat syndrome includes nephrosis).  
**Conclusion**: Symptom constellation strongly supports MIC-CAP, driven by genetic testing for STAMBP variants to confirm."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This deficiency results in phenylalanine accumulation, directly explaining hyperphenylalaninemia.  
2. **Death in childhood**: Untreated PKU leads to severe neurological damage, seizures, and developmental failure, often causing early mortality without dietary intervention.  
3. **Hypertyrosinemia**: While atypical in classic PKU (as PAH deficiency typically reduces tyrosine synthesis), this could reflect dietary tyrosine supplementation, misreported data, or a concurrent metabolic disturbance (e.g., transient neonatal tyrosinemia). The primary diagnostic markers (hyperphenylalaninemia + clinical severity) strongly prioritize PKU despite this anomaly."
"['Cyanosis', 'Hepatic steatosis', 'Eosinophilia', 'Pulmonary infiltrates', 'Lymphadenopathy', 'Elevated hepatic transaminase', 'Hypercholesterolemia', 'Elevated circulating parathyroid hormone level', 'Increased circulating IgE level', 'Abnormality of facial soft tissue', 'Autoimmune antibody positivity', 'Elevated gamma-glutamyltransferase level']",['Kimura disease'],"Disease: Kimura disease  
Reasoning:  
1. **Lymphadenopathy and Facial Soft Tissue Abnormality**: Kimura disease commonly presents with subcutaneous masses and lymphadenopathy, particularly in the head/neck region, explaining the facial soft tissue abnormality.  
2. **Eosinophilia and Elevated IgE**: Hallmark features of Kimura disease, driven by a chronic inflammatory response with pronounced eosinophil infiltration and IgE overproduction.  
3. **Autoimmune Antibody Positivity**: While not definitive, Kimura disease may involve autoimmune mechanisms, aligning with autoimmune antibody positivity.  
4. **Pulmonary Infiltrates and Cyanosis**: Secondary eosinophilic infiltration in the lungs could cause infiltrates and hypoxia, leading to cyanosis.  
5. **Hepatic Involvement (Steatosis, Elevated Transaminases/GGT)**: Uncommon in Kimura disease but may result from systemic inflammation, drug effects, or concurrent conditions (e.g., eosinophilic liver infiltration).  
6. **Hypercholesterolemia and Elevated PTH**: Likely unrelated comorbidities, as these are not characteristic of Kimura disease.  

The diagnosis prioritizes Kimura disease based on pathognomonic features (lymphadenopathy, eosinophilia, elevated IgE), while acknowledging atypical symptoms as potential secondary effects or unrelated conditions."
"['Lethargy', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Anemia', 'Vomiting', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Hypocalcemia', 'Neonatal death', 'Abnormality of acid-base homeostasis', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic acidosis**: ""Abnormality of acid-base homeostasis"" and ""hypocalcemia"" align with PA-induced metabolic acidosis due to propionate accumulation.  
2. **Neurological symptoms**: ""Lethargy,"" ""coma,"" ""drowsiness,"" and ""sleep disturbance"" result from neurotoxicity of propionic acid and ammonia.  
3. **Hematologic abnormalities**: ""Thrombocytopenia"" and ""anemia"" stem from bone marrow suppression caused by toxic metabolites.  
4. **Neonatal fatality**: ""Death in infancy"" and ""neonatal death"" reflect PA’s severe, early-onset metabolic crises if untreated.  
5. **Gastrointestinal issues**: ""Vomiting"" and ""feeding difficulties"" arise from protein intolerance and metabolic decompensation.  
6. **Muscular involvement**: ""Generalized hypotonia"" links to energy deficiency in muscle cells due to disrupted mitochondrial function.  
7. **Biomarkers**: ""Elevated urinary carboxylic acids"" (e.g., 3-hydroxypropionate, methylcitrate) and ""abnormal glycine concentrations"" are hallmark biochemical features of PA.  
8. **Respiratory distress**: ""Dyspnea"" may reflect compensatory hyperventilation to counteract acidosis.  
9. **Porphyrin disruption**: ""Abnormal circulating porphyrins"" occur due to secondary inhibition of heme synthesis pathways by propionyl-CoA.  

PA is confirmed by enzyme assays (propionyl-CoA carboxylase deficiency) and genetic testing. Early intervention with dietary protein restriction and metabolic support is critical."
"['Delayed speech and language development', '4-Hydroxyphenylpyruvic aciduria', 'Elevated urinary delta-aminolevulinic acid', 'Hypertyrosinemia', 'Death in childhood', 'Abnormal circulating phenylalanine concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia I; hepatorenal tyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I  
Reasoning:  
1. **Hypertyrosinemia** directly indicates impaired tyrosine metabolism, a hallmark of tyrosinemia.  
2. **4-Hydroxyphenylpyruvic aciduria** arises from a block in tyrosine catabolism at fumarylacetoacetate hydrolase (FAH), causing upstream accumulation of toxic intermediates like 4-hydroxyphenylpyruvate (4-HPP).  
3. **Elevated urinary delta-aminolevulinic acid (ALA)** is due to inhibition of ALA dehydratase by succinylacetone, a toxic metabolite unique to Tyrosinemia I.  
4. **Abnormal circulating phenylalanine** may reflect secondary disruption of phenylalanine metabolism or assay interference from tyrosine metabolites.  
5. **Delayed speech/language development** aligns with neurotoxicity from succinylacetone and chronic liver/kidney dysfunction.  
6. **Death in childhood** correlates with untreated HT-1 progression to liver failure, renal Fanconi syndrome, or porphyria-like crises.  
The combination of hepatic, renal, and neurological involvement with specific biochemical markers confirms Tyrosinemia type I."
"['Delayed speech and language development', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Dehydration', 'Hyperammonemia', 'Hyperhomocystinemia', 'Drowsiness', 'Sleep disturbance', 'Methylmalonic acidemia', 'Decreased plasma free carnitine', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic aciduria, vitamin B12-responsive, cblB type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits hallmark biochemical features of methylmalonic acidemia (MMA), including **methylmalonic acidemia**, **methylmalonic aciduria**, and **decreased plasma free carnitine**. These findings result from impaired methylmalonyl-CoA mutase activity or cobalamin metabolism, leading to toxic accumulation of methylmalonic acid. Symptoms like **lethargy**, **generalized hypotonia**, **hyperammonemia**, and **dehydration** align with acute metabolic decompensation seen in MMA. **Death in infancy** and **delayed speech/development** reflect the severe, early-onset nature of untreated cases.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblB type  
Reasoning: The presence of **hyperhomocystinemia** alongside methylmalonic aciduria suggests a cobalamin (vitamin B12) metabolism defect. The cblB type specifically involves mutations in the *MMAB* gene, disrupting adenosylcobalamin synthesis, which is critical for methylmalonyl-CoA mutase function. While cblB typically spares methionine synthase (thus homocysteine is usually normal), **hyperhomocystinemia** here may indicate secondary folate cycle disruption or overlapping metabolic stress. The inclusion of **vitamin B12-responsive** in the diagnosis is supported by MMA cases showing partial biochemical improvement with B12 supplementation, a hallmark of cblB/cblA subtypes. Symptoms like **drowsiness** and **sleep disturbances** further correlate with chronic neurometabolic dysfunction in this subtype."
"['Abnormality of the dentition', 'Absent eyelashes', 'Abnormal sweat gland morphology', 'Absent eyebrow', 'Absent hair', 'Nail dystrophy', 'Onycholysis of fingernails']","['Ectodermal dysplasia 9, Hair/nail type']","Disease: Ectodermal dysplasia 9, Hair/nail type  
Reasoning: The patient presents with multisystemic ectodermal abnormalities, including **absent hair, eyelashes, and eyebrows** (indicative of severe hair follicle involvement), **nail dystrophy** and **onycholysis** (reflecting defective nail development), and **abnormality of the dentition** (common in ectodermal dysplasias). **Abnormal sweat gland morphology** further supports ectodermal origin. These findings align with **ECTD9**, a subtype caused by *HOXC13* mutations, characterized by congenital atrichia, nail dysplasia, and variable dental anomalies. The absence of severe sweating dysfunction distinguishes it from hypohidrotic ectodermal dysplasia, emphasizing the hair/nail predominance in this diagnosis."
"['Generalized hypotonia', 'Hepatosplenomegaly', 'Death in infancy', 'Thrombocytopenia', 'Decreased beta-glucocerebrosidase level', 'Decreased body weight', 'Congenital nonbullous ichthyosiform erythroderma']","['Fetal Gaucher disease/Gaucher disease, perinatal lethal']","Disease: Fetal Gaucher disease/Gaucher disease, perinatal lethal  
Reasoning:  
1. **Decreased beta-glucocerebrosidase level**: Directly confirms enzyme deficiency, the hallmark of Gaucher disease.  
2. **Hepatosplenomegaly**: Caused by glucocerebroside accumulation in liver/spleen macrophages (Gaucher cells).  
3. **Thrombocytopenia**: Results from bone marrow infiltration by Gaucher cells, impairing platelet production.  
4. **Congenital nonbullous ichthyosiform erythroderma**: Seen in severe perinatal forms due to skin barrier defects and lipid metabolism disruption.  
5. **Generalized hypotonia**: Reflects neurologic involvement typical of acute neuronopathic (Type 2) or perinatal lethal subtypes.  
6. **Decreased body weight & Death in infancy**: Consistent with rapid progression of the perinatal lethal variant, often fatal prenatally or within days post-birth.  
7. Exclusion of other lysosomal disorders (e.g., Niemann-Pick) by clinical and enzymatic findings solidifies the diagnosis."
"['Upslanted palpebral fissure', 'Hypotelorism', 'Global developmental delay', 'Joint stiffness', 'Pulmonic stenosis', 'Lumbar hyperlordosis', 'Short stature', 'Dysplastic pulmonary valve', 'Depressed nasal bridge', 'Short phalanx of finger', 'Cone-shaped epiphysis', 'Acromelia', 'Midface retrusion', 'Internal notch of the femoral head']",['Geleophysic dysplasia 2'],"Disease: Geleophysic dysplasia 2  
Reasoning:  
1. **Skeletal anomalies**: Acromelia (shortened limbs), short phalanges, cone-shaped epiphyses, joint stiffness, and lumbar hyperlordosis align with geleophysic dysplasia, a skeletal disorder characterized by progressive skeletal and joint abnormalities.  
2. **Facial features**: Upslanted palpebral fissures, depressed nasal bridge, midface retrusion, and hypotelorism are classic craniofacial traits of geleophysic dysplasia.  
3. **Cardiac involvement**: Pulmonic stenosis and dysplastic pulmonary valve are hallmark cardiovascular features of geleophysic dysplasia type 2, linked to *FBN1* mutations.  
4. **Growth and development**: Short stature and global developmental delay are consistent with systemic manifestations of the disorder.  
5. **Distinctive findings**: Internal notch of the femoral head is a rare but reported skeletal feature in geleophysic dysplasia.  
6. **Differentiation from type 1**: Absence of tracheal stenosis (common in type 1) and presence of *FBN1*-associated cardiac defects support type 2."
"['Delayed speech and language development', 'Jaundice', 'Generalized hypotonia', 'Vomiting', 'Bilateral tonic-clonic seizure', 'Feeding difficulties', 'Hypergalactosemia']",['Classic galactosemia/GALACTOSEMIA'],"Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** directly indicates impaired galactose metabolism, a hallmark of galactosemia.  
2. **Feeding difficulties, vomiting, and jaundice** are early-onset symptoms in neonates with classic galactosemia, caused by toxic accumulation of galactose metabolites (e.g., galactitol, galactose-1-phosphate) damaging the liver and gastrointestinal tract.  
3. **Generalized hypotonia** and **seizures** suggest neurological involvement from metabolite toxicity or hypoglycemia secondary to hepatic dysfunction.  
4. **Delayed speech/language development** aligns with long-term neurocognitive sequelae of untreated galactosemia.  
5. **Bilateral tonic-clonic seizures** may result from cerebral edema, metabolic derangements, or direct neurotoxicity.  
6. All symptoms collectively fit the GALT enzyme deficiency (classic galactosemia), which disrupts the Leloir pathway, necessitating immediate lactose/galactose restriction to prevent irreversible complications."
"['Brachycephaly', 'Preauricular skin tag', 'Strabismus', 'Proptosis', 'Nystagmus', 'Precocious puberty', 'Single transverse palmar crease', 'Wrist flexion contracture', 'Global developmental delay', 'Generalized hypotonia', 'Overlapping toe', 'Bilateral tonic-clonic seizure', 'EEG abnormality', 'Poor head control', 'Elbow flexion contracture', 'Myoclonic spasms', 'Deep palmar crease', 'Knee flexion contracture', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Infantile muscular hypotonia']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Neuromuscular Features**: Severe generalized and infantile hypotonia, poor head control, and flexion contractures (wrist, elbow, knee) align with TBCK’s hallmark neuromuscular involvement.  
2. **Developmental Delay**: Global developmental delay and intellectual disability are core features of TBCK-related syndromes.  
3. **Seizures**: Focal-onset, tonic-clonic, and myoclonic seizures with EEG abnormalities correlate with TBCK’s association with epilepsy.  
4. **Dysmorphic Facies**: Brachycephaly, proptosis, strabismus, nystagmus, and preauricular skin tag match characteristic craniofacial features.  
5. **Skeletal/Physical Anomalies**: Single transverse palmar crease, deep palmar crease, and overlapping toe reflect congenital malformations reported in TBCK cases.  
6. **Supportive Evidence**: TBCK mutations disrupt mTOR signaling, explaining neurodevelopmental and muscular pathology. While precocious puberty is atypical, phenotypic variability is recognized in this disorder.  
7. **Exclusion**: Symptoms collectively distinguish TBCK from mimics like Prader-Willi, Angelman, or Rett syndromes, which lack the full syndromic pattern."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline and hyperammonemia strongly suggest a urea cycle disorder. Citrullinemia is characterized by impaired conversion of citrulline to argininosuccinate due to argininosuccinate synthetase (ASS1) deficiency. This results in citrulline accumulation and toxic ammonia buildup. Neonatal death and infant mortality align with the severe, early-onset form of the disease.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: The specificity of ""classic"" citrullinemia (type I) directly correlates with ASS1 deficiency. Premature birth may reflect intrauterine metabolic stress, while hyperammonemia and neonatal death are hallmarks of acute neonatal-onset cases. Elevated citrulline levels (>1,000 µmol/L) are pathognomonic for this subtype, distinguishing it from other urea cycle disorders or citrullinemia type II (citrin deficiency)."
"['Skin rash', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Neurological Symptoms**: Seizures align with Canavan's progressive leukodystrophy causing neurological deterioration.  
2. **Metabolic Abnormalities**: Elevated N-acetylaspartic acid (NAA) due to ASPA deficiency explains ""abnormal circulating aspartate family amino acid concentration."" Secondary metabolic disruption may contribute to hyperammonemia and aminoaciduria.  
3. **Early Mortality**: Neonatal death or death in infancy is consistent with severe infantile-onset Canavan disease.  
4. **Glycine Irregularity**: Abnormal glycine levels could stem from secondary metabolic disturbances in amino acid homeostasis.  
5. **Skin Manifestations**: Erythematous lesions (plaques, macules, papules) are atypical for Canavan but may reflect concurrent conditions, misreported findings, or cutaneous reactions to metabolic stress.  
6. **Exclusion of Alternatives**: Symptoms lack hallmark features of urea cycle disorders (e.g., vomiting) or organic acidemias (e.g., specific organic acid elevations), reinforcing Canavan as the primary diagnosis."
"['Lethargy', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Hypoglycemia', 'Dehydration', 'Fever', 'Hyperammonemia', 'Abdominal pain', 'Hypothermia', 'Pneumonia', 'Hyperglycinemia', 'Drowsiness', 'Sleep disturbance', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormality of bone marrow cell morphology', 'Hypervalinemia', 'Hyperisoleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Fatigue', 'Body odor']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Metabolic Abnormalities**: Hyperammonemia, hyperglycinemia, hyperalaninemia, hypervalinemia, and hyperisoleucinemia suggest a defect in branched-chain amino acid (BCAA) metabolism. IVA specifically disrupts isovaleric acid breakdown due to isovaleryl-CoA dehydrogenase deficiency.  
2. **Acute Decompensation Symptoms**: Lethargy, hypoglycemia, dehydration, fever, hypothermia, and drowsiness align with metabolic crises caused by toxic isovaleric acid accumulation, triggering acidosis and energy depletion.  
3. **Hematological Dysfunction**: Thrombocytopenia, leukopenia, and abnormal bone marrow morphology result from bone marrow suppression by toxic metabolites.  
4. **Characteristic Odor**: ""Sweaty feet"" body odor is pathognomonic for IVA, caused by excess isovaleric acid excretion.  
5. **Early Mortality**: Neonatal death, infant/childhood/adolescent fatality reflects severe, untreated IVA progression to metabolic coma, infections (e.g., pneumonia), or organ failure.  
6. **Secondary Carnitine Dysregulation**: Abnormal carnitine levels occur as the body attempts to conjugate isovaleric acid for excretion.  
7. **Feeding Difficulties/Fatigue**: Common in neonates with metabolic stress due to poor feeding tolerance and energy deficits.  
8. **Recurrent Infections**: Immune dysfunction from metabolic instability increases susceptibility to infections like pneumonia.  

IVA is distinguished from other organic acidemias (e.g., propionic acidemia) by its unique biochemical profile (elevated isovalerylcarnitine) and odor. Confirmation requires urine organic acid analysis (elevated isovalerylglycine) and genetic testing."
"['Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Vomiting', 'Hepatomegaly', 'Tachypnea', 'Neonatal death']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Metabolic Acidosis**: A hallmark of urea cycle disorders (UCDs) due to hyperammonemia and secondary organ dysfunction.  
2. **Vomiting & Hepatomegaly**: Common in UCDs; hepatomegaly specifically linked to argininosuccinic aciduria due to liver involvement from toxic metabolite accumulation.  
3. **Tachypnea & Tachycardia**: Compensatory responses to metabolic acidosis and hyperammonemia-induced encephalopathy.  
4. **Neonatal Death/Infant Mortality**: Severe UCDs like argininosuccinic aciduria often present acutely in infancy with rapid deterioration if untreated.  
5. **Distinguishing from Other UCDs**: Elevated argininosuccinic acid in blood/urine (pathognomonic) and hepatomegaly differentiate it from ornithine transcarbamylase (OTC) deficiency.  
6. **Exclusion of Organic Acidemias**: Lack of pronounced ketosis and presence of hepatomegaly favor urea cycle dysfunction over organic acidemias.  
7. **Liver Dysfunction**: Contributes to metabolic acidosis via impaired ammonia detoxification and potential lactic acidosis.  

Conclusion: Symptom constellation aligns with argininosuccinic aciduria, confirmed by biochemical markers (argininosuccinic acid elevation) and clinical progression."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The symptoms of neonatal death, death in infancy, and abnormal circulating carnitine concentration align with MCADD, a fatty acid oxidation disorder. MCADD impairs the breakdown of medium-chain fatty acids, leading to energy deficits during fasting. Hypoglycemia and metabolic crises in infancy can result in sudden death. Abnormal carnitine levels occur due to secondary carnitine depletion from conjugation with accumulating toxic acyl-CoA intermediates. While prenatal abnormalities are less typical, severe metabolic stress in utero or delayed postnatal adaptation may contribute to complications. MCADD is a common cause of metabolic emergencies in neonates and is detectable via newborn screening (elevated C8-C10 acylcarnitines)."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU, caused by deficient phenylalanine hydroxylase (PAH), impairing phenylalanine (Phe) metabolism.  
2. **Abnormal circulating tyrosine concentration**: PAH deficiency reduces tyrosine synthesis, leading to low tyrosine levels (hypotyrosinemia), consistent with PKU.  
3. **Elevated urinary carboxylic acid**: Excess Phe is metabolized via alternative pathways, producing phenylketones (e.g., phenylpyruvate) excreted in urine.  
4. **Neonatal death/Death in infancy**: Untreated PKU causes severe metabolic derangements, neurological damage, and organ failure, often fatal without early dietary intervention.  
5. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies (e.g., microcephaly) in the fetus.  
6. **Obesity**: May arise from high-calorie, low-Phe dietary management or metabolic dysregulation secondary to chronic Phe imbalance.  
7. **Death in early adulthood**: Long-term complications (e.g., cardiovascular issues, neurological decline) in poorly managed cases or late-diagnosed patients.  

PKU aligns with the biochemical markers (hyperphenylalaninemia, tyrosine deficiency, urinary phenylketones) and clinical progression described, emphasizing untreated or severe disease."
"['Irritability', 'Hyperinsulinemia', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Thrombocytopenia', 'Abnormal bleeding', 'Hypoglycemia', 'Hyperammonemia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hyperalbuminemia']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
**Reasoning**:  
1. **Hypertyrosinemia, 4-Hydroxyphenylpyruvic aciduria, and Hyperphenylalaninemia**: These indicate a defect in tyrosine metabolism. Tyrosinemia type 1 (HT-1) results from fumarylacetoacetate hydrolase (FAH) deficiency, causing toxic accumulation of tyrosine and its metabolites (e.g., succinylacetone).  
2. **Liver Dysfunction**: Elevated alpha-fetoprotein (marker of hepatic damage/regeneration), hyperammonemia (impaired urea cycle), hypoglycemia (reduced gluconeogenesis), and hypermethioninemia (secondary to liver failure) align with HT-1’s hepatotoxic effects.  
3. **Coagulopathy**: Prolonged partial thromboplastin time, thrombocytopenia, and abnormal bleeding stem from impaired hepatic synthesis of clotting factors and possible platelet dysfunction.  
4. **Renal and Systemic Toxicity**: Succinylacetone damages renal tubules and inhibits porphobilinogen synthase, explaining abnormal porphyrin levels.  
5. **Early Mortality**: Neonatal death, death in infancy/childhood, and prenatal abnormalities reflect the severe, progressive nature of untreated HT-1.  
6. **Hyperinsulinemia**: May arise from stress-induced hypoglycemia or secondary metabolic dysregulation due to liver failure.  
7. **Elevated Alkaline Phosphatase**: Consistent with cholestatic liver injury, a common feature in HT-1.  

The constellation of liver failure, tyrosine pathway abnormalities, coagulopathy, and succinylacetone-mediated toxicity confirms Tyrosinemia type 1."
"['Seizure', 'Spasticity', 'Death in infancy', 'Hyperammonemia', 'Increased serum lactate', 'Tachypnea', 'Oroticaciduria', 'Neonatal death', 'Elevated circulating acylcarnitine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Core feature of urea cycle disorders like OTCD, caused by impaired ammonia detoxification due to deficient OTC enzyme.  
2. **Oroticaciduria**: Pathognomonic for OTCD; accumulation of carbamoyl phosphate shunts into pyrimidine synthesis, increasing orotic acid excretion.  
3. **Elevated serum lactate**: Secondary to mitochondrial dysfunction from hyperammonemia or respiratory chain inhibition.  
4. **Tachypnea**: Compensatory response to metabolic acidosis induced by hyperammonemia and lactic acidosis.  
5. **Seizures/Spasticity**: Neurotoxicity from ammonia crossing the blood-brain barrier, causing cerebral edema and neuronal excitation.  
6. **Elevated acylcarnitines**: May reflect secondary carnitine depletion or metabolic stress disrupting fatty acid oxidation.  
7. **Neonatal death/Death in infancy**: Severe OTCD typically presents catastrophically in males (X-linked) shortly after birth due to hyperammonemic crisis if untreated.  

The constellation of hyperammonemia, oroticaciduria, and neonatal demise strongly prioritizes OTCD over other urea cycle disorders or metabolic diseases."
"['Thin upper lip vermilion', 'Microcephaly', 'Low anterior hairline', 'Long philtrum', 'Synophrys', 'Delayed speech and language development', 'Intellectual disability, moderate', 'Depressed nasal bridge', 'Curly eyelashes', 'Postnatal growth retardation']",['Cornelia de Lange syndrome/Cornelia de Lange syndrome 1'],"Disease: Cornelia de Lange syndrome/Cornelia de Lange syndrome 1  
Reasoning:  
1. **Facial Features**: Thin upper lip vermilion, long philtrum, depressed nasal bridge, and synophrys (unibrow) are hallmark craniofacial features of Cornelia de Lange syndrome (CdLS).  
2. **Microcephaly and Growth Retardation**: Microcephaly and postnatal growth retardation align with CdLS-associated developmental abnormalities.  
3. **Neurodevelopmental Delays**: Moderate intellectual disability and delayed speech/language development are consistent with the syndrome’s cognitive profile.  
4. **Ancillary Features**: Low anterior hairline and curly eyelashes are supportive phenotypic clues frequently observed in CdLS.  
5. **Exclusion of Alternatives**: The constellation of symptoms (especially synophrys, distinct facial gestalt, and growth/neurodevelopmental patterns) is pathognomonic for CdLS, differentiating it from other syndromes with overlapping features (e.g., Rubinstein-Taybi, fetal alcohol spectrum disorders)."
"['Coma', 'Death in infancy', 'Sudden death', 'Hypoglycemia', 'Vomiting', 'Elevated circulating alkaline phosphatase concentration', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by mutations in the *SLC22A5* gene impairing carnitine transport.  
2. **Hypoglycemia** occurs due to defective fatty acid oxidation (FAO), forcing reliance on glucose metabolism and depleting glycogen stores, particularly during fasting or metabolic stress.  
3. **Sudden death in infancy** and **coma** result from metabolic crises triggered by hypoglycemia and hyperammonemia, exacerbated by the inability to utilize fatty acids for energy in critical tissues (e.g., heart, liver).  
4. **Elevated lactate dehydrogenase (LDH)** and **abnormal alanine/aspartate family amino acids** reflect secondary mitochondrial dysfunction and anaerobic glycolysis activation under energy-deficient states.  
5. **Vomiting** and **hepatic involvement** (elevated alkaline phosphatase) stem from hepatic steatosis and impaired hepatic FAO.  
6. PCD aligns with the acute metabolic decompensation pattern in infancy, distinguishing it from other FAO disorders (e.g., MCAD deficiency lacks carnitine deficiency). Genetic testing for *SLC22A5* variants would confirm the diagnosis."
"['Focal segmental glomerulosclerosis', 'Microcephaly', 'Hypertelorism', 'Low-set ears', 'Congenital diaphragmatic hernia', 'Hiatus hernia', 'Cerebral atrophy', 'Volvulus', 'Congenital nephrotic syndrome', 'Simplified gyral pattern']",['Galloway-Mowat syndrome 4'],"Disease: Galloway-Mowat syndrome 4  
Reasoning:  
1. **Congenital nephrotic syndrome** and **focal segmental glomerulosclerosis (FSGS)** indicate early-onset renal dysfunction, a hallmark of Galloway-Mowat syndrome (GAMOS).  
2. **Microcephaly**, **cerebral atrophy**, and **simplified gyral pattern** reflect severe neurodevelopmental abnormalities, consistent with GAMOS-associated brain malformations.  
3. **Hypertelorism** and **low-set ears** are dysmorphic facial features commonly linked to GAMOS.  
4. **Congenital diaphragmatic hernia** and **hiatus hernia** suggest connective tissue or developmental defects, reported in GAMOS subtypes.  
5. **Volvulus** aligns with gastrointestinal anomalies occasionally associated with GAMOS.  
6. The combination of renal, neurological, craniofacial, and diaphragmatic defects strongly supports **Galloway-Mowat syndrome 4** (GAMOS4), caused by biallelic *WDR73* mutations, which correlates with this multisystem phenotype."
"['Horseshoe kidney', 'Thick lower lip vermilion', 'Thick upper lip vermilion', 'Microcephaly', 'High forehead', 'Deeply set eye', 'Myopia', 'Upslanted palpebral fissure', 'Carious teeth', 'Dental malocclusion', 'Patent ductus arteriosus', 'Intellectual disability, moderate', 'Long nose', 'Low hanging columella', 'High anterior hairline', 'Short palpebral fissure']",['THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome/Beaulieu-Boycott-Innes syndrome'],"Disease: THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome/Beaulieu-Boycott-Innes syndrome  
Reasoning:  
1. **Microcephaly & Intellectual Disability**: Core features of the syndrome, aligning with the patient’s microcephaly and moderate intellectual disability.  
2. **Facial Dysmorphism**:  
   - **Thick Lips**: Thick upper/lower lip vermilion are hallmark facial features.  
   - **High Forehead/High Anterior Hairline**: Consistent with the syndrome’s craniofacial profile.  
   - **Long Nose & Low Hanging Columella**: Characteristic nasal features described in THOC6-related cases.  
   - **Deeply Set Eyes, Upslanted/Short Palpebral Fissures**: Ocular findings commonly reported.  
3. **Patent Ductus Arteriosus (PDA)**: Congenital heart defects, including PDA, are associated with the syndrome.  
4. **Horseshoe Kidney**: While less common, renal anomalies (e.g., horseshoe kidney) may occur in syndromic genetic disorders.  
5. **Dental/Ocular Features**: Dental malocclusion/carious teeth and myopia are secondary manifestations linked to craniofacial and developmental abnormalities.  
6. **Genetic Basis**: The constellation of symptoms strongly matches THOC6 gene mutation effects, which disrupt mRNA processing and neurodevelopment.  
**Exclusion**: Overlap with other syndromes (e.g., Cornelia de Lange) is ruled out by the specific combination of thick lips, long nose with low columella, and THOC6-associated cardiac/renal findings."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH), preventing phenylalanine conversion to tyrosine. This aligns with the symptom ""Hyperphenylalaninemia.""  
2. **Elevated Urinary Carboxylic Acids**: In PKU, excess phenylalanine is metabolized into phenylketones and other derivatives, which may include carboxylic acid byproducts excreted in urine.  
3. **Abnormality of Prenatal Development/Neonatal Death**: Untreated maternal PKU can cause fetal developmental issues (e.g., microcephaly, congenital heart defects) via intrauterine phenylalanine toxicity. Severe neonatal cases (rare in modern screening) could lead to early mortality.  
4. **Death in Infancy/Adolescence**: Historically, untreated PKU causes profound intellectual disability, seizures, and failure to thrive, potentially leading to early death. Modern newborn screening and dietary management prevent this.  
5. **Hypertyrosinemia Discrepancy**: Classic PKU typically results in **low/normal tyrosine** (due to blocked PAH activity). Hypertyrosinemia suggests a secondary issue (e.g., transient tyrosinemia in newborns, co-occurring liver dysfunction, or a BH4 cofactor deficiency, a PKU variant affecting multiple enzymes). This may indicate atypical PKU or comorbid conditions.  

**Conclusion**: The core diagnosis is PKU, supported by hyperphenylalaninemia and urinary anomalies. Hypertyrosinemia and severe outcomes suggest either a rare PKU subtype (e.g., BH4 deficiency) or additional metabolic disruptions requiring further investigation."
"['Short attention span', 'Thrombocytopenia', 'Schistocytosis', 'Postural instability', 'Vertigo', 'Elevated hepatic transaminase', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Exercise intolerance', 'Loss of consciousness', 'Reduced von Willebrand factor activity', 'Decreased glomerular filtration rate', 'Reduced haptoglobin level', 'Increased circulating lactate dehydrogenase concentration', 'Increased circulating procalcitonin concentration', 'Trigeminal neuralgia']","['Thrombotic thrombocytopenic purpura, hereditary', 'Thrombotic thrombocytopenic purpura']","Disease: Thrombotic thrombocytopenic purpura, hereditary  
Reasoning:  
1. **Thrombocytopenia** and **schistocytosis** are hallmark features of TTP, caused by microvascular thrombosis and mechanical red blood cell destruction.  
2. **Reduced haptoglobin** and **elevated LDH** confirm hemolysis, consistent with TTP.  
3. **Neurological symptoms** (postural instability, vertigo, loss of consciousness, trigeminal neuralgia) align with microthrombi-induced ischemia in the CNS.  
4. **Renal dysfunction** (elevated urea, creatinine, reduced GFR) reflects kidney microvascular injury.  
5. Hereditary TTP (Upshaw-Schulman syndrome) is suggested by **reduced von Willebrand factor (vWF) activity**, as congenital ADAMTS13 deficiency prevents cleavage of ultra-large vWF multimers, leading to platelet aggregation. However, this finding requires confirmation via ADAMTS13 activity testing (<10% without inhibitors).  

Disease: Thrombotic thrombocytopenic purpura  
Reasoning:  
1. The classic pentad of TTP (thrombocytopenia, hemolytic anemia, neurological symptoms, renal dysfunction, fever) is partially fulfilled, with fever implied by **elevated procalcitonin** (a nonspecific marker of inflammation/infection).  
2. **Schistocytosis**, **thrombocytopenia**, and hemolysis (LDH↑, haptoglobin↓) are diagnostic cornerstones.  
3. **Neurological and renal involvement** strongly support TTP over other thrombotic microangiopathies.  
4. Acquired TTP is more likely in adults, often triggered by autoantibodies against ADAMTS13. Elevated hepatic transaminases and procalcitonin may indicate an underlying infection or inflammatory trigger.  
5. Definitive diagnosis requires demonstrating severe ADAMTS13 deficiency (<10%) with detectable inhibitors.  

**Note**: Differentiation between hereditary and acquired TTP hinges on ADAMTS13 testing and inhibitor assays, which are not provided in the symptom list. Clinical context (age, recurrence, family history) would further refine the diagnosis."
"['Hemolytic anemia', 'Spherocytosis', 'Increased red cell osmotic fragility']","['Spherocytosis, type 4']","Disease: Spherocytosis, type 4 (Hereditary Spherocytosis type 4)  
Reasoning:  
1. **Hemolytic anemia**: Caused by premature destruction of spherical red blood cells (spherocytes) in the spleen due to membrane instability.  
2. **Spherocytosis**: Results from mutations in the *SPTB* gene, leading to beta-spectrin deficiency. This disrupts the erythrocyte cytoskeleton, reducing membrane stability and causing loss of surface area, forming spherocytes.  
3. **Increased red cell osmotic fragility**: Spherocytes have decreased surface-to-volume ratio, making them prone to lysis in hypotonic solutions. This confirms the membrane defect.  
4. **Type 4 specificity**: Beta-spectrin deficiency (type 4) is distinguished from other hereditary spherocytosis subtypes (e.g., ankyrin or band 3 mutations) by its genetic etiology and biochemical profile, though clinical overlap exists."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: Core feature of PKU due to deficient phenylalanine hydroxylase (PAH), causing phenylalanine accumulation.  
- **Elevated urinary carboxylic acids**: Reflects alternative phenylalanine metabolism (e.g., phenylpyruvate, phenyllactate), excreted as urinary metabolites.  
- **Abnormality of prenatal development**: Likely due to maternal PKU during pregnancy, exposing the fetus to toxic phenylalanine levels.  
- **Neonatal death/Death in infancy**: Severe untreated PKU can lead to metabolic crises, neurological damage, and failure to thrive without early dietary intervention.  
- **Death in early adulthood**: Untreated PKU causes chronic complications (e.g., intellectual disability, seizures, organ damage) reducing life expectancy.  
- **Hypertyrosinemia anomaly**: Unusual for PKU (typically low tyrosine), possibly a lab error, co-existing condition, or secondary tyrosine dysregulation in severe metabolic disruption.  

Note: Hypertyrosinemia may warrant investigation for co-occurring disorders (e.g., BH4 deficiency) but does not override PKU diagnosis given hallmark symptoms."
"['Intellectual disability', 'Lethargy', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **elevated plasma citrulline**: Core indicators of urea cycle dysfunction. While OTCD classically presents with *low citrulline*, partial enzyme activity or compensatory mechanisms (e.g., arginine supplementation) may explain citrulline elevation in some cases.  
2. **Oroticaciduria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, producing excess orotic acid.  
3. **Hyperglutaminemia** and **hyperalaninemia**: Glutamine acts as an ammonia buffer, while alanine transports nitrogen to the liver, both elevated due to ammonia toxicity.  
4. **Neonatal/childhood death, feeding difficulties, lethargy, drowsiness**: Reflect acute hyperammonemic crises, common in severe OTCD.  
5. **Recurrent viral infections**: Metabolic stress from hyperammonemia may impair immune function.  
6. **Abnormal arginine/aspartate family amino acids**: Disrupted urea cycle alters arginine synthesis and aspartate utilization.  
7. **Obesity and sleep disturbances**: Chronic metabolic derangements may contribute to these phenotypes.  

Note: Elevated citrulline is atypical for OTCD but does not exclude the diagnosis, as atypical presentations or confounding factors (e.g., treatment, coexisting conditions) may occur. The triad of hyperammonemia, oroticaciduria, and clinical progression aligns strongly with OTCD."
"['Death in infancy', 'Abnormal bleeding', 'Hyperammonemia', 'Vomiting', 'Oroticaciduria', 'Abnormality of the coagulation cascade']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency  
Reasoning:  
1. **Hyperammonemia** is a cardinal feature of urea cycle disorders (UCDs), specifically implicating OTCD as ornithine transcarbamylase (OTC) is critical for ammonia detoxification in the urea cycle.  
2. **Oroticaciduria** is pathognomonic for OTCD. The enzyme deficiency causes carbamoyl phosphate to divert into pyrimidine synthesis, overproducing orotic acid.  
3. **Vomiting** and **death in infancy** align with acute neonatal-onset OTCD, where hyperammonemic crises trigger neurological deterioration and multi-organ failure.  
4. **Abnormal bleeding/coagulation cascade abnormalities** arise from hyperammonemia-induced platelet dysfunction and potential secondary liver impairment (reduced clotting factor synthesis).  
5. Exclusion of other UCDs (e.g., CPS1 deficiency lacks oroticaciduria; arginase deficiency presents later). The symptom constellation is specific to OTCD."
"['Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Hypertyrosinemia**: Uncommon in classic PKU but may occur secondary to metabolic dysregulation or dietary mismanagement (e.g., unbalanced tyrosine intake).  
3. **Neonatal death/Death in infancy/adolescence**: Untreated PKU can cause severe neurological damage, seizures, and organ failure, potentially leading to early mortality without strict dietary intervention.  
4. **Obesity**: May arise from excessive calorie intake in low-phenylalanine diets or metabolic imbalances from prolonged poor disease control.  
5. **Exclusion of alternatives**: Tyrosinemia or other aminoacidurias were considered but ruled out due to the prominence of hyperphenylalaninemia and alignment with PKU pathophysiology.  

Note: Hypertyrosinemia and early death suggest atypical severity or comorbidities, but PKU remains the primary diagnosis based on hyperphenylalaninemia."
"['Hamartomatous polyposis', 'Oral melanotic macule', 'Labial melanotic macule']",['Peutz-Jeghers syndrome; PJS/Peutz-Jeghers syndrome/Peutz-Jeghers syndrome'],"Disease: Peutz-Jeghers syndrome (PJS)  
Reasoning:  
1. **Hamartomatous polyposis** is a hallmark of PJS, characterized by non-cancerous hamartomatous polyps in the gastrointestinal tract.  
2. **Oral and labial melanotic macules** (dark pigmented spots on the lips and oral mucosa) are pathognomonic mucocutaneous features of PJS.  
3. The triad of gastrointestinal polyposis, mucocutaneous pigmentation, and familial inheritance aligns definitively with PJS diagnosis.  
4. Other differentials (e.g., Cronkhite-Canada syndrome) lack the distinct melanotic macules or hamartomatous polyp subtype."
"['Ptosis', 'Ectopia lentis', 'Large hands', 'Intellectual disability', 'Motor delay', 'Long foot', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Death in childhood', 'Death in adolescence', 'Fatigue']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning: The patient exhibits **hyperhomocystinemia** and **hypermethioninemia**, biochemical hallmarks of homocystinuria. Symptoms like **ectopia lentis** (lens dislocation) and **ptosis** are classic ocular manifestations. **Intellectual disability** and **motor delay** align with neurological complications from toxic homocysteine accumulation. **Long foot** and **large hands** suggest Marfanoid habitus, a skeletal feature of this disorder. Early mortality (**death in childhood/adolescence**) reflects severe untreated metabolic dysfunction.  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: This subtype is confirmed by **hypermethioninemia**, as cystathionine beta-synthase (CBS) deficiency impairs homocysteine-to-cystathionine conversion, causing methionine buildup. **Ectopia lentis** and skeletal abnormalities are pathognomonic for CBS-deficient homocystinuria. **Fatigue** may stem from metabolic stress, while early death underscores disease severity without intervention (e.g., pyridoxine responsiveness or dietary methionine restriction). The absence of cystathionine beta-synthase activity directly links to this diagnosis."
"['Oral ulcer', 'Sinusitis', 'Tinnitus', 'Hearing impairment', 'Visual loss', 'Diplopia', 'Nephrolithiasis', 'Hematuria', 'Keratoconjunctivitis sicca', 'Abnormality of the hand', 'Syncope', 'Arthritis', 'Eosinophilia', 'Renal tubular acidosis', 'Nausea', 'Abdominal pain', 'Hypercalciuria', 'Headache', 'Vertigo', 'Bone pain', 'Exertional dyspnea', 'Elevated circulating creatine kinase concentration', 'Myalgia', 'Paresthesia', 'Back pain', 'Somatic sensory dysfunction', 'Hypouricemia', 'Deviated nasal septum', 'Generalized morning stiffness', 'Limb pain', 'Decreased urinary urate', 'Fatigue', 'Mild proteinuria', 'Oral cavity bleeding', 'Neck pain', 'Wrist pain', 'Ankle pain', 'Aphthous ulcer', 'Chest pain', 'Lymphocytosis', 'Papule', 'Pustule', 'Epigastric pain']",['Behçet disease/Behcet syndrome'],"Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: Recurrent oral ulcers (""Oral ulcer,"" ""Aphthous ulcer"") and genital ulcers (implied by Behçet’s diagnostic criteria) are hallmark features. ""Oral cavity bleeding"" aligns with ulcerative mucosal damage. Skin lesions (""Papule,"" ""Pustule"") correlate with Behçet’s papulopustular eruptions.  
2. **Ocular Manifestations**: ""Visual loss"" and ""Diplopia"" suggest posterior uveitis, retinal vasculitis, or optic neuritis, common in Behçet’s. ""Keratoconjunctivitis sicca"" may indicate secondary dryness from inflammation.  
3. **Neurological Involvement**: ""Headache,"" ""Vertigo,"" ""Syncope,"" ""Paresthesia,"" and ""Somatic sensory dysfunction"" point to neuro-Behçet’s, which can cause meningoencephalitis or vascular CNS lesions.  
4. **Musculoskeletal Symptoms**: ""Arthritis,"" ""Wrist pain,"" ""Ankle pain,"" and ""Generalized morning stiffness"" reflect Behçet’s-associated non-erosive oligoarthritis.  
5. **Vascular Inflammation**: ""Chest pain"" may indicate pericarditis or vasculitis. ""Exertional dyspnea"" could stem from pulmonary artery aneurysms, a rare but severe Behçet’s complication.  
6. **Gastrointestinal Involvement**: ""Abdominal pain,"" ""Nausea,"" and ""Epigastric pain"" align with intestinal ulcers, a mimic of Crohn’s disease in Behçet’s.  
7. **Atypical Associations**: While ""Renal tubular acidosis"" and ""Hypercalciuria"" are uncommon in Behçet’s, secondary autoimmune tubulointerstitial nephritis or overlapping syndromes could explain these.  
8. **Inflammatory Markers**: ""Eosinophilia"" and ""Lymphocytosis"" suggest systemic inflammation, consistent with Behçet’s flares.  

**Key Exclusions**:  
- Sjögren’s syndrome (keratoconjunctivitis sicca) is less likely without anti-SSA/SSB antibodies or prominent sicca symptoms.  
- Sarcoidosis (hypercalciuria, lymphocytosis) lacks typical granulomas or hilar adenopathy here.  
- Vasculitides like GPA (sinusitis, renal issues) are excluded by the absence of ANCA or necrotizing glomerulonephritis.  

**Conclusion**: The constellation of mucocutaneous, ocular, neurological, and vascular symptoms strongly supports Behçet’s syndrome, despite atypical renal findings. Further evaluation with pathergy testing, HLA-B51 testing, and imaging (e.g., angiography for vasculitis) would solidify the diagnosis."
"['Intellectual disability', 'Global developmental delay', 'Generalized hypotonia', 'Abnormal facial shape', 'Delayed skeletal maturation']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Intellectual disability and global developmental delay** align with TBCK syndrome’s hallmark neurodevelopmental impairments caused by TBC1 domain-containing kinase (TBCK) gene mutations.  
2. **Generalized hypotonia** is a core feature of this disorder, reflecting neuromuscular dysfunction.  
3. **Abnormal facial shape** corresponds to characteristic facies (e.g., coarse features, hypertelorism, broad nasal tip) linked to TBCK syndrome.  
4. **Delayed skeletal maturation** matches reported skeletal anomalies, including bone age delay and scoliosis.  
5. The absence of seizures or progressive neurodegeneration (common in other hypotonia-linked disorders) supports TBCK syndrome, which is typically non-degenerative.  
6. Genetic testing for TBCK mutations would confirm the diagnosis."
"['Microcephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Anemia', 'Elevated circulating alkaline phosphatase concentration', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Feeding difficulties', 'Hypergalactosemia', 'Decreased circulating ferritin concentration', 'Decreased serum iron']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** directly indicate impaired galactose processing, a hallmark of galactosemia.  
2. **Feeding difficulties**, **generalized hypotonia**, **motor delay**, and **intellectual disability** align with metabolic dysfunction and neurological sequelae caused by toxic galactose metabolite accumulation.  
3. **Elevated alkaline phosphatase** and **anemia** suggest liver damage and hematopoietic disruption, common in untreated galactosemia due to galactitol toxicity.  
4. **Decreased serum iron/ferritin** may reflect secondary iron deficiency from malabsorption or chronic illness.  
5. **Abnormal porphyrin levels** could arise from hepatic dysfunction impairing heme synthesis.  
6. **Prenatal abnormalities**, **microcephaly**, and early mortality (**neonatal/infant/childhood death**) correlate with severe metabolic crises in classic galactosemia when galactose exposure begins in utero or postnatally.  
7. **Obesity** is atypical but reported in survivors with long-term metabolic complications.  

Disease: Galactosemia/GAL  
Reasoning:  
- This broader diagnosis encompasses the same pathophysiology as classic galactosemia, with overlapping symptoms (e.g., **hypergalactosemia**, **feeding difficulties**, **hepatic/neurologic involvement**) but allows for phenotypic variability.  
- The specificity of **abnormality of galactoside metabolism** and exclusion of other metabolic disorders (e.g., tyrosinemia) confirm galactosemia as the unifying diagnosis."
"['Hepatosplenomegaly', 'Lymphadenopathy', 'Abnormal immunoglobulin level', 'Reduced granulocyte CD18 level']","['Leukocyte adhesion deficiency, type III', 'Leukocyte adhesion deficiency type III']","Disease: Leukocyte adhesion deficiency type III  
Reasoning:  
1. **Hepatosplenomegaly and Lymphadenopathy**: These suggest systemic immune dysregulation or chronic infections, which align with LAD III's broader integrin dysfunction affecting leukocyte migration and lymphoid organ involvement.  
2. **Abnormal Immunoglobulin Levels**: Indicates B-cell dysfunction or dysregulated antibody production, consistent with LAD III's impact on integrin-mediated immune cell interactions beyond neutrophils (e.g., T/B-cell defects).  
3. **Reduced Granulocyte CD18**: While classically linked to LAD I, LAD III involves defective integrin *activation* (via FERMT3 mutations) rather than absent CD18. Reduced surface CD18 here may reflect impaired integrin stabilization or secondary downregulation due to chronic inflammation.  
4. **Differentiation from LAD I**: LAD I typically presents with severe bacterial infections and leukocytosis without prominent lymphoid enlargement. LAD III’s platelet dysfunction (not explicitly listed) and immune dysregulation better explain hepatosplenomegaly/lymphadenopathy in this context.  

Disease: Leukocyte adhesion deficiency, type III  
Reasoning:  
- Reiterates the above, emphasizing the genetic basis (FERMT3 mutation) and multifactorial integrin activation defects affecting granulocytes, lymphocytes, and platelets, leading to the observed clinical and laboratory phenotype."
"['Jaundice', 'Seizure', 'Global developmental delay', 'Periportal fibrosis', 'Failure to thrive in infancy', 'Abnormal bleeding', 'Fever', 'Vomiting', 'Hypertriglyceridemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Hypercholesterolemia', 'Abdominal distention', 'Short stature']",['Glycogen storage disease due to liver glycogen phosphorylase deficiency/Glycogen storage disease VI'],"Disease: Glycogen storage disease due to liver glycogen phosphorylase deficiency/Glycogen storage disease VI  
Reasoning:  
1. **Hepatomegaly and elevated hepatic transaminases**: Central to GSD VI, as phosphorylase deficiency causes glycogen accumulation in the liver, leading to enlargement and liver dysfunction.  
2. **Failure to thrive in infancy and short stature**: Impaired glucose mobilization from glycogen results in metabolic stress, affecting growth.  
3. **Hypertriglyceridemia and hypercholesterolemia**: Secondary metabolic disturbances due to disrupted hepatic glucose/lipid homeostasis.  
4. **Periportal fibrosis and jaundice**: Chronic liver injury from glycogen overload progresses to fibrosis, impairing bile flow and causing jaundice.  
5. **Abdominal distention**: Direct consequence of hepatomegaly.  
6. **Seizures and abnormal bleeding**: Hypoglycemia (from glycogenolysis defects) may trigger seizures; reduced hepatic synthesis of clotting factors contributes to bleeding.  
7. **Global developmental delay**: Chronic metabolic instability and growth failure impact neurodevelopment.  
8. **Fever/vomiting**: Non-specific but may reflect metabolic stress or intercurrent illness exacerbating baseline pathology.  
**Exclusion of other GSDs**: Absence of severe hypoglycemia (more typical in GSD I), muscle involvement (GSD III/V), or lactic acidosis narrows the diagnosis to GSD VI."
"['Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Micrognathia', ""Widow's peak"", 'Posteriorly rotated ears', 'Hearing impairment', 'Low-set, posteriorly rotated ears', 'Sensorineural hearing impairment', 'Bulbous nose', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Motor delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Duodenal atresia', 'Tetraparesis', 'Incoordination', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Attention deficit hyperactivity disorder', 'Broad eyebrow', 'Abnormality of fontanelles', 'Feeding difficulties', 'Head-banging', 'Nail-biting', 'Thick vermilion border', 'Narrow palpebral fissure', 'Small hand', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental Core Features**:  
   - Global developmental delay, motor delay, absent speech, and hypotonia align with central neurodevelopmental impairments.  
   - Seizures, hyperactivity, ADHD, and atypical behavior (e.g., head-banging) further support neurological dysfunction.  

2. **Ocular Anomalies**:  
   - Structural eye defects (coloboma, microphthalmia, Peters anomaly, optic atrophy) are hallmark features of NEDBEH.  
   - Additional findings (blepharophimosis, downslanted palpebral fissures, deeply set eyes) reinforce craniofacial involvement.  

3. **Cardiac Defects**:  
   - Ventricular septal defect, patent ductus arteriosus, and abnormal cardiac septum morphology match the ""heart"" criterion in NEDBEH.  

4. **Craniofacial Dysmorphism**:  
   - Microcephaly/macrocephaly (variable expressivity), frontal bossing, narrow mouth, high palate, micrognathia, and cleft lip are consistent with syndromic facial features.  

5. **Supportive Systemic Features**:  
   - Musculoskeletal anomalies (syndactyly, scoliosis, hip dysplasia) and growth abnormalities (intrauterine growth retardation, short/tall stature) reflect broad developmental disruption.  
   - Gastrointestinal issues (pyloric stenosis, annular pancreas) and renal cysts may represent variable systemic involvement.  

6. **Genetic Overlap**:  
   - Overlapping features (sensorineural hearing loss, café-au-lait spots) suggest genetic heterogeneity but do not exclude NEDBEH, which encompasses phenotypic variability.  

**Conclusion**: The constellation of neurodevelopmental delays, structural eye/heart defects, and multisystem anomalies strongly aligns with NEDBEH, a genetically heterogeneous disorder often linked to de novo variants in genes like *BRPF1* or *UBR1*."
"['Ataxia', 'Spasticity', 'Death in infancy', 'Fever', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Elevated glutaric acid in urine is a hallmark of GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Ataxia & Spasticity**: GA-I damages the basal ganglia and white matter, leading to dystonia, spasticity, and impaired coordination.  
3. **Fever-triggered crises**: Metabolic decompensation during infections/fever exacerbates symptoms due to increased catabolism and toxin accumulation.  
4. **Death in infancy**: Untreated GA-I often causes severe neurological damage, metabolic strokes, or respiratory failure in early childhood.  
5. **Consistency with presentation**: The triad of neurodevelopmental regression, organic aciduria, and acute crises aligns with GA-I’s clinical profile. Early diagnosis via newborn screening (elevated C5DC) and treatment (lysine-restricted diet, carnitine) can improve outcomes."
"['Hyperreflexia', 'Lower limb spasticity', 'Spastic ataxia', 'Diffuse cerebral atrophy', 'Ankle clonus']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Hyperreflexia** and **ankle clonus** indicate upper motor neuron dysfunction, consistent with hereditary spastic paraplegias (HSPs).  
2. **Lower limb spasticity** is a hallmark of HSPs, reflecting corticospinal tract degeneration.  
3. **Spastic ataxia** suggests combined pyramidal (spasticity) and cerebellar (ataxia) involvement, aligning with SPG76’s phenotypic overlap between HSP and spinocerebellar ataxia.  
4. **Diffuse cerebral atrophy** supports a complex HSP subtype, as SPG76 (linked to *CAPN1* mutations) often involves cerebellar and cerebral degeneration.  
5. Autosomal recessive inheritance matches SPG76’s genetic pattern, distinguishing it from dominant HSPs or other ataxias with similar features (e.g., SPG11/SPG15 may also show atrophy but typically include additional manifestations like neuropathy or retinopathy).  
6. Symptom triad (spasticity, ataxia, cerebral atrophy) and exclusion of mimics confirm SPG76."
"['Seizure', 'Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning: The combination of abnormal circulating concentrations of branched-chain amino acids (leucine, isoleucine, valine), aminoaciduria, and severe neonatal symptoms (seizures, death in infancy/neonatal period) strongly suggests MSUD. This autosomal recessive disorder results from a deficiency in the branched-chain alpha-keto acid dehydrogenase complex, impairing BCAA catabolism. Accumulation of BCAAs and their toxic keto-acid derivatives leads to metabolic decompensation, neurotoxicity (seizures), and rapid progression to lethality in untreated classic MSUD. Aminoaciduria reflects renal excretion of excess BCAAs, consistent with the biochemical profile."
"['Abnormality of eye movement', 'Seizure', 'Global developmental delay', 'Aplasia/Hypoplasia of the cerebellum', 'Reduced visual acuity']",['Joubert syndrome 30'],"Disease: Joubert syndrome 30  
Reasoning:  
1. **Aplasia/Hypoplasia of the cerebellum**: Joubert syndrome is defined by cerebellar vermis hypoplasia/aplasia, classically presenting with the ""molar tooth sign"" on neuroimaging, aligning with this symptom.  
2. **Abnormality of eye movement**: Oculomotor apraxia and nystagmus are hallmark features of Joubert syndrome due to cerebellar and midbrain malformations.  
3. **Global developmental delay**: Neurodevelopmental delays are universal in Joubert syndrome, reflecting disrupted cerebellar and brainstem function.  
4. **Seizure**: While not present in all subtypes, seizures occur in some Joubert syndrome cases, including those linked to *CPLANE1* mutations (JBTS30).  
5. **Reduced visual acuity**: Retinal dystrophy or optic nerve colobomas, common in Joubert syndrome subtypes, explain visual impairment.  
6. **Subtype specificity**: JBTS30 (linked to *CPLANE1*) is associated with cerebellar, ocular, and occasional renal/limb anomalies, fitting the clinical profile without contradicting features."
"['Osteoporosis', 'Generalized hypotonia', 'Obesity', 'Abnormal foot morphology', 'Leukopenia', 'Hyperammonemia', 'Hyperglycinemia', 'Clumsiness', 'Poor coordination', 'Hyperalaninemia', 'Severe short stature', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Hyperleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Death in early adulthood']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: PA disrupts propionyl-CoA carboxylase, impairing amino acid catabolism (isoleucine, valine), leading to toxic metabolite accumulation that inhibits the urea cycle (causing hyperammonemia) and secondary glycine elevation.  
2. **Abnormal Amino Acid Concentrations (Hyperleucinemia, Hyperalaninemia)**: Branched-chain amino acid metabolism defects result in elevated leucine and alanine due to blocked degradation pathways.  
3. **Abnormal Carnitine Levels**: Propionyl-CoA conjugates with carnitine for excretion, depleting free carnitine and causing deficiency.  
4. **Leukopenia**: Toxic metabolites (e.g., propionic acid) suppress bone marrow function, reducing white blood cell production.  
5. **Gastrointestinal Inflammation & Failure to Thrive**: Chronic metabolic acidosis and toxin buildup lead to feeding intolerance, vomiting, and malnutrition, contributing to severe short stature.  
6. **Neurological Symptoms (Hypotonia, Clumsiness, Hearing Loss)**: Metabolic crises damage the basal ganglia and nervous system, causing hypotonia, poor coordination, and sensorineural hearing impairment.  
7. **Osteoporosis**: Chronic acidosis leaches calcium from bones, weakening skeletal structure.  
8. **Early Mortality (Childhood/Adolescence/Adulthood)**: Severe metabolic decompensation episodes, cardiomyopathy, or infections result in progressive organ failure and reduced lifespan.  
9. **Abnormal Porphyrins & Aspartate Family Amino Acids**: Secondary disruption of heme synthesis and aspartate metabolism due to enzyme dysfunction and mitochondrial toxicity.  

PA’s hallmark triad of metabolic acidosis, hyperammonemia, and multisystem involvement aligns with the patient’s symptoms, confirming the diagnosis."
"['Abnormal vagina morphology', 'Oral ulcer', 'Xerostomia', 'Keratoconjunctivitis sicca', 'Abnormal finger morphology', 'Diarrhea', 'Abdominal pain', 'Hepatomegaly', 'Headache', 'Abnormality of the lower limb', 'Arthralgia', 'Neoplasm of the liver', 'Hypercholesterolemia', 'Low alkaline phosphatase', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Cachexia', 'Gastritis', 'Focal white matter lesions', 'Uterine neoplasm', 'Abnormal circulating protein concentration', 'Lower limb pain', 'Dysesthesia', 'Autoimmune antibody positivity', 'Oral cavity bleeding', 'Night sweats', 'obsolete Abnormal fecal test result', 'Esophagitis', 'Abnormality of nail color']",['Primary Sjögren syndrome/Sjogren syndrome'],"Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning:  
1. **Key diagnostic criteria**: Keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth) are hallmark features of Sjögren syndrome, reflecting exocrine gland dysfunction.  
2. **Autoimmune evidence**: Autoimmune antibody positivity (e.g., anti-SSA/Ro or anti-SSB/La) supports an autoimmune etiology, a core component of Sjögren syndrome.  
3. **Systemic involvement**:  
   - **Mucocutaneous**: Oral ulcers and oral cavity bleeding may arise from mucosal dryness and inflammation.  
   - **Gastrointestinal**: Gastritis, esophagitis, and abdominal pain align with dysmotility or autoimmune-mediated mucosal injury.  
   - **Neurological**: Somatic sensory dysfunction, dysesthesia, and focal white matter lesions suggest peripheral/CNS involvement, recognized in Sjögren-related neuropathy or vasculitis.  
   - **Musculoskeletal**: Arthralgia and lower limb pain reflect common inflammatory joint manifestations.  
4. **Lymphoproliferative risk**: Neoplasm of the liver (possibly lymphoma) and uterine neoplasm, alongside night sweats and cachexia, raise suspicion for Sjögren-associated B-cell lymphoma, a known severe complication.  
5. **Laboratory anomalies**: Abnormal circulating protein concentration (e.g., hypergammaglobulinemia) and low alkaline phosphatase (potential cholestatic liver involvement) fit with chronic autoimmune activity.  
6. **Exclusion of overlap syndromes**: While symptoms like abnormal nail color or hepatomegaly could suggest other conditions (e.g., scleroderma or autoimmune hepatitis), the constellation of sicca symptoms, autoantibodies, and systemic features prioritizes Primary Sjögren syndrome as the unifying diagnosis.  

Note: Further evaluation (e.g., salivary gland biopsy, lymphoma workup) is critical to confirm and assess disease severity."
"['Growth delay', 'Small for gestational age', 'Polyhydramnios', 'Abdominal distention', 'Secretory diarrhea', 'Hyponatriuria', 'Acidemia', 'Elevated fecal sodium', 'Reduced fecal osmolality']","['Diarrhea 8, secretory sodium, congenital']","Disease: Diarrhea 8, secretory sodium, congenital (SSCD8)  
Reasoning:  
1. **Secretory Diarrhea**: Persistent, watery diarrhea from birth, continuing despite fasting, aligns with the defining feature of SSCD8.  
2. **Elevated Fecal Sodium & Reduced Fecal Osmolality**: Impaired intestinal sodium absorption (due to SLC9A3 mutations) causes high fecal sodium. Reduced osmolality reflects electrolyte-driven fluid loss without osmotic gap.  
3. **Hyponatriuria**: Compensatory renal sodium retention to counter fecal losses, reducing urinary sodium excretion.  
4. **Acidemia**: Bicarbonate loss in stool leads to metabolic acidosis.  
5. **Growth Delay & Small for Gestational Age (SGA)**: Chronic malnutrition from unrelenting diarrhea and electrolyte imbalances.  
6. **Polyhydramnios**: Fetal diarrhea in utero reduces intestinal fluid absorption, increasing amniotic fluid volume.  
7. **Abdominal Distention**: Secondary to fluid retention and intestinal dysfunction.  
8. **Exclusion of Alternatives**: Elevated fecal sodium distinguishes SSCD8 from congenital chloride diarrhea (high fecal chloride) or osmotic diarrheas (e.g., disaccharidase deficiencies)."
"['Abnormality of visual evoked potentials', 'Decreased nerve conduction velocity', 'Pes cavus', 'Gait ataxia', 'Limb ataxia', 'Progressive cerebellar ataxia', 'Positive Romberg sign', 'Paresthesia', 'Somatic sensory dysfunction', 'Decreased amplitude of sensory action potentials', 'Sensorimotor neuropathy', 'Distal lower limb muscle weakness', 'Abnormal cranial nerve physiology', 'Cognitive impairment']","['Charcot-Marie-Tooth disease type 1C', 'Charcot-Marie-Tooth disease, demyelinating, type 1C']","Charcot-Marie-Tooth disease type 1C:  
The patient exhibits classic features of a demyelinating hereditary neuropathy, including **decreased nerve conduction velocity** (a hallmark of CMT1 subtypes) and **sensorimotor neuropathy**. **Pes cavus**, **distal lower limb muscle weakness**, and **somatic sensory dysfunction** align with progressive peripheral nerve damage. **Decreased amplitude of sensory action potentials** suggests secondary axonal degeneration, common in advanced demyelinating neuropathies. **Gait ataxia**, **limb ataxia**, and **positive Romberg sign** are likely due to severe proprioceptive loss (sensory ataxia) from sensory neuropathy rather than cerebellar dysfunction. While **cognitive impairment** and **abnormal cranial nerve physiology** are atypical for CMT, they may represent comorbidities or phenotypic variability. **Progressive cerebellar ataxia** could be misattributed to profound sensory deficits. The diagnosis is strongly supported by demyelinating electrophysiology (slow conduction velocities) and structural abnormalities (pes cavus), consistent with CMT1C linked to *LITAF* mutations."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Delayed speech and language development**: Untreated PKU causes neurotoxicity from elevated phenylalanine, impairing cognitive and language development.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies, though neonatal PKU itself may present with nonspecific metabolic instability.  
4. **Hypertyrosinemia**: Secondary tyrosine elevation is atypical in classic PKU but may occur transiently due to metabolic dysregulation or overlap with other tyrosine metabolism disorders (e.g., tyrosinemia type II), though PKU remains primary here.  
5. **Early mortality (infancy/childhood/adulthood)**: Untreated PKU leads to severe neurological deterioration, seizures, and organ damage, historically causing premature death. Neonatal death is rare unless compounded by acute metabolic crises or misdiagnosis.  

**Conclusion**: Symptoms align with severe, untreated PKU, exacerbated by delayed diagnosis or lack of dietary management. Hypertyrosinemia may indicate a complex metabolic interplay but does not override the primary PKU diagnosis."
"['Hypoplastic labia majora', 'Brachycephaly', 'Microcephaly', 'Short philtrum', 'Narrow forehead', 'Cupped ear', 'Broad nasal tip', 'Anteverted nares', 'Microcornea', 'Deeply set eye', 'Long eyelashes', 'Esotropia', 'Thick eyebrow', 'Synophrys', '11 pairs of ribs', 'Osteopenia', 'Global developmental delay', 'Intrauterine growth retardation', 'Patent ductus arteriosus', 'Short columella', 'Gastroesophageal reflux', 'Recurrent respiratory infections', 'Highly arched eyebrow', 'Short nose', 'Clinodactyly of the 5th finger', '2-3 toe cutaneous syndactyly', 'Attached earlobe', 'Midface retrusion']","['CTCF-related neurodevelopmental disorder/Intellectual developmental disorder, autosomal dominant 21']","Disease: CTCF-related neurodevelopmental disorder/Intellectual developmental disorder, autosomal dominant 21 (MRD21)  
Reasoning:  
1. **Craniofacial features**: Microcephaly, brachycephaly, narrow forehead, midface retrusion, short nose, broad nasal tip, anteverted nares, short philtrum, deeply set eyes, synophrys, thick eyebrows, long eyelashes, and cupped ears align with the characteristic facial dysmorphism of MRD21.  
2. **Ocular findings**: Microcornea and esotropia are consistent with ocular anomalies reported in CTCF-related disorders.  
3. **Skeletal anomalies**: 11 pairs of ribs (hypoplastic ribs), clinodactyly of the 5th finger, 2-3 toe syndactyly, and osteopenia correlate with skeletal manifestations of MRD21.  
4. **Neurodevelopmental/Growth issues**: Global developmental delay, intrauterine growth retardation (IUGR), and gastroesophageal reflux reflect the neurodevelopmental and systemic growth deficits central to this disorder.  
5. **Cardiac and systemic involvement**: Patent ductus arteriosus (PDA) and recurrent respiratory infections are common in MRD21 due to connective tissue and immune dysregulation.  
6. **Genetic consistency**: CTCF haploinsufficiency disrupts chromatin organization, explaining multisystem involvement (craniofacial, skeletal, neurological) observed here. Overlapping features with reported MRD21 cases confirm the diagnosis."
"['Petechiae', 'Seizure', 'Lethargy', 'Generalized hypotonia', 'Reduced tendon reflexes', 'Death in infancy', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Skeletal muscle atrophy', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Aplasia/Hypoplasia involving the musculature of the extremities']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Cytochrome C oxidase (COX)-negative muscle fibers**: A hallmark of complex IV deficiency, directly implicating dysfunction in mitochondrial respiratory chain complex IV.  
2. **Increased serum lactate and ethylmalonic aciduria**: Reflects impaired oxidative phosphorylation, leading to anaerobic metabolism and accumulation of toxic metabolites due to defective fatty acid/amino acid oxidation.  
3. **Neurological symptoms (seizures, lethargy, drowsiness)**: Result from energy deprivation in the brain, a high-energy-demand organ vulnerable to mitochondrial dysfunction.  
4. **Muscular involvement (hypotonia, reduced reflexes, atrophy, extremity musculature hypoplasia)**: Caused by deficient ATP production in skeletal muscle, leading to weakness, atrophy, and developmental defects.  
5. **Glutaric aciduria**: May arise secondary to disrupted mitochondrial metabolism, affecting organic acid pathways.  
6. **Death in infancy**: Consistent with severe infantile-onset forms of mitochondrial disorders due to multisystem energy failure.  
7. **Nuclear type 1 classification**: Indicates an autosomal recessive mutation (e.g., *SURF1* gene) affecting complex IV assembly, distinguishing it from mitochondrial DNA-related defects.  

This constellation of metabolic, muscular, and neurological findings, anchored by COX-negative fibers and elevated lactate/ethylmalonic acid, confirms the diagnosis."
"['Irritability', 'Hypertonia', 'Generalized hypotonia', 'Hyperreflexia', 'Fever', 'Recurrent pneumonia']",['Krabbe disease'],"Disease: Krabbe disease  
Reasoning:  
1. **Neurological symptoms** (hypertonia, hyperreflexia, irritability) suggest demyelination, a hallmark of Krabbe disease caused by galactocerebrosidase deficiency.  
2. **Generalized hypotonia** may reflect peripheral neuropathy due to psychosine toxicity, a feature seen in early-infantile Krabbe disease.  
3. **Recurrent pneumonia** aligns with bulbar dysfunction or aspiration risk from impaired swallowing/airway control.  
4. **Fever** is atypical in Krabbe but could stem from secondary infections (e.g., pneumonia) or autonomic dysregulation.  
5. Symptom progression (irritability → spasticity → hypotonia) matches the classic trajectory of infantile-onset Krabbe.  
6. **Combined UMN/LMN signs** (hyperreflexia + hypotonia) point to a neurodegenerative disorder affecting both central and peripheral nervous systems."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormality of urine homeostasis', 'Neonatal death', 'Death in childhood']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Delayed speech and language development**: Biotinidase deficiency causes neurological impairments, including developmental delays, due to disrupted biotin-dependent carboxylase activity, affecting myelination and neurotransmitter synthesis.  
2. **Abnormality of prenatal development or birth**: While BTDD is typically postnatal in presentation, severe metabolic instability from untreated disease may manifest as perinatal complications or nonspecific congenital anomalies.  
3. **Death in infancy/Neonatal death/Death in childhood**: Untreated BTDD leads to progressive metabolic acidosis, hyperammonemia, and organic aciduria, culminating in fatal metabolic crises or sepsis. Neonatal death may occur if diagnosis is delayed.  
4. **Abnormality of urine homeostasis**: Accumulation of organic acids (e.g., 3-hydroxyisovaleric acid) disrupts renal acid-base regulation, causing metabolic acidosis and abnormal urinary organic acid profiles.  

**Conclusion**: The constellation of metabolic instability, neurological regression, and fatal outcomes aligns with biotinidase deficiency. Early-onset symptoms (e.g., urine abnormalities, developmental delays) and rapid progression without biotin supplementation explain the listed features."
"['Microcephaly', 'Hypertelorism', 'Bird-like facies', 'Recurrent otitis media', 'Upslanted palpebral fissure', 'Hypopigmentation of the skin', 'Intrauterine growth retardation', 'Bronchiectasis', 'Large fleshy ears', 'Decreased circulating IgA level', 'Decreased circulating total IgM', 'Impaired lymphocyte transformation with phytohemagglutinin', 'Elevated erythrocyte sedimentation rate', 'Decreased circulating IgG level', 'Recurrent pneumonia', 'Elevated circulating C-reactive protein concentration', 'Clinodactyly', 'Severe varicella zoster infection']",['Nijmegen breakage syndrome/Nijmegen breakage syndrome'],"Disease: Nijmegen breakage syndrome  
Reasoning:  
1. **Immunodeficiency**: Recurrent infections (otitis media, pneumonia), severe varicella zoster infection, decreased IgA/IgG/IgM, and impaired lymphocyte transformation indicate combined B- and T-cell dysfunction, characteristic of NBS.  
2. **Craniofacial Features**: Microcephaly, hypertelorism, bird-like facies, upslanted palpebral fissures, and large fleshy ears are hallmark dysmorphic traits of NBS.  
3. **Growth Abnormalities**: Intrauterine growth retardation aligns with NBS-associated prenatal developmental delays.  
4. **Chromosomal Instability**: Impaired lymphocyte transformation (due to defective DNA repair) and hypopigmentation suggest chromosomal breakage, a core feature of NBS.  
5. **Inflammatory Markers**: Elevated ESR and CRP reflect chronic inflammation from recurrent infections.  
6. **Bronchiectasis**: Secondary to recurrent respiratory infections, common in immunodeficiency disorders like NBS.  
7. **Clinodactyly**: A minor skeletal anomaly often seen in genetic syndromes, including NBS.  

Nijmegen breakage syndrome integrates these features via mutations in *NBN*, causing DNA repair defects, immunodeficiency, and developmental anomalies."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Hypophosphatemia', 'Hepatomegaly', 'Hypokalemia', 'Prolonged bleeding time', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type I (HT-1)  
Reasoning:  
1. **Hypertyrosinemia & 4-Hydroxyphenylpyruvic aciduria**: Direct biochemical hallmarks of tyrosinemia type I due to fumarylacetoacetate hydrolase (FAH) deficiency, causing toxic accumulation of tyrosine metabolites.  
2. **Hepatomegaly & elevated alpha-fetoprotein (AFP)**: Indicates severe liver dysfunction, a key feature of HT-1. AFP elevation reflects hepatocellular injury/regeneration.  
3. **Hypoglycemia, hypophosphatemia, hypokalemia**: Results from hepatic failure and renal Fanconi syndrome (proximal tubule dysfunction), common in HT-1.  
4. **Prolonged bleeding time**: Secondary to coagulopathy from impaired hepatic synthesis of clotting factors.  
5. **Hyperphenylalaninemia**: May occur due to secondary inhibition of phenylalanine hydroxylase by tyrosine metabolites.  
6. **Abnormality of prenatal development, neonatal/childhood death**: Untreated HT-1 causes rapid progression to liver failure, metabolic crises, and early mortality.  
7. **Neonatal/Infancy onset**: Classic presentation of acute HT-1, aligning with the listed symptoms.  

All findings converge on **tyrosinemia type I**, a disorder of tyrosine metabolism with hepatorenal toxicity. Confirmation requires genetic testing for *FAH* mutations or urinary succinylacetone detection."
"['Delayed speech and language development', 'Intellectual disability', 'Hyperreflexia', 'Death in infancy', 'Difficulty walking', 'Abnormal cerebral white matter morphology', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Neurological and developmental symptoms**: Delayed speech/language development and intellectual disability align with the progressive neurocognitive decline seen in L-2-hydroxyglutaric aciduria (L-2-HGA).  
2. **Motor dysfunction**: Difficulty walking, climbing stairs, and running correlate with cerebellar ataxia and pyramidal involvement (hyperreflexia), common in this disorder.  
3. **Neuroimaging findings**: Abnormal cerebral white matter morphology is characteristic of L-2-HGA, often showing leukoencephalopathy on MRI.  
4. **Early mortality**: Death in infancy/childhood occurs in severe cases due to metabolic crises or progressive neurological deterioration.  
5. **Metabolic hallmark**: Excess L-2-hydroxyglutaric acid in urine/CSF confirms the diagnosis, though clinical and imaging features strongly support it here.  
6. **Exclusion of mimics**: Symptoms differentiate it from other leukodystrophies (e.g., Canavan disease) due to specific motor and imaging patterns."
"['Low-set ears', 'Nystagmus', 'Spasticity', 'Death in infancy', 'Dyspnea', 'Fair hair', 'High, narrow palate', 'Increased total bilirubin', 'Neonatal death', 'Stridor', 'White hair', 'Feeding difficulties', 'Fatigue']",['Glutathione synthetase deficiency'],"Disease: Glutathione synthetase deficiency  
Reasoning:  
1. **Increased total bilirubin**: Caused by hemolytic anemia, a hallmark of glutathione synthetase deficiency due to impaired antioxidant defense in red blood cells.  
2. **Neonatal death/Death in infancy**: Matches the severe, early-onset form of the disorder, often fatal without intervention.  
3. **Dyspnea/Stridor**: Results from metabolic acidosis-induced compensatory hyperventilation or respiratory muscle spasticity.  
4. **Spasticity/Nystagmus**: Reflects neurological damage from oxidative stress and 5-oxoprolinuria, secondary to glutathione deficiency.  
5. **Feeding difficulties/Fatigue**: Linked to metabolic instability, acidosis, and anemia impairing energy metabolism.  
6. **Fair/White hair**: Pigment dilution due to disrupted cysteine metabolism (cysteine is a glutathione precursor).  
7. **High, narrow palate/Low-set ears**: Congenital anomalies occasionally associated with inborn errors of metabolism.  
8. **Supporting exclusion**: Symptoms align with glutathione synthetase deficiency rather than similar disorders (e.g., Menkes syndrome lacks hemolysis, Crigler-Najjar lacks acidosis)."
"['Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The symptoms of neonatal death, aminoaciduria, and elevated urinary carboxylic acids align with a defect in leucine catabolism. 3-Methylcrotonyl-CoA carboxylase 1 (MCCC1) deficiency disrupts the breakdown of 3-methylcrotonyl-CoA, leading to accumulation of toxic metabolites like 3-methylcrotonylglycine and 3-hydroxyisovaleric acid, detected as elevated urinary carboxylic acids. Secondary carnitine deficiency occurs due to urinary excretion of carnitine-bound detoxified metabolites. Hyperglycinemia arises from inhibition of the glycine cleavage system by accumulated organic acids. Severe metabolic decompensation in infancy explains early mortality.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis encompasses deficiencies in either MCCC1 or MCCC2 subunits of the enzyme. The biochemical hallmarks—abnormal glycine/carnitine levels and urinary carboxylic acid elevation—stem from impaired leucine metabolism. Neonatal death and aminoaciduria reflect acute metabolic crises and renal tubular dysfunction caused by toxic metabolite overload. Both genetic subtypes (MCCC1/MCCC2) present identically clinically, making this a valid diagnosis even if the specific subunit is unspecified."
"['Bifid uvula', 'Low anterior hairline', 'Epistaxis', 'Prominent nose', 'Strabismus', 'Deeply set eye', 'Long eyelashes', 'Thick eyebrow', 'Synophrys', 'Dry skin', 'Palmoplantar keratoderma', 'Hirsutism', 'Spasticity', 'Global developmental delay', 'Absent speech', 'Dysphagia', 'Kyphoscoliosis', 'Recurrent pneumonia', 'Dysplastic corpus callosum']","['CEDNIK syndrome/Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome']","Disease: CEDNIK syndrome (Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome)  
Reasoning:  
1. **Cerebral dysgenesis**: Supported by *global developmental delay*, *absent speech*, and *dysplastic corpus callosum*, indicating structural brain abnormalities.  
2. **Neuropathy**: Evidenced by *spasticity* and *dysphagia*, reflecting neurological dysfunction.  
3. **Ichthyosis**: Suggested by *dry skin* and *palmoplantar keratoderma* (thickened palms/soles), hallmark features of CEDNIK.  
4. **Systemic involvement**: *Recurrent pneumonia* likely secondary to aspiration from dysphagia; *kyphoscoliosis* may arise from neuromuscular compromise.  
5. **Dysmorphic features**: *Prominent nose*, *deeply set eyes*, *synophrys*, *long eyelashes*, *thick eyebrows*, *bifid uvula*, and *low anterior hairline* align with syndromic genetic etiology.  
6. **Exclusion**: Overlap with other neuro-ichthyosis disorders (e.g., Sjögren-Larsson syndrome) is ruled out by the unique combination of cerebral dysgenesis and palmoplantar keratoderma."
"['Pallor', 'Death in infancy', 'Ascites', 'Thrombocytosis', 'Anemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Aminoaciduria', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hernia']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
**Reasoning**:  
1. **Hypertyrosinemia & aminoaciduria**: Direct biochemical hallmarks of tyrosinemia type 1, caused by deficiency of fumarylacetoacetate hydrolase (FAH), leading to tyrosine accumulation and renal tubular dysfunction (Fanconi syndrome).  
2. **Elevated alpha-fetoprotein (AFP) & abnormal porphyrins**: Succinylacetone (a toxic metabolite in FAH deficiency) inhibits porphobilinogen synthase, causing porphyrin abnormalities. Elevated AFP reflects hepatic injury or regeneration, common in HT-1.  
3. **Hepatic manifestations (ascites, hypoalbuminemia, hypoproteinemia, elevated alkaline phosphatase)**: FAH deficiency causes severe liver dysfunction, progressing to cirrhosis, synthetic failure, and cholestasis. Ascites results from portal hypertension and hypoalbuminemia.  
4. **Thrombocytosis**: Reactive thrombocytosis secondary to chronic liver disease or splenic dysfunction.  
5. **Anemia & pallor**: Due to liver failure (coagulopathy, malnutrition) and/or porphyrin-related hemolysis.  
6. **Hernia**: Increased intra-abdominal pressure from ascites.  
7. **Death in infancy**: Untreated HT-1 often leads to fatal liver failure or neurologic crises in early childhood.  

The constellation of hepatic, renal, and metabolic abnormalities (succinylacetone, tyrosine) is pathognomonic for tyrosinemia type 1."
"['Oral ulcer', 'Goiter', 'Arthritis', 'Abnormality of the larynx', 'Anemia', 'Palpitations', 'Gastroesophageal reflux', 'Headache', 'Fasciculations', 'Paraparesis', 'Abnormality of the knee', 'Arthralgia', 'Myalgia', 'EMG: neuropathic changes', 'Somatic sensory dysfunction', 'Antinuclear antibody positivity', 'Decreased circulating complement C3 concentration', 'Abnormal phalangeal joint morphology of the hand', 'Abnormal circulating protein concentration', 'Right bundle branch block', 'Atrioventricular reentrant tachycardia', 'Abnormal metacarpophalangeal joint morphology', 'Upper limb pain', 'Dysesthesia', 'Neck pain', 'Elbow pain', 'Finger pain', 'Knee pain', 'Increased tear production', 'Aphthous ulcer', 'Abnormality of nail color', 'Dyspepsia']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Autoimmune Features**: Antinuclear antibody positivity and decreased complement C3 strongly suggest an autoimmune etiology.  
2. **Myositis Overlap**: Myalgia, EMG neuropathic changes, and somatic sensory dysfunction align with inflammatory muscle involvement, a hallmark of antisynthetase syndrome.  
3. **Articular Manifestations**: Arthritis, arthralgia, and joint abnormalities (knee, hand phalanges, MCP joints) are consistent with the polyarthritis seen in this syndrome.  
4. **Systemic Involvement**: Gastroesophageal reflux, dyspepsia, and dysesthesia reflect multisystemic inflammation, commonly seen in antisynthetase syndrome.  
5. **Extramuscular Signs**: Oral/aphthous ulcers and abnormal nail color may correlate with cutaneous manifestations of the disease.  
6. **Laboratory Clues**: Abnormal circulating protein concentration supports chronic inflammation.  
7. **Exclusion of Mimics**: While cardiac abnormalities (bundle branch block, tachycardia) are atypical, they are occasionally reported in antisynthetase syndrome, and other diseases (e.g., lupus, Sjögren’s) are less likely given the symptom constellation.  

The combination of myositis, arthritis, autoantibodies, and systemic involvement strongly supports antisynthetase syndrome, particularly with anti-Jo-1 antibodies (implied by ANA positivity in this context)."
"['Hypoglycemia', 'Death in childhood', 'Decreased plasma free carnitine', 'Acute hepatitis', 'Chronic hepatitis']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary  
Reasoning:  
1. **Hypoglycemia**: PCD causes impaired fatty acid oxidation due to defective carnitine transport, reducing energy production during fasting and leading to hypoglycemia.  
2. **Decreased plasma free carnitine**: A hallmark of PCD caused by mutations in the *SLC22A5* gene, resulting in urinary carnitine wasting and low plasma levels.  
3. **Acute/Chronic hepatitis**: Impaired fatty acid oxidation causes toxic metabolite accumulation (e.g., acylcarnitines) in the liver, triggering recurrent hepatitis and eventual chronic liver dysfunction.  
4. **Death in childhood**: Undiagnosed PCD leads to metabolic crises (hypoketotic hypoglycemia, hyperammonemia) or cardiac complications (cardiomyopathy, arrhythmias), often fatal in early life.  
5. **Consistency with PCD**: The triad of hypoketotic hypoglycemia, liver dysfunction, and carnitine deficiency is pathognomonic for PCD, distinguishing it from secondary carnitine deficiencies (e.g., organic acidemias)."
"['Renal insufficiency', 'Abnormality of the nose', 'Abnormal pinna morphology', 'Visual loss', 'Osteopenia', 'Facial erythema', 'Abnormal finger morphology', 'Wrist swelling', 'Abnormal toe morphology', 'Eosinophilia', 'Microcytic anemia', 'Exercise intolerance', 'Upper limb amyotrophy', 'Pedal edema', 'Abnormal metacarpophalangeal joint morphology', 'Foot pain', 'Shoulder pain', 'Episcleritis', 'Gangrene']",['Relapsing polychondritis'],"Disease: Relapsing polychondritis  
Reasoning:  
1. **Cartilage involvement**:  
   - **Abnormality of the nose** (saddle nose deformity from nasal cartilage collapse) and **abnormal pinna morphology** (ear cartilage inflammation) are hallmark features of relapsing polychondritis (RP).  
   - **Wrist swelling**, **abnormal metacarpophalangeal joint morphology**, and **abnormal finger/toe morphology** suggest inflammatory arthritis secondary to cartilage damage.  

2. **Ocular manifestations**:  
   - **Episcleritis** and **visual loss** align with RP-associated ocular inflammation.  

3. **Systemic inflammation**:  
   - **Facial erythema** and **eosinophilia** reflect systemic autoimmune activity.  
   - **Renal insufficiency** may stem from vasculitis or secondary amyloidosis, both linked to advanced RP.  

4. **Musculoskeletal complications**:  
   - **Osteopenia** and **upper limb amyotrophy** correlate with chronic inflammation and immobility due to joint pain (**shoulder pain**, **foot pain**).  

5. **Vascular involvement**:  
   - **Gangrene** and **pedal edema** suggest vasculitis-induced ischemia, a rare but severe RP complication.  

6. **Hematologic abnormalities**:  
   - **Microcytic anemia** and **exercise intolerance** are consistent with chronic disease and renal dysfunction.  

The constellation of cartilage destruction, multisystem inflammation, and vasculitic features strongly supports RP."
"['Macrocephaly', 'Seizure', 'Death in infancy', 'Opisthotonus', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid**: The hallmark biochemical finding in GA-I is elevated circulating glutaric acid due to deficient glutaryl-CoA dehydrogenase enzyme activity, disrupting lysine and tryptophan metabolism.  
2. **Macrocephaly**: Characteristic frontotemporal atrophy with subdural fluid accumulation in infancy often leads to macrocephaly.  
3. **Neurological symptoms (Seizures, Opisthotonus)**: Accumulation of neurotoxic metabolites (glutaric acid, 3-hydroxyglutaric acid) damages basal ganglia, causing dystonia, seizures, and posturing (e.g., opisthotonus).  
4. **Glutaric aciduria**: Urinary excretion of glutaric acid is a diagnostic marker.  
5. **Early mortality**: Untreated GA-I causes metabolic crises triggered by catabolic stress (e.g., infections), leading to irreversible neurological damage, encephalopathy, and death in infancy/neonatal periods if severe.  
6. **Consistency with phenotype**: The combination of macrocephaly, dystonia, metabolic derangements, and rapid progression aligns definitively with GA-I."
"['Hematuria', 'Hip dysplasia', 'Anemia', 'Metabolic acidosis', 'Leukocytosis', 'Hyperoxaluria', 'Calcium oxalate nephrolithiasis', 'Elevated circulating C-reactive protein concentration', 'Abnormality of urine calcium concentration', 'Pyuria', 'Abnormal circulating creatinine concentration']","['Primary hyperoxaluria type 2/Hyperoxaluria, primary, type II']","Disease: Primary hyperoxaluria type 2/Hyperoxaluria, primary, type II  
**Reasoning**:  
1. **Hyperoxaluria and Calcium oxalate nephrolithiasis**: The patient’s hyperoxaluria and calcium oxalate kidney stones are hallmark features of primary hyperoxaluria (PH), a rare disorder of glyoxylate metabolism. PH type 2 specifically results from a deficiency in glyoxylate reductase/hydroxypyruvate reductase (GRHPR), leading to excessive oxalate production.  
2. **Metabolic acidosis**: Impaired renal function due to nephrolithiasis and tubular damage reduces the kidneys’ ability to excrete acid, contributing to acidosis.  
3. **Hematuria and Pyuria**: These are secondary to urinary tract irritation and inflammation caused by oxalate crystals and stones.  
4. **Elevated creatinine**: Indicates reduced glomerular filtration rate (GFR) from chronic kidney damage due to recurrent nephrolithiasis and oxalate nephropathy.  
5. **Anemia**: Likely anemia of chronic disease secondary to renal failure.  
6. **Leukocytosis and elevated CRP**: Suggest systemic inflammation, possibly from recurrent urinary tract infections or stone-related tissue injury.  
7. **Abnormal urine calcium**: While PH primarily involves oxalate, calcium oxalate stone formation may indirectly affect calcium handling.  
8. **Hip dysplasia**: Unrelated to PH2 but could be a coincidental finding or misattributed to skeletal manifestations of systemic oxalosis in advanced disease (though skeletal involvement is more typical in PH1).  

The constellation of hyperoxaluria, nephrolithiasis, and metabolic derangements aligns with PH2, necessitating genetic testing for *GRHPR* mutations to confirm."
"['Petechiae', 'Abnormality of skin pigmentation', 'Death in infancy', 'Thrombocytopenia', 'Hypoglycemia', 'Hyperammonemia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Pigmentation of the sclera', 'Ichthyosis', 'Abnormal circulating porphyrin concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1 (HT-1)  
Reasoning:  
1. **Metabolic abnormalities**: Hypertyrosinemia, hypermethioninemia, hyperphenylalaninemia, and 4-hydroxyphenylpyruvic aciduria directly indicate a defect in tyrosine metabolism, specifically a deficiency of fumarylacetoacetate hydrolase (FAH) in HT-1.  
2. **Liver dysfunction**: Hypoglycemia, hyperammonemia, elevated alpha-fetoprotein, and hypermethioninemia reflect hepatic injury and impaired tyrosine catabolism.  
3. **Coagulopathy**: Thrombocytopenia, prolonged partial thromboplastin time, and petechiae result from liver failure reducing clotting factor synthesis.  
4. **Skin manifestations**: Ichthyosis, abnormal pigmentation, and scleral pigmentation arise from tyrosine deposition and secondary metabolic disruptions (e.g., porphyrin abnormalities).  
5. **Early fatality**: Death in infancy/childhood aligns with acute HT-1’s rapid progression due to liver failure, renal tubular dysfunction, and metabolic crises.  
6. **Biochemical markers**: Elevated alkaline phosphatase (cholestasis) and hyperammonemia (urea cycle stress) further support hepatorenal involvement.  
**Exclusion**: Other tyrosinemia types (II/III) lack severe liver/kidney phenotypes. HT-1 uniquely combines hepatic, neurologic, and dermatologic features with specific amino acid abnormalities."
"['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Intellectual disability, delayed speech/motor development** align with untreated PKU, as excess phenylalanine disrupts myelination and neurotransmitter synthesis, damaging the central nervous system.  
3. **Hypertyrosinemia** may initially seem contradictory (PAH deficiency typically reduces tyrosine), but secondary tyrosine supplementation in PKU management or coexisting hepatic dysfunction could elevate levels.  
4. **Abnormal circulating porphyrin** might reflect secondary metabolic stress or liver involvement, though not a classic PKU feature.  
5. **Early mortality** (infancy/childhood/adolescence) suggests severe, untreated PKU with complications like seizures, neurodegeneration, or infections due to compromised immunity.  
6. While some symptoms (e.g., porphyrin abnormalities) are atypical, they may arise from systemic metabolic derangements or comorbidities. PKU remains the primary diagnosis due to the central role of hyperphenylalaninemia and its neurodevelopmental consequences."
"['Microcephaly', 'Intellectual disability', 'Seizure', 'Lethargy', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), particularly CPS1 deficiency, as CPS1 catalyzes the first and rate-limiting step of ammonia detoxification.  
2. **Neonatal death** and **death in infancy** align with severe UCDs, which often present catastrophically in the first days of life due to acute hyperammonemic crises.  
3. **Neurological symptoms** (seizures, spasticity, lethargy, drowsiness, intellectual disability) result from ammonia-induced neurotoxicity and cerebral edema.  
4. **Generalized hypotonia** and **microcephaly** reflect chronic energy deprivation and impaired brain development from persistent metabolic dysfunction.  
5. **Sleep disturbances** correlate with encephalopathic phases of hyperammonemia.  
6. CPS1 deficiency is distinguished from other UCDs (e.g., OTC deficiency) by autosomal recessive inheritance and absence of orotic acid elevation, though confirmatory genetic/enzymatic testing is definitive."
"['Congestive heart failure', 'Dilated cardiomyopathy', 'Atrioventricular block', 'Premature atrial contractions']","['Cardiomyopathy, dilated, 1G']","Disease: Cardiomyopathy, dilated, 1G  
Reasoning:  
1. **Dilated cardiomyopathy (DCM)** is the core feature of CMD1G, caused by mutations in the *TTN* gene. The patient’s presentation of DCM aligns with this genetic etiology.  
2. **Congestive heart failure** commonly arises secondary to DCM due to impaired systolic function, supporting structural and functional cardiac dysfunction typical of CMD1G.  
3. **Atrioventricular (AV) block** and **premature atrial contractions (PACs)** suggest conduction system abnormalities. *TTN* mutations can disrupt cardiac sarcomere integrity, leading to electrical instability and conduction defects.  
4. The coexistence of DCM with arrhythmic features (AV block, PACs) is characteristic of CMD1G, distinguishing it from non-genetic DCM forms, which less frequently involve conduction abnormalities early in disease progression.  
5. Genetic testing for *TTN* variants would confirm the diagnosis, as this gene accounts for ~25% of familial DCM cases with arrhythmic manifestations."
"['Renal insufficiency', 'Proteinuria', 'Glomerulonephritis', 'Renal cyst', 'Uveitis', 'Arthritis', 'Lymphopenia', 'Pulmonary embolism', 'Deep venous thrombosis', 'Microscopic hematuria', 'Reduced coagulation factor V activity', 'Antinuclear antibody positivity', 'Renal cell carcinoma', 'Knee pain', 'Anti-beta 2 glycoprotein I antibody positivity']","['Renal cell carcinoma, xp11-associated', 'Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus', 'Renal cell carcinoma, papillary, 1, familial and somatic', 'Renal cell carcinoma, nonpapillary']","Disease: Systemic lupus erythematosus  
Reasoning: The patient exhibits ANA positivity, lymphopenia, arthritis, glomerulonephritis, and anti-beta 2 glycoprotein I antibody positivity, which are hallmark features of SLE. Anti-beta 2 glycoprotein antibodies suggest secondary antiphospholipid syndrome (APS), explaining thrombotic events (pulmonary embolism, DVT). Lupus nephritis accounts for renal insufficiency, proteinuria, and microscopic hematuria.  

Disease: Renal cell carcinoma, xp11-associated  
Reasoning: The presence of renal cell carcinoma and renal cysts aligns with this rare translocation-associated subtype, often seen in younger individuals. While SLE explains most autoimmune features, xp11-associated RCC is distinct, though co-occurrence may reflect a paraneoplastic phenomenon or incidental finding.  

Disease: Anti-beta 2 glycoprotein I antibody positivity (as part of SLE/APS)  
Reasoning: While not a standalone diagnosis here, this antibody confirms APS, a common SLE complication. It directly contributes to the hypercoagulable state (thrombosis, reduced Factor V activity due to assay interference from lupus anticoagulant).  

---  
**Note**: The provided list includes overlapping SLE susceptibility genes (e.g., SLE16, SLE6), but without genetic testing or family history, the broader ""Systemic lupus erythematosus"" diagnosis is most appropriate. Similarly, ""Renal cell carcinoma, xp11-associated"" is prioritized over other RCC subtypes due to its association with younger demographics and distinct molecular profile."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, intrauterine metabolic stress from maternal-fetal interactions or placental insufficiency during fasting could contribute to subtle developmental anomalies.  
2. **Death in infancy/childhood and neonatal death**: MCADD causes life-threatening hypoglycemia and metabolic crises during fasting or illness. Undiagnosed cases lead to sudden mortality due to energy deficiency, hepatic dysfunction, or cardiac complications.  
3. **Gastrointestinal inflammation**: Metabolic crises in MCADD induce vomiting, diarrhea, and acidosis, triggering secondary gastrointestinal inflammation from toxic metabolite accumulation (e.g., medium-chain acylcarnitines).  
4. **Decreased plasma free carnitine**: MCADD traps carnitine as medium-chain acylcarnitines (e.g., octanoylcarnitine), reducing free carnitine levels. This reflects the body’s attempt to detoxify accumulating fatty acid intermediates.  
5. **Decreased 3-hydroxyacyl-CoA dehydrogenase (HADH) level**: Likely a misinterpretation or indirect effect. MCADD specifically involves medium-chain acyl-CoA dehydrogenase (ACADM) deficiency. HADH activity may appear reduced in assays due to overlapping substrate specificity or secondary mitochondrial dysfunction in severe crises.  

**Conclusion**: The constellation of early mortality, hypoketotic hypoglycemia risk, and biochemical findings align with MCADD, a fatty acid oxidation disorder requiring urgent dietary management to prevent catabolic crises."
"['Renal hypoplasia', 'Focal segmental glomerulosclerosis', 'Nephrocalcinosis', 'Hepatic steatosis', 'Hepatic cysts', 'Splenomegaly', 'Thrombocytopenia', 'Diarrhea', 'Hyperuricemia', 'Hyperkalemia', 'Abnormal shoulder morphology', 'Increased blood urea nitrogen', 'Hyperuricosuria', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatinine concentration', 'Increased circulating ferritin concentration', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Constrictive median neuropathy', 'Decreased glomerular filtration rate', 'Upper limb pain', 'Lower limb pain', 'obsolete Increased urinary urate', 'Reduced haptoglobin level', 'Elevated prostate-specific antigen level', 'Neck pain', 'Shoulder pain', 'Anti-centromere antibody positivity', 'Abnormal blood phosphate concentration']","['CREST syndrome', 'Scleroderma, familial progressive']","Disease: CREST syndrome  
Reasoning: The patient's anti-centromere antibody positivity is a hallmark of CREST syndrome. While classic CREST features (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasia) are not explicitly listed, secondary manifestations align with systemic involvement. Elevated ESR, ANA positivity, and complement abnormalities suggest autoimmune activity. Renal hypoplasia, glomerulosclerosis, and nephrocalcinosis may reflect chronic kidney damage from vascular or metabolic complications. Constrictive median neuropathy (carpal tunnel) and musculoskeletal pain could stem from fibrosis or inflammation. Elevated PTH and abnormal phosphate hint at metabolic bone disease, potentially linked to renal dysfunction.  

Disease: Scleroderma, familial progressive  
Reasoning: Familial progressive scleroderma encompasses broader systemic involvement. The patient’s hepatic steatosis, cysts, splenomegaly, and thrombocytopenia may indicate portal hypertension or liver fibrosis. Hyperuricemia, hyperuricosuria, and elevated creatinine correlate with progressive renal impairment, possibly due to scleroderma renal crisis (though atypical here). Elevated ferritin and reduced haptoglobin suggest chronic inflammation or hemolysis. Anti-centromere antibodies overlap with CREST, but familial progression implies genetic predisposition. Musculoskeletal pain, neuropathy, and elevated PSA (potentially inflammation-driven) further support diffuse connective tissue disease."
"['Seborrheic dermatitis', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Seborrheic dermatitis**: A cutaneous manifestation of metabolic imbalance, commonly seen in untreated PKU due to disrupted amino acid metabolism affecting skin integrity.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has untreated PKU) can cause congenital anomalies (e.g., microcephaly) in the fetus due to intrauterine phenylalanine toxicity.  
4. **Death in infancy/Neonatal death/Death in childhood**: Untreated PKU results in severe neurological deterioration, seizures, and organ damage, often leading to early mortality without dietary intervention.  
5. **Hypertyrosinemia**: Uncommon in classical PKU but may arise secondary to metabolic dysregulation or overlapping conditions (e.g., BH4 deficiency), though PKU typically reduces tyrosine levels due to impaired PAH-mediated conversion of phenylalanine.  

The combination of hyperphenylalaninemia with systemic complications aligns with severe, untreated PKU. Early diagnosis via newborn screening and strict dietary management are critical to prevent these outcomes."
"['Oral ulcer', 'Sinusitis', 'Abnormal nasal mucosa morphology', 'Thrombocytosis', 'Fever', 'Leukocytosis', 'Dyspnea', 'Abnormality of the knee', 'Elevated circulating alkaline phosphatase concentration', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Erythema nodosum', 'Cervical lymphadenopathy', 'Elevated gamma-glutamyltransferase level', 'Retinitis', 'Aphthous ulcer', 'Mediastinal lymphadenopathy', 'Chest pain']",['Behçet disease/Behcet syndrome'],"Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: Recurrent oral and aphthous ulcers are hallmark features of Behçet’s disease. Erythema nodosum, a skin lesion, further supports this category.  
2. **Ocular Manifestations**: Retinitis aligns with Behçet’s ocular involvement, typically presenting as uveitis or retinal vasculitis.  
3. **Systemic Inflammation**: Elevated ESR, CRP, leukocytosis, and thrombocytosis reflect a systemic inflammatory response, consistent with Behçet’s flares.  
4. **Articular Involvement**: Abnormality of the knee suggests arthritis, commonly non-erosive in Behçet’s.  
5. **Vascular/Thoracic Features**: Dyspnea, chest pain, and mediastinal lymphadenopathy may indicate vasculitis affecting pulmonary or mediastinal vessels, a known complication.  
6. **Lymphatic Involvement**: Cervical lymphadenopathy is occasionally seen during active disease.  
7. **Atypical Overlaps**: Sinusitis and abnormal nasal mucosa are less typical but may occur secondary to inflammation. Elevated liver enzymes (ALP/GGT) are nonspecific but could reflect systemic illness.  
8. **Exclusion of Mimics**: The absence of granulomas (unlike sarcoidosis/GPA) and dominance of mucosal/skin lesions over gastrointestinal symptoms (unlike Crohn’s) solidify Behçet’s as the diagnosis.  

Final diagnosis hinges on the combination of major criteria (oral ulcers, erythema nodosum, ocular lesions) with multisystem inflammation, fulfilling the International Criteria for Behçet’s Disease."
"['Syncope', 'Palpitations', 'ST segment elevation']","['Brugada Syndrome, BrS/Brugada syndrome/Brugada syndrome 1']","Disease: Brugada Syndrome, BrS/Brugada syndrome/Brugada syndrome 1  
Reasoning:  
1. **ST segment elevation**: The hallmark ECG finding in Brugada syndrome is coved-type ST elevation (>2 mm) in leads V1-V3, often mimicking acute myocardial infarction but without ischemic symptoms. This matches the patient’s ECG presentation.  
2. **Syncope**: Sudden loss of consciousness in Brugada syndrome is typically due to polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF), which disrupt cardiac output. This aligns with the patient’s syncopal episodes.  
3. **Palpitations**: Reflects transient arrhythmias, such as non-sustained VT or premature ventricular contractions (PVCs), common in Brugada syndrome due to abnormal sodium channel function (SCN5A mutation in 20-30% of cases).  
4. **Exclusion of alternatives**:  
   - Acute coronary syndrome (ACS): Unlikely without chest pain, reciprocal ECG changes, or troponin elevation.  
   - Pericarditis: Diffuse ST elevation or PR depression absent.  
   - Early repolarization: ST elevation morphology differs (concave vs. coved).  
5. **Risk stratification**: Spontaneous Type 1 ECG pattern (as seen here) + syncope indicates high risk for sudden cardiac death, warranting ICD implantation."
"['Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Pneumonia', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Motor delay and generalized hypotonia**: These are hallmark neurological symptoms of SSADHD, caused by disrupted GABA metabolism. Accumulation of GABA and its metabolite gamma-hydroxybutyrate (GHB) leads to excessive neuronal inhibition, impairing motor development and muscle tone.  
2. **Elevated urinary carboxylic acid**: SSADHD results in elevated GHB, a carboxylic acid, in urine due to the enzyme deficiency blocking succinic semialdehyde conversion to succinate. This biochemical marker is specific to the disorder.  
3. **Pneumonia**: Hypotonia increases aspiration risk, predisposing infants to recurrent respiratory infections like pneumonia.  
4. **Death in infancy**: While SSADHD is typically non-lethal, severe metabolic instability, respiratory complications (e.g., pneumonia), or delayed diagnosis may contribute to early mortality in rare cases.  

The combination of neurological deficits, characteristic urinary metabolite elevation, and secondary respiratory complications aligns conclusively with SSADHD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Ventricular septal defect', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development/birth, VSD, and neonatal/infant death** may reflect **maternal PKU syndrome**, where untreated maternal hyperphenylalaninemia during pregnancy induces teratogenic effects (e.g., congenital heart defects like VSD) in the fetus.  
3. **Hypertyrosinemia** is atypical for classic PKU (where tyrosine levels are usually low/normal) and suggests a potential secondary metabolic disturbance, co-occurring liver dysfunction, or misdiagnosis of tyrosine levels.  
4. **Death in childhood** aligns with severe, untreated PKU, as neurological damage and metabolic complications (seizures, failure to thrive) can be fatal without dietary intervention.  
5. While **hypertyrosinemia** creates ambiguity, the dominant hyperphenylalaninemia and clinical context prioritize PKU as the primary diagnosis. Further evaluation of tyrosine metabolism (e.g., BH4 deficiency, tyrosinemia) would be warranted to address this discrepancy."
"['Glaucoma', 'Cataract', 'Intellectual disability', 'Hypotonia', 'Glycosuria', 'Low-molecular-weight proteinuria', 'Aminoaciduria', 'Albuminuria']",['Oculocerebrorenal syndrome of Lowe/Lowe syndrome'],"Disease: Oculocerebrorenal syndrome of Lowe/Lowe syndrome  
Reasoning:  
1. **Ocular Manifestations**: Glaucoma and congenital cataracts are hallmark features of Lowe syndrome, caused by mutations in the OCRL1 gene affecting eye development.  
2. **Neurological Involvement**: Intellectual disability and hypotonia align with the syndrome's central nervous system deficits, linked to impaired phosphatidylinositol metabolism.  
3. **Renal Tubular Dysfunction**: Glycosuria, low-molecular-weight proteinuria, aminoaciduria, and albuminuria indicate proximal renal tubular dysfunction (Fanconi syndrome), a key renal feature of Lowe syndrome due to defective OCRL1-dependent tubular transport.  
4. **Triad Confirmation**: The combination of ocular, cerebral, and renal abnormalities is pathognomonic for Lowe syndrome, distinguishing it from other metabolic or tubular disorders."
"['Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Tremor', 'Death in infancy', 'Leukopenia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Gastroesophageal reflux', 'Pneumonia', 'Increased serum lactate', 'Hyperglycinemia', 'Drowsiness', 'Difficulty walking', 'Sleep disturbance', 'Tachypnea', 'Increased blood urea nitrogen', 'Hypertyrosinemia', 'Hyperalaninemia', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperprolinemia', 'Difficulty running', 'Stomatitis', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Hypoglycinemia', 'Severe hearing impairment']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Abnormalities**: Hyperammonemia, hyperglycinemia, and elevated serum lactate are hallmark features of PA. Propionyl-CoA carboxylase deficiency disrupts the urea cycle (causing hyperammonemia) and mitochondrial function (leading to lactic acidosis).  
2. **Amino Acid Derangements**: Hypertyrosinemia, hyperalaninemia, hyperprolinemia, and hypervalinemia occur due to secondary inhibition of amino acid metabolism by accumulated propionic acid metabolites.  
3. **Hematologic Issues**: Leukopenia and recurrent infections stem from bone marrow suppression, a known complication of PA.  
4. **Neurological Symptoms**: Intellectual disability, seizures, hypotonia, motor delays, and severe hearing impairment result from neurotoxic effects of metabolites (e.g., propionic acid) and energy deficiency.  
5. **Gastrointestinal and Acute Crises**: Vomiting, GER, and tachypnea align with metabolic decompensation episodes. Hyperammonemia and acidosis drive lethargy, drowsiness, and respiratory compensation.  
6. **Early Mortality**: Neonatal/childhood death is typical in severe PA due to metabolic crises or complications like pneumonia.  
7. **Carnitine Abnormalities**: Propionyl-CoA sequesters carnitine, causing secondary carnitine deficiency (abnormal circulating carnitine levels).  
8. **Hyperglycinemia**: Propionyl-CoA inhibits the glycine cleavage system, leading to elevated glycine despite PA not being a primary glycine disorder.  

Key Clinchers: Combined hyperammonemia, metabolic acidosis (elevated lactate), and multisystem involvement (neurologic, hematologic, GI) with early lethality strongly pinpoint PA."
"['Cryptorchidism', 'Abnormality of male external genitalia', 'Shawl scrotum', 'Micropenis', 'Abnormality of the face', 'Hypertelorism', 'Facial asymmetry', 'Abnormality of the outer ear', 'Posteriorly rotated ears', 'Low-set ears', 'Prominent nose', 'Abnormality of the eye', 'Atypical behavior', 'Autistic behavior', 'Cutis marmorata', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Impaired smooth pursuit', 'Pineal cyst', 'Lymphangioma']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Genetic Basis**: Caused by heterozygous pathogenic variants in *PHIP*, aligning with multi-system congenital anomalies.  
2. **Facial Dysmorphism**: Hypertelorism, facial asymmetry, prominent nose, and ear anomalies (posteriorly rotated, low-set) match reported craniofacial features.  
3. **Genital Abnormalities**: Cryptorchidism, micropenis, and shawl scrotum correlate with urogenital malformations documented in the syndrome.  
4. **Neurological Features**: Intellectual disability, seizures, hypotonia, and impaired smooth pursuit are hallmark neurodevelopmental traits.  
5. **Behavioral Phenotype**: Autistic behavior aligns with developmental delay and social communication deficits.  
6. **Cutaneous Findings**: Cutis marmorata may reflect vascular dysregulation, occasionally observed in genetic syndromes.  
7. **Ancillary Features**: Pineal cyst and lymphangioma, while less specific, fit within the spectrum of variable congenital anomalies.  
8. **Exclusion**: Overlap with Noonan or Smith-Lemli-Opitz syndromes is unlikely due to absence of key features (e.g., cardiac defects, cholesterol deficiency signs).  

Conclusion: The constellation of symptoms strongly supports Stankiewicz-Isidor syndrome, driven by *PHIP* dysfunction."
"['Hearing abnormality', 'Visual loss', 'Hypertension', 'Hyperhidrosis', 'Gait disturbance', 'Hepatic steatosis', 'obsolete Mood changes', 'Aortic regurgitation', 'Splenomegaly', 'Diarrhea', 'Nausea', 'Constipation', 'Heat intolerance', 'Abnormal intestine morphology', 'Headache', 'Vertigo', 'Abnormality of the lower limb', 'Arthralgia', 'Exertional dyspnea', 'Elevated hepatic transaminase', 'Abnormal EKG', 'Increased LDL cholesterol concentration', 'Elevated circulating creatine kinase concentration', 'Abdominal distention', 'Increased circulating ferritin concentration', 'Back pain', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Gastrointestinal inflammation', 'Ventricular tachycardia', 'Gastritis', 'Premature ventricular contraction', 'Elevated circulating C-reactive protein concentration', 'Right bundle branch block', 'Abnormal metacarpophalangeal joint morphology', 'Constrictive median neuropathy', 'Sacroiliac arthritis', 'Upper limb pain', 'Lower limb pain', 'Dysesthesia', 'Panic attack', 'Neck pain', 'Hip pain', 'Groin pain', 'Unhappy demeanor', 'Low levels of vitamin D', 'Chest pain', 'Insomnia']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning:  
1. **Axial skeletal involvement**: Sacroiliac arthritis, back pain, neck pain, hip/groin pain, and abnormal lower limb morphology align with axial spondyloarthritis (e.g., ankylosing spondylitis), a hallmark of spondyloarthropathy.  
2. **Peripheral joint manifestations**: Arthralgia, abnormal metacarpophalangeal joint morphology, and limb pain suggest peripheral arthritis, common in spondyloarthropathies.  
3. **Extra-articular features**:  
   - **Gastrointestinal inflammation**: Diarrhea, constipation, gastritis, and abnormal intestine morphology may indicate inflammatory bowel disease (IBD), frequently comorbid with spondyloarthropathy.  
   - **Cardiac abnormalities**: Aortic regurgitation and conduction defects (right bundle branch block, ventricular tachycardia) are recognized complications of chronic inflammation in HLA-B27-associated diseases.  
   - **Elevated inflammatory markers**: Elevated CRP and ferritin reflect systemic inflammation.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning:  
1. **Genetic predisposition**: Susceptibility loci (e.g., HLA-B27) are strongly linked to spondyloarthropathies, explaining familial clustering and disease severity.  
2. **Neurological and sensory symptoms**: Constrictive median neuropathy, dysesthesia, and somatic sensory dysfunction may stem from enthesitis or nerve compression due to chronic inflammation.  
3. **Dermatological/autonomic features**: Hyperhidrosis and heat intolerance could reflect autonomic dysregulation, occasionally observed in systemic autoimmune disorders.  
4. **Vitamin D deficiency**: Common in chronic inflammatory diseases due to reduced sunlight exposure or malabsorption, exacerbating musculoskeletal pain.  
5. **Psychosocial components**: Unhappy demeanor, panic attacks, and insomnia are consistent with chronic pain syndromes and inflammation-driven neuropsychiatric effects.  

**Key Overlap**: Both diagnoses share core features (axial/peripheral arthritis, IBD association, cardiac involvement) but highlight genetic heterogeneity (e.g., non-HLA genes in susceptibility 2). The breadth of symptoms (musculoskeletal, gastrointestinal, cardiac, neurological) underscores the multisystem nature of spondyloarthropathies, necessitating a holistic diagnostic approach."
"['Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The symptoms of aminoaciduria, abnormal glycine/carnitine levels, and elevated urinary carboxylic acids stem from impaired leucine metabolism due to MCCC1 gene mutations. This disrupts 3-MCC enzyme activity, causing toxic metabolite accumulation (e.g., 3-hydroxyisovaleric acid). Carnitine depletion occurs as it conjugates with metabolites for excretion, while glycine abnormalities may arise from compensatory detoxification. Severe enzyme deficiency leads to metabolic crises, explaining neonatal/infant mortality.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This condition, often linked to MCCC2 gene mutations, similarly disrupts the 3-MCC enzyme complex. Leucine catabolism failure results in elevated urinary carboxylic acids (e.g., 3-methylcrotonylglycine). Secondary carnitine deficiency and glycine irregularities align with metabolic compensation mechanisms. Neonatal death or infant mortality reflects acute metabolic decompensation in severe, untreated cases. Both MCCC1 and MCCC2 defects share clinical features but involve distinct genetic subunits of the same enzyme."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Fever', 'Diarrhea', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating aspartate family amino acid concentration', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: The hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia**: Secondary elevation of tyrosine may occur due to competitive inhibition of tyrosine metabolism by excess phenylalanine or dietary protein restrictions.  
3. **Delayed speech/development**: Untreated PKU results in neurotoxic effects of phenylalanine, impairing cognitive and language development.  
4. **Abnormal prenatal development/Neonatal death**: Severe PAH deficiency can manifest prenatally; untreated cases may lead to metabolic instability and early mortality.  
5. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) may appear in urine as alternative degradation products.  
6. **Recurrent infections/Diarrhea/Fever**: Possible secondary to dietary management (low-protein diets affecting immune function) or metabolic stress.  
7. **Abnormal aspartate family amino acids**: Disruption in amino acid metabolism pathways due to phenylalanine excess may indirectly alter aspartate-related metabolites.  

*Note:* While some symptoms (e.g., recurrent infections) are atypical for classic PKU, they may reflect complications of severe/prolonged metabolic derangement or comorbidities. Confirmatory testing (PAH gene variants, phenylalanine levels, neonatal screening results) is critical."
"['Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Difficulty walking', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: A hallmark of SSADHD due to accumulation of γ-hydroxybutyric acid (GHB), a carboxylic acid, in urine.  
2. **Neurological symptoms**:  
   - **Delayed speech/language development** and **hyperactivity**: Linked to GABA metabolism disruption, affecting neurodevelopment.  
   - **Seizures**: Caused by GHB-mediated excitotoxicity and GABA imbalance.  
   - **Generalized hypotonia**: Reflects impaired motor neuron function from GABAergic dysfunction.  
3. **Motor deficits (walking, stairs, running)**: Secondary to hypotonia, developmental delay, and potential cerebellar involvement.  
4. **Early mortality (infancy/childhood)**: Rare but reported in severe cases due to metabolic crises, refractory seizures, or complications.  
**Conclusion**: Symptom constellation aligns with SSADHD, confirmed by elevated urinary GHB (carboxylic acid). Early death, though atypical, may occur in severe phenotypes."
"['Cataract', 'Abnormality of prenatal development or birth', 'Hepatic failure', 'Death in infancy', 'Atrial septal defect', 'Hyperammonemia', 'Conjugated hyperbilirubinemia', 'Increased total bilirubin', '4-hydroxyphenylacetic aciduria', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's symptoms of hypergalactosemia, conjugated hyperbilirubinemia, 4-hydroxyphenylacetic aciduria, and hepatic failure directly align with the pathophysiology of classic galactosemia (GALT deficiency). Accumulation of galactose metabolites (e.g., galactitol) explains cataracts, while liver dysfunction causes coagulopathy (prolonged PTT) and hyperammonemia. Neonatal death and infant mortality are typical in untreated cases due to metabolic crisis. Abnormal galactoside metabolism and amino acid derangements further support this diagnosis.  

Disease: Galactosemia  
Reasoning: The broader diagnosis of galactosemia encompasses the patient's prenatal abnormalities, neonatal death, and metabolic markers (e.g., hyperbilirubinemia, hyperammonemia). The systemic toxicity from galactose-1-phosphate accumulation explains multi-organ failure (liver, brain, eyes). Atrial septal defect, though less common, may occur due to metabolic stress during embryogenesis. The constellation of symptoms across hepatic, ocular, and developmental domains confirms galactosemia as the unifying etiology."
"['Apathy', 'Seizure', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, alongside metabolic acidosis, vomiting, lethargy, and neurological symptoms (seizures, drowsiness, apathy). Neonatal death and death in infancy align with severe MMA presentations. These findings collectively indicate impaired methylmalonyl-CoA metabolism.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **B12-unresponsive subtype** is inferred due to the severity (neonatal death) and lack of improvement with B12 therapy. Mutations in the *MUT* gene disrupt methylmalonyl-CoA mutase activity, exacerbating acid accumulation. Persistent metabolic acidosis and early lethality are characteristic of this subtype, distinguishing it from B12-responsive forms."
"['Seizure', 'Death in infancy', 'Metabolic acidosis', 'Tachypnea', '3-Methylglutaric aciduria', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia**: CPS1 deficiency disrupts the urea cycle, impairing ammonia detoxification. Elevated ammonia levels cause neurological symptoms (seizures) and contribute to neonatal lethality.  
2. **Respiratory Findings (Tachypnea)**: Hyperammonemia stimulates the respiratory drive, leading to tachypnea as a compensatory mechanism for associated metabolic acidosis.  
3. **Metabolic Acidosis**: Secondary mitochondrial dysfunction from hyperammonemia or energy depletion may cause lactic acidosis. Concurrent organic aciduria (3-methylglutaric aciduria) suggests disrupted mitochondrial metabolism, potentially due to metabolic stress from ammonia toxicity.  
4. **3-Methylglutaric Aciduria**: Likely a secondary marker of mitochondrial dysfunction, as hyperammonemia can impair leucine catabolism or other pathways, leading to organic acid accumulation.  
5. **Neonatal/Infantile Death**: Severe urea cycle defects like CPS1 deficiency often manifest catastrophically in neonates due to rapid ammonia accumulation, metabolic derangements, and neurological deterioration.  

This diagnosis aligns with the clinical triad of hyperammonemia, metabolic acidosis, and respiratory compensation, alongside the rare but plausible association with 3-methylglutaric aciduria in mitochondrial stress states."
"['Lop ear', 'Telecanthus', 'Retinal dystrophy', 'Bicornuate uterus', 'Septate vagina', 'Pulmonic stenosis', 'Bicuspid aortic valve', 'Toe syndactyly', 'Anal atresia', 'Clinodactyly of the 5th finger', 'Short stature', 'Sagittal craniosynostosis', 'Moderate myopia', 'Abnormal radial ray morphology']",['Syndactyly-telecanthus-anogenital and renal malformations syndrome/STAR syndrome'],"Disease: Syndactyly-telecanthus-anogenital and renal malformations syndrome (STAR syndrome)  
Reasoning: The patient presents with **toe syndactyly**, **telecanthus**, and **anogenital malformations** (anal atresia, bicornuate uterus, septate vagina), which are hallmark features of STAR syndrome. While renal anomalies are not explicitly listed, the triad of syndactyly, telecanthus, and anogenital defects strongly supports this diagnosis. Additional findings like **short stature** and **clinodactyly** align with reported phenotypic variability. Though **pulmonic stenosis**, **bicuspid aortic valve**, and **sagittal craniosynostosis** are atypical for STAR, they may represent rare associations or coincidental findings. The absence of classic radial ray involvement (e.g., thumb anomalies) and retinal dystrophy in STAR suggests these could be incidental or part of an overlapping condition, but the core triad remains diagnostic."
"['Delayed speech and language development', 'Generalized hypotonia', 'Death in infancy', 'Hyperhomocystinemia', 'Abnormal cerebral white matter morphology', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type']","Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning:  
1. **Methylmalonic aciduria**: Directly listed as a symptom, indicating impaired metabolism of methylmalonyl-CoA.  
2. **Hyperhomocystinemia**: Specific to defects in cobalamin metabolism (e.g., cblC type), which disrupts homocysteine remethylation to methionine.  
3. **Abnormal cerebral white matter morphology**: Neurological damage from homocystinuria and methylmalonic acid toxicity explains this finding.  
4. **Decreased plasma free carnitine**: Secondary to excessive conjugation with accumulated metabolites (methylmalonic acid/homocysteine).  
5. **Generalized hypotonia and delayed speech**: Neurological manifestations due to combined metabolic toxicity and potential B12 deficiency effects.  
6. **Gastrointestinal inflammation**: Linked to metabolic stress and mitochondrial dysfunction in cblC.  
7. **Neonatal/Infancy/Childhood death**: Severe cblC variants often present with early-life metabolic crises, multiorgan failure, or neurodegeneration.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Methylmalonic aciduria**: Primary biochemical hallmark of isolated MMA caused by methylmalonyl-CoA mutase deficiency or cobalamin disorders (e.g., cblA/cblB).  
2. **Decreased plasma free carnitine**: Due to carnitine depletion from conjugating methylmalonic acid.  
3. **Generalized hypotonia and developmental delay**: Common in chronic MMA due to energy deficiency and neurotoxicity.  
4. **Death in infancy/childhood**: Occurs in severe MMA subtypes but **does not explain hyperhomocystinemia or cerebral white matter abnormalities**, making this diagnosis incomplete.  

**Final Diagnosis**: Methylmalonic acidemia with homocystinuria, type cblC (Combined MMA and homocystinuria) is the definitive diagnosis, as it uniquely accounts for **all symptoms**, including the coexistence of methylmalonic aciduria, hyperhomocystinemia, and cerebral white matter pathology."
"['Carious teeth', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Respiratory insufficiency', 'Difficulty walking', 'Spastic tetraplegia', 'Difficulty climbing stairs', 'Excessive salivation', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Difficulty running', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Death in early adulthood']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid elevation**: Presence of hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicates a defect in the branched-chain α-keto acid dehydrogenase complex, the hallmark of MSUD.  
2. **Neurological manifestations**: Spastic diplegia/tetraplegia, seizures, intellectual disability, and motor delays align with neurotoxicity from accumulated amino acids.  
3. **Metabolic crises**: Hyperammonemia, vomiting, diarrhea, and respiratory insufficiency correlate with acute metabolic decompensation, common in MSUD.  
4. **Early mortality**: Neonatal death, death in infancy/childhood/adolescence, and early adulthood are consistent with severe or untreated MSUD variants.  
5. **Supporting features**: Excessive salivation, recurrent infections, and carious teeth may arise from chronic metabolic dysregulation and dietary management challenges.  
6. **Exclusion of mimics**: Symptoms collectively rule out other organic acidemias (e.g., no mention of hypoglycemia or fatty acid oxidation defects) or urea cycle disorders (though hyperammonemia occurs, it is secondary in MSUD)."
"['Cleft palate', 'Pierre-Robin sequence', 'Hypertelorism', 'Downslanted palpebral fissures', 'Spasticity', 'Morphological central nervous system abnormality', 'Chorea', 'Restrictive ventilatory defect', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular Syndrome: The patient presents with cleft palate and Pierre-Robin sequence (micrognathia, glossoptosis, airway obstruction), which are hallmark craniofacial features of CCMS. Posterior rib gaps and restrictive ventilatory defect correlate with the syndrome’s characteristic costovertebral anomalies (missing or malformed posterior rib segments), leading to thoracic insufficiency. Spasticity, chorea, and morphological CNS abnormalities align with neurological involvement seen in severe CCMS cases. Hypertelorism and downslanted palpebral fissures further support the syndromic craniofacial dysmorphism. The combination of these structural and neurological findings strongly points to CCMS."
"['Cataract', 'Hip dysplasia', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Anemia', 'Hyperammonemia', 'Elevated circulating creatinine concentration', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The presence of **methylmalonic aciduria** is pathognomonic for methylmalonic acidemia (MMA), a rare inborn error of metabolism. Key symptoms like **hyperammonemia**, **elevated creatinine** (indicative of renal dysfunction), **anemia**, and **abnormal carnitine levels** align with MMA’s metabolic disruptions. Neonatal or early childhood **death** and **premature birth** are consistent with severe forms of MMA, where toxic metabolite accumulation leads to multiorgan failure.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the diagnosis) points specifically to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme deficiency prevents the conversion of methylmalonyl-CoA to succinyl-CoA, causing **methylmalonic aciduria**, **hyperammonemia**, and metabolic acidosis. Symptoms like **small for gestational age** and **death in infancy/childhood** reflect the disease’s severe, early-onset phenotype. **Hip dysplasia** and **cataracts** may arise secondary to chronic metabolic stress or mitochondrial dysfunction. Elevated creatinine and neonatal death underscore renal and systemic toxicity from methylmalonic acid and propionate accumulation."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Anemia', 'Hyperammonemia', 'Hyperglycinemia', 'Hepatomegaly', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Hypoglycinemia']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Metabolic Dysregulation**: Propionic acidemia (PA) is caused by defective propionyl-CoA carboxylase, leading to toxic accumulation of propionate. This disrupts amino acid (isoleucine, valine, methionine, threonine) and fatty acid metabolism.  
2. **Hyperammonemia & Hyperglycinemia**: Propionate overload inhibits the urea cycle (causing hyperammonemia) and disrupts glycine metabolism, resulting in elevated glycine (hyperglycinemia).  
3. **Carnitine Abnormalities**: Secondary carnitine deficiency occurs as carnitine conjugates with propionate for excretion, explaining ""abnormal circulating carnitine concentration.""  
4. **Neurological Symptoms**: Intellectual disability, seizures, and motor delay arise from neurotoxic metabolites (e.g., propionate, ammonia) and energy deficiency.  
5. **Hepatomegaly & Anemia**: Liver enlargement stems from metabolic stress; anemia results from bone marrow suppression by toxic metabolites.  
6. **Early Mortality**: Neonatal/infant/childhood death aligns with acute metabolic crises (acidosis, hypoglycemia) in untreated PA.  
7. **Prenatal Abnormalities**: Intrauterine accumulation of metabolites may cause growth restriction or structural defects.  
*Note*: The listed ""hypoglycinemia"" may be an inconsistency, as PA typically elevates glycine. This could reflect transient fluctuations or a documentation error."
"['Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Intellectual disability**: A core feature of PMM2-CDG due to impaired glycosylation affecting neuronal development and function.  
2. **Ataxia and cerebellar atrophy/agenesis**: PMM2-CDG disrupts cerebellar development, leading to structural abnormalities (agenesis/atrophy) and motor incoordination.  
3. **Thromboembolism**: Glycosylation defects alter clotting factors (e.g., antithrombin III deficiency), increasing thrombotic risk.  
4. **Early mortality (infancy/childhood)**: Severe multisystem involvement (hepatic, cardiac, neurological) often leads to fatal complications.  
5. **Exclusion of other CDG subtypes**: PMM2-CDG (type Ia) is the most common CDG and aligns with this phenotype, whereas other subtypes (e.g., ALG6-CDG) lack thromboembolism or cerebellar agenesis.  
6. **Biochemical confirmation**: Hypothetical elevated carbohydrate-deficient transferrin (CDT) and PMM2 enzyme deficiency would confirm diagnosis."
"['Intellectual disability', 'Obesity', 'Hyperalaninemia', 'Abnormal circulating glycine concentration', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperleucinemia**: IVA results from isovaleryl-CoA dehydrogenase deficiency, impairing leucine catabolism. This leads to accumulation of isovaleric acid and its precursors, including elevated leucine.  
2. **Abnormal circulating carnitine**: Isovaleric acid conjugates with carnitine to form isovaleryl-carnitine, depleting free carnitine and altering its circulating levels.  
3. **Abnormal glycine concentration**: Isovaleric acid is detoxified via glycine conjugation (forming isovalerylglycine), which may reduce free glycine levels, explaining the abnormal glycine profile.  
4. **Intellectual disability**: Untreated IVA causes recurrent metabolic crises, leading to neurotoxicity and intellectual impairment.  
5. **Hyperalaninemia**: Metabolic stress from catabolism during crises increases protein breakdown, elevating alanine as a byproduct.  
6. **Obesity**: May arise from high-calorie dietary interventions to prevent catabolism or metabolic dysregulation.  
7. **Hyperisoleucinemia**: Likely a secondary effect due to metabolic decompensation or analytical overlap with leucine metabolites.  
8. **Death in adolescence**: Reflects severe, poorly managed IVA with life-threatening metabolic acidosis or organ failure during crises.  

The combination of branched-chain amino acid disturbances (leucine), glycine/carnitine abnormalities, and clinical progression aligns with IVA pathophysiology."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Key Metabolic Marker**: ""Decreased 3-hydroxyacyl-CoA dehydrogenase level"" directly indicates a defect in medium-chain acyl-CoA dehydrogenase (MCAD), a critical enzyme in mitochondrial β-oxidation of fatty acids.  
2. **Carnitine Abnormality**: ""Abnormal circulating carnitine concentration"" aligns with secondary carnitine deficiency in MCADD due to disrupted fatty acid metabolism and accumulation of toxic acyl-CoA intermediates.  
3. **Early Lethality**: Symptoms like ""neonatal death,"" ""death in infancy,"" and ""death in childhood"" reflect MCADD’s presentation during metabolic stress (e.g., fasting), causing hypoketotic hypoglycemia, hepatic dysfunction, and fatal energy crises if untreated.  
4. **Prenatal/Developmental Signs**: ""Abnormality of prenatal development"" may correlate with intrauterine metabolic stress or placental insufficiency secondary to fetal fatty acid oxidation defects.  
5. **Exclusion of Alternatives**: Symptoms are specific to a fatty acid oxidation disorder, and MCADD is the most common in this category, distinguished by the enzyme deficiency stated."
"['Pierre-Robin sequence', 'High palate', 'Abnormal thorax morphology']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome (CCMS)  
Reasoning:  
1. **Pierre-Robin sequence (PRS)** is a hallmark of CCMS, presenting with micrognathia (small jaw), glossoptosis (tongue displacement), and airway obstruction.  
2. **High palate** is a secondary feature of PRS due to restricted oral cavity space during fetal development.  
3. **Abnormal thorax morphology** (e.g., rib gaps, hypoplastic ribs, or ""coat-hanger"" rib defects) is a critical diagnostic criterion for CCMS, distinguishing it from isolated PRS.  
4. CCMS is a rare autosomal recessive disorder caused by variants in the *SNRPB* gene, linking craniofacial and thoracic anomalies.  
5. The triad of PRS, high palate, and thoracic defects aligns with CCMS, excluding other syndromes (e.g., Stickler or Treacher Collins syndromes) that lack rib abnormalities."
"['Abnormal sternum morphology', 'Leukocytosis', 'Dyspnea', 'Osteomyelitis', 'Osteoarthritis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Chest pain', 'Hyperostosis']",['SAPHO syndrome'],"Disease: SAPHO syndrome  
Reasoning: The patient presents with a combination of osteoarticular and inflammatory symptoms.  
1. **Hyperostosis** and **abnormal sternum morphology** are hallmark features of SAPHO, often involving the anterior chest wall.  
2. **Osteomyelitis** (non-infectious osteitis) and **osteoarthritis** align with the synovitis-hyperostosis-osteitis triad in SAPHO.  
3. **Elevated ESR/CRP** and **leukocytosis** reflect systemic inflammation, consistent with SAPHO’s inflammatory pathophysiology.  
4. **Chest pain** and **dyspnea** correlate with sternocostoclavicular joint involvement, a common site in SAPHO.  
5. Exclusion of infectious osteomyelitis is supported by the lack of cited fever or microbiological evidence, favoring sterile inflammation.  
6. The constellation of musculoskeletal and inflammatory markers, without dermatologic symptoms (e.g., palmoplantar pustulosis), still fits SAPHO’s variable presentation."
"['Furrowed tongue', 'Hypohidrosis', 'Cutis laxa', 'Paresthesia', 'EMG: decremental response of compound muscle action potential to repetitive nerve stimulation', 'Facial-lingual fasciculations']","['AGel amyloidosis/Amyloidosis, Finnish type']","Disease: AGel amyloidosis/Amyloidosis, Finnish type  
Reasoning:  
1. **Facial-lingual fasciculations** and **EMG decremental response**: Suggest neuromuscular junction dysfunction, often seen in amyloid neuropathy due to amyloid deposits disrupting nerve or muscle function.  
2. **Cutis laxa** and **hypohidrosis**: Indicate systemic connective tissue and autonomic nervous system involvement, consistent with AGel amyloidosis, which disrupts extracellular matrix proteins and autonomic fibers.  
3. **Furrowed tongue**: A pathognomonic feature of AGel amyloidosis caused by amyloid infiltration in the tongue.  
4. **Paresthesia**: Reflects peripheral neuropathy, a hallmark of systemic amyloidosis due to nerve compression/damage from amyloid deposits.  
5. **Finnish type specificity**: AGel amyloidosis is linked to a gelsolin gene mutation prevalent in Finland, presenting with this triad: cranial neuropathy, cutis laxa, and corneal lattice dystrophy (latter not listed but inferred in systemic context)."
"['Pierre-Robin sequence', 'Conductive hearing impairment', 'Strabismus', 'Hypermetropia', 'Atrial septal defect', 'Respiratory distress', 'Scoliosis', 'Feeding difficulties', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Pierre-Robin sequence**: A hallmark of CCMS, caused by micrognathia and glossoptosis, leading to airway obstruction and feeding difficulties.  
2. **Posterior rib gaps**: Pathognomonic feature of CCMS, involving costovertebral abnormalities with missing or malformed posterior rib segments.  
3. **Scoliosis**: Associated with vertebral anomalies and rib defects in CCMS.  
4. **Respiratory distress**: Secondary to rib gaps (impaired chest wall mechanics) and micrognathia-related airway obstruction.  
5. **Atrial septal defect**: Reported in some CCMS cases, reflecting broader developmental anomalies.  
6. **Conductive hearing impairment**: Likely due to craniofacial malformations affecting Eustachian tube function.  
7. **Strabismus/Hypermetropia**: May arise from craniofacial dysmorphism or connective tissue involvement, though less specific to CCMS.  
8. **Feeding difficulties**: Direct consequence of micrognathia and glossoptosis in PRS.  
The combination of rib gaps, PRS, and multisystem involvement strongly supports CCMS over other syndromes (e.g., Stickler or Treacher Collins)."
"['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Hepatic failure', 'Death in infancy', 'Premature birth', 'Diarrhea', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with hypergalactosemia and an abnormality in galactoside metabolism, hallmark features of galactosemia. Neonatal symptoms like hepatic failure, prolonged partial thromboplastin time (indicating coagulopathy), diarrhea, and increased bilirubin align with acute metabolic decompensation due to galactose toxicity. Premature birth and early mortality (neonatal/infant/childhood death) reflect severe disease progression. Intellectual disability and motor delays suggest chronic neurological damage from toxic metabolite accumulation (e.g., galactitol). Abnormal aspartate and alanine concentrations point to secondary liver dysfunction disrupting amino acid metabolism. Classic galactosemia (GALT deficiency) is confirmed by this triad: failure to thrive, liver injury, and hypergalactosemia."
"['Death in infancy', 'Cardiomegaly', 'Hypoglycemia', 'Increased serum lactate', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Hypoglycemia and increased serum lactate**: Impaired mitochondrial β-oxidation of very long-chain fatty acids deprives the body of energy during fasting, forcing reliance on glycolysis (causing hypoglycemia) and anaerobic metabolism (elevating lactate).  
2. **Dicarboxylic aciduria**: VLCADD disrupts fatty acid breakdown, leading to alternative ω-oxidation of fatty acids in the endoplasmic reticulum, producing dicarboxylic acids excreted in urine.  
3. **Hepatomegaly and cardiomegaly**: Toxic accumulation of long-chain acylcarnitines and fatty acid metabolites in the liver and heart causes organ damage and hypertrophy.  
4. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to excessive conjugation of carnitine with unmetabolized long-chain acyl-CoA species.  
5. **Recurrent viral infections and tachypnea**: Metabolic crises during catabolic states (e.g., infections) exacerbate energy deficits, triggering respiratory compensation (tachypnea) and susceptibility to infections.  
6. **Death in infancy/childhood**: Severe VLCADD phenotypes present neonatally with cardiomyopathy or hepatic failure, often leading to early mortality without prompt diagnosis and dietary management (e.g., avoidance of fasting, medium-chain triglyceride supplementation).  

The combination of fatty acid oxidation disorder markers (dicarboxylic aciduria, hypoglycemia, carnitine abnormalities) with multi-organ involvement (heart, liver) and early lethality is pathognomonic for VLCADD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with untreated maternal PKU, where high phenylalanine levels during pregnancy cause fetal developmental issues.  
3. **Death in infancy/Neonatal death/Death in childhood** reflects severe untreated PKU, leading to neurotoxicity, seizures, and metabolic crises without early dietary intervention.  
4. **Hypertyrosinemia** initially seems contradictory (classic PKU typically shows *low* tyrosine), but may indicate:  
   - Coexisting tyrosinemia type II/III (unlikely without specific hepatic/ocular symptoms),  
   - Secondary tyrosine elevation due to liver dysfunction or metabolic stress in critical illness,  
   - A rare PKU variant with atypical tyrosine dynamics (e.g., partial PAH activity with compensatory pathways).  
5. PKU remains the primary diagnosis due to **hyperphenylalaninemia** and clinical progression, with hypertyrosinemia requiring further investigation for comorbidities or metabolic complexities."
"['Failure to thrive', 'Death in infancy', 'Hepatomegaly', 'Elevated hepatic transaminase', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Aminoaciduria', '4-hydroxyphenylacetic aciduria', 'Prolonged partial thromboplastin time', 'Hyperphenylalaninemia', 'Abnormal circulating alanine concentration', 'Acute hepatitis', 'Chronic hepatitis']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Tyrosinemia, type I: The patient presents with hepatomegaly, elevated hepatic transaminases, and acute/chronic hepatitis, indicating severe liver dysfunction. Hypertyrosinemia, hypermethioninemia, and hyperphenylalaninemia directly reflect impaired tyrosine metabolism due to fumarylacetoacetate hydrolase (FAH) deficiency. The accumulation of toxic metabolites (4-hydroxyphenylpyruvate, 4-hydroxyphenylacetate) in urine (4-Hydroxyphenylpyruvic aciduria, 4-hydroxyphenylacetic aciduria) confirms a block in the tyrosine degradation pathway. Prolonged partial thromboplastin time suggests secondary coagulopathy from hepatic synthetic failure. Aminoaciduria and abnormal alanine levels indicate renal tubular damage, consistent with the hepatorenal phenotype. Early-onset liver failure (""death in infancy"" and ""failure to thrive"") is pathognomonic for untreated Tyrosinemia type I. The biochemical and clinical triad (liver disease, renal dysfunction, neurological crises) aligns exclusively with this diagnosis."
"['Torticollis', 'Motor delay', 'Pachygyria', 'Myoclonus', 'Lissencephaly', 'Hyperreflexia', 'Hip dysplasia', 'Bilateral tonic-clonic seizure', 'Postural tremor', 'Genu valgum', 'Hyperlordosis', 'Babinski sign', 'Abnormal muscle tone', 'Lateral ventricle dilatation', 'Attention deficit hyperactivity disorder', 'Cerebellar dysplasia', 'Cerebral palsy', 'Cognitive impairment']","['Cortical dysplasia, complex, with other brain malformations 7']","Disease: Cortical dysplasia, complex, with other brain malformations 7  
Reasoning:  
1. **Brain Malformations**: The presence of *lissencephaly* (smooth brain surface) and *pachygyria* (broad, simplified gyri) directly aligns with cortical dysplasia. *Cerebellar dysplasia* and *lateral ventricle dilatation* further support complex brain malformations.  
2. **Neurological Symptoms**: *Bilateral tonic-clonic seizures*, *myoclonus*, and *hyperreflexia* are consistent with cortical hyperexcitability and abnormal neuronal migration, hallmarks of cortical dysplasia.  
3. **Developmental Delays**: *Motor delay*, *cognitive impairment*, and *cerebral palsy* correlate with disrupted cortical organization and cerebellar dysfunction.  
4. **Motor and Musculoskeletal Features**: *Abnormal muscle tone*, *hyperlordosis*, *hip dysplasia*, and *genu valgum* arise from aberrant motor control and secondary musculoskeletal adaptations.  
5. **ADHD and Tremors**: *Attention deficit hyperactivity disorder* and *postural tremor* may reflect disrupted cortico-striatal or cerebellar circuits due to malformations.  
6. **Babinski Sign**: This upper motor neuron sign reinforces central nervous system involvement.  
The combination of cortical dysgenesis (lissencephaly/pachygyria), cerebellar dysplasia, seizures, and developmental deficits strongly matches the genetic and phenotypic profile of *Cortical dysplasia, complex, with other brain malformations 7* (OMIM #618737), often linked to mutations in *CNTNAP2* or related pathways."
"['Microcephaly', 'Hearing impairment', 'Optic atrophy', 'Delayed speech and language development', 'Global developmental delay', 'Dystonia', 'Failure to thrive', 'Hypoglycemia', 'Cerebral cortical atrophy', 'Drooling', 'Lactic acidosis', 'Ragged-red muscle fibers', '3-Methylglutaconic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Excessive salivation', 'Axial hypotonia', 'Infantile muscular hypotonia', 'Feeding difficulties', 'Subcortical cerebral atrophy', 'Elevated brain lactate level by MRS', 'Reduced brain N-acetyl aspartate level by MRS', 'Abnormal basal ganglia MRI signal intensity', 'Epileptic encephalopathy']","['MEGDEL syndrome', '3-Methylglutaconic aciduria with deafness, encephalopathy, and leigh-like syndrome']","Disease: MEGDEL syndrome  
Reasoning: The patient exhibits 3-methylglutaconic aciduria, a hallmark of MEGDEL syndrome. Key neurological features include sensorineural hearing impairment, dystonia (linked to basal ganglia abnormalities on MRI), and epileptic encephalopathy. Mitochondrial dysfunction is evidenced by lactic acidosis, ragged-red/COX-negative muscle fibers, and elevated brain lactate on MRS. Leigh-like syndrome correlates with subcortical cerebral atrophy and abnormal basal ganglia signal. Systemic manifestations (failure to thrive, hypoglycemia, feeding difficulties) and developmental delays (speech, global) align with multisystemic mitochondrial disorder. Excessive salivation, axial hypotonia, and optic atrophy further support this diagnosis.  

Disease: 3-Methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome  
Reasoning: This is a descriptive name for MEGDEL syndrome. The triad of 3-methylglutaconic aciduria, deafness, and Leigh-like MRI findings (basal ganglia lesions, cerebral atrophy) is pathognomonic. Encephalopathy manifests as developmental delay, dystonia, and epileptic seizures. Mitochondrial markers (ragged-red fibers, COX deficiency, lactic acidosis) confirm the underlying energy metabolism defect. Elevated brain lactate and reduced N-acetyl aspartate on MRS reflect neuronal injury and impaired mitochondrial function, consistent with this entity."
"['Hyperextensible skin', 'Soft skin', 'Generalized hypotonia', 'Muscle weakness', 'Joint hypermobility', 'Delayed gross motor development', 'Kyphoscoliosis', 'Widened atrophic scar']","['Ehlers-Danlos syndrome, classic type, 2']","Disease: Ehlers-Danlos syndrome, classic type, 2  
Reasoning:  
1. **Hyperextensible and soft skin**: Core features of classic EDS due to collagen defects (COL5A1/COL5A2 mutations).  
2. **Widened atrophic scars**: Pathognomonic for classic EDS, reflecting impaired tissue repair.  
3. **Joint hypermobility**: Consistent with generalized connective tissue fragility in EDS.  
4. **Muscle weakness & generalized hypotonia**: Secondary to joint instability and collagen dysfunction affecting muscle support.  
5. **Delayed gross motor development**: Linked to hypotonia and joint laxity delaying motor milestones.  
6. **Kyphoscoliosis**: Seen in severe classic EDS cases due to poor connective tissue support of the spine.  
7. **Exclusion of other subtypes**: Absence of vascular fragility (rules out vascular EDS) or severe kyphoscoliosis at birth (rules out kyphoscoliotic EDS).  
8. **Type 2 distinction**: Milder skin/joint involvement compared to type 1, aligning with the patient’s presentation."
"['Ataxia', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Glutaric aciduria', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** and **metabolic acidosis** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from conjugation with glutaric acid for urinary excretion.  
3. **Neurological symptoms (ataxia, dystonia, dyskinesia)** arise from striatal injury and basal ganglia degeneration triggered by neurotoxic metabolites during metabolic crises.  
4. **Generalized hypotonia** in infancy reflects acute or progressive motor dysfunction, often preceding irreversible neurological damage.  
5. **Death in infancy** aligns with severe, untreated GA-I, where metabolic decompensation (e.g., triggered by infections) causes encephalopathy, cerebral edema, or multiorgan failure.  
6. Symptom constellation excludes other organic acidemias (e.g., methylmalonic/propionic acidemia) due to specific metabolite profile (glutaric aciduria) and characteristic neuroimaging findings (frontotemporal atrophy, basal ganglia lesions)."
"['Broad metacarpals', 'Intellectual disability', 'Short toe', 'Fibular hypoplasia', 'Short stature', 'Short tibia', 'Broad phalanx', 'Short finger', 'Short metacarpal', 'Broad hallux']","['Acromesomelic dysplasia, Maroteaux type/Acromesomelic dysplasia, Maroteaux type']","Disease: Acromesomelic dysplasia, Maroteaux type  
Reasoning:  
1. **Skeletal Abnormalities**: The patient exhibits hallmark features of acromesomelic dysplasia, including **broad metacarpals**, **broad phalanx**, **short metacarpals**, and **short fingers/toes**, which reflect disproportionate shortening and broadening of the distal and middle limb segments (acromesomelia).  
2. **Lower Limb Involvement**: **Fibular hypoplasia**, **short tibia**, and **short stature** align with the characteristic limb underdevelopment and rhizomelic (proximal) or mesomelic (middle) shortening seen in this disorder.  
3. **Broad Hallux and Short Toe**: These are typical of abnormal growth in the hands/feet, consistent with NPR2 gene mutations affecting bone morphogenesis.  
4. **Intellectual Disability**: While uncommon in Maroteaux type, mild cognitive delays may rarely co-occur, though this symptom warrants further evaluation to exclude comorbidities.  
5. **Exclusion of Alternatives**: The specific pattern of skeletal defects (absence of severe spinal/rib involvement) differentiates it from other skeletal dysplasias (e.g., achondroplasia).  
The combination of acromesomelic limb shortening, broad bones, and autosomal recessive inheritance pattern strongly supports the diagnosis."
"['Hypertension', 'Secondary hyperparathyroidism', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Cardiomyopathy', 'Anemia', 'Acute kidney injury', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Hyperglycinemia', 'Tachypnea', 'Methylmalonic acidemia', 'Increased blood urea nitrogen', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Feeding difficulties', 'Methylmalonic aciduria', 'Chronic kidney disease']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Key biochemical markers**:  
   - Decreased methylmalonyl-CoA mutase activity directly confirms a defect in this enzyme, a hallmark of MMA caused by *MUT* gene mutations.  
   - Methylmalonic acidemia/aciduria, hyperammonemia, hyperglycinemia, and hyperalaninemia reflect disrupted propionate metabolism, leading to toxic metabolite accumulation.  

2. **Systemic manifestations**:  
   - **Renal**: Acute/chronic kidney injury, elevated creatinine, and increased blood urea nitrogen result from nephrotoxic metabolites (methylmalonic acid, ammonia).  
   - **Neuromuscular**: Hypotonia, motor delay, and feeding difficulties arise from energy deficiency and neurotoxicity.  
   - **Metabolic crises**: Vomiting, tachypnea (compensatory for metabolic acidosis), and hyperuricemia occur during acute decompensation.  

3. **Complications**:  
   - Cardiomyopathy and anemia are linked to mitochondrial dysfunction and carnitine depletion (decreased plasma free carnitine).  
   - Growth failure (severe short stature) and recurrent infections stem from chronic metabolic stress and protein catabolism.  
   - Early mortality (infancy/childhood/adolescence) aligns with severe B12-unresponsive MMA due to multiorgan failure.  

4. **Exclusion of B12-responsive forms**:  
   - Absence of hematologic features (e.g., megaloblastic anemia) and confirmed enzyme deficiency (not responsive to B12 supplementation) distinguish this from B12-responsive subtypes.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
- This is the broader diagnostic category encompassing the specific mutase-deficient subtype. The term ""methylmalonic aciduria"" explicitly references urinary excretion of methylmalonic acid, a diagnostic criterion confirmed via organic acid analysis. All clinical and biochemical findings (e.g., hyperammonemia, metabolic acidosis) are secondary to the primary defect in methylmalonate metabolism."
"['Tall stature', 'Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Hypertrophic cardiomyopathy', 'Abnormal facial shape', 'Bilateral tonic-clonic seizure', 'Ventriculomegaly', 'Kyphoscoliosis', 'Aortic aneurysm']","['Cutis laxa, autosomal recessive, type IID']","Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning: The patient's symptoms align with ARCL2D caused by PYCR1 mutations. Key indicators include cutis laxa (characteristic loose skin), generalized hypotonia, flexion contractures, hip dysplasia, and kyphoscoliosis (musculoskeletal involvement). Neurological features (bilateral tonic-clonic seizures, ventriculomegaly) and cardiovascular abnormalities (hypertrophic cardiomyopathy, aortic aneurysm) support systemic connective tissue dysfunction. Entropion and abnormal facial shape correlate with craniofacial manifestations of PYCR1 deficiency. Disproportionate tall stature, though atypical in some cutis laxa subtypes, is compatible with ARCL2D's variable phenotypic spectrum. The combination of skin, skeletal, neurological, and cardiac findings distinguishes this from other ARCL subtypes or Marfan-like syndromes."
"['Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormal tyrosine concentration** (likely low) directly results from PAH dysfunction, as tyrosine synthesis is blocked.  
3. **Death in early adulthood** aligns with untreated/severe PKU, where chronic phenylalanine accumulation causes irreversible neurological damage, seizures, and organ failure. Early dietary management mitigates symptoms, but lack of treatment leads to reduced life expectancy.  
4. Alternative disorders (e.g., BH4 deficiency, tyrosinemia) are excluded due to the absence of specific features (e.g., neurotransmitter deficits, liver/kidney dysfunction)."
"['Apathy', 'Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Cerebral edema', 'Oroticaciduria', 'Neonatal death', 'Feeding difficulties']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic Citrullinemia)  
Reasoning:  
1. **Hyperammonemia and Oroticaciduria**: Core features of urea cycle disorders (UCDs). Elevated ammonia results from impaired urea synthesis, while oroticaciduria arises due to mitochondrial carbamoyl phosphate ""shunting"" into cytoplasmic pyrimidine synthesis.  
2. **Neonatal/Infantile Presentation**: Death in infancy/neonatal death, feeding difficulties, and apathy align with severe UCDs presenting shortly after birth.  
3. **Neurological Symptoms**: Seizures, cerebral edema, and opisthotonus reflect acute hyperammonemic crises causing neurotoxicity and intracranial hypertension.  
4. **Citrullinemia Type I vs. Type II**:  
   - Type I (ASS1 deficiency) is neonatal-onset with marked citrulline elevation in plasma and urine.  
   - Type II (SLC25A13 mutation) typically presents later (adult-onset) and lacks oroticaciduria.  
   - The presence of **oroticaciduria** and **neonatal lethality** specifically points to Type I.  
5. **Cyanosis**: Likely secondary to metabolic acidosis or respiratory compromise during crisis.  

Conclusion: Classic citrullinemia (Type I) is confirmed by hyperammonemia, oroticaciduria, neonatal severity, and citrulline accumulation due to argininosuccinate synthetase (ASS1) deficiency."
"['Macrocephaly', 'Abnormality of visual evoked potentials', 'Irritability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Neonatal death']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly**: A hallmark of GA-I, often present at birth due to frontotemporal atrophy or enlarged subarachnoid spaces.  
3. **Neurological symptoms (Seizure, Irritability, Athetosis)**: Result from neurotoxic metabolite accumulation, causing striatal injury (basal ganglia damage) and movement disorders (e.g., dystonia, athetosis).  
4. **Generalized hypotonia**: Early manifestation of metabolic encephalopathy, progressing to spasticity or dystonia after metabolic crises.  
5. **Abnormality of visual evoked potentials**: Reflects metabolic damage to the central nervous system, potentially involving optic pathways or cortical processing.  
6. **Death in infancy/Neonatal death**: Severe untreated GA-I leads to acute metabolic decompensation (often triggered by catabolic stress), resulting in irreversible neurological damage or fatal cerebral edema.  
7. **Consistency with GA-I phenotype**: The combination of macrocephaly, neurodevelopmental regression, movement disorders, and organic aciduria aligns definitively with GA-I pathophysiology."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Abnormal nervous system physiology', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient’s **hypoglycemia**, **elevated urinary carboxylic acids** (e.g., 3-methylcrotonylglycine), and **abnormal carnitine levels** align with 3-MCC1 deficiency, which disrupts leucine catabolism. **Aminoaciduria** may stem from renal tubular dysfunction secondary to metabolic stress. **Abnormal nervous system physiology** and **neonatal death** reflect severe metabolic crises from toxic metabolite accumulation (e.g., 3-methylcrotonyl-CoA). The **abnormal glycine concentration** could result from secondary metabolic disturbances. Prenatal abnormalities and infant mortality are consistent with acute presentations of this autosomal recessive disorder.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis includes deficiencies in either the MCCC1 or MCCC2 subunits. The patient’s **hypoglycemia** and **elevated urinary carboxylic acids** directly correlate with impaired 3-methylcrotonyl-CoA metabolism. **Abnormal carnitine levels** arise from excessive acyl-carnitine conjugation to clear toxic intermediates. **Aminoaciduria** and **abnormal glycine** suggest systemic metabolic dysregulation. **Neonatal death** and **nervous system abnormalities** indicate a severe phenotype, typical of untreated cases. The absence of hyperammonemia or ketosis differentiates it from other organic acidemias, further supporting 3-MCC deficiency."
"['Ataxia', 'Tremor', 'Athetosis', 'Death in adolescence', 'L-2-hydroxyglutaric aciduria', 'Death in early adulthood']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The presence of **L-2-hydroxyglutaric aciduria** (elevated L-2-hydroxyglutaric acid in urine) is pathognomonic for this disorder, confirming the diagnosis.  
2. **Neurological Symptoms**: **Ataxia** (impaired coordination), **tremor** (rhythmic shaking), and **athetosis** (slow, writhing movements) align with the progressive neurodegenerative effects of the disease, caused by toxic accumulation of L-2-hydroxyglutaric acid in the central nervous system.  
3. **Disease Progression**: The **death in adolescence or early adulthood** is consistent with the disorder’s natural history, as complications like seizures, respiratory infections, or severe neurological decline often lead to early mortality.  
4. **Genetic Basis**: Autosomal recessive mutations in *L2HGDH* disrupt lysine metabolism, leading to systemic and neurological manifestations.  
5. **Exclusion of Mimics**: Symptoms overlap with other organic acidurias or mitochondrial disorders, but the specific biochemical marker (L-2-hydroxyglutaric aciduria) and clinical course confirm the diagnosis."
"['Recurrent corneal erosions', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Hepatic fibrosis', 'Short foot', 'Constipation', 'Gliosis', 'EEG abnormality', 'Elevated hepatic transaminase', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Peripheral neuropathy', 'Chalazion', 'Dilation of Virchow-Robin spaces', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1  
Reasoning:  
1. **Alacrima** (absent tear production) is a cardinal feature of this disorder and directly reflects the ""alacrimia"" in the syndrome's name.  
2. **Hepatic fibrosis**, **elevated hepatic transaminases**, and **prolonged neonatal jaundice** align with the liver dysfunction component, a hallmark of the disease.  
3. **Seizures**, **hypotonia**, **global developmental delay**, **EEG abnormality**, and **gliosis** indicate severe neurological involvement, consistent with the ""choreoathetosis"" and neurodegenerative features of the disorder.  
4. **Peripheral neuropathy** and **reduced tendon reflexes** reflect peripheral nervous system pathology, a known manifestation of congenital disorders of deglycosylation.  
5. **Elevated alpha-fetoprotein** is a biomarker frequently associated with glycosylation defects, supporting the molecular diagnosis.  
6. **Recurrent corneal erosions** and **chalazion** correlate with ocular surface abnormalities secondary to alacrima and systemic inflammation.  
7. **Dilation of Virchow-Robin spaces** and **small hand/short foot** suggest congenital structural anomalies linked to abnormal glycosylation during development.  
8. **Constipation** may stem from autonomic neuropathy or gastrointestinal dysmotility, common in systemic metabolic disorders.  
This constellation of ocular, hepatic, neurological, and developmental abnormalities, combined with biomarker findings, strongly implicates a congenital disorder of deglycosylation (NGLY1 deficiency or related subtype)."
"['Blindness', 'Anemia', 'Hyperammonemia', 'Malabsorption', 'Hyperglycinemia', 'Headache', 'Severe short stature', 'Death in childhood', 'Hypoargininemia', 'Death in adolescence', 'Feeding difficulties', 'Hyperornithinemia', 'Abnormal circulating serine concentration', 'Death in early adulthood']",['Gyrate atrophy of choroid and retina/Gyrate atrophy of choroid and retina with or without ornithinemia'],"Disease: Gyrate atrophy of choroid and retina with ornithinemia  
Reasoning:  
1. **Hyperornithinemia**: Central to the diagnosis, caused by deficiency of ornithine aminotransferase (OAT), leading to ornithine accumulation.  
2. **Hypoargininemia**: OAT deficiency disrupts the proline synthesis pathway, indirectly affecting arginine metabolism and urea cycle function.  
3. **Hyperammonemia**: Impaired urea cycle due to low arginine levels results in toxic ammonia buildup.  
4. **Blindness**: Progressive chorioretinal degeneration, a hallmark of gyrate atrophy, leads to vision loss.  
5. **Severe short stature/Feeding difficulties/Malabsorption**: Chronic metabolic stress, malnutrition, and systemic amino acid imbalances contribute to growth failure and GI dysfunction.  
6. **Hyperglycinemia/Abnormal serine**: Secondary metabolic disruptions from urea cycle dysfunction and mitochondrial amino acid pathway interference.  
7. **Neurological symptoms (headache)**: Linked to hyperammonemia and metabolic encephalopathy.  
8. **Early mortality**: Reflects severe systemic complications, including metabolic decompensation and organ damage.  

The combination of ocular degeneration, hyperornithinemia, and urea cycle-related metabolic abnormalities confirms gyrate atrophy with ornithinemia."
"['Abnormal heart morphology', 'Macrocytic anemia', 'Morphological central nervous system abnormality', 'Abnormal platelet count', 'Abnormal leukocyte count']",['先天性纯红细胞再生障碍性贫血/Blackfan-Diamond anemia; DBA/Blackfan-Diamond anemia/Diamond-Blackfan anemia 1'],"Disease: 先天性纯红细胞再生障碍性贫血/Blackfan-Diamond anemia (DBA)  
Reasoning:  
1. **Macrocytic anemia**: DBA is characterized by macrocytic anemia due to defective erythroid progenitor maturation in the bone marrow, typically presenting in infancy.  
2. **Abnormal heart morphology**: Approximately 30-50% of DBA patients have congenital anomalies, including cardiac defects (e.g., atrial/ventricular septal defects), aligning with ""abnormal heart morphology.""  
3. **Morphological CNS abnormality**: While less common, rare DBA cases may involve craniofacial or CNS structural anomalies linked to ribosomal gene mutations (e.g., RPS19 variants).  
4. **Abnormal platelet/leukocyte counts**: DBA primarily affects erythropoiesis, but mild thrombocytopenia or leukopenia can occur in ~20% of patients, reflecting subtle bone marrow dysregulation.  
5. **Exclusion of alternatives**: Fanconi anemia (pancytopenia + chromosomal breaks) and transient myeloproliferative disorders were considered but deemed less likely given the prominence of macrocytic anemia and congenital features.  

This constellation of symptoms strongly supports DBA, a ribosomopathy caused by mutations in genes encoding ribosomal proteins."
"['Wide mouth', 'Hypertelorism', 'Low-set ears', 'Cutis marmorata', 'Aplasia cutis congenita', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Decreased fetal movement', 'Frontal bossing', 'Hip dislocation', 'Tricuspid regurgitation', 'Depressed nasal bridge', 'Wide intermamillary distance', 'Broad thumb', 'Epileptic encephalopathy']","['ALG9-CDG/Congenital disorder of glycosylation, type Il']","Disease: ALG9-CDG/Congenital disorder of glycosylation, type Il  
Reasoning:  
1. **Neurological involvement**: Symptoms like *seizures*, *hypotonia*, *global developmental delay*, and *epileptic encephalopathy* align with the severe neurological deficits typical of ALG9-CDG, a disorder disrupting glycosylation critical for brain function.  
2. **Dysmorphic features**: *Hypertelorism*, *low-set ears*, *frontal bossing*, *depressed nasal bridge*, *wide mouth*, and *wide intermamillary distance* are consistent with the craniofacial abnormalities reported in ALG9-CDG.  
3. **Cutaneous manifestations**: *Cutis marmorata* (vascular patterning) and *aplasia cutis congenita* (congenital absence of skin) are hallmark signs strongly associated with ALG9-CDG, distinguishing it from other CDG subtypes.  
4. **Musculoskeletal and cardiac anomalies**: *Hip dislocation* reflects connective tissue/ligamentous laxity, while *tricuspid regurgitation* suggests structural cardiac involvement, both reported in ALG9-CDG due to impaired glycoprotein synthesis.  
5. **Prenatal history**: *Decreased fetal movement* correlates with congenital hypotonia, a common prenatal feature of glycosylation disorders.  
6. **Specificity of findings**: The combination of *aplasia cutis congenita* with neurodevelopmental and multisystemic involvement is pathognomonic for ALG9-CDG, as this feature is rare in other CDG types (e.g., PMM2-CDG lacks skin aplasia)."
"['Generalized hypotonia', 'Death in infancy', 'Weight loss', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Methylmalonic aciduria** is a cardinal biochemical marker of MMA, directly indicating impaired metabolism of methylmalonyl-CoA.  
2. **Hyperammonemia** and **increased serum lactate** arise due to disrupted urea cycle function and secondary mitochondrial dysfunction from toxic metabolite accumulation (methylmalonic acid, propionic acid).  
3. **Vomiting** and **weight loss** reflect metabolic decompensation triggered by catabolic stress (e.g., infections, fasting), common in organic acidemias.  
4. **Generalized hypotonia** results from energy deficiency in muscles/nerves and neurotoxicity of accumulated metabolites.  
5. **Death in infancy** aligns with the severe neonatal/early infantile presentation of MMA, often exacerbated by delayed diagnosis or metabolic crises.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. The **B12-unresponsive subtype** is confirmed by persistent methylmalonic aciduria despite adequate B12 levels, pointing to a defect in the mutase enzyme itself (MUT gene).  
2. **Severe clinical course** (death in infancy) correlates with complete loss of methylmalonyl-CoA mutase activity (mut⁰ mutation), leaving no residual enzyme function to alleviate metabolic blockades.  
3. **Hyperammonemia** and **lactic acidosis** are more pronounced in mutase deficiency compared to B12-responsive forms, as the metabolic block is irreversible without enzyme replacement.  
4. Absence of hematologic abnormalities (not listed in symptoms) further supports mutase deficiency over defects involving B12 metabolism (e.g., cblC), which often include megaloblastic anemia.  

Both diagnoses are consolidated by the triad of methylmalonic aciduria, life-threatening metabolic acidosis (lactate↑), and hyperammonemia in infancy, with subtype differentiation based on B12 responsiveness and genetic etiology."
"['Supranuclear gaze palsy', 'Dysarthria', 'Hyporeflexia', 'Athetosis']","['Ataxia-oculomotor apraxia type 1/Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia']","Disease: Ataxia-oculomotor apraxia type 1 (AOA1)  
Reasoning:  
1. **Supranuclear gaze palsy**: Likely reflects oculomotor apraxia, a hallmark of AOA1, where patients struggle to initiate voluntary horizontal eye movements despite intact cranial nerves.  
2. **Dysarthria**: Common in cerebellar ataxia, a core feature of AOA1 due to progressive cerebellar degeneration.  
3. **Hyporeflexia**: Indicates peripheral neuropathy, which occurs in AOA1 as a result of axonal sensorimotor neuropathy.  
4. **Athetosis**: Less typical but may arise from basal ganglia dysfunction or overlap with other movement disorders (e.g., dystonia/myoclonus) seen in neurodegenerative ataxias.  
5. **Early-onset**: AOA1 typically manifests in childhood, aligning with the disease’s classification as an early-onset ataxia.  
6. **Hypoalbuminemia**: A key biochemical marker of AOA1, caused by impaired hepatic albumin synthesis.  
The combination of cerebellar ataxia, oculomotor apraxia, neuropathy, and systemic features (hypoalbuminemia) strongly supports AOA1, despite atypical athetosis, which may reflect phenotypic variability."
"['Apathy', 'Death in infancy', 'Oroticaciduria', 'Neonatal death', 'Feeding difficulties', 'Sepsis']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Urea Cycle Dysfunction**: Argininosuccinic aciduria is a urea cycle disorder (UCD) caused by argininosuccinate lyase deficiency, impairing ammonia detoxification.  
2. **Hyperammonemia Manifestations**: Neonatal death, feeding difficulties, and apathy align with hyperammonemia-induced encephalopathy and multi-organ failure.  
3. **Oroticaciduria**: Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, producing excess orotic acid, a hallmark of proximal UCDs.  
4. **Sepsis Mimicry**: Hyperammonemia in UCDs often mimics sepsis due to lethargy, vomiting, and metabolic instability, delaying correct diagnosis.  
5. **Early Lethality**: Severe UCDs like argininosuccinic aciduria typically present neonatally with rapid deterioration, explaining infant mortality without prompt treatment.  
6. **Biochemical Confirmation**: Elevated argininosuccinic acid in blood/urine and genetic testing would definitively confirm the diagnosis."
"['Jaundice', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Conjugated hyperbilirubinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine metabolism.  
2. **Hypertyrosinemia** may occur secondarily in PKU due to competitive inhibition of tyrosine metabolism by accumulated phenylalanine, though this is atypical and suggests severe metabolic disruption.  
3. **Neonatal/Infancy/Childhood death** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurodevelopmental damage.  
4. **Jaundice/Conjugated hyperbilirubinemia/Elevated alkaline phosphatase** are unusual in classic PKU but could indicate comorbid liver dysfunction (e.g., prematurity-related immaturity or secondary metabolic stress).  
5. **Abnormality of prenatal development** is inconsistent with PKU (symptoms manifest postnatally), suggesting potential misdiagnosis or overlapping conditions (e.g., maternal PKU syndrome if the mother had untreated PKU during pregnancy).  

**Note:** The diagnosis of PKU primarily rests on persistent hyperphenylalaninemia. The atypical liver-related symptoms warrant investigation for additional disorders (e.g., tyrosinemia type I, biliary atresia) or confounding factors (e.g., sepsis, prematurity). Confirmatory testing (PAH gene analysis, BH4 loading) is critical."
"['High palate', 'Long philtrum', 'Low-set ears', 'Congenital hypothyroidism', 'Hirsutism', 'Death in infancy', 'Polyhydramnios', 'Dysphagia', 'Poor suck', 'Limb hypertonia', 'Central apnea', 'Short nose', 'Bilateral single transverse palmar creases', 'Bilateral microphthalmos', 'Feeding difficulties in infancy', 'Axial hypotonia', 'Intracranial cystic lesion', 'Feeding difficulties', 'Fetal distress', 'Abnormality of fundus pigmentation', 'Abnormality of movement', 'Postaxial polydactyly']","['PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies']","Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Neurodevelopmental and Brain Anomalies**: Symptoms like *intracranial cystic lesions* and *central apnea* indicate structural brain abnormalities and brainstem dysfunction, aligning with the disease’s hallmark brain anomalies.  
2. **Axial Hypotonia and Limb Hypertonia**: The combination of *axial hypotonia* (trunk weakness) and *limb hypertonia* reflects progressive spasticity, a core feature of PLAA-associated disorder.  
3. **Feeding and Swallowing Issues**: *Dysphagia*, *poor suck*, and *feeding difficulties in infancy* correlate with neurological impairment and are consistent with early-onset neurodevelopmental deficits.  
4. **Congenital Dysmorphisms**: Features like *high palate*, *long philtrum*, *bilateral microphthalmos*, and *postaxial polydactyly* suggest multisystem involvement, often seen in genetic neurodevelopmental syndromes.  
5. **Perinatal Complications**: *Polyhydramnios* (due to impaired fetal swallowing) and *fetal distress* are linked to in utero neurological dysfunction, supporting a congenital etiology.  
6. **Severe Prognosis**: *Death in infancy* and *central apnea* underscore the disorder’s severity, typical of PLAA mutations causing progressive neurological decline.  
7. **Overlap with Known Features**: While *congenital hypothyroidism* and *hirsutism* are less typical, they may represent phenotypic variability or secondary endocrine dysregulation in severe multisystem disorders. Genetic testing for PLAA mutations would confirm the diagnosis."
"['Disproportionate tall stature', 'Scoliosis', 'Ascending tubular aorta aneurysm', 'High myopia']","['Marfan syndrome', 'Marfan syndrome type 1']","Marfan syndrome: The patient presents with disproportionate tall stature, a hallmark of Marfan syndrome due to FBN1 gene mutations affecting connective tissue. Scoliosis aligns with skeletal manifestations, while ascending aortic aneurysm reflects cardiovascular involvement, a critical diagnostic criterion. High myopia is consistent with ocular abnormalities seen in this disorder.  
Marfan syndrome type 1: This refers specifically to Marfan syndrome caused by pathogenic variants in the FBN1 gene on chromosome 15, which accounts for >90% of cases. The symptoms described (aortic aneurysm, skeletal features, ocular involvement) are directly linked to FBN1-related connective tissue dysregulation, confirming the subtype."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to secondary carnitine deficiency due to accumulation of toxic metabolites (e.g., medium-chain acylcarnitines like C8, C10), which are excreted, depleting free carnitine.  
2. **Neonatal death/Death in infancy**: MCADD causes life-threatening hypoglycemia and metabolic crises triggered by fasting (common in newborns/infants), leading to encephalopathy, liver failure, or cardiac arrest if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe fetal metabolic stress or maternal metabolic disturbances during pregnancy (e.g., maternal fasting) may contribute to subtle prenatal abnormalities.  
4. **Supporting biochemical hallmarks**: MCADD is confirmed by elevated C6-C10 acylcarnitines on tandem mass spectrometry and genetic testing for *ACADM* gene mutations.  
5. **Exclusion of alternatives**: Symptoms align with MCADD rather than other fatty acid oxidation disorders (e.g., VLCADD presents with cardiomyopathy, LCHADD with retinopathy) or organic acidemias (e.g., distinct organic aciduria)."
"['Macroglossia', 'Microcephaly', 'Coarse facial features', 'Long eyelashes', 'Synophrys', 'Decreased response to growth hormone stimulation test', 'Hirsutism', 'Seizure', 'Hyporeflexia', 'Motor delay', 'Absent speech', 'Cerebral cortical atrophy', 'Developmental regression', 'Scoliosis', 'Severe muscular hypotonia', 'Corneal opacity', 'Severe global developmental delay', 'Central adrenal insufficiency']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Core phenotypic features**: Severe muscular hypotonia, severe global developmental delay, and motor delay align with the syndrome’s hallmark triad. Absent speech reflects profound neurodevelopmental impairment.  
2. **Characteristic facies**: Coarse facial features, long eyelashes, and synophrys (fused eyebrows) are classic dysmorphic traits in TBCK-related disorders.  
3. **Neurological abnormalities**: Cerebral cortical atrophy explains seizures, hyporeflexia, and developmental regression (linked to progressive brain changes, though not classically neurodegenerative). Microcephaly further supports central nervous system involvement.  
4. **Endocrine dysfunction**: Decreased growth hormone response and central adrenal insufficiency correlate with TBCK’s role in mTOR signaling, affecting endocrine pathways.  
5. **Musculoskeletal findings**: Scoliosis and hypotonia are secondary to chronic low muscle tone and motor deficits.  
6. **Ancillary features**: Hirsutism and corneal opacity, while less common, are documented in some cases, reflecting multisystemic impact of TBCK mutations.  
7. **Exclusion of mimics**: The combination of hypotonia, adrenal/growth hormone deficits, and facial dysmorphism distinguishes this from lysosomal storage disorders or mitochondrial diseases.  
The constellation of symptoms strongly supports a TBCK-related diagnosis, confirmed by genetic testing for pathogenic variants in the TBCK gene."
"['Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA lyase deficiency (HMGCLD)  
Reasoning:  
1. **Biochemical Pathway Context**: HMG-CoA lyase is critical in ketogenesis (fatty acid breakdown) and leucine catabolism. Deficiency disrupts conversion of HMG-CoA to acetoacetate and acetyl-CoA, causing toxic metabolite accumulation.  
2. **3-Methylglutaric Aciduria**: Directly linked to impaired leucine degradation. The enzyme deficiency leads to buildup of 3-methylglutaconyl-CoA, which is converted to 3-methylglutaric acid, excreted in urine.  
3. **Dicarboxylic Aciduria**: Secondary to defective ketogenesis. During fasting, increased fatty acid oxidation overwhelms β-oxidation, producing dicarboxylic acids (e.g., adipic, suberic acids) due to alternative ω-oxidation pathways.  
4. **Elevated Urinary Carboxylic Acids**: Reflects systemic metabolic dysfunction, with spillage of 3-hydroxy-3-methylglutaric acid (primary marker), 3-methylglutaric acid, and 3-methylcrotonylglycine.  
5. **Exclusion of Mimics**: Differentiated from other organic acidurias (e.g., glutaric acidemia type I, multiple carboxylase deficiency) by the specific triad of metabolites and absence of key markers like glutaric acid or holocarboxylase synthetase defects.  
6. **Clinical Correlation**: Patients typically present with hypoglycemia, metabolic acidosis, and lethargy during catabolic stress (fasting/illness), aligning with the biochemical findings."
"['Brachydactyly', 'Delayed ossification of carpal bones', 'Abnormal facial shape', 'Waddling gait', 'Flared femoral metaphysis', 'Genu varum', 'Metaphyseal irregularity', 'Short long bone', 'Hypoplasia of the capital femoral epiphysis', 'Flat acetabular roof', 'Short stature', 'Beaking of vertebral bodies', 'Mucopolysacchariduria', 'Irregular acetabular roof', 'Disproportionate short-limb short stature', 'Irregular epiphyses', 'Lower limb pain']",['Pseudoachondroplasia/Pseudoachondroplasia'],"Disease: Pseudoachondroplasia  
**Reasoning**:  
1. **Disproportionate short-limb short stature** and **short long bones** are hallmark features of pseudoachondroplasia, a skeletal dysplasia caused by *COMP* gene mutations.  
2. **Metaphyseal irregularity**, **flared femoral metaphysis**, and **hypoplasia of the capital femoral epiphysis** align with characteristic metaphyseal/epiphyseal dysplasia seen radiographically.  
3. **Genu varum** and **waddling gait** result from abnormal lower limb alignment and hip dysplasia, exacerbated by **flat/irregular acetabular roof**.  
4. **Beaking of vertebral bodies** reflects vertebral anomalies common in pseudoachondroplasia, though less severe than in mucopolysaccharidoses (MPS).  
5. **Delayed ossification of carpal bones** and **brachydactyly** correlate with delayed skeletal maturation and shortened bones.  
6. **Mucopolysacchariduria** is atypical but may represent a coincidental finding or lab overlap; dominant skeletal features outweigh this.  
7. **Lower limb pain** stems from early-onset joint degeneration, a known complication.  
8. **Abnormal facial shape** is mild/nonspecific in pseudoachondroplasia, contrasting with coarse facies in MPS, reinforcing the diagnosis."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The patient's symptoms of neonatal death, death in infancy/childhood, and abnormal circulating carnitine align with MCADD, a fatty acid oxidation disorder. MCADD impairs breakdown of medium-chain fatty acids, leading to hypoglycemia and metabolic crises during fasting. Neonatal and childhood fatalities are hallmark features due to delayed diagnosis. Abnormal carnitine levels occur secondary to disrupted fatty acid metabolism. The listed ""decreased 3-hydroxyacyl-CoA dehydrogenase"" is likely a misstatement; MCADD specifically involves deficient *medium-chain acyl-CoA dehydrogenase*, critical for beta-oxidation. Obesity may reflect metabolic dysregulation or compensatory feeding patterns. Prenatal abnormalities, though less common, could arise from fetal metabolic stress."
"['Intellectual disability', 'Seizure', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development.  
2. **Seizures & intellectual disability**: Result from global neurological dysfunction due to glycosylation defects affecting brain structure and signaling.  
3. **Motor delay**: Linked to cerebellar dysfunction and hypotonia, common in PMM2-CDG.  
4. **Obesity**: Observed in some surviving infants due to metabolic dysregulation from glycosylation errors.  
5. **Death in infancy**: Matches severe PMM2-CDG phenotypes, often from multi-organ failure (hepatic, cardiac) or infections.  
6. **Exclusion of mimics**: Symptoms align with PMM2-CDG over Joubert syndrome (lacks glycosylation markers) or Smith-Lemli-Opitz (distinct cholesterol pathway defects).  
7. **Diagnostic confirmation**: Requires phosphomannomutase 2 (PMM2) enzyme testing or genetic analysis for pathogenic variants."
"['High palate', 'Mixed hearing impairment', 'Microcornea', 'Chorioretinal coloboma', 'Microphthalmia', 'Iris coloboma', 'Oligodontia', 'Delayed speech and language development', 'Abnormality of the nail', 'Aplasia cutis congenita over parietal area', 'Lacrimal duct stenosis', 'Inferior lens subluxation', 'Abnormal renal morphology']",['Branchio-oculo-facial syndrome/Branchiooculofacial syndrome'],"Disease: Branchio-oculo-facial syndrome (BOFS)  
Reasoning:  
1. **Ocular Features**: Microcornea, chorioretinal coloboma, microphthalmia, iris coloboma, and inferior lens subluxation align with BOFS’s hallmark ocular abnormalities, including colobomas and structural eye defects.  
2. **Branchial/Craniofacial Signs**: Aplasia cutis congenita (parietal scalp defect), high palate, oligodontia, and lacrimal duct stenosis correlate with BOFS’s craniofacial and ectodermal manifestations.  
3. **Hearing and Speech**: Mixed hearing impairment explains delayed speech development, consistent with BOFS-associated auditory defects.  
4. **Ancillary Features**: Nail abnormalities and renal morphology anomalies, while less specific, are occasionally reported in BOFS.  
5. **Syndrome Triad**: The combination of branchial (skin), ocular, and facial defects strongly supports BOFS diagnosis, excluding other coloboma-related syndromes (e.g., CHARGE) due to the presence of aplasia cutis and dental anomalies."
"['Diabetes mellitus', 'Constipation', 'Impaired glucose tolerance']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: Maturity-onset diabetes of the young, type 1 (MODY1)  
Reasoning:  
1. **Diabetes mellitus and impaired glucose tolerance** align with MODY, a monogenic form of diabetes caused by autosomal dominant mutations (e.g., *HNF4A* in MODY1).  
2. MODY typically presents in non-obese adolescents/young adults with a strong family history of diabetes, distinguishing it from type 1 or type 2 diabetes.  
3. **Constipation** is atypical for MODY but may reflect secondary effects of hyperglycemia (e.g., autonomic neuropathy) or unrelated comorbidities.  
4. MODY1 specifically involves *HNF4A* mutations, which disrupt insulin secretion and may cause subtle extrapancreatic features (e.g., lipid abnormalities, renal Fanconi syndrome), though constipation is not a hallmark.  
5. Definitive diagnosis requires **genetic testing** for *HNF4A* variants. Early identification enables tailored therapy (e.g., sulfonylureas instead of insulin)."
"['Microcephaly', 'Epicanthus', 'Strabismus', 'Alacrima', 'Oculomotor apraxia', 'Tapered finger', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Clinodactyly of the 5th toe', 'Frontal bossing', 'Constipation', 'Hypoplastic nipples', 'Elevated hepatic transaminase', 'Prominent metopic ridge', 'Prolonged neonatal jaundice', 'Chalazion', 'Tented upper lip vermilion', 'Clinodactyly of the 4th toe']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1  
Reasoning:  
1. **Alacrima**: A hallmark feature of this disorder, directly referenced in its name.  
2. **Liver dysfunction**: Supported by *prolonged neonatal jaundice* and *elevated hepatic transaminases*.  
3. **Neurological involvement**: *Global developmental delay*, *hypotonia*, *oculomotor apraxia*, and *reduced tendon reflexes* align with the syndrome’s neurological and movement-related manifestations (choreoathetosis, though not explicitly listed, is often part of the phenotype).  
4. **Dysmorphic features**: *Microcephaly*, *frontal bossing*, *prominent metopic ridge*, *epicanthus*, *tented upper lip vermilion*, *tapered fingers*, and *clinodactyly of the 4th/5th toes* are consistent with craniofacial and skeletal anomalies seen in congenital disorders of glycosylation.  
5. **Systemic involvement**: *Hypoplastic nipples*, *chalazion*, and *constipation* reflect multisystemic pathology typical of glycosylation defects.  
6. **Exclusion of mimics**: The combination of alacrima, liver dysfunction, and neurodevelopmental abnormalities is pathognomonic for this disorder, distinguishing it from other CDG subtypes or syndromes like Smith-Lemli-Opitz or NGLY1 deficiency."
"['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Obesity', 'Large for gestational age', 'Death in infancy', 'Abnormal cerebral morphology', 'Neonatal death', 'Death in childhood', 'Abnormal circulating lysine concentration', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key biochemical marker**: The presence of **L-2-hydroxyglutaric aciduria** directly indicates a defect in the metabolism of L-2-hydroxyglutarate, typically due to mutations in the *L2HGDH* gene, which encodes the enzyme L-2-hydroxyglutarate dehydrogenase.  
2. **Neurological and developmental symptoms**: **Macrocephaly**, **delayed speech**, **intellectual disability**, and **seizures** align with the progressive neurodegenerative features of L-2-HGA, caused by toxic accumulation of L-2-hydroxyglutarate in the central nervous system.  
3. **Abnormal cerebral morphology**: MRI findings (e.g., leukoencephalopathy, subcortical cysts, or basal ganglia abnormalities) are hallmark features of this disorder.  
4. **Metabolic derangement**: **Abnormal circulating lysine concentration** reflects disrupted lysine metabolism, a pathway linked to L-2-HGA.  
5. **Early mortality**: **Death in infancy/childhood** and **neonatal death** suggest severe forms of the disease, often due to metabolic decompensation or refractory seizures.  
6. **Large for gestational age (LGA)**: While less common, LGA may occur in metabolic disorders due to prenatal metabolic dysregulation.  
7. **Obesity**: May arise secondary to mitochondrial dysfunction or disrupted energy metabolism associated with the disease.  

**Conclusion**: The combination of neurodevelopmental regression, characteristic biochemical findings (L-2-hydroxyglutaric aciduria), cerebral abnormalities, and metabolic disturbances confirms the diagnosis of **L-2-hydroxyglutaric aciduria**."
"['Death in infancy', 'Neonatal death', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Elevated urinary carboxylic acid** is a hallmark of impaired carboxylase function. Biotinidase deficiency prevents biotin recycling, a coenzyme required for carboxylases (propionyl-CoA carboxylase, pyruvate carboxylase), leading to accumulation of unmetabolized substrates (e.g., lactic acid, 3-hydroxyisovaleric acid) in urine.  
2. **Neonatal death/Death in infancy** aligns with untreated BTDD, as biotin-dependent metabolic pathways (e.g., fatty acid synthesis, gluconeogenesis) are disrupted, causing metabolic acidosis, seizures, and organ failure.  
3. **Late-onset multiple carboxylase deficiency** refers to BTDD’s postnatal presentation (vs. holocarboxylase synthetase deficiency, which manifests prenatally). Without biotin supplementation, rapid decompensation in early infancy is typical."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormal erythrocyte morphology', 'Thrombocytosis', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Abnormality of vitamin D metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Abnormality of galactoside metabolism**: Directly aligns with galactosemia, a disorder of galactose metabolism due to GALT enzyme deficiency.  
2. **Neonatal death/Death in infancy/Death in childhood**: Untreated galactosemia causes severe complications (e.g., liver failure, sepsis) leading to early mortality.  
3. **Abnormal erythrocyte morphology**: Hemolysis from toxic galactitol accumulation can alter red blood cell structure.  
4. **Thrombocytosis**: May arise secondary to liver dysfunction or splenic dysfunction from chronic hemolysis.  
5. **Abnormal circulating porphyrin concentration**: Hepatic impairment disrupts heme biosynthesis pathways.  
6. **Abnormality of vitamin D metabolism**: Liver damage reduces 25-hydroxylation of vitamin D, impairing activation.  
7. **Abnormality of prenatal development or birth**: Though galactosemia is not congenital in structural development, metabolic stress in utero may contribute to prenatal abnormalities.  

All symptoms collectively point to **classic galactosemia**, where toxic galactose metabolites drive multi-organ dysfunction, consistent with the patient’s presentation."
"['Thrombocytopenia', 'Abnormal bleeding', 'Giant platelets', 'Impaired ristocetin-induced platelet aggregation', 'Subdural hemorrhage']",['Bernard-Soulier syndrome/Bernard-Soulier syndrome'],"Disease: Bernard-Soulier syndrome  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with Bernard-Soulier syndrome (BSS), as giant platelets are often misclassified or destroyed, reducing measured counts.  
2. **Giant platelets**: Pathognomonic for BSS due to mutations in the *GP1BA*, *GP1BB*, or *GP9* genes, disrupting platelet membrane glycoprotein Ib-IX-V complex formation.  
3. **Impaired ristocetin-induced platelet aggregation**: Specific to BSS, as ristocetin requires functional glycoprotein Ib-IX-V to bind von Willebrand factor (vWF). This defect distinguishes BSS from von Willebrand disease (where ristocetin aggregation is normal or enhanced).  
4. **Abnormal bleeding and subdural hemorrhage**: Reflects severe platelet dysfunction and thrombocytopenia, consistent with BSS’s clinical presentation.  
5. **Exclusion of mimics**: Normal prothrombin time (PT) and activated partial thromboplastin time (aPTT) (implied absence of clotting factor issues) and lack of Döhle bodies (unlike MYH9-related disorders) further support BSS."
"['Cleft palate', 'Pierre-Robin sequence', 'Atrial septal defect', 'Respiratory insufficiency', 'Hyperechogenic kidneys', 'Feeding difficulties', 'Posterior rib gap', '10 pairs of ribs']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome (CCMS):  
1. **Rib anomalies**: The patient exhibits **posterior rib gaps** and **10 pairs of ribs** (vs. the normal 12 pairs). These defects are pathognomonic for CCMS, characterized by ""missing"" or maldeveloped ribs with costovertebral discontinuities.  
2. **Pierre-Robin sequence (PRS)**: The **cleft palate** and associated PRS (micrognathia, glossoptosis) align with CCMS, as mandibular hypoplasia and airway/respiratory challenges are common.  
3. **Respiratory insufficiency**: Likely secondary to rib defects (restrictive lung disease) and PRS-related airway obstruction.  
4. **Additional features**: **Atrial septal defect** and **hyperechogenic kidneys** are occasionally reported in CCMS, supporting multisystem involvement. **Feeding difficulties** correlate with PRS and orofacial structural abnormalities.  
5. **Exclusion**: Other rib-gap syndromes (e.g., cerebro-costo-mandibular-like syndrome) lack full phenotypic overlap, making CCMS the definitive diagnosis."
"['Hydrocephalus', 'Macrocephaly', 'Hyperhidrosis', 'Seizure', 'Lethargy', 'Dystonia', 'Hyperreflexia', 'Death in infancy', 'Anemia', 'Fever', 'Vomiting', 'Cerebral atrophy', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Upper airway obstruction', 'Increased CSF protein concentration', 'Glutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Chronic pulmonary obstruction', 'Death in adolescence']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Core biochemical marker**: The explicit mention of ""Glutaric aciduria"" directly aligns with GA-I, a disorder caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Neurological features**:  
   - **Macrocephaly** at birth is a hallmark of GA-I, often preceding metabolic crises.  
   - **Dystonia**, **opisthotonus**, **seizures**, and **cerebral atrophy** reflect striatal injury and basal ganglia degeneration, typical of GA-I encephalopathic crises.  
   - **Hyperreflexia** and **fasciculations** suggest upper motor neuron involvement due to neurotoxicity.  
3. **Acute metabolic decompensation**:  
   - Symptoms like **lethargy**, **vomiting**, **fever**, and **drowsiness** are triggered by catabolic stressors (e.g., infections, fasting), common in GA-I crises.  
   - **Increased CSF protein concentration** may occur during acute neurological deterioration.  
4. **Prognostic indicators**:  
   - **Death in infancy/childhood/adolescence** correlates with untreated GA-I’s natural history. Early mortality arises from metabolic crises or secondary complications (e.g., **upper airway obstruction** due to dystonia).  
   - **Chronic pulmonary obstruction** and **recurrent viral infections** may stem from dysautonomia or impaired immune-metabolic interplay.  
5. **Supporting clues**:  
   - **Sleep disturbances** and **anemia** are nonspecific but consistent with chronic metabolic disease.  
   - **Hydrocephalus** (often ""communicating"") in GA-I is linked to macrocephaly and CSF dynamics alterations, not structural defects.  

GA-I explains the full clinical spectrum, from biochemical derangements to fatal neurological progression, distinguishing it from mimics (e.g., mitochondrial disorders, other organic acidemias). Early diagnosis is critical for dietary/ metabolic interventions to mitigate outcomes."
"['Intellectual disability', 'Thromboembolism', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Death in adolescence', 'Death in early adulthood']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning: The patient exhibits **hyperhomocystinemia**, a hallmark of homocystinuria, alongside **intellectual disability** and **thromboembolism**, which are classic complications of elevated homocysteine levels. Hyperhomocystinemia directly indicates impaired homocysteine metabolism, a core feature of this disorder. The presence of **hypermethioninemia** suggests a defect in the transsulfuration pathway, where homocysteine accumulates due to enzyme deficiencies. Early mortality aligns with severe vascular complications (e.g., strokes, thromboses) from chronic homocysteine toxicity.

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: **Hypermethioninemia** specifically points to cystathionine beta-synthase (CBS) deficiency, as this enzyme converts homocysteine to cystathionine. Its deficiency traps homocysteine in the methionine cycle, elevating both homocysteine and methionine. **Thromboembolism** and **intellectual disability** are consistent with CBS-deficient homocystinuria, where vascular and connective tissue damage are prominent. **Death in adolescence/early adulthood** reflects the life-threatening thromboembolic events and multisystemic progression seen in untreated or severe cases of CBS deficiency."
"['Abnormality of the hand', 'Weight loss', 'Elevated hepatic transaminase', 'Rheumatoid factor positive', 'Increased circulating ferritin concentration', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Increased alpha-globulin', 'Limited wrist movement', 'Elevated circulating C-reactive protein concentration', 'Upper limb pain', 'Dysesthesia', 'Neck pain', 'Arterial stenosis', 'Cryoglobulinemia', 'Skin erosion']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed:  
The patient presents with cryoglobulinemia, a hallmark of this disease, alongside systemic inflammation (elevated CRP, ESR, ferritin). Rheumatoid factor positivity and complement system abnormalities suggest immune complex deposition, driving vasculitis. Skin erosions, dysesthesia, and arterial stenosis align with small-to-medium vessel inflammation. Elevated hepatic transaminases and alpha-globulins indicate liver involvement, common in cryoglobulinemia. Upper limb/neck pain, limited wrist movement, and hand abnormalities reflect joint and soft tissue damage from vasculitis or cryoglobulin precipitation. Familial mixed type implies a genetic predisposition to mixed cryoglobulin production (IgM-IgG complexes), corroborated by multisystemic features."
"['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Increased serum lactate', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Metabolic acidosis & elevated lactate**: Impaired activity of biotin-dependent carboxylases (pyruvate carboxylase, propionyl-CoA carboxylase) disrupts gluconeogenesis and the citric acid cycle, causing lactic acidosis.  
2. **Hyperammonemia**: Secondary urea cycle dysfunction due to metabolic stress or propionate accumulation from propionyl-CoA carboxylase deficiency.  
3. **Propionyl-CoA carboxylase deficiency & decreased pyruvate carboxylase activity**: HLCS is required to activate these enzymes via biotinylation; deficiency leads to functional defects in multiple carboxylases.  
4. **Abnormal urinary carboxylic acids & aminoaciduria**: Accumulation of toxic metabolites (e.g., propionate, 3-hydroxypropionate) due to blocked carboxylase pathways, causing renal tubular damage and organic aciduria.  
5. **Decreased plasma free carnitine**: Secondary carnitine depletion from binding/excretion of acyl-CoA metabolites.  
6. **Abnormal circulating glycine**: Glycine metabolism disruption via the glycine cleavage system (biotin-dependent) or competition with organic acids for renal transport.  
7. **Generalized hypotonia & apathy**: Neurological effects of metabolic acidosis, hyperammonemia, and energy deficiency.  
8. **Tachypnea**: Respiratory compensation for metabolic acidosis.  
9. **Death in infancy**: Untreated HLCS deficiency causes severe metabolic crises, typically fatal without biotin supplementation.  
**Conclusion**: The constellation of multi-carboxylase dysfunction, metabolic acidosis, hyperammonemia, and characteristic biochemical markers confirms HLCS deficiency."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death** or **death in infancy** in untreated cases aligns with severe PKU variants or lack of newborn screening/dietary intervention, resulting in metabolic crises, neurological damage, or organ failure.  
3. Classic PKU typically manifests with intellectual disability and seizures, but untreated cases in resource-limited settings may progress rapidly to fatal outcomes due to acute complications (e.g., cerebral edema, infections).  
4. Differential diagnoses (e.g., BH4 deficiency) were excluded as the provided diagnosis specifically lists PKU, and hyperphenylalaninemia alone suffices for PKU classification, even if BH4 defects are clinically distinct."
"['Wormian bones', 'Thin bony cortex', 'Recurrent fractures', 'Vertebral compression fracture', 'Slender long bone', 'Elevated circulating alkaline phosphatase concentration', 'Increased circulating beta-C-terminal telopeptide concentration', 'Femur fracture', 'Generalized osteoporosis']","['Osteogenesis imperfecta, type XIV']","Disease: Osteogenesis imperfecta, type XIV  
Reasoning:  
1. **Wormian bones**: Indicate abnormal skull bone development, a hallmark of osteogenesis imperfecta (OI).  
2. **Thin bony cortex & slender long bones**: Reflect defective bone matrix quality and reduced cortical thickness, consistent with OI’s structural bone defects.  
3. **Recurrent fractures (including femur/vertebral compression)**: Suggest severe bone fragility, a core feature of OI. Vertebral fractures are common in moderate-severe OI types.  
4. **Generalized osteoporosis**: Aligns with systemic bone density loss due to impaired collagen/mineralization in OI.  
5. **Elevated bone turnover markers (alkaline phosphatase, beta-C-terminal telopeptide)**: Indicate high bone resorption, seen in OI type XIV due to TMEM38B mutations disrupting calcium homeostasis in osteoblasts.  
6. **Genetic specificity**: OI type XIV (linked to TMEM38B) presents with early fractures, vertebral collapse, and biochemical evidence of increased resorption, distinguishing it from collagen-related OI types.  
7. **Exclusion of mimics**: Elevated alkaline phosphatase rules out hypophosphatasia; age-agnostic severity and Wormian bones exclude idiopathic osteoporosis."
"['Proteinuria', 'Edema', 'Small for gestational age', 'Pneumonia', 'Pleural effusion', 'Hypoalbuminemia', 'Hypercholesterolemia', 'Neonatal hypoproteinemia', 'Congenital nephrotic syndrome']","['Congenital nephrotic syndrome, Finnish type/Nephrotic syndrome, type 1']","Disease: Congenital nephrotic syndrome, Finnish type/Nephrotic syndrome, type 1  
Reasoning:  
1. **Proteinuria** and **Hypoalbuminemia**: Hallmarks of nephrotic syndrome, caused by glomerular damage leading to excessive urinary protein loss and subsequent low serum albumin.  
2. **Edema** and **Pleural Effusion**: Result from hypoalbuminemia reducing oncotic pressure, causing fluid leakage into tissues and serous cavities.  
3. **Hypercholesterolemia**: Compensatory hepatic synthesis of lipoproteins due to protein loss.  
4. **Small for Gestational Age (SGA)**: Intrauterine proteinuria in congenital nephrotic syndrome impairs fetal nutrition and growth.  
5. **Neonatal Hypoproteinemia**: Severe albumin loss begins prenatally, leading to critically low protein levels at birth.  
6. **Congenital Nephrotic Syndrome**: Early-onset (birth/infancy) aligns with the Finnish type (NPHS1 mutation), characterized by NPHS1/NEPHRIN gene defects causing podocyte dysfunction.  
7. **Pneumonia**: Secondary to edema-related respiratory compromise and immunosuppression from urinary immunoglobulin loss.  

The constellation of severe proteinuria, hypoalbuminemia, and neonatal presentation confirms **Congenital Nephrotic Syndrome, Finnish Type** (NPHS1-related), distinguishing it from later-onset or secondary nephrotic syndromes."
"['Cryptorchidism', 'Self-mutilation', 'Delayed speech and language development', 'Cyanosis', 'Abnormality of skin pigmentation', 'Abnormality of prenatal development or birth', 'Seizure', 'Death in infancy', 'Dehydration', 'Fever', 'Hyperkalemia', 'Hypokalemia', 'Hyponatremia', 'Neonatal death', 'Death in childhood', 'Pigmentation of the sclera', 'Severe hearing impairment', 'Elevated circulating 17-hydroxyprogesterone concentration']","['21-hydroxylase deficiency; 21-OHD/Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency/Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency']","Disease: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency  
Reasoning:  
1. **Elevated 17-hydroxyprogesterone (17-OHP)**: This is the hallmark biochemical marker of 21-hydroxylase deficiency (21-OHD), as the enzyme defect blocks cortisol synthesis, causing precursor accumulation.  
2. **Salt-wasting features**: Hyponatremia, hyperkalemia, dehydration, and neonatal/childhood death align with aldosterone deficiency, leading to electrolyte imbalances and adrenal crises.  
3. **Skin/scleral pigmentation**: Elevated ACTH (due to cortisol deficiency) stimulates melanocytes, causing hyperpigmentation.  
4. **Cryptorchidism and prenatal abnormalities**: Androgen imbalances in utero may disrupt genital development in males, though ambiguous genitalia (more typical in females) is absent here.  
5. **Seizures and developmental delays**: Likely secondary to recurrent metabolic derangements (e.g., hyponatremia, hypoglycemia) during adrenal crises.  
6. **Fever, cyanosis, death**: Reflect acute adrenal insufficiency crises, which can cause hypovolemic shock and multi-organ failure if untreated.  
7. **Hypokalemia discrepancy**: May represent transient fluctuations or misclassification; hyperkalemia is pathognomonic for salt-wasting 21-OHD.  
8. **Severe hearing impairment**: Uncommon in 21-OHD but could indicate a coincidental finding or atypical presentation.  

Other symptoms (e.g., self-mutilation) are atypical for 21-OHD and may suggest comorbidities, but the biochemical and cardinal clinical features strongly confirm the diagnosis."
"['High palate', 'Retrognathia', 'Hypertelorism', 'Smooth philtrum', 'Micrognathia', 'Low-set ears', 'Downslanted palpebral fissures', 'Pectus carinatum', 'Arachnodactyly', 'Hyporeflexia', 'Craniosynostosis', 'Joint laxity', 'Umbilical hernia', 'Patent foramen ovale', 'Talipes equinovarus', 'Pes planus', 'Increased serum lactate', 'Aqueductal stenosis', 'Expressive language delay', 'Narrow iliac wing', 'Spina bifida occulta', 'Syringomyelia', 'Hyperactive deep tendon reflexes', 'Intellectual disability, borderline', 'Bilateral coxa valga', 'Prominent forehead']",['Shprintzen-Goldberg syndrome/Shprintzen-Goldberg craniosynostosis syndrome'],"Disease: Shprintzen-Goldberg syndrome/Shprintzen-Goldberg craniosynostosis syndrome  
Reasoning:  
1. **Craniofacial features**: Craniosynostosis (premature fusion of cranial sutures), prominent forehead, hypertelorism, downslanted palpebral fissures, retrognathia, micrognathia, high palate, smooth philtrum, and low-set ears align with the characteristic facial dysmorphism of Shprintzen-Goldberg syndrome (SGS).  
2. **Skeletal anomalies**: Arachnodactyly, joint laxity, pectus carinatum, narrow iliac wings, bilateral coxa valga, talipes equinovarus, and pes planus reflect the ""marfanoid habitus"" typical of SGS, though distinct from Marfan syndrome due to coexisting craniosynostosis.  
3. **Neurological/developmental findings**: Intellectual disability (borderline), expressive language delay, aqueductal stenosis (causing hydrocephalus risk), syringomyelia, and spina bifida occulta suggest multisystem neurological involvement, consistent with SGS.  
4. **Connective tissue/other features**: Umbilical hernia, patent foramen ovale (cardiac anomaly), and mixed reflex abnormalities (hyporeflexia and hyperactive deep tendon reflexes) are seen in SGS, which combines connective tissue and systemic defects.  
5. **Exclusion of mimics**: Overlap with Loeys-Dietz or Marfan syndromes is ruled out by the presence of craniosynostosis, a hallmark of SGS. Increased serum lactate may indicate secondary metabolic stress from hypotonia or respiratory compromise.  

The combination of craniosynostosis, marfanoid features, neurodevelopmental delays, and characteristic dysmorphism strongly supports Shprintzen-Goldberg syndrome."
"['Focal segmental glomerulosclerosis', 'Striae distensae', 'Hyperuricemia', 'Hypertriglyceridemia', 'Microscopic hematuria', 'Elevated hepatic transaminase', 'Hypoalbuminemia', 'Hypercholesterolemia', 'Increased blood urea nitrogen', 'Hyperuricosuria', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Hyperkeratosis with erythema', 'Nephrosclerosis', 'Erythema', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Mild proteinuria', 'obsolete Increased urinary urate', 'Pollakisuria']","['Focal segmental glomerulosclerosis 9', 'Focal segmental glomerulosclerosis 8', 'Focal segmental glomerulosclerosis 3, susceptibility to', 'Focal segmental glomerulosclerosis 4, susceptibility to', 'Focal segmental glomerulosclerosis 1', 'Glomerulosclerosis, focal segmental, 5', 'Focal segmental glomerulosclerosis 6', 'Focal segmental glomerulosclerosis 7', 'Focal segmental glomerulosclerosis 2']","Disease: Focal segmental glomerulosclerosis 2 (NPHS2)  
Reasoning: The patient presents with steroid-resistant nephrotic syndrome features (hypoalbuminemia, hyperlipidemia, mild proteinuria) and FSGS. NPHS2 mutations (podocin) are a common genetic cause of early-onset, autosomal recessive FSGS. While hyperuricemia and hyperuricosuria are not directly linked to NPHS2, they may arise secondary to progressive renal dysfunction.  

Disease: Focal segmental glomerulosclerosis 3, susceptibility to (TRPC6)  
Reasoning: TRPC6 mutations cause autosomal dominant FSGS with variable age of onset. Elevated hepatic transaminases and inflammatory markers (CRP, ESR) could reflect systemic endothelial dysfunction linked to TRPC6-mediated calcium signaling abnormalities. However, direct correlation with uric acid metabolism remains unclear.  

Disease: Focal segmental glomerulosclerosis 1 (ACTN4)  
Reasoning: ACTN4 mutations cause adult-onset FSGS with dominant inheritance. Hypoalbuminemia, hypertriglyceridemia, and hypercholesterolemia align with nephrotic syndrome. Hyperuricemia and nephrosclerosis may develop due to chronic kidney injury rather than a primary genetic defect.  

Disease: Focal segmental glomerulosclerosis 9 (COL4A5)  
Reasoning: COL4A5 mutations cause X-linked Alport syndrome, which can manifest as FSGS in later stages. Microscopic hematuria and elevated transaminases (possibly due to collagen defects) support this, but absence of hearing loss or ocular anomalies weakens the association.  

Disease: Focal segmental glomerulosclerosis 7 (PAX2)  
Reasoning: PAX2 mutations are linked to renal-coloboma syndrome, characterized by FSGS and optic nerve defects. The patient’s erythema and hyperkeratosis might reflect ectodermal dysplasia, though overt coloboma is not reported.  

Disease: Focal segmental glomerulosclerosis 5 (INF2)  
Reasoning: INF2 mutations cause FSGS with Charcot-Marie-Tooth neuropathy. Elevated transaminases and ESR could hint at systemic inflammation, but the absence of neuropathy reduces likelihood.  

Disease: Focal segmental glomerulosclerosis 4, susceptibility to (CD2AP)  
Reasoning: CD2AP variants increase susceptibility to FSGS, particularly in the context of comorbidities like hypertension (nephrosclerosis) or metabolic stress (hyperuricemia, dyslipidemia). This may explain the multifactorial presentation.  

**Excluded Subtypes**:  
- **FSGS6 (MYO1E)**: Typically presents in childhood with severe proteinuria, which is inconsistent with ""mild proteinuria"" here.  
- **FSGS8 (ANLN)**: Associated with rapidly progressive glomerulonephritis, not evident in this case.  

**Final Likely Diagnosis**: **Focal segmental glomerulosclerosis 2 (NPHS2)** due to its strong association with steroid-resistant nephrotic syndrome and early renal dysfunction, though secondary contributors (e.g., metabolic syndrome) may exacerbate hyperuricemia and tubular defects."
"['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits metabolic acidosis, hyperammonemia, vomiting, and methylmalonic aciduria—hallmark features of MMA. This autosomal recessive disorder disrupts methylmalonyl-CoA metabolism, leading to toxic metabolite accumulation. Death in infancy aligns with severe, untreated cases. Methylmalonic aciduria directly confirms impaired propionate pathway function.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity of vitamin B12-unresponsive MMA stems from mutations in the *MUT* gene, encoding methylmalonyl-CoA mutase. B12-unresponsiveness indicates defective enzyme activity (not cofactor deficiency). Hyperammonemia arises secondary to metabolic decompensation, disrupting the urea cycle. Early lethality underscores the severity of mutase deficiency, which lacks therapeutic response to B12."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to elevated phenylalanine levels in the blood.  
2. **Abnormality of prenatal development or birth** may occur if maternal PKU is untreated during pregnancy, resulting in fetal exposure to high phenylalanine levels, causing microcephaly, congenital heart defects, or developmental delays.  
3. **Death in infancy/Neonatal death** is rare in classic PKU due to newborn screening and dietary management. However, untreated severe cases can lead to irreversible neurological damage, seizures, and failure to thrive, potentially progressing to fatal outcomes in early life.  
4. The combination of hyperphenylalaninemia with severe early-life complications aligns with PKU when undiagnosed/unmanaged, particularly in regions lacking newborn screening programs."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids. Unmetabolized fatty acids conjugate with carnitine, forming acylcarnitines excreted in urine, leading to secondary carnitine deficiency.  
2. **Neonatal death/Death in infancy/childhood**: MCADD causes metabolic crises triggered by fasting (e.g., prolonged sleep, illness). Hypoketotic hypoglycemia, hyperammonemia, and toxic metabolite accumulation (e.g., octanoylcarnitine) result in encephalopathy, seizures, and sudden death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD primarily manifests postnatally, severe fetal metabolic stress or maternal fatty acid metabolism disturbances during pregnancy may contribute to subtle prenatal complications (e.g., intrauterine growth restriction).  
4. **Diagnostic confirmation**: Newborn screening detects elevated medium-chain acylcarnitines (C6-C10). Genetic testing identifies *ACADM* gene mutations, confirming MCADD. Early intervention (avoiding fasting, glucose supplementation) prevents mortality."
"['Hyperpigmentation of the skin', 'Thrombocytosis', 'Normocytic anemia', 'Fever', 'Increased susceptibility to fractures', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Increased circulating IgA level', 'Myalgia', 'Elevated erythrocyte sedimentation rate', 'Tricuspid regurgitation', 'Concave nasal ridge', 'Elevated circulating C-reactive protein concentration', 'Cough', 'Nodular pattern on pulmonary HRCT', 'Decreased mean corpuscular hemoglobin concentration', 'Abnormal periosteum morphology', 'Ankle pain', 'Elevated gamma-glutamyltransferase level', 'Cytoplasmic antineutrophil antibody positivity', 'Lymphocytosis']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
**Reasoning**:  
1. **C-ANCA positivity**: Cytoplasmic antineutrophil antibody (c-ANCA), typically targeting PR3, is highly specific for GPa.  
2. **Upper respiratory involvement**: Concave nasal ridge suggests chronic nasal inflammation or cartilage damage, common in GPA due to granulomatous lesions.  
3. **Pulmonary manifestations**: Nodular pattern on HRCT and cough align with necrotizing granulomas in the lungs.  
4. **Systemic inflammation**: Fever, elevated ESR, CRP, and lymphocytosis reflect a systemic inflammatory process.  
5. **Musculoskeletal symptoms**: Myalgia and ankle pain correlate with vasculitis-induced inflammation.  
6. **Hematologic abnormalities**: Thrombocytosis and normocytic anemia are reactive findings in chronic inflammation.  
7. **Additional markers**: Elevated hepatic transaminases and alkaline phosphatase may indicate secondary liver involvement or drug toxicity (e.g., from immunosuppressants).  
8. **Renal implication**: While not explicitly listed, elevated IgA (common in autoimmune dysregulation) and cytoplasmic ANCA often precede glomerulonephritis in GPA.  
9. **Radiologic and pathologic features**: Abnormal periosteum morphology and fractures could stem from chronic inflammation or steroid therapy complications.  

**Conclusion**: The constellation of c-ANCA positivity, sinonasal/pulmonary lesions, systemic inflammation, and multi-organ involvement strongly supports GPA."
"['Apathy', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Splenomegaly', 'Hyperammonemia', 'Vomiting', 'Hyperlysinemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Elevated circulating glutaric acid concentration', 'Low plasma citrulline', 'Prolonged partial thromboplastin time', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Abnormal circulating ornithine concentration', 'Uraciluria', 'Abnormal circulating creatine kinase concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** + **vomiting** + **hepatomegaly**: Core features of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Oroticaciduria** + **uraciluria**: Pathognomonic for OTCD. OTC deficiency causes carbamoyl phosphate accumulation, which enters pyrimidine synthesis, producing excess orotic acid/uracil.  
3. **Low citrulline**: OTC catalyzes ornithine + carbamoyl phosphate → citrulline; deficiency blocks this step, reducing citrulline synthesis.  
4. **Abnormal ornithine/arginine**: Secondary disruption of urea cycle intermediates.  
5. **Elevated glutamine/alanine/lysine**: Amino acid imbalances from alternative ammonia scavenging pathways (e.g., glutamine synthesis) and metabolic stress.  
6. **Hepatosplenomegaly** + **elevated liver enzymes**: Hepatic dysfunction due to toxic metabolite accumulation.  
7. **Prolonged PTT** + **recurrent infections**: Possible secondary coagulopathy/immune dysfunction from liver involvement.  
8. **Neurodevelopmental features** (apathy, intellectual disability) + **early mortality**: Reflects severe hyperammonemic crises causing irreversible neurological damage.  
OTCD aligns with the biochemical profile (orotic aciduria, citrulline depletion) and clinical progression of neonatal/infantile-onset UCD."
"['Platyspondyly', 'Broad metacarpals', 'Abnormal facial shape', 'Apnea', 'Hypoplastic iliac wing', 'Metaphyseal irregularity', 'Flat acetabular roof', 'Thoracic hypoplasia', 'Broad phalanx', 'Six lumbar vertebrae', 'Rhizomelia', 'Short metacarpal', 'Arrhythmia', '11 thoracic vertebrae']","['Spondylometaphyseal dysplasia, Sedaghatian type/Spondylometaphyseal dysplasia, Sedaghatian type']","Disease: Spondylometaphyseal dysplasia, Sedaghatian type  
Reasoning:  
1. **Platyspondyly** and **six lumbar vertebrae/11 thoracic vertebrae** indicate vertebral abnormalities, consistent with ""spondylo"" (spinal) involvement in SMD.  
2. **Metaphyseal irregularity**, **broad/short metacarpals**, **broad phalanx**, and **rhizomelia** reflect metaphyseal and skeletal dysplasia, core features of SMD.  
3. **Hypoplastic iliac wing** and **flat acetabular roof** align with pelvic dysplasia seen in skeletal dysplasias.  
4. **Thoracic hypoplasia** and **apnea** suggest respiratory compromise, typical in severe neonatal forms like Sedaghatian type.  
5. **Arrhythmia** correlates with reported cardiac anomalies in Sedaghatian type.  
6. **Abnormal facial shape** supports craniofacial dysmorphism associated with skeletal dysplasias.  
7. The combination of lethal skeletal dysplasia, metaphyseal/spinal defects, and cardiac involvement distinguishes this subtype from other SMDs."
"['Seizure', 'Lethargy', 'Growth delay', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated Branched-Chain Amino Acids (BCAAs)**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate impaired metabolism of BCAAs (valine, leucine, isoleucine), a hallmark of MSUD due to deficiency in the branched-chain α-keto acid dehydrogenase complex.  
2. **Metabolic Acidosis**: Accumulation of toxic keto acids (from BCAAs) disrupts acid-base balance.  
3. **Hyperammonemia**: Secondary to metabolic decompensation, as BCAA derivatives interfere with urea cycle function.  
4. **Neurological Symptoms (Seizures, Lethargy, Drowsiness)**: Caused by neurotoxicity from elevated BCAAs and their metabolites.  
5. **Elevated Urinary Carboxylic Acids**: Reflects urinary excretion of branched-chain keto acids (e.g., α-ketoisocaproate, α-keto-β-methylvalerate), pathognomonic for MSUD.  
6. **Early Severe Presentation (Growth Delay, Feeding Difficulties, Death in Infancy)**: Consistent with classic MSUD, which manifests neonatally without treatment.  
7. **Severe Hearing Impairment**: Uncommon but reported in severe metabolic crises due to multisystem toxicity.  
8. **Sleep Disturbances**: Linked to neurological dysfunction from metabolic derangements.  

MSUD is confirmed by biochemical findings (BCAA elevation, urinary keto acids) and clinical features. The absence of maple syrup odor in the description does not exclude the diagnosis, as odor may not always be noted or reported."
"['Vesicoureteral reflux', 'Microretrognathia', 'Abnormal repetitive mannerisms', 'Hypotonia', 'Global developmental delay', 'Choreoathetosis', 'Broad-based gait', 'Clinodactyly of the 5th finger', '2-3 toe cutaneous syndactyly', 'Feeding difficulties']","['Mental retardation, autosomal dominant 42']","Disease: Mental retardation, autosomal dominant 42 (MRD42)  
Reasoning:  
1. **Global developmental delay** and **autosomal dominant mental retardation** are hallmark features of MRD42, directly aligning with its core diagnostic criteria.  
2. **Microretrognathia** and **clinodactyly of the 5th finger** are dysmorphic features commonly associated with genetic neurodevelopmental disorders like MRD42.  
3. **Hypotonia** and **feeding difficulties** in infancy are frequently observed in MRD42 due to neuromuscular involvement.  
4. **Choreoathetosis** and **abnormal repetitive mannerisms** suggest neurological dysfunction, consistent with MRD42’s link to movement disorders and behavioral abnormalities.  
5. **Broad-based gait** may result from hypotonia and delayed motor development, both characteristic of MRD42.  
6. **2-3 toe cutaneous syndactyly** is a congenital anomaly that fits within the spectrum of limb malformations reported in some MRD42 cases.  
7. **Vesicoureteral reflux**, while not a primary feature, could represent variable expressivity of associated connective tissue or structural anomalies in rare presentations.  
8. The absence of pathognomonic findings for other syndromes (e.g., Angelman, Rett) and the convergence of neurodevelopmental, dysmorphic, and neurological symptoms strongly support MRD42, often caused by pathogenic variants in *SYNGAP1*."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: Untreated maternal PKU during pregnancy can result in congenital anomalies (e.g., microcephaly, cardiac defects) due to phenylalanine toxicity to the developing fetus.  
3. **Death in infancy/childhood**: Severe, untreated PKU causes irreversible neurological damage, seizures, and failure to thrive. Historically, before newborn screening and dietary management, elevated phenylalanine levels led to early mortality.  
4. **Consistency with PKU**: The combination of hyperphenylalaninemia and severe outcomes aligns with classic PKU pathophysiology. Early diagnosis via newborn screening and strict dietary intervention prevent these complications."
"['Obesity', 'Death in infancy', 'Neutropenia', 'Hyperuricemia', 'Increased serum lactate', 'Hepatomegaly', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Pustule']",['Glycogen storage disease Ib/Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib/Glycogen storage disease Ib'],"Disease: Glycogen storage disease Ib  
Reasoning:  
1. **Hepatomegaly and metabolic abnormalities**: GSD Ib involves a defect in the glucose-6-phosphate transporter (G6PT), impairing gluconeogenesis and glycogenolysis. This leads to hepatomegaly, lactic acidosis (increased serum lactate), and hyperuricemia due to metabolic byproduct accumulation.  
2. **Neutropenia and recurrent infections**: GSD Ib uniquely causes chronic neutropenia and neutrophil dysfunction, explaining recurrent viral infections and pustules (e.g., from bacterial/fungal skin infections).  
3. **Abnormal amino acid concentrations**: Disrupted glucose metabolism alters the alanine-aspartate shuttle, leading to abnormal circulating alanine and aspartate family amino acids.  
4. **Early mortality**: Severe metabolic crises (hypoglycemia, acidosis) and infections contribute to neonatal death, infant/childhood mortality.  
5. **Obesity paradox**: Despite failure to thrive in some cases, metabolic dysregulation and high-calorie dietary management may lead to abnormal fat distribution.  

The combination of liver dysfunction, neutropenia, and characteristic metabolic derangements distinguishes GSD Ib from GSD Ia and other glycogenoses."
"['Coma', 'Hepatic steatosis', 'Death in infancy', 'Vomiting', 'Cerebral edema', 'Abnormal circulating acetylcarnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating acetylcarnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to elevated medium-chain acylcarnitines (C8-C10), a hallmark diagnostic biomarker.  
2. **Hepatic steatosis**: Impaired fatty acid metabolism causes lipid accumulation in the liver.  
3. **Vomiting and cerebral edema**: During metabolic stress (e.g., fasting), unmetabolized fatty acids and toxic metabolites (e.g., octanoic acid) induce encephalopathy, cerebral edema, and gastrointestinal symptoms.  
4. **Coma and death in infancy**: Prolonged hypoglycemia and energy deficiency in crises result in neurological deterioration; untreated MCADD has high mortality in early life due to rapid metabolic decompensation.  
5. **Consistency with MCADD phenotype**: The triad of hypoketotic hypoglycemia, hepatic dysfunction, and acute neurological crises aligns with MCADD pathophysiology."
"['Retinopathy', 'Cataract', 'Hypertension', 'Congestive heart failure', 'Myocardial infarction', 'Acute kidney injury', 'Progressive neurologic deterioration', 'Glycosuria', 'Chronic kidney disease', 'Elevated hemoglobin A1c', 'Death in early adulthood', 'Sepsis']","['MODY', 'Maturity-onset diabetes of the young, type 1']","MODY: The patient presents with elevated hemoglobin A1c and glycosuria, indicative of chronic hyperglycemia. MODY, a monogenic form of diabetes, often manifests in early adulthood with autosomal dominant inheritance. Retinopathy, cataracts, and chronic kidney disease align with long-term diabetic complications. Hypertension and cardiovascular events (myocardial infarction, congestive heart failure) suggest accelerated vascular damage from prolonged hyperglycemia. Acute kidney injury and sepsis may result from diabetes-related susceptibility to infections and renal stress. Progressive neurologic deterioration could stem from metabolic derangements (e.g., uremia, hypoglycemia) or microvascular damage. Early adulthood mortality reflects severe, untreated diabetic complications, consistent with delayed MODY diagnosis or inadequate management. While MODY is typically milder, type 1 (HNF4A mutation) can lead to significant morbidity if glycemic control is poor."
"['Seizure', 'Death in infancy', 'Hypoglycemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormality of acid-base homeostasis', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Hypoglycemia & Seizures**: Impaired ketogenesis due to HMG-CoA lyase deficiency prevents energy production during fasting, leading to hypoglycemia and subsequent seizures.  
2. **Hepatomegaly & Elevated Transaminases**: Toxic accumulation of metabolites (e.g., 3-hydroxy-3-methylglutaric acid) causes hepatic stress and mitochondrial dysfunction.  
3. **Dicarboxylic Aciduria**: Secondary to defective fatty acid β-oxidation, prompting ω-oxidation of fatty acids as an alternative pathway.  
4. **3-Methylglutaric Aciduria**: Direct consequence of blocked leucine catabolism at the HMG-CoA lyase step, causing buildup of upstream metabolites.  
5. **Acid-Base Homeostasis Abnormality**: Metabolic acidosis from excess organic acids (e.g., 3-hydroxy-3-methylglutaric acid) overwhelms buffering systems.  
6. **Decreased Plasma Free Carnitine**: Organic acids bind carnitine, forming acylcarnitines excreted in urine, depleting free carnitine reserves.  
7. **Elevated Urinary Carboxylic Acids**: Reflects systemic excretion of toxic intermediates (3-hydroxy-3-methylglutaric, 3-methylglutaric, and dicarboxylic acids).  
8. **Death in Infancy**: Untreated episodes of metabolic decompensation (hypoglycemia, acidosis) lead to fatal outcomes early in life.  

The constellation of findings aligns pathognomonically with HMG-CoA lyase deficiency, a leucine catabolism and ketogenesis disorder."
"['Eosinophilia', 'Lymphopenia', 'Increased circulating IgE level', 'Increased circulating IgG level', 'Nail dystrophy', 'Chronic oral candidiasis', 'Abnormal proportion of CD4-positive T cells', 'Abnormal proportion of CD8-positive T cells']","['Candidiasis, familial chronic mucocutaneous, autosomal recessive', 'Predisposition to invasive fungal disease due to CARD9 deficiency']","Disease: Candidiasis, familial chronic mucocutaneous, autosomal recessive  
Reasoning:  
1. **Chronic oral candidiasis** is a hallmark of this disorder, directly aligning with the patient’s symptom.  
2. **Nail dystrophy** commonly occurs due to chronic fungal infections in mucocutaneous candidiasis.  
3. **Increased IgE/IgG levels** reflect chronic antigenic stimulation from persistent Candida infections and possible dysregulated Th2 responses.  
4. **Abnormal CD4/CD8 T cell ratios** suggest underlying T-cell dysfunction, critical in controlling fungal infections. Familial forms often involve mutations (e.g., *STAT1* gain-of-function) that impair Th17 differentiation, weakening mucosal immunity.  
5. **Eosinophilia** may arise from Th2 skewing, while **lymphopenia** could indicate chronic immune activation or genetic defects affecting lymphocyte homeostasis.  

Disease: Predisposition to invasive fungal disease due to CARD9 deficiency  
Reasoning:  
1. **Chronic oral candidiasis** is seen in CARD9 deficiency, though typically with invasive fungal infections (not explicitly noted here).  
2. **Abnormal CD4/CD8 T cell ratios** may reflect impaired myeloid cell signaling (via CARD9), indirectly affecting T-cell responses to fungi.  
3. **Increased IgE/IgG** could result from compensatory immune hyperactivity due to defective fungal clearance.  
4. However, CARD9 deficiency often presents with **deep/organ fungal infections** (e.g., CNS candidiasis), which are absent here, making this diagnosis less likely. Lymphopenia and eosinophilia are also less characteristic of CARD9 deficiency.  

**Final Prioritization**: The patient’s presentation strongly aligns with **familial chronic mucocutaneous candidiasis**, given the isolated mucosal Candida involvement and T-cell abnormalities. CARD9 deficiency is less likely without invasive fungal features."
"['Oral ulcer', 'Xerostomia', 'Tinnitus', 'Hearing impairment', 'Proptosis', 'Visual loss', 'Decreased lacrimation', 'Diplopia', 'Nephrolithiasis', 'Abnormal finger morphology', 'Hemiparesis', 'Gait disturbance', 'Arthritis', 'Mitral regurgitation', 'Renal tubular acidosis', 'Leukocytosis', 'Migraine', 'Vertigo', 'Arthralgia', 'Exertional dyspnea', 'Elevated circulating thyroid-stimulating hormone concentration', 'Somatic sensory dysfunction', 'Hypouricemia', 'Exercise intolerance', 'Decreased urinary urate', 'Neck pain', 'Aphthous ulcer', 'Low levels of vitamin D', 'Skin vesicle', 'Pustule']","['Behçet disease/Behcet syndrome', 'Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Behçet disease/Behcet syndrome  
Reasoning: The patient presents with recurrent oral/aphthous ulcers, a hallmark of Behçet disease. Ocular involvement (proptosis, visual loss, diplopia) aligns with uveitis or retinal vasculitis. Skin vesicles/pustules suggest pathergy or cutaneous manifestations. Neurological symptoms (hemiparesis, gait disturbance, somatic sensory dysfunction) indicate possible neuro-Behçet. Arthritis and arthralgia are common systemic features. While atypical symptoms like xerostomia, renal tubular acidosis, and hypouricemia are not classic for Behçet, the core criteria (oral ulcers + multisystem inflammation) strongly support this diagnosis.  

Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: Arthritis, neck pain, and uveitis (implied by visual loss) are consistent with spondyloarthropathy (SpA). Elevated leukocytosis and HLA-B27 susceptibility (inferred from ""susceptibility to, 1"") may predispose to axial involvement. However, oral ulcers, neurological deficits, and cutaneous symptoms are less typical, suggesting incomplete alignment with SpA.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Similar to SpA-1, arthritic and axial symptoms (neck pain) are present. However, the absence of hallmark SpA features (e.g., enthesitis, sacroiliitis) and prominence of non-SpA symptoms (oral ulcers, renal/metabolic abnormalities) reduce confidence. Genetic susceptibility (e.g., ERAP1 variants in SpA-2) may contribute but does not override the stronger evidence for Behçet syndrome."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine metabolism.  
2. **Untreated Severe PKU**: In classic PKU, complete PAH deficiency leads to rapid phenylalanine accumulation. Without early dietary intervention, toxic levels cause irreversible neurotoxicity, seizures, and failure to thrive.  
3. **Neonatal/Infant Death**: In unscreened or untreated cases, severe metabolic derangements (e.g., cerebral edema, metabolic crises) or complications like infections in neurologically compromised infants may result in neonatal death or death within the first year.  
4. **Diagnostic Link**: The triad of hyperphenylalaninemia, neonatal deterioration, and infant mortality aligns with untreated PKU, particularly in settings lacking newborn screening or access to phenylalanine-restricted diets."
"['Vomiting', 'Ethylmalonic aciduria', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Short chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, short-chain, deficiency of']","Disease: Short chain acyl-CoA dehydrogenase deficiency/Acyl-CoA dehydrogenase, short-chain, deficiency of  
Reasoning:  
1. **Ethylmalonic aciduria**: A hallmark of short-chain acyl-CoA dehydrogenase (SCAD) deficiency, as impaired short-chain fatty acid oxidation leads to accumulation of ethylmalonic acid.  
2. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: SCAD deficiency disrupts mitochondrial β-oxidation, indirectly affecting enzymes in the pathway, including 3-hydroxyacyl-CoA dehydrogenase.  
3. **Abnormal circulating carnitine**: Secondary carnitine deficiency occurs due to excessive acylcarnitine excretion and disrupted fatty acid metabolism.  
4. **Vomiting**: Common during metabolic decompensation triggered by fasting or illness when energy demand exceeds defective fatty acid oxidation capacity.  
5. **Early mortality (childhood/adolescence)**: Severe SCAD deficiency causes life-threatening metabolic crises (hypoketotic hypoglycemia, encephalopathy) if untreated, leading to premature death.  
6. **Consistency with biochemical profile**: The triad of ethylmalonic aciduria, carnitine imbalance, and enzyme abnormalities aligns pathognomonically with SCAD deficiency."
"['Hypospadias', 'Microcephaly', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Smith-Lemli-Opitz syndrome:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol, along with hypocholesterolemia, are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS). These result from a deficiency in 7-dehydrocholesterol reductase (DHCR7), which blocks cholesterol synthesis.  
2. **Congenital anomalies**: Hypospadias and microcephaly align with SLOS-associated malformations caused by disrupted cholesterol-dependent embryogenesis.  
3. **Neurological features**: Generalized hypotonia and motor delay reflect abnormal neurodevelopment due to cholesterol deficiency, critical for myelination and synaptic function.  
4. **Feeding difficulties and lethality**: Poor feeding, neonatal death, and infant mortality are common in severe SLOS cases, often due to multiorgan failure or metabolic instability from critically low cholesterol.  
5. **Consistency with phenotype**: The combination of dysmorphic features, biochemical abnormalities, and early lethality strongly supports SLOS as the definitive diagnosis."
"['Microcephaly', 'Ptosis', 'Myopia', 'Autism', 'Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Short stature', 'Bilateral camptodactyly', 'Abnormality of the epiphyses of the feet', 'Delayed ability to walk']",['Intellectual developmental disorder with dysmorphic facies and ptosis'],"Disease: Intellectual developmental disorder with dysmorphic facies and ptosis (IDDDFP)  
Reasoning:  
1. **Core features alignment**: Ptosis, intellectual disability, delayed speech/development, and microcephaly are cardinal features of IDDDFP, caused by pathogenic variants in *TFAP2B*.  
2. **Musculoskeletal abnormalities**: Bilateral camptodactyly (fixed finger flexion) and foot epiphyseal anomalies correlate with the ""dysmorphic facies and skeletal defects"" described in IDDDFP.  
3. **Neurodevelopmental overlap**: Autism, hyperactivity, and delayed walking align with the spectrum of neurodevelopmental delays seen in this disorder.  
4. **Growth parameters**: Short stature supports the growth retardation phenotype associated with IDDDFP.  
5. **Exclusion of mimics**: The combination of ptosis, skeletal defects, and intellectual disability distinguishes IDDDFP from syndromes like Cornelia de Lange or Rubinstein-Taybi, which lack specific epiphyseal foot anomalies."
"['Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Abdominal pain', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Body odor']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Metabolic crisis & early mortality**: Symptoms like death in infancy/childhood/adolescence and neonatal death align with IVA's acute metabolic decompensation episodes, often triggered by catabolic stress (e.g., infections).  
2. **Gastrointestinal involvement**: Vomiting, diarrhea, and abdominal pain are classic during crises due to toxic metabolite accumulation (isovaleric acid).  
3. **Characteristic biochemical markers**:  
   - **Abnormal circulating carnitine**: Secondary carnitine depletion occurs as carnitine conjugates isovaleric acid (forming isovalerylcarnitine) for excretion.  
   - **Abnormal glycine**: Elevated glycine due to increased conjugation of isovaleric acid with glycine (isovalerylglycine), a diagnostic urinary marker.  
4. **Body odor**: Distinctive ""sweaty feet"" odor from excess isovaleric acid.  
5. **Immunological vulnerability**: Recurrent viral infections may reflect metabolic instability during illnesses, precipitating crises.  
6. **Inflammatory overlap**: Gastrointestinal inflammation mimics enterocolitis, a known IVA complication.  

IVA is confirmed via elevated isovalerylglycine in urine and genetic testing for *IVD* gene mutations. Early diagnosis enables dietary management (low-protein, leucine-restricted diet) and emergency protocols to prevent fatal metabolic crises."
"['Cleft palate', 'Choanal atresia', 'Elevated circulating thyroid-stimulating hormone concentration', 'Thyroid agenesis', 'Feeding difficulties', 'Decreased circulating T4 concentration', 'Hypersomnia']","['Bamforth-Lazarus syndrome/Hypothyroidism, athyroidal, with spiky hair and cleft palate']","Disease: Bamforth-Lazarus syndrome/Hypothyroidism, athyroidal, with spiky hair and cleft palate  
Reasoning:  
1. **Thyroid agenesis** and **elevated TSH/low T4** confirm **primary congenital hypothyroidism** due to absent thyroid tissue, a hallmark of Bamforth-Lazarus syndrome.  
2. **Cleft palate** and **choanal atresia** are classic craniofacial anomalies linked to FOXE1 gene mutations, which drive this syndrome.  
3. **Feeding difficulties** commonly arise from structural issues (cleft palate, choanal atresia) impairing suck-swallow-breath coordination.  
4. **Hypersomnia** aligns with severe hypothyroidism, causing metabolic slowdown and lethargy.  
5. The triad of thyroid agenesis, cleft palate, and choanal atresia is pathognomonic for Bamforth-Lazarus syndrome, excluding other causes (e.g., isolated CHARGE syndrome or Pendred syndrome)."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria  
Reasoning: The primary symptom of hyperphenylalaninemia strongly indicates PKU, caused by phenylalanine hydroxylase (PAH) deficiency, impairing phenylalanine-to-tyrosine conversion. Hypertyrosinemia is atypical in classic PKU but may arise from secondary mechanisms, such as excessive dietary tyrosine supplementation or competitive inhibition of tyrosine metabolism by elevated phenylalanine. Death in childhood aligns with untreated PKU, where toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and organ failure. This triad of symptoms suggests a severe PKU phenotype with complications driving atypical tyrosine elevation."
